data_2m74_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m74 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 17.6 mt . . . . . 0 N--CA 1.455 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 110.606 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -135.61 -176.77 4.4 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.732 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.71 158.73 29.32 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -76.59 8.29 3.08 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.764 2.309 . . . . 0.0 112.105 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.578 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 81.2 m-20 -119.88 65.79 0.81 Allowed 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.658 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 10.7 p -112.55 128.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -148.51 171.85 15.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.379 -179.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.55 166.46 34.97 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.7 m -79.08 165.04 23.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.7 0.286 . . . . 0.0 110.307 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.6 ttm-85 -58.85 -42.26 88.92 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.241 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -61.18 -39.42 90.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.832 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -131.63 51.13 2.17 Favored 'General case' 0 C--O 1.226 -0.151 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.033 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.08 142.83 50.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.536 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 11.8 p90 -160.94 176.32 11.55 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 121.069 0.461 . . . . 0.0 110.523 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.8 m -73.39 133.89 43.89 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -47.1 169.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.033 -178.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -58.32 133.86 57.73 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 121.883 1.722 . . . . 0.0 112.364 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 93.39 -16.63 60.2 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.578 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 92.5 m95 -110.25 138.49 46.55 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -121.98 -164.52 1.16 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.316 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 72.3 p -125.07 164.83 19.35 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.523 ' O ' ' N ' ' A' ' 77' ' ' GLY . 24.6 mt -89.16 151.99 47.42 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 -179.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -40.44 107.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.256 0 C-N-CA 122.219 1.946 . . . . 0.0 112.259 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.27 -11.2 9.03 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -87.96 177.76 46.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.924 -0.871 . . . . 0.0 110.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -138.01 17.06 2.83 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.892 0.377 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -81.93 130.15 34.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.046 -179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 53.6 m -95.66 55.26 1.64 Allowed 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.451 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.3 pt -114.32 22.05 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.995 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.04 99.51 40.92 Favored Pre-proline 0 N--CA 1.467 0.401 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.573 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.95 156.45 26.84 Favored 'Trans proline' 0 N--CA 1.487 1.113 0 C-N-CA 122.164 1.91 . . . . 0.0 112.202 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.438 ' O ' ' NH1' ' A' ' 86' ' ' ARG . 96.0 mt -101.57 122.12 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-O 120.945 0.403 . . . . 0.0 110.202 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.27 126.29 45.06 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.494 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 9.0 mpt_? -64.97 -40.33 94.82 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.743 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -117.71 145.68 44.27 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.192 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.2 m -63.24 136.29 57.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.0 0.429 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 44.5 m -77.95 -32.24 51.37 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.326 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.44 -107.19 2.25 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -68.38 -12.32 60.95 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.777 0.323 . . . . 0.0 110.797 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -110.53 -161.91 18.2 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -145.94 151.52 37.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.006 0.432 . . . . 0.0 111.072 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.7 m -66.95 115.18 6.39 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.225 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -106.46 -20.72 13.29 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.754 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -157.49 161.66 28.78 Favored Pre-proline 0 CA--C 1.531 0.238 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.364 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_exo -48.93 122.23 7.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 121.748 1.632 . . . . 0.0 111.254 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 52.05 41.74 30.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.004 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 80.9 mtp -148.33 116.72 6.54 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.62 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.44 ' N ' ' O ' ' A' ' 108' ' ' ALA . 33.7 m -100.44 148.28 24.92 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.366 178.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.6 m -120.58 123.28 42.48 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.741 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.16 157.92 53.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.275 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.71 -18.64 65.17 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.719 2.279 . . . . 0.0 111.855 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.8 m -71.95 -17.38 62.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.432 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 109.16 -20.32 28.57 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -66.82 150.03 49.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.934 0.397 . . . . 0.0 110.194 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.68 132.74 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.642 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.44 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -167.77 179.05 0.99 Allowed Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.379 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . 0.414 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 38.8 Cg_exo -57.92 -22.76 56.11 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.814 2.343 . . . . 0.0 112.306 179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.2 p -153.74 161.84 41.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.243 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.885 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 119' ' ' CYS . 45.0 t . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.877 0.37 . . . . 0.0 110.735 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.69 30.61 20.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.128 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.3 tt -158.59 165.22 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.265 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.4 mmt85 -101.2 106.13 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.195 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.39 127.37 52.06 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -147.01 168.63 21.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 59.54 39.92 21.03 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 120.792 0.329 . . . . 0.0 111.064 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.33 20.85 65.97 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -65.02 149.15 51.74 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 36.9 m -127.16 144.66 50.98 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.903 0.383 . . . . 0.0 110.403 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 37.1 t -82.55 124.39 30.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.568 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -148.18 111.67 4.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.472 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.9 49.98 17.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.067 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 57.41 34.55 24.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -144.48 139.54 28.36 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.508 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.4 m -88.05 126.89 35.33 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.25 126.85 40.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.628 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -103.02 137.88 40.62 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.683 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -83.27 175.34 9.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.437 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.533 ' NZ ' ' OE2' ' A' ' 151' ' ' GLU . 64.6 tttm -63.29 133.15 53.7 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.444 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.53 -24.52 28.48 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.459 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 95.1 m-85 -123.74 138.25 54.55 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.911 0.386 . . . . 0.0 110.55 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 16.7 pt -139.73 -168.93 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.496 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.97 165.29 31.43 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -46.25 88.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.742 0.306 . . . . 0.0 110.35 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -84.58 -1.42 55.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.612 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 145' ' ' CYS . 33.7 t 55.14 63.47 2.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -140.51 -4.18 1.26 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -86.48 114.54 58.21 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.385 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.49 156.2 36.37 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 122.295 1.997 . . . . 0.0 112.4 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.2 t -119.61 124.55 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 120.954 0.407 . . . . 0.0 110.197 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.3 107.54 20.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.2 -179.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . 0.533 ' OE2' ' NZ ' ' A' ' 138' ' ' LYS . 96.7 mt-10 -69.32 -38.23 78.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.101 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 94.7 p -85.38 -9.11 58.0 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.032 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 63.5 -163.82 31.1 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 71.8 m -116.12 152.24 34.04 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 96.9 mt -82.03 -1.95 50.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.49 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.567 ' C ' ' H ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -170.66 -147.62 0.05 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.336 179.508 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.551 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.64 26.99 0.49 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.567 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -64.23 175.51 11.21 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 78.1 ttt180 -128.14 136.64 51.42 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.65 0.262 . . . . 0.0 110.849 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 81.3 m -79.56 98.46 6.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 69.7 t -75.91 -44.1 38.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.533 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -145.13 174.26 3.61 Favored Pre-proline 0 C--N 1.331 -0.222 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -52.27 129.59 32.01 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 121.95 1.767 . . . . 0.0 112.102 179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 52.37 32.87 11.83 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.984 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.1 ttt85 -138.84 127.56 23.42 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.314 0.578 . . . . 0.0 110.691 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 42.1 t -139.37 149.99 44.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.722 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.24 134.31 49.57 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.566 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . 0.602 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 0.2 OUTLIER -81.0 120.28 24.58 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.846 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 12.1 m -70.38 -45.45 66.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.79 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -101.85 26.99 6.86 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.821 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.7 33.64 83.29 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -62.44 127.14 29.92 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -178.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 61.8 p -84.58 161.69 20.08 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.924 0.392 . . . . 0.0 110.979 -179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 143.24 160.25 8.31 Favored Glycine 0 CA--C 1.531 1.033 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.0 -25.41 44.38 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.537 2.158 . . . . 0.0 112.689 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -76.28 -49.27 17.45 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.45 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.0 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.736 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.853 0.359 . . . . 0.0 110.067 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . 0.632 ' HZ3' HD22 ' A' ' 78' ' ' ASN . 64.0 mttp -104.77 162.83 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.952 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.27 161.05 20.51 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -78.76 3.51 7.25 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.725 2.283 . . . . 0.0 112.146 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.63 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 1.7 m120 -123.51 68.69 1.02 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.77 0.319 . . . . 0.0 110.502 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.455 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.8 t -117.01 131.43 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-O 120.884 0.373 . . . . 0.0 110.032 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -142.56 175.96 9.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.333 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.83 170.28 46.86 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.538 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -77.77 167.66 21.19 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 43.7 ttm180 -60.98 -44.11 97.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.634 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -66.86 -39.3 87.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.225 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -121.91 47.45 1.89 Allowed 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.488 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.538 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -69.44 144.29 53.35 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.553 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.9 p90 -153.33 167.59 28.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.944 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.1 m -73.21 132.49 43.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.51 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.455 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 54.2 m -51.65 151.78 5.55 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.983 -179.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -46.37 129.35 13.28 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 C-N-CA 121.819 1.679 . . . . 0.0 112.424 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.93 -21.16 46.05 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.63 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 78.2 m95 -111.89 138.41 48.54 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.75 0.31 . . . . 0.0 110.279 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 ptpt -118.47 -176.05 3.0 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.324 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 72.5 p -106.94 153.71 22.15 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.493 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.509 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.1 mt -88.31 151.53 48.83 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.403 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.484 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.4 Cg_exo -39.04 105.47 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.187 1.925 . . . . 0.0 112.228 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.58 -9.2 2.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.16 168.94 47.36 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.632 HD22 ' HZ3' ' A' ' 54' ' ' LYS . 42.7 p-10 -126.49 13.49 7.59 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.657 0.265 . . . . 0.0 110.784 179.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . 0.443 ' NE2' ' OD1' ' A' ' 78' ' ' ASN . 10.8 mp0 -90.68 123.83 34.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.868 0.366 . . . . 0.0 110.898 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.48 68.57 4.87 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 27.2 pt -120.99 23.45 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.788 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.78 95.98 48.78 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.541 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.55 157.31 32.37 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.702 2.268 . . . . 0.0 112.236 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.407 HD11 HG21 ' A' ' 84' ' ' ILE . 96.1 mt -111.63 131.53 62.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.755 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 28.6 m -84.78 139.4 31.97 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.408 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -63.04 -45.15 93.63 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.279 0.561 . . . . 0.0 110.251 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -123.33 -118.08 0.29 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.29 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 t -143.81 133.71 23.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.35 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -94.05 -21.28 19.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.591 179.732 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.33 -99.18 0.7 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 39.5 p-10 -75.95 -1.71 26.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.772 0.32 . . . . 0.0 110.615 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.86 -175.29 26.79 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -141.12 153.86 45.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.934 0.397 . . . . 0.0 110.822 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.6 m -71.53 106.84 4.14 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.877 -179.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.7 p -96.69 -20.12 18.49 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.053 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mtt180 -162.14 168.92 10.11 Favored Pre-proline 0 C--O 1.235 0.329 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.987 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . 0.414 ' O ' ' CG ' ' A' ' 98' ' ' ASN . 52.4 Cg_exo -51.83 130.08 32.81 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 121.981 1.788 . . . . 0.0 110.827 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.414 ' CG ' ' O ' ' A' ' 97' ' ' PRO . 12.6 p30 43.01 34.85 0.68 Allowed 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.692 0.62 . . . . 0.0 109.918 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 47.3 mmm -148.62 120.81 8.34 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 121.312 0.577 . . . . 0.0 110.571 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 13.8 p -119.82 161.68 20.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.023 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 77.8 m -119.41 128.08 53.71 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.431 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.433 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.1 OUTLIER -92.0 153.15 43.36 Favored Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.72 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . 0.433 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 75.3 Cg_exo -46.45 -27.54 5.16 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.581 2.188 . . . . 0.0 112.011 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.8 t -63.43 -17.46 62.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.43 -3.01 63.32 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . 0.448 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 2.2 tm0? -81.0 148.54 29.69 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.785 0.326 . . . . 0.0 110.314 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.448 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 94.8 mt -122.06 135.18 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.549 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -176.74 175.69 0.6 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.691 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.27 -25.78 58.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.769 2.313 . . . . 0.0 111.508 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 49.5 p -136.09 168.11 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.194 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.597 -178.727 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.457 -0.109 0 CA-C-O 120.832 0.348 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.28 7.22 33.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.531 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.505 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 12.7 tt -130.44 166.29 28.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.505 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 16.1 mmm180 -100.98 125.22 47.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.304 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 82.6 m -118.29 129.21 55.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.941 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.0 mtm -140.97 166.84 23.68 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.339 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 58.48 41.31 22.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.03 74.38 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.16 145.12 49.44 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' SER . . . . . 0.505 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 30.3 t -102.39 128.33 49.03 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.745 0.307 . . . . 0.0 110.367 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 39.9 t -84.63 120.45 26.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.226 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 133' ' ' HIS . 39.7 t -142.35 136.37 29.58 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.305 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 39.88 -118.32 0.29 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.753 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -112.87 12.91 19.55 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.51 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.456 ' O ' ' O ' ' A' ' 130' ' ' SER . 78.2 t60 -133.08 152.99 51.92 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.856 0.36 . . . . 0.0 110.469 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 128' ' ' SER . 7.8 t -120.71 148.64 43.67 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.19 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.7 mt -105.73 134.29 49.09 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.351 -179.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 22.3 m -97.68 141.18 31.02 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.131 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -73.39 170.72 14.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.729 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -66.67 132.89 49.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 105.52 -20.03 38.01 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -122.27 137.03 54.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.796 0.331 . . . . 0.0 110.322 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -127.85 170.26 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.103 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 118.65 163.31 12.47 Favored Glycine 0 N--CA 1.464 0.516 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.505 ' HG1' ' CD2' ' A' ' 144' ' ' HIS . 67.3 p -63.39 -41.42 98.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.338 . . . . 0.0 110.562 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.505 ' CD2' ' HG1' ' A' ' 143' ' ' THR . 15.6 m170 -107.42 1.43 23.59 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.6 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.445 ' SG ' ' C ' ' A' ' 144' ' ' HIS . 1.8 m 71.14 140.65 0.05 OUTLIER 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.933 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 158.99 -26.95 0.38 Allowed Glycine 0 C--N 1.322 -0.224 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.64 117.1 67.71 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.45 -0.5 . . . . 0.0 110.482 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.51 153.39 39.36 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.432 2.088 . . . . 0.0 112.417 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 49.4 t -114.35 128.46 71.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.57 100.03 10.4 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.097 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 11.9 tm-20 -64.44 -36.73 85.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.274 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 80.0 p -83.6 -7.24 59.55 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 61.31 -168.89 10.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.1 m -140.41 115.87 10.05 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 10.7 mp -62.92 -42.07 99.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.663 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.581 ' C ' ' H ' ' A' ' 158' ' ' GLY . 63.9 t30 -93.45 173.34 7.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.524 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.17 34.6 0.31 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.03 174.42 26.02 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -123.75 138.25 54.55 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.807 0.337 . . . . 0.0 110.66 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 63.4 m -81.26 107.15 13.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.277 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.5 m -83.66 -29.98 7.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.547 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -158.93 172.38 6.21 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.54 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.55 129.64 33.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.062 1.841 . . . . 0.0 111.926 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 11.0 m120 53.55 33.96 17.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.601 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? -139.06 125.25 20.13 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.054 0.454 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -128.54 145.31 51.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -118.25 146.2 44.45 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.123 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 10.9 m -82.78 135.73 34.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.552 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 20.5 m -63.76 -45.4 90.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.85 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.69 22.65 10.64 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.011 0.434 . . . . 0.0 110.633 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 63.74 30.88 78.96 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -54.65 157.16 3.11 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.351 . . . . 0.0 110.353 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.15 140.47 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.284 0.564 . . . . 0.0 110.452 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 101.79 147.49 19.98 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.13 -31.31 36.73 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.591 2.194 . . . . 0.0 112.215 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.442 ' O ' ' O ' ' A' ' 177' ' ' CYS . 1.0 OUTLIER -88.12 -9.37 53.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.303 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.442 ' O ' ' O ' ' A' ' 176' ' ' GLN . 34.3 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 123.481 0.488 . . . . 0.0 109.933 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 CA--C 1.514 -0.409 0 CA-C-O 121.092 0.472 . . . . 0.0 110.559 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -137.45 162.46 33.59 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.308 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.71 161.13 23.03 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.51 -4.84 15.84 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 C-N-CA 122.953 2.435 . . . . 0.0 112.234 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.606 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 87.6 m-20 -112.54 74.42 0.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.074 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.436 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 8.2 p -116.04 130.38 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.904 179.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -139.91 177.92 7.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.098 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.8 161.28 27.82 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.8 m -82.61 171.54 13.93 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.0 ttt-85 -59.21 -40.49 85.95 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.302 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -60.01 -40.2 88.44 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.68 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -135.56 52.51 2.01 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.699 -0.228 . . . . 0.0 110.944 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.4 141.88 52.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.791 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.409 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 9.7 p90 -158.7 172.35 18.42 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.2 0.524 . . . . 0.0 110.421 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.563 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 94.6 m -69.03 140.42 54.94 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.131 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.436 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 64.2 m -58.72 149.44 63.31 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -56.29 131.09 43.72 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 121.581 1.52 . . . . 0.0 112.291 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.55 -16.34 40.95 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.606 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 93.0 m95 -119.07 134.73 55.02 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-O 120.804 0.335 . . . . 0.0 110.228 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -115.04 -176.69 2.96 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.375 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.563 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 30.3 p -132.59 172.53 12.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.005 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.446 HD13 ' H ' ' A' ' 74' ' ' LEU . 0.2 OUTLIER -92.02 160.32 35.95 Favored Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.363 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.51 ' C ' ' H ' ' A' ' 77' ' ' GLY . 45.6 Cg_exo -53.83 132.5 49.84 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.591 1.528 . . . . 0.0 112.144 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.6 -8.01 1.83 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.56 178.77 38.4 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 77' ' ' GLY . 29.4 m120 -146.9 16.77 1.23 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.006 0.431 . . . . 0.0 110.719 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -84.83 121.3 27.52 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.058 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 7.0 m -88.43 39.23 0.9 Allowed 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.2 -1.72 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.619 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 90.4 t -97.93 114.52 65.17 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.664 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -75.28 155.59 41.68 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 C-N-CA 121.982 1.788 . . . . 0.0 112.564 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 81.9 mt -106.42 124.44 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.192 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -106.16 115.84 30.92 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -64.15 -40.4 96.07 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.797 0.332 . . . . 0.0 110.686 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -117.0 149.39 40.32 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.537 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 m -66.22 138.2 57.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.501 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 40.5 m -79.02 -26.81 43.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.715 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.78 -104.2 2.17 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -78.6 -4.11 47.23 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.78 0.324 . . . . 0.0 110.97 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.59 -156.42 12.01 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.5 p90 -152.6 157.25 40.74 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.97 0.414 . . . . 0.0 111.023 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -64.1 112.95 3.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.052 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.44 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 91.9 p -102.83 -25.32 13.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.56 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -157.79 159.93 30.27 Favored Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.312 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -44.84 119.34 2.3 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 122.157 1.904 . . . . 0.0 111.607 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 66.2 t30 53.55 42.02 31.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.11 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mmm -148.39 118.76 7.35 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.915 0.388 . . . . 0.0 110.682 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 108' ' ' ALA . 17.7 m -100.79 146.14 27.64 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.149 178.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' THR . . . . . 0.44 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.0 m -122.24 123.94 42.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.627 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -87.74 156.84 52.69 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.644 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -61.95 -19.95 67.76 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 122.469 2.113 . . . . 0.0 111.798 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -66.28 -17.23 64.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.459 179.116 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 107.12 -19.31 35.1 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -67.0 149.83 50.09 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.957 0.408 . . . . 0.0 110.253 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 94.7 mt -129.18 130.2 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.743 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -169.44 178.11 1.02 Allowed Pre-proline 0 CA--C 1.538 0.482 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.314 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -57.67 -25.45 67.99 Favored 'Trans proline' 0 N--CA 1.499 1.837 0 C-N-CA 122.818 2.346 . . . . 0.0 111.968 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 95.5 p -149.83 162.33 40.51 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.499 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.667 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.214 0 CA-C-O 121.048 0.451 . . . . 0.0 110.031 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -98.5 13.73 30.77 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.745 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.485 ' CG2' ' N ' ' A' ' 122' ' ' ARG . 92.4 mt -119.24 165.52 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.204 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.56 ' NH2' ' CE1' ' A' ' 144' ' ' HIS . 5.9 ptt85 -119.19 101.95 8.37 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.581 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 76.3 m -107.03 146.69 30.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.744 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.9 mtm -142.9 174.56 10.55 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.255 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 59.02 37.43 24.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.787 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 73.99 22.37 78.04 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.56 134.71 16.94 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 15.2 m -86.31 129.64 34.78 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 121.052 -0.259 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.413 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 4.3 t -87.12 85.28 7.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.574 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 133' ' ' HIS . 14.7 p -74.96 161.84 29.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.383 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -50.23 110.87 0.44 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.408 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.401 ' O ' ' CG ' ' A' ' 133' ' ' HIS . 98.6 m-20 52.35 28.59 5.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.555 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.505 ' O ' ' N ' ' A' ' 130' ' ' SER . 31.5 m-70 -162.25 153.36 17.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.596 179.57 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 12.4 t -126.78 130.64 50.68 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.335 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.2 mt -102.06 131.07 48.74 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.902 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . 0.434 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 57.6 m -91.38 129.75 37.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.394 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -79.03 173.05 12.97 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.927 0.394 . . . . 0.0 110.575 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -63.42 134.2 55.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.334 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -21.62 37.79 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -129.02 139.62 51.98 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.772 0.32 . . . . 0.0 110.545 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 10.9 pt -134.09 176.79 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.986 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.434 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 107.52 169.08 21.88 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.5 m -62.08 -45.28 94.2 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.531 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.56 ' CE1' ' NH2' ' A' ' 122' ' ' ARG . 59.1 m80 -98.35 5.92 47.78 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.736 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 3.9 m 58.2 37.24 26.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -103.28 17.68 50.69 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 50.4 tp60 -119.19 96.73 50.22 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.754 0.277 . . . . 0.0 110.806 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -58.23 152.49 52.53 Favored 'Trans proline' 0 N--CA 1.499 1.819 0 C-N-CA 122.583 2.189 . . . . 0.0 111.916 178.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 70.8 t -89.94 129.76 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-O 121.048 0.452 . . . . 0.0 110.325 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.4 m -103.11 86.47 2.7 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -62.32 -46.43 88.77 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.267 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 90.0 p -111.99 -21.21 11.67 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.964 0.411 . . . . 0.0 110.502 179.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 49.67 177.91 0.02 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.6 m -98.54 139.8 33.73 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.934 0.397 . . . . 0.0 110.184 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 92.5 mt -63.22 -40.99 99.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.626 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.5 ' ND2' ' H ' ' A' ' 169' ' ' THR . 51.9 p30 -82.37 178.68 8.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.376 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.92 42.26 0.35 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.2 -176.57 19.15 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -130.15 142.18 50.61 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 98.6 m -76.69 102.45 6.19 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.037 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.8 t -83.17 -50.62 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.221 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -135.65 177.31 2.28 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.178 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -53.71 133.12 52.73 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.821 1.68 . . . . 0.0 111.489 179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 47.9 23.02 0.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.643 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -132.68 140.58 48.2 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.439 0.638 . . . . 0.0 111.025 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 5.8 p -149.1 155.69 41.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.379 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -89.92 143.88 26.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.65 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 66.1 m -85.05 155.14 21.66 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.612 -179.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.5 ' H ' ' ND2' ' A' ' 156' ' ' ASN . 97.9 m -62.08 -45.7 92.36 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.168 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.45 22.55 15.64 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.992 0.425 . . . . 0.0 111.262 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.13 35.09 91.31 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.408 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 2.7 m-85 -68.32 146.99 52.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.117 0.484 . . . . 0.0 110.643 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 60.6 p -81.58 166.67 20.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.179 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 91.28 154.62 30.81 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -67.83 -20.97 45.06 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.609 2.206 . . . . 0.0 112.405 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -111.26 18.79 18.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.737 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 79.7 m . . . . . 0 C--N 1.327 -0.399 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.29 -179.762 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -130.23 160.46 33.81 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 121.125 0.488 . . . . 0.0 110.142 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.6 174.76 36.46 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.04 -172.3 0.97 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.898 2.399 . . . . 0.0 111.81 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.526 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 53.5 m-80 59.16 38.95 23.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.997 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.46 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 11.8 p -98.69 131.59 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.278 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -141.5 -178.75 5.78 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.251 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.47 162.3 29.03 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 13.6 m -82.52 172.84 12.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.4 ttt-85 -60.86 -43.03 98.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.483 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -62.12 -39.62 93.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -133.02 55.2 1.91 Allowed 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.669 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.2 142.29 52.45 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -155.21 169.56 23.89 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.997 0.427 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.8 m -74.14 139.72 44.72 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.188 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.46 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 61.9 m -56.81 153.63 21.68 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.252 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.78 131.87 35.15 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 121.244 1.296 . . . . 0.0 112.203 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.92 -18.82 51.55 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.556 ' CD1' ' N ' ' A' ' 71' ' ' TRP . 8.9 m95 -119.01 140.04 50.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.746 0.308 . . . . 0.0 110.649 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -121.6 -175.84 3.18 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 60.8 p -108.81 154.12 22.53 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.482 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.9 mt -83.37 152.43 64.3 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.688 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.447 ' C ' ' H ' ' A' ' 77' ' ' GLY . 74.0 Cg_exo -41.3 110.33 0.13 Allowed 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.017 1.811 . . . . 0.0 112.197 179.125 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.36 -4.78 7.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -89.09 173.64 41.37 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -135.94 11.96 3.37 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.969 0.414 . . . . 0.0 111.059 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -89.61 126.64 35.7 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.552 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -89.61 69.1 7.79 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.8 pt -122.05 21.78 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.96 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -118.87 86.72 31.48 Favored Pre-proline 0 N--CA 1.464 0.251 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.793 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.47 150.76 83.74 Favored 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.773 2.315 . . . . 0.0 111.994 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.495 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.4 mt -106.05 128.74 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.439 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 5.9 m -89.62 135.67 33.48 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.49 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 -45.59 92.89 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.18 0.514 . . . . 0.0 109.758 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -119.0 167.86 11.36 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.64 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 96.4 p -57.15 137.81 55.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.544 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 31.5 m -86.06 -32.96 21.12 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.863 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.77 -108.91 2.74 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -93.74 0.96 56.62 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.744 0.306 . . . . 0.0 111.066 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.62 -176.25 31.12 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.449 ' C ' ' SG ' ' A' ' 100' ' ' CYS . 44.8 p90 -135.18 145.39 47.69 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.114 0.483 . . . . 0.0 110.902 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 85' ' ' CYS . 0.5 OUTLIER -70.11 113.41 7.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.54 -178.786 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.594 ' HG ' ' HG1' ' A' ' 101' ' ' THR . 33.9 m -99.79 -21.04 15.92 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.535 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.0 mtt180 -160.2 164.74 19.11 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.662 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.22 127.85 25.19 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 121.676 1.584 . . . . 0.0 111.474 179.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 63.9 m-20 50.52 35.36 11.15 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.874 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 68.3 mmm -150.26 122.05 8.11 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.416 0.627 . . . . 0.0 110.485 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.449 ' SG ' ' C ' ' A' ' 93' ' ' PHE . 0.7 OUTLIER -120.79 161.64 21.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.059 179.65 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' THR . . . . . 0.594 ' HG1' ' HG ' ' A' ' 95' ' ' SER . 96.5 m -127.75 127.45 43.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.693 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.94 156.7 36.9 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.24 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -50.89 -26.2 17.55 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.252 1.968 . . . . 0.0 111.896 177.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.12 -17.76 64.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.859 0.361 . . . . 0.0 110.489 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.1 -16.43 53.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.3 tp60 -63.91 150.34 45.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.909 0.385 . . . . 0.0 110.07 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.49 131.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -179.51 174.5 0.47 Allowed Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.558 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo -57.32 -22.03 47.39 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.708 2.272 . . . . 0.0 111.751 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.5 p -140.16 159.98 40.98 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.754 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.452 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 14.9 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.998 0.428 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -65.11 -40.55 94.67 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.26 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 25.3 pt -92.8 -170.83 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.624 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -107.53 108.56 19.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.215 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 57.7 m -114.81 139.39 49.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.992 178.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 90.0 mtp -138.97 168.23 20.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 2.4 m-20 59.56 41.75 18.47 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.249 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.7 20.21 79.6 Favored Glycine 0 CA--C 1.52 0.375 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.23 156.57 52.35 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.4 m -133.29 146.64 51.55 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.733 0.301 . . . . 0.0 110.247 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 7.6 p -91.53 130.1 37.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.377 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.6 t -148.11 137.69 22.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.058 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' A' ' 131' ' ' ASP . 3.7 p-10 45.01 41.29 5.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.006 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t0 62.0 36.69 15.4 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.637 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 69.1 t60 -150.02 140.59 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.585 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 9.4 t -88.55 130.92 35.13 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.48 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.6 mt -105.4 130.51 53.48 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 15.6 m -101.88 145.39 29.29 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.518 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.89 175.39 9.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.742 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -66.14 129.92 41.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.54 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.84 -20.06 44.96 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -120.28 134.57 55.24 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.792 0.329 . . . . 0.0 110.235 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.93 173.32 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.227 -179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 107.01 164.29 22.18 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 43.5 p -61.4 -44.78 96.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.754 0.311 . . . . 0.0 110.491 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.452 ' ND1' ' N ' ' A' ' 144' ' ' HIS . 3.0 p-80 -98.52 14.41 28.39 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.431 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.525 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 5.2 m 46.39 43.4 11.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.11 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.74 12.31 42.1 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -121.45 119.28 29.44 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.63 0.215 . . . . 0.0 110.972 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -76.44 157.69 36.7 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.676 2.25 . . . . 0.0 112.266 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.0 t -99.31 111.19 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 121.015 0.436 . . . . 0.0 110.653 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.53 90.63 8.08 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.0 tt0 -70.18 -39.15 75.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.546 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 10.6 m -88.39 -12.9 41.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.65 161.4 0.02 OUTLIER Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 160' ' ' CYS . 25.6 m -106.55 159.18 16.37 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . 0.42 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 56.7 mt -62.37 -42.87 99.75 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.244 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.42 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 t-20 161.67 -58.92 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.747 0.654 . . . . 0.0 110.61 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.03 -42.21 99.72 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -71.41 168.83 50.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 22.8 mmm180 -130.03 149.07 51.91 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.912 0.386 . . . . 0.0 110.21 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 87.9 m -81.15 95.16 6.8 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.668 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 41.6 t -79.48 -47.86 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.577 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -131.24 177.79 2.06 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.341 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.08 134.85 66.07 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.833 1.689 . . . . 0.0 111.597 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 40.78 33.53 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.948 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -132.7 104.49 6.66 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 121.364 0.602 . . . . 0.0 111.316 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.16 132.15 36.85 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.151 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -92.7 141.1 28.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.029 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.4 m -90.99 132.87 35.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.098 0.475 . . . . 0.0 110.757 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.9 m -63.64 -46.29 86.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.496 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -104.36 24.04 12.22 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.952 0.405 . . . . 0.0 111.246 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 62.42 29.86 74.58 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -54.67 168.0 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.04 0.448 . . . . 0.0 110.508 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.4 p -81.89 164.66 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.217 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.06 151.81 0.14 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.77 -24.8 40.29 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.375 2.05 . . . . 0.0 112.232 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 177' ' ' CYS . 85.2 mt-30 -84.09 -11.38 56.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.556 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 176' ' ' GLN . 10.1 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.47 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.2 mt . . . . . 0 N--CA 1.451 -0.39 0 CA-C-O 120.995 0.426 . . . . 0.0 110.421 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -131.72 161.73 32.14 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.565 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.79 172.73 22.25 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.52 -167.46 0.18 Allowed 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 122.924 2.416 . . . . 0.0 111.885 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.581 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 5.2 m120 58.2 37.0 26.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.535 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.481 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 13.3 p -100.41 134.15 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 109.95 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 57.6 m -142.98 177.46 8.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.275 -179.186 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.55 162.64 31.83 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 65' ' ' ALA . 11.8 m -80.46 173.72 12.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.628 0.252 . . . . 0.0 110.465 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -60.6 -44.12 96.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.74 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -64.72 -39.26 93.34 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.421 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 58.6 t30 -125.39 51.12 1.73 Allowed 'General case' 0 CA--C 1.522 -0.113 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.819 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.5 142.52 50.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.466 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.421 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 10.2 p90 -160.2 167.54 27.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.219 0.533 . . . . 0.0 111.189 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.547 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 74.6 m -71.13 141.22 50.78 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.35 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.481 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 65.2 m -58.94 150.85 58.44 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.973 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -56.0 128.56 30.76 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.835 1.69 . . . . 0.0 112.037 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.1 47.02 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.581 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.3 m95 -125.39 135.29 52.24 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.025 0.441 . . . . 0.0 110.527 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -119.76 -177.36 3.37 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.437 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.547 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 19.2 p -129.24 165.6 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.285 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.5 mt -84.46 149.89 55.82 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.723 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -43.02 120.46 1.94 Allowed 'Trans proline' 0 N--CA 1.489 1.242 0 C-N-CA 121.881 1.721 . . . . 0.0 112.312 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.4 -0.25 55.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.901 -0.879 . . . . 0.0 110.901 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -89.84 171.17 37.27 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -136.64 2.15 2.64 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.038 0.447 . . . . 0.0 110.836 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -82.22 131.66 35.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.191 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.3 m -99.21 43.49 1.06 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -98.89 2.68 10.49 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.362 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.61 110.37 60.25 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.611 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -73.39 158.52 48.11 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.202 1.934 . . . . 0.0 112.226 -179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -104.14 124.74 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.081 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.55 127.2 36.18 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.94 -45.29 93.15 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -136.81 154.96 50.39 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 17.0 m -60.08 136.39 58.0 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.321 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 1.8 t -94.03 4.04 54.47 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.562 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 61.73 -100.02 0.25 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.402 ' OD1' ' SG ' ' A' ' 102' ' ' CYS . 37.7 p30 -90.73 8.47 34.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.699 0.285 . . . . 0.0 110.838 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.87 -173.46 29.15 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.491 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -142.41 154.16 44.36 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.073 0.464 . . . . 0.0 110.9 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.8 m -72.15 106.42 4.36 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.804 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.491 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 2.1 m -95.9 -24.3 16.48 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.671 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.9 mtm-85 -159.96 167.17 14.49 Favored Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.891 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -51.96 125.4 17.07 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.73 1.62 . . . . 0.0 111.311 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 50.81 34.7 10.64 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.552 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.2 mmm -149.69 124.13 9.65 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.286 0.565 . . . . 0.0 110.614 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 10.1 p -123.92 163.58 21.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.794 179.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 94.8 m -125.46 130.63 52.19 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.705 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . 0.402 ' SG ' ' OD1' ' A' ' 91' ' ' ASP . 0.1 OUTLIER -94.28 155.74 39.56 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -48.01 -29.6 12.39 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.443 2.095 . . . . 0.0 112.133 177.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 37.5 m -62.63 -19.87 64.22 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.975 0.417 . . . . 0.0 110.688 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.4 57.27 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -70.94 152.0 44.09 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 110.168 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.36 131.55 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.57 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.414 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -174.67 178.22 0.55 Allowed Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.584 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . 0.414 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 31.6 Cg_exo -59.97 -18.57 50.84 Favored 'Trans proline' 0 N--CA 1.5 1.911 0 C-N-CA 122.794 2.329 . . . . 0.0 111.588 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.4 p -149.6 164.65 34.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.5 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.5 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.875 0.369 . . . . 0.0 110.182 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -63.91 -40.08 95.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 21.0 mm -80.7 160.23 4.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.152 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 88.8 mmt-85 -81.73 98.52 8.46 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.184 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -105.64 122.24 45.63 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -141.78 167.63 21.69 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.845 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.19 37.95 23.7 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.79 22.29 61.96 Favored Glycine 0 CA--C 1.522 0.485 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.06 119.25 9.44 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 7.3 m -80.2 138.59 36.88 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.487 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 22.6 m -91.08 128.48 36.92 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.774 0.321 . . . . 0.0 110.378 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.4 m -141.6 140.02 33.24 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' SER . 97.2 m-20 36.11 -97.15 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.965 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -136.02 22.25 3.27 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.728 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -132.48 147.04 52.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.496 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.98 125.65 44.49 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.861 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.1 mt -103.9 131.53 51.03 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.37 143.69 29.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.738 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -68.19 -174.77 0.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.319 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 27.8 tptp -69.02 132.09 46.09 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.541 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 96.93 -8.4 65.37 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -118.58 136.29 53.95 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.856 0.36 . . . . 0.0 110.559 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.7 pt -134.29 172.47 16.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.064 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 104.42 160.73 24.19 Favored Glycine 0 N--CA 1.461 0.342 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.34 -42.74 92.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.738 0.304 . . . . 0.0 110.547 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -97.13 5.17 50.69 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 31.0 m 58.12 37.31 26.38 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.371 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -100.73 5.28 56.67 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -119.8 107.8 39.83 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.801 0.3 . . . . 0.0 110.601 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.23 159.85 29.71 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 C-N-CA 122.65 2.233 . . . . 0.0 112.127 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.4 t -97.88 105.18 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -86.47 100.04 12.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.657 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -66.29 -45.57 79.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.283 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' SER . . . . . 0.443 ' O ' ' O ' ' A' ' 153' ' ' GLY . 23.4 t -89.53 -16.7 30.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.702 0.287 . . . . 0.0 110.883 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.49 156.15 0.01 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 10.9 m -93.95 133.08 37.76 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 64.3 mt -62.31 -43.9 97.76 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.189 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 178.23 -60.79 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 O-C-N 123.615 0.572 . . . . 0.0 110.52 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.84 51.13 1.54 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -166.82 154.62 25.18 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -123.25 129.32 51.21 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 2.4 t -75.33 102.84 5.23 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.068 0.461 . . . . 0.0 110.69 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . 0.414 ' O ' ' CG2' ' A' ' 161' ' ' VAL . 4.6 p -107.34 -2.91 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.412 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -166.6 171.65 4.47 Favored Pre-proline 0 C--N 1.322 -0.599 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.581 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -52.15 128.8 28.52 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 121.773 1.649 . . . . 0.0 111.395 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 40.93 36.14 0.4 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.682 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.528 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.8 OUTLIER -127.07 110.27 12.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.228 0.537 . . . . 0.0 110.409 -179.447 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.528 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 66.5 m -105.07 124.64 49.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.751 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -85.09 91.06 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.655 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.23 118.11 35.91 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.438 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.4 OUTLIER -111.27 11.36 21.7 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.63 -179.529 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 47.2 t80 -109.07 31.28 5.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.153 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 105.91 58.76 0.63 Allowed Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -53.02 126.12 19.53 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.534 -0.467 . . . . 0.0 110.325 -179.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 173' ' ' THR . . . . . 0.444 ' O ' ' O ' ' A' ' 174' ' ' GLY . 3.0 t -149.09 150.37 32.64 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.498 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 173' ' ' THR . . . 53.36 165.85 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.09 -18.66 45.73 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.83 2.353 . . . . 0.0 112.112 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -92.15 47.9 1.37 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.094 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 173' ' ' THR . 53.2 t . . . . . 0 N--CA 1.462 0.17 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.697 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.9 mt . . . . . 0 N--CA 1.451 -0.376 0 CA-C-O 120.88 0.371 . . . . 0.0 110.724 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.44 160.67 28.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.355 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.18 174.8 38.37 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.47 -169.36 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.991 2.461 . . . . 0.0 111.627 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 57.52 38.56 28.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.907 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.0 p -99.91 130.8 48.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . 0.438 ' O ' ' O ' ' A' ' 66' ' ' TYR . 52.7 m -145.64 175.58 10.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.613 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.23 167.1 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -75.06 165.04 25.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.623 0.249 . . . . 0.0 110.391 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.8 ttt180 -60.89 -44.2 97.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.653 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -66.24 -39.24 89.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -123.84 49.91 1.69 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.645 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.95 143.88 50.73 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.47 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.438 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -159.38 166.59 30.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.991 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 53.9 m -72.66 133.24 44.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.763 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -45.62 162.52 0.23 Allowed Pre-proline 0 CA--C 1.538 0.494 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -55.12 134.36 63.32 Favored 'Trans proline' 0 N--CA 1.495 1.604 0 C-N-CA 122.547 2.165 . . . . 0.0 111.68 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.65 -14.67 64.5 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -115.88 141.64 47.83 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.81 0.338 . . . . 0.0 110.239 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -125.7 -157.99 0.82 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.138 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 73.3 p -127.23 164.46 21.64 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.945 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.2 mt -87.09 152.05 52.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.435 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.7 Cg_exo -40.66 105.98 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.146 1.897 . . . . 0.0 111.939 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.65 -12.33 6.19 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.05 176.65 53.89 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 44.9 p30 -134.66 11.22 3.72 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.803 0.335 . . . . 0.0 110.744 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -82.37 130.62 35.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.474 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 79.7 m -90.96 47.66 1.43 Allowed 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.811 0.339 . . . . 0.0 110.308 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 38.4 pt -107.39 24.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.49 94.07 48.62 Favored Pre-proline 0 CA--C 1.537 0.449 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.249 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.85 156.82 24.05 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.463 2.108 . . . . 0.0 111.981 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.4 HD11 HG21 ' A' ' 84' ' ' ILE . 96.1 mt -101.99 125.77 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.025 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.03 119.28 38.52 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -45.37 94.74 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.969 0.414 . . . . 0.0 109.981 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -114.09 144.59 42.89 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.533 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.9 m -62.51 134.99 57.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.249 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 37.8 m -77.16 -31.72 55.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.633 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.08 -106.78 2.26 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.42 -8.01 52.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.664 0.269 . . . . 0.0 110.719 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.88 -161.48 18.81 Favored Glycine 0 N--CA 1.463 0.46 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.516 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -146.84 153.06 39.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.028 0.442 . . . . 0.0 110.755 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.25 114.56 5.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.28 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.516 ' OG ' ' CE2' ' A' ' 93' ' ' PHE . 75.7 m -105.11 -22.54 13.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.443 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 3.0 mtt180 -156.34 160.95 30.41 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.796 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -47.47 118.24 2.81 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 122.138 1.892 . . . . 0.0 111.519 179.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 54.27 41.67 31.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.344 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 77.0 mtp -148.33 120.13 8.12 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.367 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' ALA . 46.5 m -103.75 148.95 25.47 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.831 179.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' THR . . . . . 0.449 ' CB ' ' HG ' ' A' ' 95' ' ' SER . 97.5 m -118.51 123.06 44.2 Favored 'General case' 0 CA--C 1.515 -0.385 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.57 147.84 35.06 Favored Pre-proline 0 CA--C 1.541 0.598 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.651 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -47.39 -23.97 3.69 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.636 2.224 . . . . 0.0 112.09 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.9 t -64.35 -17.3 63.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.767 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.61 -14.99 56.26 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 59.6 tp60 -73.08 152.25 41.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.896 0.379 . . . . 0.0 110.248 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 91.4 mt -126.59 131.95 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.546 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -174.05 173.32 1.2 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.448 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_exo -55.08 -28.37 60.07 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.719 2.279 . . . . 0.0 112.142 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 p -136.61 164.25 28.64 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.567 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.648 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 93.7 m . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 120.953 0.406 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -161.75 29.59 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.478 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 18.5 tt -121.13 171.09 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.441 -179.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.478 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 27.2 mmt180 -95.86 127.46 41.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.928 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 85.0 m -117.52 134.78 54.48 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.971 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtt -138.24 156.53 47.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.231 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 58.92 51.47 7.31 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.059 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 66.48 26.9 72.84 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.52 139.5 35.45 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' SER . . . . . 0.51 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 51.5 m -110.3 141.75 42.87 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.2 t -85.01 126.16 33.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 0.0 110.621 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.484 ' HG ' ' CE1' ' A' ' 133' ' ' HIS . 11.4 p -148.5 127.91 13.09 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.448 0.642 . . . . 0.0 111.01 179.527 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.444 ' O ' ' CB ' ' A' ' 132' ' ' ASP . 9.6 t70 50.18 42.79 25.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.562 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 131' ' ' ASP . 9.5 t0 78.29 -40.68 0.29 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.484 ' CE1' ' HG ' ' A' ' 130' ' ' SER . 6.8 p80 -85.42 147.64 26.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.971 0.415 . . . . 0.0 110.531 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.3 t -99.93 149.09 23.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.847 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.5 137.27 49.54 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.25 144.67 27.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.481 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -59.95 176.13 0.33 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.658 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 49.7 tttm -66.61 131.22 45.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.641 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 99.01 -15.86 60.1 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -111.28 136.44 50.38 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.791 0.329 . . . . 0.0 110.35 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.45 171.7 17.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.973 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.72 158.36 10.58 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 98.6 m -62.53 -46.39 88.62 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.916 -0.314 . . . . 0.0 110.715 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 96.3 m-70 -105.28 11.82 32.48 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.491 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 14.6 m 60.68 139.13 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.809 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 153.13 -1.15 0.24 Allowed Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -113.09 108.66 52.84 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 121.303 -0.159 . . . . 0.0 110.785 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -77.43 159.32 32.61 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.676 2.25 . . . . 0.0 111.909 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 81.9 t -120.81 120.49 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-O 121.009 0.433 . . . . 0.0 110.12 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 60.5 m -91.44 114.65 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.56 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -64.03 -42.22 97.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.88 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.1 p -86.27 -6.36 58.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.532 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.11 166.31 0.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 73.4 m -100.27 102.9 14.29 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.879 0.371 . . . . 0.0 110.067 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.8 mt -63.62 -41.98 98.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.552 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.594 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.5 t30 -93.28 -176.97 4.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.387 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.551 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.79 23.25 0.41 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.594 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.41 174.99 26.35 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 52.3 mmm-85 -127.42 147.12 50.29 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.695 0.283 . . . . 0.0 110.449 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 21.5 m -86.01 111.67 20.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.09 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -97.16 -16.26 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.331 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -168.34 173.65 2.56 Favored Pre-proline 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.71 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -57.08 135.65 71.92 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.068 1.845 . . . . 0.0 112.029 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.8 t30 44.43 32.79 0.77 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.837 179.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.86 101.0 3.77 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.386 0.612 . . . . 0.0 111.152 179.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 31.2 t -101.81 148.2 25.58 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.284 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.0 137.37 39.45 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.88 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 87.8 m -81.7 150.34 28.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.822 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.4 m -61.72 -45.99 91.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.735 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.541 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 53.3 t80 -110.36 25.71 11.48 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.058 0.456 . . . . 0.0 110.694 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 67.13 30.51 75.83 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' A' ' 173' ' ' THR . 65.9 t80 -58.76 159.35 6.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.83 0.348 . . . . 0.0 110.444 -179.522 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 173' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 8.1 p -81.94 167.09 19.29 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.392 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 104.36 142.0 11.36 Favored Glycine 0 CA--C 1.535 1.287 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.06 -33.01 20.23 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 122.524 2.149 . . . . 0.0 112.596 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.419 ' O ' ' O ' ' A' ' 177' ' ' CYS . 20.8 pt20 -108.05 1.15 22.2 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.566 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.419 ' O ' ' O ' ' A' ' 176' ' ' GLN . 1.1 t . . . . . 0 C--N 1.326 -0.444 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.421 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 78.2 mt . . . . . 0 N--CA 1.454 -0.261 0 CA-C-O 121.013 0.435 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -138.5 159.84 41.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.526 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.58 169.1 29.22 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.59 -168.79 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.938 2.426 . . . . 0.0 111.821 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.626 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 46.4 m-80 59.35 41.04 20.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.743 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.4 p -105.33 131.69 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.6 m -141.88 -175.45 4.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.128 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.37 173.5 49.71 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.746 -0.941 . . . . 0.0 110.746 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.4 m -72.88 155.96 39.36 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -58.99 -43.2 91.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.775 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.23 -41.87 98.8 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.173 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -127.74 50.65 2.01 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.723 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.03 151.36 47.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.28 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -154.67 164.94 38.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.158 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.434 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 69.0 m -63.41 128.99 38.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.783 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 12.4 m -48.53 150.92 2.18 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.34 -178.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.61 133.5 38.37 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 121.572 1.514 . . . . 0.0 112.178 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.26 -7.94 64.42 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.626 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 54.6 m95 -118.89 138.71 52.57 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 110.592 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -127.83 -176.05 3.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.412 179.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.434 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 5.4 p -133.46 177.99 7.27 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.54 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 77' ' ' GLY . 48.6 mt -89.91 148.86 40.67 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.507 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.41 116.16 0.47 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.108 1.872 . . . . 0.0 112.491 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.19 -4.56 54.3 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -86.33 171.1 43.59 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.431 ' C ' ' ND2' ' A' ' 78' ' ' ASN . 0.5 OUTLIER -133.58 9.19 3.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.977 0.418 . . . . 0.0 110.811 179.929 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -87.28 132.33 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.487 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -97.88 40.0 1.19 Allowed 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 35.4 pt -97.24 12.93 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.855 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.6 t -116.29 87.98 21.65 Favored Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.471 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo -60.69 148.87 90.23 Favored 'Trans proline' 0 N--CA 1.496 1.659 0 C-N-CA 122.819 2.346 . . . . 0.0 111.987 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 91.9 mt -89.17 123.55 41.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.47 110.1 22.74 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.17 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 2.1 mpt_? -65.31 -39.08 92.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.025 0.441 . . . . 0.0 110.328 178.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -119.05 143.36 47.15 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.104 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.7 p -60.86 134.46 57.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.397 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 60.3 m -77.89 -28.07 49.78 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.706 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.4 -102.56 1.74 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -89.19 2.37 54.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.658 0.266 . . . . 0.0 110.639 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.29 -168.86 22.96 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -138.71 150.53 46.26 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.124 0.488 . . . . 0.0 110.854 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 90.8 m -65.89 112.86 3.99 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.33 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 t -107.29 -25.87 11.29 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.467 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.4 mtt-85 -158.09 164.3 21.79 Favored Pre-proline 0 C--N 1.328 -0.334 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.66 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -51.01 121.77 8.79 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.96 1.773 . . . . 0.0 111.485 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 52.09 40.83 29.35 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 48.7 mtt -146.9 114.91 6.54 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.699 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.454 ' N ' ' O ' ' A' ' 108' ' ' ALA . 65.3 m -100.05 146.84 26.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.232 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 66.6 m -115.61 121.6 43.09 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.87 149.55 37.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.498 -179.464 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.65 -21.81 2.58 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.567 2.178 . . . . 0.0 111.974 177.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.8 t -68.02 -17.91 64.55 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.8 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.87 -14.68 57.34 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -68.42 153.82 43.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.974 0.416 . . . . 0.0 110.243 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.42 133.15 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.677 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . 179.71 168.49 0.69 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.301 178.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -48.8 -33.76 26.02 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 122.597 2.198 . . . . 0.0 112.083 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 38.8 m -133.01 165.6 24.34 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.538 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.484 . . . . 0.0 109.84 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . 0.47 ' C ' ' H ' ' A' ' 121' ' ' ILE . 12.1 t . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.803 0.335 . . . . 0.0 110.944 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.3 t-20 61.09 3.22 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.595 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.47 ' H ' ' C ' ' A' ' 119' ' ' CYS . 18.8 tt -143.84 172.25 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.427 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.469 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 38.0 mtt85 -122.73 99.97 6.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.777 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 28.8 m -90.34 147.16 23.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.739 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.7 mtm -139.97 170.6 15.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.356 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.0 m120 67.48 39.13 2.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.508 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.55 32.44 83.26 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.31 -173.98 14.0 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.1 m -130.98 136.69 48.76 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.4 t -73.33 112.08 9.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.188 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 69.5 m -128.97 119.82 24.99 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.959 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 43.17 -108.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.746 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -121.81 19.81 10.97 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.507 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -131.87 156.02 46.82 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.955 0.407 . . . . 0.0 110.293 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 97.1 m -106.42 131.24 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.0 mt -99.22 131.35 45.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.672 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -100.3 143.2 30.78 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.438 -179.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.56 -179.09 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.57 132.84 49.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.53 -179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.25 -19.36 46.1 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -118.11 136.99 53.25 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.784 0.326 . . . . 0.0 110.295 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.6 pt -130.94 171.79 17.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.992 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.01 157.73 10.48 Favored Glycine 0 N--CA 1.464 0.519 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 61.6 p -64.09 -42.53 96.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.835 0.35 . . . . 0.0 110.536 -179.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -105.8 5.64 31.0 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.692 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 5.0 m 65.04 140.1 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.076 0.465 . . . . 0.0 109.965 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 152.86 -11.04 0.59 Allowed Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -102.44 110.2 62.32 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.535 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.29 157.46 33.31 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.486 2.124 . . . . 0.0 112.31 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.46 116.66 50.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 120.989 0.423 . . . . 0.0 110.179 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.7 m -88.98 96.38 10.7 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -66.12 -38.5 88.34 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.426 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 97.4 p -82.42 -7.96 59.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.684 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 59.2 161.93 0.07 OUTLIER Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.06 114.5 28.73 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.57 -42.16 98.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.562 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.1 m-20 -100.07 -177.37 3.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.456 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -70.81 33.58 0.49 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.046 -0.821 . . . . 0.0 111.046 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.562 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.55 176.05 28.79 Favored Glycine 0 CA--C 1.52 0.349 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -126.03 142.33 51.57 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.68 0.276 . . . . 0.0 110.494 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.66 122.03 30.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.442 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.2 m -110.16 -9.87 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.308 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -171.91 170.97 2.34 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.41 -0.516 . . . . 0.0 110.737 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.05 128.48 29.16 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 121.913 1.742 . . . . 0.0 111.402 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 52.58 32.69 12.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.119 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.76 127.8 37.52 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.15 0.5 . . . . 0.0 109.773 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 4.4 t -139.01 148.58 43.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.858 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.51 129.11 47.52 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.471 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 26.8 m -74.43 151.43 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.311 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.8 m -62.96 -45.8 90.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.204 -179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.96 19.52 19.29 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-O 121.077 0.465 . . . . 0.0 110.734 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 68.53 26.71 74.23 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -55.45 149.66 13.05 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 51.8 p -82.29 165.42 20.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.576 -179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 87.44 150.45 18.85 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.82 -23.18 41.89 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.69 2.26 . . . . 0.0 112.272 -179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 76.6 mt-30 -101.34 7.32 42.81 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.554 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 77.9 m . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.185 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 13.0 mt . . . . . 0 CA--C 1.517 -0.289 0 CA-C-O 121.166 0.508 . . . . 0.0 110.225 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -133.22 163.03 30.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.32 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.47 160.31 23.13 Favored Glycine 0 CA--C 1.531 1.039 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.54 2.94 6.82 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.862 2.375 . . . . 0.0 112.212 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.591 ' ND2' ' CZ2' ' A' ' 71' ' ' TRP . 3.0 m120 -114.95 69.07 0.71 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.355 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.457 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.1 t -120.42 130.83 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 93.1 m -141.15 176.8 8.54 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.032 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.22 169.15 45.49 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.557 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -74.51 163.25 27.97 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -59.27 -43.94 92.45 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.47 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -64.11 -39.96 95.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.007 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -122.54 46.62 2.1 Favored 'General case' 0 N--CA 1.461 0.079 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.783 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.557 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.92 145.09 48.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.52 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -156.05 168.19 28.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.821 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.5 m -67.47 130.11 42.04 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.189 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.457 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 53.5 m -49.21 153.29 1.73 Allowed Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.246 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -51.64 131.68 38.26 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 121.43 1.42 . . . . 0.0 112.398 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 100.9 -16.53 57.33 Favored Glycine 0 N--CA 1.467 0.737 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.591 ' CZ2' ' ND2' ' A' ' 57' ' ' ASN . 9.1 m95 -115.63 139.58 49.97 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.787 0.327 . . . . 0.0 110.498 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.9 ptpt -120.23 -168.66 1.66 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.312 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 64.1 p -118.13 160.53 21.39 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.483 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.1 mt -87.4 152.84 52.96 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.744 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.44 107.58 0.08 OUTLIER 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.145 1.897 . . . . 0.0 112.184 179.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.34 -11.63 12.19 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -88.29 175.99 44.84 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -135.56 15.75 3.4 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.12 0.486 . . . . 0.0 110.639 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -79.87 128.53 33.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.495 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 29.9 m -96.9 55.68 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 30.3 pt -115.92 21.01 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.993 -179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.5 t -119.32 85.74 31.62 Favored Pre-proline 0 N--CA 1.467 0.39 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.697 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -61.35 148.48 92.83 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.936 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.8 mt -90.9 128.63 42.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 3.2 m -99.62 109.02 21.54 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.229 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -65.88 -39.36 90.59 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.052 0.453 . . . . 0.0 109.906 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 61.3 m170 -110.51 142.06 42.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.002 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.5 t -59.62 130.07 45.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.681 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 61.2 m -80.28 -31.52 38.28 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.875 179.374 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.07 -112.48 3.67 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -81.91 -0.55 44.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.16 -175.74 30.35 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.0 147.79 52.47 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.018 0.437 . . . . 0.0 110.794 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.2 m -64.4 111.26 2.57 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.42 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 69.8 p -102.64 -27.51 12.69 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.302 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.1 mtt85 -157.83 163.94 23.03 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.583 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -51.55 121.9 9.32 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 121.634 1.556 . . . . 0.0 111.48 179.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 55.17 40.34 31.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.878 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.8 mmm -149.27 115.81 5.87 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.198 0.523 . . . . 0.0 109.97 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 86.7 m -101.23 151.12 22.25 Favored 'General case' 0 N--CA 1.461 0.116 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.674 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 97.1 m -121.91 126.26 48.26 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.68 151.59 40.12 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.642 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -50.02 -22.73 8.11 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.459 2.106 . . . . 0.0 111.867 177.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -66.85 -16.96 64.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.684 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.82 -18.5 49.89 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tt0 -68.05 153.16 44.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.894 0.378 . . . . 0.0 110.304 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.17 130.38 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.581 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -173.27 164.88 3.21 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.962 -179.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo -57.44 -22.81 52.28 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.916 2.411 . . . . 0.0 111.829 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.9 p -135.38 154.53 51.45 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.97 0.414 . . . . 0.0 110.227 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.68 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 120.782 0.325 . . . . 0.0 110.207 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -63.4 -40.21 96.61 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.444 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.405 HG23 ' H ' ' A' ' 122' ' ' ARG . 1.1 mt -113.31 -157.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.811 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.505 ' NH2' ' NE2' ' A' ' 144' ' ' HIS . 36.6 ptt-85 -120.59 121.72 38.99 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.7 m -124.86 147.0 49.01 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.15 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 70.9 mtm -145.17 174.13 11.34 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.315 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 5.7 m120 59.61 37.2 22.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.44 15.47 79.84 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.7 123.76 10.16 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.158 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 39.9 t -83.51 140.98 31.96 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.75 0.309 . . . . 0.0 110.881 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 5.8 m -83.32 129.94 35.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.18 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.4 m -126.45 158.3 36.38 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.134 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.442 ' O ' ' OD1' ' A' ' 131' ' ' ASP . 43.4 p-10 -48.24 109.35 0.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.09 0.472 . . . . 0.0 110.991 -178.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 50.24 30.26 4.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.531 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -159.78 154.9 24.95 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.495 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 47.6 t -129.55 132.32 46.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.784 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 80.3 mt -101.09 128.47 47.14 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 55.6 m -84.77 132.19 34.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.382 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -56.1 161.14 2.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.906 0.384 . . . . 0.0 110.352 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -59.25 130.81 48.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.873 0.368 . . . . 0.0 110.816 -179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 94.5 -6.91 71.37 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -119.74 137.43 53.94 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.924 0.392 . . . . 0.0 110.098 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 22.3 pt -129.61 169.59 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.953 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 121.69 159.34 10.64 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.4 m -62.17 -45.64 92.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 0.0 110.687 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.505 ' NE2' ' NH2' ' A' ' 122' ' ' ARG . 31.9 m-70 -102.75 3.24 36.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.347 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.37 142.94 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.894 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 149.53 -8.24 0.86 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -101.39 109.38 58.73 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.371 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.3 157.49 45.65 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.359 2.039 . . . . 0.0 112.437 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.8 t -124.83 126.81 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.412 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 66.3 m -94.41 109.13 21.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.129 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -66.89 -39.54 87.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.9 m -88.66 -9.16 53.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.712 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . 0.505 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 60.03 177.47 1.48 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 9.0 m -116.08 119.98 37.61 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.024 0.44 . . . . 0.0 110.191 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 94.9 mt -63.57 -42.38 98.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.534 ' C ' ' H ' ' A' ' 158' ' ' GLY . 18.9 m120 -93.6 -178.49 4.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.525 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.34 29.55 0.69 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.534 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.61 179.41 16.81 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -126.2 149.64 48.89 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.942 0.401 . . . . 0.0 110.349 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.52 105.09 17.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -88.41 -19.64 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.566 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -165.93 174.28 2.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.47 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -52.84 133.82 52.41 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 121.892 1.728 . . . . 0.0 111.854 179.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 64.7 t30 45.34 36.42 2.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.397 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -130.34 103.82 6.91 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.29 0.567 . . . . 0.0 110.909 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 153' ' ' GLY . 23.2 m -102.2 135.15 44.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.087 -0.961 . . . . 0.0 110.685 179.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.98 92.29 3.97 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 178.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.6 p -102.23 141.76 34.56 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.468 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.1 OUTLIER -111.6 13.79 21.28 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.298 0.57 . . . . 0.0 110.568 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -102.32 30.45 4.56 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.164 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 100.28 59.42 0.84 Allowed Glycine 0 N--CA 1.464 0.553 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 172' ' ' PHE . 21.9 t80 -44.51 119.04 1.73 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.033 0.444 . . . . 0.0 110.484 -179.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.3 m -153.3 130.61 11.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.375 179.229 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 78.03 164.71 24.83 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -66.94 -22.32 48.64 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.896 2.397 . . . . 0.0 112.253 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -89.09 14.01 11.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.951 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.327 -0.377 0 CA-C-O 121.021 0.438 . . . . 0.0 110.166 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 44.3 mt . . . . . 0 N--CA 1.452 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -135.42 161.8 34.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.037 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.9 163.92 26.88 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -75.03 -7.35 19.05 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 123.058 2.505 . . . . 0.0 112.344 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.447 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 71.9 m-80 -105.32 70.38 0.89 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.597 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.466 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 60.7 t -121.63 130.24 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.925 179.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 87.1 m -144.55 -174.1 4.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.009 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.28 171.43 47.51 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.6 m -84.19 167.56 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -59.52 -43.79 93.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.777 0.323 . . . . 0.0 110.738 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -63.97 -36.76 85.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.977 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -129.25 50.33 2.16 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.987 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -73.18 142.81 47.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.371 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -160.75 167.16 27.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.995 0.426 . . . . 0.0 111.03 179.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.403 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 79.1 m -64.04 130.92 45.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.17 -179.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.466 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 32.5 m -47.72 151.02 1.64 Allowed Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.103 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -49.62 129.76 24.37 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.498 1.465 . . . . 0.0 112.301 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.67 -18.54 47.09 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.447 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 98.6 m95 -111.77 134.76 53.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.965 0.412 . . . . 0.0 110.085 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -110.99 -167.75 1.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.133 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.403 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.1 p -129.83 165.29 22.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.049 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 12.1 mt -91.53 150.58 41.39 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.834 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.405 ' C ' ' H ' ' A' ' 77' ' ' GLY . 59.8 Cg_exo -44.21 115.4 0.75 Allowed 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.864 1.709 . . . . 0.0 112.036 179.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.12 -8.73 7.93 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.405 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -91.11 177.94 41.63 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.659 ' H ' ' NE2' ' A' ' 79' ' ' GLN . 26.7 p30 -139.51 13.39 2.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.931 0.396 . . . . 0.0 110.864 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . 0.659 ' NE2' ' H ' ' A' ' 78' ' ' ASN . 12.1 mp0 -84.08 131.78 34.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.469 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 22.5 m -95.88 43.29 1.08 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.361 -0.382 . . . . 0.0 109.987 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 42.4 pt -98.2 6.89 8.66 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.246 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.734 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.66 112.54 60.52 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.417 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.29 156.87 29.52 Favored 'Trans proline' 0 N--CA 1.486 1.059 0 C-N-CA 122.01 1.807 . . . . 0.0 111.864 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.6 mt -100.72 118.91 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.8 115.42 27.12 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.73 -45.24 87.36 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.37 0.605 . . . . 0.0 110.106 179.242 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -119.41 -167.89 1.49 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.674 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.2 t -97.04 125.07 41.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.722 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.6 m -74.39 -32.16 62.62 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.776 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -106.08 2.23 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.439 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 31.4 p-10 -81.99 -2.63 52.21 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.719 0.295 . . . . 0.0 110.773 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.63 -176.36 27.14 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -133.72 146.12 50.5 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.058 0.456 . . . . 0.0 110.788 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 70.1 m -64.57 111.3 2.65 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.578 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 89.0 p -105.98 -26.07 11.83 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.33 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 -153.23 159.58 32.01 Favored Pre-proline 0 C--N 1.325 -0.464 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.291 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -48.92 119.07 3.96 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.477 2.118 . . . . 0.0 111.915 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 54.0 t30 55.11 42.88 30.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.228 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mtp -149.06 118.87 7.06 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.09 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 69.2 m -100.64 148.72 24.54 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.792 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.5 m -119.99 115.59 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.422 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.44 154.0 68.66 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -50.07 -26.56 14.95 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.693 2.262 . . . . 0.0 112.016 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 m -66.49 -15.5 63.41 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.831 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.92 -15.18 58.37 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -65.86 149.31 50.39 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.418 HG21 HD12 ' A' ' 107' ' ' ILE . 96.3 mt -128.2 130.64 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.869 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.433 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -170.29 179.43 0.74 Allowed Pre-proline 0 C--N 1.327 -0.406 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.446 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . 0.433 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 35.7 Cg_exo -58.81 -22.71 63.34 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.877 2.385 . . . . 0.0 111.78 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 82.7 p -152.3 163.98 38.36 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.598 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.315 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 75.8 m . . . . . 0 CA--C 1.522 -0.131 0 CA-C-O 120.655 0.264 . . . . 0.0 111.224 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -64.36 -40.77 96.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.551 ' CG2' ' H ' ' A' ' 122' ' ' ARG . 24.7 mm -64.48 177.83 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.962 0.41 . . . . 0.0 109.999 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.551 ' H ' ' CG2' ' A' ' 121' ' ' ILE . 36.8 mmt180 -117.46 98.27 6.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.721 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.2 m -94.33 135.27 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.322 179.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.6 mtm -130.17 170.13 14.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.346 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 m120 63.6 41.48 7.19 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.717 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.87 23.61 71.04 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.574 -1.01 . . . . 0.0 110.574 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.93 141.96 24.88 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 20.1 m -99.87 144.69 28.63 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.725 0.298 . . . . 0.0 110.314 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . 0.5 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 0.5 OUTLIER -93.99 129.79 40.35 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.682 179.897 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 28.8 t -149.36 134.99 18.61 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.394 178.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 51.11 45.82 27.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 56.95 33.65 23.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -143.98 138.2 28.26 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.467 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 95.9 m -91.05 131.4 36.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 110.828 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 76.6 mt -101.83 128.53 48.15 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.338 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . 0.452 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 8.4 m -89.01 135.78 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.53 -179.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -73.32 172.6 10.91 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.444 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -62.82 126.12 26.25 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.12 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 107.96 -26.27 17.93 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.61 133.73 54.5 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.946 0.403 . . . . 0.0 110.065 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.3 pt -127.35 169.14 19.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.934 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.452 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 118.79 159.87 11.23 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.1 m -62.12 -46.07 90.67 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.566 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -100.68 2.14 41.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.58 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.6 m 62.85 132.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.996 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 164.91 -11.99 0.08 OUTLIER Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -100.27 112.72 64.72 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -75.74 157.76 39.57 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 C-N-CA 122.42 2.08 . . . . 0.0 112.053 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 52.5 t -120.56 130.47 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 18.1 m -90.06 98.81 11.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.183 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.34 -39.36 92.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 0.0 110.418 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 83.1 p -81.83 -6.86 59.44 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.482 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 64.99 161.07 0.56 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.6 m -114.06 104.93 12.63 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.834 0.349 . . . . 0.0 110.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 85.5 mt -63.67 -42.19 98.08 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.598 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.9 t-20 -90.73 173.31 8.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.342 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.69 33.2 0.28 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.598 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.47 -179.01 26.38 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 53.4 mmm-85 -130.46 147.37 52.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.918 0.389 . . . . 0.0 110.218 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 84.0 m -83.99 111.05 18.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.362 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.9 m -95.38 -20.54 5.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.376 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -167.62 173.82 2.71 Favored Pre-proline 0 C--N 1.326 -0.455 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -53.97 130.89 41.61 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.164 1.909 . . . . 0.0 111.95 179.252 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . 0.408 ' O ' ' OD1' ' A' ' 164' ' ' ASN . 60.5 t-20 49.74 32.33 5.13 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.084 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -137.0 129.14 29.52 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.447 0.642 . . . . 0.0 110.045 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -131.79 145.38 51.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.0 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -97.13 137.15 36.62 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.703 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . 0.549 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 44.2 m -81.75 142.79 32.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.079 0.466 . . . . 0.0 111.054 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.9 m -63.38 -45.59 90.39 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.084 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -97.89 17.23 18.65 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.106 0.479 . . . . 0.0 111.086 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.79 24.18 77.01 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.549 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 3.1 m-85 -66.01 151.49 46.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.238 0.542 . . . . 0.0 110.191 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -87.61 166.05 14.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.97 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.83 148.51 11.52 Favored Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.17 -29.06 39.98 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 122.448 2.099 . . . . 0.0 112.409 -179.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -115.12 0.89 13.74 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.604 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.784 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 120.985 0.421 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.42 165.0 22.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.655 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 70.18 172.43 10.7 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.55 -171.36 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.984 2.456 . . . . 0.0 111.794 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.576 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 62.6 m-20 58.78 38.78 24.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.081 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.451 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 7.4 p -95.53 133.72 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.288 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 60.6 m -151.22 -174.32 4.78 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.275 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.28 174.38 44.92 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.561 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.1 m -82.47 160.81 22.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.607 0.241 . . . . 0.0 110.437 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.53 -43.29 97.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.725 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -61.72 -41.15 97.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.273 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -133.61 54.66 1.94 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.649 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.11 147.54 53.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.291 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.417 ' O ' ' O ' ' A' ' 59' ' ' CYS . 11.7 p90 -153.81 170.16 21.62 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.005 0.431 . . . . 0.0 110.766 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.1 m -73.79 135.42 43.51 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -49.0 167.9 0.2 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.386 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -57.17 132.29 50.37 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.014 1.809 . . . . 0.0 111.643 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 97.14 -17.25 59.51 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.576 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 31.5 m95 -113.61 139.79 48.73 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.927 0.394 . . . . 0.0 110.363 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -125.48 -174.01 2.97 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.192 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 74.6 p -115.48 161.51 18.48 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.432 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' A' ' 77' ' ' GLY . 17.8 mt -87.62 151.68 50.72 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.468 ' C ' ' H ' ' A' ' 77' ' ' GLY . 73.1 Cg_exo -39.21 107.03 0.06 OUTLIER 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 122.235 1.957 . . . . 0.0 112.116 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 72.98 -11.17 4.88 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.01 174.48 53.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -135.28 13.49 3.53 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.06 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -84.63 129.09 34.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.503 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 63.5 m -95.2 60.45 2.33 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 37.3 pt -119.17 26.65 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.855 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.3 t -123.06 84.45 51.03 Favored Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.953 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -63.32 150.26 89.04 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.597 2.198 . . . . 0.0 111.69 179.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.9 mt -94.0 121.98 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.33 129.81 45.57 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -63.18 -45.92 89.51 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.206 0.527 . . . . 0.0 110.169 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -122.38 146.57 47.22 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -52.42 125.42 16.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.376 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.8 m -66.56 -2.03 4.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.544 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 55.59 -116.23 6.84 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.431 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 31.8 p-10 -74.91 -1.26 21.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 110.676 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.61 -164.29 19.83 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.48 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 54.9 p90 -142.84 150.97 40.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.966 0.412 . . . . 0.0 110.646 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -69.64 114.97 8.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.832 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.48 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 5.0 m -105.25 -19.03 13.93 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.586 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.4 mtt85 -157.08 162.54 27.39 Favored Pre-proline 0 N--CA 1.454 -0.263 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.737 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -50.09 122.45 9.22 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 121.95 1.767 . . . . 0.0 111.341 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 52.93 38.64 27.52 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.982 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.7 mtp -146.29 118.76 8.47 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.492 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 37.8 m -105.95 150.42 25.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.718 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' THR . . . . . 0.437 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.7 m -119.69 113.38 20.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.582 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.64 157.19 72.51 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.629 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.3 -21.19 71.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.65 2.234 . . . . 0.0 111.474 178.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -67.71 -16.59 64.21 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.727 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 105.63 -20.38 36.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -68.75 151.54 46.51 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.888 0.375 . . . . 0.0 110.528 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -131.22 135.15 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.446 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -167.26 -179.19 0.75 Allowed Pre-proline 0 C--N 1.326 -0.447 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.647 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 31.5 Cg_exo -60.29 -16.02 38.43 Favored 'Trans proline' 0 N--CA 1.499 1.806 0 C-N-CA 122.953 2.435 . . . . 0.0 111.907 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 27.8 m -160.29 159.81 31.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.756 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.23 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.467 0.424 0 CA-C-O 121.008 0.432 . . . . 0.0 110.082 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -62.6 -40.36 96.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.112 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.591 ' CG2' ' H ' ' A' ' 122' ' ' ARG . 36.1 mm -74.24 178.04 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.239 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.591 ' H ' ' CG2' ' A' ' 121' ' ' ILE . 1.0 OUTLIER -127.68 134.03 49.6 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.166 179.354 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.5 m -118.21 144.6 45.61 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtm -144.3 169.37 18.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.284 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 59.28 40.52 21.23 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.32 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 23.47 67.76 Favored Glycine 0 C--N 1.333 0.371 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.03 119.92 5.07 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 120.432 -0.89 . . . . 0.0 110.929 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.2 p -79.43 145.29 33.39 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.035 -0.266 . . . . 0.0 110.54 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.8 t -97.4 118.44 33.88 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.75 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.422 ' O ' ' N ' ' A' ' 133' ' ' HIS . 29.8 t -148.13 139.76 23.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.575 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.501 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 4.5 p-10 41.98 45.93 3.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 178.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 55.45 36.99 28.25 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.457 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.501 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 58.4 m80 -142.7 141.89 31.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.261 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . 0.467 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 81.4 m -99.93 119.82 38.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.497 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.6 mt -98.06 128.26 44.48 Favored 'General case' 0 CA--C 1.518 -0.267 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.79 134.61 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.858 -179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -72.26 -173.77 1.16 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.34 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -67.77 129.13 38.97 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.731 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.64 -9.33 55.48 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -125.46 141.54 52.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.859 0.361 . . . . 0.0 110.528 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.6 pt -132.66 173.79 14.26 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.743 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 112.61 153.54 11.74 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.0 p -63.01 -45.5 92.1 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.698 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -97.83 1.75 48.6 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.511 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 16.4 m 62.62 133.21 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.871 -179.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 161.29 -6.71 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -109.21 111.58 60.04 Favored Pre-proline 0 CA--C 1.543 0.693 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.58 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -75.64 156.77 40.23 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.517 2.145 . . . . 0.0 112.435 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 90.9 t -101.98 114.92 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.05 98.25 11.65 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.306 -179.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -65.77 -39.66 91.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.71 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 72.1 m -79.62 -7.55 58.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.84 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.46 161.69 0.05 OUTLIER Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 66.7 m -106.51 111.17 23.61 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 89.0 mt -63.18 -42.26 99.35 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.551 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.8 t30 -95.7 173.0 7.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.416 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.59 37.5 0.36 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -76.55 -172.05 34.5 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -132.21 143.46 49.96 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.872 0.367 . . . . 0.0 110.521 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.6 m -81.92 113.51 19.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.281 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.3 m -88.42 -23.69 6.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.536 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -167.5 171.99 3.81 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.511 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.45 127.96 21.93 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.711 1.607 . . . . 0.0 112.01 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.8 t30 53.93 36.7 24.97 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.715 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -141.42 132.8 26.7 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.207 0.527 . . . . 0.0 110.632 178.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 3.4 t -141.45 150.77 42.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.954 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.52 53.57 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.687 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.97 137.13 32.62 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.035 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.0 p -112.58 19.2 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.88 0.371 . . . . 0.0 111.44 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.476 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 34.3 t80 -114.49 31.75 6.42 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.725 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 79.34 15.63 79.69 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -108.26 163.22 13.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.281 0.562 . . . . 0.0 110.917 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.9 t -147.1 152.31 38.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 129.72 162.42 10.82 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.83 -22.86 36.01 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 122.721 2.281 . . . . 0.0 112.186 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -124.37 7.29 8.38 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.523 -179.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 73.2 m . . . . . 0 C--N 1.326 -0.428 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.642 -179.813 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 64.8 mt . . . . . 0 CA--C 1.516 -0.339 0 CA-C-O 120.823 0.344 . . . . 0.0 110.491 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -127.0 161.16 29.03 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.377 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.55 169.7 44.33 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.41 -176.08 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 123.009 2.473 . . . . 0.0 111.908 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 58.9 42.05 20.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.459 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 50.3 t -107.86 133.72 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' TYR . 88.8 m -142.69 -179.02 6.07 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.025 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.34 164.37 40.06 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.531 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.3 m -79.74 168.21 19.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.786 0.327 . . . . 0.0 110.394 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.7 ttt-85 -61.04 -43.23 99.2 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.502 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -62.36 -40.54 96.75 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.962 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -129.35 52.87 1.94 Allowed 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.618 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.531 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.77 142.48 54.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.352 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.406 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -154.7 165.3 36.99 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.492 179.441 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.541 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 81.9 m -71.03 137.92 49.42 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.489 -0.484 . . . . 0.0 109.782 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.459 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 27.4 m -52.9 151.77 8.06 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.106 -178.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.93 130.75 32.32 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 121.559 1.506 . . . . 0.0 112.755 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -6.95 61.4 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -119.49 137.2 53.95 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.007 0.432 . . . . 0.0 110.79 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -123.85 -177.05 3.63 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.398 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.541 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 35.8 p -131.21 172.08 12.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.35 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.49 ' O ' ' N ' ' A' ' 77' ' ' GLY . 43.1 mt -90.31 148.59 39.43 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.67 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -40.49 111.49 0.14 Allowed 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.014 1.81 . . . . 0.0 112.574 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 82.02 -16.58 21.06 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -74.76 165.0 54.72 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -129.72 8.66 5.36 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.045 0.45 . . . . 0.0 110.958 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -87.23 130.04 34.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.381 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 56.8 m -94.21 40.8 1.08 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -94.67 11.68 3.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.606 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.64 107.02 53.45 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.684 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -76.53 157.78 36.29 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.282 1.988 . . . . 0.0 112.243 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -103.12 126.18 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.063 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -100.16 127.08 46.48 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.27 -45.27 94.02 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.472 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -126.19 157.32 38.48 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.637 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -60.97 136.49 58.1 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.422 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 57.7 m -78.78 -26.03 44.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.809 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 82.68 -109.32 3.07 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 23.0 p-10 -78.87 -2.61 40.64 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.674 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.55 -160.46 16.16 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -147.73 153.15 38.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.977 0.418 . . . . 0.0 110.826 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.6 m -63.58 113.4 3.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.973 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 92.6 p -100.89 -22.91 14.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.309 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 mtp180 -158.68 161.14 28.9 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.688 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -45.91 119.47 2.9 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 121.926 1.751 . . . . 0.0 111.725 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 54.82 39.56 31.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.271 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 69.8 mmm -145.83 122.13 10.91 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.441 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 27.3 m -105.8 147.55 28.52 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.286 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 78.7 m -122.3 113.44 19.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.753 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.23 157.38 83.06 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.021 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.29 -21.67 72.97 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.837 2.358 . . . . 0.0 111.48 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 m -63.61 -33.69 76.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.555 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 123.32 -17.24 7.96 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . 0.459 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 1.2 tm0? -69.29 145.0 53.42 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.902 0.382 . . . . 0.0 110.648 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.459 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 92.0 mt -124.29 131.29 73.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.626 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.42 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -171.19 179.43 0.67 Allowed Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.416 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . 0.42 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 35.4 Cg_exo -58.95 -21.8 59.94 Favored 'Trans proline' 0 N--CA 1.498 1.793 0 C-N-CA 122.772 2.315 . . . . 0.0 111.999 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 92.7 p -151.27 164.28 36.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.333 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.573 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.2 m . . . . . 0 CA--C 1.533 0.299 0 CA-C-O 121.103 0.477 . . . . 0.0 110.756 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -63.97 -39.98 95.36 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.255 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.534 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 11.3 tt -112.17 169.7 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.188 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.676 HH21 ' CE1' ' A' ' 144' ' ' HIS . 28.5 ptt180 -83.21 118.88 23.92 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.034 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.7 143.14 50.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.64 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.573 ' N ' ' SD ' ' A' ' 124' ' ' MET . 2.1 mpp? -141.96 161.49 37.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.182 179.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 57.98 51.79 8.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.282 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.79 19.08 77.89 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.44 143.22 40.31 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.0 t -121.4 141.12 51.28 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 10.5 p -93.15 131.55 38.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.76 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.546 ' O ' ' N ' ' A' ' 132' ' ' ASP . 44.1 t -138.19 131.47 30.39 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.187 179.11 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 60.8 t0 55.31 -80.57 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.504 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.546 ' N ' ' O ' ' A' ' 130' ' ' SER . 37.7 p-10 -155.42 23.28 0.41 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.734 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.443 ' CD2' ' OD1' ' A' ' 132' ' ' ASP . 96.0 m-70 -141.79 158.05 44.27 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.519 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.96 131.73 43.46 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.154 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.3 mt -92.68 128.86 38.69 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.756 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . 0.466 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -105.96 132.59 51.87 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.694 -179.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -79.83 173.06 12.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.359 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -63.06 133.7 54.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.288 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.62 -25.84 24.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.466 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 96.5 m-85 -116.13 130.94 57.04 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 28.7 pt -129.68 178.48 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.021 -179.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 115.92 159.72 12.07 Favored Glycine 0 N--CA 1.462 0.424 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.7 p -66.12 -33.86 76.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.765 0.317 . . . . 0.0 110.546 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.676 ' CE1' HH21 ' A' ' 122' ' ' ARG . 54.7 m-70 -103.97 1.64 31.41 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.751 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.414 ' O ' ' O ' ' A' ' 144' ' ' HIS . 41.8 t 59.82 122.9 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 159.64 -23.56 0.29 Allowed Glycine 0 CA--C 1.519 0.317 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 1.1 tp-100 -76.89 118.04 69.06 Favored Pre-proline 0 CA--C 1.543 0.673 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.629 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -75.46 157.42 40.84 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.641 2.227 . . . . 0.0 112.393 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.6 t -121.11 129.8 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.445 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.1 m -92.96 98.97 11.7 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -67.07 -36.99 83.21 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.471 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.0 p -85.88 -6.4 59.09 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.93 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.94 -172.17 33.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 57.3 m -139.81 106.69 5.41 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 82.2 mt -63.45 -42.18 98.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.785 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.578 ' C ' ' H ' ' A' ' 158' ' ' GLY . 27.6 t-20 -90.56 170.28 10.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.8 35.38 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.578 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -71.77 -174.63 21.86 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -131.3 147.1 52.54 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.72 0.295 . . . . 0.0 110.812 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 3.6 t -88.12 112.87 23.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.719 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.47 -54.89 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -131.06 175.91 3.31 Favored Pre-proline 0 N--CA 1.466 0.328 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.196 -179.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.22 130.29 37.59 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 121.813 1.675 . . . . 0.0 112.023 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 66.5 t30 51.38 35.78 14.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.47 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.7 ttt85 -137.08 124.34 21.83 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.588 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.9 t -130.21 138.27 50.49 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.02 140.65 29.67 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.768 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.3 m -81.23 143.3 32.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.839 0.352 . . . . 0.0 110.158 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.1 m -63.46 -45.37 91.12 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.024 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.525 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 80.3 t80 -98.56 24.54 7.32 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.169 0.509 . . . . 0.0 110.815 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.16 24.2 70.28 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -56.27 159.57 3.46 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.88 0.371 . . . . 0.0 110.18 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 173' ' ' THR . . . . . 0.432 ' CG2' ' N ' ' A' ' 174' ' ' GLY . 89.4 m -82.26 162.42 22.33 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.198 0.523 . . . . 0.0 111.143 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 173' ' ' THR . . . 66.94 152.03 0.2 Allowed Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 179.423 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.57 -29.1 44.52 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.695 2.263 . . . . 0.0 112.056 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -78.75 -15.46 58.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.603 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 39.4 m . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.42 179.612 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.6 mt . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.877 0.37 . . . . 0.0 110.428 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.0 mtpt -128.86 160.4 32.73 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.3 0.571 . . . . 0.0 110.77 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 162.74 25.29 Favored Glycine 0 CA--C 1.528 0.904 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.08 3.08 7.35 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.704 2.269 . . . . 0.0 112.248 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.6 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 0.3 OUTLIER -112.58 61.3 0.63 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.105 0.479 . . . . 0.0 110.429 -179.654 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.9 t -109.71 129.68 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-O 121.193 0.52 . . . . 0.0 109.72 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 85.1 m -141.92 176.91 8.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.664 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 171.5 45.85 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.3 m -82.19 165.1 20.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.703 0.287 . . . . 0.0 110.457 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -60.02 -42.67 94.86 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.659 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -61.17 -41.36 96.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.006 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -132.72 54.75 1.93 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.489 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.52 142.49 56.54 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.493 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 13.6 p90 -151.45 165.89 32.77 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.186 0.517 . . . . 0.0 110.901 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 57' ' ' ASN . 1.6 t -73.59 138.42 44.89 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.436 179.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -58.42 157.97 16.3 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.859 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -60.76 137.35 72.4 Favored 'Trans proline' 0 N--CA 1.493 1.442 0 C-N-CA 121.903 1.735 . . . . 0.0 111.817 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.59 55.21 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.6 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.1 m95 -112.79 134.69 54.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 117.066 0.433 . . . . 0.0 109.84 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.8 ptpt -114.2 -175.1 2.6 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.5 p -125.4 165.94 17.49 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.67 149.19 45.66 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.721 -179.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.528 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.8 Cg_exo -44.77 123.15 4.61 Favored 'Trans proline' 0 N--CA 1.491 1.362 0 C-N-CA 121.693 1.596 . . . . 0.0 112.208 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.42 -7.56 0.9 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 179.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.77 179.48 38.48 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 46.9 p30 -138.0 11.89 2.86 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.831 0.348 . . . . 0.0 110.797 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -82.37 129.46 34.88 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 8.0 m -106.09 80.75 1.55 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.316 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.6 pt -129.69 15.88 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.651 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 t -126.77 99.77 29.01 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -77.45 163.16 30.05 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.364 2.043 . . . . 0.0 111.939 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 45.7 mm -94.99 122.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -95.71 121.39 37.38 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.74 -45.68 91.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.172 0.511 . . . . 0.0 109.766 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -112.77 137.92 50.37 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.087 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.9 m -60.56 134.35 56.99 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.958 0.409 . . . . 0.0 110.129 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 28.7 m -76.45 -31.78 58.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.182 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 66.88 -101.56 0.67 Allowed Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.437 -0.665 . . . . 0.0 111.437 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -67.54 -17.71 64.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.835 0.35 . . . . 0.0 111.004 -179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.78 -161.56 21.11 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.443 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 54.8 p90 -143.2 151.7 40.93 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.903 0.382 . . . . 0.0 111.2 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.9 t -64.49 114.14 4.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.157 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.446 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 68.2 m -103.05 -23.75 13.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.769 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.7 mtt180 -162.31 165.47 15.58 Favored Pre-proline 0 CA--C 1.531 0.248 0 C-N-CA 120.396 -0.521 . . . . 0.0 110.407 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.6 123.55 11.65 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 121.601 1.534 . . . . 0.0 111.49 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.2 t-20 51.57 40.51 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.033 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.9 mmm -147.47 114.48 6.16 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.576 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.412 ' N ' ' O ' ' A' ' 108' ' ' ALA . 35.5 m -101.28 149.28 24.18 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.323 178.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' THR . . . . . 0.446 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 63.6 m -120.97 119.68 33.25 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.706 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 157.28 60.32 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.143 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -62.7 -19.23 67.63 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.66 2.24 . . . . 0.0 111.78 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 42.0 m -69.79 -14.27 62.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.331 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.67 -20.4 39.32 Favored Glycine 0 N--CA 1.464 0.517 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -69.19 149.5 48.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.985 0.421 . . . . 0.0 110.092 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.33 133.6 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.422 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -166.55 -179.82 0.9 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.287 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . 0.422 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 32.2 Cg_exo -59.52 -20.07 55.29 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.835 2.357 . . . . 0.0 112.162 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.7 p -155.58 163.03 40.51 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.414 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.331 -0.204 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.35 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 76.9 m . . . . . 0 C--O 1.23 0.044 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -92.14 9.34 33.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.027 0.441 . . . . 0.0 110.369 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.501 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 14.8 tt -134.11 169.19 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.607 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.501 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.6 ptm180 -100.12 106.45 18.17 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.04 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.9 m -99.73 138.04 37.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.099 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 66.2 mtt -143.23 160.64 40.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.249 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.618 ' ND2' ' CD1' ' A' ' 140' ' ' TYR . 98.0 m-20 59.86 40.18 19.58 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.841 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.52 28.58 63.2 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.01 128.79 23.3 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' SER . . . . . 0.483 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 13.3 m -88.87 137.84 31.95 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 122.739 -0.271 . . . . 0.0 110.537 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 62.4 m -77.63 129.67 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.166 179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 40.9 t -143.85 136.39 27.03 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' SER . 96.5 m-20 33.75 -99.91 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.387 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -125.3 4.75 7.75 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.365 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -129.65 154.48 47.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.739 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.9 t -102.77 146.27 28.49 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.442 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.9 mt -98.61 131.26 44.94 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.155 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -97.83 134.26 41.22 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.68 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -80.67 178.23 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.707 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -66.59 133.24 49.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.283 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.54 35.08 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.618 ' CD1' ' ND2' ' A' ' 125' ' ' ASN . 92.9 m-85 -121.63 134.41 54.99 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.093 0.473 . . . . 0.0 110.531 179.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 36.6 pt -121.94 -163.84 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.357 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.4 152.93 28.95 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.9 m -63.11 -45.03 93.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.881 0.372 . . . . 0.0 110.661 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -94.73 3.17 55.36 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.876 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 33.7 t 61.4 116.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.472 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . 0.55 ' N ' HE21 ' A' ' 147' ' ' GLN . . . 173.71 -20.59 0.06 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . 0.685 HE21 ' H ' ' A' ' 147' ' ' GLN . 0.0 OUTLIER -94.68 128.92 37.94 Favored Pre-proline 0 CA--C 1.548 0.888 0 CA-C-N 117.048 0.424 . . . . 0.0 110.267 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -76.99 161.72 32.64 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.821 2.347 . . . . 0.0 111.809 178.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 54.7 t -99.15 127.9 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.3 -179.418 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -101.57 90.53 4.09 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -65.46 -43.09 91.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.519 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 85.8 p -89.15 -8.75 53.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.527 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . 0.447 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 56.82 -179.46 0.63 Allowed Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.3 m -117.73 118.78 33.0 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.1 mt -63.21 -42.25 99.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.032 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.581 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.0 t-20 -93.18 179.93 5.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.462 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.22 32.93 0.32 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.44 177.16 26.23 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 23.2 mmm180 -128.49 143.61 51.01 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.811 0.338 . . . . 0.0 110.269 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 33.8 m -83.06 113.08 20.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -101.56 -18.25 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.704 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -162.97 171.4 6.39 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.248 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -51.7 129.16 28.84 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 121.705 1.603 . . . . 0.0 111.921 179.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 50.81 34.34 10.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.734 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.5 OUTLIER -127.55 119.03 25.09 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.028 0.442 . . . . 0.0 110.175 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.523 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 26.4 m -110.8 122.66 48.39 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.075 179.555 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -88.02 135.65 33.32 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . 0.582 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 87.8 m -84.05 141.4 31.18 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.039 0.447 . . . . 0.0 110.382 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.7 m -63.24 -45.58 90.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.283 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -104.78 18.58 22.04 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.133 0.492 . . . . 0.0 110.984 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 72.19 24.8 75.86 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.53 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 91.5 t80 -54.64 143.9 23.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.883 0.373 . . . . 0.0 110.403 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 96.3 m -103.86 125.56 50.37 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.375 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -179.21 162.05 28.62 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.28 -31.4 73.82 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.67 2.247 . . . . 0.0 112.4 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -110.27 4.57 20.99 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.292 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.582 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.7 t . . . . . 0 C--N 1.33 -0.27 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.716 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 92.2 mt . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.7 mtpt -123.25 166.26 15.55 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.845 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 69.13 165.7 4.29 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.47 -166.17 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.956 2.437 . . . . 0.0 111.876 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 4.0 m120 58.64 36.14 24.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.8 p -100.46 136.56 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.031 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 60.4 m -141.41 176.9 8.5 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.994 0.426 . . . . 0.0 110.283 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.15 161.71 31.43 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.1 m -77.91 171.07 15.54 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 44.9 ttm180 -59.98 -42.91 95.19 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.852 0.358 . . . . 0.0 110.392 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -62.89 -40.45 97.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.994 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.471 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 21.2 m120 -125.67 50.52 1.82 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.578 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.92 138.27 49.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.607 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.471 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.9 p90 -158.45 165.64 34.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.106 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 79.4 m -69.2 139.08 54.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.296 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 25.7 m -54.42 146.89 30.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.095 -179.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -48.01 125.58 11.85 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 C-N-CA 121.605 1.537 . . . . 0.0 112.344 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.424 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.45 -12.89 58.4 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 88.9 m95 -114.82 134.38 55.18 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 110.213 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -125.25 -170.26 2.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.51 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 3.2 p -131.33 168.9 16.77 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.332 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.508 HD11 ' H ' ' A' ' 74' ' ' LEU . 0.0 OUTLIER -87.29 164.46 35.56 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.436 -179.21 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -53.0 125.41 18.21 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 121.875 1.717 . . . . 0.0 112.035 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.05 -0.31 11.89 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.89 174.48 35.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -140.14 7.54 2.22 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.881 0.372 . . . . 0.0 110.698 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 -83.33 131.22 35.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 54.1 m -94.27 38.53 1.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.905 0.383 . . . . 0.0 110.11 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.09 6.54 6.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.646 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.0 t -107.03 117.08 57.36 Favored Pre-proline 0 CA--C 1.537 0.446 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.913 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.73 155.71 44.24 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.418 2.079 . . . . 0.0 112.433 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.424 ' N ' ' O ' ' A' ' 70' ' ' GLY . 83.2 mt -107.34 119.12 56.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.199 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.89 113.85 26.23 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.461 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 1.8 mpt_? -62.31 -40.21 95.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.375 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -109.59 127.8 54.76 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 109.842 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.6 p -49.41 122.13 5.81 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.209 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.63 -24.24 56.42 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.919 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.72 -115.48 4.26 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -77.52 -4.46 45.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.37 175.9 36.5 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 40.2 t80 -123.17 132.57 54.11 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.221 0.534 . . . . 0.0 111.172 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . 0.479 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 3.4 m -65.57 117.57 8.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.827 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.461 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 47.1 m -104.87 -21.94 13.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.53 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 -158.44 163.15 25.26 Favored Pre-proline 0 C--N 1.331 -0.214 0 C-N-CA 120.264 -0.575 . . . . 0.0 110.748 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -48.98 120.48 5.5 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.926 1.751 . . . . 0.0 111.501 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 98' ' ' ASN . 56.3 t-20 54.69 41.47 31.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.975 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.0 mmm -146.59 115.68 6.97 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.954 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' ALA . 91.0 m -99.15 146.74 25.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.71 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' THR . . . . . 0.461 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 32.8 m -118.84 114.19 22.25 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.151 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.9 158.75 64.45 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.997 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -55.36 -28.01 60.89 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 122.749 2.299 . . . . 0.0 111.817 178.027 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.3 t -63.97 -16.6 61.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.591 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.73 -13.64 59.27 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -69.46 149.85 47.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.918 0.389 . . . . 0.0 110.039 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.4 HG21 HD12 ' A' ' 107' ' ' ILE . 95.4 mt -125.44 129.45 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.812 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.447 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -164.23 179.16 1.23 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.498 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . 0.443 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 32.4 Cg_exo -59.21 -23.39 69.27 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.824 2.349 . . . . 0.0 111.944 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 36.2 p -155.53 162.95 40.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.677 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.532 0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.365 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 5.1 m . . . . . 0 N--CA 1.464 0.267 0 CA-C-O 120.98 0.419 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -64.27 -39.79 94.66 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.216 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 19.7 tt -77.93 166.05 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.348 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -93.41 123.13 36.5 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.951 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.3 m -123.66 141.27 52.17 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.598 179.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.9 mtm -146.19 163.25 36.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.431 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.53 ' OD1' ' CE1' ' A' ' 140' ' ' TYR . 5.2 t-20 63.11 44.05 6.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.953 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.43 22.64 78.83 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.53 162.76 36.97 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.2 t -133.35 141.56 47.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.308 . . . . 0.0 110.204 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.31 123.15 36.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.77 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 25.1 t -148.45 134.34 19.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.605 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 48.46 46.77 20.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.5 t0 55.24 27.89 10.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.452 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -137.74 137.3 38.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.231 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 13.8 t -92.14 129.96 37.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.921 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 83.0 mt -113.5 143.57 44.3 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.115 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.6 m -103.99 144.51 31.44 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.54 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.19 174.55 3.83 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -66.28 131.3 45.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.578 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.57 -15.46 53.13 Favored Glycine 0 N--CA 1.467 0.762 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.53 ' CE1' ' OD1' ' A' ' 125' ' ' ASN . 86.8 m-85 -116.88 134.83 54.28 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.275 -0.269 . . . . 0.0 110.275 179.533 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.8 pt -125.37 165.36 22.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 122.35 153.47 8.87 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 20.1 m -62.22 -47.07 86.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 110.681 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -99.58 2.98 45.17 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.79 136.84 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 154.6 -9.72 0.4 Allowed Glycine 0 CA--C 1.518 0.247 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -103.19 108.57 59.32 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.324 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.82 161.61 36.13 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.711 2.274 . . . . 0.0 112.069 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.5 t -116.54 129.31 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.01 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 21.5 m -97.46 107.24 19.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -66.26 -40.16 89.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.448 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.8 m -86.36 -10.72 53.82 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 68.43 -177.47 25.46 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 22.5 m -128.91 114.14 16.1 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.0 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.6 mt -63.38 -42.13 98.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.465 ' C ' ' H ' ' A' ' 158' ' ' GLY . 98.0 m-20 -95.94 -172.36 2.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.389 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.65 38.24 1.24 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -72.55 176.38 42.29 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -130.2 148.36 52.03 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.2 m -85.05 120.18 26.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.081 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.8 m -104.01 -11.68 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.295 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -176.55 174.79 0.69 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -55.24 125.13 18.14 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.163 1.908 . . . . 0.0 111.116 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 56.15 34.66 24.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.682 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.1 mmt-85 -135.37 131.64 36.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.402 0.62 . . . . 0.0 110.624 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.48 ' O ' ' CE1' ' A' ' 172' ' ' PHE . 7.7 t -142.82 147.1 34.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.756 179.524 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -120.99 122.06 39.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.947 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.72 154.95 22.18 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.877 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.4 p -106.96 15.23 25.58 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.957 0.408 . . . . 0.0 110.836 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.414 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 23.9 t80 -119.71 32.94 5.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.933 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.46 57.52 1.64 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.779 -0.929 . . . . 0.0 110.779 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.48 ' CE1' ' O ' ' A' ' 166' ' ' CYS . 89.7 t80 -47.29 110.03 0.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.893 0.378 . . . . 0.0 110.646 -179.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 173' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 177' ' ' CYS . 91.0 m -129.16 126.86 40.17 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.22 179.272 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 64.15 166.44 1.05 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.364 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 177' ' ' CYS . 38.2 Cg_exo -55.88 -36.91 96.3 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 C-N-CA 122.75 2.3 . . . . 0.0 112.313 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -74.96 46.46 0.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.448 -179.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.44 ' O ' ' N ' ' A' ' 173' ' ' THR . 42.3 t . . . . . 0 C--N 1.325 -0.458 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.646 -179.707 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.0 mt . . . . . 0 N--CA 1.451 -0.424 0 CA-C-O 120.544 0.211 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -138.36 159.84 41.02 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 120.997 0.427 . . . . 0.0 110.69 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.42 166.1 19.31 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -77.19 -1.31 11.48 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.902 2.402 . . . . 0.0 112.281 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.61 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 78.5 m-20 -117.34 71.8 0.82 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.777 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.491 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.9 t -121.45 130.32 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 75.3 m -142.89 -174.7 4.25 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.201 -179.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.83 171.08 45.38 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.5 m -78.89 163.57 25.17 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -59.93 -42.88 94.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.555 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -61.67 -42.39 98.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -127.25 49.38 2.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.871 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.07 146.87 53.86 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.669 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -152.9 168.82 24.51 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.824 0.345 . . . . 0.0 110.949 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 91.5 m -70.51 131.32 43.84 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.188 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 62.1 m -49.35 152.37 2.21 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.076 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_exo -51.59 131.64 37.92 Favored 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 121.387 1.392 . . . . 0.0 112.459 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.84 -5.08 53.48 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.61 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 44.5 m95 -132.24 140.86 48.82 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.625 0.25 . . . . 0.0 110.455 179.314 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -115.4 -166.4 1.12 Allowed 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.005 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 76.9 p -115.87 158.21 23.3 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' A' ' 77' ' ' GLY . 18.9 mt -89.91 151.08 44.88 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.604 -179.191 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.454 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.5 Cg_exo -39.94 106.68 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.206 1.937 . . . . 0.0 112.142 179.43 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.42 -10.57 2.66 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.19 171.81 52.18 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.1 p30 -127.87 11.39 6.62 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.551 0.215 . . . . 0.0 111.117 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -89.46 139.1 30.86 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.887 -179.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.2 m -99.26 43.18 1.07 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.921 0.391 . . . . 0.0 110.018 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 43.4 pt -94.2 19.23 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.474 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.32 95.05 49.03 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -77.59 159.79 31.87 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.265 1.976 . . . . 0.0 112.221 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.59 120.67 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.498 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.07 109.37 21.34 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.485 ' HE ' HD22 ' A' ' 98' ' ' ASN . 1.1 mpt_? -64.55 -39.6 94.05 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.521 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -103.42 133.47 48.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.147 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 31.2 t -61.94 134.43 56.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.33 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 32.4 m -78.97 -28.21 43.57 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.507 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 76.19 -104.72 1.87 Allowed Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 179.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -80.04 -3.48 48.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.659 0.266 . . . . 0.0 111.083 -179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.3 -160.1 20.19 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -147.05 152.19 38.14 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.918 0.39 . . . . 0.0 111.33 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.41 115.61 5.28 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 20.7 t -109.84 -24.17 10.99 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.927 -179.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -156.14 158.43 31.58 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.095 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -52.51 125.63 18.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.043 1.829 . . . . 0.0 111.22 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.485 HD22 ' HE ' ' A' ' 86' ' ' ARG . 60.9 m-80 53.04 37.76 25.58 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.5 mtp -148.94 114.65 5.66 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-O 121.37 0.605 . . . . 0.0 110.895 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 108' ' ' ALA . 27.6 m -96.9 147.54 23.86 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.441 178.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 87.0 m -119.89 123.77 44.39 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.572 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.82 155.3 45.46 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.74 -20.03 67.53 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.332 2.021 . . . . 0.0 111.654 179.253 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.6 t -66.57 -17.04 64.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.282 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.28 -20.84 34.45 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 52.5 tp60 -67.87 150.7 48.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.839 0.352 . . . . 0.0 110.252 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.5 mt -130.54 132.56 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.858 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -169.42 177.75 1.08 Allowed Pre-proline 0 CA--C 1.536 0.433 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.28 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.32 -23.76 47.93 Favored 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 122.602 2.201 . . . . 0.0 111.911 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 30.0 p -151.79 162.23 41.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.433 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.3 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . 0.492 ' SG ' ' N ' ' A' ' 120' ' ' ASN . 34.3 t . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.767 0.318 . . . . 0.0 110.704 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . 0.492 ' N ' ' SG ' ' A' ' 119' ' ' CYS . 25.0 p-10 -95.96 10.44 37.36 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.687 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -139.31 165.46 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.785 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -77.41 98.62 5.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.75 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.2 m -111.07 119.06 37.76 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 95.9 mtp -139.82 165.26 27.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.447 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.513 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 3.7 m-20 59.92 39.61 20.06 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.702 0.287 . . . . 0.0 110.992 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.15 25.22 69.29 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.16 126.55 26.03 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' SER . . . . . 0.496 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 4.9 m -82.21 133.38 35.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.65 0.262 . . . . 0.0 110.311 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.2 t -95.05 116.92 29.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.254 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 32.4 t -139.01 143.98 38.69 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.124 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 41.67 -116.8 0.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -119.57 21.93 11.88 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -143.0 145.67 33.14 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.522 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.3 t -105.11 140.76 37.81 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.247 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.0 mt -102.33 131.84 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.022 -179.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 20.6 m -92.25 134.37 34.95 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -61.33 173.49 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . 0.417 ' HD3' ' N ' ' A' ' 138' ' ' LYS . 0.0 OUTLIER -62.95 136.18 57.7 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.368 0.604 . . . . 0.0 111.499 179.52 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 88.72 -8.61 78.91 Favored Glycine 0 CA--C 1.519 0.316 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -118.76 135.33 54.57 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.953 0.406 . . . . 0.0 110.326 179.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 48.7 pt -133.94 173.31 14.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.507 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.103 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 103.0 163.46 25.78 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.1 p -65.61 -39.68 91.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.609 0.242 . . . . 0.0 110.832 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.46 10.74 37.32 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.853 0.358 . . . . 0.0 110.461 179.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.513 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 14.7 m 45.76 41.16 7.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.037 -179.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -108.78 5.44 32.66 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -112.38 110.62 53.01 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 116.793 0.297 . . . . 0.0 110.718 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.7 161.85 27.43 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.514 2.142 . . . . 0.0 112.193 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.7 t -111.99 129.08 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.188 0.518 . . . . 0.0 109.988 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -98.71 93.1 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -68.69 -42.01 78.39 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.4 m -97.77 -10.23 25.19 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.915 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 66.43 179.48 10.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -98.12 179.18 4.85 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . 0.532 ' CD1' ' H ' ' A' ' 177' ' ' CYS . 86.0 mt -88.18 -3.54 58.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' A' ' 158' ' ' GLY . 0.1 OUTLIER -170.64 -147.21 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.403 179.723 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -73.8 30.95 0.9 Allowed Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -61.68 173.49 7.34 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 71.9 ttt-85 -114.06 123.18 49.05 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.486 0.184 . . . . 0.0 110.903 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 69.0 m -68.23 91.32 0.37 Allowed 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.12 -27.48 14.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.301 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -156.95 173.87 4.58 Favored Pre-proline 0 C--N 1.329 -0.302 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 165' ' ' ARG . 51.3 Cg_exo -52.33 136.54 55.46 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 121.588 1.525 . . . . 0.0 111.941 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 41.89 25.74 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.627 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 163' ' ' PRO . 75.0 mmt-85 -134.21 140.55 46.56 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.709 0.766 . . . . 0.0 110.984 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 28.7 p -150.37 161.17 43.01 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.517 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.85 139.09 45.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.012 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . 0.6 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 88.2 m -70.08 138.59 52.16 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-O 121.012 0.435 . . . . 0.0 110.173 -179.319 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.0 m -62.66 -46.07 89.9 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.89 -178.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -117.48 28.27 8.56 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 59.4 30.09 67.44 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.454 ' CZ ' ' SG ' ' A' ' 168' ' ' CYS . 24.5 p90 -67.54 152.37 45.76 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.644 0.259 . . . . 0.0 110.829 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 20.4 p -80.96 143.22 32.75 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.002 -179.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -178.54 158.2 22.53 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.04 -51.44 2.21 Favored 'Trans proline' 0 N--CA 1.499 1.795 0 C-N-CA 122.422 2.081 . . . . 0.0 112.92 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -80.66 -50.08 10.39 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.086 0.469 . . . . 0.0 110.534 -179.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.6 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 36.5 t . . . . . 0 CA--C 1.514 -0.43 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.383 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 29.0 mt . . . . . 0 CA--C 1.517 -0.29 0 CA-C-O 121.238 0.542 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -142.91 164.01 31.24 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.53 22.8 Favored Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.212 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -76.01 7.43 3.26 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.792 2.328 . . . . 0.0 112.187 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.459 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 80.1 m-20 -123.12 70.5 1.03 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.891 0.377 . . . . 0.0 111.087 -179.661 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.444 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 51.8 t -115.07 130.82 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 57.2 m -151.3 178.44 9.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.457 -179.673 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.3 172.23 39.98 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -81.18 163.76 22.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.63 0.253 . . . . 0.0 110.326 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 73.3 ttp85 -59.54 -43.25 93.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.685 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -62.9 -37.25 86.2 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . 0.434 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 41.9 t30 -132.51 53.75 1.99 Allowed 'General case' 0 C--O 1.23 0.078 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.906 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.543 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -72.51 142.56 48.52 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.266 179.247 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.434 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.8 p90 -159.36 171.21 20.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.4 m -67.97 135.33 52.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.153 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -48.36 168.43 0.17 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -178.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.47 133.62 58.12 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.093 1.862 . . . . 0.0 112.114 179.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 94.98 -17.19 59.78 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.459 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.8 m95 -112.79 138.18 50.0 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -122.25 -165.49 1.28 Allowed 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.2 p -126.04 164.7 20.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.202 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.528 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.6 mt -88.96 151.44 47.12 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.814 -179.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.417 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.7 Cg_exo -39.86 107.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.348 2.032 . . . . 0.0 112.121 179.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.17 -14.95 7.25 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.76 178.59 52.32 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -139.35 15.21 2.58 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 121.105 0.479 . . . . 0.0 110.7 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -80.34 131.99 35.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.262 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.93 47.89 1.11 Allowed 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.732 0.301 . . . . 0.0 110.403 -179.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.7 pt -105.71 22.38 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.758 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 t -124.45 97.78 39.05 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.725 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -78.76 157.15 27.82 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.691 2.261 . . . . 0.0 112.097 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.491 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.7 mt -109.51 118.63 57.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.963 0.411 . . . . 0.0 110.297 179.109 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 17.0 m -90.64 130.38 36.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.157 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -61.75 -45.44 93.92 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.183 0.515 . . . . 0.0 110.08 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -107.46 142.31 37.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.231 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.8 m -60.72 133.79 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.264 -179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 52.8 m -76.1 -27.84 57.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.583 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.32 -113.45 3.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -72.57 -9.1 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.887 0.375 . . . . 0.0 110.785 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.42 -166.66 29.86 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -139.81 146.25 39.17 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.09 0.472 . . . . 0.0 110.902 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 18.6 t -69.05 116.3 9.34 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.5 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 83.6 p -105.26 -22.02 13.14 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.413 -179.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . 0.467 ' CG ' HH11 ' A' ' 96' ' ' ARG . 0.1 OUTLIER -158.99 165.53 18.26 Favored Pre-proline 0 C--O 1.236 0.385 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.845 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -51.97 122.35 10.37 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 121.836 1.691 . . . . 0.0 111.581 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 53.17 39.74 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.74 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 98.0 mtp -146.86 116.85 7.26 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 121.137 0.494 . . . . 0.0 110.408 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 56.6 m -104.53 149.67 25.27 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.77 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.6 m -121.06 122.91 41.09 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.864 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.53 155.44 43.97 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.604 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -51.61 -27.67 26.48 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.574 2.182 . . . . 0.0 111.906 177.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.57 -16.28 64.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.662 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.73 -15.37 55.73 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . 0.61 ' NE2' ' N ' ' A' ' 107' ' ' ILE . 0.0 OUTLIER -67.69 143.15 56.08 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 120.826 0.346 . . . . 0.0 110.271 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.61 ' N ' ' NE2' ' A' ' 106' ' ' GLN . 96.0 mt -122.26 130.48 74.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.812 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -173.01 173.23 1.41 Allowed Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.558 179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.09 -31.34 53.82 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 122.67 2.247 . . . . 0.0 112.233 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.1 m -136.46 159.28 42.26 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.338 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 58.6 m . . . . . 0 N--CA 1.464 0.252 0 CA-C-O 121.075 0.464 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -97.41 16.01 21.4 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.501 179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.424 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 16.9 tt -118.11 166.19 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.517 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.424 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 31.7 mmt180 -89.96 99.54 12.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.441 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 59.8 m -103.71 128.99 51.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.17 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 73.8 mtm -139.72 165.55 26.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.079 -179.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 60.25 48.73 7.84 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 123.404 0.44 . . . . 0.0 111.151 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 64.72 33.12 86.38 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.75 130.76 9.9 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.3 p -91.61 142.1 27.99 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 122.747 -0.267 . . . . 0.0 110.439 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -105.11 123.18 47.37 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.891 0.377 . . . . 0.0 110.283 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 49.7 m -148.81 142.24 25.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.879 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 47.61 45.85 17.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.935 179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.452 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 99.9 m-20 55.15 29.66 13.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.452 ' ND1' ' O ' ' A' ' 132' ' ' ASP . 7.7 m-70 -139.41 145.38 38.84 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 179.528 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.2 t -99.32 119.73 38.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 68.9 mt -101.25 131.24 47.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.77 138.39 37.89 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.152 -179.128 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -64.68 177.4 0.93 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.59 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -59.03 135.4 57.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.643 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 92.39 -1.82 73.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -126.55 138.81 53.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.784 0.326 . . . . 0.0 110.329 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 42.6 pt -135.05 174.65 12.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.821 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 113.54 152.43 10.93 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.4 m -62.87 -44.83 95.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.7 0.286 . . . . 0.0 110.439 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' A' ' 145' ' ' CYS . 26.4 m80 -100.94 5.9 43.39 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.643 -179.682 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' O ' ' O ' ' A' ' 144' ' ' HIS . 39.3 m 60.32 138.78 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.072 0.463 . . . . 0.0 109.925 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 147.66 4.57 0.36 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -119.52 88.73 39.33 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-O 120.775 0.321 . . . . 0.0 110.484 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.45 160.97 15.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.97 2.447 . . . . 0.0 111.697 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 58.6 t -101.45 110.77 29.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 16.1 m -92.22 108.5 20.0 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -65.9 -40.88 91.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.467 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' SER . . . . . 0.429 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 14.2 t -83.55 -13.69 53.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.626 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 65.44 175.09 5.14 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 99.1 m -108.82 123.79 49.6 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.469 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 41.0 mt -63.96 -41.75 97.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.825 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.434 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.4 m-20 -105.03 -172.93 2.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.55 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.34 37.7 1.58 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -75.7 -172.04 31.78 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -129.84 149.71 51.46 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.657 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 59.5 m -86.36 119.31 26.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.516 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 93.8 t -83.05 -27.02 7.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.541 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -167.69 176.15 1.74 Allowed Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.586 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -56.67 135.81 72.55 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.347 2.032 . . . . 0.0 111.733 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 63.4 t30 50.59 30.82 5.1 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.428 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 90.0 mtt180 -142.74 101.06 3.79 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.402 0.62 . . . . 0.0 111.232 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 167' ' ' ALA . 14.7 t -104.52 150.71 24.37 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.157 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . 0.429 ' N ' ' SG ' ' A' ' 166' ' ' CYS . . . -132.95 123.49 26.03 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.298 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 84.6 m -101.92 132.2 47.86 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 169' ' ' THR . 0.5 OUTLIER -111.21 19.24 18.55 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.228 0.537 . . . . 0.0 110.939 -179.451 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.535 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 49.8 t80 -93.79 31.65 1.57 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.577 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.72 3.69 80.29 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -106.45 148.67 27.88 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.955 0.407 . . . . 0.0 110.547 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.0 t -138.74 154.33 48.54 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.256 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 152.39 177.43 26.05 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -65.11 -24.14 59.69 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.765 2.31 . . . . 0.0 111.897 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.429 ' OE1' ' OG ' ' A' ' 152' ' ' SER . 25.2 pt20 -127.87 -44.36 1.48 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.71 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 7.3 t . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.453 -0.311 0 CA-C-O 121.212 0.529 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -134.42 162.48 32.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.272 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.75 159.21 28.66 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -76.12 -1.34 11.32 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.882 2.388 . . . . 0.0 112.304 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -109.85 70.05 0.72 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.419 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.483 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.8 t -121.85 130.06 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 99.3 m -142.03 -172.01 3.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.99 -179.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.13 168.08 43.39 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.8 m -77.39 165.04 24.93 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 60.6 ttt85 -59.25 -43.4 92.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.676 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -62.38 -42.24 99.26 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.353 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -123.46 46.0 2.31 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.83 145.33 54.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.214 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.424 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 15.8 p90 -159.69 -174.97 4.89 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.915 0.388 . . . . 0.0 110.453 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.424 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 74.0 m -78.45 129.25 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.772 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . 0.483 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 34.5 m -47.59 153.83 0.98 Allowed Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.347 -179.199 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -52.56 132.67 46.48 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 121.431 1.42 . . . . 0.0 112.208 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.59 -22.17 39.7 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.563 ' CD1' ' N ' ' A' ' 71' ' ' TRP . 7.2 m95 -112.51 139.21 48.28 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.472 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.49 -166.83 1.16 Allowed 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.499 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.3 p -118.07 161.0 20.55 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.742 0.306 . . . . 0.0 110.349 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.562 ' CD2' ' N ' ' A' ' 74' ' ' LEU . 2.6 mm? -85.87 151.3 54.78 Favored Pre-proline 0 N--CA 1.448 -0.549 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.1 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -44.2 108.39 0.12 Allowed 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 121.718 1.612 . . . . 0.0 111.911 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.33 -8.08 27.46 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -96.37 -178.46 35.62 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -138.04 17.86 2.81 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.998 0.428 . . . . 0.0 110.884 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -79.0 128.29 33.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.39 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 19.7 m -99.18 70.41 1.77 Allowed 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.9 pt -129.96 19.69 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.106 -179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.64 87.71 27.14 Favored Pre-proline 0 N--CA 1.465 0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.371 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.35 147.3 95.89 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.691 2.261 . . . . 0.0 111.976 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.451 ' N ' ' O ' ' A' ' 70' ' ' GLY . 95.7 mt -99.12 119.9 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.027 179.08 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -90.77 127.3 36.29 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.6 -45.55 92.37 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.147 0.499 . . . . 0.0 109.774 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -122.82 152.51 40.64 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.468 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 m -59.48 135.64 57.73 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.318 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.4 m -79.15 -26.13 42.81 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.811 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -113.02 3.62 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -72.75 -8.51 55.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.797 0.332 . . . . 0.0 110.657 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.81 -168.79 25.32 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -141.75 149.75 40.86 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.959 0.409 . . . . 0.0 110.882 179.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.1 m -65.68 113.0 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.13 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.5 t -102.78 -24.01 13.75 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.122 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.0 mtt85 -153.47 164.85 19.18 Favored Pre-proline 0 C--N 1.329 -0.284 0 C-N-CA 120.414 -0.515 . . . . 0.0 110.706 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.51 119.84 6.52 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.73 1.62 . . . . 0.0 111.662 179.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.2 m120 55.51 39.66 31.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.113 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 63.9 mmm -147.86 119.96 8.28 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.129 0.49 . . . . 0.0 110.102 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -102.25 150.14 23.6 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.632 179.001 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 98.7 m -121.7 124.62 44.68 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.531 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.71 152.34 40.67 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.535 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -49.72 -24.86 10.47 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.536 2.157 . . . . 0.0 111.762 177.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -64.62 -17.57 64.13 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.589 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.63 -13.4 58.03 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -71.25 151.79 43.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.901 0.381 . . . . 0.0 110.294 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -127.93 131.21 69.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.652 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -172.65 177.84 0.74 Allowed Pre-proline 0 C--N 1.327 -0.402 0 C-N-CA 120.526 -0.469 . . . . 0.0 110.474 179.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -56.93 -23.34 50.83 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.816 2.344 . . . . 0.0 111.921 179.363 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.6 p -150.67 167.71 26.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 110.212 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.327 -0.383 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.748 -179.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.464 0.258 0 CA-C-O 120.904 0.383 . . . . 0.0 110.586 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -63.25 -40.16 96.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.498 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.559 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 14.4 tt -87.68 174.08 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 121.145 0.497 . . . . 0.0 110.077 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.559 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 10.2 ptm180 -122.28 119.27 30.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.311 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 9.0 m -124.37 157.17 35.7 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.657 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 71.5 mtm -136.09 173.6 11.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.259 -179.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 4.0 m-80 61.74 39.78 13.76 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.92 24.59 76.34 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.12 134.2 29.17 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.3 t -86.1 135.78 33.48 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.354 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 95.4 m -69.98 119.38 14.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.364 -179.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -131.36 100.62 5.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.195 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 48.79 -111.37 0.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.696 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -111.42 17.2 20.34 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.856 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -131.94 153.77 49.95 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.495 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 94.4 m -105.78 132.54 51.78 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 88.4 mt -97.91 127.21 43.71 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . 0.463 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 5.7 m -89.66 133.67 34.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.076 -179.017 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 -74.07 178.07 5.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.256 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -64.32 125.67 25.32 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.433 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.94 -18.65 45.95 Favored Glycine 0 N--CA 1.466 0.691 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -118.48 137.34 53.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.801 0.334 . . . . 0.0 110.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 18.9 pt -135.99 175.42 10.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.932 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.463 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 101.19 163.78 27.57 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 40.3 p -62.51 -42.74 99.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.817 0.341 . . . . 0.0 110.471 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.438 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -90.72 4.06 52.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.356 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.446 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 36.4 m 48.44 37.64 9.26 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.461 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . 0.438 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -105.1 7.32 43.99 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.732 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -109.4 109.08 60.26 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.67 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -77.47 160.42 32.03 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.548 2.165 . . . . 0.0 112.191 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.4 t -115.61 131.04 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 55.9 m -99.18 101.98 13.5 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.963 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.48 -61.38 2.38 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.834 0.35 . . . . 0.0 110.232 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.5 t -116.93 -4.99 11.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.755 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -78.84 -178.72 50.88 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.442 ' H ' ' CB ' ' A' ' 166' ' ' CYS . 9.4 m 45.09 48.96 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.914 0.387 . . . . 0.0 110.505 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 81.5 mt -62.88 -42.04 99.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.864 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.402 ' CG ' ' H ' ' A' ' 157' ' ' GLY . 44.4 t30 -109.88 -113.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.329 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.402 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -95.64 11.32 68.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.59 151.67 32.29 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 -179.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . 0.483 ' O ' ' SG ' ' A' ' 166' ' ' CYS . 3.2 mpt_? -102.3 136.17 42.61 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.527 0.203 . . . . 0.0 110.507 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 70.7 m -85.49 120.52 27.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.998 0.428 . . . . 0.0 111.085 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.5 t -104.01 -29.17 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.343 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -161.44 169.18 10.12 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.457 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -49.87 127.98 20.53 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.093 1.862 . . . . 0.0 111.874 178.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 54.74 32.26 17.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.967 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.1 tpt85 -139.24 131.57 28.39 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-O 121.213 0.53 . . . . 0.0 110.231 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 159' ' ' ARG . 1.8 t -145.25 154.43 42.37 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.217 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -98.42 138.67 35.32 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.698 179.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 20.9 m -75.3 143.77 42.78 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.392 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.3 m -62.99 -45.47 92.28 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.741 -179.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -104.21 19.51 20.04 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 121.01 0.433 . . . . 0.0 110.861 -179.4 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.57 26.58 72.83 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 177' ' ' CYS . 2.2 t80 -56.66 169.79 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.927 0.394 . . . . 0.0 110.258 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 43.9 p -98.09 164.27 12.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.466 0.65 . . . . 0.0 110.518 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 79.09 144.08 2.74 Favored Glycine 0 CA--C 1.54 1.636 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.173 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -52.92 -39.45 78.59 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.506 2.137 . . . . 0.0 112.386 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -74.85 -9.71 58.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.663 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.42 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 91.9 m . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.608 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.923 0.392 . . . . 0.0 110.718 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -126.82 161.72 27.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.465 0.65 . . . . 0.0 110.616 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.05 167.44 15.95 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.73 -168.24 0.35 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 123.029 2.486 . . . . 0.0 111.7 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.517 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 98.4 m-20 57.19 36.91 28.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.711 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.04 137.74 24.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.403 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 34.2 m -138.98 178.96 6.78 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.001 0.429 . . . . 0.0 110.232 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.06 164.13 31.62 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 65' ' ' ALA . 7.8 m -83.38 173.83 11.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.682 0.277 . . . . 0.0 110.561 179.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -61.85 -42.84 99.54 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.888 0.375 . . . . 0.0 110.518 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -62.78 -38.94 92.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.896 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -132.98 55.85 1.88 Allowed 'General case' 0 N--CA 1.457 -0.113 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.652 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.534 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.82 145.45 50.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.47 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -159.12 166.37 31.71 Favored 'General case' 0 CA--C 1.519 -0.221 0 CA-C-O 121.054 0.454 . . . . 0.0 110.995 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 75.0 m -72.04 142.03 49.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.187 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 63.8 m -58.67 150.09 59.34 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.814 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -56.05 119.44 6.61 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.17 1.913 . . . . 0.0 112.357 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 116.72 -14.82 14.5 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.517 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.0 m95 -119.55 132.73 55.81 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.109 0.481 . . . . 0.0 110.412 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -111.86 -177.04 3.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.292 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.539 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 51.2 p -130.63 166.34 20.89 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.515 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 87.6 mt -90.2 151.75 45.12 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.443 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.2 Cg_exo -47.52 128.44 15.2 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 121.51 1.473 . . . . 0.0 112.212 178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.74 -5.82 7.12 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 179.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -91.87 171.95 34.95 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 77' ' ' GLY . 96.3 m-20 -140.57 8.79 2.19 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.955 0.407 . . . . 0.0 110.992 179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -86.67 129.29 34.92 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.435 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 18.4 m -92.86 46.23 1.22 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.856 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 45.2 pt -98.01 -4.45 9.68 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.528 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.8 t -97.64 111.59 59.13 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.498 -0.481 . . . . 0.0 111.13 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.88 159.5 41.68 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.306 2.004 . . . . 0.0 111.962 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.41 HD11 HG23 ' A' ' 84' ' ' ILE . 93.4 mt -98.83 121.67 49.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.34 122.66 34.14 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.6 -45.32 87.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.372 0.606 . . . . 0.0 109.551 179.462 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 74.5 m-70 -137.17 149.46 47.27 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.646 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.5 p -52.3 128.87 26.6 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.361 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.5 m -72.31 -31.84 66.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.83 -112.81 3.54 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -70.42 -6.58 36.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.635 0.255 . . . . 0.0 110.496 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.07 -162.93 21.1 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.88 152.81 39.31 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.998 0.428 . . . . 0.0 110.772 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.77 113.92 5.93 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 36.9 t -106.5 -23.27 12.54 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.254 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -156.82 162.02 28.41 Favored Pre-proline 0 C--N 1.327 -0.378 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.542 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_exo -48.4 119.27 3.93 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 121.907 1.738 . . . . 0.0 111.331 179.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 54.33 40.58 31.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 83.4 mmm -146.84 115.04 6.61 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.484 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -96.72 145.88 25.39 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.148 178.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 61.0 m -119.99 114.39 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.771 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.57 157.63 74.53 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.71 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.43 -19.27 67.65 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.946 2.431 . . . . 0.0 111.352 178.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -69.41 -17.02 63.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.862 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 108.35 -21.79 28.05 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -65.98 150.89 47.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.086 0.47 . . . . 0.0 110.218 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.89 131.62 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.999 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -169.02 178.29 1.02 Allowed Pre-proline 0 C--N 1.325 -0.478 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.578 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -57.06 -23.79 54.44 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.771 2.314 . . . . 0.0 111.639 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.1 p -151.02 163.26 39.16 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.962 0.41 . . . . 0.0 110.291 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.302 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 120.931 0.396 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -93.63 4.06 54.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.324 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.465 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.6 tt -132.52 168.48 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.332 179.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.465 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.5 ptm180 -100.95 118.13 36.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.201 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . 0.445 ' C ' ' SD ' ' A' ' 124' ' ' MET . 61.7 m -116.17 138.58 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.689 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' MET . . . . . 0.531 ' SD ' ' N ' ' A' ' 124' ' ' MET . 3.2 mpp? -142.56 165.69 26.7 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.474 -179.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 59.15 51.22 7.18 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.454 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 70.84 26.16 74.48 Favored Glycine 0 C--N 1.331 0.27 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.81 114.49 3.92 Favored Glycine 0 CA--C 1.53 0.983 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 30.6 t -79.49 148.21 31.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.511 0.196 . . . . 0.0 110.976 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.4 m -92.38 102.83 15.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.185 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 35.1 t -149.04 138.59 21.77 Favored 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.498 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 98.5 m-20 51.72 36.57 17.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.788 0.328 . . . . 0.0 110.994 179.375 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 54.19 27.91 8.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.682 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.498 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 44.2 m80 -136.34 143.09 43.93 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.961 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 120.44 31.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.093 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.68 120.02 37.3 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.22 137.6 32.21 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.642 -178.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.3 -174.1 0.62 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.021 0.439 . . . . 0.0 110.39 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 48.6 tttp -67.82 132.26 47.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 97.78 -7.88 63.31 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -122.1 137.95 54.63 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.866 0.365 . . . . 0.0 110.447 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.5 pt -138.11 -176.62 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.084 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 116.01 162.77 13.33 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.577 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 49.5 p -60.71 -45.04 95.74 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.409 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 12.2 m80 -120.64 27.53 8.49 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.59 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 5.8 m 58.05 118.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.086 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.85 5.36 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 55.4 tp60 -132.51 114.9 14.62 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 120.894 -0.323 . . . . 0.0 110.596 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.35 158.59 40.75 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.772 2.315 . . . . 0.0 112.095 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.49 131.16 39.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.93 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 88.36 2.79 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.085 0.469 . . . . 0.0 109.85 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -59.02 -61.92 2.28 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.472 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 153' ' ' GLY . 97.3 p -117.95 -3.5 11.15 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.527 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 152' ' ' SER . . . -58.98 -152.42 0.01 OUTLIER Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.599 ' N ' ' SG ' ' A' ' 166' ' ' CYS . 73.5 m -68.88 126.39 29.63 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.758 0.314 . . . . 0.0 110.202 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.11 -42.93 99.65 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 -169.79 -25.93 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.66 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -60.16 -43.4 98.41 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.64 179.14 32.92 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.5 ttp180 -110.55 131.05 55.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.781 0.324 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 61.4 m -83.24 122.93 29.06 Favored 'General case' 0 CA--C 1.52 -0.175 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.079 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.8 m -104.12 -18.35 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -162.61 172.81 5.0 Favored Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.622 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.73 127.49 25.7 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 121.925 1.75 . . . . 0.0 111.687 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 51.88 34.26 13.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.255 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -140.75 134.7 30.64 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.391 0.615 . . . . 0.0 110.39 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.599 ' SG ' ' N ' ' A' ' 154' ' ' CYS . 11.9 p -154.94 166.9 32.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.039 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -122.03 142.76 50.01 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.059 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . 0.422 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 87.5 m -78.08 124.12 27.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.418 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.7 m -64.55 -46.25 83.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.575 -179.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -107.71 16.18 23.9 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.349 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 69.54 27.9 72.94 Favored Glycine 0 C--N 1.31 -0.872 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.516 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 13.9 m-85 -64.63 139.82 58.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.345 0.593 . . . . 0.0 110.045 -179.461 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -82.93 167.67 17.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.008 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.25 151.56 13.14 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -67.29 -24.15 44.0 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.628 2.219 . . . . 0.0 112.133 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.44 ' O ' ' O ' ' A' ' 177' ' ' CYS . 74.1 mt-30 -104.91 -7.99 18.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.577 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.516 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 2.6 t . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.197 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.4 mt . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 121.12 0.486 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -127.37 158.7 36.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.008 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.61 152.87 15.98 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.04 11.96 1.08 Allowed 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 122.67 2.246 . . . . 0.0 112.438 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -125.14 52.12 1.62 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.075 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.45 133.05 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 99.2 m -144.56 175.49 10.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 169.61 44.76 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.56 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.5 m -73.83 160.86 30.85 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.2 ttm-85 -59.28 -43.7 92.52 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.646 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -61.75 -43.53 98.67 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.899 -0.321 . . . . 0.0 111.395 -179.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -125.35 47.86 2.12 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.537 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.32 142.82 58.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.603 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 24.3 p90 -152.04 168.14 26.19 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 121.279 0.562 . . . . 0.0 110.437 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.5 t -71.56 139.0 49.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.208 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 159.49 19.37 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -60.29 135.01 58.99 Favored 'Trans proline' 0 N--CA 1.497 1.707 0 C-N-CA 122.131 1.887 . . . . 0.0 111.627 179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.15 -23.5 34.26 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -114.32 135.93 53.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.732 0.266 . . . . 0.0 110.284 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -121.09 -174.04 2.74 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.159 179.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 70.8 p -124.1 163.49 21.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 0.0 110.183 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.432 ' O ' ' N ' ' A' ' 77' ' ' GLY . 86.1 mt -83.52 149.86 58.62 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.781 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.435 ' C ' ' H ' ' A' ' 77' ' ' GLY . 76.0 Cg_exo -42.62 117.49 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.288 0 C-N-CA 121.734 1.623 . . . . 0.0 112.371 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.72 -3.96 5.9 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 179.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -91.76 175.1 38.37 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -134.68 8.28 3.57 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.646 0.26 . . . . 0.0 110.926 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -82.35 129.26 34.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.826 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 9.9 m -103.53 78.6 1.6 Allowed 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.538 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.7 pt -130.98 20.03 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -120.73 103.16 43.81 Favored Pre-proline 0 CA--C 1.537 0.479 0 CA-C-N 116.811 -0.177 . . . . 0.0 110.624 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.15 160.34 29.81 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 C-N-CA 122.165 1.91 . . . . 0.0 112.266 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 92.6 mt -105.82 127.39 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.413 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 100' ' ' CYS . 4.9 m -91.3 136.26 33.23 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.804 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.427 ' NH1' ' NE2' ' A' ' 87' ' ' HIS . 0.0 OUTLIER -61.83 -44.87 95.98 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.401 -179.725 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . 0.427 ' NE2' ' NH1' ' A' ' 86' ' ' ARG . 96.1 m-70 -110.82 152.74 26.3 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.391 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -53.92 131.18 39.7 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.65 -33.08 53.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.039 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.06 -105.85 1.79 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -92.69 0.83 57.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.882 0.372 . . . . 0.0 110.573 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -98.27 172.05 26.16 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . 0.461 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 24.2 t80 -122.26 130.52 53.24 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.848 0.356 . . . . 0.0 110.943 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . 0.461 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 1.7 t -64.19 119.18 9.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.835 179.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 73.3 p -104.8 -19.14 14.0 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.478 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -162.03 164.88 16.86 Favored Pre-proline 0 CA--C 1.533 0.309 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.849 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -53.0 128.29 28.35 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 121.412 1.408 . . . . 0.0 111.041 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.433 ' OD1' ' N ' ' A' ' 98' ' ' ASN . 1.2 m-20 51.46 37.97 20.76 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.718 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.1 mtp -147.75 108.95 4.27 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.218 0.532 . . . . 0.0 110.305 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 0.8 OUTLIER -97.13 149.05 22.41 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.606 179.266 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.1 m -120.5 122.8 41.44 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.54 158.98 35.89 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.488 -178.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -55.84 -26.82 59.37 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.496 2.131 . . . . 0.0 112.245 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.1 t -64.09 -17.43 63.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.575 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.43 -17.44 50.76 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -67.37 153.73 42.99 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.981 0.419 . . . . 0.0 110.124 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 90.0 mt -126.83 128.26 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.398 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . 0.527 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -165.63 162.88 13.12 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.934 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -52.36 -15.93 4.44 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.955 2.436 . . . . 0.0 112.165 179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 97.2 p -155.51 159.39 39.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.28 179.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.06 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 7.4 m . . . . . 0 N--CA 1.465 0.304 0 CA-C-O 120.907 0.385 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -96.6 10.54 38.21 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.417 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 10.9 tp -125.44 156.96 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.521 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 12.6 mtt180 -106.91 120.19 41.38 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.542 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 12.0 m -121.11 142.5 49.8 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -143.25 169.61 17.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.108 -179.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 67.6 m-80 58.81 41.76 21.04 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.549 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.44 18.33 76.15 Favored Glycine 0 CA--C 1.517 0.205 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.88 121.56 6.32 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.2 t -79.85 140.43 36.8 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.5 t -91.54 124.4 35.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.136 179.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 132' ' ' ASP . 31.8 t -141.75 143.04 33.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.213 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 41.14 -92.37 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 130' ' ' SER . 39.5 p-10 -146.5 23.68 1.27 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.755 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -138.53 148.36 44.16 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.445 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 84.3 m -96.49 128.69 43.66 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.107 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.6 mt -92.69 126.13 37.64 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 16.7 m -89.33 127.5 35.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.58 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.75 174.89 4.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.343 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -63.42 127.01 29.39 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.091 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.37 -13.84 54.67 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 -179.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -121.59 136.44 54.95 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.931 0.396 . . . . 0.0 110.42 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -133.58 172.76 15.81 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.214 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 102.8 163.34 25.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' THR . . . . . 0.412 ' HG1' ' H ' ' A' ' 144' ' ' HIS . 24.0 p -62.42 -43.84 97.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.749 0.309 . . . . 0.0 110.631 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . 0.412 ' H ' ' HG1' ' A' ' 143' ' ' THR . 2.2 p-80 -94.77 10.75 33.96 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.096 0.474 . . . . 0.0 110.468 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 12.4 m 46.85 36.59 4.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.101 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -99.74 8.46 59.83 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 32.7 tt0 -116.08 112.77 41.97 Favored Pre-proline 0 CA--C 1.548 0.898 0 CA-C-N 116.76 0.28 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -78.39 159.6 29.23 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.441 2.094 . . . . 0.0 112.273 179.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.5 t -113.56 127.74 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 121.016 0.436 . . . . 0.0 110.142 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 2.2 m -100.05 98.18 8.95 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -62.88 -51.67 66.07 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.339 -178.375 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 79.3 p -118.37 -9.45 10.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.896 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -79.74 171.82 54.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 150' ' ' CYS . 17.9 m 57.08 59.99 3.18 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.885 0.374 . . . . 0.0 110.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . 0.405 ' CD1' ' N ' ' A' ' 155' ' ' LEU . 10.9 mp -62.93 -42.19 99.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.752 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' A' ' 157' ' ' GLY . 24.9 t-20 -121.5 -112.69 0.32 Allowed 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.994 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.527 ' N ' ' OD1' ' A' ' 156' ' ' ASN . . . -84.6 3.49 86.52 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -54.75 148.3 23.01 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . 0.479 ' C ' ' SG ' ' A' ' 166' ' ' CYS . 17.8 tpt180 -102.66 131.31 49.54 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.775 0.322 . . . . 0.0 110.451 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 4.8 t -76.04 100.3 4.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.088 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.5 t -76.91 -43.82 32.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.768 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -151.02 175.03 3.07 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.979 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -51.73 130.06 32.43 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 121.605 1.537 . . . . 0.0 112.385 179.322 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.0 m-20 52.43 32.02 10.61 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.372 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . 0.442 ' O ' ' SG ' ' A' ' 150' ' ' CYS . 74.2 mtm180 -141.6 136.33 30.92 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.473 0.654 . . . . 0.0 110.921 179.212 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . 0.479 ' SG ' ' C ' ' A' ' 159' ' ' ARG . 1.7 t -144.35 156.22 44.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.994 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.37 143.5 42.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.69 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 76.0 m -72.21 127.44 32.55 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.232 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 98.7 m -63.37 -46.12 87.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.458 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . 0.537 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 74.7 t80 -110.54 27.95 9.14 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.992 0.425 . . . . 0.0 111.327 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.46 25.51 63.06 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . 0.462 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 66.8 t80 -63.53 131.76 49.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.421 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 173' ' ' THR . . . . . 0.439 ' O ' ' CE2' ' A' ' 172' ' ' PHE . 68.0 p -82.52 163.43 21.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.144 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 144.38 160.44 8.49 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . 0.424 ' O ' ' OE1' ' A' ' 176' ' ' GLN . 36.2 Cg_endo -63.51 -31.9 70.9 Favored 'Trans proline' 0 N--CA 1.496 1.671 0 C-N-CA 122.578 2.185 . . . . 0.0 112.4 -179.701 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . 0.424 ' OE1' ' O ' ' A' ' 175' ' ' PRO . 1.9 mp0 -131.4 8.66 4.65 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.201 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 1.8 t . . . . . 0 C--N 1.326 -0.415 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.267 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.2 mt . . . . . 0 N--CA 1.451 -0.385 0 CA-C-O 121.019 0.438 . . . . 0.0 110.725 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -137.17 159.84 40.73 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.15 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.38 163.24 24.51 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.75 -5.87 17.42 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 123.089 2.526 . . . . 0.0 112.263 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . 0.604 ' ND2' ' CD2' ' A' ' 71' ' ' TRP . 78.9 m-20 -103.59 68.32 0.93 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.56 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.9 t -119.96 129.41 75.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.838 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.2 m -134.76 173.6 11.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.002 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.92 164.65 37.44 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' ALA . 12.5 m -80.1 173.25 12.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -60.38 -42.82 96.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -62.16 -41.75 98.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -125.58 49.55 1.91 Allowed 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.747 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.21 140.44 52.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.304 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -155.3 165.71 35.8 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.978 0.418 . . . . 0.0 110.878 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 5.8 m -72.89 135.0 45.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.089 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 35.1 m -55.81 149.84 30.46 Favored Pre-proline 0 C--N 1.323 -0.577 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.213 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -56.23 134.98 67.56 Favored 'Trans proline' 0 N--CA 1.498 1.791 0 C-N-CA 121.498 1.465 . . . . 0.0 112.234 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.95 -14.95 52.31 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.604 ' CD2' ' ND2' ' A' ' 57' ' ' ASN . 85.4 m95 -115.92 134.99 54.41 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.758 0.314 . . . . 0.0 110.372 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 80' ' ' CYS . 17.4 ptpt -110.14 -175.95 2.87 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.333 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 41.4 p -123.09 161.19 24.85 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . 0.576 ' CD2' ' N ' ' A' ' 74' ' ' LEU . 2.7 mm? -84.53 149.04 53.67 Favored Pre-proline 0 N--CA 1.449 -0.48 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.158 -179.534 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -46.23 112.59 0.47 Allowed 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.591 1.528 . . . . 0.0 112.236 179.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.15 -6.48 28.16 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.99 174.77 36.04 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -129.04 0.58 5.25 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.816 0.341 . . . . 0.0 110.643 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.2 mt-30 -78.84 134.4 36.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.688 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . 0.445 ' SG ' ' O ' ' A' ' 72' ' ' LYS . 1.5 m -115.0 79.03 1.22 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.164 0.507 . . . . 0.0 110.189 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.3 pt -120.74 14.59 6.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.657 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 t -117.55 107.01 45.46 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 121.273 -0.171 . . . . 0.0 110.796 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.14 159.97 33.33 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.21 1.94 . . . . 0.0 111.987 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.5 mt -99.54 123.17 52.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.85 125.31 35.7 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . 0.426 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.9 OUTLIER -63.32 -45.77 89.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.27 0.557 . . . . 0.0 109.932 179.657 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -121.73 143.5 49.33 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.462 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -53.1 128.29 27.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.424 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.7 m -71.33 -27.87 63.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.573 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.45 -116.33 4.89 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -70.38 -8.73 52.96 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.737 0.304 . . . . 0.0 110.925 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.54 -164.81 25.34 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -142.65 150.38 40.14 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.995 0.426 . . . . 0.0 110.788 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.7 m -69.53 116.96 10.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.568 -179.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.3 t -104.11 -20.78 13.71 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.322 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.0 mtt85 -160.76 167.99 12.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.56 123.3 13.0 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.613 1.542 . . . . 0.0 111.143 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . 0.426 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.1 t-20 52.26 40.35 28.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.088 -179.58 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.2 mtp -146.95 115.72 6.81 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.362 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 58.0 m -102.07 148.08 25.82 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.438 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 84.1 m -121.47 117.73 27.58 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.971 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -84.38 157.84 61.35 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.801 179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.64 -22.24 73.96 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.743 2.296 . . . . 0.0 111.828 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.4 t -66.28 -16.62 64.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.19 -19.02 38.29 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.0 tp60 -65.19 149.1 50.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.011 0.434 . . . . 0.0 110.427 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.09 131.63 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.828 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -172.36 172.43 1.78 Allowed Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.471 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -48.82 -23.63 6.04 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.454 2.103 . . . . 0.0 111.992 178.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.0 p -153.6 165.47 35.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.251 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.246 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.1 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -64.01 -40.56 96.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.461 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.457 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.5 tt -80.18 166.26 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.229 179.689 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.457 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 20.3 mmm180 -98.75 98.07 9.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.775 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 87.4 m -92.98 134.47 35.08 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.88 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 72.6 mtm -145.31 165.07 29.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.86 39.9 19.94 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.039 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.56 24.78 69.41 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.97 128.24 22.81 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' SER . . . . . 0.498 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 17.3 m -86.24 137.68 32.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.661 0.267 . . . . 0.0 110.494 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.56 129.93 34.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.514 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.45 ' O ' ' O ' ' A' ' 133' ' ' HIS . 52.3 p -146.58 109.66 4.7 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.165 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 50.12 -116.52 0.93 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.516 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . 0.432 ' N ' ' OD1' ' A' ' 132' ' ' ASP . 32.4 p-10 -106.95 9.29 30.75 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.885 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 130' ' ' SER . 69.2 m80 -131.15 153.02 49.84 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.95 0.405 . . . . 0.0 110.798 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.4 t -114.62 145.06 42.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.293 179.779 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.9 mt -100.8 129.96 46.75 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.676 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 10.5 m -96.34 139.22 32.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.455 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.55 179.15 0.85 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.533 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -67.33 129.71 40.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.613 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 98.07 -10.77 63.92 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -117.34 133.8 55.56 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.9 0.381 . . . . 0.0 110.638 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 45.8 pt -131.95 170.36 20.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.315 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 106.37 164.41 22.77 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.5 m -63.26 -45.52 91.15 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.449 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -97.52 5.24 49.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.902 0.382 . . . . 0.0 110.682 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 6.0 m 59.87 37.25 21.79 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.123 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -98.88 5.72 59.86 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -119.65 107.09 41.09 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.679 0.239 . . . . 0.0 110.535 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.73 163.5 23.72 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.564 2.176 . . . . 0.0 111.911 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.2 t -106.15 126.3 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 121.158 0.504 . . . . 0.0 109.918 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.88 92.71 7.54 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -63.61 -46.53 85.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.761 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' SER . . . . . 0.533 ' OG ' ' ND2' ' A' ' 164' ' ' ASN . 9.9 m -89.93 -11.93 40.32 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.861 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.12 161.29 1.28 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.2 m -104.23 145.29 30.43 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . 0.425 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 4.3 mp -62.95 -43.42 98.84 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.13 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 m-20 165.4 -58.38 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.352 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.53 -37.95 95.01 Favored Glycine 0 CA--C 1.517 0.164 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.35 159.86 50.5 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -127.43 145.91 50.66 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.725 0.297 . . . . 0.0 110.81 179.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 60.2 m -73.2 104.68 4.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.616 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 70.2 t -106.49 -13.04 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.354 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -166.18 177.76 1.45 Allowed Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 120.369 -0.532 . . . . 0.0 110.341 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.64 128.44 30.35 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 121.896 1.731 . . . . 0.0 111.539 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . 0.533 ' ND2' ' OG ' ' A' ' 152' ' ' SER . 2.8 t-20 43.23 38.7 1.71 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.9 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -131.37 127.07 36.82 Favored 'General case' 0 C--O 1.24 0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 110.53 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 94.3 m -117.79 118.81 33.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.846 179.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -77.96 92.34 4.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.927 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.75 129.46 55.37 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.501 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 169' ' ' THR . . . . . 0.434 ' O ' ' OG1' ' A' ' 169' ' ' THR . 1.2 t -114.01 24.79 11.71 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.295 179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -100.86 29.02 4.79 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.011 0.434 . . . . 0.0 110.945 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.98 28.71 73.89 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -50.41 163.24 0.18 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.769 0.319 . . . . 0.0 110.476 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -130.02 131.65 45.93 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.308 179.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 80.19 176.95 50.42 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -78.38 -10.7 16.1 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.809 2.339 . . . . 0.0 112.03 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -83.45 6.32 20.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.846 -178.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . 0.515 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 50.3 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.624 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 87.5 mt . . . . . 0 N--CA 1.452 -0.351 0 CA-C-O 120.897 0.379 . . . . 0.0 110.331 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -135.85 165.87 24.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.784 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.69 168.63 9.92 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.26 -172.49 0.89 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 122.938 2.425 . . . . 0.0 111.805 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 57.48 42.14 24.95 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.094 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.93 133.24 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.91 0.386 . . . . 0.0 110.101 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 m -140.12 175.88 9.22 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.425 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.94 160.18 26.05 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 65' ' ' ALA . 14.9 m -81.21 174.79 11.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.319 . . . . 0.0 110.398 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.4 ttt85 -60.59 -43.15 97.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.599 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -62.05 -39.12 91.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.917 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -131.84 53.57 1.99 Allowed 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.11 139.96 52.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.391 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -154.18 169.7 22.97 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.088 0.471 . . . . 0.0 110.641 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' CYS . . . . . 0.407 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 73.2 m -79.45 136.29 36.9 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 38.6 m -52.99 154.97 4.65 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.246 -178.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.84 132.51 42.3 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.103 1.202 . . . . 0.0 112.785 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.69 -7.27 57.61 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' TRP . . . . . 0.534 ' CD1' ' N ' ' A' ' 71' ' ' TRP . 9.5 m95 -132.02 143.08 49.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.519 179.352 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -127.72 -166.08 1.57 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' THR . . . . . 0.407 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.3 p -123.49 164.76 18.31 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -108.4 156.56 38.39 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.206 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PRO . . . . . 0.492 ' C ' ' H ' ' A' ' 77' ' ' GLY . 46.7 Cg_exo -52.88 138.66 60.82 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 121.379 1.386 . . . . 0.0 111.808 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.38 -38.08 0.34 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' GLY . . . . . 0.492 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -82.7 169.83 49.34 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.0 p30 -136.48 16.06 3.17 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.611 -0.294 . . . . 0.0 110.88 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -87.6 133.7 33.76 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.781 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 62.6 m -86.28 42.69 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.5 pt -94.02 26.45 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.253 -179.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.91 94.18 47.61 Favored Pre-proline 0 N--CA 1.466 0.37 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.76 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -79.48 161.26 25.39 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.198 1.932 . . . . 0.0 112.182 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' ILE . . . . . 0.426 HD11 HG21 ' A' ' 84' ' ' ILE . 96.6 mt -100.47 127.86 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.4 131.37 43.03 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.09 -45.88 86.73 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-O 121.177 0.513 . . . . 0.0 110.256 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -127.18 174.0 9.27 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.97 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 p -63.84 146.08 54.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.405 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 1.4 m -88.56 -32.4 18.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.53 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.29 -107.99 2.56 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -92.93 3.63 55.38 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.556 0.217 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.06 -161.67 17.45 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -146.94 152.18 38.23 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.985 0.421 . . . . 0.0 110.98 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.6 m -69.65 115.6 9.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.131 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 95' ' ' SER . . . . . 0.492 ' CB ' ' HG1' ' A' ' 101' ' ' THR . 85.6 p -103.82 -17.35 15.09 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.952 -179.099 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtp85 -159.74 163.6 22.4 Favored Pre-proline 0 CA--C 1.532 0.285 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.068 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -51.99 127.09 22.07 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.565 1.51 . . . . 0.0 111.034 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 49.62 36.5 10.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.88 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 38.1 mtt -147.6 122.31 9.88 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.36 0.6 . . . . 0.0 111.048 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 20.2 t -108.17 149.45 28.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.474 179.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 101' ' ' THR . . . . . 0.492 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 99.8 m -121.38 124.72 45.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.79 179.423 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -93.73 157.78 37.66 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.543 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.04 -20.44 69.67 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.551 2.167 . . . . 0.0 111.766 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 t -68.05 -22.85 64.93 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.601 178.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 113.88 -22.94 13.7 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 106' ' ' GLN . . . . . 0.468 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 8.1 tm0? -63.44 146.25 53.99 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.212 0.53 . . . . 0.0 110.362 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 107' ' ' ILE . . . . . 0.468 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 96.7 mt -129.89 133.78 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.402 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -178.64 171.61 0.71 Allowed Pre-proline 0 CA--C 1.535 0.392 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -50.35 -25.77 14.46 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 122.645 2.23 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.7 p -140.75 161.99 36.48 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.239 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.324 -0.501 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.684 -179.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 64.5 m . . . . . 0 N--CA 1.469 0.495 0 CA-C-O 120.908 0.385 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 120' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' A' ' 120' ' ' ASN . 53.5 t-20 -63.58 -40.43 96.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.658 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 121' ' ' ILE . . . . . 0.416 ' CG2' ' H ' ' A' ' 122' ' ' ARG . 15.6 mm -82.71 174.33 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.956 -179.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 122' ' ' ARG . . . . . 0.416 ' H ' ' CG2' ' A' ' 121' ' ' ILE . 27.2 ptt180 -106.02 114.08 28.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.544 0.688 . . . . 0.0 110.534 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 94.2 m -124.26 148.03 47.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.263 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.2 mtm -142.27 174.24 10.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.916 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 10.8 m120 60.88 44.93 10.2 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.119 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.29 26.17 71.53 Favored Glycine 0 CA--C 1.518 0.261 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -66.52 156.66 50.78 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 28.3 t -109.62 134.51 51.86 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-O 121.05 0.452 . . . . 0.0 110.373 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 15.5 m -80.94 132.1 35.38 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 130' ' ' SER . . . . . 0.501 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.1 m -123.56 158.41 31.46 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.486 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 131' ' ' ASP . . . . . 0.501 ' C ' ' O ' ' A' ' 130' ' ' SER . 99.6 m-20 -12.01 -77.5 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 O-C-N 123.899 0.75 . . . . 0.0 112.725 -179.562 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -136.21 29.74 3.03 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.397 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -139.89 159.08 42.98 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.782 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 40.7 t -104.64 122.37 45.49 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.035 179.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 135' ' ' LEU . . . . . 0.468 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 3.5 mm? -98.18 127.19 43.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.081 0.467 . . . . 0.0 110.169 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 61.1 m -106.98 140.43 39.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.807 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -76.8 168.94 19.21 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.32 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 56.1 tptt -64.71 133.31 51.85 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 108.76 -26.41 15.95 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 140' ' ' TYR . . . . . 0.437 ' HH ' ' CD ' ' A' ' 163' ' ' PRO . 93.7 m-85 -116.61 133.58 55.84 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 120.898 0.38 . . . . 0.0 110.67 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.6 pt -131.04 170.76 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.936 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.61 157.62 10.36 Favored Glycine 0 N--CA 1.464 0.565 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.6 p -64.07 -42.69 96.89 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.869 0.366 . . . . 0.0 110.602 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.21 5.02 34.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.25 139.29 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 151.41 -10.74 0.73 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -99.0 110.53 58.07 Favored Pre-proline 0 CA--C 1.544 0.715 0 O-C-N 122.517 -0.402 . . . . 0.0 110.422 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -76.77 159.01 35.14 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.175 1.916 . . . . 0.0 112.524 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.8 t -124.76 130.06 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.11 0.481 . . . . 0.0 110.577 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -104.35 117.68 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.087 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -65.75 -39.48 91.12 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.3 m -86.12 -7.44 58.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.531 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 45.73 -166.48 0.06 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 1.3 m -141.34 119.61 12.18 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.5 mt -63.9 -41.7 97.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.766 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 156' ' ' ASN . . . . . 0.554 ' C ' ' H ' ' A' ' 158' ' ' GLY . 6.1 t-20 -86.03 -167.88 2.02 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.332 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 157' ' ' GLY . . . . . 0.538 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.79 23.67 0.53 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 158' ' ' GLY . . . . . 0.554 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -60.01 160.17 21.59 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -126.75 147.18 50.0 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.778 0.323 . . . . 0.0 110.668 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 12.3 t -90.88 104.78 17.33 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.853 0.359 . . . . 0.0 110.497 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.98 -35.04 20.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -155.81 177.29 2.11 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.36 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 163' ' ' PRO . . . . . 0.437 ' CD ' ' HH ' ' A' ' 140' ' ' TYR . 50.8 Cg_exo -54.26 132.22 49.36 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.023 1.816 . . . . 0.0 112.259 179.436 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 49.33 31.79 4.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.259 179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -135.42 102.09 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.58 0.705 . . . . 0.0 110.751 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -107.52 141.17 39.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.821 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.64 133.71 50.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.444 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 67.3 m -86.3 146.51 26.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.102 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -62.35 -45.1 94.73 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.118 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -97.52 15.93 21.8 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.322 0.582 . . . . 0.0 110.847 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.15 20.95 78.37 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -54.84 161.7 1.49 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.967 0.413 . . . . 0.0 110.595 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 8.8 t -82.54 160.52 22.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.479 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.6 142.52 0.05 OUTLIER Glycine 0 CA--C 1.539 1.534 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -53.48 -40.67 77.84 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.329 2.019 . . . . 0.0 112.971 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -67.3 -26.22 66.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.455 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 11.8 m . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.673 -179.88 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.2 m . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.75 -38.55 91.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.551 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -74.56 152.65 39.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -154.29 161.9 30.32 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 86.69 7.09 79.14 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -63.89 -39.87 97.78 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.21 164.6 39.96 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 55.2 p-80 -82.4 -16.7 48.09 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.857 0.361 . . . . 0.0 110.566 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 58.4 p30 -73.21 148.9 43.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.753 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.61 -36.54 84.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.462 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.93 142.93 51.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.606 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -135.61 -176.77 4.4 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.732 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.71 158.73 29.32 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -76.59 8.29 3.08 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.764 2.309 . . . . 0.0 112.105 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.578 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 81.2 m-20 -119.88 65.79 0.81 Allowed 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.658 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 10.7 p -112.55 128.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -148.51 171.85 15.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.379 -179.153 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.55 166.46 34.97 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.7 m -79.08 165.04 23.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.7 0.286 . . . . 0.0 110.307 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.6 ttm-85 -58.85 -42.26 88.92 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.241 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -61.18 -39.42 90.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.832 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -131.63 51.13 2.17 Favored 'General case' 0 C--O 1.226 -0.151 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.033 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.08 142.83 50.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.536 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 11.8 p90 -160.94 176.32 11.55 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 121.069 0.461 . . . . 0.0 110.523 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.8 m -73.39 133.89 43.89 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -47.1 169.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.033 -178.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -58.32 133.86 57.73 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 121.883 1.722 . . . . 0.0 112.364 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 93.39 -16.63 60.2 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.578 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 92.5 m95 -110.25 138.49 46.55 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -121.98 -164.52 1.16 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.316 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 72.3 p -125.07 164.83 19.35 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.523 ' O ' ' N ' ' A' ' 77' ' ' GLY . 24.6 mt -89.16 151.99 47.42 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 -179.074 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -40.44 107.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.256 0 C-N-CA 122.219 1.946 . . . . 0.0 112.259 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.27 -11.2 9.03 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.523 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -87.96 177.76 46.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.924 -0.871 . . . . 0.0 110.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -138.01 17.06 2.83 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.892 0.377 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -81.93 130.15 34.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.046 -179.243 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 53.6 m -95.66 55.26 1.64 Allowed 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.451 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.3 pt -114.32 22.05 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.995 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.04 99.51 40.92 Favored Pre-proline 0 N--CA 1.467 0.401 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.573 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.95 156.45 26.84 Favored 'Trans proline' 0 N--CA 1.487 1.113 0 C-N-CA 122.164 1.91 . . . . 0.0 112.202 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.438 ' O ' ' NH1' ' A' ' 86' ' ' ARG . 96.0 mt -101.57 122.12 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-O 120.945 0.403 . . . . 0.0 110.202 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.27 126.29 45.06 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.494 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 9.0 mpt_? -64.97 -40.33 94.82 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.743 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -117.71 145.68 44.27 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.192 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.2 m -63.24 136.29 57.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.0 0.429 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 44.5 m -77.95 -32.24 51.37 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.326 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.44 -107.19 2.25 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -68.38 -12.32 60.95 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.777 0.323 . . . . 0.0 110.797 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -110.53 -161.91 18.2 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -145.94 151.52 37.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.006 0.432 . . . . 0.0 111.072 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.7 m -66.95 115.18 6.39 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.225 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -106.46 -20.72 13.29 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.754 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -157.49 161.66 28.78 Favored Pre-proline 0 CA--C 1.531 0.238 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.364 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_exo -48.93 122.23 7.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 121.748 1.632 . . . . 0.0 111.254 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 52.05 41.74 30.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.004 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 80.9 mtp -148.33 116.72 6.54 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.62 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.44 ' N ' ' O ' ' A' ' 108' ' ' ALA . 33.7 m -100.44 148.28 24.92 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.366 178.947 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.6 m -120.58 123.28 42.48 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.741 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.16 157.92 53.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.275 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.71 -18.64 65.17 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.719 2.279 . . . . 0.0 111.855 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.8 m -71.95 -17.38 62.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.432 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 109.16 -20.32 28.57 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -66.82 150.03 49.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.934 0.397 . . . . 0.0 110.194 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.68 132.74 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.642 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.44 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -167.77 179.05 0.99 Allowed Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.379 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.414 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 38.8 Cg_exo -57.92 -22.76 56.11 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.814 2.343 . . . . 0.0 112.306 179.373 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.2 p -153.74 161.84 41.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.243 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -85.72 127.77 34.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.885 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 170.01 160.51 18.51 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -68.43 -18.81 64.52 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 121.01 -0.276 . . . . 0.0 110.833 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 80.6 mtp85 -73.67 127.37 32.6 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.872 0.368 . . . . 0.0 110.621 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.6 t -170.87 165.89 7.74 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.357 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.5 mt -92.49 122.06 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.128 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.427 ' O ' ' N ' ' A' ' 120' ' ' ASN . 67.1 tp60 -171.8 118.47 0.42 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.11 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.641 ' ND1' ' N ' ' A' ' 119' ' ' CYS . 59.0 t-80 49.39 -106.01 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.65 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.641 ' N ' ' ND1' ' A' ' 118' ' ' HIS . 45.0 t -80.48 7.34 10.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.877 0.37 . . . . 0.0 110.735 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . 0.427 ' N ' ' O ' ' A' ' 117' ' ' GLN . 63.3 m-20 58.69 30.61 20.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.128 179.615 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.3 tt -158.59 165.22 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.265 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.4 mmt85 -101.2 106.13 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.195 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.39 127.37 52.06 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -147.01 168.63 21.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 59.54 39.92 21.03 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 120.792 0.329 . . . . 0.0 111.064 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.33 20.85 65.97 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -65.02 149.15 51.74 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 36.9 m -127.16 144.66 50.98 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.903 0.383 . . . . 0.0 110.403 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 37.1 t -82.55 124.39 30.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.568 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -148.18 111.67 4.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.472 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.9 49.98 17.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.067 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 57.41 34.55 24.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -144.48 139.54 28.36 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.508 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.4 m -88.05 126.89 35.33 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.2 mt -95.25 126.85 40.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.628 179.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -103.02 137.88 40.62 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.683 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -83.27 175.34 9.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.437 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.533 ' NZ ' ' OE2' ' A' ' 151' ' ' GLU . 64.6 tttm -63.29 133.15 53.7 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.444 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.53 -24.52 28.48 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.459 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 95.1 m-85 -123.74 138.25 54.55 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.911 0.386 . . . . 0.0 110.55 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 16.7 pt -139.73 -168.93 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.496 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.97 165.29 31.43 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -46.25 88.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.742 0.306 . . . . 0.0 110.35 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -84.58 -1.42 55.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.612 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 145' ' ' CYS . 33.7 t 55.14 63.47 2.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -140.51 -4.18 1.26 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -86.48 114.54 58.21 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.385 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.49 156.2 36.37 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 122.295 1.997 . . . . 0.0 112.4 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.2 t -119.61 124.55 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 120.954 0.407 . . . . 0.0 110.197 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.3 107.54 20.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.2 -179.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . 0.533 ' OE2' ' NZ ' ' A' ' 138' ' ' LYS . 96.7 mt-10 -69.32 -38.23 78.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.101 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 94.7 p -85.38 -9.11 58.0 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.032 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 63.5 -163.82 31.1 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 71.8 m -116.12 152.24 34.04 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 96.9 mt -82.03 -1.95 50.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.49 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.567 ' C ' ' H ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -170.66 -147.62 0.05 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.336 179.508 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.551 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.64 26.99 0.49 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.567 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -64.23 175.51 11.21 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 78.1 ttt180 -128.14 136.64 51.42 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.65 0.262 . . . . 0.0 110.849 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 81.3 m -79.56 98.46 6.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 69.7 t -75.91 -44.1 38.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.533 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -145.13 174.26 3.61 Favored Pre-proline 0 C--N 1.331 -0.222 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.466 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -52.27 129.59 32.01 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 121.95 1.767 . . . . 0.0 112.102 179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 52.37 32.87 11.83 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.984 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.1 ttt85 -138.84 127.56 23.42 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.314 0.578 . . . . 0.0 110.691 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 42.1 t -139.37 149.99 44.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.722 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.24 134.31 49.57 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.566 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . 0.644 ' SG ' ' N ' ' A' ' 178' ' ' GLU . 0.2 OUTLIER -81.0 120.28 24.58 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.846 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 12.1 m -70.38 -45.45 66.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.79 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -101.85 26.99 6.86 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.821 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.7 33.64 83.29 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -62.44 127.14 29.92 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -178.77 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 61.8 p -84.58 161.69 20.08 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.924 0.392 . . . . 0.0 110.979 -179.341 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 143.24 160.25 8.31 Favored Glycine 0 CA--C 1.531 1.033 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.0 -25.41 44.38 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.537 2.158 . . . . 0.0 112.689 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -76.28 -49.27 17.45 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.45 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.0 t -111.61 -104.93 0.38 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.736 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . 0.644 ' N ' ' SG ' ' A' ' 168' ' ' CYS . 81.1 tt0 . . . . . 0 C--N 1.325 -0.478 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.661 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' A' ' 44' ' ' ALA . 18.0 t . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.459 ' N ' ' OG ' ' A' ' 43' ' ' SER . . . -66.36 139.62 58.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.534 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -80.52 145.13 31.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.455 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.0 176.23 54.68 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -170.49 170.55 43.12 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -176.3 -168.51 36.55 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -63.72 172.17 14.86 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . 0.462 ' ND1' ' O ' ' A' ' 50' ' ' HIS . 0.8 OUTLIER -64.68 -44.65 89.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.709 0.29 . . . . 0.0 110.664 -179.633 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -64.22 -36.69 84.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.491 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.32 150.26 48.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.53 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 74.9 mt -63.2 143.97 57.33 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.067 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . 0.632 ' HZ3' HD22 ' A' ' 78' ' ' ASN . 64.0 mttp -104.77 162.83 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.952 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.27 161.05 20.51 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -78.76 3.51 7.25 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.725 2.283 . . . . 0.0 112.146 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.63 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 1.7 m120 -123.51 68.69 1.02 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.77 0.319 . . . . 0.0 110.502 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.455 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.8 t -117.01 131.43 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-O 120.884 0.373 . . . . 0.0 110.032 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -142.56 175.96 9.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.333 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.83 170.28 46.86 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.538 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -77.77 167.66 21.19 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 43.7 ttm180 -60.98 -44.11 97.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.634 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -66.86 -39.3 87.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.225 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -121.91 47.45 1.89 Allowed 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.488 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.538 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -69.44 144.29 53.35 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.553 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.9 p90 -153.33 167.59 28.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.944 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 77.1 m -73.21 132.49 43.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.51 179.936 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.455 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 54.2 m -51.65 151.78 5.55 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.983 -179.1 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -46.37 129.35 13.28 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 C-N-CA 121.819 1.679 . . . . 0.0 112.424 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.93 -21.16 46.05 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.63 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 78.2 m95 -111.89 138.41 48.54 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.75 0.31 . . . . 0.0 110.279 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 ptpt -118.47 -176.05 3.0 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.324 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 72.5 p -106.94 153.71 22.15 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.493 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.509 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.1 mt -88.31 151.53 48.83 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.403 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.484 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.4 Cg_exo -39.04 105.47 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.187 1.925 . . . . 0.0 112.228 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.58 -9.2 2.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.16 168.94 47.36 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.632 HD22 ' HZ3' ' A' ' 54' ' ' LYS . 42.7 p-10 -126.49 13.49 7.59 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.657 0.265 . . . . 0.0 110.784 179.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . 0.443 ' NE2' ' OD1' ' A' ' 78' ' ' ASN . 10.8 mp0 -90.68 123.83 34.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.868 0.366 . . . . 0.0 110.898 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.48 68.57 4.87 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 27.2 pt -120.99 23.45 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.788 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.78 95.98 48.78 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.541 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.55 157.31 32.37 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.702 2.268 . . . . 0.0 112.236 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.407 HD11 HG21 ' A' ' 84' ' ' ILE . 96.1 mt -111.63 131.53 62.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.755 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 28.6 m -84.78 139.4 31.97 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.408 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -63.04 -45.15 93.63 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.279 0.561 . . . . 0.0 110.251 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -123.33 -118.08 0.29 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.29 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 t -143.81 133.71 23.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.35 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -94.05 -21.28 19.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.591 179.732 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.33 -99.18 0.7 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 39.5 p-10 -75.95 -1.71 26.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.772 0.32 . . . . 0.0 110.615 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.86 -175.29 26.79 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -141.12 153.86 45.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.934 0.397 . . . . 0.0 110.822 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.6 m -71.53 106.84 4.14 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.877 -179.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.7 p -96.69 -20.12 18.49 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.053 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mtt180 -162.14 168.92 10.11 Favored Pre-proline 0 C--O 1.235 0.329 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.987 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . 0.414 ' O ' ' CG ' ' A' ' 98' ' ' ASN . 52.4 Cg_exo -51.83 130.08 32.81 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 121.981 1.788 . . . . 0.0 110.827 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.414 ' CG ' ' O ' ' A' ' 97' ' ' PRO . 12.6 p30 43.01 34.85 0.68 Allowed 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.692 0.62 . . . . 0.0 109.918 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 47.3 mmm -148.62 120.81 8.34 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 121.312 0.577 . . . . 0.0 110.571 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 13.8 p -119.82 161.68 20.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.023 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 77.8 m -119.41 128.08 53.71 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.431 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.433 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.1 OUTLIER -92.0 153.15 43.36 Favored Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.72 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . 0.433 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 75.3 Cg_exo -46.45 -27.54 5.16 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.581 2.188 . . . . 0.0 112.011 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.8 t -63.43 -17.46 62.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.43 -3.01 63.32 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . 0.448 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 2.2 tm0? -81.0 148.54 29.69 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.785 0.326 . . . . 0.0 110.314 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.448 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 94.8 mt -122.06 135.18 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.549 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -176.74 175.69 0.6 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.691 179.741 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_exo -56.27 -25.78 58.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.769 2.313 . . . . 0.0 111.508 178.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.49 ' C ' ' H ' ' A' ' 112' ' ' GLY . 49.5 p -136.09 168.11 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.194 -179.362 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.0 OUTLIER -76.25 20.31 0.21 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.597 -178.727 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.49 ' H ' ' C ' ' A' ' 110' ' ' SER . . . -90.52 118.77 5.41 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 40.2 t -63.62 128.22 34.83 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.731 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 78.2 ttt-85 -68.57 -42.85 77.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.452 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.8 m -148.22 145.39 28.24 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.561 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.7 mt -64.7 -44.25 96.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.637 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -90.19 117.23 28.79 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.585 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.577 ' CG ' ' H ' ' A' ' 119' ' ' CYS . 86.4 t60 -174.13 172.52 3.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.595 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.577 ' H ' ' CG ' ' A' ' 118' ' ' HIS . 4.5 t -61.13 121.57 12.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.306 179.402 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.28 7.22 33.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.531 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.505 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 12.7 tt -130.44 166.29 28.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.505 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 16.1 mmm180 -100.98 125.22 47.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.304 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 82.6 m -118.29 129.21 55.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.941 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.0 mtm -140.97 166.84 23.68 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.339 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 58.48 41.31 22.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.03 74.38 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.16 145.12 49.44 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' SER . . . . . 0.505 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 30.3 t -102.39 128.33 49.03 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.745 0.307 . . . . 0.0 110.367 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 39.9 t -84.63 120.45 26.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.226 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 133' ' ' HIS . 39.7 t -142.35 136.37 29.58 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.305 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 39.88 -118.32 0.29 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.753 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -112.87 12.91 19.55 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.51 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.456 ' O ' ' O ' ' A' ' 130' ' ' SER . 78.2 t60 -133.08 152.99 51.92 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.856 0.36 . . . . 0.0 110.469 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 128' ' ' SER . 7.8 t -120.71 148.64 43.67 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.19 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.7 mt -105.73 134.29 49.09 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.351 -179.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 22.3 m -97.68 141.18 31.02 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.131 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -73.39 170.72 14.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.729 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -66.67 132.89 49.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 105.52 -20.03 38.01 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -122.27 137.03 54.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.796 0.331 . . . . 0.0 110.322 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -127.85 170.26 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.103 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 118.65 163.31 12.47 Favored Glycine 0 N--CA 1.464 0.516 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.505 ' HG1' ' CD2' ' A' ' 144' ' ' HIS . 67.3 p -63.39 -41.42 98.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.338 . . . . 0.0 110.562 -179.801 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.505 ' CD2' ' HG1' ' A' ' 143' ' ' THR . 15.6 m170 -107.42 1.43 23.59 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.6 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.445 ' SG ' ' C ' ' A' ' 144' ' ' HIS . 1.8 m 71.14 140.65 0.05 OUTLIER 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.933 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 158.99 -26.95 0.38 Allowed Glycine 0 C--N 1.322 -0.224 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.64 117.1 67.71 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.45 -0.5 . . . . 0.0 110.482 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.51 153.39 39.36 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.432 2.088 . . . . 0.0 112.417 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 49.4 t -114.35 128.46 71.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.57 100.03 10.4 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.097 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 11.9 tm-20 -64.44 -36.73 85.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.274 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 80.0 p -83.6 -7.24 59.55 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 61.31 -168.89 10.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.1 m -140.41 115.87 10.05 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 10.7 mp -62.92 -42.07 99.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.663 -179.278 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.581 ' C ' ' H ' ' A' ' 158' ' ' GLY . 63.9 t30 -93.45 173.34 7.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.524 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.17 34.6 0.31 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.03 174.42 26.02 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -123.75 138.25 54.55 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.807 0.337 . . . . 0.0 110.66 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 63.4 m -81.26 107.15 13.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.277 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.5 m -83.66 -29.98 7.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.547 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -158.93 172.38 6.21 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.54 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -52.55 129.64 33.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.062 1.841 . . . . 0.0 111.926 179.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 11.0 m120 53.55 33.96 17.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.601 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? -139.06 125.25 20.13 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.054 0.454 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -128.54 145.31 51.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -118.25 146.2 44.45 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.123 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 10.9 m -82.78 135.73 34.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.552 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 20.5 m -63.76 -45.4 90.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.85 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.69 22.65 10.64 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.011 0.434 . . . . 0.0 110.633 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 63.74 30.88 78.96 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -54.65 157.16 3.11 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.351 . . . . 0.0 110.353 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.15 140.47 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.284 0.564 . . . . 0.0 110.452 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 101.79 147.49 19.98 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.13 -31.31 36.73 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.591 2.194 . . . . 0.0 112.215 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.442 ' O ' ' O ' ' A' ' 177' ' ' CYS . 1.0 OUTLIER -88.12 -9.37 53.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.303 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.442 ' O ' ' O ' ' A' ' 176' ' ' GLN . 34.3 m 58.75 119.62 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.51 0 O-C-N 123.481 0.488 . . . . 0.0 109.933 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.878 -1.058 . . . . 0.0 110.488 179.902 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 66.2 m . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.05 56.63 0.76 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.401 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 80.8 mtp85 41.54 85.31 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.716 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.34 3.79 81.44 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -65.5 -27.29 72.4 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -56.08 -40.34 82.72 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.8 -166.24 38.47 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . 0.533 ' CG ' ' OD1' ' A' ' 78' ' ' ASN . 45.0 p-80 -69.35 135.84 50.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.89 0.376 . . . . 0.0 110.304 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -62.61 -42.84 99.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.816 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . 179.2 -167.78 0.08 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.344 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 15.9 mt -73.24 151.68 41.32 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.559 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -137.45 162.46 33.59 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.308 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.71 161.13 23.03 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.51 -4.84 15.84 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 C-N-CA 122.953 2.435 . . . . 0.0 112.234 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.606 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 87.6 m-20 -112.54 74.42 0.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.074 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.436 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 8.2 p -116.04 130.38 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.904 179.465 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -139.91 177.92 7.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.098 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.8 161.28 27.82 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.8 m -82.61 171.54 13.93 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.0 ttt-85 -59.21 -40.49 85.95 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.302 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -60.01 -40.2 88.44 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.68 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -135.56 52.51 2.01 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.699 -0.228 . . . . 0.0 110.944 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.4 141.88 52.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.791 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.409 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 9.7 p90 -158.7 172.35 18.42 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.2 0.524 . . . . 0.0 110.421 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.563 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 94.6 m -69.03 140.42 54.94 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.131 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.436 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 64.2 m -58.72 149.44 63.31 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -56.29 131.09 43.72 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 121.581 1.52 . . . . 0.0 112.291 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.55 -16.34 40.95 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.606 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 93.0 m95 -119.07 134.73 55.02 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-O 120.804 0.335 . . . . 0.0 110.228 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -115.04 -176.69 2.96 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.375 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.563 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 30.3 p -132.59 172.53 12.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.005 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.446 HD13 ' H ' ' A' ' 74' ' ' LEU . 0.2 OUTLIER -92.02 160.32 35.95 Favored Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.363 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.51 ' C ' ' H ' ' A' ' 77' ' ' GLY . 45.6 Cg_exo -53.83 132.5 49.84 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.591 1.528 . . . . 0.0 112.144 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.6 -8.01 1.83 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.51 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.56 178.77 38.4 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.533 ' OD1' ' CG ' ' A' ' 50' ' ' HIS . 29.4 m120 -146.9 16.77 1.23 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.006 0.431 . . . . 0.0 110.719 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -84.83 121.3 27.52 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.058 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 7.0 m -88.43 39.23 0.9 Allowed 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.2 -1.72 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.619 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 90.4 t -97.93 114.52 65.17 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.664 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -75.28 155.59 41.68 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 C-N-CA 121.982 1.788 . . . . 0.0 112.564 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 81.9 mt -106.42 124.44 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.192 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -106.16 115.84 30.92 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -64.15 -40.4 96.07 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.797 0.332 . . . . 0.0 110.686 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -117.0 149.39 40.32 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.537 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 m -66.22 138.2 57.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.501 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 40.5 m -79.02 -26.81 43.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.715 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.78 -104.2 2.17 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -78.6 -4.11 47.23 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.78 0.324 . . . . 0.0 110.97 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.59 -156.42 12.01 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.5 p90 -152.6 157.25 40.74 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.97 0.414 . . . . 0.0 111.023 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -64.1 112.95 3.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.052 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.44 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 91.9 p -102.83 -25.32 13.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.56 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -157.79 159.93 30.27 Favored Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.312 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -44.84 119.34 2.3 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 122.157 1.904 . . . . 0.0 111.607 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 66.2 t30 53.55 42.02 31.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.11 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mmm -148.39 118.76 7.35 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.915 0.388 . . . . 0.0 110.682 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 108' ' ' ALA . 17.7 m -100.79 146.14 27.64 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.149 178.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' THR . . . . . 0.44 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.0 m -122.24 123.94 42.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.627 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -87.74 156.84 52.69 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.644 -179.586 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -61.95 -19.95 67.76 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 122.469 2.113 . . . . 0.0 111.798 178.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -66.28 -17.23 64.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.459 179.116 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 107.12 -19.31 35.1 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -67.0 149.83 50.09 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.957 0.408 . . . . 0.0 110.253 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 94.7 mt -129.18 130.2 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.743 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -169.44 178.11 1.02 Allowed Pre-proline 0 CA--C 1.538 0.482 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.314 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_exo -57.67 -25.45 67.99 Favored 'Trans proline' 0 N--CA 1.499 1.837 0 C-N-CA 122.818 2.346 . . . . 0.0 111.968 179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 95.5 p -149.83 162.33 40.51 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.499 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -26.85 48.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.667 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -124.09 78.18 0.36 Allowed Glycine 0 N--CA 1.467 0.745 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.4 t -61.82 -41.89 98.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.359 . . . . 0.0 110.335 179.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.7 mmm180 -127.14 145.22 50.83 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.657 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 93.1 p -99.6 -1.56 37.83 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.167 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.526 ' O ' ' NE2' ' A' ' 117' ' ' GLN . 21.1 tt -96.95 119.28 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.897 0.38 . . . . 0.0 110.061 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . 0.526 ' NE2' ' O ' ' A' ' 116' ' ' ILE . 99.3 mm-40 -142.18 41.71 1.65 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.17 -179.671 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.64 ' CG ' ' H ' ' A' ' 119' ' ' CYS . 59.1 t-80 -69.38 175.15 4.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.418 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.64 ' H ' ' CG ' ' A' ' 118' ' ' HIS . 0.8 OUTLIER -73.06 127.61 33.08 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.031 -179.607 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -98.5 13.73 30.77 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.745 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.485 ' CG2' ' N ' ' A' ' 122' ' ' ARG . 92.4 mt -119.24 165.52 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.204 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.56 ' NH2' ' CE1' ' A' ' 144' ' ' HIS . 5.9 ptt85 -119.19 101.95 8.37 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.581 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 76.3 m -107.03 146.69 30.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.744 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.9 mtm -142.9 174.56 10.55 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.255 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 59.02 37.43 24.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.787 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 73.99 22.37 78.04 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.56 134.71 16.94 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 15.2 m -86.31 129.64 34.78 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 121.052 -0.259 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.413 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 4.3 t -87.12 85.28 7.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.574 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 133' ' ' HIS . 14.7 p -74.96 161.84 29.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.383 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -50.23 110.87 0.44 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.408 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.401 ' O ' ' CG ' ' A' ' 133' ' ' HIS . 98.6 m-20 52.35 28.59 5.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.555 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.505 ' O ' ' N ' ' A' ' 130' ' ' SER . 31.5 m-70 -162.25 153.36 17.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.596 179.57 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 12.4 t -126.78 130.64 50.68 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.335 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.2 mt -102.06 131.07 48.74 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.902 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . 0.434 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 57.6 m -91.38 129.75 37.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.394 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -79.03 173.05 12.97 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.927 0.394 . . . . 0.0 110.575 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -63.42 134.2 55.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.334 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -21.62 37.79 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -129.02 139.62 51.98 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.772 0.32 . . . . 0.0 110.545 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 10.9 pt -134.09 176.79 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.986 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.434 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 107.52 169.08 21.88 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.5 m -62.08 -45.28 94.2 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.531 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.56 ' CE1' ' NH2' ' A' ' 122' ' ' ARG . 59.1 m80 -98.35 5.92 47.78 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.736 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 3.9 m 58.2 37.24 26.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -103.28 17.68 50.69 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 50.4 tp60 -119.19 96.73 50.22 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.754 0.277 . . . . 0.0 110.806 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -58.23 152.49 52.53 Favored 'Trans proline' 0 N--CA 1.499 1.819 0 C-N-CA 122.583 2.189 . . . . 0.0 111.916 178.716 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 70.8 t -89.94 129.76 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-O 121.048 0.452 . . . . 0.0 110.325 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.4 m -103.11 86.47 2.7 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -62.32 -46.43 88.77 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.267 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 90.0 p -111.99 -21.21 11.67 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.964 0.411 . . . . 0.0 110.502 179.25 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 49.67 177.91 0.02 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.6 m -98.54 139.8 33.73 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.934 0.397 . . . . 0.0 110.184 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 92.5 mt -63.22 -40.99 99.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.626 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.5 ' ND2' ' H ' ' A' ' 169' ' ' THR . 51.9 p30 -82.37 178.68 8.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.376 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.92 42.26 0.35 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.494 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.2 -176.57 19.15 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -130.15 142.18 50.61 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 98.6 m -76.69 102.45 6.19 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.037 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.8 t -83.17 -50.62 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.221 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -135.65 177.31 2.28 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.178 -178.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -53.71 133.12 52.73 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.821 1.68 . . . . 0.0 111.489 179.53 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 47.9 23.02 0.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.643 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -132.68 140.58 48.2 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.439 0.638 . . . . 0.0 111.025 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 5.8 p -149.1 155.69 41.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.379 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -89.92 143.88 26.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.65 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 66.1 m -85.05 155.14 21.66 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.612 -179.246 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.5 ' H ' ' ND2' ' A' ' 156' ' ' ASN . 97.9 m -62.08 -45.7 92.36 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.168 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.45 22.55 15.64 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.992 0.425 . . . . 0.0 111.262 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.13 35.09 91.31 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.408 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 2.7 m-85 -68.32 146.99 52.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.117 0.484 . . . . 0.0 110.643 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 60.6 p -81.58 166.67 20.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.179 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 91.28 154.62 30.81 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -67.83 -20.97 45.06 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.609 2.206 . . . . 0.0 112.405 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.499 ' C ' ' H ' ' A' ' 178' ' ' GLU . 75.0 mt-30 -111.26 18.79 18.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.737 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 79.7 m 50.19 11.55 0.07 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.29 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . 0.499 ' H ' ' C ' ' A' ' 176' ' ' GLN . 80.8 tt0 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.573 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 25.2 t . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.23 141.66 57.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.523 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . 0.406 ' NH1' ' O ' ' A' ' 46' ' ' GLY . 22.6 tpt85 -74.11 131.72 41.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.421 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' O ' ' NH1' ' A' ' 45' ' ' ARG . . . -96.29 164.19 23.32 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 56.71 -137.1 48.99 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.33 168.71 40.59 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.11 167.86 44.13 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.689 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 34.0 m170 -134.57 141.08 46.56 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.81 0.338 . . . . 0.0 110.471 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.436 ' O ' ' O ' ' A' ' 52' ' ' ALA . 98.0 m-20 -70.26 -19.21 63.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.622 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.436 ' O ' ' O ' ' A' ' 51' ' ' ASP . . . 56.7 155.94 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.647 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.42 150.11 38.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.629 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -130.23 160.46 33.81 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 121.125 0.488 . . . . 0.0 110.142 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.6 174.76 36.46 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.04 -172.3 0.97 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.898 2.399 . . . . 0.0 111.81 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.526 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 53.5 m-80 59.16 38.95 23.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.997 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.46 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 11.8 p -98.69 131.59 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.278 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -141.5 -178.75 5.78 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.251 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.47 162.3 29.03 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 13.6 m -82.52 172.84 12.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.4 ttt-85 -60.86 -43.03 98.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.483 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -62.12 -39.62 93.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.567 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -133.02 55.2 1.91 Allowed 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.669 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.2 142.29 52.45 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -155.21 169.56 23.89 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.997 0.427 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.8 m -74.14 139.72 44.72 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.188 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.46 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 61.9 m -56.81 153.63 21.68 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.252 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.78 131.87 35.15 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 121.244 1.296 . . . . 0.0 112.203 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.92 -18.82 51.55 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.556 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 8.9 m95 -119.01 140.04 50.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.746 0.308 . . . . 0.0 110.649 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -121.6 -175.84 3.18 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 60.8 p -108.81 154.12 22.53 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.744 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.482 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.9 mt -83.37 152.43 64.3 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.688 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.447 ' C ' ' H ' ' A' ' 77' ' ' GLY . 74.0 Cg_exo -41.3 110.33 0.13 Allowed 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.017 1.811 . . . . 0.0 112.197 179.125 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.36 -4.78 7.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -89.09 173.64 41.37 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -135.94 11.96 3.37 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.969 0.414 . . . . 0.0 111.059 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -89.61 126.64 35.7 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.552 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -89.61 69.1 7.79 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.8 pt -122.05 21.78 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.96 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -118.87 86.72 31.48 Favored Pre-proline 0 N--CA 1.464 0.251 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.793 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.47 150.76 83.74 Favored 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.773 2.315 . . . . 0.0 111.994 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.495 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.4 mt -106.05 128.74 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.439 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 5.9 m -89.62 135.67 33.48 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.49 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.04 -45.59 92.89 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.18 0.514 . . . . 0.0 109.758 -179.208 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -119.0 167.86 11.36 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.64 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 96.4 p -57.15 137.81 55.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.544 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 31.5 m -86.06 -32.96 21.12 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.863 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.77 -108.91 2.74 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -93.74 0.96 56.62 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.744 0.306 . . . . 0.0 111.066 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.62 -176.25 31.12 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.449 ' C ' ' SG ' ' A' ' 100' ' ' CYS . 44.8 p90 -135.18 145.39 47.69 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.114 0.483 . . . . 0.0 110.902 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 85' ' ' CYS . 0.5 OUTLIER -70.11 113.41 7.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.54 -178.786 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.594 ' HG ' ' HG1' ' A' ' 101' ' ' THR . 33.9 m -99.79 -21.04 15.92 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.535 -179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.0 mtt180 -160.2 164.74 19.11 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.662 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.22 127.85 25.19 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 121.676 1.584 . . . . 0.0 111.474 179.064 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 63.9 m-20 50.52 35.36 11.15 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.874 -179.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 68.3 mmm -150.26 122.05 8.11 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.416 0.627 . . . . 0.0 110.485 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.449 ' SG ' ' C ' ' A' ' 93' ' ' PHE . 0.7 OUTLIER -120.79 161.64 21.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.059 179.65 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' THR . . . . . 0.594 ' HG1' ' HG ' ' A' ' 95' ' ' SER . 96.5 m -127.75 127.45 43.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.693 179.928 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.94 156.7 36.9 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.24 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -50.89 -26.2 17.55 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.252 1.968 . . . . 0.0 111.896 177.975 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.12 -17.76 64.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.859 0.361 . . . . 0.0 110.489 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.1 -16.43 53.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.3 tp60 -63.91 150.34 45.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.909 0.385 . . . . 0.0 110.07 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.49 131.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -179.51 174.5 0.47 Allowed Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.558 178.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 40.6 Cg_exo -57.32 -22.03 47.39 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.708 2.272 . . . . 0.0 111.751 179.009 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.5 p -140.16 159.98 40.98 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.754 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.43 -32.01 48.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.452 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -175.85 -178.37 45.61 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 93.2 p -82.16 -6.42 59.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.659 0.266 . . . . 0.0 110.526 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.409 ' O ' ' O ' ' A' ' 115' ' ' SER . 75.9 ttt180 -65.73 123.62 20.23 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 115' ' ' SER . 14.2 p 38.31 93.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.4 pt -96.57 -4.56 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 -69.78 130.65 42.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.411 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.425 ' CG ' ' N ' ' A' ' 119' ' ' CYS . 47.1 p-80 -65.91 -44.45 85.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.471 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.425 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 14.9 m -138.57 138.78 38.26 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.998 0.428 . . . . 0.0 110.974 179.617 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -65.11 -40.55 94.67 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.26 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 25.3 pt -92.8 -170.83 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.624 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -107.53 108.56 19.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.215 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 57.7 m -114.81 139.39 49.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.992 178.671 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 90.0 mtp -138.97 168.23 20.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 2.4 m-20 59.56 41.75 18.47 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.249 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.7 20.21 79.6 Favored Glycine 0 CA--C 1.52 0.375 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.23 156.57 52.35 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.4 m -133.29 146.64 51.55 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.733 0.301 . . . . 0.0 110.247 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 7.6 p -91.53 130.1 37.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.377 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.6 t -148.11 137.69 22.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.058 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' O ' ' OD2' ' A' ' 131' ' ' ASP . 3.7 p-10 45.01 41.29 5.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.006 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t0 62.0 36.69 15.4 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.637 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 69.1 t60 -150.02 140.59 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.585 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 9.4 t -88.55 130.92 35.13 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.48 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.6 mt -105.4 130.51 53.48 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 15.6 m -101.88 145.39 29.29 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.518 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.89 175.39 9.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.742 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -66.14 129.92 41.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.54 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.84 -20.06 44.96 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -120.28 134.57 55.24 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.792 0.329 . . . . 0.0 110.235 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.93 173.32 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.227 -179.577 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 107.01 164.29 22.18 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 43.5 p -61.4 -44.78 96.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.754 0.311 . . . . 0.0 110.491 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.452 ' ND1' ' N ' ' A' ' 144' ' ' HIS . 3.0 p-80 -98.52 14.41 28.39 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.431 179.827 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.525 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 5.2 m 46.39 43.4 11.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.11 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.74 12.31 42.1 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -121.45 119.28 29.44 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.63 0.215 . . . . 0.0 110.972 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -76.44 157.69 36.7 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.676 2.25 . . . . 0.0 112.266 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.0 t -99.31 111.19 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 121.015 0.436 . . . . 0.0 110.653 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.53 90.63 8.08 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.0 tt0 -70.18 -39.15 75.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.546 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 10.6 m -88.39 -12.9 41.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.65 161.4 0.02 OUTLIER Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 160' ' ' CYS . 25.6 m -106.55 159.18 16.37 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . 0.42 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 56.7 mt -62.37 -42.87 99.75 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.244 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.42 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 t-20 161.67 -58.92 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.747 0.654 . . . . 0.0 110.61 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.03 -42.21 99.72 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -71.41 168.83 50.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 22.8 mmm180 -130.03 149.07 51.91 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.912 0.386 . . . . 0.0 110.21 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 87.9 m -81.15 95.16 6.8 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.668 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 41.6 t -79.48 -47.86 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.577 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -131.24 177.79 2.06 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.341 -179.223 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -55.08 134.85 66.07 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.833 1.689 . . . . 0.0 111.597 179.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 40.78 33.53 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.948 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -132.7 104.49 6.66 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 121.364 0.602 . . . . 0.0 111.316 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.16 132.15 36.85 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.151 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -92.7 141.1 28.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.029 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.4 m -90.99 132.87 35.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.098 0.475 . . . . 0.0 110.757 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.9 m -63.64 -46.29 86.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.496 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -104.36 24.04 12.22 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.952 0.405 . . . . 0.0 111.246 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 62.42 29.86 74.58 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -54.67 168.0 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.04 0.448 . . . . 0.0 110.508 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.4 p -81.89 164.66 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.217 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.06 151.81 0.14 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.77 -24.8 40.29 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.375 2.05 . . . . 0.0 112.232 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 177' ' ' CYS . 85.2 mt-30 -84.09 -11.38 56.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.556 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 176' ' ' GLN . 10.1 m 59.56 124.5 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.47 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.414 179.592 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 48.11 46.97 19.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.443 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 88.5 mtm-85 50.87 81.12 0.07 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.59 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.32 -169.91 37.64 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 143.28 -10.57 2.24 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 62.23 -129.22 42.96 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 86.21 5.18 83.19 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -86.8 -9.17 56.45 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.737 0.303 . . . . 0.0 110.637 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -85.42 112.03 20.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.971 0.415 . . . . 0.0 110.625 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.41 69.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.518 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.2 mt -68.98 143.73 54.31 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.995 0.426 . . . . 0.0 110.421 -179.864 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -131.72 161.73 32.14 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.565 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.79 172.73 22.25 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.52 -167.46 0.18 Allowed 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 122.924 2.416 . . . . 0.0 111.885 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.581 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 5.2 m120 58.2 37.0 26.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.535 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.481 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 13.3 p -100.41 134.15 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 109.95 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 57.6 m -142.98 177.46 8.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.275 -179.186 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.55 162.64 31.83 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 65' ' ' ALA . 11.8 m -80.46 173.72 12.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.628 0.252 . . . . 0.0 110.465 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -60.6 -44.12 96.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.74 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -64.72 -39.26 93.34 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.421 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 58.6 t30 -125.39 51.12 1.73 Allowed 'General case' 0 CA--C 1.522 -0.113 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.819 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.5 142.52 50.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.466 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.421 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 10.2 p90 -160.2 167.54 27.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.219 0.533 . . . . 0.0 111.189 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.547 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 74.6 m -71.13 141.22 50.78 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.35 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.481 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 65.2 m -58.94 150.85 58.44 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.973 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -56.0 128.56 30.76 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.835 1.69 . . . . 0.0 112.037 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.1 47.02 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.581 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.3 m95 -125.39 135.29 52.24 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.025 0.441 . . . . 0.0 110.527 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -119.76 -177.36 3.37 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.437 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.547 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 19.2 p -129.24 165.6 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.285 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.5 mt -84.46 149.89 55.82 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.723 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -43.02 120.46 1.94 Allowed 'Trans proline' 0 N--CA 1.489 1.242 0 C-N-CA 121.881 1.721 . . . . 0.0 112.312 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.4 -0.25 55.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.901 -0.879 . . . . 0.0 110.901 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -89.84 171.17 37.27 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -136.64 2.15 2.64 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.038 0.447 . . . . 0.0 110.836 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -82.22 131.66 35.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.191 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.3 m -99.21 43.49 1.06 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -98.89 2.68 10.49 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.362 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.61 110.37 60.25 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.611 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -73.39 158.52 48.11 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.202 1.934 . . . . 0.0 112.226 -179.651 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -104.14 124.74 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.081 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.55 127.2 36.18 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.94 -45.29 93.15 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -136.81 154.96 50.39 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 17.0 m -60.08 136.39 58.0 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.321 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 1.8 t -94.03 4.04 54.47 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.562 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 61.73 -100.02 0.25 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.402 ' OD1' ' SG ' ' A' ' 102' ' ' CYS . 37.7 p30 -90.73 8.47 34.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.699 0.285 . . . . 0.0 110.838 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.87 -173.46 29.15 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.491 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -142.41 154.16 44.36 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.073 0.464 . . . . 0.0 110.9 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.8 m -72.15 106.42 4.36 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.804 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.491 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 2.1 m -95.9 -24.3 16.48 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.671 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.9 mtm-85 -159.96 167.17 14.49 Favored Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.891 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -51.96 125.4 17.07 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.73 1.62 . . . . 0.0 111.311 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 50.81 34.7 10.64 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.552 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.2 mmm -149.69 124.13 9.65 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.286 0.565 . . . . 0.0 110.614 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 10.1 p -123.92 163.58 21.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.794 179.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 94.8 m -125.46 130.63 52.19 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.705 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . 0.402 ' SG ' ' OD1' ' A' ' 91' ' ' ASP . 0.1 OUTLIER -94.28 155.74 39.56 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -48.01 -29.6 12.39 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.443 2.095 . . . . 0.0 112.133 177.368 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 37.5 m -62.63 -19.87 64.22 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.975 0.417 . . . . 0.0 110.688 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.4 57.27 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -70.94 152.0 44.09 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 110.168 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.36 131.55 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.57 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.414 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -174.67 178.22 0.55 Allowed Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.584 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.414 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 31.6 Cg_exo -59.97 -18.57 50.84 Favored 'Trans proline' 0 N--CA 1.5 1.911 0 C-N-CA 122.794 2.329 . . . . 0.0 111.588 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.4 p -149.6 164.65 34.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.5 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.5 OUTLIER -79.42 132.1 36.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.5 -179.531 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 113' ' ' SER . . . 50.92 -176.46 0.06 OUTLIER Glycine 0 CA--C 1.521 0.45 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.204 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 112' ' ' GLY . 2.4 p 58.09 132.91 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.897 0.38 . . . . 0.0 110.637 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -99.66 135.01 41.71 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.293 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 20.3 m -71.07 143.09 50.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.385 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.428 HG22 HD11 ' A' ' 116' ' ' ILE . 95.0 mt -64.13 -44.26 97.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.711 179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -169.23 145.23 3.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.621 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 60.9 t-80 -66.07 -44.98 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.679 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 95.2 m -80.36 97.34 7.0 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.182 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -63.91 -40.08 95.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 21.0 mm -80.7 160.23 4.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.152 -179.98 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 88.8 mmt-85 -81.73 98.52 8.46 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.184 -179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -105.64 122.24 45.63 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -141.78 167.63 21.69 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.845 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.19 37.95 23.7 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.79 22.29 61.96 Favored Glycine 0 CA--C 1.522 0.485 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.06 119.25 9.44 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 7.3 m -80.2 138.59 36.88 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.487 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 22.6 m -91.08 128.48 36.92 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.774 0.321 . . . . 0.0 110.378 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.4 m -141.6 140.02 33.24 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' SER . 97.2 m-20 36.11 -97.15 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.965 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -136.02 22.25 3.27 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.728 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -132.48 147.04 52.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.496 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.98 125.65 44.49 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.861 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.1 mt -103.9 131.53 51.03 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.37 143.69 29.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.738 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -68.19 -174.77 0.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.319 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 27.8 tptp -69.02 132.09 46.09 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.541 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 96.93 -8.4 65.37 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -118.58 136.29 53.95 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.856 0.36 . . . . 0.0 110.559 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.7 pt -134.29 172.47 16.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.064 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 104.42 160.73 24.19 Favored Glycine 0 N--CA 1.461 0.342 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -65.34 -42.74 92.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.738 0.304 . . . . 0.0 110.547 -179.897 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -97.13 5.17 50.69 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 31.0 m 58.12 37.31 26.38 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.371 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -100.73 5.28 56.67 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -119.8 107.8 39.83 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.801 0.3 . . . . 0.0 110.601 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.23 159.85 29.71 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 C-N-CA 122.65 2.233 . . . . 0.0 112.127 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.4 t -97.88 105.18 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -86.47 100.04 12.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.657 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -66.29 -45.57 79.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.283 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' SER . . . . . 0.443 ' O ' ' O ' ' A' ' 153' ' ' GLY . 23.4 t -89.53 -16.7 30.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.702 0.287 . . . . 0.0 110.883 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.49 156.15 0.01 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 10.9 m -93.95 133.08 37.76 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 64.3 mt -62.31 -43.9 97.76 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.189 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 178.23 -60.79 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 O-C-N 123.615 0.572 . . . . 0.0 110.52 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.84 51.13 1.54 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -166.82 154.62 25.18 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -123.25 129.32 51.21 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 2.4 t -75.33 102.84 5.23 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.068 0.461 . . . . 0.0 110.69 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . 0.414 ' O ' ' CG2' ' A' ' 161' ' ' VAL . 4.6 p -107.34 -2.91 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.412 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -166.6 171.65 4.47 Favored Pre-proline 0 C--N 1.322 -0.599 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.581 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -52.15 128.8 28.52 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 121.773 1.649 . . . . 0.0 111.395 178.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 40.93 36.14 0.4 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.682 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.528 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.8 OUTLIER -127.07 110.27 12.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.228 0.537 . . . . 0.0 110.409 -179.447 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.528 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 66.5 m -105.07 124.64 49.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.751 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -85.09 91.06 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.655 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.23 118.11 35.91 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.438 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.4 OUTLIER -111.27 11.36 21.7 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.63 -179.529 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 47.2 t80 -109.07 31.28 5.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.153 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 105.91 58.76 0.63 Allowed Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -53.02 126.12 19.53 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.534 -0.467 . . . . 0.0 110.325 -179.156 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.444 ' O ' ' O ' ' A' ' 174' ' ' GLY . 3.0 t -149.09 150.37 32.64 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.498 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 173' ' ' THR . . . 53.36 165.85 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.09 -18.66 45.73 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.83 2.353 . . . . 0.0 112.112 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -92.15 47.9 1.37 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.094 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 173' ' ' THR . 53.2 t 57.88 -89.27 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.697 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.483 179.572 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 80.8 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.67 141.17 58.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.214 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -128.97 127.68 42.19 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.311 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.11 177.13 31.1 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -82.22 -146.12 5.69 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -169.16 169.09 41.7 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 85.03 104.86 0.65 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -155.7 159.73 39.77 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.681 0.277 . . . . 0.0 110.41 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -92.21 108.95 20.32 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.211 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.518 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -102.61 156.35 17.68 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.443 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.9 mt -74.02 141.24 45.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.724 179.868 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.44 160.67 28.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.355 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.18 174.8 38.37 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.47 -169.36 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.991 2.461 . . . . 0.0 111.627 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 57.52 38.56 28.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.907 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.0 p -99.91 130.8 48.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . 0.438 ' O ' ' O ' ' A' ' 66' ' ' TYR . 52.7 m -145.64 175.58 10.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.613 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.23 167.1 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -75.06 165.04 25.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.623 0.249 . . . . 0.0 110.391 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.8 ttt180 -60.89 -44.2 97.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.653 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -66.24 -39.24 89.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -123.84 49.91 1.69 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.645 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.95 143.88 50.73 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.47 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.438 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -159.38 166.59 30.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.991 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 53.9 m -72.66 133.24 44.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.763 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -45.62 162.52 0.23 Allowed Pre-proline 0 CA--C 1.538 0.494 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -55.12 134.36 63.32 Favored 'Trans proline' 0 N--CA 1.495 1.604 0 C-N-CA 122.547 2.165 . . . . 0.0 111.68 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.65 -14.67 64.5 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -115.88 141.64 47.83 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.81 0.338 . . . . 0.0 110.239 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -125.7 -157.99 0.82 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.138 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 73.3 p -127.23 164.46 21.64 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.945 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.2 mt -87.09 152.05 52.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.435 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.7 Cg_exo -40.66 105.98 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.146 1.897 . . . . 0.0 111.939 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.65 -12.33 6.19 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.05 176.65 53.89 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 44.9 p30 -134.66 11.22 3.72 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.803 0.335 . . . . 0.0 110.744 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -82.37 130.62 35.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.474 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 79.7 m -90.96 47.66 1.43 Allowed 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.811 0.339 . . . . 0.0 110.308 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 38.4 pt -107.39 24.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.49 94.07 48.62 Favored Pre-proline 0 CA--C 1.537 0.449 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.249 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.85 156.82 24.05 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.463 2.108 . . . . 0.0 111.981 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.4 HD11 HG21 ' A' ' 84' ' ' ILE . 96.1 mt -101.99 125.77 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.025 179.545 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.03 119.28 38.52 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -45.37 94.74 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.969 0.414 . . . . 0.0 109.981 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -114.09 144.59 42.89 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.533 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.9 m -62.51 134.99 57.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.249 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 37.8 m -77.16 -31.72 55.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.633 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.08 -106.78 2.26 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.42 -8.01 52.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.664 0.269 . . . . 0.0 110.719 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.88 -161.48 18.81 Favored Glycine 0 N--CA 1.463 0.46 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.516 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -146.84 153.06 39.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.028 0.442 . . . . 0.0 110.755 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.25 114.56 5.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.28 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.516 ' OG ' ' CE2' ' A' ' 93' ' ' PHE . 75.7 m -105.11 -22.54 13.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.443 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 3.0 mtt180 -156.34 160.95 30.41 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.796 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -47.47 118.24 2.81 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 122.138 1.892 . . . . 0.0 111.519 179.04 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 54.27 41.67 31.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.344 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 77.0 mtp -148.33 120.13 8.12 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.367 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' ALA . 46.5 m -103.75 148.95 25.47 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.831 179.382 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' THR . . . . . 0.449 ' CB ' ' HG ' ' A' ' 95' ' ' SER . 97.5 m -118.51 123.06 44.2 Favored 'General case' 0 CA--C 1.515 -0.385 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.57 147.84 35.06 Favored Pre-proline 0 CA--C 1.541 0.598 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.651 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -47.39 -23.97 3.69 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.636 2.224 . . . . 0.0 112.09 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.9 t -64.35 -17.3 63.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.767 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.61 -14.99 56.26 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 59.6 tp60 -73.08 152.25 41.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.896 0.379 . . . . 0.0 110.248 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 91.4 mt -126.59 131.95 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.546 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.47 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -174.05 173.32 1.2 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.448 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_exo -55.08 -28.37 60.07 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.719 2.279 . . . . 0.0 112.142 179.282 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 p -136.61 164.25 28.64 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.567 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.05 145.68 33.71 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.648 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -139.59 58.89 0.59 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 85.8 p -66.26 -16.31 63.92 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.73 0.3 . . . . 0.0 110.209 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -44.51 125.52 4.81 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.629 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 84.4 p -76.71 160.9 28.95 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.521 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.417 HD11 HG23 ' A' ' 116' ' ' ILE . 96.5 mt -119.15 123.75 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.335 179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -171.8 90.32 0.12 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.478 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 57.0 m170 42.31 -162.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.557 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 93.7 m -94.65 134.33 37.34 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.953 0.406 . . . . 0.0 110.7 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -161.75 29.59 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.478 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 18.5 tt -121.13 171.09 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.441 -179.238 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.478 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 27.2 mmt180 -95.86 127.46 41.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.928 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 85.0 m -117.52 134.78 54.48 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.971 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtt -138.24 156.53 47.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.231 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 58.92 51.47 7.31 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.059 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 66.48 26.9 72.84 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.52 139.5 35.45 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' SER . . . . . 0.51 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 51.5 m -110.3 141.75 42.87 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.2 t -85.01 126.16 33.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 0.0 110.621 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.484 ' HG ' ' CE1' ' A' ' 133' ' ' HIS . 11.4 p -148.5 127.91 13.09 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.448 0.642 . . . . 0.0 111.01 179.527 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.444 ' O ' ' CB ' ' A' ' 132' ' ' ASP . 9.6 t70 50.18 42.79 25.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.562 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 131' ' ' ASP . 9.5 t0 78.29 -40.68 0.29 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.484 ' CE1' ' HG ' ' A' ' 130' ' ' SER . 6.8 p80 -85.42 147.64 26.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.971 0.415 . . . . 0.0 110.531 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.3 t -99.93 149.09 23.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.847 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.5 137.27 49.54 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.25 144.67 27.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.481 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -59.95 176.13 0.33 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.658 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 49.7 tttm -66.61 131.22 45.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.641 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 99.01 -15.86 60.1 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -111.28 136.44 50.38 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.791 0.329 . . . . 0.0 110.35 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.45 171.7 17.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.973 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.72 158.36 10.58 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 98.6 m -62.53 -46.39 88.62 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.916 -0.314 . . . . 0.0 110.715 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 96.3 m-70 -105.28 11.82 32.48 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.491 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 14.6 m 60.68 139.13 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.809 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 153.13 -1.15 0.24 Allowed Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -113.09 108.66 52.84 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 121.303 -0.159 . . . . 0.0 110.785 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -77.43 159.32 32.61 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.676 2.25 . . . . 0.0 111.909 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 81.9 t -120.81 120.49 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-O 121.009 0.433 . . . . 0.0 110.12 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 60.5 m -91.44 114.65 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.56 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -64.03 -42.22 97.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.88 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.1 p -86.27 -6.36 58.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.532 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.11 166.31 0.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 73.4 m -100.27 102.9 14.29 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.879 0.371 . . . . 0.0 110.067 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.8 mt -63.62 -41.98 98.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.552 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.594 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.5 t30 -93.28 -176.97 4.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.387 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.551 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.79 23.25 0.41 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.594 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.41 174.99 26.35 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 52.3 mmm-85 -127.42 147.12 50.29 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.695 0.283 . . . . 0.0 110.449 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 21.5 m -86.01 111.67 20.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.09 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -97.16 -16.26 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.331 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -168.34 173.65 2.56 Favored Pre-proline 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.71 179.523 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 41.7 Cg_exo -57.08 135.65 71.92 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.068 1.845 . . . . 0.0 112.029 179.294 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.8 t30 44.43 32.79 0.77 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.837 179.295 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.86 101.0 3.77 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.386 0.612 . . . . 0.0 111.152 179.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 31.2 t -101.81 148.2 25.58 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.284 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.0 137.37 39.45 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.88 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 87.8 m -81.7 150.34 28.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.822 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.4 m -61.72 -45.99 91.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.735 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.541 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 53.3 t80 -110.36 25.71 11.48 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.058 0.456 . . . . 0.0 110.694 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 67.13 30.51 75.83 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' A' ' 173' ' ' THR . 65.9 t80 -58.76 159.35 6.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.83 0.348 . . . . 0.0 110.444 -179.522 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 8.1 p -81.94 167.09 19.29 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.392 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 104.36 142.0 11.36 Favored Glycine 0 CA--C 1.535 1.287 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.06 -33.01 20.23 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 122.524 2.149 . . . . 0.0 112.596 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.419 ' O ' ' O ' ' A' ' 177' ' ' CYS . 20.8 pt20 -108.05 1.15 22.2 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.566 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.419 ' O ' ' O ' ' A' ' 176' ' ' GLN . 1.1 t 57.17 159.8 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.421 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.257 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 m . . . . . 0 N--CA 1.491 1.624 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.74 146.28 54.63 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.734 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 86.9 mtm180 45.59 31.93 1.05 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.491 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -153.13 91.69 0.13 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -88.24 134.95 12.76 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -104.22 118.64 6.03 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 80.04 166.53 33.8 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -103.91 -55.07 2.44 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.735 0.302 . . . . 0.0 110.447 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -92.15 93.87 8.92 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -178.29 138.58 0.19 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.62 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 78.2 mt -78.57 149.04 33.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.967 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -138.5 159.84 41.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.526 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.58 169.1 29.22 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.59 -168.79 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.938 2.426 . . . . 0.0 111.821 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.626 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 46.4 m-80 59.35 41.04 20.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.743 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 11.4 p -105.33 131.69 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.6 m -141.88 -175.45 4.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.128 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.37 173.5 49.71 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.746 -0.941 . . . . 0.0 110.746 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.4 m -72.88 155.96 39.36 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -58.99 -43.2 91.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.775 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.23 -41.87 98.8 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.173 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -127.74 50.65 2.01 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.723 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.03 151.36 47.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.28 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -154.67 164.94 38.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.158 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.434 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 69.0 m -63.41 128.99 38.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.783 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 12.4 m -48.53 150.92 2.18 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.34 -178.915 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.61 133.5 38.37 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 121.572 1.514 . . . . 0.0 112.178 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.26 -7.94 64.42 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.626 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 54.6 m95 -118.89 138.71 52.57 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 110.592 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -127.83 -176.05 3.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.412 179.278 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.434 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 5.4 p -133.46 177.99 7.27 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.54 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.459 ' O ' ' N ' ' A' ' 77' ' ' GLY . 48.6 mt -89.91 148.86 40.67 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.507 -179.785 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.41 116.16 0.47 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.108 1.872 . . . . 0.0 112.491 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.19 -4.56 54.3 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -86.33 171.1 43.59 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.878 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.431 ' C ' ' ND2' ' A' ' 78' ' ' ASN . 0.5 OUTLIER -133.58 9.19 3.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.977 0.418 . . . . 0.0 110.811 179.929 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -87.28 132.33 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.487 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -97.88 40.0 1.19 Allowed 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 35.4 pt -97.24 12.93 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.855 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.6 t -116.29 87.98 21.65 Favored Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.471 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo -60.69 148.87 90.23 Favored 'Trans proline' 0 N--CA 1.496 1.659 0 C-N-CA 122.819 2.346 . . . . 0.0 111.987 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 91.9 mt -89.17 123.55 41.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.47 110.1 22.74 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.17 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 2.1 mpt_? -65.31 -39.08 92.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.025 0.441 . . . . 0.0 110.328 178.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -119.05 143.36 47.15 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.104 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.7 p -60.86 134.46 57.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.397 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 60.3 m -77.89 -28.07 49.78 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.706 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.4 -102.56 1.74 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -89.19 2.37 54.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.658 0.266 . . . . 0.0 110.639 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.29 -168.86 22.96 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -138.71 150.53 46.26 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.124 0.488 . . . . 0.0 110.854 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 90.8 m -65.89 112.86 3.99 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.33 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 t -107.29 -25.87 11.29 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.467 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.4 mtt-85 -158.09 164.3 21.79 Favored Pre-proline 0 C--N 1.328 -0.334 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.66 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -51.01 121.77 8.79 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.96 1.773 . . . . 0.0 111.485 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 52.09 40.83 29.35 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 48.7 mtt -146.9 114.91 6.54 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.699 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.454 ' N ' ' O ' ' A' ' 108' ' ' ALA . 65.3 m -100.05 146.84 26.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.232 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 66.6 m -115.61 121.6 43.09 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.87 149.55 37.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.498 -179.464 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.65 -21.81 2.58 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.567 2.178 . . . . 0.0 111.974 177.484 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.8 t -68.02 -17.91 64.55 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.8 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.87 -14.68 57.34 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -68.42 153.82 43.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.974 0.416 . . . . 0.0 110.243 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.42 133.15 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.677 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.454 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . 179.71 168.49 0.69 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.301 178.995 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 64.7 Cg_exo -48.8 -33.76 26.02 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 122.597 2.198 . . . . 0.0 112.083 179.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 38.8 m -133.01 165.6 24.34 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.538 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -78.18 123.69 27.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.484 . . . . 0.0 109.84 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 78.96 95.51 0.28 Allowed Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 10.3 t -152.33 -161.13 1.24 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.872 0.368 . . . . 0.0 110.54 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.9 148.47 46.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.482 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 66.4 m -128.48 148.55 50.74 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.121 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.524 ' N ' ' CD1' ' A' ' 116' ' ' ILE . 0.1 OUTLIER -133.2 165.1 33.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.467 -179.437 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -68.58 139.46 55.56 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.107 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.547 ' C ' ' H ' ' A' ' 120' ' ' ASN . 76.1 m80 -112.07 153.76 26.42 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.406 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.47 ' C ' ' H ' ' A' ' 121' ' ' ILE . 12.1 t -62.36 4.52 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.944 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . 0.547 ' H ' ' C ' ' A' ' 118' ' ' HIS . 47.3 t-20 61.09 3.22 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.595 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.47 ' H ' ' C ' ' A' ' 119' ' ' CYS . 18.8 tt -143.84 172.25 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.427 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.469 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 38.0 mtt85 -122.73 99.97 6.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.777 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 28.8 m -90.34 147.16 23.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.739 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.7 mtm -139.97 170.6 15.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.356 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.0 m120 67.48 39.13 2.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.508 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.55 32.44 83.26 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.31 -173.98 14.0 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.1 m -130.98 136.69 48.76 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.4 t -73.33 112.08 9.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.188 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 69.5 m -128.97 119.82 24.99 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.959 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 43.17 -108.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.746 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -121.81 19.81 10.97 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.507 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -131.87 156.02 46.82 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.955 0.407 . . . . 0.0 110.293 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 97.1 m -106.42 131.24 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.0 mt -99.22 131.35 45.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.672 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -100.3 143.2 30.78 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.438 -179.372 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.56 -179.09 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.57 132.84 49.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.53 -179.77 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.25 -19.36 46.1 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -118.11 136.99 53.25 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.784 0.326 . . . . 0.0 110.295 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.6 pt -130.94 171.79 17.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.992 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.01 157.73 10.48 Favored Glycine 0 N--CA 1.464 0.519 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 61.6 p -64.09 -42.53 96.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.835 0.35 . . . . 0.0 110.536 -179.579 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -105.8 5.64 31.0 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.692 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 5.0 m 65.04 140.1 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.076 0.465 . . . . 0.0 109.965 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 152.86 -11.04 0.59 Allowed Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -102.44 110.2 62.32 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.535 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.29 157.46 33.31 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.486 2.124 . . . . 0.0 112.31 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.46 116.66 50.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 120.989 0.423 . . . . 0.0 110.179 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.7 m -88.98 96.38 10.7 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -66.12 -38.5 88.34 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.426 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 97.4 p -82.42 -7.96 59.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.684 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 59.2 161.93 0.07 OUTLIER Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.06 114.5 28.73 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.57 -42.16 98.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.562 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.1 m-20 -100.07 -177.37 3.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.456 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -70.81 33.58 0.49 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.046 -0.821 . . . . 0.0 111.046 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.562 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.55 176.05 28.79 Favored Glycine 0 CA--C 1.52 0.349 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -126.03 142.33 51.57 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.68 0.276 . . . . 0.0 110.494 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.66 122.03 30.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.442 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.2 m -110.16 -9.87 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.308 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -171.91 170.97 2.34 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.41 -0.516 . . . . 0.0 110.737 179.622 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.9 Cg_exo -53.05 128.48 29.16 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 121.913 1.742 . . . . 0.0 111.402 178.768 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 52.58 32.69 12.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.119 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.76 127.8 37.52 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.15 0.5 . . . . 0.0 109.773 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 4.4 t -139.01 148.58 43.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.858 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.51 129.11 47.52 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.471 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 26.8 m -74.43 151.43 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.311 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.8 m -62.96 -45.8 90.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.204 -179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.96 19.52 19.29 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-O 121.077 0.465 . . . . 0.0 110.734 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 68.53 26.71 74.23 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -55.45 149.66 13.05 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 51.8 p -82.29 165.42 20.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.576 -179.32 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 87.44 150.45 18.85 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.82 -23.18 41.89 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.69 2.26 . . . . 0.0 112.272 -179.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 76.6 mt-30 -101.34 7.32 42.81 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.554 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 77.9 m 53.52 -92.68 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.185 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.517 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.8 t . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 48.99 35.11 6.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.541 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -65.05 -39.25 93.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.317 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -56.45 -103.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 92.04 -7.78 78.45 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.13 164.22 54.92 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.71 175.68 44.42 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -66.89 -41.29 87.43 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.526 ' O ' ' N ' ' A' ' 53' ' ' LEU . 99.6 m-20 53.08 83.02 0.07 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.794 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.556 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . 62.43 -68.19 0.07 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.898 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.526 ' N ' ' O ' ' A' ' 51' ' ' ASP . 13.0 mt -64.99 138.58 58.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.166 0.508 . . . . 0.0 110.225 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -133.22 163.03 30.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.32 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.47 160.31 23.13 Favored Glycine 0 CA--C 1.531 1.039 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.54 2.94 6.82 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.862 2.375 . . . . 0.0 112.212 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.591 ' ND2' ' CZ2' ' A' ' 71' ' ' TRP . 3.0 m120 -114.95 69.07 0.71 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.355 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.457 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.1 t -120.42 130.83 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 93.1 m -141.15 176.8 8.54 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.032 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.22 169.15 45.49 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.557 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -74.51 163.25 27.97 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -59.27 -43.94 92.45 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.47 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -64.11 -39.96 95.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.007 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -122.54 46.62 2.1 Favored 'General case' 0 N--CA 1.461 0.079 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.783 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.557 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.92 145.09 48.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.52 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -156.05 168.19 28.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.821 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.5 m -67.47 130.11 42.04 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.189 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.457 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 53.5 m -49.21 153.29 1.73 Allowed Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.246 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -51.64 131.68 38.26 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 121.43 1.42 . . . . 0.0 112.398 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 100.9 -16.53 57.33 Favored Glycine 0 N--CA 1.467 0.737 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.591 ' CZ2' ' ND2' ' A' ' 57' ' ' ASN . 9.1 m95 -115.63 139.58 49.97 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.787 0.327 . . . . 0.0 110.498 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.9 ptpt -120.23 -168.66 1.66 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.312 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 64.1 p -118.13 160.53 21.39 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.483 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.1 mt -87.4 152.84 52.96 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.744 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.44 107.58 0.08 OUTLIER 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.145 1.897 . . . . 0.0 112.184 179.309 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.34 -11.63 12.19 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -88.29 175.99 44.84 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.556 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 34.6 p30 -135.56 15.75 3.4 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.12 0.486 . . . . 0.0 110.639 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -79.87 128.53 33.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.495 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 29.9 m -96.9 55.68 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 30.3 pt -115.92 21.01 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.993 -179.217 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.5 t -119.32 85.74 31.62 Favored Pre-proline 0 N--CA 1.467 0.39 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.697 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -61.35 148.48 92.83 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.936 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.8 mt -90.9 128.63 42.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 3.2 m -99.62 109.02 21.54 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.229 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -65.88 -39.36 90.59 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.052 0.453 . . . . 0.0 109.906 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 61.3 m170 -110.51 142.06 42.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.002 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.5 t -59.62 130.07 45.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.681 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 61.2 m -80.28 -31.52 38.28 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.875 179.374 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.07 -112.48 3.67 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -81.91 -0.55 44.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.16 -175.74 30.35 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.0 147.79 52.47 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.018 0.437 . . . . 0.0 110.794 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.2 m -64.4 111.26 2.57 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.42 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 69.8 p -102.64 -27.51 12.69 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.302 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.1 mtt85 -157.83 163.94 23.03 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.583 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -51.55 121.9 9.32 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 121.634 1.556 . . . . 0.0 111.48 179.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 55.17 40.34 31.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.878 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.8 mmm -149.27 115.81 5.87 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.198 0.523 . . . . 0.0 109.97 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 86.7 m -101.23 151.12 22.25 Favored 'General case' 0 N--CA 1.461 0.116 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.674 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 97.1 m -121.91 126.26 48.26 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.68 151.59 40.12 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.642 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -50.02 -22.73 8.11 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.459 2.106 . . . . 0.0 111.867 177.59 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -66.85 -16.96 64.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.684 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.82 -18.5 49.89 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tt0 -68.05 153.16 44.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.894 0.378 . . . . 0.0 110.304 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.17 130.38 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.581 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -173.27 164.88 3.21 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.962 -179.538 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 15.3 Cg_endo -57.44 -22.81 52.28 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.916 2.411 . . . . 0.0 111.829 178.66 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.9 p -135.38 154.53 51.45 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.97 0.414 . . . . 0.0 110.227 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.86 144.13 30.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.68 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 55.22 46.84 77.61 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.181 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.0 t -60.3 -44.59 95.29 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.697 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 115' ' ' SER . 77.0 ttt180 -167.77 -18.05 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.401 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 114' ' ' ARG . 0.9 OUTLIER 82.9 81.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.398 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.418 HD13 HG22 ' A' ' 116' ' ' ILE . 97.2 mt -120.75 128.52 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-O 120.956 0.408 . . . . 0.0 110.319 179.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -81.53 111.26 17.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.411 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.454 ' H ' ' CD2' ' A' ' 118' ' ' HIS . 9.2 p80 -95.72 -50.57 4.87 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.931 0.396 . . . . 0.0 110.467 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.441 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 96.3 m -116.97 134.53 54.62 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.207 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -63.4 -40.21 96.61 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.444 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.405 HG23 ' H ' ' A' ' 122' ' ' ARG . 1.1 mt -113.31 -157.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.811 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.505 ' NH2' ' NE2' ' A' ' 144' ' ' HIS . 36.6 ptt-85 -120.59 121.72 38.99 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.7 m -124.86 147.0 49.01 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.15 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 70.9 mtm -145.17 174.13 11.34 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.315 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 5.7 m120 59.61 37.2 22.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.44 15.47 79.84 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.7 123.76 10.16 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.158 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 39.9 t -83.51 140.98 31.96 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.75 0.309 . . . . 0.0 110.881 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 5.8 m -83.32 129.94 35.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.18 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.4 m -126.45 158.3 36.38 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.134 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 131' ' ' ASP . 43.4 p-10 -48.24 109.35 0.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.09 0.472 . . . . 0.0 110.991 -178.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 50.24 30.26 4.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.531 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -159.78 154.9 24.95 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.495 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 47.6 t -129.55 132.32 46.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.784 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 80.3 mt -101.09 128.47 47.14 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.598 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 55.6 m -84.77 132.19 34.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.382 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -56.1 161.14 2.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.906 0.384 . . . . 0.0 110.352 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -59.25 130.81 48.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.873 0.368 . . . . 0.0 110.816 -179.552 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 94.5 -6.91 71.37 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -119.74 137.43 53.94 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.924 0.392 . . . . 0.0 110.098 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 22.3 pt -129.61 169.59 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.953 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 121.69 159.34 10.64 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.4 m -62.17 -45.64 92.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 0.0 110.687 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.505 ' NE2' ' NH2' ' A' ' 122' ' ' ARG . 31.9 m-70 -102.75 3.24 36.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.347 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.37 142.94 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.894 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 149.53 -8.24 0.86 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -101.39 109.38 58.73 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.371 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.3 157.49 45.65 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.359 2.039 . . . . 0.0 112.437 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.8 t -124.83 126.81 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.412 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 66.3 m -94.41 109.13 21.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.129 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -66.89 -39.54 87.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.9 m -88.66 -9.16 53.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.712 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.505 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 60.03 177.47 1.48 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 9.0 m -116.08 119.98 37.61 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.024 0.44 . . . . 0.0 110.191 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 94.9 mt -63.57 -42.38 98.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.534 ' C ' ' H ' ' A' ' 158' ' ' GLY . 18.9 m120 -93.6 -178.49 4.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.525 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.34 29.55 0.69 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.534 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.61 179.41 16.81 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -126.2 149.64 48.89 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.942 0.401 . . . . 0.0 110.349 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.52 105.09 17.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -88.41 -19.64 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.566 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -165.93 174.28 2.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.47 -179.889 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_exo -52.84 133.82 52.41 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 121.892 1.728 . . . . 0.0 111.854 179.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 64.7 t30 45.34 36.42 2.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.397 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -130.34 103.82 6.91 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.29 0.567 . . . . 0.0 110.909 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 153' ' ' GLY . 23.2 m -102.2 135.15 44.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.087 -0.961 . . . . 0.0 110.685 179.4 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.98 92.29 3.97 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 178.764 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.6 p -102.23 141.76 34.56 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.468 ' OG1' ' O ' ' A' ' 169' ' ' THR . 0.1 OUTLIER -111.6 13.79 21.28 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.298 0.57 . . . . 0.0 110.568 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -102.32 30.45 4.56 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.164 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 100.28 59.42 0.84 Allowed Glycine 0 N--CA 1.464 0.553 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 172' ' ' PHE . 21.9 t80 -44.51 119.04 1.73 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.033 0.444 . . . . 0.0 110.484 -179.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.825 ' H ' ' H ' ' A' ' 178' ' ' GLU . 7.3 m -153.3 130.61 11.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.375 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 78.03 164.71 24.83 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -66.94 -22.32 48.64 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.896 2.397 . . . . 0.0 112.253 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -89.09 14.01 11.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.951 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.79 111.69 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.021 0.438 . . . . 0.0 110.166 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . 0.825 ' H ' ' H ' ' A' ' 173' ' ' THR . 3.1 tm-20 . . . . . 0 C--N 1.324 -0.53 0 CA-C-O 118.1 -0.953 . . . . 0.0 110.555 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 66.5 p . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.4 143.87 57.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.244 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.3 ttp180 -128.67 133.75 48.31 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.263 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.12 21.01 61.66 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.34 129.3 19.92 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -103.76 -178.38 25.75 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -64.09 -29.57 75.29 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 55.4 68.62 0.84 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 110.439 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.457 ' O ' ' N ' ' A' ' 53' ' ' LEU . 38.3 t70 -70.19 135.97 49.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.527 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . 66.37 -65.98 0.18 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.909 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 51' ' ' ASP . 44.3 mt -72.81 147.71 45.22 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.413 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -135.42 161.8 34.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.037 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.9 163.92 26.88 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -75.03 -7.35 19.05 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 123.058 2.505 . . . . 0.0 112.344 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.447 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 71.9 m-80 -105.32 70.38 0.89 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.597 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.466 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 60.7 t -121.63 130.24 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.925 179.1 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 87.1 m -144.55 -174.1 4.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.009 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.28 171.43 47.51 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.6 m -84.19 167.56 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -59.52 -43.79 93.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.777 0.323 . . . . 0.0 110.738 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -63.97 -36.76 85.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.977 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -129.25 50.33 2.16 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.987 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -73.18 142.81 47.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.371 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -160.75 167.16 27.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.995 0.426 . . . . 0.0 111.03 179.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.403 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 79.1 m -64.04 130.92 45.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.17 -179.491 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.466 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 32.5 m -47.72 151.02 1.64 Allowed Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.103 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -49.62 129.76 24.37 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.498 1.465 . . . . 0.0 112.301 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.67 -18.54 47.09 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.447 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 98.6 m95 -111.77 134.76 53.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.965 0.412 . . . . 0.0 110.085 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -110.99 -167.75 1.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.133 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.403 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.1 p -129.83 165.29 22.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.049 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 12.1 mt -91.53 150.58 41.39 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.834 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.405 ' C ' ' H ' ' A' ' 77' ' ' GLY . 59.8 Cg_exo -44.21 115.4 0.75 Allowed 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.864 1.709 . . . . 0.0 112.036 179.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.12 -8.73 7.93 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.165 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.405 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -91.11 177.94 41.63 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.659 ' H ' ' NE2' ' A' ' 79' ' ' GLN . 26.7 p30 -139.51 13.39 2.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.931 0.396 . . . . 0.0 110.864 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . 0.659 ' NE2' ' H ' ' A' ' 78' ' ' ASN . 12.1 mp0 -84.08 131.78 34.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.469 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 22.5 m -95.88 43.29 1.08 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.361 -0.382 . . . . 0.0 109.987 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 42.4 pt -98.2 6.89 8.66 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.246 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.734 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.66 112.54 60.52 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.417 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.29 156.87 29.52 Favored 'Trans proline' 0 N--CA 1.486 1.059 0 C-N-CA 122.01 1.807 . . . . 0.0 111.864 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.6 mt -100.72 118.91 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.8 115.42 27.12 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -64.73 -45.24 87.36 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.37 0.605 . . . . 0.0 110.106 179.242 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -119.41 -167.89 1.49 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.674 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.2 t -97.04 125.07 41.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.722 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.6 m -74.39 -32.16 62.62 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.776 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -106.08 2.23 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.439 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 31.4 p-10 -81.99 -2.63 52.21 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.719 0.295 . . . . 0.0 110.773 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.63 -176.36 27.14 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -133.72 146.12 50.5 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.058 0.456 . . . . 0.0 110.788 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 70.1 m -64.57 111.3 2.65 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.578 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 89.0 p -105.98 -26.07 11.83 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.33 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 -153.23 159.58 32.01 Favored Pre-proline 0 C--N 1.325 -0.464 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.291 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -48.92 119.07 3.96 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.477 2.118 . . . . 0.0 111.915 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 54.0 t30 55.11 42.88 30.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.228 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mtp -149.06 118.87 7.06 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.09 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 69.2 m -100.64 148.72 24.54 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.792 179.178 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.5 m -119.99 115.59 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.422 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.44 154.0 68.66 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -50.07 -26.56 14.95 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.693 2.262 . . . . 0.0 112.016 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 m -66.49 -15.5 63.41 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.831 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.92 -15.18 58.37 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -65.86 149.31 50.39 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.418 HG21 HD12 ' A' ' 107' ' ' ILE . 96.3 mt -128.2 130.64 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.869 -179.765 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.433 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -170.29 179.43 0.74 Allowed Pre-proline 0 C--N 1.327 -0.406 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.446 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.433 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 35.7 Cg_exo -58.81 -22.71 63.34 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.877 2.385 . . . . 0.0 111.78 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 82.7 p -152.3 163.98 38.36 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.598 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -77.5 -27.55 51.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.315 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.8 98.14 0.46 Allowed Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.1 m -137.35 -24.14 1.08 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.789 0.328 . . . . 0.0 110.57 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -100.45 139.41 36.18 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.8 m -58.76 -40.54 84.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.573 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 79.0 mt -104.3 123.67 58.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.211 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -87.34 141.85 28.33 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.56 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.563 ' O ' ' N ' ' A' ' 120' ' ' ASN . 97.3 m-70 -78.97 150.39 32.02 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.309 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 75.8 m -51.67 82.43 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.224 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . 0.563 ' N ' ' O ' ' A' ' 118' ' ' HIS . 92.3 m-20 -64.36 -40.77 96.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.63 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.551 ' CG2' ' H ' ' A' ' 122' ' ' ARG . 24.7 mm -64.48 177.83 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.962 0.41 . . . . 0.0 109.999 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.551 ' H ' ' CG2' ' A' ' 121' ' ' ILE . 36.8 mmt180 -117.46 98.27 6.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.721 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.2 m -94.33 135.27 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.322 179.175 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.6 mtm -130.17 170.13 14.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.346 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 m120 63.6 41.48 7.19 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.717 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.87 23.61 71.04 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.574 -1.01 . . . . 0.0 110.574 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.93 141.96 24.88 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.635 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 20.1 m -99.87 144.69 28.63 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.725 0.298 . . . . 0.0 110.314 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . 0.5 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 0.5 OUTLIER -93.99 129.79 40.35 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.682 179.897 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 28.8 t -149.36 134.99 18.61 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.394 178.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 51.11 45.82 27.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 56.95 33.65 23.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -143.98 138.2 28.26 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.467 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 95.9 m -91.05 131.4 36.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 110.828 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 76.6 mt -101.83 128.53 48.15 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.338 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . 0.452 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 8.4 m -89.01 135.78 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.53 -179.253 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -73.32 172.6 10.91 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.444 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -62.82 126.12 26.25 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.12 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 107.96 -26.27 17.93 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.61 133.73 54.5 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.946 0.403 . . . . 0.0 110.065 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.3 pt -127.35 169.14 19.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.934 -179.598 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.452 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 118.79 159.87 11.23 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.1 m -62.12 -46.07 90.67 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.566 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -100.68 2.14 41.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.58 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.6 m 62.85 132.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.996 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 164.91 -11.99 0.08 OUTLIER Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -100.27 112.72 64.72 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -75.74 157.76 39.57 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 C-N-CA 122.42 2.08 . . . . 0.0 112.053 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 52.5 t -120.56 130.47 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 18.1 m -90.06 98.81 11.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.183 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.34 -39.36 92.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 0.0 110.418 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 83.1 p -81.83 -6.86 59.44 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.482 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 64.99 161.07 0.56 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.6 m -114.06 104.93 12.63 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.834 0.349 . . . . 0.0 110.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 85.5 mt -63.67 -42.19 98.08 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.598 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.9 t-20 -90.73 173.31 8.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.342 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.69 33.2 0.28 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.598 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.47 -179.01 26.38 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 53.4 mmm-85 -130.46 147.37 52.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.918 0.389 . . . . 0.0 110.218 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 84.0 m -83.99 111.05 18.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.362 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.9 m -95.38 -20.54 5.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.376 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -167.62 173.82 2.71 Favored Pre-proline 0 C--N 1.326 -0.455 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.627 179.926 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -53.97 130.89 41.61 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.164 1.909 . . . . 0.0 111.95 179.252 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . 0.408 ' O ' ' OD1' ' A' ' 164' ' ' ASN . 60.5 t-20 49.74 32.33 5.13 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.084 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -137.0 129.14 29.52 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.447 0.642 . . . . 0.0 110.045 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -131.79 145.38 51.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.0 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -97.13 137.15 36.62 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.703 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . 0.549 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 44.2 m -81.75 142.79 32.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.079 0.466 . . . . 0.0 111.054 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.9 m -63.38 -45.59 90.39 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.084 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -97.89 17.23 18.65 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.106 0.479 . . . . 0.0 111.086 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.79 24.18 77.01 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.549 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 3.1 m-85 -66.01 151.49 46.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.238 0.542 . . . . 0.0 110.191 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -87.61 166.05 14.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.97 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.83 148.51 11.52 Favored Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.17 -29.06 39.98 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 122.448 2.099 . . . . 0.0 112.409 -179.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -115.12 0.89 13.74 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.604 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 73.15 -72.68 0.11 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.784 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.218 -0.566 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.515 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.1 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 51.46 42.16 29.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.505 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -63.91 -39.75 94.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.403 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.84 110.77 0.24 Allowed Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 56.75 -135.74 50.68 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 69.86 -153.49 52.23 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.58 -10.24 68.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 22.9 t-160 39.19 79.85 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.853 0.358 . . . . 0.0 110.874 -179.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 52' ' ' ALA . 38.1 p-10 -65.11 -34.45 78.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.61 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.48 ' N ' ' OD1' ' A' ' 51' ' ' ASP . . . 52.7 -179.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.592 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt -74.34 151.17 39.82 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.58 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.42 165.0 22.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.655 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 70.18 172.43 10.7 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.55 -171.36 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.984 2.456 . . . . 0.0 111.794 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.576 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 62.6 m-20 58.78 38.78 24.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.081 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.451 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 7.4 p -95.53 133.72 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.288 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 60.6 m -151.22 -174.32 4.78 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.275 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.28 174.38 44.92 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.561 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.1 m -82.47 160.81 22.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.607 0.241 . . . . 0.0 110.437 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.53 -43.29 97.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.725 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -61.72 -41.15 97.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.273 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -133.61 54.66 1.94 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.649 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.11 147.54 53.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.291 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.417 ' O ' ' O ' ' A' ' 59' ' ' CYS . 11.7 p90 -153.81 170.16 21.62 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.005 0.431 . . . . 0.0 110.766 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.1 m -73.79 135.42 43.51 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -49.0 167.9 0.2 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.386 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -57.17 132.29 50.37 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.014 1.809 . . . . 0.0 111.643 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 97.14 -17.25 59.51 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.576 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 31.5 m95 -113.61 139.79 48.73 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.927 0.394 . . . . 0.0 110.363 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -125.48 -174.01 2.97 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.192 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 74.6 p -115.48 161.51 18.48 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.432 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' A' ' 77' ' ' GLY . 17.8 mt -87.62 151.68 50.72 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.468 ' C ' ' H ' ' A' ' 77' ' ' GLY . 73.1 Cg_exo -39.21 107.03 0.06 OUTLIER 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 122.235 1.957 . . . . 0.0 112.116 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 72.98 -11.17 4.88 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.01 174.48 53.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -135.28 13.49 3.53 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.06 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -84.63 129.09 34.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.503 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 63.5 m -95.2 60.45 2.33 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 37.3 pt -119.17 26.65 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.855 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.3 t -123.06 84.45 51.03 Favored Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.953 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -63.32 150.26 89.04 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.597 2.198 . . . . 0.0 111.69 179.077 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.9 mt -94.0 121.98 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.33 129.81 45.57 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -63.18 -45.92 89.51 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.206 0.527 . . . . 0.0 110.169 179.951 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -122.38 146.57 47.22 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -52.42 125.42 16.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.376 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.8 m -66.56 -2.03 4.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.544 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 55.59 -116.23 6.84 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.8 p-10 -74.91 -1.26 21.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 110.676 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.61 -164.29 19.83 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.48 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 54.9 p90 -142.84 150.97 40.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.966 0.412 . . . . 0.0 110.646 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -69.64 114.97 8.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.832 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.48 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 5.0 m -105.25 -19.03 13.93 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.586 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.4 mtt85 -157.08 162.54 27.39 Favored Pre-proline 0 N--CA 1.454 -0.263 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.737 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -50.09 122.45 9.22 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 121.95 1.767 . . . . 0.0 111.341 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 72.0 m-20 52.93 38.64 27.52 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.982 179.798 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.7 mtp -146.29 118.76 8.47 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.492 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 37.8 m -105.95 150.42 25.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.718 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' THR . . . . . 0.437 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.7 m -119.69 113.38 20.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.582 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.64 157.19 72.51 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.629 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.3 -21.19 71.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.65 2.234 . . . . 0.0 111.474 178.897 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -67.71 -16.59 64.21 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.727 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 105.63 -20.38 36.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -68.75 151.54 46.51 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.888 0.375 . . . . 0.0 110.528 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -131.22 135.15 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.446 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -167.26 -179.19 0.75 Allowed Pre-proline 0 C--N 1.326 -0.447 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.647 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.446 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 31.5 Cg_exo -60.29 -16.02 38.43 Favored 'Trans proline' 0 N--CA 1.499 1.806 0 C-N-CA 122.953 2.435 . . . . 0.0 111.907 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 27.8 m -160.29 159.81 31.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.756 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -82.64 167.15 18.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.23 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.32 158.26 31.36 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 179.684 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.5 t -60.68 -42.83 97.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.747 0.308 . . . . 0.0 110.819 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 85.7 mtp180 -125.15 148.51 48.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.488 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.6 m -73.54 157.47 36.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.52 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.407 HG23 HD11 ' A' ' 116' ' ' ILE . 24.4 mm -71.89 131.8 34.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.107 -179.704 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -137.01 162.01 34.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.538 -179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 78.5 m80 44.87 -117.82 0.62 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.432 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 177.37 4.87 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.008 0.432 . . . . 0.0 110.082 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -62.6 -40.36 96.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.112 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.591 ' CG2' ' H ' ' A' ' 122' ' ' ARG . 36.1 mm -74.24 178.04 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.239 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.591 ' H ' ' CG2' ' A' ' 121' ' ' ILE . 1.0 OUTLIER -127.68 134.03 49.6 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.166 179.354 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.5 m -118.21 144.6 45.61 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtm -144.3 169.37 18.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.284 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 59.28 40.52 21.23 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.32 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 23.47 67.76 Favored Glycine 0 C--N 1.333 0.371 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.03 119.92 5.07 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 120.432 -0.89 . . . . 0.0 110.929 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.2 p -79.43 145.29 33.39 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.035 -0.266 . . . . 0.0 110.54 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.8 t -97.4 118.44 33.88 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.75 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.422 ' O ' ' N ' ' A' ' 133' ' ' HIS . 29.8 t -148.13 139.76 23.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.575 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.501 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 4.5 p-10 41.98 45.93 3.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 178.974 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 55.45 36.99 28.25 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.457 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.501 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 58.4 m80 -142.7 141.89 31.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.261 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . 0.467 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 81.4 m -99.93 119.82 38.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.497 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.6 mt -98.06 128.26 44.48 Favored 'General case' 0 CA--C 1.518 -0.267 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.79 134.61 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.858 -179.397 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -72.26 -173.77 1.16 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.34 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -67.77 129.13 38.97 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.731 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.64 -9.33 55.48 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -125.46 141.54 52.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.859 0.361 . . . . 0.0 110.528 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.6 pt -132.66 173.79 14.26 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.743 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 112.61 153.54 11.74 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.0 p -63.01 -45.5 92.1 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.698 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -97.83 1.75 48.6 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.511 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 16.4 m 62.62 133.21 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.871 -179.398 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 161.29 -6.71 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -109.21 111.58 60.04 Favored Pre-proline 0 CA--C 1.543 0.693 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.58 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -75.64 156.77 40.23 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.517 2.145 . . . . 0.0 112.435 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 90.9 t -101.98 114.92 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.05 98.25 11.65 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.306 -179.064 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -65.77 -39.66 91.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.71 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 72.1 m -79.62 -7.55 58.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.84 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.46 161.69 0.05 OUTLIER Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 66.7 m -106.51 111.17 23.61 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 89.0 mt -63.18 -42.26 99.35 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.551 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.8 t30 -95.7 173.0 7.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.416 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.59 37.5 0.36 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.551 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -76.55 -172.05 34.5 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -132.21 143.46 49.96 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.872 0.367 . . . . 0.0 110.521 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.6 m -81.92 113.51 19.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.281 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.3 m -88.42 -23.69 6.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.536 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -167.5 171.99 3.81 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.511 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -50.45 127.96 21.93 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.711 1.607 . . . . 0.0 112.01 178.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.8 t30 53.93 36.7 24.97 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.715 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 94.7 mtt-85 -141.42 132.8 26.7 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.207 0.527 . . . . 0.0 110.632 178.973 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 3.4 t -141.45 150.77 42.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.954 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.52 53.57 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.687 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.97 137.13 32.62 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.035 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.0 p -112.58 19.2 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.88 0.371 . . . . 0.0 111.44 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.476 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 34.3 t80 -114.49 31.75 6.42 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.725 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 79.34 15.63 79.69 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -108.26 163.22 13.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.281 0.562 . . . . 0.0 110.917 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.9 t -147.1 152.31 38.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 129.72 162.42 10.82 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.83 -22.86 36.01 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 122.721 2.281 . . . . 0.0 112.186 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -124.37 7.29 8.38 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.523 -179.071 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 73.2 m 48.36 61.96 2.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.642 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.111 -0.947 . . . . 0.0 110.584 -179.979 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.19 -40.39 95.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.452 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -69.19 -37.92 78.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.432 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -72.92 163.36 54.92 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -169.64 170.98 43.06 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.26 176.78 48.2 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.74 -177.34 48.1 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -81.34 137.56 35.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.846 0.355 . . . . 0.0 110.274 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 38.5 t0 -156.64 175.09 14.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.487 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.23 149.09 50.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.393 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 64.8 mt -66.14 151.48 46.85 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.491 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -127.0 161.16 29.03 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.377 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.55 169.7 44.33 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.41 -176.08 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 123.009 2.473 . . . . 0.0 111.908 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 58.9 42.05 20.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.459 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 50.3 t -107.86 133.72 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' TYR . 88.8 m -142.69 -179.02 6.07 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.025 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.34 164.37 40.06 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.531 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.3 m -79.74 168.21 19.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.786 0.327 . . . . 0.0 110.394 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.7 ttt-85 -61.04 -43.23 99.2 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.502 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -62.36 -40.54 96.75 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.962 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -129.35 52.87 1.94 Allowed 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.618 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.531 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.77 142.48 54.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.352 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.406 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -154.7 165.3 36.99 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.492 179.441 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.541 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 81.9 m -71.03 137.92 49.42 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.489 -0.484 . . . . 0.0 109.782 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.459 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 27.4 m -52.9 151.77 8.06 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.106 -178.852 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.93 130.75 32.32 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 121.559 1.506 . . . . 0.0 112.755 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -6.95 61.4 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -119.49 137.2 53.95 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.007 0.432 . . . . 0.0 110.79 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -123.85 -177.05 3.63 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.398 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.541 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 35.8 p -131.21 172.08 12.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.35 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.49 ' O ' ' N ' ' A' ' 77' ' ' GLY . 43.1 mt -90.31 148.59 39.43 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.67 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -40.49 111.49 0.14 Allowed 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.014 1.81 . . . . 0.0 112.574 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 82.02 -16.58 21.06 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -74.76 165.0 54.72 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -129.72 8.66 5.36 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.045 0.45 . . . . 0.0 110.958 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -87.23 130.04 34.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.381 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 56.8 m -94.21 40.8 1.08 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -94.67 11.68 3.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.606 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.64 107.02 53.45 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.684 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -76.53 157.78 36.29 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.282 1.988 . . . . 0.0 112.243 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -103.12 126.18 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.063 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -100.16 127.08 46.48 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.27 -45.27 94.02 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.472 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -126.19 157.32 38.48 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.637 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -60.97 136.49 58.1 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.422 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 57.7 m -78.78 -26.03 44.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.809 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 82.68 -109.32 3.07 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . 0.493 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 23.0 p-10 -78.87 -2.61 40.64 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.674 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.55 -160.46 16.16 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -147.73 153.15 38.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.977 0.418 . . . . 0.0 110.826 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.6 m -63.58 113.4 3.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.973 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 92.6 p -100.89 -22.91 14.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.309 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 mtp180 -158.68 161.14 28.9 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.688 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -45.91 119.47 2.9 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 121.926 1.751 . . . . 0.0 111.725 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 54.82 39.56 31.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.271 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 69.8 mmm -145.83 122.13 10.91 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.441 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 27.3 m -105.8 147.55 28.52 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.286 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 78.7 m -122.3 113.44 19.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.753 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -76.23 157.38 83.06 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.021 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_endo -62.29 -21.67 72.97 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.837 2.358 . . . . 0.0 111.48 178.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 m -63.61 -33.69 76.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.555 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 123.32 -17.24 7.96 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . 0.459 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 1.2 tm0? -69.29 145.0 53.42 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.902 0.382 . . . . 0.0 110.648 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.459 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 92.0 mt -124.29 131.29 73.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.626 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.42 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -171.19 179.43 0.67 Allowed Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.416 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.42 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 35.4 Cg_exo -58.95 -21.8 59.94 Favored 'Trans proline' 0 N--CA 1.498 1.793 0 C-N-CA 122.772 2.315 . . . . 0.0 111.999 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 92.7 p -151.27 164.28 36.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.333 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.33 144.71 33.96 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.573 -179.479 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -173.36 139.61 5.19 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.7 m -84.13 -12.83 54.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.77 0.319 . . . . 0.0 110.35 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -80.57 142.98 33.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.448 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.468 ' O ' ' OG ' ' A' ' 115' ' ' SER . 3.8 p 59.47 100.28 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.293 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 94.3 mt -111.3 128.85 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.238 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -121.34 144.59 48.56 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.147 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.44 ' O ' ' O ' ' A' ' 119' ' ' CYS . 4.7 p80 -97.33 175.17 6.35 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.073 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.44 ' O ' ' O ' ' A' ' 118' ' ' HIS . 1.2 m 58.03 146.08 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.103 0.477 . . . . 0.0 110.756 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -63.97 -39.98 95.36 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.255 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.534 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 11.3 tt -112.17 169.7 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.188 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.676 HH21 ' CE1' ' A' ' 144' ' ' HIS . 28.5 ptt180 -83.21 118.88 23.92 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.034 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.7 143.14 50.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.64 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.573 ' N ' ' SD ' ' A' ' 124' ' ' MET . 2.1 mpp? -141.96 161.49 37.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.182 179.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 57.98 51.79 8.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.282 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.79 19.08 77.89 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.44 143.22 40.31 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.0 t -121.4 141.12 51.28 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 10.5 p -93.15 131.55 38.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.76 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.546 ' O ' ' N ' ' A' ' 132' ' ' ASP . 44.1 t -138.19 131.47 30.39 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.187 179.11 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 60.8 t0 55.31 -80.57 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.504 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.546 ' N ' ' O ' ' A' ' 130' ' ' SER . 37.7 p-10 -155.42 23.28 0.41 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.734 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.443 ' CD2' ' OD1' ' A' ' 132' ' ' ASP . 96.0 m-70 -141.79 158.05 44.27 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.519 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -96.96 131.73 43.46 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.154 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.3 mt -92.68 128.86 38.69 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.756 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . 0.466 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -105.96 132.59 51.87 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.694 -179.595 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -79.83 173.06 12.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.359 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -63.06 133.7 54.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.288 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.62 -25.84 24.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.24 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.466 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 96.5 m-85 -116.13 130.94 57.04 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 28.7 pt -129.68 178.48 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.021 -179.319 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 115.92 159.72 12.07 Favored Glycine 0 N--CA 1.462 0.424 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.7 p -66.12 -33.86 76.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.765 0.317 . . . . 0.0 110.546 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.676 ' CE1' HH21 ' A' ' 122' ' ' ARG . 54.7 m-70 -103.97 1.64 31.41 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.751 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.414 ' O ' ' O ' ' A' ' 144' ' ' HIS . 41.8 t 59.82 122.9 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 159.64 -23.56 0.29 Allowed Glycine 0 CA--C 1.519 0.317 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 1.1 tp-100 -76.89 118.04 69.06 Favored Pre-proline 0 CA--C 1.543 0.673 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.629 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -75.46 157.42 40.84 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.641 2.227 . . . . 0.0 112.393 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.6 t -121.11 129.8 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.445 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.1 m -92.96 98.97 11.7 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -67.07 -36.99 83.21 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.471 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.0 p -85.88 -6.4 59.09 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.93 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.94 -172.17 33.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 57.3 m -139.81 106.69 5.41 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 82.2 mt -63.45 -42.18 98.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.785 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.578 ' C ' ' H ' ' A' ' 158' ' ' GLY . 27.6 t-20 -90.56 170.28 10.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.8 35.38 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.578 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -71.77 -174.63 21.86 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -131.3 147.1 52.54 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.72 0.295 . . . . 0.0 110.812 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 3.6 t -88.12 112.87 23.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.719 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.47 -54.89 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -131.06 175.91 3.31 Favored Pre-proline 0 N--CA 1.466 0.328 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.196 -179.498 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -53.22 130.29 37.59 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 121.813 1.675 . . . . 0.0 112.023 179.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 66.5 t30 51.38 35.78 14.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.47 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.7 ttt85 -137.08 124.34 21.83 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.588 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.9 t -130.21 138.27 50.49 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.02 140.65 29.67 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.768 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.3 m -81.23 143.3 32.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.839 0.352 . . . . 0.0 110.158 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.1 m -63.46 -45.37 91.12 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.024 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.525 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 80.3 t80 -98.56 24.54 7.32 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.169 0.509 . . . . 0.0 110.815 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.16 24.2 70.28 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -56.27 159.57 3.46 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.88 0.371 . . . . 0.0 110.18 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.432 ' CG2' ' N ' ' A' ' 174' ' ' GLY . 89.4 m -82.26 162.42 22.33 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.198 0.523 . . . . 0.0 111.143 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . 0.432 ' N ' ' CG2' ' A' ' 173' ' ' THR . . . 66.94 152.03 0.2 Allowed Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 179.423 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.57 -29.1 44.52 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.695 2.263 . . . . 0.0 112.056 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -78.75 -15.46 58.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.603 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 39.4 m 54.22 52.26 12.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.42 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.501 -179.968 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.3 m . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.08 141.07 57.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -93.11 139.33 30.68 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.463 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.78 155.5 13.1 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -102.44 120.6 6.88 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -94.43 177.22 36.05 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -140.1 123.72 2.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.629 -0.989 . . . . 0.0 110.629 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -134.07 131.59 38.98 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 110.336 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -74.67 142.01 44.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.558 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.405 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -150.95 131.56 13.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.511 179.644 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.6 mt -76.69 146.2 38.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.428 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.0 mtpt -128.86 160.4 32.73 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.3 0.571 . . . . 0.0 110.77 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 162.74 25.29 Favored Glycine 0 CA--C 1.528 0.904 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.08 3.08 7.35 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.704 2.269 . . . . 0.0 112.248 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.6 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 0.3 OUTLIER -112.58 61.3 0.63 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.105 0.479 . . . . 0.0 110.429 -179.654 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.9 t -109.71 129.68 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-O 121.193 0.52 . . . . 0.0 109.72 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 85.1 m -141.92 176.91 8.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.664 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 171.5 45.85 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.3 m -82.19 165.1 20.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.703 0.287 . . . . 0.0 110.457 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -60.02 -42.67 94.86 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.659 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -61.17 -41.36 96.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.006 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -132.72 54.75 1.93 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.489 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.52 142.49 56.54 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.493 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 13.6 p90 -151.45 165.89 32.77 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.186 0.517 . . . . 0.0 110.901 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 57' ' ' ASN . 1.6 t -73.59 138.42 44.89 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.436 179.51 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -58.42 157.97 16.3 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.859 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -60.76 137.35 72.4 Favored 'Trans proline' 0 N--CA 1.493 1.442 0 C-N-CA 121.903 1.735 . . . . 0.0 111.817 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.59 55.21 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.6 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.1 m95 -112.79 134.69 54.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 117.066 0.433 . . . . 0.0 109.84 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.8 ptpt -114.2 -175.1 2.6 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.5 p -125.4 165.94 17.49 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.67 149.19 45.66 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.721 -179.344 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.528 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.8 Cg_exo -44.77 123.15 4.61 Favored 'Trans proline' 0 N--CA 1.491 1.362 0 C-N-CA 121.693 1.596 . . . . 0.0 112.208 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.42 -7.56 0.9 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 179.564 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.77 179.48 38.48 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.405 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 46.9 p30 -138.0 11.89 2.86 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.831 0.348 . . . . 0.0 110.797 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -82.37 129.46 34.88 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 8.0 m -106.09 80.75 1.55 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.316 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.6 pt -129.69 15.88 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.651 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 t -126.77 99.77 29.01 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -77.45 163.16 30.05 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.364 2.043 . . . . 0.0 111.939 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 45.7 mm -94.99 122.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -95.71 121.39 37.38 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.74 -45.68 91.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.172 0.511 . . . . 0.0 109.766 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -112.77 137.92 50.37 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.087 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.9 m -60.56 134.35 56.99 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.958 0.409 . . . . 0.0 110.129 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 28.7 m -76.45 -31.78 58.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.182 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 66.88 -101.56 0.67 Allowed Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.437 -0.665 . . . . 0.0 111.437 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -67.54 -17.71 64.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.835 0.35 . . . . 0.0 111.004 -179.462 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.78 -161.56 21.11 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.443 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 54.8 p90 -143.2 151.7 40.93 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.903 0.382 . . . . 0.0 111.2 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.9 t -64.49 114.14 4.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.157 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.446 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 68.2 m -103.05 -23.75 13.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.769 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.7 mtt180 -162.31 165.47 15.58 Favored Pre-proline 0 CA--C 1.531 0.248 0 C-N-CA 120.396 -0.521 . . . . 0.0 110.407 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.6 123.55 11.65 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 121.601 1.534 . . . . 0.0 111.49 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 8.2 t-20 51.57 40.51 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.033 179.992 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.9 mmm -147.47 114.48 6.16 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.576 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.412 ' N ' ' O ' ' A' ' 108' ' ' ALA . 35.5 m -101.28 149.28 24.18 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.323 178.994 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' THR . . . . . 0.446 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 63.6 m -120.97 119.68 33.25 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.706 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 157.28 60.32 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.143 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -62.7 -19.23 67.63 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.66 2.24 . . . . 0.0 111.78 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 42.0 m -69.79 -14.27 62.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.331 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.67 -20.4 39.32 Favored Glycine 0 N--CA 1.464 0.517 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -69.19 149.5 48.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.985 0.421 . . . . 0.0 110.092 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.33 133.6 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.422 ' CB ' ' CD ' ' A' ' 109' ' ' PRO . . . -166.55 -179.82 0.9 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.287 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.422 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 32.2 Cg_exo -59.52 -20.07 55.29 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.835 2.357 . . . . 0.0 112.162 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.7 p -155.58 163.03 40.51 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.414 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -86.49 141.03 29.38 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.68 -167.65 31.56 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 12.7 p -149.68 157.59 43.38 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.855 0.36 . . . . 0.0 110.059 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -90.43 135.79 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.541 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 12.2 p -154.11 153.16 31.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.275 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 19.6 tt -157.62 138.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.531 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -112.97 146.48 38.97 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.325 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.404 ' CD2' ' O ' ' A' ' 119' ' ' CYS . 49.5 p-80 -154.11 -163.53 1.65 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.26 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.404 ' O ' ' CD2' ' A' ' 118' ' ' HIS . 76.9 m -69.45 126.3 29.35 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -92.14 9.34 33.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.027 0.441 . . . . 0.0 110.369 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.501 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 14.8 tt -134.11 169.19 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.607 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.501 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.6 ptm180 -100.12 106.45 18.17 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.04 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.9 m -99.73 138.04 37.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.099 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 66.2 mtt -143.23 160.64 40.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.249 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.618 ' ND2' ' CD1' ' A' ' 140' ' ' TYR . 98.0 m-20 59.86 40.18 19.58 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.841 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.52 28.58 63.2 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.01 128.79 23.3 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' SER . . . . . 0.483 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 13.3 m -88.87 137.84 31.95 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 122.739 -0.271 . . . . 0.0 110.537 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 62.4 m -77.63 129.67 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.166 179.725 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 40.9 t -143.85 136.39 27.03 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.575 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' SER . 96.5 m-20 33.75 -99.91 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.387 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -125.3 4.75 7.75 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.365 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -129.65 154.48 47.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.739 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.9 t -102.77 146.27 28.49 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.442 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.9 mt -98.61 131.26 44.94 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.155 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -97.83 134.26 41.22 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.68 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -80.67 178.23 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.707 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -66.59 133.24 49.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.283 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.54 35.08 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.618 ' CD1' ' ND2' ' A' ' 125' ' ' ASN . 92.9 m-85 -121.63 134.41 54.99 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.093 0.473 . . . . 0.0 110.531 179.52 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 36.6 pt -121.94 -163.84 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.357 -179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.4 152.93 28.95 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.9 m -63.11 -45.03 93.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.881 0.372 . . . . 0.0 110.661 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -94.73 3.17 55.36 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.876 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 33.7 t 61.4 116.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.472 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.55 ' N ' HE21 ' A' ' 147' ' ' GLN . . . 173.71 -20.59 0.06 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . 0.685 HE21 ' H ' ' A' ' 147' ' ' GLN . 0.0 OUTLIER -94.68 128.92 37.94 Favored Pre-proline 0 CA--C 1.548 0.888 0 CA-C-N 117.048 0.424 . . . . 0.0 110.267 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -76.99 161.72 32.64 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.821 2.347 . . . . 0.0 111.809 178.918 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 54.7 t -99.15 127.9 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.3 -179.418 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -101.57 90.53 4.09 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -65.46 -43.09 91.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.519 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 85.8 p -89.15 -8.75 53.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.527 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.447 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 56.82 -179.46 0.63 Allowed Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.3 m -117.73 118.78 33.0 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.1 mt -63.21 -42.25 99.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.032 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.581 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.0 t-20 -93.18 179.93 5.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.462 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.22 32.93 0.32 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.581 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.44 177.16 26.23 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 23.2 mmm180 -128.49 143.61 51.01 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.811 0.338 . . . . 0.0 110.269 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 33.8 m -83.06 113.08 20.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -101.56 -18.25 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.704 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -162.97 171.4 6.39 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.248 179.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -51.7 129.16 28.84 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 121.705 1.603 . . . . 0.0 111.921 179.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 50.81 34.34 10.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.734 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.5 OUTLIER -127.55 119.03 25.09 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.028 0.442 . . . . 0.0 110.175 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.523 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 26.4 m -110.8 122.66 48.39 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.075 179.555 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -88.02 135.65 33.32 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . 0.582 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 87.8 m -84.05 141.4 31.18 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.039 0.447 . . . . 0.0 110.382 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.7 m -63.24 -45.58 90.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.283 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -104.78 18.58 22.04 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.133 0.492 . . . . 0.0 110.984 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 72.19 24.8 75.86 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.53 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 91.5 t80 -54.64 143.9 23.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.883 0.373 . . . . 0.0 110.403 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 96.3 m -103.86 125.56 50.37 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.375 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -179.21 162.05 28.62 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.28 -31.4 73.82 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.67 2.247 . . . . 0.0 112.4 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -110.27 4.57 20.99 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.292 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.582 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.7 t 49.74 71.67 0.38 Allowed 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.716 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.681 179.928 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 73.6 m . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -72.59 -10.34 59.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.534 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -68.46 140.27 55.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.578 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.73 -174.23 36.34 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.841 -0.903 . . . . 0.0 110.841 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -164.86 118.31 0.8 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 165.33 -172.36 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 141.38 49.75 0.05 OUTLIER Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.984 -0.847 . . . . 0.0 110.984 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . 0.735 ' CG ' ' H ' ' A' ' 51' ' ' ASP . 26.1 t-80 -63.19 -168.09 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.709 0.29 . . . . 0.0 110.373 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.735 ' H ' ' CG ' ' A' ' 50' ' ' HIS . 96.8 m-20 -61.9 -40.69 96.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.511 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -158.63 153.09 24.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.586 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 92.2 mt -82.34 161.9 22.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.662 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.7 mtpt -123.25 166.26 15.55 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.845 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 69.13 165.7 4.29 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.47 -166.17 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.956 2.437 . . . . 0.0 111.876 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 4.0 m120 58.64 36.14 24.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.8 p -100.46 136.56 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.031 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 60.4 m -141.41 176.9 8.5 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.994 0.426 . . . . 0.0 110.283 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.15 161.71 31.43 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.1 m -77.91 171.07 15.54 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 44.9 ttm180 -59.98 -42.91 95.19 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.852 0.358 . . . . 0.0 110.392 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -62.89 -40.45 97.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.994 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.471 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 21.2 m120 -125.67 50.52 1.82 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.578 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.92 138.27 49.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.607 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.471 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.9 p90 -158.45 165.64 34.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.106 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 79.4 m -69.2 139.08 54.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.296 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 25.7 m -54.42 146.89 30.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.095 -179.155 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -48.01 125.58 11.85 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 C-N-CA 121.605 1.537 . . . . 0.0 112.344 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.424 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.45 -12.89 58.4 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 88.9 m95 -114.82 134.38 55.18 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 110.213 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -125.25 -170.26 2.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.51 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 3.2 p -131.33 168.9 16.77 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.332 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.508 HD11 ' H ' ' A' ' 74' ' ' LEU . 0.0 OUTLIER -87.29 164.46 35.56 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.436 -179.21 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -53.0 125.41 18.21 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 121.875 1.717 . . . . 0.0 112.035 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.05 -0.31 11.89 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.89 174.48 35.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -140.14 7.54 2.22 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.881 0.372 . . . . 0.0 110.698 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 -83.33 131.22 35.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 54.1 m -94.27 38.53 1.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.905 0.383 . . . . 0.0 110.11 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.09 6.54 6.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.646 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.0 t -107.03 117.08 57.36 Favored Pre-proline 0 CA--C 1.537 0.446 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.913 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.73 155.71 44.24 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.418 2.079 . . . . 0.0 112.433 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.424 ' N ' ' O ' ' A' ' 70' ' ' GLY . 83.2 mt -107.34 119.12 56.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.199 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.89 113.85 26.23 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.461 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 1.8 mpt_? -62.31 -40.21 95.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.375 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -109.59 127.8 54.76 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 109.842 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.6 p -49.41 122.13 5.81 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.209 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.63 -24.24 56.42 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.919 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.72 -115.48 4.26 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -77.52 -4.46 45.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.37 175.9 36.5 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 40.2 t80 -123.17 132.57 54.11 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.221 0.534 . . . . 0.0 111.172 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . 0.479 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 3.4 m -65.57 117.57 8.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.827 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.461 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 47.1 m -104.87 -21.94 13.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.53 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 -158.44 163.15 25.26 Favored Pre-proline 0 C--N 1.331 -0.214 0 C-N-CA 120.264 -0.575 . . . . 0.0 110.748 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -48.98 120.48 5.5 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.926 1.751 . . . . 0.0 111.501 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 98' ' ' ASN . 56.3 t-20 54.69 41.47 31.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.975 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.0 mmm -146.59 115.68 6.97 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.954 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' ALA . 91.0 m -99.15 146.74 25.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.71 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' THR . . . . . 0.461 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 32.8 m -118.84 114.19 22.25 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.151 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.9 158.75 64.45 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.997 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -55.36 -28.01 60.89 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 122.749 2.299 . . . . 0.0 111.817 178.027 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.3 t -63.97 -16.6 61.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.591 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.73 -13.64 59.27 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -69.46 149.85 47.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.918 0.389 . . . . 0.0 110.039 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.4 HG21 HD12 ' A' ' 107' ' ' ILE . 95.4 mt -125.44 129.45 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.812 179.855 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.447 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -164.23 179.16 1.23 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.498 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . 0.443 ' CD ' ' CB ' ' A' ' 108' ' ' ALA . 32.4 Cg_exo -59.21 -23.39 69.27 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.824 2.349 . . . . 0.0 111.944 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 36.2 p -155.53 162.95 40.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.677 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.35 -37.76 43.62 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.365 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.9 -40.05 96.96 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 42.0 t -68.44 138.6 55.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 85.8 mtp180 -125.11 47.77 2.11 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -69.62 149.09 48.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.583 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 20.0 tt -68.45 130.3 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.459 -179.896 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 51.08 -116.53 0.99 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.63 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -159.01 -40.24 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.326 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 5.1 m -95.94 78.42 3.21 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.537 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -64.27 -39.79 94.66 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.216 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 19.7 tt -77.93 166.05 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.348 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -93.41 123.13 36.5 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.951 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.3 m -123.66 141.27 52.17 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.598 179.513 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.9 mtm -146.19 163.25 36.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.431 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.53 ' OD1' ' CE1' ' A' ' 140' ' ' TYR . 5.2 t-20 63.11 44.05 6.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.953 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.43 22.64 78.83 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.344 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.53 162.76 36.97 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.2 t -133.35 141.56 47.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.308 . . . . 0.0 110.204 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.31 123.15 36.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.77 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 25.1 t -148.45 134.34 19.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.605 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 48.46 46.77 20.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.5 t0 55.24 27.89 10.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.452 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -137.74 137.3 38.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.231 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 13.8 t -92.14 129.96 37.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.921 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 83.0 mt -113.5 143.57 44.3 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.115 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.6 m -103.99 144.51 31.44 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.54 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 48.4 mt-30 -68.19 174.55 3.83 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -66.28 131.3 45.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.578 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.57 -15.46 53.13 Favored Glycine 0 N--CA 1.467 0.762 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.53 ' CE1' ' OD1' ' A' ' 125' ' ' ASN . 86.8 m-85 -116.88 134.83 54.28 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.275 -0.269 . . . . 0.0 110.275 179.533 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.8 pt -125.37 165.36 22.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 122.35 153.47 8.87 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 20.1 m -62.22 -47.07 86.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 110.681 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -99.58 2.98 45.17 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.79 136.84 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 154.6 -9.72 0.4 Allowed Glycine 0 CA--C 1.518 0.247 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -103.19 108.57 59.32 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.324 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.82 161.61 36.13 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.711 2.274 . . . . 0.0 112.069 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.5 t -116.54 129.31 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.01 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 21.5 m -97.46 107.24 19.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -66.26 -40.16 89.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.448 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.8 m -86.36 -10.72 53.82 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 68.43 -177.47 25.46 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 22.5 m -128.91 114.14 16.1 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.0 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.6 mt -63.38 -42.13 98.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.549 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.465 ' C ' ' H ' ' A' ' 158' ' ' GLY . 98.0 m-20 -95.94 -172.36 2.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.389 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.65 38.24 1.24 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.465 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -72.55 176.38 42.29 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -130.2 148.36 52.03 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.2 m -85.05 120.18 26.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.081 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.8 m -104.01 -11.68 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.295 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -176.55 174.79 0.69 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -55.24 125.13 18.14 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.163 1.908 . . . . 0.0 111.116 178.99 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 16.3 t-20 56.15 34.66 24.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.682 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.1 mmt-85 -135.37 131.64 36.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.402 0.62 . . . . 0.0 110.624 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.48 ' O ' ' CE1' ' A' ' 172' ' ' PHE . 7.7 t -142.82 147.1 34.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.756 179.524 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -120.99 122.06 39.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.947 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.72 154.95 22.18 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.877 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.4 p -106.96 15.23 25.58 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.957 0.408 . . . . 0.0 110.836 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.414 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 23.9 t80 -119.71 32.94 5.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.933 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.46 57.52 1.64 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.779 -0.929 . . . . 0.0 110.779 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.48 ' CE1' ' O ' ' A' ' 166' ' ' CYS . 89.7 t80 -47.29 110.03 0.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.893 0.378 . . . . 0.0 110.646 -179.527 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 177' ' ' CYS . 91.0 m -129.16 126.86 40.17 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.22 179.272 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 64.15 166.44 1.05 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.364 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.401 ' C ' ' H ' ' A' ' 177' ' ' CYS . 38.2 Cg_exo -55.88 -36.91 96.3 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 C-N-CA 122.75 2.3 . . . . 0.0 112.313 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -74.96 46.46 0.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.448 -179.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.44 ' O ' ' N ' ' A' ' 173' ' ' THR . 42.3 t 54.2 -93.35 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.646 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.953 -1.022 . . . . 0.0 110.198 -179.857 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 60.2 p . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -137.14 140.6 41.98 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.333 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 51.2 mmm-85 -76.71 147.6 37.3 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.436 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -62.21 -43.01 99.71 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 63.2 29.41 74.38 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -62.57 -38.65 96.73 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.441 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 55.97 95.51 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 74.7 m80 54.72 95.49 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 110.377 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' A' ' 53' ' ' LEU . 44.2 p-10 -143.05 177.09 8.61 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.33 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.524 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -60.26 -44.6 95.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.619 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . 0.437 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 81.0 mt -76.45 153.04 35.96 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -138.36 159.84 41.02 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 120.997 0.427 . . . . 0.0 110.69 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.42 166.1 19.31 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -77.19 -1.31 11.48 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.902 2.402 . . . . 0.0 112.281 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.61 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 78.5 m-20 -117.34 71.8 0.82 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.777 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.491 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.9 t -121.45 130.32 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 75.3 m -142.89 -174.7 4.25 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.201 -179.081 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.83 171.08 45.38 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.5 m -78.89 163.57 25.17 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -59.93 -42.88 94.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.555 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -61.67 -42.39 98.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -127.25 49.38 2.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.871 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.07 146.87 53.86 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.669 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -152.9 168.82 24.51 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.824 0.345 . . . . 0.0 110.949 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 91.5 m -70.51 131.32 43.84 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.188 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 62.1 m -49.35 152.37 2.21 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.076 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_exo -51.59 131.64 37.92 Favored 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 121.387 1.392 . . . . 0.0 112.459 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.84 -5.08 53.48 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.61 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 44.5 m95 -132.24 140.86 48.82 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.625 0.25 . . . . 0.0 110.455 179.314 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -115.4 -166.4 1.12 Allowed 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.005 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 76.9 p -115.87 158.21 23.3 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.478 ' O ' ' N ' ' A' ' 77' ' ' GLY . 18.9 mt -89.91 151.08 44.88 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.604 -179.191 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.454 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.5 Cg_exo -39.94 106.68 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.206 1.937 . . . . 0.0 112.142 179.43 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.42 -10.57 2.66 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.478 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.19 171.81 52.18 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.524 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 55.1 p30 -127.87 11.39 6.62 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.551 0.215 . . . . 0.0 111.117 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -89.46 139.1 30.86 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.887 -179.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.2 m -99.26 43.18 1.07 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.921 0.391 . . . . 0.0 110.018 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 43.4 pt -94.2 19.23 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.474 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.32 95.05 49.03 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -77.59 159.79 31.87 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.265 1.976 . . . . 0.0 112.221 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.59 120.67 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.498 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.07 109.37 21.34 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.485 ' HE ' HD22 ' A' ' 98' ' ' ASN . 1.1 mpt_? -64.55 -39.6 94.05 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.521 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -103.42 133.47 48.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.147 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 31.2 t -61.94 134.43 56.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.33 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 32.4 m -78.97 -28.21 43.57 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.507 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 76.19 -104.72 1.87 Allowed Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 179.543 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -80.04 -3.48 48.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.659 0.266 . . . . 0.0 111.083 -179.492 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.3 -160.1 20.19 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -147.05 152.19 38.14 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.918 0.39 . . . . 0.0 111.33 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.41 115.61 5.28 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 20.7 t -109.84 -24.17 10.99 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.927 -179.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -156.14 158.43 31.58 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.095 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -52.51 125.63 18.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.043 1.829 . . . . 0.0 111.22 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.485 HD22 ' HE ' ' A' ' 86' ' ' ARG . 60.9 m-80 53.04 37.76 25.58 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.5 mtp -148.94 114.65 5.66 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-O 121.37 0.605 . . . . 0.0 110.895 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 108' ' ' ALA . 27.6 m -96.9 147.54 23.86 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.441 178.846 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 87.0 m -119.89 123.77 44.39 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.572 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.82 155.3 45.46 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.74 -20.03 67.53 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.332 2.021 . . . . 0.0 111.654 179.253 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.6 t -66.57 -17.04 64.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.282 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.28 -20.84 34.45 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 52.5 tp60 -67.87 150.7 48.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.839 0.352 . . . . 0.0 110.252 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.5 mt -130.54 132.56 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.858 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.411 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -169.42 177.75 1.08 Allowed Pre-proline 0 CA--C 1.536 0.433 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.28 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_exo -56.32 -23.76 47.93 Favored 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 122.602 2.201 . . . . 0.0 111.911 179.555 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 30.0 p -151.79 162.23 41.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.433 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . 0.407 ' C ' ' H ' ' A' ' 113' ' ' SER . 0.8 OUTLIER -78.14 -27.52 48.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.3 179.796 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -75.37 42.98 1.49 Allowed Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.407 ' H ' ' C ' ' A' ' 111' ' ' CYS . 39.9 t -62.96 139.76 58.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.038 0.447 . . . . 0.0 110.694 -179.565 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.1 mmt-85 -79.01 -13.67 59.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.371 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 47.7 t -73.34 101.6 3.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.313 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 42.4 pt -141.67 -159.85 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.669 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -56.84 134.32 55.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.098 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -58.78 -42.55 89.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.376 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . 0.492 ' SG ' ' N ' ' A' ' 120' ' ' ASN . 34.3 t -172.25 175.03 3.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.704 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . 0.492 ' N ' ' SG ' ' A' ' 119' ' ' CYS . 25.0 p-10 -95.96 10.44 37.36 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.687 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -139.31 165.46 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.785 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -77.41 98.62 5.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.75 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.2 m -111.07 119.06 37.76 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 95.9 mtp -139.82 165.26 27.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.447 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.513 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 3.7 m-20 59.92 39.61 20.06 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.702 0.287 . . . . 0.0 110.992 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.15 25.22 69.29 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.16 126.55 26.03 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' SER . . . . . 0.496 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 4.9 m -82.21 133.38 35.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.65 0.262 . . . . 0.0 110.311 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.2 t -95.05 116.92 29.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.254 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 32.4 t -139.01 143.98 38.69 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.124 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 41.67 -116.8 0.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -119.57 21.93 11.88 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -143.0 145.67 33.14 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.522 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.3 t -105.11 140.76 37.81 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.247 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.0 mt -102.33 131.84 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.022 -179.657 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 20.6 m -92.25 134.37 34.95 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -61.33 173.49 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . 0.417 ' HD3' ' N ' ' A' ' 138' ' ' LYS . 0.0 OUTLIER -62.95 136.18 57.7 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.368 0.604 . . . . 0.0 111.499 179.52 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 88.72 -8.61 78.91 Favored Glycine 0 CA--C 1.519 0.316 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.16 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -118.76 135.33 54.57 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.953 0.406 . . . . 0.0 110.326 179.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 48.7 pt -133.94 173.31 14.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.507 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.103 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 103.0 163.46 25.78 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.1 p -65.61 -39.68 91.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.609 0.242 . . . . 0.0 110.832 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -96.46 10.74 37.32 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.853 0.358 . . . . 0.0 110.461 179.713 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.513 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 14.7 m 45.76 41.16 7.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.037 -179.551 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -108.78 5.44 32.66 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -112.38 110.62 53.01 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 116.793 0.297 . . . . 0.0 110.718 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.7 161.85 27.43 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.514 2.142 . . . . 0.0 112.193 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.7 t -111.99 129.08 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.188 0.518 . . . . 0.0 109.988 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -98.71 93.1 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -68.69 -42.01 78.39 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.4 m -97.77 -10.23 25.19 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.915 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 66.43 179.48 10.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -98.12 179.18 4.85 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . 0.532 ' CD1' ' H ' ' A' ' 177' ' ' CYS . 86.0 mt -88.18 -3.54 58.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.528 ' C ' ' H ' ' A' ' 158' ' ' GLY . 0.1 OUTLIER -170.64 -147.21 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.403 179.723 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -73.8 30.95 0.9 Allowed Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.528 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -61.68 173.49 7.34 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 71.9 ttt-85 -114.06 123.18 49.05 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.486 0.184 . . . . 0.0 110.903 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 69.0 m -68.23 91.32 0.37 Allowed 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.12 -27.48 14.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.301 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -156.95 173.87 4.58 Favored Pre-proline 0 C--N 1.329 -0.302 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.421 ' O ' ' N ' ' A' ' 165' ' ' ARG . 51.3 Cg_exo -52.33 136.54 55.46 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 121.588 1.525 . . . . 0.0 111.941 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 41.89 25.74 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.627 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 163' ' ' PRO . 75.0 mmt-85 -134.21 140.55 46.56 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.709 0.766 . . . . 0.0 110.984 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 28.7 p -150.37 161.17 43.01 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.517 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.85 139.09 45.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.012 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . 0.6 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 88.2 m -70.08 138.59 52.16 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-O 121.012 0.435 . . . . 0.0 110.173 -179.319 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.0 m -62.66 -46.07 89.9 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.89 -178.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -117.48 28.27 8.56 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 59.4 30.09 67.44 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.454 ' CZ ' ' SG ' ' A' ' 168' ' ' CYS . 24.5 p90 -67.54 152.37 45.76 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.644 0.259 . . . . 0.0 110.829 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 20.4 p -80.96 143.22 32.75 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.002 -179.393 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -178.54 158.2 22.53 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.04 -51.44 2.21 Favored 'Trans proline' 0 N--CA 1.499 1.795 0 C-N-CA 122.422 2.081 . . . . 0.0 112.92 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 46.8 mt-30 -80.66 -50.08 10.39 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.086 0.469 . . . . 0.0 110.534 -179.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.6 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 36.5 t -116.61 115.22 25.29 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.383 178.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . 0.442 ' OXT' ' O ' ' A' ' 172' ' ' PHE . 75.0 tt0 . . . . . 0 C--N 1.325 -0.471 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.988 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -74.44 99.43 3.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.301 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.8 mtt-85 -63.44 -38.53 91.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.208 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -80.42 167.65 50.8 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.79 156.36 25.27 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -95.65 172.19 29.76 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.53 112.66 4.34 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -111.72 124.36 52.17 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.926 0.393 . . . . 0.0 110.443 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.546 ' OD1' ' N ' ' A' ' 52' ' ' ALA . 45.7 p-10 -65.6 -35.21 80.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.616 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.546 ' N ' ' OD1' ' A' ' 51' ' ' ASP . . . -174.32 -13.66 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.512 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 29.0 mt -70.54 137.08 49.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.238 0.542 . . . . 0.0 110.795 179.943 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -142.91 164.01 31.24 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.53 22.8 Favored Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.212 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -76.01 7.43 3.26 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.792 2.328 . . . . 0.0 112.187 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.459 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 80.1 m-20 -123.12 70.5 1.03 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.891 0.377 . . . . 0.0 111.087 -179.661 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.444 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 51.8 t -115.07 130.82 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 57.2 m -151.3 178.44 9.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.457 -179.673 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.3 172.23 39.98 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -81.18 163.76 22.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.63 0.253 . . . . 0.0 110.326 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 73.3 ttp85 -59.54 -43.25 93.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.685 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -62.9 -37.25 86.2 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . 0.434 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 41.9 t30 -132.51 53.75 1.99 Allowed 'General case' 0 C--O 1.23 0.078 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.906 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.543 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -72.51 142.56 48.52 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.266 179.247 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.434 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.8 p90 -159.36 171.21 20.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.4 m -67.97 135.33 52.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.153 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -48.36 168.43 0.17 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -178.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.47 133.62 58.12 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.093 1.862 . . . . 0.0 112.114 179.046 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 94.98 -17.19 59.78 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.459 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.8 m95 -112.79 138.18 50.0 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -122.25 -165.49 1.28 Allowed 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.2 p -126.04 164.7 20.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.202 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.528 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.6 mt -88.96 151.44 47.12 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.814 -179.119 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.417 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.7 Cg_exo -39.86 107.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.348 2.032 . . . . 0.0 112.121 179.171 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.17 -14.95 7.25 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.528 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.76 178.59 52.32 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -139.35 15.21 2.58 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 121.105 0.479 . . . . 0.0 110.7 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -80.34 131.99 35.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.262 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.93 47.89 1.11 Allowed 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.732 0.301 . . . . 0.0 110.403 -179.573 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.7 pt -105.71 22.38 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.758 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 t -124.45 97.78 39.05 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.725 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -78.76 157.15 27.82 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.691 2.261 . . . . 0.0 112.097 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.491 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.7 mt -109.51 118.63 57.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.963 0.411 . . . . 0.0 110.297 179.109 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 17.0 m -90.64 130.38 36.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.157 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -61.75 -45.44 93.92 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.183 0.515 . . . . 0.0 110.08 -179.635 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -107.46 142.31 37.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.231 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.8 m -60.72 133.79 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.264 -179.499 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 52.8 m -76.1 -27.84 57.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.583 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.32 -113.45 3.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -72.57 -9.1 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.887 0.375 . . . . 0.0 110.785 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.42 -166.66 29.86 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -139.81 146.25 39.17 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.09 0.472 . . . . 0.0 110.902 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 18.6 t -69.05 116.3 9.34 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.5 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 83.6 p -105.26 -22.02 13.14 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.413 -179.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . 0.467 ' CG ' HH11 ' A' ' 96' ' ' ARG . 0.1 OUTLIER -158.99 165.53 18.26 Favored Pre-proline 0 C--O 1.236 0.385 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.845 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -51.97 122.35 10.37 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 121.836 1.691 . . . . 0.0 111.581 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 9.6 t-20 53.17 39.74 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.74 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 98.0 mtp -146.86 116.85 7.26 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 121.137 0.494 . . . . 0.0 110.408 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 56.6 m -104.53 149.67 25.27 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.77 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.6 m -121.06 122.91 41.09 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.864 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.53 155.44 43.97 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.604 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -51.61 -27.67 26.48 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.574 2.182 . . . . 0.0 111.906 177.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.57 -16.28 64.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.662 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.73 -15.37 55.73 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . 0.61 ' NE2' ' N ' ' A' ' 107' ' ' ILE . 0.0 OUTLIER -67.69 143.15 56.08 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 120.826 0.346 . . . . 0.0 110.271 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.61 ' N ' ' NE2' ' A' ' 106' ' ' GLN . 96.0 mt -122.26 130.48 74.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.812 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -173.01 173.23 1.41 Allowed Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.558 179.448 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -53.09 -31.34 53.82 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 122.67 2.247 . . . . 0.0 112.233 179.071 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.1 m -136.46 159.28 42.26 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.66 145.31 34.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.338 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 165.04 116.69 0.37 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 46.9 t -147.87 141.62 25.67 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.756 0.312 . . . . 0.0 110.557 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 87.8 mtm-85 -69.76 -105.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.45 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -171.42 67.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.481 179.798 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 20.2 tt -128.04 132.55 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.463 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -134.04 98.52 4.16 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.3 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -148.56 152.06 36.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.555 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 58.6 m -118.36 78.47 1.26 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.51 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -97.41 16.01 21.4 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.501 179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.424 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 16.9 tt -118.11 166.19 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.517 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.424 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 31.7 mmt180 -89.96 99.54 12.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.441 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 59.8 m -103.71 128.99 51.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.17 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 73.8 mtm -139.72 165.55 26.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.079 -179.486 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 60.25 48.73 7.84 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 123.404 0.44 . . . . 0.0 111.151 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 64.72 33.12 86.38 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.75 130.76 9.9 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.3 p -91.61 142.1 27.99 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 122.747 -0.267 . . . . 0.0 110.439 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -105.11 123.18 47.37 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.891 0.377 . . . . 0.0 110.283 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 49.7 m -148.81 142.24 25.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.879 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 47.61 45.85 17.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.935 179.403 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.452 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 99.9 m-20 55.15 29.66 13.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.452 ' ND1' ' O ' ' A' ' 132' ' ' ASP . 7.7 m-70 -139.41 145.38 38.84 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 179.528 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.2 t -99.32 119.73 38.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 68.9 mt -101.25 131.24 47.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.77 138.39 37.89 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.152 -179.128 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -64.68 177.4 0.93 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.59 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -59.03 135.4 57.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.643 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 92.39 -1.82 73.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -126.55 138.81 53.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.784 0.326 . . . . 0.0 110.329 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 42.6 pt -135.05 174.65 12.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.821 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 113.54 152.43 10.93 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.4 m -62.87 -44.83 95.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.7 0.286 . . . . 0.0 110.439 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' A' ' 145' ' ' CYS . 26.4 m80 -100.94 5.9 43.39 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.643 -179.682 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' O ' ' O ' ' A' ' 144' ' ' HIS . 39.3 m 60.32 138.78 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.072 0.463 . . . . 0.0 109.925 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 147.66 4.57 0.36 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -119.52 88.73 39.33 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-O 120.775 0.321 . . . . 0.0 110.484 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.45 160.97 15.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.97 2.447 . . . . 0.0 111.697 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 58.6 t -101.45 110.77 29.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 16.1 m -92.22 108.5 20.0 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -65.9 -40.88 91.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.467 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' SER . . . . . 0.429 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 14.2 t -83.55 -13.69 53.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.626 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 65.44 175.09 5.14 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 99.1 m -108.82 123.79 49.6 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.469 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 41.0 mt -63.96 -41.75 97.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.825 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.434 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.4 m-20 -105.03 -172.93 2.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.55 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.34 37.7 1.58 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.434 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -75.7 -172.04 31.78 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.2 mpt_? -129.84 149.71 51.46 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.657 -179.754 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 59.5 m -86.36 119.31 26.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.516 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 93.8 t -83.05 -27.02 7.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.541 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -167.69 176.15 1.74 Allowed Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.586 179.802 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 41.2 Cg_exo -56.67 135.81 72.55 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.347 2.032 . . . . 0.0 111.733 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 63.4 t30 50.59 30.82 5.1 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.428 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 90.0 mtt180 -142.74 101.06 3.79 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.402 0.62 . . . . 0.0 111.232 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 167' ' ' ALA . 14.7 t -104.52 150.71 24.37 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.157 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . 0.429 ' N ' ' SG ' ' A' ' 166' ' ' CYS . . . -132.95 123.49 26.03 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.298 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 84.6 m -101.92 132.2 47.86 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.439 ' OG1' ' O ' ' A' ' 169' ' ' THR . 0.5 OUTLIER -111.21 19.24 18.55 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.228 0.537 . . . . 0.0 110.939 -179.451 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.535 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 49.8 t80 -93.79 31.65 1.57 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.577 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.72 3.69 80.29 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.524 ' CD1' ' OXT' ' A' ' 178' ' ' GLU . 49.7 m-85 -106.45 148.67 27.88 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.955 0.407 . . . . 0.0 110.547 179.707 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.0 t -138.74 154.33 48.54 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.256 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 152.39 177.43 26.05 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -65.11 -24.14 59.69 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.765 2.31 . . . . 0.0 111.897 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.429 ' OE1' ' OG ' ' A' ' 152' ' ' SER . 25.2 pt20 -127.87 -44.36 1.48 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.71 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 7.3 t -174.23 -74.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . 0.524 ' OXT' ' CD1' ' A' ' 172' ' ' PHE . 84.3 tt0 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.065 -0.969 . . . . 0.0 110.584 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.2 m . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.58 167.67 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.598 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -66.87 146.85 53.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.484 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.83 18.05 66.41 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.662 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 61.05 -128.3 44.4 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -153.02 151.74 23.49 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . 0.522 ' O ' ' NH1' ' A' ' 62' ' ' ARG . . . -100.57 179.57 29.27 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . 0.521 ' C ' ' H ' ' A' ' 52' ' ' ALA . 58.7 t-80 -66.99 -1.78 4.52 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.472 0.177 . . . . 0.0 110.707 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.3 t0 70.72 -13.07 0.5 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.562 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.521 ' H ' ' C ' ' A' ' 50' ' ' HIS . . . -65.3 -36.8 85.17 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.573 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 21.1 mt -75.55 148.78 38.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.828 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -134.42 162.48 32.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.272 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.75 159.21 28.66 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -76.12 -1.34 11.32 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.882 2.388 . . . . 0.0 112.304 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -109.85 70.05 0.72 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.419 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.483 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.8 t -121.85 130.06 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 99.3 m -142.03 -172.01 3.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.99 -179.588 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.13 168.08 43.39 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.8 m -77.39 165.04 24.93 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . 0.522 ' NH1' ' O ' ' A' ' 49' ' ' GLY . 60.6 ttt85 -59.25 -43.4 92.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.676 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -62.38 -42.24 99.26 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.353 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -123.46 46.0 2.31 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.83 145.33 54.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.214 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.424 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 15.8 p90 -159.69 -174.97 4.89 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.915 0.388 . . . . 0.0 110.453 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.424 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 74.0 m -78.45 129.25 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.772 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . 0.483 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 34.5 m -47.59 153.83 0.98 Allowed Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.347 -179.199 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -52.56 132.67 46.48 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 121.431 1.42 . . . . 0.0 112.208 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.59 -22.17 39.7 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.563 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 7.2 m95 -112.51 139.21 48.28 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.472 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.49 -166.83 1.16 Allowed 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.499 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.3 p -118.07 161.0 20.55 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.742 0.306 . . . . 0.0 110.349 179.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.562 ' N ' ' CD2' ' A' ' 74' ' ' LEU . 2.6 mm? -85.87 151.3 54.78 Favored Pre-proline 0 N--CA 1.448 -0.549 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.1 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -44.2 108.39 0.12 Allowed 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 121.718 1.612 . . . . 0.0 111.911 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.33 -8.08 27.46 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.437 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -96.37 -178.46 35.62 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -138.04 17.86 2.81 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.998 0.428 . . . . 0.0 110.884 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -79.0 128.29 33.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.39 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 19.7 m -99.18 70.41 1.77 Allowed 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.9 pt -129.96 19.69 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.106 -179.505 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.64 87.71 27.14 Favored Pre-proline 0 N--CA 1.465 0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.371 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.35 147.3 95.89 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.691 2.261 . . . . 0.0 111.976 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.451 ' N ' ' O ' ' A' ' 70' ' ' GLY . 95.7 mt -99.12 119.9 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.027 179.08 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -90.77 127.3 36.29 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -62.6 -45.55 92.37 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.147 0.499 . . . . 0.0 109.774 -179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -122.82 152.51 40.64 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.468 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 m -59.48 135.64 57.73 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.318 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.4 m -79.15 -26.13 42.81 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.811 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -113.02 3.62 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -72.75 -8.51 55.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.797 0.332 . . . . 0.0 110.657 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.81 -168.79 25.32 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -141.75 149.75 40.86 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.959 0.409 . . . . 0.0 110.882 179.623 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.1 m -65.68 113.0 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.13 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.5 t -102.78 -24.01 13.75 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.122 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.0 mtt85 -153.47 164.85 19.18 Favored Pre-proline 0 C--N 1.329 -0.284 0 C-N-CA 120.414 -0.515 . . . . 0.0 110.706 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.51 119.84 6.52 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.73 1.62 . . . . 0.0 111.662 179.293 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.2 m120 55.51 39.66 31.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.113 179.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 63.9 mmm -147.86 119.96 8.28 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.129 0.49 . . . . 0.0 110.102 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -102.25 150.14 23.6 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.632 179.001 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 98.7 m -121.7 124.62 44.68 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.531 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.71 152.34 40.67 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.535 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -49.72 -24.86 10.47 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.536 2.157 . . . . 0.0 111.762 177.529 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -64.62 -17.57 64.13 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.589 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.63 -13.4 58.03 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -71.25 151.79 43.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.901 0.381 . . . . 0.0 110.294 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -127.93 131.21 69.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.652 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.421 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -172.65 177.84 0.74 Allowed Pre-proline 0 C--N 1.327 -0.402 0 C-N-CA 120.526 -0.469 . . . . 0.0 110.474 179.339 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -56.93 -23.34 50.83 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.816 2.344 . . . . 0.0 111.921 179.363 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.471 ' OG ' ' OG ' ' A' ' 113' ' ' SER . 33.6 p -150.67 167.71 26.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 110.212 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.93 -28.57 58.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.748 -179.268 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -120.51 88.97 0.44 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.471 ' OG ' ' OG ' ' A' ' 110' ' ' SER . 4.8 m -154.56 154.78 33.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.437 . . . . 0.0 110.409 179.617 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -91.52 -166.42 1.56 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.156 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 p -153.75 161.08 42.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.375 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . 0.403 HG23 HD12 ' A' ' 116' ' ' ILE . 33.3 pt -82.1 44.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.816 179.692 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 48.98 -116.89 0.89 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.502 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' A' ' 118' ' ' HIS . 57.9 t-80 40.66 43.4 1.6 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 6.3 p -102.55 175.96 5.33 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.586 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -63.25 -40.16 96.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.498 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.559 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 14.4 tt -87.68 174.08 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 121.145 0.497 . . . . 0.0 110.077 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.559 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 10.2 ptm180 -122.28 119.27 30.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.311 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 9.0 m -124.37 157.17 35.7 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.657 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 71.5 mtm -136.09 173.6 11.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.259 -179.483 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 4.0 m-80 61.74 39.78 13.76 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.92 24.59 76.34 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.12 134.2 29.17 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.3 t -86.1 135.78 33.48 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.354 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 95.4 m -69.98 119.38 14.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.364 -179.597 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -131.36 100.62 5.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.195 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 48.79 -111.37 0.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.696 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -111.42 17.2 20.34 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.856 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -131.94 153.77 49.95 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.495 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 94.4 m -105.78 132.54 51.78 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 88.4 mt -97.91 127.21 43.71 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . 0.463 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 5.7 m -89.66 133.67 34.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.076 -179.017 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 -74.07 178.07 5.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.256 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -64.32 125.67 25.32 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.433 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.94 -18.65 45.95 Favored Glycine 0 N--CA 1.466 0.691 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -118.48 137.34 53.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.801 0.334 . . . . 0.0 110.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 18.9 pt -135.99 175.42 10.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.932 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.463 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 101.19 163.78 27.57 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 40.3 p -62.51 -42.74 99.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.817 0.341 . . . . 0.0 110.471 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.438 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -90.72 4.06 52.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.356 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.446 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 36.4 m 48.44 37.64 9.26 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.461 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . 0.438 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -105.1 7.32 43.99 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.732 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -109.4 109.08 60.26 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.67 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -77.47 160.42 32.03 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.548 2.165 . . . . 0.0 112.191 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.4 t -115.61 131.04 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 55.9 m -99.18 101.98 13.5 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.963 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.48 -61.38 2.38 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.834 0.35 . . . . 0.0 110.232 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.5 t -116.93 -4.99 11.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.755 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -78.84 -178.72 50.88 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.442 ' H ' ' CB ' ' A' ' 166' ' ' CYS . 9.4 m 45.09 48.96 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.914 0.387 . . . . 0.0 110.505 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 81.5 mt -62.88 -42.04 99.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.864 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.402 ' CG ' ' H ' ' A' ' 157' ' ' GLY . 44.4 t30 -109.88 -113.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.329 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.402 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -95.64 11.32 68.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.59 151.67 32.29 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 -179.379 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . 0.483 ' O ' ' SG ' ' A' ' 166' ' ' CYS . 3.2 mpt_? -102.3 136.17 42.61 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.527 0.203 . . . . 0.0 110.507 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 70.7 m -85.49 120.52 27.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.998 0.428 . . . . 0.0 111.085 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.5 t -104.01 -29.17 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.343 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -161.44 169.18 10.12 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.457 179.699 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 69.8 Cg_exo -49.87 127.98 20.53 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.093 1.862 . . . . 0.0 111.874 178.719 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 54.74 32.26 17.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.967 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.1 tpt85 -139.24 131.57 28.39 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-O 121.213 0.53 . . . . 0.0 110.231 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 159' ' ' ARG . 1.8 t -145.25 154.43 42.37 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.217 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -98.42 138.67 35.32 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.698 179.149 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 20.9 m -75.3 143.77 42.78 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.392 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.3 m -62.99 -45.47 92.28 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.741 -179.197 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -104.21 19.51 20.04 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 121.01 0.433 . . . . 0.0 110.861 -179.4 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.57 26.58 72.83 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 177' ' ' CYS . 2.2 t80 -56.66 169.79 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.927 0.394 . . . . 0.0 110.258 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 43.9 p -98.09 164.27 12.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.466 0.65 . . . . 0.0 110.518 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 79.09 144.08 2.74 Favored Glycine 0 CA--C 1.54 1.636 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.173 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -52.92 -39.45 78.59 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.506 2.137 . . . . 0.0 112.386 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.52 ' O ' ' N ' ' A' ' 178' ' ' GLU . 75.9 mt-30 -74.85 -9.71 58.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.663 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.42 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 91.9 m 55.75 -80.73 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.608 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . 0.52 ' N ' ' O ' ' A' ' 176' ' ' GLN . 80.0 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.685 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.5 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.28 -38.26 89.73 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.848 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 61.1 ttm-85 -60.66 -43.4 97.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.011 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.89 -125.5 5.72 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.39 -177.64 47.87 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -167.78 174.1 42.77 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.53 54.44 0.23 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 45.0 m80 -61.86 -41.67 98.13 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.82 0.343 . . . . 0.0 110.676 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.552 ' CG ' HD21 ' A' ' 78' ' ' ASN . 67.7 t0 -88.94 114.53 25.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.359 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.9 147.42 53.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.664 -179.843 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 94.8 mt -71.75 152.8 42.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.718 -179.88 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -126.82 161.72 27.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.465 0.65 . . . . 0.0 110.616 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.05 167.44 15.95 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.73 -168.24 0.35 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 123.029 2.486 . . . . 0.0 111.7 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.517 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 98.4 m-20 57.19 36.91 28.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.711 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.04 137.74 24.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.403 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 34.2 m -138.98 178.96 6.78 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.001 0.429 . . . . 0.0 110.232 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.06 164.13 31.62 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 65' ' ' ALA . 7.8 m -83.38 173.83 11.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.682 0.277 . . . . 0.0 110.561 179.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -61.85 -42.84 99.54 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.888 0.375 . . . . 0.0 110.518 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -62.78 -38.94 92.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.896 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -132.98 55.85 1.88 Allowed 'General case' 0 N--CA 1.457 -0.113 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.652 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.534 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.82 145.45 50.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.47 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -159.12 166.37 31.71 Favored 'General case' 0 CA--C 1.519 -0.221 0 CA-C-O 121.054 0.454 . . . . 0.0 110.995 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 75.0 m -72.04 142.03 49.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.187 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 63.8 m -58.67 150.09 59.34 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.814 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -56.05 119.44 6.61 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.17 1.913 . . . . 0.0 112.357 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 116.72 -14.82 14.5 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.517 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.0 m95 -119.55 132.73 55.81 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.109 0.481 . . . . 0.0 110.412 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -111.86 -177.04 3.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.292 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.539 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 51.2 p -130.63 166.34 20.89 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.515 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 87.6 mt -90.2 151.75 45.12 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.451 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.443 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.2 Cg_exo -47.52 128.44 15.2 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 121.51 1.473 . . . . 0.0 112.212 178.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.74 -5.82 7.12 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 179.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.443 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -91.87 171.95 34.95 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . 0.552 HD21 ' CG ' ' A' ' 51' ' ' ASP . 96.3 m-20 -140.57 8.79 2.19 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.955 0.407 . . . . 0.0 110.992 179.477 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -86.67 129.29 34.92 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.435 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 18.4 m -92.86 46.23 1.22 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.856 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 45.2 pt -98.01 -4.45 9.68 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.528 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 57.8 t -97.64 111.59 59.13 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.498 -0.481 . . . . 0.0 111.13 -179.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.88 159.5 41.68 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.306 2.004 . . . . 0.0 111.962 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.41 HD11 HG23 ' A' ' 84' ' ' ILE . 93.4 mt -98.83 121.67 49.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.426 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.34 122.66 34.14 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.6 -45.32 87.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.372 0.606 . . . . 0.0 109.551 179.462 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 74.5 m-70 -137.17 149.46 47.27 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.646 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.5 p -52.3 128.87 26.6 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.361 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.5 m -72.31 -31.84 66.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.83 -112.81 3.54 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -70.42 -6.58 36.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.635 0.255 . . . . 0.0 110.496 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.07 -162.93 21.1 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.88 152.81 39.31 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.998 0.428 . . . . 0.0 110.772 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.77 113.92 5.93 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 36.9 t -106.5 -23.27 12.54 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.254 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -156.82 162.02 28.41 Favored Pre-proline 0 C--N 1.327 -0.378 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.542 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_exo -48.4 119.27 3.93 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 121.907 1.738 . . . . 0.0 111.331 179.091 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 54.33 40.58 31.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.35 179.514 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 83.4 mmm -146.84 115.04 6.61 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.484 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -96.72 145.88 25.39 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.148 178.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 61.0 m -119.99 114.39 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.771 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -79.57 157.63 74.53 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.71 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.43 -19.27 67.65 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.946 2.431 . . . . 0.0 111.352 178.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -69.41 -17.02 63.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.862 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 108.35 -21.79 28.05 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -65.98 150.89 47.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.086 0.47 . . . . 0.0 110.218 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.89 131.62 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.999 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.484 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -169.02 178.29 1.02 Allowed Pre-proline 0 C--N 1.325 -0.478 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.578 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 46.1 Cg_exo -57.06 -23.79 54.44 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.771 2.314 . . . . 0.0 111.639 178.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.1 p -151.02 163.26 39.16 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.962 0.41 . . . . 0.0 110.291 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -80.18 140.75 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.302 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 113' ' ' SER . . . -84.27 -174.85 50.58 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.646 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 112' ' ' GLY . 8.6 t -58.52 -152.12 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.679 0.276 . . . . 0.0 110.453 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 54.92 80.89 0.12 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.7 t -154.88 164.02 39.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.381 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 37.5 mm -101.66 120.29 51.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.958 0.409 . . . . 0.0 109.96 -179.752 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -141.27 -7.52 1.02 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.429 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -75.01 70.77 2.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.378 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.8 t -129.76 126.74 38.89 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.542 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -93.63 4.06 54.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.324 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.465 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.6 tt -132.52 168.48 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.332 179.583 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.465 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.5 ptm180 -100.95 118.13 36.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.201 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . 0.445 ' C ' ' SD ' ' A' ' 124' ' ' MET . 61.7 m -116.17 138.58 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.689 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' MET . . . . . 0.531 ' N ' ' SD ' ' A' ' 124' ' ' MET . 3.2 mpp? -142.56 165.69 26.7 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.474 -179.0 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 59.15 51.22 7.18 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.454 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 70.84 26.16 74.48 Favored Glycine 0 C--N 1.331 0.27 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.81 114.49 3.92 Favored Glycine 0 CA--C 1.53 0.983 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 30.6 t -79.49 148.21 31.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.511 0.196 . . . . 0.0 110.976 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.4 m -92.38 102.83 15.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.185 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 35.1 t -149.04 138.59 21.77 Favored 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.498 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 98.5 m-20 51.72 36.57 17.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.788 0.328 . . . . 0.0 110.994 179.375 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 54.19 27.91 8.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.682 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.498 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 44.2 m80 -136.34 143.09 43.93 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.961 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 120.44 31.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.093 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.68 120.02 37.3 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.22 137.6 32.21 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.642 -178.746 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.3 -174.1 0.62 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.021 0.439 . . . . 0.0 110.39 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 48.6 tttp -67.82 132.26 47.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 97.78 -7.88 63.31 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -122.1 137.95 54.63 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.866 0.365 . . . . 0.0 110.447 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.5 pt -138.11 -176.62 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.084 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 116.01 162.77 13.33 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.577 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 49.5 p -60.71 -45.04 95.74 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.409 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 12.2 m80 -120.64 27.53 8.49 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.59 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 5.8 m 58.05 118.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.086 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 174.85 5.36 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.723 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 55.4 tp60 -132.51 114.9 14.62 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 120.894 -0.323 . . . . 0.0 110.596 179.332 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.35 158.59 40.75 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.772 2.315 . . . . 0.0 112.095 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.49 131.16 39.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.93 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 88.36 2.79 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.085 0.469 . . . . 0.0 109.85 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -59.02 -61.92 2.28 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.472 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 153' ' ' GLY . 97.3 p -117.95 -3.5 11.15 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.527 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 152' ' ' SER . . . -58.98 -152.42 0.01 OUTLIER Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.599 ' N ' ' SG ' ' A' ' 166' ' ' CYS . 73.5 m -68.88 126.39 29.63 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.758 0.314 . . . . 0.0 110.202 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.11 -42.93 99.65 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 -169.79 -25.93 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.66 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -60.16 -43.4 98.41 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.241 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -97.64 179.14 32.92 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.462 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.5 ttp180 -110.55 131.05 55.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.781 0.324 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 61.4 m -83.24 122.93 29.06 Favored 'General case' 0 CA--C 1.52 -0.175 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.079 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.8 m -104.12 -18.35 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -162.61 172.81 5.0 Favored Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.622 179.467 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -53.73 127.49 25.7 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 121.925 1.75 . . . . 0.0 111.687 178.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 51.88 34.26 13.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.255 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -140.75 134.7 30.64 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.391 0.615 . . . . 0.0 110.39 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.599 ' SG ' ' N ' ' A' ' 154' ' ' CYS . 11.9 p -154.94 166.9 32.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.039 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -122.03 142.76 50.01 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.059 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . 0.422 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 87.5 m -78.08 124.12 27.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.418 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.7 m -64.55 -46.25 83.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.575 -179.275 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -107.71 16.18 23.9 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.349 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 69.54 27.9 72.94 Favored Glycine 0 C--N 1.31 -0.872 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.516 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 13.9 m-85 -64.63 139.82 58.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.345 0.593 . . . . 0.0 110.045 -179.461 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -82.93 167.67 17.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.008 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.25 151.56 13.14 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -67.29 -24.15 44.0 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.628 2.219 . . . . 0.0 112.133 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.44 ' O ' ' O ' ' A' ' 177' ' ' CYS . 74.1 mt-30 -104.91 -7.99 18.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.577 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.516 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 2.6 t 39.33 95.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.197 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.674 -179.859 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 55.16 167.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.707 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 76.0 ttt180 49.55 78.99 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.49 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.6 -9.51 71.91 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.98 -131.01 50.13 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.82 162.47 24.04 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -69.61 162.14 52.35 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' A' ' 50' ' ' HIS . 11.0 p80 -129.49 124.16 33.29 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.779 0.323 . . . . 0.0 110.224 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . 0.45 ' O ' ' O ' ' A' ' 52' ' ' ALA . 54.6 t0 -91.23 99.27 12.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.317 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' A' ' 51' ' ' ASP . . . 53.87 112.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.172 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.4 mt -74.0 144.81 45.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.12 0.486 . . . . 0.0 110.33 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -127.37 158.7 36.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.008 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.61 152.87 15.98 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.04 11.96 1.08 Allowed 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 122.67 2.246 . . . . 0.0 112.438 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -125.14 52.12 1.62 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.075 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.45 133.05 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 99.2 m -144.56 175.49 10.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 169.61 44.76 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.56 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.5 m -73.83 160.86 30.85 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.2 ttm-85 -59.28 -43.7 92.52 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.646 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -61.75 -43.53 98.67 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.899 -0.321 . . . . 0.0 111.395 -179.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -125.35 47.86 2.12 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.537 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.32 142.82 58.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.603 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 24.3 p90 -152.04 168.14 26.19 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 121.279 0.562 . . . . 0.0 110.437 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.5 t -71.56 139.0 49.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.208 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 159.49 19.37 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -60.29 135.01 58.99 Favored 'Trans proline' 0 N--CA 1.497 1.707 0 C-N-CA 122.131 1.887 . . . . 0.0 111.627 179.268 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.15 -23.5 34.26 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.432 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -114.32 135.93 53.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.732 0.266 . . . . 0.0 110.284 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -121.09 -174.04 2.74 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.159 179.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 70.8 p -124.1 163.49 21.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 0.0 110.183 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.432 ' O ' ' N ' ' A' ' 77' ' ' GLY . 86.1 mt -83.52 149.86 58.62 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.781 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.435 ' C ' ' H ' ' A' ' 77' ' ' GLY . 76.0 Cg_exo -42.62 117.49 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.288 0 C-N-CA 121.734 1.623 . . . . 0.0 112.371 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.72 -3.96 5.9 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 179.348 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.435 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -91.76 175.1 38.37 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -134.68 8.28 3.57 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.646 0.26 . . . . 0.0 110.926 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -82.35 129.26 34.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.826 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 9.9 m -103.53 78.6 1.6 Allowed 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.538 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.7 pt -130.98 20.03 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -120.73 103.16 43.81 Favored Pre-proline 0 CA--C 1.537 0.479 0 CA-C-N 116.811 -0.177 . . . . 0.0 110.624 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.15 160.34 29.81 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 C-N-CA 122.165 1.91 . . . . 0.0 112.266 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 92.6 mt -105.82 127.39 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.413 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 100' ' ' CYS . 4.9 m -91.3 136.26 33.23 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.804 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.427 ' NH1' ' NE2' ' A' ' 87' ' ' HIS . 0.0 OUTLIER -61.83 -44.87 95.98 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.401 -179.725 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . 0.427 ' NE2' ' NH1' ' A' ' 86' ' ' ARG . 96.1 m-70 -110.82 152.74 26.3 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.391 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -53.92 131.18 39.7 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.65 -33.08 53.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.039 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.06 -105.85 1.79 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -92.69 0.83 57.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.882 0.372 . . . . 0.0 110.573 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -98.27 172.05 26.16 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . 0.461 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 24.2 t80 -122.26 130.52 53.24 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.848 0.356 . . . . 0.0 110.943 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . 0.461 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 1.7 t -64.19 119.18 9.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.835 179.209 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 73.3 p -104.8 -19.14 14.0 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.478 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -162.03 164.88 16.86 Favored Pre-proline 0 CA--C 1.533 0.309 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.849 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -53.0 128.29 28.35 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 121.412 1.408 . . . . 0.0 111.041 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.433 ' OD1' ' N ' ' A' ' 98' ' ' ASN . 1.2 m-20 51.46 37.97 20.76 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.718 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.1 mtp -147.75 108.95 4.27 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.218 0.532 . . . . 0.0 110.305 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 0.8 OUTLIER -97.13 149.05 22.41 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.606 179.266 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.1 m -120.5 122.8 41.44 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.54 158.98 35.89 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.488 -178.971 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -55.84 -26.82 59.37 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.496 2.131 . . . . 0.0 112.245 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.1 t -64.09 -17.43 63.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.575 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.43 -17.44 50.76 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -67.37 153.73 42.99 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.981 0.419 . . . . 0.0 110.124 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 90.0 mt -126.83 128.26 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.398 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . 0.527 ' O ' ' N ' ' A' ' 100' ' ' CYS . . . -165.63 162.88 13.12 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.934 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 11.6 Cg_endo -52.36 -15.93 4.44 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.955 2.436 . . . . 0.0 112.165 179.576 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 97.2 p -155.51 159.39 39.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.28 179.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.51 -21.01 49.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.06 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -50.19 117.67 5.16 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 87.2 p -97.01 2.7 51.79 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.622 0.249 . . . . 0.0 110.664 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -71.39 -6.7 42.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.569 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.1 m -57.7 -35.96 71.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.648 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 2.6 pp -63.43 153.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.285 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -111.2 -17.76 13.12 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -139.43 148.23 42.49 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.626 -179.632 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 7.4 m -120.64 124.38 45.1 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.163 179.805 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -96.6 10.54 38.21 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.417 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 10.9 tp -125.44 156.96 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.521 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 12.6 mtt180 -106.91 120.19 41.38 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.542 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 12.0 m -121.11 142.5 49.8 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -143.25 169.61 17.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.108 -179.065 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 67.6 m-80 58.81 41.76 21.04 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.549 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.44 18.33 76.15 Favored Glycine 0 CA--C 1.517 0.205 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.88 121.56 6.32 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.2 t -79.85 140.43 36.8 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.5 t -91.54 124.4 35.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.136 179.237 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 132' ' ' ASP . 31.8 t -141.75 143.04 33.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.213 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 41.14 -92.37 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 130' ' ' SER . 39.5 p-10 -146.5 23.68 1.27 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.755 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -138.53 148.36 44.16 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.445 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 84.3 m -96.49 128.69 43.66 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.107 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.6 mt -92.69 126.13 37.64 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 16.7 m -89.33 127.5 35.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.58 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.75 174.89 4.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.343 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -63.42 127.01 29.39 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.091 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.37 -13.84 54.67 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 -179.592 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -121.59 136.44 54.95 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.931 0.396 . . . . 0.0 110.42 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -133.58 172.76 15.81 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.214 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 102.8 163.34 25.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' THR . . . . . 0.412 ' HG1' ' H ' ' A' ' 144' ' ' HIS . 24.0 p -62.42 -43.84 97.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.749 0.309 . . . . 0.0 110.631 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . 0.412 ' H ' ' HG1' ' A' ' 143' ' ' THR . 2.2 p-80 -94.77 10.75 33.96 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.096 0.474 . . . . 0.0 110.468 179.762 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 12.4 m 46.85 36.59 4.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.101 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -99.74 8.46 59.83 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 32.7 tt0 -116.08 112.77 41.97 Favored Pre-proline 0 CA--C 1.548 0.898 0 CA-C-N 116.76 0.28 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -78.39 159.6 29.23 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.441 2.094 . . . . 0.0 112.273 179.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.5 t -113.56 127.74 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 121.016 0.436 . . . . 0.0 110.142 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 2.2 m -100.05 98.18 8.95 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -62.88 -51.67 66.07 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.339 -178.375 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 79.3 p -118.37 -9.45 10.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.896 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -79.74 171.82 54.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.108 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 150' ' ' CYS . 17.9 m 57.08 59.99 3.18 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.885 0.374 . . . . 0.0 110.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . 0.405 ' CD1' ' N ' ' A' ' 155' ' ' LEU . 10.9 mp -62.93 -42.19 99.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.752 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' A' ' 157' ' ' GLY . 24.9 t-20 -121.5 -112.69 0.32 Allowed 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.994 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.527 ' N ' ' OD1' ' A' ' 156' ' ' ASN . . . -84.6 3.49 86.52 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -54.75 148.3 23.01 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . 0.479 ' C ' ' SG ' ' A' ' 166' ' ' CYS . 17.8 tpt180 -102.66 131.31 49.54 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.775 0.322 . . . . 0.0 110.451 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 4.8 t -76.04 100.3 4.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.088 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.5 t -76.91 -43.82 32.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.768 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -151.02 175.03 3.07 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.979 -179.686 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_exo -51.73 130.06 32.43 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 121.605 1.537 . . . . 0.0 112.385 179.322 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.0 m-20 52.43 32.02 10.61 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.372 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . 0.442 ' O ' ' SG ' ' A' ' 150' ' ' CYS . 74.2 mtm180 -141.6 136.33 30.92 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.473 0.654 . . . . 0.0 110.921 179.212 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . 0.479 ' SG ' ' C ' ' A' ' 159' ' ' ARG . 1.7 t -144.35 156.22 44.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.994 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.37 143.5 42.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.69 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 76.0 m -72.21 127.44 32.55 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.232 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 98.7 m -63.37 -46.12 87.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.458 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . 0.537 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 74.7 t80 -110.54 27.95 9.14 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.992 0.425 . . . . 0.0 111.327 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.46 25.51 63.06 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . 0.462 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 66.8 t80 -63.53 131.76 49.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.421 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 173' ' ' THR . . . . . 0.439 ' O ' ' CE2' ' A' ' 172' ' ' PHE . 68.0 p -82.52 163.43 21.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.144 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 144.38 160.44 8.49 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . 0.424 ' O ' ' OE1' ' A' ' 176' ' ' GLN . 36.2 Cg_endo -63.51 -31.9 70.9 Favored 'Trans proline' 0 N--CA 1.496 1.671 0 C-N-CA 122.578 2.185 . . . . 0.0 112.4 -179.701 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . 0.424 ' OE1' ' O ' ' A' ' 175' ' ' PRO . 1.9 mp0 -131.4 8.66 4.65 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.201 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 1.8 t 49.82 96.97 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.267 -179.631 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.524 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' SER . . . . . 0.438 ' O ' ' O ' ' A' ' 44' ' ' ALA . 19.4 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.438 ' O ' ' O ' ' A' ' 43' ' ' SER . . . 55.53 161.02 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.604 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -148.52 143.9 26.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.618 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.78 14.87 78.96 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.76 -36.8 93.79 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -63.53 149.76 50.01 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.97 141.06 12.27 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 74.1 m80 -66.1 -43.06 88.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -106.68 141.42 37.97 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.335 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -125.72 137.65 53.84 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.349 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.2 mt -75.82 144.03 41.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -137.17 159.84 40.73 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.15 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.38 163.24 24.51 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.75 -5.87 17.42 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 123.089 2.526 . . . . 0.0 112.263 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . 0.604 ' ND2' ' CD2' ' A' ' 71' ' ' TRP . 78.9 m-20 -103.59 68.32 0.93 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.56 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.9 t -119.96 129.41 75.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.838 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.2 m -134.76 173.6 11.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.002 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.92 164.65 37.44 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' ALA . 12.5 m -80.1 173.25 12.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -60.38 -42.82 96.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -62.16 -41.75 98.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -125.58 49.55 1.91 Allowed 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.747 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.21 140.44 52.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.304 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -155.3 165.71 35.8 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.978 0.418 . . . . 0.0 110.878 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 5.8 m -72.89 135.0 45.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.089 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 35.1 m -55.81 149.84 30.46 Favored Pre-proline 0 C--N 1.323 -0.577 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.213 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -56.23 134.98 67.56 Favored 'Trans proline' 0 N--CA 1.498 1.791 0 C-N-CA 121.498 1.465 . . . . 0.0 112.234 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.95 -14.95 52.31 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.604 ' CD2' ' ND2' ' A' ' 57' ' ' ASN . 85.4 m95 -115.92 134.99 54.41 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.758 0.314 . . . . 0.0 110.372 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 80' ' ' CYS . 17.4 ptpt -110.14 -175.95 2.87 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.333 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 41.4 p -123.09 161.19 24.85 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.875 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . 0.576 ' CD2' ' N ' ' A' ' 74' ' ' LEU . 2.7 mm? -84.53 149.04 53.67 Favored Pre-proline 0 N--CA 1.449 -0.48 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.158 -179.534 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -46.23 112.59 0.47 Allowed 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.591 1.528 . . . . 0.0 112.236 179.1 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.15 -6.48 28.16 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.99 174.77 36.04 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -129.04 0.58 5.25 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.816 0.341 . . . . 0.0 110.643 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.2 mt-30 -78.84 134.4 36.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.688 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . 0.445 ' SG ' ' O ' ' A' ' 72' ' ' LYS . 1.5 m -115.0 79.03 1.22 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.164 0.507 . . . . 0.0 110.189 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.3 pt -120.74 14.59 6.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.657 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 t -117.55 107.01 45.46 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 121.273 -0.171 . . . . 0.0 110.796 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.14 159.97 33.33 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.21 1.94 . . . . 0.0 111.987 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.5 mt -99.54 123.17 52.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.85 125.31 35.7 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . 0.426 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.9 OUTLIER -63.32 -45.77 89.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.27 0.557 . . . . 0.0 109.932 179.657 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -121.73 143.5 49.33 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.462 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -53.1 128.29 27.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.424 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.7 m -71.33 -27.87 63.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.573 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.45 -116.33 4.89 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -70.38 -8.73 52.96 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.737 0.304 . . . . 0.0 110.925 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.54 -164.81 25.34 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -142.65 150.38 40.14 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.995 0.426 . . . . 0.0 110.788 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.7 m -69.53 116.96 10.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.568 -179.305 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.3 t -104.11 -20.78 13.71 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.322 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.0 mtt85 -160.76 167.99 12.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.56 123.3 13.0 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.613 1.542 . . . . 0.0 111.143 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . 0.426 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.1 t-20 52.26 40.35 28.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.088 -179.58 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.2 mtp -146.95 115.72 6.81 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.362 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 58.0 m -102.07 148.08 25.82 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.438 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 84.1 m -121.47 117.73 27.58 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.971 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -84.38 157.84 61.35 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.801 179.683 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 24.0 Cg_endo -61.64 -22.24 73.96 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.743 2.296 . . . . 0.0 111.828 179.195 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.4 t -66.28 -16.62 64.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.19 -19.02 38.29 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.0 tp60 -65.19 149.1 50.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.011 0.434 . . . . 0.0 110.427 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.09 131.63 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.828 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -172.36 172.43 1.78 Allowed Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.471 179.453 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_exo -48.82 -23.63 6.04 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.454 2.103 . . . . 0.0 111.992 178.726 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' SER . . . . . 0.469 ' OG ' ' OG ' ' A' ' 113' ' ' SER . 8.0 p -153.6 165.47 35.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.251 179.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.49 -24.57 50.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.246 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -113.22 32.48 6.09 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.469 ' OG ' ' OG ' ' A' ' 110' ' ' SER . 4.3 m -76.92 -18.0 58.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.686 0.279 . . . . 0.0 110.577 179.83 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 115' ' ' SER . 99.7 mtt180 53.93 179.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.123 -179.279 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' SER . . . . . 0.479 ' O ' ' O ' ' A' ' 114' ' ' ARG . 15.9 m 49.79 108.52 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.119 0.485 . . . . 0.0 110.95 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 37.8 pt -78.61 138.32 20.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.815 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -146.31 150.07 35.04 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.397 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -153.53 164.46 38.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.627 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.1 m -68.92 110.38 4.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.496 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -64.01 -40.56 96.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.461 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.457 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.5 tt -80.18 166.26 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.229 179.689 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.457 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 20.3 mmm180 -98.75 98.07 9.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.775 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 87.4 m -92.98 134.47 35.08 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.88 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 72.6 mtm -145.31 165.07 29.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.86 39.9 19.94 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.039 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.56 24.78 69.41 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.97 128.24 22.81 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' SER . . . . . 0.498 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 17.3 m -86.24 137.68 32.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.661 0.267 . . . . 0.0 110.494 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.56 129.93 34.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.514 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.45 ' O ' ' O ' ' A' ' 133' ' ' HIS . 52.3 p -146.58 109.66 4.7 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.165 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 50.12 -116.52 0.93 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.516 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . 0.432 ' N ' ' OD1' ' A' ' 132' ' ' ASP . 32.4 p-10 -106.95 9.29 30.75 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.885 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 130' ' ' SER . 69.2 m80 -131.15 153.02 49.84 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.95 0.405 . . . . 0.0 110.798 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.4 t -114.62 145.06 42.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.293 179.779 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.9 mt -100.8 129.96 46.75 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.676 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 10.5 m -96.34 139.22 32.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.455 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.55 179.15 0.85 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.533 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -67.33 129.71 40.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.613 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 98.07 -10.77 63.92 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -117.34 133.8 55.56 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.9 0.381 . . . . 0.0 110.638 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 45.8 pt -131.95 170.36 20.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.315 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 106.37 164.41 22.77 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.5 m -63.26 -45.52 91.15 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.449 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -97.52 5.24 49.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.902 0.382 . . . . 0.0 110.682 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 6.0 m 59.87 37.25 21.79 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.123 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -98.88 5.72 59.86 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -119.65 107.09 41.09 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.679 0.239 . . . . 0.0 110.535 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.73 163.5 23.72 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.564 2.176 . . . . 0.0 111.911 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.2 t -106.15 126.3 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 121.158 0.504 . . . . 0.0 109.918 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.88 92.71 7.54 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -63.61 -46.53 85.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.761 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' SER . . . . . 0.533 ' OG ' ' ND2' ' A' ' 164' ' ' ASN . 9.9 m -89.93 -11.93 40.32 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.861 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.12 161.29 1.28 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.2 m -104.23 145.29 30.43 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . 0.425 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 4.3 mp -62.95 -43.42 98.84 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.13 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 m-20 165.4 -58.38 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.352 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.53 -37.95 95.01 Favored Glycine 0 CA--C 1.517 0.164 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.35 159.86 50.5 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -127.43 145.91 50.66 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.725 0.297 . . . . 0.0 110.81 179.108 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 60.2 m -73.2 104.68 4.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.616 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 70.2 t -106.49 -13.04 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.354 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -166.18 177.76 1.45 Allowed Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 120.369 -0.532 . . . . 0.0 110.341 179.807 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -55.64 128.44 30.35 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 121.896 1.731 . . . . 0.0 111.539 179.905 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . 0.533 ' ND2' ' OG ' ' A' ' 152' ' ' SER . 2.8 t-20 43.23 38.7 1.71 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.9 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -131.37 127.07 36.82 Favored 'General case' 0 C--O 1.24 0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 110.53 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 94.3 m -117.79 118.81 33.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.846 179.301 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -77.96 92.34 4.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.927 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.75 129.46 55.37 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.501 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 169' ' ' THR . . . . . 0.434 ' O ' ' OG1' ' A' ' 169' ' ' THR . 1.2 t -114.01 24.79 11.71 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.295 179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -100.86 29.02 4.79 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.011 0.434 . . . . 0.0 110.945 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.98 28.71 73.89 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -50.41 163.24 0.18 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.769 0.319 . . . . 0.0 110.476 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -130.02 131.65 45.93 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.308 179.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 80.19 176.95 50.42 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -78.38 -10.7 16.1 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.809 2.339 . . . . 0.0 112.03 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -83.45 6.32 20.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.846 -178.496 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . 0.515 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 50.3 t 56.39 40.15 29.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.624 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.043 -0.98 . . . . 0.0 110.601 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.6 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.68 141.5 56.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.663 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -81.97 -7.22 59.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -62.55 -34.54 89.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.47 -162.7 38.28 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 84.49 179.89 51.5 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.711 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.31 175.9 44.74 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -89.72 171.48 9.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.757 0.313 . . . . 0.0 110.376 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.58 91.49 3.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.416 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -164.73 -79.36 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.328 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 87.5 mt -70.03 176.03 4.06 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.331 179.604 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -135.85 165.87 24.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.784 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.69 168.63 9.92 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.26 -172.49 0.89 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 122.938 2.425 . . . . 0.0 111.805 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 57.48 42.14 24.95 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.094 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.6 p -97.93 133.24 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.91 0.386 . . . . 0.0 110.101 179.802 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 m -140.12 175.88 9.22 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.425 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.94 160.18 26.05 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 65' ' ' ALA . 14.9 m -81.21 174.79 11.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.319 . . . . 0.0 110.398 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.4 ttt85 -60.59 -43.15 97.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.599 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -62.05 -39.12 91.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.917 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -131.84 53.57 1.99 Allowed 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.11 139.96 52.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.391 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -154.18 169.7 22.97 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.088 0.471 . . . . 0.0 110.641 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' CYS . . . . . 0.407 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 73.2 m -79.45 136.29 36.9 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 38.6 m -52.99 154.97 4.65 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.246 -178.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.84 132.51 42.3 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.103 1.202 . . . . 0.0 112.785 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.69 -7.27 57.61 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' TRP . . . . . 0.534 ' CD1' ' N ' ' A' ' 71' ' ' TRP . 9.5 m95 -132.02 143.08 49.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.519 179.352 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -127.72 -166.08 1.57 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' THR . . . . . 0.407 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.3 p -123.49 164.76 18.31 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -108.4 156.56 38.39 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.206 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PRO . . . . . 0.492 ' C ' ' H ' ' A' ' 77' ' ' GLY . 46.7 Cg_exo -52.88 138.66 60.82 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 121.379 1.386 . . . . 0.0 111.808 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.38 -38.08 0.34 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . 0.492 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -82.7 169.83 49.34 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 50.0 p30 -136.48 16.06 3.17 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.611 -0.294 . . . . 0.0 110.88 179.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -87.6 133.7 33.76 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.781 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 62.6 m -86.28 42.69 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.5 pt -94.02 26.45 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.253 -179.454 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.91 94.18 47.61 Favored Pre-proline 0 N--CA 1.466 0.37 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.76 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -79.48 161.26 25.39 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.198 1.932 . . . . 0.0 112.182 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' ILE . . . . . 0.426 HD11 HG21 ' A' ' 84' ' ' ILE . 96.6 mt -100.47 127.86 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.718 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.4 131.37 43.03 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -64.09 -45.88 86.73 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-O 121.177 0.513 . . . . 0.0 110.256 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -127.18 174.0 9.27 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.97 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 p -63.84 146.08 54.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.405 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 1.4 m -88.56 -32.4 18.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.53 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.29 -107.99 2.56 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.341 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -92.93 3.63 55.38 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.556 0.217 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.06 -161.67 17.45 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -146.94 152.18 38.23 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.985 0.421 . . . . 0.0 110.98 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.6 m -69.65 115.6 9.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.131 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' SER . . . . . 0.492 ' CB ' ' HG1' ' A' ' 101' ' ' THR . 85.6 p -103.82 -17.35 15.09 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.952 -179.099 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtp85 -159.74 163.6 22.4 Favored Pre-proline 0 CA--C 1.532 0.285 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.068 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -51.99 127.09 22.07 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.565 1.51 . . . . 0.0 111.034 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 92.0 m-20 49.62 36.5 10.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.88 179.576 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 38.1 mtt -147.6 122.31 9.88 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.36 0.6 . . . . 0.0 111.048 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 20.2 t -108.17 149.45 28.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.474 179.115 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 101' ' ' THR . . . . . 0.492 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 99.8 m -121.38 124.72 45.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.79 179.423 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -93.73 157.78 37.66 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.543 -179.916 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.04 -20.44 69.67 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.551 2.167 . . . . 0.0 111.766 178.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 t -68.05 -22.85 64.93 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.601 178.827 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 113.88 -22.94 13.7 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 106' ' ' GLN . . . . . 0.468 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 8.1 tm0? -63.44 146.25 53.99 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.212 0.53 . . . . 0.0 110.362 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 107' ' ' ILE . . . . . 0.468 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 96.7 mt -129.89 133.78 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.402 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 108' ' ' ALA . . . . . . . . . . . . . . . -178.64 171.61 0.71 Allowed Pre-proline 0 CA--C 1.535 0.392 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.168 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 109' ' ' PRO . . . . . . . . . . . . . 56.9 Cg_exo -50.35 -25.77 14.46 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 122.645 2.23 . . . . 0.0 112.247 179.015 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.7 p -140.75 161.99 36.48 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.239 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.38 140.68 32.26 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.684 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -164.03 124.06 1.23 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 113' ' ' SER . . . . . 0.413 ' H ' ' HG ' ' A' ' 113' ' ' SER . 13.1 p -74.44 141.06 45.03 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.147 179.807 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -147.7 -50.34 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.911 0.386 . . . . 0.0 110.606 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.6 p -157.75 -159.32 0.82 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.253 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 21.8 pt -126.28 148.27 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.421 179.742 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -152.82 148.82 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.979 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 118' ' ' HIS . . . . . 0.445 ' CD2' ' H ' ' A' ' 118' ' ' HIS . 5.7 p80 -113.86 39.48 2.68 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.505 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 64.5 m -124.29 79.97 1.79 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.473 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 120' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' A' ' 120' ' ' ASN . 53.5 t-20 -63.58 -40.43 96.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.658 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 121' ' ' ILE . . . . . 0.416 ' CG2' ' H ' ' A' ' 122' ' ' ARG . 15.6 mm -82.71 174.33 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.956 -179.488 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 122' ' ' ARG . . . . . 0.416 ' H ' ' CG2' ' A' ' 121' ' ' ILE . 27.2 ptt180 -106.02 114.08 28.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.544 0.688 . . . . 0.0 110.534 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 94.2 m -124.26 148.03 47.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.263 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.2 mtm -142.27 174.24 10.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.916 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 10.8 m120 60.88 44.93 10.2 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.119 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.29 26.17 71.53 Favored Glycine 0 CA--C 1.518 0.261 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -66.52 156.66 50.78 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 28.3 t -109.62 134.51 51.86 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-O 121.05 0.452 . . . . 0.0 110.373 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 15.5 m -80.94 132.1 35.38 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 130' ' ' SER . . . . . 0.501 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.1 m -123.56 158.41 31.46 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.486 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 131' ' ' ASP . . . . . 0.501 ' C ' ' O ' ' A' ' 130' ' ' SER . 99.6 m-20 -12.01 -77.5 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 O-C-N 123.899 0.75 . . . . 0.0 112.725 -179.562 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -136.21 29.74 3.03 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.397 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -139.89 159.08 42.98 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.782 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 40.7 t -104.64 122.37 45.49 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.035 179.434 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 135' ' ' LEU . . . . . 0.468 ' CD2' ' N ' ' A' ' 135' ' ' LEU . 3.5 mm? -98.18 127.19 43.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.081 0.467 . . . . 0.0 110.169 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 61.1 m -106.98 140.43 39.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.807 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -76.8 168.94 19.21 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.32 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 56.1 tptt -64.71 133.31 51.85 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 108.76 -26.41 15.95 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 140' ' ' TYR . . . . . 0.437 ' HH ' ' CD ' ' A' ' 163' ' ' PRO . 93.7 m-85 -116.61 133.58 55.84 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 120.898 0.38 . . . . 0.0 110.67 179.639 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.6 pt -131.04 170.76 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.936 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.61 157.62 10.36 Favored Glycine 0 N--CA 1.464 0.565 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.6 p -64.07 -42.69 96.89 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.869 0.366 . . . . 0.0 110.602 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.21 5.02 34.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.25 139.29 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 151.41 -10.74 0.73 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -99.0 110.53 58.07 Favored Pre-proline 0 CA--C 1.544 0.715 0 O-C-N 122.517 -0.402 . . . . 0.0 110.422 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -76.77 159.01 35.14 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.175 1.916 . . . . 0.0 112.524 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.8 t -124.76 130.06 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.11 0.481 . . . . 0.0 110.577 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -104.35 117.68 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.087 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -65.75 -39.48 91.12 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.3 m -86.12 -7.44 58.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.531 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 45.73 -166.48 0.06 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 1.3 m -141.34 119.61 12.18 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.5 mt -63.9 -41.7 97.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.766 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 156' ' ' ASN . . . . . 0.554 ' C ' ' H ' ' A' ' 158' ' ' GLY . 6.1 t-20 -86.03 -167.88 2.02 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.332 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 157' ' ' GLY . . . . . 0.538 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.79 23.67 0.53 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 158' ' ' GLY . . . . . 0.554 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -60.01 160.17 21.59 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -126.75 147.18 50.0 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.778 0.323 . . . . 0.0 110.668 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 12.3 t -90.88 104.78 17.33 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.853 0.359 . . . . 0.0 110.497 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.98 -35.04 20.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 162' ' ' ALA . . . . . . . . . . . . . . . -155.81 177.29 2.11 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.36 -179.309 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 163' ' ' PRO . . . . . 0.437 ' CD ' ' HH ' ' A' ' 140' ' ' TYR . 50.8 Cg_exo -54.26 132.22 49.36 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.023 1.816 . . . . 0.0 112.259 179.436 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 49.33 31.79 4.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.259 179.728 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -135.42 102.09 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.58 0.705 . . . . 0.0 110.751 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -107.52 141.17 39.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.821 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.64 133.71 50.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.444 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 67.3 m -86.3 146.51 26.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.102 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -62.35 -45.1 94.73 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.118 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -97.52 15.93 21.8 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.322 0.582 . . . . 0.0 110.847 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.15 20.95 78.37 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.748 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -54.84 161.7 1.49 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.967 0.413 . . . . 0.0 110.595 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 8.8 t -82.54 160.52 22.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.479 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.6 142.52 0.05 OUTLIER Glycine 0 CA--C 1.539 1.534 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.694 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -53.48 -40.67 77.84 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.329 2.019 . . . . 0.0 112.971 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -67.3 -26.22 66.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.455 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 11.8 m 65.04 60.76 0.79 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.673 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.93 -179.935 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 17.6 mt . . . . . 0 N--CA 1.455 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 110.606 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -135.61 -176.77 4.4 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.732 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.71 158.73 29.32 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -76.59 8.29 3.08 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.764 2.309 . . . . 0.0 112.105 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.426 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 26.0 m120 -119.88 65.79 0.81 Allowed 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.658 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 58' ' ' VAL . 10.7 p -112.55 128.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.164 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -148.51 171.85 15.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.379 -179.153 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.55 166.46 34.97 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.7 m -79.08 165.04 23.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.7 0.286 . . . . 0.0 110.307 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.6 ttm-85 -58.85 -42.26 88.92 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.241 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -61.18 -39.42 90.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.832 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -131.63 51.13 2.17 Favored 'General case' 0 C--O 1.226 -0.151 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.033 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.08 142.83 50.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.536 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 11.8 p90 -160.94 176.32 11.55 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 121.069 0.461 . . . . 0.0 110.523 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.402 ' SG ' HG22 ' A' ' 73' ' ' THR . 62.8 m -73.39 133.89 43.89 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -47.1 169.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.033 -178.758 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -58.32 133.86 57.73 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 121.883 1.722 . . . . 0.0 112.364 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 93.39 -16.63 60.2 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.426 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 92.5 m95 -110.25 138.49 46.55 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -121.98 -164.52 1.16 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.316 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.402 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.3 p -125.07 164.83 19.35 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.486 ' O ' ' N ' ' A' ' 77' ' ' GLY . 24.6 mt -89.16 151.99 47.42 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 -179.074 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -40.44 107.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.256 0 C-N-CA 122.219 1.946 . . . . 0.0 112.259 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.27 -11.2 9.03 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -87.96 177.76 46.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.924 -0.871 . . . . 0.0 110.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -138.01 17.06 2.83 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.892 0.377 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -81.93 130.15 34.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.046 -179.243 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 53.6 m -95.66 55.26 1.64 Allowed 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.451 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.3 pt -114.32 22.05 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.995 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.04 99.51 40.92 Favored Pre-proline 0 N--CA 1.467 0.401 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.573 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.95 156.45 26.84 Favored 'Trans proline' 0 N--CA 1.487 1.113 0 C-N-CA 122.164 1.91 . . . . 0.0 112.202 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.438 ' O ' ' NH1' ' A' ' 86' ' ' ARG . 96.0 mt -101.57 122.12 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-O 120.945 0.403 . . . . 0.0 110.202 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.27 126.29 45.06 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.494 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 9.0 mpt_? -64.97 -40.33 94.82 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.743 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -117.71 145.68 44.27 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.192 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.2 m -63.24 136.29 57.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.0 0.429 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 44.5 m -77.95 -32.24 51.37 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.326 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.44 -107.19 2.25 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -68.38 -12.32 60.95 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.777 0.323 . . . . 0.0 110.797 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -110.53 -161.91 18.2 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -145.94 151.52 37.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.006 0.432 . . . . 0.0 111.072 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.7 m -66.95 115.18 6.39 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.225 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -106.46 -20.72 13.29 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.754 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -157.49 161.66 28.78 Favored Pre-proline 0 CA--C 1.531 0.238 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.364 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_exo -48.93 122.23 7.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 121.748 1.632 . . . . 0.0 111.254 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 39.2 t-20 52.05 41.74 30.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.004 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 80.9 mtp -148.33 116.72 6.54 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.62 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.44 ' N ' ' O ' ' A' ' 108' ' ' ALA . 33.7 m -100.44 148.28 24.92 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.366 178.947 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.6 m -120.58 123.28 42.48 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.741 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.16 157.92 53.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.275 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.71 -18.64 65.17 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.719 2.279 . . . . 0.0 111.855 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.8 m -71.95 -17.38 62.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.432 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 109.16 -20.32 28.57 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -66.82 150.03 49.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.934 0.397 . . . . 0.0 110.194 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.68 132.74 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.642 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -167.77 179.05 0.99 Allowed Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.379 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 38.8 Cg_exo -57.92 -22.76 56.11 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.814 2.343 . . . . 0.0 112.306 179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.2 p -153.74 161.84 41.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.243 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.885 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' CYS . . . . . 0.507 ' O ' ' SG ' ' A' ' 119' ' ' CYS . 45.0 t . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.877 0.37 . . . . 0.0 110.735 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.69 30.61 20.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.128 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.3 tt -158.59 165.22 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.265 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.4 mmt85 -101.2 106.13 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.195 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.39 127.37 52.06 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.266 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -147.01 168.63 21.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.7 m120 59.54 39.92 21.03 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 120.792 0.329 . . . . 0.0 111.064 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.33 20.85 65.97 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -65.02 149.15 51.74 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 36.9 m -127.16 144.66 50.98 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.903 0.383 . . . . 0.0 110.403 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 37.1 t -82.55 124.39 30.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.568 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.408 ' CB ' HD11 ' A' ' 135' ' ' LEU . 48.2 t -148.18 111.67 4.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.472 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.9 49.98 17.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.067 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 57.41 34.55 24.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -144.48 139.54 28.36 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.508 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.4 m -88.05 126.89 35.33 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.408 HD11 ' CB ' ' A' ' 130' ' ' SER . 86.2 mt -95.25 126.85 40.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -103.02 137.88 40.62 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.683 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -83.27 175.34 9.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.437 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.533 ' NZ ' ' OE2' ' A' ' 151' ' ' GLU . 64.6 tttm -63.29 133.15 53.7 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.444 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.53 -24.52 28.48 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.459 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 95.1 m-85 -123.74 138.25 54.55 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.911 0.386 . . . . 0.0 110.55 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 16.7 pt -139.73 -168.93 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.496 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.97 165.29 31.43 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -46.25 88.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.742 0.306 . . . . 0.0 110.35 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -84.58 -1.42 55.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.612 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.496 ' O ' ' SG ' ' A' ' 145' ' ' CYS . 33.7 t 55.14 63.47 2.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -140.51 -4.18 1.26 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -86.48 114.54 58.21 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.385 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.49 156.2 36.37 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 122.295 1.997 . . . . 0.0 112.4 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.2 t -119.61 124.55 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 120.954 0.407 . . . . 0.0 110.197 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.3 107.54 20.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.2 -179.477 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 151' ' ' GLU . . . . . 0.533 ' OE2' ' NZ ' ' A' ' 138' ' ' LYS . 96.7 mt-10 -69.32 -38.23 78.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.101 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 94.7 p -85.38 -9.11 58.0 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.032 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 63.5 -163.82 31.1 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 71.8 m -116.12 152.24 34.04 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 96.9 mt -82.03 -1.95 50.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.49 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.527 ' C ' ' H ' ' A' ' 158' ' ' GLY . 32.8 t-20 -170.66 -147.62 0.05 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.336 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.511 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.64 26.99 0.49 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.527 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -64.23 175.51 11.21 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 78.1 ttt180 -128.14 136.64 51.42 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.65 0.262 . . . . 0.0 110.849 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 81.3 m -79.56 98.46 6.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 69.7 t -75.91 -44.1 38.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.533 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.649 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -145.13 174.26 3.61 Favored Pre-proline 0 C--N 1.331 -0.222 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.649 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.27 129.59 32.01 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 121.95 1.767 . . . . 0.0 112.102 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 52.37 32.87 11.83 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.984 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.1 ttt85 -138.84 127.56 23.42 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.314 0.578 . . . . 0.0 110.691 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 42.1 t -139.37 149.99 44.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.722 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.24 134.31 49.57 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.566 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 168' ' ' CYS . . . . . 0.602 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 0.2 OUTLIER -81.0 120.28 24.58 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.846 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 12.1 m -70.38 -45.45 66.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.79 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -101.85 26.99 6.86 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.821 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.7 33.64 83.29 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -62.44 127.14 29.92 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -178.77 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 61.8 p -84.58 161.69 20.08 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.924 0.392 . . . . 0.0 110.979 -179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 143.24 160.25 8.31 Favored Glycine 0 CA--C 1.531 1.033 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.0 -25.41 44.38 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.537 2.158 . . . . 0.0 112.689 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -76.28 -49.27 17.45 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.45 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.0 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.736 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.853 0.359 . . . . 0.0 110.067 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -104.77 162.83 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.952 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.27 161.05 20.51 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -78.76 3.51 7.25 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.725 2.283 . . . . 0.0 112.146 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.482 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 1.2 m-80 -123.51 68.69 1.02 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.77 0.319 . . . . 0.0 110.502 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.455 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.8 t -117.01 131.43 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-O 120.884 0.373 . . . . 0.0 110.032 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -142.56 175.96 9.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.333 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.83 170.28 46.86 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.538 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -77.77 167.66 21.19 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 43.7 ttm180 -60.98 -44.11 97.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.634 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -66.86 -39.3 87.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.225 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -121.91 47.45 1.89 Allowed 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.488 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.538 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -69.44 144.29 53.35 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.553 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.9 p90 -153.33 167.59 28.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.944 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 73' ' ' THR . 77.1 m -73.21 132.49 43.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.51 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.455 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 54.2 m -51.65 151.78 5.55 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.983 -179.1 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -46.37 129.35 13.28 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 C-N-CA 121.819 1.679 . . . . 0.0 112.424 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.93 -21.16 46.05 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.482 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 78.2 m95 -111.89 138.41 48.54 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.75 0.31 . . . . 0.0 110.279 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 ptpt -118.47 -176.05 3.0 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.324 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.511 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.5 p -106.94 153.71 22.15 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.493 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.509 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.1 mt -88.31 151.53 48.83 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.403 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.459 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.4 Cg_exo -39.04 105.47 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.187 1.925 . . . . 0.0 112.228 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.58 -9.2 2.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.16 168.94 47.36 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.443 ' OD1' ' NE2' ' A' ' 79' ' ' GLN . 42.7 p-10 -126.49 13.49 7.59 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.657 0.265 . . . . 0.0 110.784 179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLN . . . . . 0.443 ' NE2' ' OD1' ' A' ' 78' ' ' ASN . 10.8 mp0 -90.68 123.83 34.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.868 0.366 . . . . 0.0 110.898 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.48 68.57 4.87 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 27.2 pt -120.99 23.45 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.788 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.78 95.98 48.78 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.541 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.55 157.31 32.37 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.702 2.268 . . . . 0.0 112.236 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -111.63 131.53 62.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.755 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 28.6 m -84.78 139.4 31.97 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.408 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.439 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -63.04 -45.15 93.63 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.279 0.561 . . . . 0.0 110.251 -179.83 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -123.33 -118.08 0.29 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.29 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 t -143.81 133.71 23.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.35 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -94.05 -21.28 19.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.591 179.732 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.33 -99.18 0.7 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 39.5 p-10 -75.95 -1.71 26.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.772 0.32 . . . . 0.0 110.615 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.86 -175.29 26.79 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -141.12 153.86 45.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.934 0.397 . . . . 0.0 110.822 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.6 m -71.53 106.84 4.14 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.877 -179.32 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.7 p -96.69 -20.12 18.49 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.053 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mtt180 -162.14 168.92 10.11 Favored Pre-proline 0 C--O 1.235 0.329 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.987 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' PRO . . . . . 0.414 ' O ' ' CG ' ' A' ' 98' ' ' ASN . 52.4 Cg_exo -51.83 130.08 32.81 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 121.981 1.788 . . . . 0.0 110.827 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.439 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 12.6 p30 43.01 34.85 0.68 Allowed 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.692 0.62 . . . . 0.0 109.918 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 47.3 mmm -148.62 120.81 8.34 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 121.312 0.577 . . . . 0.0 110.571 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 13.8 p -119.82 161.68 20.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.023 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 77.8 m -119.41 128.08 53.71 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.431 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.46 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.1 OUTLIER -92.0 153.15 43.36 Favored Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.72 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 75.3 Cg_exo -46.45 -27.54 5.16 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.581 2.188 . . . . 0.0 112.011 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.8 t -63.43 -17.46 62.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.43 -3.01 63.32 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 106' ' ' GLN . . . . . 0.448 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 2.2 tm0? -81.0 148.54 29.69 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.785 0.326 . . . . 0.0 110.314 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.448 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 94.8 mt -122.06 135.18 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.549 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.685 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -176.74 175.69 0.6 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.691 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.685 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 45.6 Cg_exo -56.27 -25.78 58.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.769 2.313 . . . . 0.0 111.508 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 49.5 p -136.09 168.11 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.194 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.597 -178.727 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.457 -0.109 0 CA-C-O 120.832 0.348 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.28 7.22 33.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.531 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.505 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 12.7 tt -130.44 166.29 28.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.505 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 16.1 mmm180 -100.98 125.22 47.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.304 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 82.6 m -118.29 129.21 55.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.941 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.0 mtm -140.97 166.84 23.68 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.339 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 58.48 41.31 22.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.03 74.38 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.16 145.12 49.44 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' SER . . . . . 0.505 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 30.3 t -102.39 128.33 49.03 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.745 0.307 . . . . 0.0 110.367 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 39.9 t -84.63 120.45 26.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.226 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 133' ' ' HIS . 39.7 t -142.35 136.37 29.58 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.305 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 39.88 -118.32 0.29 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.753 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -112.87 12.91 19.55 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.51 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' HIS . . . . . 0.456 ' O ' ' O ' ' A' ' 130' ' ' SER . 78.2 t60 -133.08 152.99 51.92 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.856 0.36 . . . . 0.0 110.469 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 128' ' ' SER . 7.8 t -120.71 148.64 43.67 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.19 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.7 mt -105.73 134.29 49.09 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.351 -179.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 22.3 m -97.68 141.18 31.02 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.131 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -73.39 170.72 14.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.729 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -66.67 132.89 49.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 105.52 -20.03 38.01 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -122.27 137.03 54.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.796 0.331 . . . . 0.0 110.322 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -127.85 170.26 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.103 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 118.65 163.31 12.47 Favored Glycine 0 N--CA 1.464 0.516 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.3 p -63.39 -41.42 98.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.338 . . . . 0.0 110.562 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.445 ' C ' ' SG ' ' A' ' 145' ' ' CYS . 4.8 m-70 -107.42 1.43 23.59 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.6 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.445 ' SG ' ' C ' ' A' ' 144' ' ' HIS . 1.8 m 71.14 140.65 0.05 OUTLIER 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.933 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 158.99 -26.95 0.38 Allowed Glycine 0 C--N 1.322 -0.224 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.64 117.1 67.71 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.45 -0.5 . . . . 0.0 110.482 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.51 153.39 39.36 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.432 2.088 . . . . 0.0 112.417 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 49.4 t -114.35 128.46 71.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.57 100.03 10.4 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.097 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 11.9 tm-20 -64.44 -36.73 85.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.274 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 80.0 p -83.6 -7.24 59.55 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 61.31 -168.89 10.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.1 m -140.41 115.87 10.05 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 155' ' ' LEU . 10.7 mp -62.92 -42.07 99.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.663 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.547 ' C ' ' H ' ' A' ' 158' ' ' GLY . 63.9 t30 -93.45 173.34 7.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.524 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.17 34.6 0.31 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.547 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.03 174.42 26.02 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -123.75 138.25 54.55 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.807 0.337 . . . . 0.0 110.66 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 63.4 m -81.26 107.15 13.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.277 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.5 m -83.66 -29.98 7.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.547 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.677 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -158.93 172.38 6.21 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.54 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.677 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.5 Cg_exo -52.55 129.64 33.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.062 1.841 . . . . 0.0 111.926 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.1 m-20 53.55 33.96 17.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.601 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? -139.06 125.25 20.13 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.054 0.454 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -128.54 145.31 51.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -118.25 146.2 44.45 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.123 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 10.9 m -82.78 135.73 34.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.552 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 20.5 m -63.76 -45.4 90.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.85 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.69 22.65 10.64 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.011 0.434 . . . . 0.0 110.633 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 63.74 30.88 78.96 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -54.65 157.16 3.11 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.351 . . . . 0.0 110.353 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.15 140.47 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.284 0.564 . . . . 0.0 110.452 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 101.79 147.49 19.98 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.13 -31.31 36.73 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.591 2.194 . . . . 0.0 112.215 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.442 ' O ' ' O ' ' A' ' 177' ' ' CYS . 1.0 OUTLIER -88.12 -9.37 53.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.303 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.442 ' O ' ' O ' ' A' ' 176' ' ' GLN . 34.3 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 123.481 0.488 . . . . 0.0 109.933 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 CA--C 1.514 -0.409 0 CA-C-O 121.092 0.472 . . . . 0.0 110.559 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -137.45 162.46 33.59 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.308 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.71 161.13 23.03 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.51 -4.84 15.84 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 C-N-CA 122.953 2.435 . . . . 0.0 112.234 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.463 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 20.5 m120 -112.54 74.42 0.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.074 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 58' ' ' VAL . 8.2 p -116.04 130.38 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.904 179.465 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -139.91 177.92 7.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.098 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.8 161.28 27.82 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.8 m -82.61 171.54 13.93 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.0 ttt-85 -59.21 -40.49 85.95 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.302 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -60.01 -40.2 88.44 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.68 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -135.56 52.51 2.01 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.699 -0.228 . . . . 0.0 110.944 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.4 141.88 52.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.791 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.409 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 9.7 p90 -158.7 172.35 18.42 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.2 0.524 . . . . 0.0 110.421 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.563 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 94.6 m -69.03 140.42 54.94 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.131 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.436 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 64.2 m -58.72 149.44 63.31 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -56.29 131.09 43.72 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 121.581 1.52 . . . . 0.0 112.291 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.55 -16.34 40.95 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.463 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 93.0 m95 -119.07 134.73 55.02 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-O 120.804 0.335 . . . . 0.0 110.228 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -115.04 -176.69 2.96 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.375 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.563 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 30.3 p -132.59 172.53 12.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.005 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.698 ' H ' HD12 ' A' ' 74' ' ' LEU . 0.2 OUTLIER -92.02 160.32 35.95 Favored Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.363 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.476 ' C ' ' H ' ' A' ' 77' ' ' GLY . 45.6 Cg_exo -53.83 132.5 49.84 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.591 1.528 . . . . 0.0 112.144 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.6 -8.01 1.83 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.56 178.77 38.4 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 75.0 m-20 -146.9 16.77 1.23 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.006 0.431 . . . . 0.0 110.719 179.814 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -84.83 121.3 27.52 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.058 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 7.0 m -88.43 39.23 0.9 Allowed 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.2 -1.72 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.619 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 90.4 t -97.93 114.52 65.17 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.664 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -75.28 155.59 41.68 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 C-N-CA 121.982 1.788 . . . . 0.0 112.564 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 81.9 mt -106.42 124.44 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.192 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -106.16 115.84 30.92 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -64.15 -40.4 96.07 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.797 0.332 . . . . 0.0 110.686 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -117.0 149.39 40.32 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.537 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 m -66.22 138.2 57.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.501 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 40.5 m -79.02 -26.81 43.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.715 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.78 -104.2 2.17 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -78.6 -4.11 47.23 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.78 0.324 . . . . 0.0 110.97 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.59 -156.42 12.01 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.5 p90 -152.6 157.25 40.74 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.97 0.414 . . . . 0.0 111.023 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -64.1 112.95 3.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.052 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.432 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 91.9 p -102.83 -25.32 13.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.56 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -157.79 159.93 30.27 Favored Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.312 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -44.84 119.34 2.3 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 122.157 1.904 . . . . 0.0 111.607 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 66.2 t30 53.55 42.02 31.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.11 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mmm -148.39 118.76 7.35 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.915 0.388 . . . . 0.0 110.682 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 108' ' ' ALA . 17.7 m -100.79 146.14 27.64 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.149 178.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 101' ' ' THR . . . . . 0.432 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.0 m -122.24 123.94 42.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.627 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.401 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -87.74 156.84 52.69 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.644 -179.586 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.401 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -61.95 -19.95 67.76 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 122.469 2.113 . . . . 0.0 111.798 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -66.28 -17.23 64.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.459 179.116 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 107.12 -19.31 35.1 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -67.0 149.83 50.09 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.957 0.408 . . . . 0.0 110.253 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 94.7 mt -129.18 130.2 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.743 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.648 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.44 178.11 1.02 Allowed Pre-proline 0 CA--C 1.538 0.482 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.314 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.648 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 44.1 Cg_exo -57.67 -25.45 67.99 Favored 'Trans proline' 0 N--CA 1.499 1.837 0 C-N-CA 122.818 2.346 . . . . 0.0 111.968 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 95.5 p -149.83 162.33 40.51 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.499 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.667 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.214 0 CA-C-O 121.048 0.451 . . . . 0.0 110.031 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -98.5 13.73 30.77 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.745 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.625 HG22 ' N ' ' A' ' 122' ' ' ARG . 92.4 mt -119.24 165.52 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.204 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.625 ' N ' HG22 ' A' ' 121' ' ' ILE . 5.9 ptt85 -119.19 101.95 8.37 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.581 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 76.3 m -107.03 146.69 30.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.744 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.9 mtm -142.9 174.56 10.55 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.255 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 59.02 37.43 24.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.787 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 73.99 22.37 78.04 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.56 134.71 16.94 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 15.2 m -86.31 129.64 34.78 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 121.052 -0.259 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.413 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 4.3 t -87.12 85.28 7.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.574 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 133' ' ' HIS . 14.7 p -74.96 161.84 29.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.383 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -50.23 110.87 0.44 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.408 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.401 ' O ' ' CG ' ' A' ' 133' ' ' HIS . 98.6 m-20 52.35 28.59 5.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.555 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' HIS . . . . . 0.505 ' O ' ' N ' ' A' ' 130' ' ' SER . 31.5 m-70 -162.25 153.36 17.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.596 179.57 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 12.4 t -126.78 130.64 50.68 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.335 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.2 mt -102.06 131.07 48.74 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.902 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' CYS . . . . . 0.434 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 57.6 m -91.38 129.75 37.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.394 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -79.03 173.05 12.97 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.927 0.394 . . . . 0.0 110.575 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -63.42 134.2 55.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.334 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -21.62 37.79 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -129.02 139.62 51.98 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.772 0.32 . . . . 0.0 110.545 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 10.9 pt -134.09 176.79 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.986 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.434 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 107.52 169.08 21.88 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.5 m -62.08 -45.28 94.2 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.531 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.56 ' CE1' ' NH2' ' A' ' 122' ' ' ARG . 59.1 m80 -98.35 5.92 47.78 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.736 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 3.9 m 58.2 37.24 26.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -103.28 17.68 50.69 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 50.4 tp60 -119.19 96.73 50.22 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.754 0.277 . . . . 0.0 110.806 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -58.23 152.49 52.53 Favored 'Trans proline' 0 N--CA 1.499 1.819 0 C-N-CA 122.583 2.189 . . . . 0.0 111.916 178.716 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 70.8 t -89.94 129.76 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-O 121.048 0.452 . . . . 0.0 110.325 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.4 m -103.11 86.47 2.7 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -62.32 -46.43 88.77 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.267 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 90.0 p -111.99 -21.21 11.67 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.964 0.411 . . . . 0.0 110.502 179.25 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 49.67 177.91 0.02 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.6 m -98.54 139.8 33.73 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.934 0.397 . . . . 0.0 110.184 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 92.5 mt -63.22 -40.99 99.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.626 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.522 ' ND2' ' H ' ' A' ' 169' ' ' THR . 51.9 p30 -82.37 178.68 8.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.376 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.92 42.26 0.35 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.2 -176.57 19.15 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -130.15 142.18 50.61 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 98.6 m -76.69 102.45 6.19 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.037 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.8 t -83.17 -50.62 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.221 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.625 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -135.65 177.31 2.28 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.178 -178.935 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.625 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.71 133.12 52.73 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.821 1.68 . . . . 0.0 111.489 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 47.9 23.02 0.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.643 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -132.68 140.58 48.2 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.439 0.638 . . . . 0.0 111.025 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 5.8 p -149.1 155.69 41.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.379 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -89.92 143.88 26.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.65 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 168' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 66.1 m -85.05 155.14 21.66 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.612 -179.246 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.522 ' H ' ' ND2' ' A' ' 156' ' ' ASN . 97.9 m -62.08 -45.7 92.36 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.168 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.45 22.55 15.64 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.992 0.425 . . . . 0.0 111.262 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.13 35.09 91.31 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.408 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 2.7 m-85 -68.32 146.99 52.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.117 0.484 . . . . 0.0 110.643 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 60.6 p -81.58 166.67 20.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.179 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 91.28 154.62 30.81 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -67.83 -20.97 45.06 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.609 2.206 . . . . 0.0 112.405 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -111.26 18.79 18.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.737 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 79.7 m . . . . . 0 C--N 1.327 -0.399 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.29 -179.762 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -130.23 160.46 33.81 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 121.125 0.488 . . . . 0.0 110.142 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.6 174.76 36.46 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.04 -172.3 0.97 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.898 2.399 . . . . 0.0 111.81 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.402 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 24.5 m120 59.16 38.95 23.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.997 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.46 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 11.8 p -98.69 131.59 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.278 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -141.5 -178.75 5.78 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.251 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.47 162.3 29.03 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 13.6 m -82.52 172.84 12.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.4 ttt-85 -60.86 -43.03 98.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.483 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -62.12 -39.62 93.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -133.02 55.2 1.91 Allowed 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.669 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.2 142.29 52.45 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -155.21 169.56 23.89 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.997 0.427 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.453 ' SG ' HG22 ' A' ' 73' ' ' THR . 71.8 m -74.14 139.72 44.72 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.188 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.46 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 61.9 m -56.81 153.63 21.68 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.252 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.78 131.87 35.15 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 121.244 1.296 . . . . 0.0 112.203 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.92 -18.82 51.55 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.556 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 8.9 m95 -119.01 140.04 50.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.746 0.308 . . . . 0.0 110.649 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -121.6 -175.84 3.18 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.453 HG22 ' SG ' ' A' ' 67' ' ' CYS . 60.8 p -108.81 154.12 22.53 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.482 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.9 mt -83.37 152.43 64.3 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.688 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.406 ' C ' ' H ' ' A' ' 77' ' ' GLY . 74.0 Cg_exo -41.3 110.33 0.13 Allowed 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.017 1.811 . . . . 0.0 112.197 179.125 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.36 -4.78 7.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -89.09 173.64 41.37 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -135.94 11.96 3.37 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.969 0.414 . . . . 0.0 111.059 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -89.61 126.64 35.7 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.552 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -89.61 69.1 7.79 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.8 pt -122.05 21.78 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.96 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -118.87 86.72 31.48 Favored Pre-proline 0 N--CA 1.464 0.251 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.793 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.47 150.76 83.74 Favored 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.773 2.315 . . . . 0.0 111.994 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.495 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.4 mt -106.05 128.74 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.439 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 5.9 m -89.62 135.67 33.48 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.49 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.4 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.04 -45.59 92.89 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.18 0.514 . . . . 0.0 109.758 -179.208 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -119.0 167.86 11.36 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.64 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 96.4 p -57.15 137.81 55.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.544 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 31.5 m -86.06 -32.96 21.12 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.863 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.77 -108.91 2.74 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -93.74 0.96 56.62 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.744 0.306 . . . . 0.0 111.066 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.62 -176.25 31.12 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.449 ' C ' ' SG ' ' A' ' 100' ' ' CYS . 44.8 p90 -135.18 145.39 47.69 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.114 0.483 . . . . 0.0 110.902 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 85' ' ' CYS . 0.5 OUTLIER -70.11 113.41 7.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.54 -178.786 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 33.9 m -99.79 -21.04 15.92 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.535 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.0 mtt180 -160.2 164.74 19.11 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.662 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.22 127.85 25.19 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 121.676 1.584 . . . . 0.0 111.474 179.064 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.4 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 63.9 m-20 50.52 35.36 11.15 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.874 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 68.3 mmm -150.26 122.05 8.11 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.416 0.627 . . . . 0.0 110.485 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.449 ' SG ' ' C ' ' A' ' 93' ' ' PHE . 0.7 OUTLIER -120.79 161.64 21.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.059 179.65 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.5 m -127.75 127.45 43.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.693 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.94 156.7 36.9 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.24 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -50.89 -26.2 17.55 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.252 1.968 . . . . 0.0 111.896 177.975 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.12 -17.76 64.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.859 0.361 . . . . 0.0 110.489 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.1 -16.43 53.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.3 tp60 -63.91 150.34 45.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.909 0.385 . . . . 0.0 110.07 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.49 131.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.641 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -179.51 174.5 0.47 Allowed Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.558 178.798 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.641 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 40.6 Cg_exo -57.32 -22.03 47.39 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.708 2.272 . . . . 0.0 111.751 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.5 p -140.16 159.98 40.98 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.754 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.452 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 14.9 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.998 0.428 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -65.11 -40.55 94.67 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.26 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 25.3 pt -92.8 -170.83 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.624 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -107.53 108.56 19.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.215 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 57.7 m -114.81 139.39 49.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.992 178.671 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 90.0 mtp -138.97 168.23 20.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 2.4 m-20 59.56 41.75 18.47 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.249 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.7 20.21 79.6 Favored Glycine 0 CA--C 1.52 0.375 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.23 156.57 52.35 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.4 m -133.29 146.64 51.55 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.733 0.301 . . . . 0.0 110.247 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 7.6 p -91.53 130.1 37.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.377 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.6 t -148.11 137.69 22.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.058 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' A' ' 131' ' ' ASP . 3.7 p-10 45.01 41.29 5.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.006 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t0 62.0 36.69 15.4 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.637 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 69.1 t60 -150.02 140.59 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.585 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 9.4 t -88.55 130.92 35.13 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.48 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.6 mt -105.4 130.51 53.48 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 15.6 m -101.88 145.39 29.29 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.518 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.89 175.39 9.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.742 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -66.14 129.92 41.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.54 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.84 -20.06 44.96 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -120.28 134.57 55.24 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.792 0.329 . . . . 0.0 110.235 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.93 173.32 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.227 -179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 107.01 164.29 22.18 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 43.5 p -61.4 -44.78 96.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.754 0.311 . . . . 0.0 110.491 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 3.0 p-80 -98.52 14.41 28.39 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.431 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.525 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 5.2 m 46.39 43.4 11.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.11 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.74 12.31 42.1 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -121.45 119.28 29.44 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.63 0.215 . . . . 0.0 110.972 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -76.44 157.69 36.7 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.676 2.25 . . . . 0.0 112.266 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.0 t -99.31 111.19 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 121.015 0.436 . . . . 0.0 110.653 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.53 90.63 8.08 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.0 tt0 -70.18 -39.15 75.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.546 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 10.6 m -88.39 -12.9 41.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.65 161.4 0.02 OUTLIER Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 160' ' ' CYS . 25.6 m -106.55 159.18 16.37 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 155' ' ' LEU . . . . . 0.42 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 56.7 mt -62.37 -42.87 99.75 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.244 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.42 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 t-20 161.67 -58.92 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.747 0.654 . . . . 0.0 110.61 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.03 -42.21 99.72 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -71.41 168.83 50.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 22.8 mmm180 -130.03 149.07 51.91 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.912 0.386 . . . . 0.0 110.21 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 87.9 m -81.15 95.16 6.8 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.668 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 41.6 t -79.48 -47.86 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.577 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.676 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.24 177.79 2.06 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.341 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.676 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -55.08 134.85 66.07 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.833 1.689 . . . . 0.0 111.597 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 40.78 33.53 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.948 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -132.7 104.49 6.66 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 121.364 0.602 . . . . 0.0 111.316 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.16 132.15 36.85 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.151 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -92.7 141.1 28.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.029 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.4 m -90.99 132.87 35.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.098 0.475 . . . . 0.0 110.757 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.9 m -63.64 -46.29 86.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.496 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -104.36 24.04 12.22 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.952 0.405 . . . . 0.0 111.246 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 62.42 29.86 74.58 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -54.67 168.0 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.04 0.448 . . . . 0.0 110.508 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.4 p -81.89 164.66 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.217 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.06 151.81 0.14 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.77 -24.8 40.29 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.375 2.05 . . . . 0.0 112.232 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 177' ' ' CYS . 85.2 mt-30 -84.09 -11.38 56.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.556 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 176' ' ' GLN . 10.1 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.47 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.405 HD12 ' HB1' ' A' ' 65' ' ' ALA . 96.2 mt . . . . . 0 N--CA 1.451 -0.39 0 CA-C-O 120.995 0.426 . . . . 0.0 110.421 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -131.72 161.73 32.14 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.565 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.79 172.73 22.25 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.52 -167.46 0.18 Allowed 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 122.924 2.416 . . . . 0.0 111.885 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.581 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 5.2 m120 58.2 37.0 26.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.535 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.481 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 13.3 p -100.41 134.15 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 109.95 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 57.6 m -142.98 177.46 8.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.275 -179.186 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.55 162.64 31.83 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 65' ' ' ALA . 11.8 m -80.46 173.72 12.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.628 0.252 . . . . 0.0 110.465 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -60.6 -44.12 96.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.74 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -64.72 -39.26 93.34 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.421 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 58.6 t30 -125.39 51.12 1.73 Allowed 'General case' 0 CA--C 1.522 -0.113 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.819 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.5 142.52 50.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.466 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.421 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 10.2 p90 -160.2 167.54 27.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.219 0.533 . . . . 0.0 111.189 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.547 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 74.6 m -71.13 141.22 50.78 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.35 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.481 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 65.2 m -58.94 150.85 58.44 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.973 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -56.0 128.56 30.76 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.835 1.69 . . . . 0.0 112.037 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.1 47.02 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.581 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.3 m95 -125.39 135.29 52.24 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.025 0.441 . . . . 0.0 110.527 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -119.76 -177.36 3.37 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.437 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.547 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 19.2 p -129.24 165.6 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.285 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.5 mt -84.46 149.89 55.82 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.723 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -43.02 120.46 1.94 Allowed 'Trans proline' 0 N--CA 1.489 1.242 0 C-N-CA 121.881 1.721 . . . . 0.0 112.312 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.4 -0.25 55.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.901 -0.879 . . . . 0.0 110.901 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -89.84 171.17 37.27 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -136.64 2.15 2.64 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.038 0.447 . . . . 0.0 110.836 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -82.22 131.66 35.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.191 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.3 m -99.21 43.49 1.06 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -98.89 2.68 10.49 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.362 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.61 110.37 60.25 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.611 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -73.39 158.52 48.11 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.202 1.934 . . . . 0.0 112.226 -179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -104.14 124.74 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.081 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.55 127.2 36.18 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.94 -45.29 93.15 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -136.81 154.96 50.39 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 17.0 m -60.08 136.39 58.0 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.321 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 1.8 t -94.03 4.04 54.47 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.562 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 61.73 -100.02 0.25 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.402 ' OD1' ' SG ' ' A' ' 102' ' ' CYS . 37.7 p30 -90.73 8.47 34.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.699 0.285 . . . . 0.0 110.838 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.87 -173.46 29.15 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.433 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -142.41 154.16 44.36 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.073 0.464 . . . . 0.0 110.9 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.8 m -72.15 106.42 4.36 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.804 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.433 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 2.1 m -95.9 -24.3 16.48 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.671 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.9 mtm-85 -159.96 167.17 14.49 Favored Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.891 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -51.96 125.4 17.07 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.73 1.62 . . . . 0.0 111.311 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 50.81 34.7 10.64 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.552 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.2 mmm -149.69 124.13 9.65 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.286 0.565 . . . . 0.0 110.614 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 10.1 p -123.92 163.58 21.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.794 179.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 94.8 m -125.46 130.63 52.19 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.705 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.402 ' SG ' ' OD1' ' A' ' 91' ' ' ASP . 0.1 OUTLIER -94.28 155.74 39.56 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -48.01 -29.6 12.39 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.443 2.095 . . . . 0.0 112.133 177.368 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 37.5 m -62.63 -19.87 64.22 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.975 0.417 . . . . 0.0 110.688 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.4 57.27 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -70.94 152.0 44.09 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 110.168 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.36 131.55 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.57 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.67 178.22 0.55 Allowed Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.584 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 31.6 Cg_exo -59.97 -18.57 50.84 Favored 'Trans proline' 0 N--CA 1.5 1.911 0 C-N-CA 122.794 2.329 . . . . 0.0 111.588 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.4 p -149.6 164.65 34.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.5 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.5 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.875 0.369 . . . . 0.0 110.182 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -63.91 -40.08 95.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.41 HG22 ' N ' ' A' ' 122' ' ' ARG . 21.0 mm -80.7 160.23 4.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.152 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.41 ' N ' HG22 ' A' ' 121' ' ' ILE . 88.8 mmt-85 -81.73 98.52 8.46 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.184 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -105.64 122.24 45.63 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -141.78 167.63 21.69 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.845 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.19 37.95 23.7 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.79 22.29 61.96 Favored Glycine 0 CA--C 1.522 0.485 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.06 119.25 9.44 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 7.3 m -80.2 138.59 36.88 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.487 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 22.6 m -91.08 128.48 36.92 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.774 0.321 . . . . 0.0 110.378 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.4 m -141.6 140.02 33.24 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' SER . 97.2 m-20 36.11 -97.15 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.965 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -136.02 22.25 3.27 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.728 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -132.48 147.04 52.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.496 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.98 125.65 44.49 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.861 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.1 mt -103.9 131.53 51.03 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.37 143.69 29.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.738 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -68.19 -174.77 0.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.319 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 27.8 tptp -69.02 132.09 46.09 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.541 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 96.93 -8.4 65.37 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -118.58 136.29 53.95 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.856 0.36 . . . . 0.0 110.559 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.7 pt -134.29 172.47 16.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.064 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 104.42 160.73 24.19 Favored Glycine 0 N--CA 1.461 0.342 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' THR . . . . . 0.436 ' H ' HG22 ' A' ' 143' ' ' THR . 0.1 OUTLIER -65.34 -42.74 92.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.738 0.304 . . . . 0.0 110.547 -179.897 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -97.13 5.17 50.69 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 31.0 m 58.12 37.31 26.38 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.371 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -100.73 5.28 56.67 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -119.8 107.8 39.83 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.801 0.3 . . . . 0.0 110.601 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.23 159.85 29.71 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 C-N-CA 122.65 2.233 . . . . 0.0 112.127 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.4 t -97.88 105.18 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -86.47 100.04 12.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.657 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -66.29 -45.57 79.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.283 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' SER . . . . . 0.443 ' O ' ' O ' ' A' ' 153' ' ' GLY . 23.4 t -89.53 -16.7 30.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.702 0.287 . . . . 0.0 110.883 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.49 156.15 0.01 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 10.9 m -93.95 133.08 37.76 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 64.3 mt -62.31 -43.9 97.76 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.189 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 178.23 -60.79 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 O-C-N 123.615 0.572 . . . . 0.0 110.52 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.84 51.13 1.54 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -166.82 154.62 25.18 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -123.25 129.32 51.21 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 2.4 t -75.33 102.84 5.23 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.068 0.461 . . . . 0.0 110.69 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 161' ' ' VAL . 4.6 p -107.34 -2.91 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.412 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.6 171.65 4.47 Favored Pre-proline 0 C--N 1.322 -0.599 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.581 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.6 Cg_exo -52.15 128.8 28.52 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 121.773 1.649 . . . . 0.0 111.395 178.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 40.93 36.14 0.4 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.682 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.528 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.8 OUTLIER -127.07 110.27 12.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.228 0.537 . . . . 0.0 110.409 -179.447 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.528 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 66.5 m -105.07 124.64 49.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.751 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -85.09 91.06 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.655 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.23 118.11 35.91 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.436 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.4 OUTLIER -111.27 11.36 21.7 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.63 -179.529 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 47.2 t80 -109.07 31.28 5.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.153 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 105.91 58.76 0.63 Allowed Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -53.02 126.12 19.53 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.534 -0.467 . . . . 0.0 110.325 -179.156 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.444 ' O ' ' O ' ' A' ' 174' ' ' GLY . 3.0 t -149.09 150.37 32.64 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.498 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 173' ' ' THR . . . 53.36 165.85 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.09 -18.66 45.73 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.83 2.353 . . . . 0.0 112.112 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -92.15 47.9 1.37 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.094 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 173' ' ' THR . 53.2 t . . . . . 0 N--CA 1.462 0.17 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.697 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.469 HD12 ' HB1' ' A' ' 65' ' ' ALA . 88.9 mt . . . . . 0 N--CA 1.451 -0.376 0 CA-C-O 120.88 0.371 . . . . 0.0 110.724 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.44 160.67 28.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.355 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.18 174.8 38.37 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.47 -169.36 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.991 2.461 . . . . 0.0 111.627 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 57.52 38.56 28.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.907 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.42 HG13 ' O ' ' A' ' 58' ' ' VAL . 12.0 p -99.91 130.8 48.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 59' ' ' CYS . . . . . 0.438 ' O ' ' O ' ' A' ' 66' ' ' TYR . 52.7 m -145.64 175.58 10.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.613 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.23 167.1 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -75.06 165.04 25.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.623 0.249 . . . . 0.0 110.391 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.8 ttt180 -60.89 -44.2 97.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.653 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -66.24 -39.24 89.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -123.84 49.91 1.69 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.645 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.95 143.88 50.73 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.47 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.438 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -159.38 166.59 30.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.991 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 53.9 m -72.66 133.24 44.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.763 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -45.62 162.52 0.23 Allowed Pre-proline 0 CA--C 1.538 0.494 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -55.12 134.36 63.32 Favored 'Trans proline' 0 N--CA 1.495 1.604 0 C-N-CA 122.547 2.165 . . . . 0.0 111.68 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.65 -14.67 64.5 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -115.88 141.64 47.83 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.81 0.338 . . . . 0.0 110.239 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -125.7 -157.99 0.82 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.138 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 73.3 p -127.23 164.46 21.64 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.945 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.2 mt -87.09 152.05 52.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.414 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.7 Cg_exo -40.66 105.98 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.146 1.897 . . . . 0.0 111.939 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.65 -12.33 6.19 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.05 176.65 53.89 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 44.9 p30 -134.66 11.22 3.72 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.803 0.335 . . . . 0.0 110.744 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -82.37 130.62 35.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.474 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 79.7 m -90.96 47.66 1.43 Allowed 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.811 0.339 . . . . 0.0 110.308 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 38.4 pt -107.39 24.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.49 94.07 48.62 Favored Pre-proline 0 CA--C 1.537 0.449 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.249 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.85 156.82 24.05 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.463 2.108 . . . . 0.0 111.981 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -101.99 125.77 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.025 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.03 119.28 38.52 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -45.37 94.74 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.969 0.414 . . . . 0.0 109.981 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -114.09 144.59 42.89 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.533 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.9 m -62.51 134.99 57.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.249 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 37.8 m -77.16 -31.72 55.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.633 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.08 -106.78 2.26 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.42 -8.01 52.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.664 0.269 . . . . 0.0 110.719 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.88 -161.48 18.81 Favored Glycine 0 N--CA 1.463 0.46 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.513 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -146.84 153.06 39.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.028 0.442 . . . . 0.0 110.755 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.25 114.56 5.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.28 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.513 ' OG ' ' CE2' ' A' ' 93' ' ' PHE . 75.7 m -105.11 -22.54 13.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.443 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 3.0 mtt180 -156.34 160.95 30.41 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.796 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -47.47 118.24 2.81 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 122.138 1.892 . . . . 0.0 111.519 179.04 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 62.1 t30 54.27 41.67 31.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.344 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 77.0 mtp -148.33 120.13 8.12 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.367 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' ALA . 46.5 m -103.75 148.95 25.47 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.831 179.382 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 101' ' ' THR . . . . . 0.403 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 97.5 m -118.51 123.06 44.2 Favored 'General case' 0 CA--C 1.515 -0.385 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.57 147.84 35.06 Favored Pre-proline 0 CA--C 1.541 0.598 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.651 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -47.39 -23.97 3.69 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.636 2.224 . . . . 0.0 112.09 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.9 t -64.35 -17.3 63.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.767 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.61 -14.99 56.26 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 59.6 tp60 -73.08 152.25 41.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.896 0.379 . . . . 0.0 110.248 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 91.4 mt -126.59 131.95 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.546 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.05 173.32 1.2 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.448 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 49.4 Cg_exo -55.08 -28.37 60.07 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.719 2.279 . . . . 0.0 112.142 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 p -136.61 164.25 28.64 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.567 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.648 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 93.7 m . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 120.953 0.406 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 46.1 t30 -161.75 29.59 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.442 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 18.5 tt -121.13 171.09 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.441 -179.238 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.442 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 27.2 mmt180 -95.86 127.46 41.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.928 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 85.0 m -117.52 134.78 54.48 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.971 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtt -138.24 156.53 47.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.231 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 58.92 51.47 7.31 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.059 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 66.48 26.9 72.84 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.52 139.5 35.45 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' SER . . . . . 0.51 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 51.5 m -110.3 141.75 42.87 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.2 t -85.01 126.16 33.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 0.0 110.621 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.457 ' O ' ' O ' ' A' ' 133' ' ' HIS . 11.4 p -148.5 127.91 13.09 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.448 0.642 . . . . 0.0 111.01 179.527 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.444 ' O ' ' CB ' ' A' ' 132' ' ' ASP . 9.6 t70 50.18 42.79 25.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.562 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 131' ' ' ASP . 9.5 t0 78.29 -40.68 0.29 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 133' ' ' HIS . . . . . 0.682 ' CD2' ' O ' ' A' ' 133' ' ' HIS . 3.9 p-80 -85.42 147.64 26.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.971 0.415 . . . . 0.0 110.531 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.3 t -99.93 149.09 23.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.847 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.5 137.27 49.54 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.25 144.67 27.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.481 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -59.95 176.13 0.33 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.658 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 49.7 tttm -66.61 131.22 45.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.641 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 99.01 -15.86 60.1 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -111.28 136.44 50.38 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.791 0.329 . . . . 0.0 110.35 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.45 171.7 17.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.973 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.72 158.36 10.58 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 98.6 m -62.53 -46.39 88.62 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.916 -0.314 . . . . 0.0 110.715 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 96.3 m-70 -105.28 11.82 32.48 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.491 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 14.6 m 60.68 139.13 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.809 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 153.13 -1.15 0.24 Allowed Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -113.09 108.66 52.84 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 121.303 -0.159 . . . . 0.0 110.785 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -77.43 159.32 32.61 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.676 2.25 . . . . 0.0 111.909 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 81.9 t -120.81 120.49 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-O 121.009 0.433 . . . . 0.0 110.12 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 60.5 m -91.44 114.65 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.56 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -64.03 -42.22 97.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.88 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.1 p -86.27 -6.36 58.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.532 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.11 166.31 0.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 73.4 m -100.27 102.9 14.29 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.879 0.371 . . . . 0.0 110.067 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.8 mt -63.62 -41.98 98.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.552 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.557 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.5 t30 -93.28 -176.97 4.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.387 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.523 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.79 23.25 0.41 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.557 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.41 174.99 26.35 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 52.3 mmm-85 -127.42 147.12 50.29 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.695 0.283 . . . . 0.0 110.449 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 21.5 m -86.01 111.67 20.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.09 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -97.16 -16.26 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.331 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.633 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -168.34 173.65 2.56 Favored Pre-proline 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.71 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.633 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.7 Cg_exo -57.08 135.65 71.92 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.068 1.845 . . . . 0.0 112.029 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.8 t30 44.43 32.79 0.77 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.837 179.295 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.86 101.0 3.77 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.386 0.612 . . . . 0.0 111.152 179.077 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 31.2 t -101.81 148.2 25.58 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.284 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.0 137.37 39.45 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.88 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 87.8 m -81.7 150.34 28.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.822 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.4 m -61.72 -45.99 91.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.735 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 53.3 t80 -110.36 25.71 11.48 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.058 0.456 . . . . 0.0 110.694 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 67.13 30.51 75.83 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' A' ' 173' ' ' THR . 65.9 t80 -58.76 159.35 6.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.83 0.348 . . . . 0.0 110.444 -179.522 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 8.1 p -81.94 167.09 19.29 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.392 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 104.36 142.0 11.36 Favored Glycine 0 CA--C 1.535 1.287 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.06 -33.01 20.23 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 122.524 2.149 . . . . 0.0 112.596 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.419 ' O ' ' O ' ' A' ' 177' ' ' CYS . 20.8 pt20 -108.05 1.15 22.2 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.566 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.419 ' O ' ' O ' ' A' ' 176' ' ' GLN . 1.1 t . . . . . 0 C--N 1.326 -0.444 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.421 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 78.2 mt . . . . . 0 N--CA 1.454 -0.261 0 CA-C-O 121.013 0.435 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -138.5 159.84 41.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.526 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.58 169.1 29.22 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.59 -168.79 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.938 2.426 . . . . 0.0 111.821 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.626 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 46.4 m-80 59.35 41.04 20.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.743 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 58' ' ' VAL . 11.4 p -105.33 131.69 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.6 m -141.88 -175.45 4.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.128 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.37 173.5 49.71 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.746 -0.941 . . . . 0.0 110.746 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.4 m -72.88 155.96 39.36 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -58.99 -43.2 91.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.775 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.23 -41.87 98.8 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.173 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -127.74 50.65 2.01 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.723 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.03 151.36 47.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.28 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -154.67 164.94 38.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.158 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.434 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 69.0 m -63.41 128.99 38.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.783 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 12.4 m -48.53 150.92 2.18 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.34 -178.915 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.61 133.5 38.37 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 121.572 1.514 . . . . 0.0 112.178 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.26 -7.94 64.42 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.626 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 54.6 m95 -118.89 138.71 52.57 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 110.592 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -127.83 -176.05 3.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.412 179.278 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.434 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 5.4 p -133.46 177.99 7.27 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.54 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 48.6 mt -89.91 148.86 40.67 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.507 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.41 116.16 0.47 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.108 1.872 . . . . 0.0 112.491 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.19 -4.56 54.3 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.33 171.1 43.59 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -133.58 9.19 3.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.977 0.418 . . . . 0.0 110.811 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -87.28 132.33 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.487 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -97.88 40.0 1.19 Allowed 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 35.4 pt -97.24 12.93 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.855 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.6 t -116.29 87.98 21.65 Favored Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.471 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo -60.69 148.87 90.23 Favored 'Trans proline' 0 N--CA 1.496 1.659 0 C-N-CA 122.819 2.346 . . . . 0.0 111.987 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 91.9 mt -89.17 123.55 41.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.47 110.1 22.74 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.17 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 2.1 mpt_? -65.31 -39.08 92.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.025 0.441 . . . . 0.0 110.328 178.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -119.05 143.36 47.15 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.104 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.7 p -60.86 134.46 57.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.397 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 60.3 m -77.89 -28.07 49.78 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.706 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.4 -102.56 1.74 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -89.19 2.37 54.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.658 0.266 . . . . 0.0 110.639 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.29 -168.86 22.96 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -138.71 150.53 46.26 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.124 0.488 . . . . 0.0 110.854 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 90.8 m -65.89 112.86 3.99 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.33 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 t -107.29 -25.87 11.29 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.467 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.4 mtt-85 -158.09 164.3 21.79 Favored Pre-proline 0 C--N 1.328 -0.334 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.66 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -51.01 121.77 8.79 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.96 1.773 . . . . 0.0 111.485 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 52.09 40.83 29.35 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 48.7 mtt -146.9 114.91 6.54 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.699 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' ALA . 65.3 m -100.05 146.84 26.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.232 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 66.6 m -115.61 121.6 43.09 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.87 149.55 37.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.498 -179.464 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.65 -21.81 2.58 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.567 2.178 . . . . 0.0 111.974 177.484 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.8 t -68.02 -17.91 64.55 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.8 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.87 -14.68 57.34 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -68.42 153.82 43.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.974 0.416 . . . . 0.0 110.243 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.42 133.15 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.677 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.637 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . 179.71 168.49 0.69 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.301 178.995 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.637 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 64.7 Cg_exo -48.8 -33.76 26.02 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 122.597 2.198 . . . . 0.0 112.083 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 38.8 m -133.01 165.6 24.34 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.538 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.484 . . . . 0.0 109.84 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' CYS . . . . . 0.445 ' C ' ' H ' ' A' ' 121' ' ' ILE . 12.1 t . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.803 0.335 . . . . 0.0 110.944 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.3 t-20 61.09 3.22 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.595 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.445 ' H ' ' C ' ' A' ' 119' ' ' CYS . 18.8 tt -143.84 172.25 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.427 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.421 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 38.0 mtt85 -122.73 99.97 6.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.777 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 28.8 m -90.34 147.16 23.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.739 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.7 mtm -139.97 170.6 15.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.356 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.0 m120 67.48 39.13 2.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.508 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.55 32.44 83.26 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.31 -173.98 14.0 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.1 m -130.98 136.69 48.76 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.4 t -73.33 112.08 9.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.188 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 69.5 m -128.97 119.82 24.99 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.959 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 43.17 -108.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.746 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -121.81 19.81 10.97 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.507 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -131.87 156.02 46.82 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.955 0.407 . . . . 0.0 110.293 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 97.1 m -106.42 131.24 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.0 mt -99.22 131.35 45.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.672 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -100.3 143.2 30.78 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.438 -179.372 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.56 -179.09 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.57 132.84 49.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.53 -179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.25 -19.36 46.1 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -118.11 136.99 53.25 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.784 0.326 . . . . 0.0 110.295 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.6 pt -130.94 171.79 17.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.992 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.01 157.73 10.48 Favored Glycine 0 N--CA 1.464 0.519 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 61.6 p -64.09 -42.53 96.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.835 0.35 . . . . 0.0 110.536 -179.579 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -105.8 5.64 31.0 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.692 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 5.0 m 65.04 140.1 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.076 0.465 . . . . 0.0 109.965 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 152.86 -11.04 0.59 Allowed Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -102.44 110.2 62.32 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.535 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.29 157.46 33.31 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.486 2.124 . . . . 0.0 112.31 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.46 116.66 50.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 120.989 0.423 . . . . 0.0 110.179 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.7 m -88.98 96.38 10.7 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -66.12 -38.5 88.34 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.426 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 97.4 p -82.42 -7.96 59.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.684 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 59.2 161.93 0.07 OUTLIER Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.06 114.5 28.73 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.57 -42.16 98.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.1 m-20 -100.07 -177.37 3.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.456 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -70.81 33.58 0.49 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.046 -0.821 . . . . 0.0 111.046 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.55 176.05 28.79 Favored Glycine 0 CA--C 1.52 0.349 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -126.03 142.33 51.57 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.68 0.276 . . . . 0.0 110.494 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.66 122.03 30.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.442 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.2 m -110.16 -9.87 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.308 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -171.91 170.97 2.34 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.41 -0.516 . . . . 0.0 110.737 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.9 Cg_exo -53.05 128.48 29.16 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 121.913 1.742 . . . . 0.0 111.402 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 52.58 32.69 12.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.119 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.76 127.8 37.52 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.15 0.5 . . . . 0.0 109.773 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 4.4 t -139.01 148.58 43.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.858 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.51 129.11 47.52 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.471 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 26.8 m -74.43 151.43 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.311 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.8 m -62.96 -45.8 90.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.204 -179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.96 19.52 19.29 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-O 121.077 0.465 . . . . 0.0 110.734 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 68.53 26.71 74.23 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -55.45 149.66 13.05 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 51.8 p -82.29 165.42 20.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.576 -179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 87.44 150.45 18.85 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.82 -23.18 41.89 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.69 2.26 . . . . 0.0 112.272 -179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 76.6 mt-30 -101.34 7.32 42.81 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.554 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 77.9 m . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.185 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 13.0 mt . . . . . 0 CA--C 1.517 -0.289 0 CA-C-O 121.166 0.508 . . . . 0.0 110.225 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -133.22 163.03 30.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.32 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.47 160.31 23.13 Favored Glycine 0 CA--C 1.531 1.039 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.54 2.94 6.82 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.862 2.375 . . . . 0.0 112.212 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.441 ' OD1' ' CZ2' ' A' ' 71' ' ' TRP . 3.0 m-80 -114.95 69.07 0.71 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.355 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.457 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.1 t -120.42 130.83 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 93.1 m -141.15 176.8 8.54 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.032 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.22 169.15 45.49 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.557 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -74.51 163.25 27.97 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -59.27 -43.94 92.45 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.47 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -64.11 -39.96 95.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.007 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -122.54 46.62 2.1 Favored 'General case' 0 N--CA 1.461 0.079 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.783 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.557 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.92 145.09 48.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.52 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -156.05 168.19 28.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.821 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.5 m -67.47 130.11 42.04 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.189 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.457 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 53.5 m -49.21 153.29 1.73 Allowed Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.246 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -51.64 131.68 38.26 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 121.43 1.42 . . . . 0.0 112.398 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 100.9 -16.53 57.33 Favored Glycine 0 N--CA 1.467 0.737 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.55 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 9.1 m95 -115.63 139.58 49.97 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.787 0.327 . . . . 0.0 110.498 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.9 ptpt -120.23 -168.66 1.66 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.312 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 64.1 p -118.13 160.53 21.39 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.483 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.1 mt -87.4 152.84 52.96 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.744 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.44 107.58 0.08 OUTLIER 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.145 1.897 . . . . 0.0 112.184 179.309 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.34 -11.63 12.19 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -88.29 175.99 44.84 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -135.56 15.75 3.4 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.12 0.486 . . . . 0.0 110.639 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -79.87 128.53 33.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.495 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' CYS . . . . . 0.405 ' O ' ' ND2' ' A' ' 57' ' ' ASN . 29.9 m -96.9 55.68 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 30.3 pt -115.92 21.01 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.993 -179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.5 t -119.32 85.74 31.62 Favored Pre-proline 0 N--CA 1.467 0.39 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.697 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -61.35 148.48 92.83 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.936 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.8 mt -90.9 128.63 42.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 3.2 m -99.62 109.02 21.54 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.229 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -65.88 -39.36 90.59 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.052 0.453 . . . . 0.0 109.906 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 61.3 m170 -110.51 142.06 42.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.002 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.5 t -59.62 130.07 45.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.681 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 61.2 m -80.28 -31.52 38.28 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.875 179.374 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.07 -112.48 3.67 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -81.91 -0.55 44.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.16 -175.74 30.35 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.0 147.79 52.47 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.018 0.437 . . . . 0.0 110.794 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.2 m -64.4 111.26 2.57 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.42 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 69.8 p -102.64 -27.51 12.69 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.302 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.1 mtt85 -157.83 163.94 23.03 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.583 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -51.55 121.9 9.32 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 121.634 1.556 . . . . 0.0 111.48 179.126 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 55.17 40.34 31.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.878 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.8 mmm -149.27 115.81 5.87 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.198 0.523 . . . . 0.0 109.97 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 86.7 m -101.23 151.12 22.25 Favored 'General case' 0 N--CA 1.461 0.116 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.674 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 97.1 m -121.91 126.26 48.26 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.68 151.59 40.12 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.642 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -50.02 -22.73 8.11 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.459 2.106 . . . . 0.0 111.867 177.59 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -66.85 -16.96 64.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.684 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.82 -18.5 49.89 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tt0 -68.05 153.16 44.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.894 0.378 . . . . 0.0 110.304 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.17 130.38 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.581 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.545 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.27 164.88 3.21 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.962 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.545 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 15.3 Cg_endo -57.44 -22.81 52.28 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.916 2.411 . . . . 0.0 111.829 178.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.9 p -135.38 154.53 51.45 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.97 0.414 . . . . 0.0 110.227 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.68 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 120.782 0.325 . . . . 0.0 110.207 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -63.4 -40.21 96.61 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.444 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.539 HG22 ' H ' ' A' ' 122' ' ' ARG . 1.1 mt -113.31 -157.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.811 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.539 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.6 ptt-85 -120.59 121.72 38.99 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.7 m -124.86 147.0 49.01 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.15 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 70.9 mtm -145.17 174.13 11.34 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.315 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 5.7 m120 59.61 37.2 22.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.44 15.47 79.84 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.7 123.76 10.16 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.158 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 39.9 t -83.51 140.98 31.96 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.75 0.309 . . . . 0.0 110.881 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 5.8 m -83.32 129.94 35.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.18 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.4 m -126.45 158.3 36.38 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.134 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.442 ' O ' ' OD1' ' A' ' 131' ' ' ASP . 43.4 p-10 -48.24 109.35 0.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.09 0.472 . . . . 0.0 110.991 -178.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 50.24 30.26 4.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.531 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -159.78 154.9 24.95 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.495 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 47.6 t -129.55 132.32 46.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.784 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 80.3 mt -101.09 128.47 47.14 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 55.6 m -84.77 132.19 34.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.382 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -56.1 161.14 2.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.906 0.384 . . . . 0.0 110.352 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -59.25 130.81 48.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.873 0.368 . . . . 0.0 110.816 -179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 94.5 -6.91 71.37 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -119.74 137.43 53.94 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.924 0.392 . . . . 0.0 110.098 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 22.3 pt -129.61 169.59 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.953 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 121.69 159.34 10.64 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.4 m -62.17 -45.64 92.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 0.0 110.687 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.505 ' NE2' ' NH2' ' A' ' 122' ' ' ARG . 31.9 m-70 -102.75 3.24 36.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.347 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.37 142.94 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.894 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 149.53 -8.24 0.86 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -101.39 109.38 58.73 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.371 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.3 157.49 45.65 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.359 2.039 . . . . 0.0 112.437 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.8 t -124.83 126.81 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.412 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 66.3 m -94.41 109.13 21.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.129 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -66.89 -39.54 87.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.9 m -88.66 -9.16 53.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.712 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLY . . . . . 0.505 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 60.03 177.47 1.48 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 9.0 m -116.08 119.98 37.61 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.024 0.44 . . . . 0.0 110.191 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 94.9 mt -63.57 -42.38 98.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.506 ' C ' ' H ' ' A' ' 158' ' ' GLY . 18.9 m120 -93.6 -178.49 4.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.525 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.34 29.55 0.69 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.61 179.41 16.81 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -126.2 149.64 48.89 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.942 0.401 . . . . 0.0 110.349 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.52 105.09 17.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -88.41 -19.64 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.566 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.639 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -165.93 174.28 2.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.47 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.639 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.84 133.82 52.41 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 121.892 1.728 . . . . 0.0 111.854 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 64.7 t30 45.34 36.42 2.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.397 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -130.34 103.82 6.91 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.29 0.567 . . . . 0.0 110.909 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 153' ' ' GLY . 23.2 m -102.2 135.15 44.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.087 -0.961 . . . . 0.0 110.685 179.4 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.98 92.29 3.97 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 178.764 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.6 p -102.23 141.76 34.56 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.468 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.1 OUTLIER -111.6 13.79 21.28 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.298 0.57 . . . . 0.0 110.568 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -102.32 30.45 4.56 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.164 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 100.28 59.42 0.84 Allowed Glycine 0 N--CA 1.464 0.553 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 172' ' ' PHE . 21.9 t80 -44.51 119.04 1.73 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.033 0.444 . . . . 0.0 110.484 -179.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.3 m -153.3 130.61 11.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.375 179.229 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 78.03 164.71 24.83 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -66.94 -22.32 48.64 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.896 2.397 . . . . 0.0 112.253 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -89.09 14.01 11.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.951 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.327 -0.377 0 CA-C-O 121.021 0.438 . . . . 0.0 110.166 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 44.3 mt . . . . . 0 N--CA 1.452 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -135.42 161.8 34.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.037 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.9 163.92 26.88 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -75.03 -7.35 19.05 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 123.058 2.505 . . . . 0.0 112.344 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.447 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 71.9 m-80 -105.32 70.38 0.89 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.597 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.466 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 60.7 t -121.63 130.24 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.925 179.1 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 87.1 m -144.55 -174.1 4.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.009 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.28 171.43 47.51 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.6 m -84.19 167.56 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -59.52 -43.79 93.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.777 0.323 . . . . 0.0 110.738 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -63.97 -36.76 85.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.977 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -129.25 50.33 2.16 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.987 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -73.18 142.81 47.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.371 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -160.75 167.16 27.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.995 0.426 . . . . 0.0 111.03 179.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.426 ' SG ' HG22 ' A' ' 73' ' ' THR . 79.1 m -64.04 130.92 45.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.17 -179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.466 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 32.5 m -47.72 151.02 1.64 Allowed Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.103 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -49.62 129.76 24.37 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.498 1.465 . . . . 0.0 112.301 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.67 -18.54 47.09 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.447 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 98.6 m95 -111.77 134.76 53.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.965 0.412 . . . . 0.0 110.085 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -110.99 -167.75 1.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.133 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.426 HG22 ' SG ' ' A' ' 67' ' ' CYS . 71.1 p -129.83 165.29 22.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.049 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 12.1 mt -91.53 150.58 41.39 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.834 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_exo -44.21 115.4 0.75 Allowed 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.864 1.709 . . . . 0.0 112.036 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.12 -8.73 7.93 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.165 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -91.11 177.94 41.63 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 26.7 p30 -139.51 13.39 2.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.931 0.396 . . . . 0.0 110.864 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLN . . . . . 0.452 ' H ' ' CD ' ' A' ' 79' ' ' GLN . 1.1 mp0 -84.08 131.78 34.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.469 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 22.5 m -95.88 43.29 1.08 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.361 -0.382 . . . . 0.0 109.987 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 42.4 pt -98.2 6.89 8.66 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.246 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.734 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.66 112.54 60.52 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.417 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.29 156.87 29.52 Favored 'Trans proline' 0 N--CA 1.486 1.059 0 C-N-CA 122.01 1.807 . . . . 0.0 111.864 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.6 mt -100.72 118.91 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.8 115.42 27.12 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.402 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -64.73 -45.24 87.36 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.37 0.605 . . . . 0.0 110.106 179.242 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -119.41 -167.89 1.49 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.674 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.2 t -97.04 125.07 41.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.722 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.6 m -74.39 -32.16 62.62 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.776 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -106.08 2.23 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.439 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.4 p-10 -81.99 -2.63 52.21 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.719 0.295 . . . . 0.0 110.773 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.63 -176.36 27.14 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -133.72 146.12 50.5 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.058 0.456 . . . . 0.0 110.788 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 70.1 m -64.57 111.3 2.65 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.578 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 89.0 p -105.98 -26.07 11.83 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.33 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 -153.23 159.58 32.01 Favored Pre-proline 0 C--N 1.325 -0.464 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.291 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -48.92 119.07 3.96 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.477 2.118 . . . . 0.0 111.915 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.402 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 54.0 t30 55.11 42.88 30.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.228 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mtp -149.06 118.87 7.06 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.09 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' ALA . 69.2 m -100.64 148.72 24.54 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.792 179.178 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.5 m -119.99 115.59 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.422 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.44 154.0 68.66 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -50.07 -26.56 14.95 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.693 2.262 . . . . 0.0 112.016 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 m -66.49 -15.5 63.41 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.831 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.92 -15.18 58.37 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -65.86 149.31 50.39 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.2 130.64 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.656 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -170.29 179.43 0.74 Allowed Pre-proline 0 C--N 1.327 -0.406 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.446 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.656 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 35.7 Cg_exo -58.81 -22.71 63.34 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.877 2.385 . . . . 0.0 111.78 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 82.7 p -152.3 163.98 38.36 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.598 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.315 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 75.8 m . . . . . 0 CA--C 1.522 -0.131 0 CA-C-O 120.655 0.264 . . . . 0.0 111.224 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -64.36 -40.77 96.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.736 HG22 ' H ' ' A' ' 122' ' ' ARG . 24.7 mm -64.48 177.83 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.962 0.41 . . . . 0.0 109.999 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.736 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.8 mmt180 -117.46 98.27 6.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.721 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.2 m -94.33 135.27 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.322 179.175 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.6 mtm -130.17 170.13 14.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.346 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 m120 63.6 41.48 7.19 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.717 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.87 23.61 71.04 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.574 -1.01 . . . . 0.0 110.574 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.93 141.96 24.88 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.635 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 20.1 m -99.87 144.69 28.63 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.725 0.298 . . . . 0.0 110.314 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' CYS . . . . . 0.5 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 0.5 OUTLIER -93.99 129.79 40.35 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.682 179.897 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 28.8 t -149.36 134.99 18.61 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.394 178.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 51.11 45.82 27.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 56.95 33.65 23.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -143.98 138.2 28.26 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.467 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 95.9 m -91.05 131.4 36.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 110.828 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 76.6 mt -101.83 128.53 48.15 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.338 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' CYS . . . . . 0.452 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 8.4 m -89.01 135.78 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.53 -179.253 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -73.32 172.6 10.91 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.444 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -62.82 126.12 26.25 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.12 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 107.96 -26.27 17.93 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.61 133.73 54.5 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.946 0.403 . . . . 0.0 110.065 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 141' ' ' ILE . 23.3 pt -127.35 169.14 19.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.934 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.452 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 118.79 159.87 11.23 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.1 m -62.12 -46.07 90.67 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.566 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -100.68 2.14 41.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.58 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.6 m 62.85 132.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.996 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 164.91 -11.99 0.08 OUTLIER Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -100.27 112.72 64.72 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -75.74 157.76 39.57 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 C-N-CA 122.42 2.08 . . . . 0.0 112.053 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 52.5 t -120.56 130.47 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 18.1 m -90.06 98.81 11.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.183 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.34 -39.36 92.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 0.0 110.418 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 83.1 p -81.83 -6.86 59.44 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.482 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 64.99 161.07 0.56 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.6 m -114.06 104.93 12.63 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.834 0.349 . . . . 0.0 110.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 85.5 mt -63.67 -42.19 98.08 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.561 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.9 t-20 -90.73 173.31 8.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.342 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.69 33.2 0.28 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.561 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.47 -179.01 26.38 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 53.4 mmm-85 -130.46 147.37 52.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.918 0.389 . . . . 0.0 110.218 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 84.0 m -83.99 111.05 18.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.362 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.9 m -95.38 -20.54 5.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.376 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.64 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.62 173.82 2.71 Favored Pre-proline 0 C--N 1.326 -0.455 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.627 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.64 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.97 130.89 41.61 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.164 1.909 . . . . 0.0 111.95 179.252 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 164' ' ' ASN . . . . . 0.408 ' O ' ' OD1' ' A' ' 164' ' ' ASN . 60.5 t-20 49.74 32.33 5.13 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.084 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -137.0 129.14 29.52 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.447 0.642 . . . . 0.0 110.045 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -131.79 145.38 51.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.0 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -97.13 137.15 36.62 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.703 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 168' ' ' CYS . . . . . 0.549 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 44.2 m -81.75 142.79 32.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.079 0.466 . . . . 0.0 111.054 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.9 m -63.38 -45.59 90.39 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.084 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -97.89 17.23 18.65 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.106 0.479 . . . . 0.0 111.086 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.79 24.18 77.01 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.549 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 3.1 m-85 -66.01 151.49 46.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.238 0.542 . . . . 0.0 110.191 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -87.61 166.05 14.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.97 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.83 148.51 11.52 Favored Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.17 -29.06 39.98 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 122.448 2.099 . . . . 0.0 112.409 -179.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -115.12 0.89 13.74 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.604 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.784 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 120.985 0.421 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.42 165.0 22.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.655 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 70.18 172.43 10.7 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.55 -171.36 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.984 2.456 . . . . 0.0 111.794 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OD1' ' CZ3' ' A' ' 71' ' ' TRP . 26.1 m120 58.78 38.78 24.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.081 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.451 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 7.4 p -95.53 133.72 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.288 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 59' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 60.6 m -151.22 -174.32 4.78 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.275 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.28 174.38 44.92 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.561 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.1 m -82.47 160.81 22.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.607 0.241 . . . . 0.0 110.437 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.53 -43.29 97.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.725 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -61.72 -41.15 97.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.273 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -133.61 54.66 1.94 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.649 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.11 147.54 53.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.291 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.417 ' O ' ' O ' ' A' ' 59' ' ' CYS . 11.7 p90 -153.81 170.16 21.62 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.005 0.431 . . . . 0.0 110.766 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.1 m -73.79 135.42 43.51 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -49.0 167.9 0.2 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.386 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -57.17 132.29 50.37 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.014 1.809 . . . . 0.0 111.643 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 97.14 -17.25 59.51 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.425 ' CZ3' ' OD1' ' A' ' 57' ' ' ASN . 31.5 m95 -113.61 139.79 48.73 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.927 0.394 . . . . 0.0 110.363 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -125.48 -174.01 2.97 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.192 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 74.6 p -115.48 161.51 18.48 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.432 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' A' ' 77' ' ' GLY . 17.8 mt -87.62 151.68 50.72 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.437 ' C ' ' H ' ' A' ' 77' ' ' GLY . 73.1 Cg_exo -39.21 107.03 0.06 OUTLIER 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 122.235 1.957 . . . . 0.0 112.116 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 72.98 -11.17 4.88 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.01 174.48 53.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -135.28 13.49 3.53 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.06 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -84.63 129.09 34.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.503 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 63.5 m -95.2 60.45 2.33 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 37.3 pt -119.17 26.65 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.855 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.3 t -123.06 84.45 51.03 Favored Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.953 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -63.32 150.26 89.04 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.597 2.198 . . . . 0.0 111.69 179.077 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.9 mt -94.0 121.98 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.33 129.81 45.57 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.403 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -63.18 -45.92 89.51 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.206 0.527 . . . . 0.0 110.169 179.951 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -122.38 146.57 47.22 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -52.42 125.42 16.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.376 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.8 m -66.56 -2.03 4.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.544 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 55.59 -116.23 6.84 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.8 p-10 -74.91 -1.26 21.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 110.676 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.61 -164.29 19.83 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.475 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 54.9 p90 -142.84 150.97 40.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.966 0.412 . . . . 0.0 110.646 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -69.64 114.97 8.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.832 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.475 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 5.0 m -105.25 -19.03 13.93 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.586 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.4 mtt85 -157.08 162.54 27.39 Favored Pre-proline 0 N--CA 1.454 -0.263 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.737 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -50.09 122.45 9.22 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 121.95 1.767 . . . . 0.0 111.341 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.403 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 72.0 m-20 52.93 38.64 27.52 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.982 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.7 mtp -146.29 118.76 8.47 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.492 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 37.8 m -105.95 150.42 25.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.718 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' THR . . . . . 0.432 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 64.7 m -119.69 113.38 20.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.582 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.64 157.19 72.51 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.629 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.3 -21.19 71.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.65 2.234 . . . . 0.0 111.474 178.897 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -67.71 -16.59 64.21 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.727 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 105.63 -20.38 36.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -68.75 151.54 46.51 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.888 0.375 . . . . 0.0 110.528 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -131.22 135.15 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.676 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -167.26 -179.19 0.75 Allowed Pre-proline 0 C--N 1.326 -0.447 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.647 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.676 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 31.5 Cg_exo -60.29 -16.02 38.43 Favored 'Trans proline' 0 N--CA 1.499 1.806 0 C-N-CA 122.953 2.435 . . . . 0.0 111.907 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 27.8 m -160.29 159.81 31.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.756 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.23 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.467 0.424 0 CA-C-O 121.008 0.432 . . . . 0.0 110.082 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -62.6 -40.36 96.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.112 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.757 HG22 ' H ' ' A' ' 122' ' ' ARG . 36.1 mm -74.24 178.04 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.239 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.757 ' H ' HG22 ' A' ' 121' ' ' ILE . 1.0 OUTLIER -127.68 134.03 49.6 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.166 179.354 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.5 m -118.21 144.6 45.61 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtm -144.3 169.37 18.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.284 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 59.28 40.52 21.23 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.32 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 23.47 67.76 Favored Glycine 0 C--N 1.333 0.371 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.03 119.92 5.07 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 120.432 -0.89 . . . . 0.0 110.929 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.2 p -79.43 145.29 33.39 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.035 -0.266 . . . . 0.0 110.54 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.8 t -97.4 118.44 33.88 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.75 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.422 ' O ' ' N ' ' A' ' 133' ' ' HIS . 29.8 t -148.13 139.76 23.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.575 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 41.98 45.93 3.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 55.45 36.99 28.25 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.457 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' HIS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' SER . 58.4 m80 -142.7 141.89 31.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.261 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.467 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 81.4 m -99.93 119.82 38.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.497 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.6 mt -98.06 128.26 44.48 Favored 'General case' 0 CA--C 1.518 -0.267 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.79 134.61 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.858 -179.397 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -72.26 -173.77 1.16 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.34 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -67.77 129.13 38.97 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.731 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.64 -9.33 55.48 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -125.46 141.54 52.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.859 0.361 . . . . 0.0 110.528 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.6 pt -132.66 173.79 14.26 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.743 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 112.61 153.54 11.74 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.0 p -63.01 -45.5 92.1 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.698 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -97.83 1.75 48.6 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.511 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 16.4 m 62.62 133.21 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.871 -179.398 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 161.29 -6.71 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 39.2 tp60 -109.21 111.58 60.04 Favored Pre-proline 0 CA--C 1.543 0.693 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.58 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -75.64 156.77 40.23 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.517 2.145 . . . . 0.0 112.435 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 90.9 t -101.98 114.92 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.05 98.25 11.65 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.306 -179.064 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -65.77 -39.66 91.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.71 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 72.1 m -79.62 -7.55 58.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.84 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.46 161.69 0.05 OUTLIER Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 66.7 m -106.51 111.17 23.61 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 89.0 mt -63.18 -42.26 99.35 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.8 t30 -95.7 173.0 7.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.416 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.59 37.5 0.36 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -76.55 -172.05 34.5 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -132.21 143.46 49.96 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.872 0.367 . . . . 0.0 110.521 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.6 m -81.92 113.51 19.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.281 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.3 m -88.42 -23.69 6.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.536 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.5 171.99 3.81 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.511 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.6 Cg_exo -50.45 127.96 21.93 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.711 1.607 . . . . 0.0 112.01 178.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.8 t30 53.93 36.7 24.97 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.715 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.414 ' HD2' ' HB3' ' A' ' 162' ' ' ALA . 94.7 mtt-85 -141.42 132.8 26.7 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.207 0.527 . . . . 0.0 110.632 178.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 3.4 t -141.45 150.77 42.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.954 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.52 53.57 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.687 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.97 137.13 32.62 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.035 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.0 p -112.58 19.2 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.88 0.371 . . . . 0.0 111.44 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.476 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 34.3 t80 -114.49 31.75 6.42 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.725 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 79.34 15.63 79.69 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -108.26 163.22 13.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.281 0.562 . . . . 0.0 110.917 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.9 t -147.1 152.31 38.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 129.72 162.42 10.82 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.83 -22.86 36.01 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 122.721 2.281 . . . . 0.0 112.186 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -124.37 7.29 8.38 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.523 -179.071 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 73.2 m . . . . . 0 C--N 1.326 -0.428 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.642 -179.813 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 64.8 mt . . . . . 0 CA--C 1.516 -0.339 0 CA-C-O 120.823 0.344 . . . . 0.0 110.491 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -127.0 161.16 29.03 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.377 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.55 169.7 44.33 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.41 -176.08 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 123.009 2.473 . . . . 0.0 111.908 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 58.9 42.05 20.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.459 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 50.3 t -107.86 133.72 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 59' ' ' CYS . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' TYR . 88.8 m -142.69 -179.02 6.07 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.025 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.34 164.37 40.06 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.531 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.3 m -79.74 168.21 19.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.786 0.327 . . . . 0.0 110.394 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.7 ttt-85 -61.04 -43.23 99.2 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.502 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -62.36 -40.54 96.75 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.962 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -129.35 52.87 1.94 Allowed 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.618 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.531 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.77 142.48 54.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.352 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.406 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -154.7 165.3 36.99 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.492 179.441 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.541 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 81.9 m -71.03 137.92 49.42 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.489 -0.484 . . . . 0.0 109.782 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.459 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 27.4 m -52.9 151.77 8.06 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.106 -178.852 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.93 130.75 32.32 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 121.559 1.506 . . . . 0.0 112.755 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -6.95 61.4 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -119.49 137.2 53.95 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.007 0.432 . . . . 0.0 110.79 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -123.85 -177.05 3.63 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.398 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.541 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 35.8 p -131.21 172.08 12.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.35 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.49 ' O ' ' N ' ' A' ' 77' ' ' GLY . 43.1 mt -90.31 148.59 39.43 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.67 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -40.49 111.49 0.14 Allowed 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.014 1.81 . . . . 0.0 112.574 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 82.02 -16.58 21.06 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -74.76 165.0 54.72 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -129.72 8.66 5.36 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.045 0.45 . . . . 0.0 110.958 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -87.23 130.04 34.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.381 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 56.8 m -94.21 40.8 1.08 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -94.67 11.68 3.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.606 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.64 107.02 53.45 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.684 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -76.53 157.78 36.29 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.282 1.988 . . . . 0.0 112.243 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -103.12 126.18 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.063 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -100.16 127.08 46.48 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.27 -45.27 94.02 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.472 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -126.19 157.32 38.48 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.637 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -60.97 136.49 58.1 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.422 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 57.7 m -78.78 -26.03 44.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.809 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 82.68 -109.32 3.07 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 23.0 p-10 -78.87 -2.61 40.64 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.674 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.55 -160.46 16.16 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -147.73 153.15 38.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.977 0.418 . . . . 0.0 110.826 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.6 m -63.58 113.4 3.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.973 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 92.6 p -100.89 -22.91 14.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.309 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 mtp180 -158.68 161.14 28.9 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.688 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -45.91 119.47 2.9 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 121.926 1.751 . . . . 0.0 111.725 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 54.82 39.56 31.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.271 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 69.8 mmm -145.83 122.13 10.91 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.441 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 27.3 m -105.8 147.55 28.52 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.286 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 78.7 m -122.3 113.44 19.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.753 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.422 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -76.23 157.38 83.06 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.021 179.895 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.422 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -62.29 -21.67 72.97 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.837 2.358 . . . . 0.0 111.48 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 m -63.61 -33.69 76.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.555 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 123.32 -17.24 7.96 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' GLN . . . . . 0.467 ' NE2' ' H ' ' A' ' 107' ' ' ILE . 1.2 tm0? -69.29 145.0 53.42 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.902 0.382 . . . . 0.0 110.648 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.467 ' H ' ' NE2' ' A' ' 106' ' ' GLN . 92.0 mt -124.29 131.29 73.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.626 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.66 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -171.19 179.43 0.67 Allowed Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.416 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.66 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 35.4 Cg_exo -58.95 -21.8 59.94 Favored 'Trans proline' 0 N--CA 1.498 1.793 0 C-N-CA 122.772 2.315 . . . . 0.0 111.999 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 92.7 p -151.27 164.28 36.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.333 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.573 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.2 m . . . . . 0 CA--C 1.533 0.299 0 CA-C-O 121.103 0.477 . . . . 0.0 110.756 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -63.97 -39.98 95.36 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.255 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.534 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 11.3 tt -112.17 169.7 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.188 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.691 HH21 ' CE1' ' A' ' 144' ' ' HIS . 28.5 ptt180 -83.21 118.88 23.92 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.034 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.7 143.14 50.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.64 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 124' ' ' MET . 2.1 mpp? -141.96 161.49 37.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.182 179.656 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 32.9 m120 57.98 51.79 8.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.282 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.79 19.08 77.89 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.44 143.22 40.31 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.0 t -121.4 141.12 51.28 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 10.5 p -93.15 131.55 38.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.76 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.546 ' O ' ' N ' ' A' ' 132' ' ' ASP . 44.1 t -138.19 131.47 30.39 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.187 179.11 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 60.8 t0 55.31 -80.57 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.504 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.546 ' N ' ' O ' ' A' ' 130' ' ' SER . 37.7 p-10 -155.42 23.28 0.41 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.734 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 43.1 m80 -141.79 158.05 44.27 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.519 -179.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.464 ' SG ' HG23 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -96.96 131.73 43.46 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.154 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.3 mt -92.68 128.86 38.69 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.756 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' CYS . . . . . 0.466 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -105.96 132.59 51.87 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.694 -179.595 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -79.83 173.06 12.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.359 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -63.06 133.7 54.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.288 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.62 -25.84 24.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.466 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 96.5 m-85 -116.13 130.94 57.04 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 28.7 pt -129.68 178.48 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.021 -179.319 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 115.92 159.72 12.07 Favored Glycine 0 N--CA 1.462 0.424 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.7 p -66.12 -33.86 76.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.765 0.317 . . . . 0.0 110.546 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.691 ' CE1' HH21 ' A' ' 122' ' ' ARG . 54.7 m-70 -103.97 1.64 31.41 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.751 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.414 ' O ' ' O ' ' A' ' 144' ' ' HIS . 41.8 t 59.82 122.9 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 159.64 -23.56 0.29 Allowed Glycine 0 CA--C 1.519 0.317 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 14.6 tp60 -76.89 118.04 69.06 Favored Pre-proline 0 CA--C 1.543 0.673 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.629 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -75.46 157.42 40.84 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.641 2.227 . . . . 0.0 112.393 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.6 t -121.11 129.8 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.445 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.1 m -92.96 98.97 11.7 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -67.07 -36.99 83.21 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.471 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.0 p -85.88 -6.4 59.09 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.93 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.94 -172.17 33.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 57.3 m -139.81 106.69 5.41 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 82.2 mt -63.45 -42.18 98.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.785 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.539 ' C ' ' H ' ' A' ' 158' ' ' GLY . 27.6 t-20 -90.56 170.28 10.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.8 35.38 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -71.77 -174.63 21.86 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -131.3 147.1 52.54 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.72 0.295 . . . . 0.0 110.812 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 3.6 t -88.12 112.87 23.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.719 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.47 -54.89 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.06 175.91 3.31 Favored Pre-proline 0 N--CA 1.466 0.328 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.196 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -53.22 130.29 37.59 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 121.813 1.675 . . . . 0.0 112.023 179.702 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 66.5 t30 51.38 35.78 14.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.47 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.7 ttt85 -137.08 124.34 21.83 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.588 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.9 t -130.21 138.27 50.49 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.02 140.65 29.67 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.768 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.3 m -81.23 143.3 32.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.839 0.352 . . . . 0.0 110.158 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.1 m -63.46 -45.37 91.12 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.024 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.525 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 80.3 t80 -98.56 24.54 7.32 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.169 0.509 . . . . 0.0 110.815 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.16 24.2 70.28 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -56.27 159.57 3.46 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.88 0.371 . . . . 0.0 110.18 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.563 HG22 ' N ' ' A' ' 174' ' ' GLY . 89.4 m -82.26 162.42 22.33 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.198 0.523 . . . . 0.0 111.143 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 174' ' ' GLY . . . . . 0.563 ' N ' HG22 ' A' ' 173' ' ' THR . . . 66.94 152.03 0.2 Allowed Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 179.423 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.57 -29.1 44.52 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.695 2.263 . . . . 0.0 112.056 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -78.75 -15.46 58.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.603 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 39.4 m . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.42 179.612 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.6 mt . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.877 0.37 . . . . 0.0 110.428 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.0 mtpt -128.86 160.4 32.73 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.3 0.571 . . . . 0.0 110.77 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 162.74 25.29 Favored Glycine 0 CA--C 1.528 0.904 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.08 3.08 7.35 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.704 2.269 . . . . 0.0 112.248 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.6 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 0.3 OUTLIER -112.58 61.3 0.63 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.105 0.479 . . . . 0.0 110.429 -179.654 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.9 t -109.71 129.68 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-O 121.193 0.52 . . . . 0.0 109.72 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 85.1 m -141.92 176.91 8.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.664 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 171.5 45.85 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.3 m -82.19 165.1 20.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.703 0.287 . . . . 0.0 110.457 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -60.02 -42.67 94.86 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.659 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -61.17 -41.36 96.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.006 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -132.72 54.75 1.93 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.489 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.52 142.49 56.54 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.493 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 13.6 p90 -151.45 165.89 32.77 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.186 0.517 . . . . 0.0 110.901 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 57' ' ' ASN . 1.6 t -73.59 138.42 44.89 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.436 179.51 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -58.42 157.97 16.3 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.859 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -60.76 137.35 72.4 Favored 'Trans proline' 0 N--CA 1.493 1.442 0 C-N-CA 121.903 1.735 . . . . 0.0 111.817 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.59 55.21 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.6 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.1 m95 -112.79 134.69 54.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 117.066 0.433 . . . . 0.0 109.84 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.8 ptpt -114.2 -175.1 2.6 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.5 p -125.4 165.94 17.49 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.67 149.19 45.66 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.721 -179.344 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.8 Cg_exo -44.77 123.15 4.61 Favored 'Trans proline' 0 N--CA 1.491 1.362 0 C-N-CA 121.693 1.596 . . . . 0.0 112.208 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.42 -7.56 0.9 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 179.564 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.77 179.48 38.48 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 46.9 p30 -138.0 11.89 2.86 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.831 0.348 . . . . 0.0 110.797 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -82.37 129.46 34.88 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 8.0 m -106.09 80.75 1.55 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.316 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.6 pt -129.69 15.88 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.651 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 t -126.77 99.77 29.01 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -77.45 163.16 30.05 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.364 2.043 . . . . 0.0 111.939 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 45.7 mm -94.99 122.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -95.71 121.39 37.38 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.41 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.74 -45.68 91.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.172 0.511 . . . . 0.0 109.766 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -112.77 137.92 50.37 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.087 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.9 m -60.56 134.35 56.99 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.958 0.409 . . . . 0.0 110.129 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 28.7 m -76.45 -31.78 58.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.182 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 66.88 -101.56 0.67 Allowed Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.437 -0.665 . . . . 0.0 111.437 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -67.54 -17.71 64.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.835 0.35 . . . . 0.0 111.004 -179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.78 -161.56 21.11 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.435 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 54.8 p90 -143.2 151.7 40.93 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.903 0.382 . . . . 0.0 111.2 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.9 t -64.49 114.14 4.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.157 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.445 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 68.2 m -103.05 -23.75 13.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.769 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.7 mtt180 -162.31 165.47 15.58 Favored Pre-proline 0 CA--C 1.531 0.248 0 C-N-CA 120.396 -0.521 . . . . 0.0 110.407 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.6 123.55 11.65 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 121.601 1.534 . . . . 0.0 111.49 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.41 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 51.3 t30 51.57 40.51 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.033 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.9 mmm -147.47 114.48 6.16 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.576 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.42 ' N ' ' O ' ' A' ' 108' ' ' ALA . 35.5 m -101.28 149.28 24.18 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.323 178.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 101' ' ' THR . . . . . 0.445 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 63.6 m -120.97 119.68 33.25 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.706 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 157.28 60.32 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.143 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -62.7 -19.23 67.63 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.66 2.24 . . . . 0.0 111.78 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 42.0 m -69.79 -14.27 62.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.331 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.67 -20.4 39.32 Favored Glycine 0 N--CA 1.464 0.517 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -69.19 149.5 48.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.985 0.421 . . . . 0.0 110.092 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.33 133.6 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -166.55 -179.82 0.9 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.287 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.658 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 32.2 Cg_exo -59.52 -20.07 55.29 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.835 2.357 . . . . 0.0 112.162 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.7 p -155.58 163.03 40.51 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.414 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.331 -0.204 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.35 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 76.9 m . . . . . 0 C--O 1.23 0.044 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -92.14 9.34 33.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.027 0.441 . . . . 0.0 110.369 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.501 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 14.8 tt -134.11 169.19 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.607 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.501 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.6 ptm180 -100.12 106.45 18.17 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.04 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.9 m -99.73 138.04 37.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.099 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 66.2 mtt -143.23 160.64 40.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.249 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.618 ' ND2' ' CD1' ' A' ' 140' ' ' TYR . 98.0 m-20 59.86 40.18 19.58 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.841 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.52 28.58 63.2 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.01 128.79 23.3 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' SER . . . . . 0.483 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 13.3 m -88.87 137.84 31.95 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 122.739 -0.271 . . . . 0.0 110.537 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 62.4 m -77.63 129.67 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.166 179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 40.9 t -143.85 136.39 27.03 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' SER . 96.5 m-20 33.75 -99.91 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.387 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -125.3 4.75 7.75 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.365 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -129.65 154.48 47.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.739 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.9 t -102.77 146.27 28.49 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.442 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.9 mt -98.61 131.26 44.94 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.155 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -97.83 134.26 41.22 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.68 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -80.67 178.23 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.707 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -66.59 133.24 49.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.283 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.54 35.08 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.618 ' CD1' ' ND2' ' A' ' 125' ' ' ASN . 92.9 m-85 -121.63 134.41 54.99 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.093 0.473 . . . . 0.0 110.531 179.52 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' ILE . . . . . 0.42 HG23 ' CG2' ' A' ' 149' ' ' VAL . 36.6 pt -121.94 -163.84 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.357 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.4 152.93 28.95 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.9 m -63.11 -45.03 93.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.881 0.372 . . . . 0.0 110.661 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -94.73 3.17 55.36 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.876 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 33.7 t 61.4 116.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.472 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 173.71 -20.59 0.06 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLN . . . . . 0.452 ' OE1' ' N ' ' A' ' 147' ' ' GLN . 0.0 OUTLIER -94.68 128.92 37.94 Favored Pre-proline 0 CA--C 1.548 0.888 0 CA-C-N 117.048 0.424 . . . . 0.0 110.267 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -76.99 161.72 32.64 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.821 2.347 . . . . 0.0 111.809 178.918 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' VAL . . . . . 0.42 ' CG2' HG23 ' A' ' 141' ' ' ILE . 54.7 t -99.15 127.9 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.3 -179.418 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -101.57 90.53 4.09 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -65.46 -43.09 91.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.519 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 85.8 p -89.15 -8.75 53.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.527 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLY . . . . . 0.447 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 56.82 -179.46 0.63 Allowed Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.3 m -117.73 118.78 33.0 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.1 mt -63.21 -42.25 99.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.032 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.554 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.0 t-20 -93.18 179.93 5.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.434 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.22 32.93 0.32 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.554 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.44 177.16 26.23 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 23.2 mmm180 -128.49 143.61 51.01 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.811 0.338 . . . . 0.0 110.269 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 33.8 m -83.06 113.08 20.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -101.56 -18.25 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.704 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.97 171.4 6.39 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.248 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -51.7 129.16 28.84 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 121.705 1.603 . . . . 0.0 111.921 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 50.81 34.34 10.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.734 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.5 OUTLIER -127.55 119.03 25.09 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.028 0.442 . . . . 0.0 110.175 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.523 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 26.4 m -110.8 122.66 48.39 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.075 179.555 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -88.02 135.65 33.32 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 168' ' ' CYS . . . . . 0.582 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 87.8 m -84.05 141.4 31.18 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.039 0.447 . . . . 0.0 110.382 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.7 m -63.24 -45.58 90.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.283 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -104.78 18.58 22.04 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.133 0.492 . . . . 0.0 110.984 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 72.19 24.8 75.86 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.53 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 91.5 t80 -54.64 143.9 23.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.883 0.373 . . . . 0.0 110.403 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 96.3 m -103.86 125.56 50.37 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.375 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -179.21 162.05 28.62 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.28 -31.4 73.82 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.67 2.247 . . . . 0.0 112.4 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -110.27 4.57 20.99 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.292 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.582 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.7 t . . . . . 0 C--N 1.33 -0.27 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.716 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.454 HD11 ' HA ' ' A' ' 66' ' ' TYR . 92.2 mt . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.7 mtpt -123.25 166.26 15.55 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.845 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 69.13 165.7 4.29 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.47 -166.17 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.956 2.437 . . . . 0.0 111.876 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 12.6 m-20 58.64 36.14 24.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.8 p -100.46 136.56 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.031 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 60.4 m -141.41 176.9 8.5 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.994 0.426 . . . . 0.0 110.283 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.15 161.71 31.43 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.1 m -77.91 171.07 15.54 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 44.9 ttm180 -59.98 -42.91 95.19 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.852 0.358 . . . . 0.0 110.392 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -62.89 -40.45 97.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.994 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.471 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 21.2 m120 -125.67 50.52 1.82 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.578 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.92 138.27 49.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.607 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.471 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.9 p90 -158.45 165.64 34.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.106 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 79.4 m -69.2 139.08 54.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.296 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 25.7 m -54.42 146.89 30.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.095 -179.155 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -48.01 125.58 11.85 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 C-N-CA 121.605 1.537 . . . . 0.0 112.344 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.424 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.45 -12.89 58.4 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 88.9 m95 -114.82 134.38 55.18 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 110.213 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -125.25 -170.26 2.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.51 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 3.2 p -131.33 168.9 16.77 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.332 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.76 ' H ' HD12 ' A' ' 74' ' ' LEU . 0.0 OUTLIER -87.29 164.46 35.56 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.436 -179.21 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -53.0 125.41 18.21 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 121.875 1.717 . . . . 0.0 112.035 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.05 -0.31 11.89 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.89 174.48 35.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -140.14 7.54 2.22 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.881 0.372 . . . . 0.0 110.698 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 -83.33 131.22 35.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 54.1 m -94.27 38.53 1.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.905 0.383 . . . . 0.0 110.11 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.09 6.54 6.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.646 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.0 t -107.03 117.08 57.36 Favored Pre-proline 0 CA--C 1.537 0.446 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.913 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.73 155.71 44.24 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.418 2.079 . . . . 0.0 112.433 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.424 ' N ' ' O ' ' A' ' 70' ' ' GLY . 83.2 mt -107.34 119.12 56.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.199 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.89 113.85 26.23 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.461 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 1.8 mpt_? -62.31 -40.21 95.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.375 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -109.59 127.8 54.76 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 109.842 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.6 p -49.41 122.13 5.81 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.209 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.63 -24.24 56.42 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.919 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.72 -115.48 4.26 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -77.52 -4.46 45.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.37 175.9 36.5 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 40.2 t80 -123.17 132.57 54.11 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.221 0.534 . . . . 0.0 111.172 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 94' ' ' CYS . . . . . 0.479 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 3.4 m -65.57 117.57 8.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.827 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 95' ' ' SER . . . . . 0.434 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 47.1 m -104.87 -21.94 13.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.53 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 -158.44 163.15 25.26 Favored Pre-proline 0 C--N 1.331 -0.214 0 C-N-CA 120.264 -0.575 . . . . 0.0 110.748 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -48.98 120.48 5.5 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.926 1.751 . . . . 0.0 111.501 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.422 ' O ' ' OD1' ' A' ' 98' ' ' ASN . 56.3 t-20 54.69 41.47 31.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.975 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.0 mmm -146.59 115.68 6.97 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.954 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' ALA . 91.0 m -99.15 146.74 25.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.71 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' THR . . . . . 0.434 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 32.8 m -118.84 114.19 22.25 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.151 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.9 158.75 64.45 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.997 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -55.36 -28.01 60.89 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 122.749 2.299 . . . . 0.0 111.817 178.027 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.3 t -63.97 -16.6 61.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.591 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.73 -13.64 59.27 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -69.46 149.85 47.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.918 0.389 . . . . 0.0 110.039 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.44 129.45 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.812 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.692 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -164.23 179.16 1.23 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.498 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.692 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 32.4 Cg_exo -59.21 -23.39 69.27 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.824 2.349 . . . . 0.0 111.944 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 36.2 p -155.53 162.95 40.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.677 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.532 0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.365 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 5.1 m . . . . . 0 N--CA 1.464 0.267 0 CA-C-O 120.98 0.419 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -64.27 -39.79 94.66 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.216 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 19.7 tt -77.93 166.05 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.348 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -93.41 123.13 36.5 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.951 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.3 m -123.66 141.27 52.17 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.598 179.513 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.9 mtm -146.19 163.25 36.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.431 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.53 ' OD1' ' CE1' ' A' ' 140' ' ' TYR . 5.2 t-20 63.11 44.05 6.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.953 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.43 22.64 78.83 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.344 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.53 162.76 36.97 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.2 t -133.35 141.56 47.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.308 . . . . 0.0 110.204 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.31 123.15 36.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.77 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 25.1 t -148.45 134.34 19.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.605 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 48.46 46.77 20.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.5 t0 55.24 27.89 10.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.452 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -137.74 137.3 38.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.231 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 13.8 t -92.14 129.96 37.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.921 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 83.0 mt -113.5 143.57 44.3 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.115 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.6 m -103.99 144.51 31.44 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.54 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 -68.19 174.55 3.83 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -66.28 131.3 45.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.578 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.57 -15.46 53.13 Favored Glycine 0 N--CA 1.467 0.762 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' TYR . . . . . 0.53 ' CE1' ' OD1' ' A' ' 125' ' ' ASN . 86.8 m-85 -116.88 134.83 54.28 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.275 -0.269 . . . . 0.0 110.275 179.533 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.8 pt -125.37 165.36 22.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 122.35 153.47 8.87 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 20.1 m -62.22 -47.07 86.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 110.681 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -99.58 2.98 45.17 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.79 136.84 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 154.6 -9.72 0.4 Allowed Glycine 0 CA--C 1.518 0.247 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -103.19 108.57 59.32 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.324 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.82 161.61 36.13 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.711 2.274 . . . . 0.0 112.069 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.5 t -116.54 129.31 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.01 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 21.5 m -97.46 107.24 19.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -66.26 -40.16 89.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.448 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.8 m -86.36 -10.72 53.82 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 68.43 -177.47 25.46 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 22.5 m -128.91 114.14 16.1 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.0 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.6 mt -63.38 -42.13 98.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.549 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.427 ' C ' ' H ' ' A' ' 158' ' ' GLY . 98.0 m-20 -95.94 -172.36 2.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.389 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.65 38.24 1.24 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -72.55 176.38 42.29 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -130.2 148.36 52.03 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.2 m -85.05 120.18 26.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.081 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.8 m -104.01 -11.68 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.295 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.687 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -176.55 174.79 0.69 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.687 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 43.8 Cg_exo -55.24 125.13 18.14 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.163 1.908 . . . . 0.0 111.116 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 23.4 t30 56.15 34.66 24.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.682 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.1 mmt-85 -135.37 131.64 36.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.402 0.62 . . . . 0.0 110.624 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.48 ' O ' ' CE1' ' A' ' 172' ' ' PHE . 7.7 t -142.82 147.1 34.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.756 179.524 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -120.99 122.06 39.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.947 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.72 154.95 22.18 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.877 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.4 p -106.96 15.23 25.58 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.957 0.408 . . . . 0.0 110.836 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.414 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 23.9 t80 -119.71 32.94 5.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.933 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.46 57.52 1.64 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.779 -0.929 . . . . 0.0 110.779 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.48 ' CE1' ' O ' ' A' ' 166' ' ' CYS . 89.7 t80 -47.29 110.03 0.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.893 0.378 . . . . 0.0 110.646 -179.527 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 177' ' ' CYS . 91.0 m -129.16 126.86 40.17 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.22 179.272 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 64.15 166.44 1.05 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.364 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -55.88 -36.91 96.3 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 C-N-CA 122.75 2.3 . . . . 0.0 112.313 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -74.96 46.46 0.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.448 -179.107 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.44 ' O ' ' N ' ' A' ' 173' ' ' THR . 42.3 t . . . . . 0 C--N 1.325 -0.458 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.646 -179.707 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.0 mt . . . . . 0 N--CA 1.451 -0.424 0 CA-C-O 120.544 0.211 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -138.36 159.84 41.02 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 120.997 0.427 . . . . 0.0 110.69 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.42 166.1 19.31 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -77.19 -1.31 11.48 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.902 2.402 . . . . 0.0 112.281 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.465 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 29.5 m120 -117.34 71.8 0.82 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.777 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.491 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.9 t -121.45 130.32 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 75.3 m -142.89 -174.7 4.25 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.201 -179.081 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.83 171.08 45.38 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.5 m -78.89 163.57 25.17 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -59.93 -42.88 94.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.555 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -61.67 -42.39 98.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -127.25 49.38 2.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.871 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.07 146.87 53.86 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.669 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -152.9 168.82 24.51 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.824 0.345 . . . . 0.0 110.949 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 91.5 m -70.51 131.32 43.84 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.188 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 62.1 m -49.35 152.37 2.21 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.076 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_exo -51.59 131.64 37.92 Favored 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 121.387 1.392 . . . . 0.0 112.459 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.84 -5.08 53.48 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.465 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 44.5 m95 -132.24 140.86 48.82 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.625 0.25 . . . . 0.0 110.455 179.314 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -115.4 -166.4 1.12 Allowed 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.005 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 76.9 p -115.87 158.21 23.3 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 77' ' ' GLY . 18.9 mt -89.91 151.08 44.88 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.604 -179.191 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.427 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.5 Cg_exo -39.94 106.68 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.206 1.937 . . . . 0.0 112.142 179.43 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.42 -10.57 2.66 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.19 171.81 52.18 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.1 p30 -127.87 11.39 6.62 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.551 0.215 . . . . 0.0 111.117 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -89.46 139.1 30.86 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.887 -179.48 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.2 m -99.26 43.18 1.07 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.921 0.391 . . . . 0.0 110.018 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 43.4 pt -94.2 19.23 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.474 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.32 95.05 49.03 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -77.59 159.79 31.87 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.265 1.976 . . . . 0.0 112.221 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.59 120.67 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.498 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.07 109.37 21.34 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.55 ' HE ' HD21 ' A' ' 98' ' ' ASN . 1.1 mpt_? -64.55 -39.6 94.05 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.521 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -103.42 133.47 48.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.147 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 31.2 t -61.94 134.43 56.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.33 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 32.4 m -78.97 -28.21 43.57 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.507 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 76.19 -104.72 1.87 Allowed Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 179.543 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -80.04 -3.48 48.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.659 0.266 . . . . 0.0 111.083 -179.492 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.3 -160.1 20.19 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -147.05 152.19 38.14 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.918 0.39 . . . . 0.0 111.33 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.41 115.61 5.28 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 20.7 t -109.84 -24.17 10.99 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.927 -179.684 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -156.14 158.43 31.58 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.095 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -52.51 125.63 18.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.043 1.829 . . . . 0.0 111.22 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.55 HD21 ' HE ' ' A' ' 86' ' ' ARG . 60.9 m-80 53.04 37.76 25.58 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.5 mtp -148.94 114.65 5.66 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-O 121.37 0.605 . . . . 0.0 110.895 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 108' ' ' ALA . 27.6 m -96.9 147.54 23.86 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.441 178.846 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 87.0 m -119.89 123.77 44.39 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.572 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.82 155.3 45.46 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.74 -20.03 67.53 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.332 2.021 . . . . 0.0 111.654 179.253 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.6 t -66.57 -17.04 64.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.282 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.28 -20.84 34.45 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 52.5 tp60 -67.87 150.7 48.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.839 0.352 . . . . 0.0 110.252 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.5 mt -130.54 132.56 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.858 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.665 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.42 177.75 1.08 Allowed Pre-proline 0 CA--C 1.536 0.433 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.28 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.665 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 51.4 Cg_exo -56.32 -23.76 47.93 Favored 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 122.602 2.201 . . . . 0.0 111.911 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 30.0 p -151.79 162.23 41.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.433 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.3 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' CYS . . . . . 0.497 ' SG ' ' N ' ' A' ' 120' ' ' ASN . 34.3 t . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.767 0.318 . . . . 0.0 110.704 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' ASN . . . . . 0.497 ' N ' ' SG ' ' A' ' 119' ' ' CYS . 25.0 p-10 -95.96 10.44 37.36 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.687 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -139.31 165.46 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.785 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -77.41 98.62 5.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.75 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.2 m -111.07 119.06 37.76 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 95.9 mtp -139.82 165.26 27.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.447 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASN . . . . . 0.513 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 3.7 m-20 59.92 39.61 20.06 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.702 0.287 . . . . 0.0 110.992 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.15 25.22 69.29 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.16 126.55 26.03 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' SER . . . . . 0.496 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 4.9 m -82.21 133.38 35.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.65 0.262 . . . . 0.0 110.311 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.2 t -95.05 116.92 29.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.254 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 32.4 t -139.01 143.98 38.69 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.124 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 41.67 -116.8 0.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -119.57 21.93 11.88 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -143.0 145.67 33.14 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.522 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.3 t -105.11 140.76 37.81 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.247 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.0 mt -102.33 131.84 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.022 -179.657 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 20.6 m -92.25 134.37 34.95 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 -61.33 173.49 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' LYS . . . . . 0.449 ' HD3' ' N ' ' A' ' 138' ' ' LYS . 0.0 OUTLIER -62.95 136.18 57.7 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.368 0.604 . . . . 0.0 111.499 179.52 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 88.72 -8.61 78.91 Favored Glycine 0 CA--C 1.519 0.316 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.16 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -118.76 135.33 54.57 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.953 0.406 . . . . 0.0 110.326 179.564 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 48.7 pt -133.94 173.31 14.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.507 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.103 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 103.0 163.46 25.78 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.1 p -65.61 -39.68 91.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.609 0.242 . . . . 0.0 110.832 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.439 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -96.46 10.74 37.32 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.853 0.358 . . . . 0.0 110.461 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.513 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 14.7 m 45.76 41.16 7.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.037 -179.551 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' GLY . . . . . 0.439 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -108.78 5.44 32.66 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -112.38 110.62 53.01 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 116.793 0.297 . . . . 0.0 110.718 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.7 161.85 27.43 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.514 2.142 . . . . 0.0 112.193 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.7 t -111.99 129.08 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.188 0.518 . . . . 0.0 109.988 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -98.71 93.1 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -68.69 -42.01 78.39 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.4 m -97.77 -10.23 25.19 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.915 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 66.43 179.48 10.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -98.12 179.18 4.85 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 155' ' ' LEU . . . . . 0.589 ' CD1' ' H ' ' A' ' 177' ' ' CYS . 86.0 mt -88.18 -3.54 58.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 158' ' ' GLY . 30.2 p-10 -170.64 -147.21 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.403 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -73.8 30.95 0.9 Allowed Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -61.68 173.49 7.34 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 71.9 ttt-85 -114.06 123.18 49.05 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.486 0.184 . . . . 0.0 110.903 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 69.0 m -68.23 91.32 0.37 Allowed 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.12 -27.48 14.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.301 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -156.95 173.87 4.58 Favored Pre-proline 0 C--N 1.329 -0.302 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -52.33 136.54 55.46 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 121.588 1.525 . . . . 0.0 111.941 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 41.89 25.74 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.627 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 163' ' ' PRO . 75.0 mmt-85 -134.21 140.55 46.56 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.709 0.766 . . . . 0.0 110.984 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 28.7 p -150.37 161.17 43.01 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.517 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.85 139.09 45.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.012 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 168' ' ' CYS . . . . . 0.6 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 88.2 m -70.08 138.59 52.16 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-O 121.012 0.435 . . . . 0.0 110.173 -179.319 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.0 m -62.66 -46.07 89.9 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.89 -178.615 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -117.48 28.27 8.56 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 59.4 30.09 67.44 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.454 ' CZ ' ' SG ' ' A' ' 168' ' ' CYS . 24.5 p90 -67.54 152.37 45.76 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.644 0.259 . . . . 0.0 110.829 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 20.4 p -80.96 143.22 32.75 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.002 -179.393 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -178.54 158.2 22.53 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.04 -51.44 2.21 Favored 'Trans proline' 0 N--CA 1.499 1.795 0 C-N-CA 122.422 2.081 . . . . 0.0 112.92 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.415 ' OE1' HD21 ' A' ' 155' ' ' LEU . 49.0 mt-30 -80.66 -50.08 10.39 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.086 0.469 . . . . 0.0 110.534 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.6 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 36.5 t . . . . . 0 CA--C 1.514 -0.43 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.383 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 29.0 mt . . . . . 0 CA--C 1.517 -0.29 0 CA-C-O 121.238 0.542 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -142.91 164.01 31.24 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.53 22.8 Favored Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.212 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -76.01 7.43 3.26 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.792 2.328 . . . . 0.0 112.187 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -123.12 70.5 1.03 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.891 0.377 . . . . 0.0 111.087 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.444 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 51.8 t -115.07 130.82 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 59' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 57.2 m -151.3 178.44 9.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.457 -179.673 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.3 172.23 39.98 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -81.18 163.76 22.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.63 0.253 . . . . 0.0 110.326 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 73.3 ttp85 -59.54 -43.25 93.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.685 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -62.9 -37.25 86.2 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' ASN . . . . . 0.434 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 41.9 t30 -132.51 53.75 1.99 Allowed 'General case' 0 C--O 1.23 0.078 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.906 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.543 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -72.51 142.56 48.52 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.266 179.247 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.434 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.8 p90 -159.36 171.21 20.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.4 m -67.97 135.33 52.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.153 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -48.36 168.43 0.17 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -178.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.47 133.62 58.12 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.093 1.862 . . . . 0.0 112.114 179.046 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 94.98 -17.19 59.78 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 86.8 m95 -112.79 138.18 50.0 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -122.25 -165.49 1.28 Allowed 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.2 p -126.04 164.7 20.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.202 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.501 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.6 mt -88.96 151.44 47.12 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.814 -179.119 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_exo -39.86 107.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.348 2.032 . . . . 0.0 112.121 179.171 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.17 -14.95 7.25 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.76 178.59 52.32 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 86.4 m-20 -139.35 15.21 2.58 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 121.105 0.479 . . . . 0.0 110.7 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -80.34 131.99 35.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.262 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.93 47.89 1.11 Allowed 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.732 0.301 . . . . 0.0 110.403 -179.573 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.7 pt -105.71 22.38 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.758 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 t -124.45 97.78 39.05 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.725 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -78.76 157.15 27.82 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.691 2.261 . . . . 0.0 112.097 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.491 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.7 mt -109.51 118.63 57.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.963 0.411 . . . . 0.0 110.297 179.109 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 17.0 m -90.64 130.38 36.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.157 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.443 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -61.75 -45.44 93.92 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.183 0.515 . . . . 0.0 110.08 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -107.46 142.31 37.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.231 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.8 m -60.72 133.79 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.264 -179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 52.8 m -76.1 -27.84 57.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.583 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.32 -113.45 3.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -72.57 -9.1 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.887 0.375 . . . . 0.0 110.785 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.42 -166.66 29.86 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -139.81 146.25 39.17 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.09 0.472 . . . . 0.0 110.902 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 18.6 t -69.05 116.3 9.34 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.5 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 83.6 p -105.26 -22.02 13.14 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.413 -179.317 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ARG . . . . . 0.477 ' CG ' HH11 ' A' ' 96' ' ' ARG . 0.1 OUTLIER -158.99 165.53 18.26 Favored Pre-proline 0 C--O 1.236 0.385 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.845 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -51.97 122.35 10.37 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 121.836 1.691 . . . . 0.0 111.581 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.443 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 60.4 t30 53.17 39.74 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.74 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 98.0 mtp -146.86 116.85 7.26 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 121.137 0.494 . . . . 0.0 110.408 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 56.6 m -104.53 149.67 25.27 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.77 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.6 m -121.06 122.91 41.09 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.864 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.53 155.44 43.97 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.604 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -51.61 -27.67 26.48 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.574 2.182 . . . . 0.0 111.906 177.921 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.57 -16.28 64.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.662 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.73 -15.37 55.73 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 106' ' ' GLN . . . . . 0.459 ' OE1' ' N ' ' A' ' 107' ' ' ILE . 1.7 tm0? -67.69 143.15 56.08 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 120.826 0.346 . . . . 0.0 110.271 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.459 ' N ' ' OE1' ' A' ' 106' ' ' GLN . 96.0 mt -122.26 130.48 74.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.812 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.671 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.01 173.23 1.41 Allowed Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.558 179.448 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 52.1 Cg_exo -53.09 -31.34 53.82 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 122.67 2.247 . . . . 0.0 112.233 179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.1 m -136.46 159.28 42.26 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.338 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 58.6 m . . . . . 0 N--CA 1.464 0.252 0 CA-C-O 121.075 0.464 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -97.41 16.01 21.4 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.501 179.669 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.424 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 16.9 tt -118.11 166.19 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.517 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.424 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 31.7 mmt180 -89.96 99.54 12.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.441 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 59.8 m -103.71 128.99 51.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.17 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 73.8 mtm -139.72 165.55 26.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.079 -179.486 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 60.25 48.73 7.84 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 123.404 0.44 . . . . 0.0 111.151 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 64.72 33.12 86.38 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.75 130.76 9.9 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.3 p -91.61 142.1 27.99 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 122.747 -0.267 . . . . 0.0 110.439 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -105.11 123.18 47.37 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.891 0.377 . . . . 0.0 110.283 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 49.7 m -148.81 142.24 25.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.879 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 47.61 45.85 17.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.935 179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.452 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 99.9 m-20 55.15 29.66 13.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' HIS . . . . . 0.452 ' ND1' ' O ' ' A' ' 132' ' ' ASP . 7.7 m-70 -139.41 145.38 38.84 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 179.528 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.2 t -99.32 119.73 38.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 68.9 mt -101.25 131.24 47.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.77 138.39 37.89 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.152 -179.128 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -64.68 177.4 0.93 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.59 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -59.03 135.4 57.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.643 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 92.39 -1.82 73.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -126.55 138.81 53.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.784 0.326 . . . . 0.0 110.329 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 42.6 pt -135.05 174.65 12.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.821 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 113.54 152.43 10.93 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.4 m -62.87 -44.83 95.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.7 0.286 . . . . 0.0 110.439 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' A' ' 145' ' ' CYS . 26.4 m80 -100.94 5.9 43.39 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.643 -179.682 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' O ' ' O ' ' A' ' 144' ' ' HIS . 39.3 m 60.32 138.78 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.072 0.463 . . . . 0.0 109.925 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 147.66 4.57 0.36 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -119.52 88.73 39.33 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-O 120.775 0.321 . . . . 0.0 110.484 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.45 160.97 15.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.97 2.447 . . . . 0.0 111.697 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 58.6 t -101.45 110.77 29.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 16.1 m -92.22 108.5 20.0 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -65.9 -40.88 91.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.467 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 152' ' ' SER . . . . . 0.407 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 14.2 t -83.55 -13.69 53.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.626 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 65.44 175.09 5.14 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 99.1 m -108.82 123.79 49.6 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.469 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 41.0 mt -63.96 -41.75 97.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.825 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.412 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.4 m-20 -105.03 -172.93 2.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.55 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.34 37.7 1.58 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -75.7 -172.04 31.78 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' ARG . . . . . 0.408 ' NH1' HG21 ' A' ' 169' ' ' THR . 1.2 mpt_? -129.84 149.71 51.46 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.657 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 59.5 m -86.36 119.31 26.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.516 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 93.8 t -83.05 -27.02 7.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.541 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.678 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.69 176.15 1.74 Allowed Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.586 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.678 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.2 Cg_exo -56.67 135.81 72.55 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.347 2.032 . . . . 0.0 111.733 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 63.4 t30 50.59 30.82 5.1 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.428 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 90.0 mtt180 -142.74 101.06 3.79 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.402 0.62 . . . . 0.0 111.232 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 167' ' ' ALA . 14.7 t -104.52 150.71 24.37 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.157 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 167' ' ' ALA . . . . . 0.429 ' N ' ' SG ' ' A' ' 166' ' ' CYS . . . -132.95 123.49 26.03 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.298 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 84.6 m -101.92 132.2 47.86 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 169' ' ' THR . . . . . 0.439 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.5 OUTLIER -111.21 19.24 18.55 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.228 0.537 . . . . 0.0 110.939 -179.451 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.535 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 49.8 t80 -93.79 31.65 1.57 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.577 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.72 3.69 80.29 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -106.45 148.67 27.88 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.955 0.407 . . . . 0.0 110.547 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.0 t -138.74 154.33 48.54 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.256 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 152.39 177.43 26.05 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -65.11 -24.14 59.69 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.765 2.31 . . . . 0.0 111.897 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.407 ' OE1' ' OG ' ' A' ' 152' ' ' SER . 25.2 pt20 -127.87 -44.36 1.48 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.71 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 7.3 t . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.453 -0.311 0 CA-C-O 121.212 0.529 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -134.42 162.48 32.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.272 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.75 159.21 28.66 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -76.12 -1.34 11.32 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.882 2.388 . . . . 0.0 112.304 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.505 ' ND2' ' CE3' ' A' ' 71' ' ' TRP . 5.5 m-80 -109.85 70.05 0.72 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.419 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.483 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.8 t -121.85 130.06 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.379 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 99.3 m -142.03 -172.01 3.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.99 -179.588 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.13 168.08 43.39 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.8 m -77.39 165.04 24.93 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 60.6 ttt85 -59.25 -43.4 92.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.676 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -62.38 -42.24 99.26 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.353 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -123.46 46.0 2.31 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.83 145.33 54.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.214 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.424 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 15.8 p90 -159.69 -174.97 4.89 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.915 0.388 . . . . 0.0 110.453 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.449 ' SG ' HG22 ' A' ' 73' ' ' THR . 74.0 m -78.45 129.25 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.772 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' CYS . . . . . 0.483 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 34.5 m -47.59 153.83 0.98 Allowed Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.347 -179.199 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -52.56 132.67 46.48 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 121.431 1.42 . . . . 0.0 112.208 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.59 -22.17 39.7 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.563 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 7.2 m95 -112.51 139.21 48.28 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.472 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.49 -166.83 1.16 Allowed 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.499 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.449 HG22 ' SG ' ' A' ' 67' ' ' CYS . 69.3 p -118.07 161.0 20.55 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.742 0.306 . . . . 0.0 110.349 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.565 HD22 ' N ' ' A' ' 74' ' ' LEU . 2.6 mm? -85.87 151.3 54.78 Favored Pre-proline 0 N--CA 1.448 -0.549 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.1 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -44.2 108.39 0.12 Allowed 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 121.718 1.612 . . . . 0.0 111.911 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.33 -8.08 27.46 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -96.37 -178.46 35.62 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -138.04 17.86 2.81 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.998 0.428 . . . . 0.0 110.884 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -79.0 128.29 33.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.39 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 19.7 m -99.18 70.41 1.77 Allowed 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.9 pt -129.96 19.69 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.106 -179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.64 87.71 27.14 Favored Pre-proline 0 N--CA 1.465 0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.371 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.35 147.3 95.89 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.691 2.261 . . . . 0.0 111.976 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' ILE . . . . . 0.451 ' N ' ' O ' ' A' ' 70' ' ' GLY . 95.7 mt -99.12 119.9 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.027 179.08 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -90.77 127.3 36.29 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.444 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.6 OUTLIER -62.6 -45.55 92.37 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.147 0.499 . . . . 0.0 109.774 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -122.82 152.51 40.64 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.468 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 m -59.48 135.64 57.73 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.318 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.4 m -79.15 -26.13 42.81 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.811 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -113.02 3.62 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -72.75 -8.51 55.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.797 0.332 . . . . 0.0 110.657 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.81 -168.79 25.32 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -141.75 149.75 40.86 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.959 0.409 . . . . 0.0 110.882 179.623 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.1 m -65.68 113.0 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.13 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.5 t -102.78 -24.01 13.75 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.122 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.0 mtt85 -153.47 164.85 19.18 Favored Pre-proline 0 C--N 1.329 -0.284 0 C-N-CA 120.414 -0.515 . . . . 0.0 110.706 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.51 119.84 6.52 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.73 1.62 . . . . 0.0 111.662 179.293 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.444 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 14.8 m-20 55.51 39.66 31.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.113 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 63.9 mmm -147.86 119.96 8.28 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.129 0.49 . . . . 0.0 110.102 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -102.25 150.14 23.6 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.632 179.001 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 98.7 m -121.7 124.62 44.68 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.531 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.71 152.34 40.67 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.535 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -49.72 -24.86 10.47 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.536 2.157 . . . . 0.0 111.762 177.529 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -64.62 -17.57 64.13 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.589 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.63 -13.4 58.03 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -71.25 151.79 43.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.901 0.381 . . . . 0.0 110.294 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -127.93 131.21 69.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.652 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.65 177.84 0.74 Allowed Pre-proline 0 C--N 1.327 -0.402 0 C-N-CA 120.526 -0.469 . . . . 0.0 110.474 179.339 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -56.93 -23.34 50.83 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.816 2.344 . . . . 0.0 111.921 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.6 p -150.67 167.71 26.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 110.212 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.327 -0.383 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.748 -179.268 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.464 0.258 0 CA-C-O 120.904 0.383 . . . . 0.0 110.586 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -63.25 -40.16 96.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.498 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.518 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 14.4 tt -87.68 174.08 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 121.145 0.497 . . . . 0.0 110.077 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.518 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 10.2 ptm180 -122.28 119.27 30.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.311 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 9.0 m -124.37 157.17 35.7 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.657 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 71.5 mtm -136.09 173.6 11.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.259 -179.483 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.9 m120 61.74 39.78 13.76 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.92 24.59 76.34 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.12 134.2 29.17 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.3 t -86.1 135.78 33.48 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.354 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 95.4 m -69.98 119.38 14.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.364 -179.597 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -131.36 100.62 5.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.195 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 48.79 -111.37 0.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.696 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -111.42 17.2 20.34 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.856 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -131.94 153.77 49.95 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.495 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 94.4 m -105.78 132.54 51.78 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 88.4 mt -97.91 127.21 43.71 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' CYS . . . . . 0.463 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 5.7 m -89.66 133.67 34.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.076 -179.017 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 -74.07 178.07 5.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.256 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -64.32 125.67 25.32 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.433 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.94 -18.65 45.95 Favored Glycine 0 N--CA 1.466 0.691 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -118.48 137.34 53.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.801 0.334 . . . . 0.0 110.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 18.9 pt -135.99 175.42 10.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.932 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.463 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 101.19 163.78 27.57 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 40.3 p -62.51 -42.74 99.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.817 0.341 . . . . 0.0 110.471 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -90.72 4.06 52.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.356 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 36.4 m 48.44 37.64 9.26 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.461 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' GLY . . . . . 0.526 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -105.1 7.32 43.99 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.732 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -109.4 109.08 60.26 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.67 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -77.47 160.42 32.03 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.548 2.165 . . . . 0.0 112.191 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.4 t -115.61 131.04 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 55.9 m -99.18 101.98 13.5 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.963 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.48 -61.38 2.38 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.834 0.35 . . . . 0.0 110.232 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.5 t -116.93 -4.99 11.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.755 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -78.84 -178.72 50.88 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.488 ' H ' ' CB ' ' A' ' 166' ' ' CYS . 9.4 m 45.09 48.96 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.914 0.387 . . . . 0.0 110.505 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 81.5 mt -62.88 -42.04 99.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.864 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -109.88 -113.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.329 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.64 11.32 68.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.59 151.67 32.29 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 -179.379 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 159' ' ' ARG . . . . . 0.483 ' O ' ' SG ' ' A' ' 166' ' ' CYS . 3.2 mpt_? -102.3 136.17 42.61 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.527 0.203 . . . . 0.0 110.507 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 70.7 m -85.49 120.52 27.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.998 0.428 . . . . 0.0 111.085 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.5 t -104.01 -29.17 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.343 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -161.44 169.18 10.12 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.457 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 69.8 Cg_exo -49.87 127.98 20.53 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.093 1.862 . . . . 0.0 111.874 178.719 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 54.74 32.26 17.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.967 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.1 tpt85 -139.24 131.57 28.39 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-O 121.213 0.53 . . . . 0.0 110.231 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.488 ' CB ' ' H ' ' A' ' 154' ' ' CYS . 1.8 t -145.25 154.43 42.37 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.217 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -98.42 138.67 35.32 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.698 179.149 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 20.9 m -75.3 143.77 42.78 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.392 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.3 m -62.99 -45.47 92.28 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.741 -179.197 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -104.21 19.51 20.04 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 121.01 0.433 . . . . 0.0 110.861 -179.4 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.57 26.58 72.83 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 177' ' ' CYS . 2.2 t80 -56.66 169.79 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.927 0.394 . . . . 0.0 110.258 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 43.9 p -98.09 164.27 12.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.466 0.65 . . . . 0.0 110.518 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 79.09 144.08 2.74 Favored Glycine 0 CA--C 1.54 1.636 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.173 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -52.92 -39.45 78.59 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.506 2.137 . . . . 0.0 112.386 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -74.85 -9.71 58.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.663 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.42 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 91.9 m . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.608 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.431 HD12 ' HB1' ' A' ' 65' ' ' ALA . 94.8 mt . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.923 0.392 . . . . 0.0 110.718 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -126.82 161.72 27.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.465 0.65 . . . . 0.0 110.616 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.05 167.44 15.95 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.73 -168.24 0.35 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 123.029 2.486 . . . . 0.0 111.7 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.517 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 98.4 m-20 57.19 36.91 28.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.711 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.04 137.74 24.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.403 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 34.2 m -138.98 178.96 6.78 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.001 0.429 . . . . 0.0 110.232 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.06 164.13 31.62 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 65' ' ' ALA . 7.8 m -83.38 173.83 11.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.682 0.277 . . . . 0.0 110.561 179.715 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -61.85 -42.84 99.54 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.888 0.375 . . . . 0.0 110.518 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -62.78 -38.94 92.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.896 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -132.98 55.85 1.88 Allowed 'General case' 0 N--CA 1.457 -0.113 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.652 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.534 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.82 145.45 50.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.47 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -159.12 166.37 31.71 Favored 'General case' 0 CA--C 1.519 -0.221 0 CA-C-O 121.054 0.454 . . . . 0.0 110.995 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 75.0 m -72.04 142.03 49.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.187 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 63.8 m -58.67 150.09 59.34 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.814 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -56.05 119.44 6.61 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.17 1.913 . . . . 0.0 112.357 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 116.72 -14.82 14.5 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.517 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.0 m95 -119.55 132.73 55.81 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.109 0.481 . . . . 0.0 110.412 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -111.86 -177.04 3.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.292 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.539 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 51.2 p -130.63 166.34 20.89 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.515 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.4 ' HG ' HG21 ' A' ' 82' ' ' VAL . 87.6 mt -90.2 151.75 45.12 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.2 Cg_exo -47.52 128.44 15.2 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 121.51 1.473 . . . . 0.0 112.212 178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.74 -5.82 7.12 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 179.67 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.411 ' O ' ' OD1' ' A' ' 78' ' ' ASN . . . -91.87 171.95 34.95 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 77' ' ' GLY . 96.3 m-20 -140.57 8.79 2.19 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.955 0.407 . . . . 0.0 110.992 179.477 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -86.67 129.29 34.92 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.435 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 18.4 m -92.86 46.23 1.22 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.856 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 45.2 pt -98.01 -4.45 9.68 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.528 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' VAL . . . . . 0.4 HG21 ' HG ' ' A' ' 74' ' ' LEU . 57.8 t -97.64 111.59 59.13 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.498 -0.481 . . . . 0.0 111.13 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.88 159.5 41.68 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.306 2.004 . . . . 0.0 111.962 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 93.4 mt -98.83 121.67 49.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.426 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.34 122.66 34.14 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.448 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -64.6 -45.32 87.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.372 0.606 . . . . 0.0 109.551 179.462 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 74.5 m-70 -137.17 149.46 47.27 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.646 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.5 p -52.3 128.87 26.6 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.361 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.5 m -72.31 -31.84 66.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.83 -112.81 3.54 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -70.42 -6.58 36.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.635 0.255 . . . . 0.0 110.496 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.07 -162.93 21.1 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.88 152.81 39.31 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.998 0.428 . . . . 0.0 110.772 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.77 113.92 5.93 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 36.9 t -106.5 -23.27 12.54 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.254 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -156.82 162.02 28.41 Favored Pre-proline 0 C--N 1.327 -0.378 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.542 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_exo -48.4 119.27 3.93 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 121.907 1.738 . . . . 0.0 111.331 179.091 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.448 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 96.4 m-20 54.33 40.58 31.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.35 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 83.4 mmm -146.84 115.04 6.61 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.484 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -96.72 145.88 25.39 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.148 178.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 61.0 m -119.99 114.39 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.771 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.413 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -79.57 157.63 74.53 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.71 -179.715 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.413 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 28.0 Cg_endo -63.43 -19.27 67.65 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.946 2.431 . . . . 0.0 111.352 178.759 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -69.41 -17.02 63.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.862 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 108.35 -21.79 28.05 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -65.98 150.89 47.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.086 0.47 . . . . 0.0 110.218 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.89 131.62 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.999 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.683 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.02 178.29 1.02 Allowed Pre-proline 0 C--N 1.325 -0.478 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.578 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.683 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -57.06 -23.79 54.44 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.771 2.314 . . . . 0.0 111.639 178.806 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.1 p -151.02 163.26 39.16 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.962 0.41 . . . . 0.0 110.291 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.302 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 120.931 0.396 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -93.63 4.06 54.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.324 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.465 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.6 tt -132.52 168.48 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.332 179.583 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.465 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.5 ptm180 -100.95 118.13 36.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.201 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' CYS . . . . . 0.445 ' C ' ' SD ' ' A' ' 124' ' ' MET . 61.7 m -116.17 138.58 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.689 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' MET . . . . . 0.531 ' SD ' ' N ' ' A' ' 124' ' ' MET . 3.2 mpp? -142.56 165.69 26.7 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.474 -179.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 59.15 51.22 7.18 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.454 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 70.84 26.16 74.48 Favored Glycine 0 C--N 1.331 0.27 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.81 114.49 3.92 Favored Glycine 0 CA--C 1.53 0.983 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 30.6 t -79.49 148.21 31.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.511 0.196 . . . . 0.0 110.976 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.4 m -92.38 102.83 15.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.185 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 35.1 t -149.04 138.59 21.77 Favored 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.498 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 98.5 m-20 51.72 36.57 17.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.788 0.328 . . . . 0.0 110.994 179.375 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 54.19 27.91 8.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.682 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 133' ' ' HIS . . . . . 0.498 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 44.2 m80 -136.34 143.09 43.93 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.961 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 120.44 31.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.093 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.68 120.02 37.3 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.22 137.6 32.21 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.642 -178.746 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.3 -174.1 0.62 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.021 0.439 . . . . 0.0 110.39 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 48.6 tttp -67.82 132.26 47.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 97.78 -7.88 63.31 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -122.1 137.95 54.63 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.866 0.365 . . . . 0.0 110.447 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.5 pt -138.11 -176.62 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.084 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 116.01 162.77 13.33 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.577 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 49.5 p -60.71 -45.04 95.74 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.409 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 12.2 m80 -120.64 27.53 8.49 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.59 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 5.8 m 58.05 118.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.086 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' GLY . . . . . 0.424 ' H ' ' H ' ' A' ' 147' ' ' GLN . . . 174.85 5.36 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLN . . . . . 0.424 ' H ' ' H ' ' A' ' 146' ' ' GLY . 8.0 tp-100 -132.51 114.9 14.62 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 120.894 -0.323 . . . . 0.0 110.596 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.35 158.59 40.75 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.772 2.315 . . . . 0.0 112.095 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.49 131.16 39.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.93 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 88.36 2.79 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.085 0.469 . . . . 0.0 109.85 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -59.02 -61.92 2.28 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.472 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 153' ' ' GLY . 97.3 p -117.95 -3.5 11.15 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.527 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 152' ' ' SER . . . -58.98 -152.42 0.01 OUTLIER Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.599 ' N ' ' SG ' ' A' ' 166' ' ' CYS . 73.5 m -68.88 126.39 29.63 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.758 0.314 . . . . 0.0 110.202 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.11 -42.93 99.65 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 -169.79 -25.93 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.66 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -60.16 -43.4 98.41 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.241 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 154' ' ' CYS . . . -97.64 179.14 32.92 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.462 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.5 ttp180 -110.55 131.05 55.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.781 0.324 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 61.4 m -83.24 122.93 29.06 Favored 'General case' 0 CA--C 1.52 -0.175 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.079 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.8 m -104.12 -18.35 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.628 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.61 172.81 5.0 Favored Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.622 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.628 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.4 Cg_exo -53.73 127.49 25.7 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 121.925 1.75 . . . . 0.0 111.687 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 51.88 34.26 13.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.255 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -140.75 134.7 30.64 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.391 0.615 . . . . 0.0 110.39 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.599 ' SG ' ' N ' ' A' ' 154' ' ' CYS . 11.9 p -154.94 166.9 32.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.039 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -122.03 142.76 50.01 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.059 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 168' ' ' CYS . . . . . 0.422 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 87.5 m -78.08 124.12 27.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.418 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.7 m -64.55 -46.25 83.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.575 -179.275 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -107.71 16.18 23.9 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.349 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 69.54 27.9 72.94 Favored Glycine 0 C--N 1.31 -0.872 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.516 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 13.9 m-85 -64.63 139.82 58.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.345 0.593 . . . . 0.0 110.045 -179.461 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -82.93 167.67 17.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.008 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.25 151.56 13.14 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -67.29 -24.15 44.0 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.628 2.219 . . . . 0.0 112.133 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.44 ' O ' ' O ' ' A' ' 177' ' ' CYS . 74.1 mt-30 -104.91 -7.99 18.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.577 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.516 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 2.6 t . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.197 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.4 mt . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 121.12 0.486 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -127.37 158.7 36.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.008 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.61 152.87 15.98 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.04 11.96 1.08 Allowed 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 122.67 2.246 . . . . 0.0 112.438 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -125.14 52.12 1.62 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.075 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.45 133.05 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 99.2 m -144.56 175.49 10.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 169.61 44.76 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.56 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.5 m -73.83 160.86 30.85 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.2 ttm-85 -59.28 -43.7 92.52 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.646 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -61.75 -43.53 98.67 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.899 -0.321 . . . . 0.0 111.395 -179.278 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -125.35 47.86 2.12 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.537 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.32 142.82 58.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.603 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 24.3 p90 -152.04 168.14 26.19 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 121.279 0.562 . . . . 0.0 110.437 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.5 t -71.56 139.0 49.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.208 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 159.49 19.37 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -60.29 135.01 58.99 Favored 'Trans proline' 0 N--CA 1.497 1.707 0 C-N-CA 122.131 1.887 . . . . 0.0 111.627 179.268 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.15 -23.5 34.26 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.432 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -114.32 135.93 53.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.732 0.266 . . . . 0.0 110.284 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -121.09 -174.04 2.74 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.159 179.441 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 70.8 p -124.1 163.49 21.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 0.0 110.183 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.432 ' O ' ' N ' ' A' ' 77' ' ' GLY . 86.1 mt -83.52 149.86 58.62 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.781 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 77' ' ' GLY . 76.0 Cg_exo -42.62 117.49 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.288 0 C-N-CA 121.734 1.623 . . . . 0.0 112.371 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.72 -3.96 5.9 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 179.348 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -91.76 175.1 38.37 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -134.68 8.28 3.57 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.646 0.26 . . . . 0.0 110.926 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -82.35 129.26 34.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.826 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 9.9 m -103.53 78.6 1.6 Allowed 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.538 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.7 pt -130.98 20.03 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -120.73 103.16 43.81 Favored Pre-proline 0 CA--C 1.537 0.479 0 CA-C-N 116.811 -0.177 . . . . 0.0 110.624 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.15 160.34 29.81 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 C-N-CA 122.165 1.91 . . . . 0.0 112.266 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 92.6 mt -105.82 127.39 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.413 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 100' ' ' CYS . 4.9 m -91.3 136.26 33.23 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.804 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.436 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -61.83 -44.87 95.98 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.401 -179.725 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 87' ' ' HIS . . . . . 0.427 ' NE2' ' NH1' ' A' ' 86' ' ' ARG . 96.1 m-70 -110.82 152.74 26.3 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.391 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -53.92 131.18 39.7 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.65 -33.08 53.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.039 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.06 -105.85 1.79 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -92.69 0.83 57.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.882 0.372 . . . . 0.0 110.573 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -98.27 172.05 26.16 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' PHE . . . . . 0.461 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 24.2 t80 -122.26 130.52 53.24 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.848 0.356 . . . . 0.0 110.943 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 94' ' ' CYS . . . . . 0.461 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 1.7 t -64.19 119.18 9.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.835 179.209 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 73.3 p -104.8 -19.14 14.0 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.478 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -162.03 164.88 16.86 Favored Pre-proline 0 CA--C 1.533 0.309 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.849 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -53.0 128.29 28.35 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 121.412 1.408 . . . . 0.0 111.041 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.436 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.2 m-20 51.46 37.97 20.76 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.718 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.1 mtp -147.75 108.95 4.27 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.218 0.532 . . . . 0.0 110.305 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 100' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 0.8 OUTLIER -97.13 149.05 22.41 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.606 179.266 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.1 m -120.5 122.8 41.44 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.54 158.98 35.89 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.488 -178.971 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -55.84 -26.82 59.37 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.496 2.131 . . . . 0.0 112.245 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.1 t -64.09 -17.43 63.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.575 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.43 -17.44 50.76 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -67.37 153.73 42.99 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.981 0.419 . . . . 0.0 110.124 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 90.0 mt -126.83 128.26 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.398 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.528 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -165.63 162.88 13.12 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.934 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.528 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 11.6 Cg_endo -52.36 -15.93 4.44 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.955 2.436 . . . . 0.0 112.165 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 97.2 p -155.51 159.39 39.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.28 179.11 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.06 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 7.4 m . . . . . 0 N--CA 1.465 0.304 0 CA-C-O 120.907 0.385 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -96.6 10.54 38.21 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.417 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 10.9 tp -125.44 156.96 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.521 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 12.6 mtt180 -106.91 120.19 41.38 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.542 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 12.0 m -121.11 142.5 49.8 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -143.25 169.61 17.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.108 -179.065 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 28.8 m120 58.81 41.76 21.04 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.549 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.44 18.33 76.15 Favored Glycine 0 CA--C 1.517 0.205 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.88 121.56 6.32 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.2 t -79.85 140.43 36.8 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.5 t -91.54 124.4 35.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.136 179.237 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 132' ' ' ASP . 31.8 t -141.75 143.04 33.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.213 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 41.14 -92.37 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 130' ' ' SER . 39.5 p-10 -146.5 23.68 1.27 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.755 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -138.53 148.36 44.16 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.445 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 84.3 m -96.49 128.69 43.66 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.107 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.6 mt -92.69 126.13 37.64 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 16.7 m -89.33 127.5 35.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.58 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.75 174.89 4.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.343 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -63.42 127.01 29.39 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.091 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.37 -13.84 54.67 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 -179.592 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -121.59 136.44 54.95 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.931 0.396 . . . . 0.0 110.42 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -133.58 172.76 15.81 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.214 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 102.8 163.34 25.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 24.0 p -62.42 -43.84 97.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.749 0.309 . . . . 0.0 110.631 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 2.2 p-80 -94.77 10.75 33.96 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.096 0.474 . . . . 0.0 110.468 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 12.4 m 46.85 36.59 4.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.101 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -99.74 8.46 59.83 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 32.7 tt0 -116.08 112.77 41.97 Favored Pre-proline 0 CA--C 1.548 0.898 0 CA-C-N 116.76 0.28 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -78.39 159.6 29.23 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.441 2.094 . . . . 0.0 112.273 179.356 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.5 t -113.56 127.74 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 121.016 0.436 . . . . 0.0 110.142 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 150' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 2.2 m -100.05 98.18 8.95 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -62.88 -51.67 66.07 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.339 -178.375 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 79.3 p -118.37 -9.45 10.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.896 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -79.74 171.82 54.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.108 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 154' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 150' ' ' CYS . 17.9 m 57.08 59.99 3.18 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.885 0.374 . . . . 0.0 110.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 155' ' ' LEU . . . . . 0.526 HD12 ' N ' ' A' ' 155' ' ' LEU . 10.9 mp -62.93 -42.19 99.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.752 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' A' ' 157' ' ' GLY . 24.9 t-20 -121.5 -112.69 0.32 Allowed 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.994 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.527 ' N ' ' OD1' ' A' ' 156' ' ' ASN . . . -84.6 3.49 86.52 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -54.75 148.3 23.01 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 159' ' ' ARG . . . . . 0.479 ' C ' ' SG ' ' A' ' 166' ' ' CYS . 17.8 tpt180 -102.66 131.31 49.54 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.775 0.322 . . . . 0.0 110.451 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 4.8 t -76.04 100.3 4.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.088 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.5 t -76.91 -43.82 32.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.768 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.647 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -151.02 175.03 3.07 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.979 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.647 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 71.8 Cg_exo -51.73 130.06 32.43 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 121.605 1.537 . . . . 0.0 112.385 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.0 m-20 52.43 32.02 10.61 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.372 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 165' ' ' ARG . . . . . 0.442 ' O ' ' SG ' ' A' ' 150' ' ' CYS . 74.2 mtm180 -141.6 136.33 30.92 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.473 0.654 . . . . 0.0 110.921 179.212 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 166' ' ' CYS . . . . . 0.479 ' SG ' ' C ' ' A' ' 159' ' ' ARG . 1.7 t -144.35 156.22 44.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.994 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.37 143.5 42.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.69 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 76.0 m -72.21 127.44 32.55 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.232 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 98.7 m -63.37 -46.12 87.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.458 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 170' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 74.7 t80 -110.54 27.95 9.14 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.992 0.425 . . . . 0.0 111.327 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.46 25.51 63.06 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 172' ' ' PHE . . . . . 0.462 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 66.8 t80 -63.53 131.76 49.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.421 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 173' ' ' THR . . . . . 0.439 ' O ' ' CE2' ' A' ' 172' ' ' PHE . 68.0 p -82.52 163.43 21.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.144 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 144.38 160.44 8.49 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 175' ' ' PRO . . . . . 0.424 ' O ' ' OE1' ' A' ' 176' ' ' GLN . 36.2 Cg_endo -63.51 -31.9 70.9 Favored 'Trans proline' 0 N--CA 1.496 1.671 0 C-N-CA 122.578 2.185 . . . . 0.0 112.4 -179.701 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 176' ' ' GLN . . . . . 0.424 ' OE1' ' O ' ' A' ' 175' ' ' PRO . 1.9 mp0 -131.4 8.66 4.65 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.201 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 1.8 t . . . . . 0 C--N 1.326 -0.415 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.267 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.2 mt . . . . . 0 N--CA 1.451 -0.385 0 CA-C-O 121.019 0.438 . . . . 0.0 110.725 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -137.17 159.84 40.73 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.15 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.38 163.24 24.51 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.75 -5.87 17.42 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 123.089 2.526 . . . . 0.0 112.263 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASN . . . . . 0.454 ' OD1' ' CD2' ' A' ' 71' ' ' TRP . 31.7 m120 -103.59 68.32 0.93 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.56 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.9 t -119.96 129.41 75.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.838 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.2 m -134.76 173.6 11.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.002 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.92 164.65 37.44 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' ALA . 12.5 m -80.1 173.25 12.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -60.38 -42.82 96.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -62.16 -41.75 98.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -125.58 49.55 1.91 Allowed 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.747 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.21 140.44 52.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.304 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -155.3 165.71 35.8 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.978 0.418 . . . . 0.0 110.878 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 5.8 m -72.89 135.0 45.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.089 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 35.1 m -55.81 149.84 30.46 Favored Pre-proline 0 C--N 1.323 -0.577 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.213 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -56.23 134.98 67.56 Favored 'Trans proline' 0 N--CA 1.498 1.791 0 C-N-CA 121.498 1.465 . . . . 0.0 112.234 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.95 -14.95 52.31 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.454 ' CD2' ' OD1' ' A' ' 57' ' ' ASN . 85.4 m95 -115.92 134.99 54.41 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.758 0.314 . . . . 0.0 110.372 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 72' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 80' ' ' CYS . 17.4 ptpt -110.14 -175.95 2.87 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.333 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.436 HG22 ' SG ' ' A' ' 80' ' ' CYS . 41.4 p -123.09 161.19 24.85 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 74' ' ' LEU . . . . . 0.58 HD22 ' N ' ' A' ' 74' ' ' LEU . 2.7 mm? -84.53 149.04 53.67 Favored Pre-proline 0 N--CA 1.449 -0.48 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.158 -179.534 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -46.23 112.59 0.47 Allowed 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.591 1.528 . . . . 0.0 112.236 179.1 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.15 -6.48 28.16 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.99 174.77 36.04 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -129.04 0.58 5.25 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.816 0.341 . . . . 0.0 110.643 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.2 mt-30 -78.84 134.4 36.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.688 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' CYS . . . . . 0.445 ' SG ' ' O ' ' A' ' 72' ' ' LYS . 1.5 m -115.0 79.03 1.22 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.164 0.507 . . . . 0.0 110.189 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.3 pt -120.74 14.59 6.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.657 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 t -117.55 107.01 45.46 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 121.273 -0.171 . . . . 0.0 110.796 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.14 159.97 33.33 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.21 1.94 . . . . 0.0 111.987 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.5 mt -99.54 123.17 52.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.85 125.31 35.7 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.124 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.5 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.9 OUTLIER -63.32 -45.77 89.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.27 0.557 . . . . 0.0 109.932 179.657 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -121.73 143.5 49.33 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.462 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -53.1 128.29 27.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.424 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.7 m -71.33 -27.87 63.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.573 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.45 -116.33 4.89 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -70.38 -8.73 52.96 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.737 0.304 . . . . 0.0 110.925 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.54 -164.81 25.34 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -142.65 150.38 40.14 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.995 0.426 . . . . 0.0 110.788 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.7 m -69.53 116.96 10.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.568 -179.305 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.3 t -104.11 -20.78 13.71 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.322 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.0 mtt85 -160.76 167.99 12.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.56 123.3 13.0 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.613 1.542 . . . . 0.0 111.143 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.5 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 49.2 t30 52.26 40.35 28.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.088 -179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.2 mtp -146.95 115.72 6.81 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.362 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 58.0 m -102.07 148.08 25.82 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.438 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 84.1 m -121.47 117.73 27.58 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.971 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -84.38 157.84 61.35 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.801 179.683 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.423 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.0 Cg_endo -61.64 -22.24 73.96 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.743 2.296 . . . . 0.0 111.828 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.4 t -66.28 -16.62 64.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.19 -19.02 38.29 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.0 tp60 -65.19 149.1 50.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.011 0.434 . . . . 0.0 110.427 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.09 131.63 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.828 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.36 172.43 1.78 Allowed Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.471 179.453 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 73.8 Cg_exo -48.82 -23.63 6.04 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.454 2.103 . . . . 0.0 111.992 178.726 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.0 p -153.6 165.47 35.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.251 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.246 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.1 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -64.01 -40.56 96.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.461 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.457 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.5 tt -80.18 166.26 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.229 179.689 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.457 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 20.3 mmm180 -98.75 98.07 9.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.775 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 87.4 m -92.98 134.47 35.08 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.88 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 72.6 mtm -145.31 165.07 29.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.86 39.9 19.94 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.039 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.56 24.78 69.41 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.97 128.24 22.81 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' SER . . . . . 0.498 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 17.3 m -86.24 137.68 32.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.661 0.267 . . . . 0.0 110.494 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.56 129.93 34.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.514 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.45 ' O ' ' O ' ' A' ' 133' ' ' HIS . 52.3 p -146.58 109.66 4.7 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.165 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 50.12 -116.52 0.93 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.516 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 132' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 132' ' ' ASP . 32.4 p-10 -106.95 9.29 30.75 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.885 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 130' ' ' SER . 69.2 m80 -131.15 153.02 49.84 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.95 0.405 . . . . 0.0 110.798 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.4 t -114.62 145.06 42.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.293 179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.9 mt -100.8 129.96 46.75 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.676 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 10.5 m -96.34 139.22 32.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.455 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.55 179.15 0.85 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.533 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -67.33 129.71 40.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.613 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 98.07 -10.77 63.92 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -117.34 133.8 55.56 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.9 0.381 . . . . 0.0 110.638 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 45.8 pt -131.95 170.36 20.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.315 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 106.37 164.41 22.77 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.5 m -63.26 -45.52 91.15 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.449 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 -97.52 5.24 49.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.902 0.382 . . . . 0.0 110.682 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 6.0 m 59.87 37.25 21.79 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.123 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -98.88 5.72 59.86 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -119.65 107.09 41.09 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.679 0.239 . . . . 0.0 110.535 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.73 163.5 23.72 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.564 2.176 . . . . 0.0 111.911 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.2 t -106.15 126.3 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 121.158 0.504 . . . . 0.0 109.918 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.88 92.71 7.54 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -63.61 -46.53 85.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.761 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 9.9 m -89.93 -11.93 40.32 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.861 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.12 161.29 1.28 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.2 m -104.23 145.29 30.43 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 155' ' ' LEU . . . . . 0.509 ' H ' HD12 ' A' ' 155' ' ' LEU . 4.3 mp -62.95 -43.42 98.84 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.13 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 m-20 165.4 -58.38 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.352 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.53 -37.95 95.01 Favored Glycine 0 CA--C 1.517 0.164 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.35 159.86 50.5 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -127.43 145.91 50.66 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.725 0.297 . . . . 0.0 110.81 179.108 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 60.2 m -73.2 104.68 4.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.616 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 161' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 161' ' ' VAL . 70.2 t -106.49 -13.04 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.354 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.654 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.18 177.76 1.45 Allowed Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 120.369 -0.532 . . . . 0.0 110.341 179.807 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.654 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.3 Cg_exo -55.64 128.44 30.35 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 121.896 1.731 . . . . 0.0 111.539 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 55.6 t30 43.23 38.7 1.71 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.9 179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -131.37 127.07 36.82 Favored 'General case' 0 C--O 1.24 0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 110.53 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 94.3 m -117.79 118.81 33.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.846 179.301 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -77.96 92.34 4.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.927 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.75 129.46 55.37 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.501 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.2 t -114.01 24.79 11.71 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.295 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -100.86 29.02 4.79 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.011 0.434 . . . . 0.0 110.945 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.98 28.71 73.89 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -50.41 163.24 0.18 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.769 0.319 . . . . 0.0 110.476 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -130.02 131.65 45.93 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.308 179.365 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 80.19 176.95 50.42 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -78.38 -10.7 16.1 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.809 2.339 . . . . 0.0 112.03 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 33.0 tt0 -83.45 6.32 20.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.846 -178.496 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 177' ' ' CYS . . . . . 0.515 ' SG ' ' O ' ' A' ' 177' ' ' CYS . 50.3 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.624 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' LEU . . . . . 0.401 HD23 ' HB2' ' A' ' 78' ' ' ASN . 87.5 mt . . . . . 0 N--CA 1.452 -0.351 0 CA-C-O 120.897 0.379 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -135.85 165.87 24.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.784 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.69 168.63 9.92 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.26 -172.49 0.89 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 122.938 2.425 . . . . 0.0 111.805 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 57.48 42.14 24.95 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.094 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 58' ' ' VAL . 14.6 p -97.93 133.24 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.91 0.386 . . . . 0.0 110.101 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 m -140.12 175.88 9.22 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.425 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.94 160.18 26.05 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 65' ' ' ALA . 14.9 m -81.21 174.79 11.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.319 . . . . 0.0 110.398 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.4 ttt85 -60.59 -43.15 97.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.599 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -62.05 -39.12 91.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.917 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -131.84 53.57 1.99 Allowed 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.11 139.96 52.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.391 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -154.18 169.7 22.97 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.088 0.471 . . . . 0.0 110.641 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 67' ' ' CYS . . . . . 0.407 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 73.2 m -79.45 136.29 36.9 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 38.6 m -52.99 154.97 4.65 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.246 -178.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.84 132.51 42.3 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.103 1.202 . . . . 0.0 112.785 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.69 -7.27 57.61 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' TRP . . . . . 0.534 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 9.5 m95 -132.02 143.08 49.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.519 179.352 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -127.72 -166.08 1.57 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' THR . . . . . 0.407 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.3 p -123.49 164.76 18.31 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -108.4 156.56 38.39 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.206 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 77' ' ' GLY . 46.7 Cg_exo -52.88 138.66 60.82 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 121.379 1.386 . . . . 0.0 111.808 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.38 -38.08 0.34 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 77' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -82.7 169.83 49.34 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' ASN . . . . . 0.401 ' HB2' HD23 ' A' ' 53' ' ' LEU . 50.0 p30 -136.48 16.06 3.17 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.611 -0.294 . . . . 0.0 110.88 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -87.6 133.7 33.76 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.781 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 62.6 m -86.28 42.69 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.5 pt -94.02 26.45 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.253 -179.454 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.91 94.18 47.61 Favored Pre-proline 0 N--CA 1.466 0.37 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.76 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -79.48 161.26 25.39 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.198 1.932 . . . . 0.0 112.182 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.47 127.86 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.4 131.37 43.03 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' ARG . . . . . 0.419 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -64.09 -45.88 86.73 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-O 121.177 0.513 . . . . 0.0 110.256 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -127.18 174.0 9.27 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.97 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 p -63.84 146.08 54.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.405 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 1.4 m -88.56 -32.4 18.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.53 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.29 -107.99 2.56 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.341 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -92.93 3.63 55.38 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.556 0.217 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.06 -161.67 17.45 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -146.94 152.18 38.23 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.985 0.421 . . . . 0.0 110.98 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.6 m -69.65 115.6 9.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.131 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.6 p -103.82 -17.35 15.09 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.952 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtp85 -159.74 163.6 22.4 Favored Pre-proline 0 CA--C 1.532 0.285 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.068 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -51.99 127.09 22.07 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.565 1.51 . . . . 0.0 111.034 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 98' ' ' ASN . . . . . 0.419 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 92.0 m-20 49.62 36.5 10.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.88 179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 38.1 mtt -147.6 122.31 9.88 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.36 0.6 . . . . 0.0 111.048 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 20.2 t -108.17 149.45 28.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.474 179.115 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 99.8 m -121.38 124.72 45.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.79 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 102' ' ' CYS . . . . . 0.404 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -93.73 157.78 37.66 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.543 -179.916 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 103' ' ' PRO . . . . . 0.404 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 27.3 Cg_endo -62.04 -20.44 69.67 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.551 2.167 . . . . 0.0 111.766 178.929 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 t -68.05 -22.85 64.93 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.601 178.827 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 113.88 -22.94 13.7 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 106' ' ' GLN . . . . . 0.468 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 8.1 tm0? -63.44 146.25 53.99 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.212 0.53 . . . . 0.0 110.362 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 107' ' ' ILE . . . . . 0.468 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 96.7 mt -129.89 133.78 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.402 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 108' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -178.64 171.61 0.71 Allowed Pre-proline 0 CA--C 1.535 0.392 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 109' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 56.9 Cg_exo -50.35 -25.77 14.46 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 122.645 2.23 . . . . 0.0 112.247 179.015 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.7 p -140.75 161.99 36.48 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.239 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.324 -0.501 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.684 -179.576 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 64.5 m . . . . . 0 N--CA 1.469 0.495 0 CA-C-O 120.908 0.385 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 120' ' ' ASN . . . . . 0.416 ' O ' ' OD1' ' A' ' 120' ' ' ASN . 53.5 t-20 -63.58 -40.43 96.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.658 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 121' ' ' ILE . . . . . 0.661 HG22 ' H ' ' A' ' 122' ' ' ARG . 15.6 mm -82.71 174.33 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.956 -179.488 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 122' ' ' ARG . . . . . 0.661 ' H ' HG22 ' A' ' 121' ' ' ILE . 27.2 ptt180 -106.02 114.08 28.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.544 0.688 . . . . 0.0 110.534 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 94.2 m -124.26 148.03 47.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.263 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.2 mtm -142.27 174.24 10.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.916 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 10.8 m120 60.88 44.93 10.2 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.119 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.29 26.17 71.53 Favored Glycine 0 CA--C 1.518 0.261 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -66.52 156.66 50.78 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 28.3 t -109.62 134.51 51.86 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-O 121.05 0.452 . . . . 0.0 110.373 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 15.5 m -80.94 132.1 35.38 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 130' ' ' SER . . . . . 0.505 ' OG ' HD23 ' A' ' 135' ' ' LEU . 69.1 m -123.56 158.41 31.46 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.486 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 131' ' ' ASP . . . . . 0.501 ' C ' ' O ' ' A' ' 130' ' ' SER . 99.6 m-20 -12.01 -77.5 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 O-C-N 123.899 0.75 . . . . 0.0 112.725 -179.562 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -136.21 29.74 3.03 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.397 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -139.89 159.08 42.98 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.782 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 134' ' ' CYS . . . . . 0.407 ' C ' HD22 ' A' ' 135' ' ' LEU . 40.7 t -104.64 122.37 45.49 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.035 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 135' ' ' LEU . . . . . 0.505 HD23 ' OG ' ' A' ' 130' ' ' SER . 3.5 mm? -98.18 127.19 43.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.081 0.467 . . . . 0.0 110.169 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 61.1 m -106.98 140.43 39.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.807 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -76.8 168.94 19.21 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.32 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 56.1 tptt -64.71 133.31 51.85 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 108.76 -26.41 15.95 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -116.61 133.58 55.84 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 120.898 0.38 . . . . 0.0 110.67 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.6 pt -131.04 170.76 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.936 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.61 157.62 10.36 Favored Glycine 0 N--CA 1.464 0.565 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.6 p -64.07 -42.69 96.89 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.869 0.366 . . . . 0.0 110.602 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.21 5.02 34.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.25 139.29 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 151.41 -10.74 0.73 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -99.0 110.53 58.07 Favored Pre-proline 0 CA--C 1.544 0.715 0 O-C-N 122.517 -0.402 . . . . 0.0 110.422 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -76.77 159.01 35.14 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.175 1.916 . . . . 0.0 112.524 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.8 t -124.76 130.06 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.11 0.481 . . . . 0.0 110.577 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -104.35 117.68 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.087 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -65.75 -39.48 91.12 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.3 m -86.12 -7.44 58.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.531 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 45.73 -166.48 0.06 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 1.3 m -141.34 119.61 12.18 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.5 mt -63.9 -41.7 97.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.766 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 156' ' ' ASN . . . . . 0.526 ' C ' ' H ' ' A' ' 158' ' ' GLY . 6.1 t-20 -86.03 -167.88 2.02 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.332 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 157' ' ' GLY . . . . . 0.496 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.79 23.67 0.53 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 158' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -60.01 160.17 21.59 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -126.75 147.18 50.0 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.778 0.323 . . . . 0.0 110.668 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 12.3 t -90.88 104.78 17.33 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.853 0.359 . . . . 0.0 110.497 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.98 -35.04 20.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 162' ' ' ALA . . . . . 0.63 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -155.81 177.29 2.11 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.36 -179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 163' ' ' PRO . . . . . 0.63 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.8 Cg_exo -54.26 132.22 49.36 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.023 1.816 . . . . 0.0 112.259 179.436 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.5 t30 49.33 31.79 4.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.259 179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -135.42 102.09 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.58 0.705 . . . . 0.0 110.751 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -107.52 141.17 39.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.821 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.64 133.71 50.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.444 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 67.3 m -86.3 146.51 26.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.102 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -62.35 -45.1 94.73 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.118 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -97.52 15.93 21.8 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.322 0.582 . . . . 0.0 110.847 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.15 20.95 78.37 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -54.84 161.7 1.49 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.967 0.413 . . . . 0.0 110.595 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 8.8 t -82.54 160.52 22.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.479 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.6 142.52 0.05 OUTLIER Glycine 0 CA--C 1.539 1.534 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.694 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -53.48 -40.67 77.84 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.329 2.019 . . . . 0.0 112.971 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -67.3 -26.22 66.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.455 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 11.8 m . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.673 -179.88 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.2 m . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.75 -38.55 91.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.551 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -74.56 152.65 39.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -154.29 161.9 30.32 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 86.69 7.09 79.14 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -63.89 -39.87 97.78 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.21 164.6 39.96 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 55.2 p-80 -82.4 -16.7 48.09 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.857 0.361 . . . . 0.0 110.566 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.431 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 58.4 p30 -73.21 148.9 43.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.753 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.61 -36.54 84.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.462 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.93 142.93 51.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.606 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -135.61 -176.77 4.4 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.732 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.71 158.73 29.32 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -76.59 8.29 3.08 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.764 2.309 . . . . 0.0 112.105 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.426 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 26.0 m120 -119.88 65.79 0.81 Allowed 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.658 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.459 HG13 ' O ' ' A' ' 58' ' ' VAL . 10.7 p -112.55 128.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -148.51 171.85 15.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.379 -179.153 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.55 166.46 34.97 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.7 m -79.08 165.04 23.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.7 0.286 . . . . 0.0 110.307 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.6 ttm-85 -58.85 -42.26 88.92 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.241 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -61.18 -39.42 90.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.832 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -131.63 51.13 2.17 Favored 'General case' 0 C--O 1.226 -0.151 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.033 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.08 142.83 50.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.536 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 11.8 p90 -160.94 176.32 11.55 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 121.069 0.461 . . . . 0.0 110.523 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.402 ' SG ' HG22 ' A' ' 73' ' ' THR . 62.8 m -73.39 133.89 43.89 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -47.1 169.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.033 -178.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -58.32 133.86 57.73 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 121.883 1.722 . . . . 0.0 112.364 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 93.39 -16.63 60.2 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.426 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 92.5 m95 -110.25 138.49 46.55 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -121.98 -164.52 1.16 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.316 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.402 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.3 p -125.07 164.83 19.35 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.486 ' O ' ' N ' ' A' ' 77' ' ' GLY . 24.6 mt -89.16 151.99 47.42 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 -179.074 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -40.44 107.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.256 0 C-N-CA 122.219 1.946 . . . . 0.0 112.259 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.27 -11.2 9.03 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -87.96 177.76 46.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.924 -0.871 . . . . 0.0 110.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -138.01 17.06 2.83 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.892 0.377 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -81.93 130.15 34.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.046 -179.243 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 53.6 m -95.66 55.26 1.64 Allowed 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.451 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.3 pt -114.32 22.05 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.995 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.04 99.51 40.92 Favored Pre-proline 0 N--CA 1.467 0.401 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.573 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.95 156.45 26.84 Favored 'Trans proline' 0 N--CA 1.487 1.113 0 C-N-CA 122.164 1.91 . . . . 0.0 112.202 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.438 ' O ' ' NH1' ' A' ' 86' ' ' ARG . 96.0 mt -101.57 122.12 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-O 120.945 0.403 . . . . 0.0 110.202 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.27 126.29 45.06 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.494 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 9.0 mpt_? -64.97 -40.33 94.82 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.743 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -117.71 145.68 44.27 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.192 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.2 m -63.24 136.29 57.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.0 0.429 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 44.5 m -77.95 -32.24 51.37 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.326 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.44 -107.19 2.25 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -68.38 -12.32 60.95 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.777 0.323 . . . . 0.0 110.797 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -110.53 -161.91 18.2 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -145.94 151.52 37.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.006 0.432 . . . . 0.0 111.072 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.7 m -66.95 115.18 6.39 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.225 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -106.46 -20.72 13.29 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.754 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -157.49 161.66 28.78 Favored Pre-proline 0 CA--C 1.531 0.238 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.364 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_exo -48.93 122.23 7.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 121.748 1.632 . . . . 0.0 111.254 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 39.2 t-20 52.05 41.74 30.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.004 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 80.9 mtp -148.33 116.72 6.54 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.62 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.44 ' N ' ' O ' ' A' ' 108' ' ' ALA . 33.7 m -100.44 148.28 24.92 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.366 178.947 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.6 m -120.58 123.28 42.48 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.741 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.16 157.92 53.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.275 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.71 -18.64 65.17 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.719 2.279 . . . . 0.0 111.855 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.8 m -71.95 -17.38 62.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.432 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 109.16 -20.32 28.57 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -66.82 150.03 49.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.934 0.397 . . . . 0.0 110.194 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.68 132.74 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.642 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -167.77 179.05 0.99 Allowed Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.379 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 38.8 Cg_exo -57.92 -22.76 56.11 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.814 2.343 . . . . 0.0 112.306 179.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.2 p -153.74 161.84 41.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.243 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -85.72 127.77 34.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.885 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 170.01 160.51 18.51 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -68.43 -18.81 64.52 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 121.01 -0.276 . . . . 0.0 110.833 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 80.6 mtp85 -73.67 127.37 32.6 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.872 0.368 . . . . 0.0 110.621 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.6 t -170.87 165.89 7.74 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.357 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.5 mt -92.49 122.06 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.128 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -171.8 118.47 0.42 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.11 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.641 ' ND1' ' N ' ' A' ' 119' ' ' CYS . 59.0 t-80 49.39 -106.01 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.65 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.641 ' N ' ' ND1' ' A' ' 118' ' ' HIS . 45.0 t -80.48 7.34 10.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.877 0.37 . . . . 0.0 110.735 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.69 30.61 20.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.128 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.3 tt -158.59 165.22 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.265 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.4 mmt85 -101.2 106.13 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.195 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.39 127.37 52.06 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -147.01 168.63 21.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 7.7 m120 59.54 39.92 21.03 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 120.792 0.329 . . . . 0.0 111.064 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.33 20.85 65.97 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -65.02 149.15 51.74 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 36.9 m -127.16 144.66 50.98 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.903 0.383 . . . . 0.0 110.403 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 37.1 t -82.55 124.39 30.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.568 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.408 ' CB ' HD11 ' A' ' 135' ' ' LEU . 48.2 t -148.18 111.67 4.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.472 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.9 49.98 17.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.067 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 57.41 34.55 24.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -144.48 139.54 28.36 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.508 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.4 m -88.05 126.89 35.33 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.408 HD11 ' CB ' ' A' ' 130' ' ' SER . 86.2 mt -95.25 126.85 40.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -103.02 137.88 40.62 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.683 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -83.27 175.34 9.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.437 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.533 ' NZ ' ' OE2' ' A' ' 151' ' ' GLU . 64.6 tttm -63.29 133.15 53.7 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.444 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.53 -24.52 28.48 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.459 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 95.1 m-85 -123.74 138.25 54.55 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.911 0.386 . . . . 0.0 110.55 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 16.7 pt -139.73 -168.93 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.496 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.97 165.29 31.43 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -46.25 88.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.742 0.306 . . . . 0.0 110.35 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -84.58 -1.42 55.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.612 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.496 ' O ' ' SG ' ' A' ' 145' ' ' CYS . 33.7 t 55.14 63.47 2.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -140.51 -4.18 1.26 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -86.48 114.54 58.21 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.385 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.49 156.2 36.37 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 122.295 1.997 . . . . 0.0 112.4 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.2 t -119.61 124.55 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 120.954 0.407 . . . . 0.0 110.197 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.3 107.54 20.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.2 -179.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 151' ' ' GLU . . . . . 0.533 ' OE2' ' NZ ' ' A' ' 138' ' ' LYS . 96.7 mt-10 -69.32 -38.23 78.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.101 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 94.7 p -85.38 -9.11 58.0 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.032 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 63.5 -163.82 31.1 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 71.8 m -116.12 152.24 34.04 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 96.9 mt -82.03 -1.95 50.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.49 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.527 ' C ' ' H ' ' A' ' 158' ' ' GLY . 32.8 t-20 -170.66 -147.62 0.05 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.336 179.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.511 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.64 26.99 0.49 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.527 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -64.23 175.51 11.21 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 78.1 ttt180 -128.14 136.64 51.42 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.65 0.262 . . . . 0.0 110.849 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 81.3 m -79.56 98.46 6.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 69.7 t -75.91 -44.1 38.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.533 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.649 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -145.13 174.26 3.61 Favored Pre-proline 0 C--N 1.331 -0.222 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.649 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.27 129.59 32.01 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 121.95 1.767 . . . . 0.0 112.102 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 52.37 32.87 11.83 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.984 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.1 ttt85 -138.84 127.56 23.42 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.314 0.578 . . . . 0.0 110.691 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 42.1 t -139.37 149.99 44.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.722 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.24 134.31 49.57 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.566 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 168' ' ' CYS . . . . . 0.644 ' SG ' ' N ' ' A' ' 178' ' ' GLU . 0.2 OUTLIER -81.0 120.28 24.58 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.846 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 12.1 m -70.38 -45.45 66.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.79 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -101.85 26.99 6.86 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.821 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.7 33.64 83.29 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -62.44 127.14 29.92 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -178.77 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 61.8 p -84.58 161.69 20.08 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.924 0.392 . . . . 0.0 110.979 -179.341 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 143.24 160.25 8.31 Favored Glycine 0 CA--C 1.531 1.033 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.0 -25.41 44.38 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.537 2.158 . . . . 0.0 112.689 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -76.28 -49.27 17.45 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.45 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.0 t -111.61 -104.93 0.38 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.736 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 178' ' ' GLU . . . . . 0.644 ' N ' ' SG ' ' A' ' 168' ' ' CYS . 81.1 tt0 . . . . . 0 C--N 1.325 -0.478 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.661 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' A' ' 44' ' ' ALA . 18.0 t . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.459 ' N ' ' OG ' ' A' ' 43' ' ' SER . . . -66.36 139.62 58.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.534 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -80.52 145.13 31.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.455 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.0 176.23 54.68 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -170.49 170.55 43.12 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -176.3 -168.51 36.55 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -63.72 172.17 14.86 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' HIS . . . . . 0.553 ' C ' ' HD1' ' A' ' 50' ' ' HIS . 0.8 OUTLIER -64.68 -44.65 89.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.709 0.29 . . . . 0.0 110.664 -179.633 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -64.22 -36.69 84.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.491 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.32 150.26 48.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.53 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 74.9 mt -63.2 143.97 57.33 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.067 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HZ1' ' HA ' ' A' ' 50' ' ' HIS . 64.0 mttp -104.77 162.83 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.952 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.27 161.05 20.51 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -78.76 3.51 7.25 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.725 2.283 . . . . 0.0 112.146 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.482 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 1.2 m-80 -123.51 68.69 1.02 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.77 0.319 . . . . 0.0 110.502 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.455 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.8 t -117.01 131.43 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-O 120.884 0.373 . . . . 0.0 110.032 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -142.56 175.96 9.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.333 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.83 170.28 46.86 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.538 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -77.77 167.66 21.19 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 43.7 ttm180 -60.98 -44.11 97.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.634 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -66.86 -39.3 87.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.225 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -121.91 47.45 1.89 Allowed 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.488 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.538 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -69.44 144.29 53.35 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.553 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.9 p90 -153.33 167.59 28.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.944 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 73' ' ' THR . 77.1 m -73.21 132.49 43.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.51 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.455 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 54.2 m -51.65 151.78 5.55 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.983 -179.1 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -46.37 129.35 13.28 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 C-N-CA 121.819 1.679 . . . . 0.0 112.424 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.93 -21.16 46.05 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.482 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 78.2 m95 -111.89 138.41 48.54 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.75 0.31 . . . . 0.0 110.279 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 ptpt -118.47 -176.05 3.0 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.324 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.511 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.5 p -106.94 153.71 22.15 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.493 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.509 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.1 mt -88.31 151.53 48.83 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.403 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.459 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.4 Cg_exo -39.04 105.47 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.187 1.925 . . . . 0.0 112.228 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.58 -9.2 2.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.16 168.94 47.36 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.443 ' OD1' ' NE2' ' A' ' 79' ' ' GLN . 42.7 p-10 -126.49 13.49 7.59 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.657 0.265 . . . . 0.0 110.784 179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLN . . . . . 0.443 ' NE2' ' OD1' ' A' ' 78' ' ' ASN . 10.8 mp0 -90.68 123.83 34.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.868 0.366 . . . . 0.0 110.898 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.48 68.57 4.87 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 27.2 pt -120.99 23.45 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.788 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.78 95.98 48.78 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.541 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.55 157.31 32.37 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.702 2.268 . . . . 0.0 112.236 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -111.63 131.53 62.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.755 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 28.6 m -84.78 139.4 31.97 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.408 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.439 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -63.04 -45.15 93.63 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.279 0.561 . . . . 0.0 110.251 -179.83 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -123.33 -118.08 0.29 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.29 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 t -143.81 133.71 23.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.35 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -94.05 -21.28 19.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.591 179.732 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.33 -99.18 0.7 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 39.5 p-10 -75.95 -1.71 26.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.772 0.32 . . . . 0.0 110.615 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.86 -175.29 26.79 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -141.12 153.86 45.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.934 0.397 . . . . 0.0 110.822 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.6 m -71.53 106.84 4.14 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.877 -179.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.7 p -96.69 -20.12 18.49 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.053 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mtt180 -162.14 168.92 10.11 Favored Pre-proline 0 C--O 1.235 0.329 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.987 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' PRO . . . . . 0.414 ' O ' ' CG ' ' A' ' 98' ' ' ASN . 52.4 Cg_exo -51.83 130.08 32.81 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 121.981 1.788 . . . . 0.0 110.827 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.439 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 12.6 p30 43.01 34.85 0.68 Allowed 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.692 0.62 . . . . 0.0 109.918 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 47.3 mmm -148.62 120.81 8.34 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 121.312 0.577 . . . . 0.0 110.571 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 13.8 p -119.82 161.68 20.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.023 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 77.8 m -119.41 128.08 53.71 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.431 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.46 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.1 OUTLIER -92.0 153.15 43.36 Favored Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.72 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 75.3 Cg_exo -46.45 -27.54 5.16 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.581 2.188 . . . . 0.0 112.011 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.8 t -63.43 -17.46 62.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.43 -3.01 63.32 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 106' ' ' GLN . . . . . 0.448 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 2.2 tm0? -81.0 148.54 29.69 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.785 0.326 . . . . 0.0 110.314 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.448 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 94.8 mt -122.06 135.18 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.549 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.685 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -176.74 175.69 0.6 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.691 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.685 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 45.6 Cg_exo -56.27 -25.78 58.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.769 2.313 . . . . 0.0 111.508 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.448 ' C ' ' H ' ' A' ' 112' ' ' GLY . 49.5 p -136.09 168.11 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.194 -179.362 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.0 OUTLIER -76.25 20.31 0.21 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.597 -178.727 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.448 ' H ' ' C ' ' A' ' 110' ' ' SER . . . -90.52 118.77 5.41 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 40.2 t -63.62 128.22 34.83 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.731 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 78.2 ttt-85 -68.57 -42.85 77.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.452 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.8 m -148.22 145.39 28.24 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.561 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.7 mt -64.7 -44.25 96.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.637 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -90.19 117.23 28.79 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.585 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' A' ' 119' ' ' CYS . 86.4 t60 -174.13 172.52 3.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.595 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.577 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 4.5 t -61.13 121.57 12.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.306 179.402 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.28 7.22 33.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.531 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.505 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 12.7 tt -130.44 166.29 28.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.505 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 16.1 mmm180 -100.98 125.22 47.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.304 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 82.6 m -118.29 129.21 55.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.941 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.0 mtm -140.97 166.84 23.68 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.339 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 58.48 41.31 22.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.03 74.38 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.16 145.12 49.44 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' SER . . . . . 0.505 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 30.3 t -102.39 128.33 49.03 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.745 0.307 . . . . 0.0 110.367 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 39.9 t -84.63 120.45 26.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.226 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 133' ' ' HIS . 39.7 t -142.35 136.37 29.58 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.305 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 39.88 -118.32 0.29 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.753 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -112.87 12.91 19.55 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.51 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' HIS . . . . . 0.456 ' O ' ' O ' ' A' ' 130' ' ' SER . 78.2 t60 -133.08 152.99 51.92 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.856 0.36 . . . . 0.0 110.469 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 128' ' ' SER . 7.8 t -120.71 148.64 43.67 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.19 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.7 mt -105.73 134.29 49.09 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.351 -179.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 22.3 m -97.68 141.18 31.02 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.131 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 94.8 mt-30 -73.39 170.72 14.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.729 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -66.67 132.89 49.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 105.52 -20.03 38.01 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -122.27 137.03 54.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.796 0.331 . . . . 0.0 110.322 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -127.85 170.26 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.103 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 118.65 163.31 12.47 Favored Glycine 0 N--CA 1.464 0.516 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.3 p -63.39 -41.42 98.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.338 . . . . 0.0 110.562 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.445 ' C ' ' SG ' ' A' ' 145' ' ' CYS . 4.8 m-70 -107.42 1.43 23.59 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.6 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.445 ' SG ' ' C ' ' A' ' 144' ' ' HIS . 1.8 m 71.14 140.65 0.05 OUTLIER 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.933 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 158.99 -26.95 0.38 Allowed Glycine 0 C--N 1.322 -0.224 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.64 117.1 67.71 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.45 -0.5 . . . . 0.0 110.482 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.51 153.39 39.36 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.432 2.088 . . . . 0.0 112.417 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 49.4 t -114.35 128.46 71.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.57 100.03 10.4 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.097 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 11.9 tm-20 -64.44 -36.73 85.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.274 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 80.0 p -83.6 -7.24 59.55 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 61.31 -168.89 10.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.1 m -140.41 115.87 10.05 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' LEU . . . . . 0.505 HD12 ' N ' ' A' ' 155' ' ' LEU . 10.7 mp -62.92 -42.07 99.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.663 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.547 ' C ' ' H ' ' A' ' 158' ' ' GLY . 63.9 t30 -93.45 173.34 7.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.524 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.17 34.6 0.31 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.547 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.03 174.42 26.02 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -123.75 138.25 54.55 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.807 0.337 . . . . 0.0 110.66 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 63.4 m -81.26 107.15 13.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.277 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.5 m -83.66 -29.98 7.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.547 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.677 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -158.93 172.38 6.21 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.54 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.677 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.5 Cg_exo -52.55 129.64 33.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.062 1.841 . . . . 0.0 111.926 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.1 m-20 53.55 33.96 17.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.601 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? -139.06 125.25 20.13 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.054 0.454 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -128.54 145.31 51.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -118.25 146.2 44.45 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.123 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 10.9 m -82.78 135.73 34.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.552 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 20.5 m -63.76 -45.4 90.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.85 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.69 22.65 10.64 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.011 0.434 . . . . 0.0 110.633 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 63.74 30.88 78.96 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -54.65 157.16 3.11 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.351 . . . . 0.0 110.353 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.15 140.47 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.284 0.564 . . . . 0.0 110.452 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 101.79 147.49 19.98 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.13 -31.31 36.73 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.591 2.194 . . . . 0.0 112.215 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.442 ' O ' ' O ' ' A' ' 177' ' ' CYS . 1.0 OUTLIER -88.12 -9.37 53.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.303 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.442 ' O ' ' O ' ' A' ' 176' ' ' GLN . 34.3 m 58.75 119.62 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.51 0 O-C-N 123.481 0.488 . . . . 0.0 109.933 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.878 -1.058 . . . . 0.0 110.488 179.902 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 66.2 m . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.05 56.63 0.76 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.401 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 80.8 mtp85 41.54 85.31 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.716 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.34 3.79 81.44 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -65.5 -27.29 72.4 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -56.08 -40.34 82.72 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.8 -166.24 38.47 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 50' ' ' HIS . . . . . 0.533 ' CG ' ' OD1' ' A' ' 78' ' ' ASN . 45.0 p-80 -69.35 135.84 50.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.89 0.376 . . . . 0.0 110.304 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -62.61 -42.84 99.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.816 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . 179.2 -167.78 0.08 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.344 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 15.9 mt -73.24 151.68 41.32 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.559 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -137.45 162.46 33.59 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.308 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.71 161.13 23.03 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.51 -4.84 15.84 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 C-N-CA 122.953 2.435 . . . . 0.0 112.234 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.463 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 20.5 m120 -112.54 74.42 0.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.074 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.462 HG13 ' O ' ' A' ' 58' ' ' VAL . 8.2 p -116.04 130.38 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.904 179.465 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -139.91 177.92 7.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.098 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.8 161.28 27.82 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.8 m -82.61 171.54 13.93 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.0 ttt-85 -59.21 -40.49 85.95 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.302 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -60.01 -40.2 88.44 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.68 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -135.56 52.51 2.01 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.699 -0.228 . . . . 0.0 110.944 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.4 141.88 52.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.791 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.409 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 9.7 p90 -158.7 172.35 18.42 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.2 0.524 . . . . 0.0 110.421 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.563 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 94.6 m -69.03 140.42 54.94 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.131 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.436 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 64.2 m -58.72 149.44 63.31 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -56.29 131.09 43.72 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 121.581 1.52 . . . . 0.0 112.291 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.55 -16.34 40.95 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.463 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 93.0 m95 -119.07 134.73 55.02 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-O 120.804 0.335 . . . . 0.0 110.228 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -115.04 -176.69 2.96 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.375 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.563 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 30.3 p -132.59 172.53 12.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.005 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.698 ' H ' HD12 ' A' ' 74' ' ' LEU . 0.2 OUTLIER -92.02 160.32 35.95 Favored Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.363 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.476 ' C ' ' H ' ' A' ' 77' ' ' GLY . 45.6 Cg_exo -53.83 132.5 49.84 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.591 1.528 . . . . 0.0 112.144 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.6 -8.01 1.83 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.56 178.77 38.4 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.533 ' OD1' ' CG ' ' A' ' 50' ' ' HIS . 29.4 m120 -146.9 16.77 1.23 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.006 0.431 . . . . 0.0 110.719 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -84.83 121.3 27.52 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.058 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 7.0 m -88.43 39.23 0.9 Allowed 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.2 -1.72 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.619 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 90.4 t -97.93 114.52 65.17 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.664 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -75.28 155.59 41.68 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 C-N-CA 121.982 1.788 . . . . 0.0 112.564 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 81.9 mt -106.42 124.44 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.192 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -106.16 115.84 30.92 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -64.15 -40.4 96.07 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.797 0.332 . . . . 0.0 110.686 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -117.0 149.39 40.32 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.537 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 m -66.22 138.2 57.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.501 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 40.5 m -79.02 -26.81 43.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.715 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.78 -104.2 2.17 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -78.6 -4.11 47.23 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.78 0.324 . . . . 0.0 110.97 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.59 -156.42 12.01 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.5 p90 -152.6 157.25 40.74 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.97 0.414 . . . . 0.0 111.023 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -64.1 112.95 3.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.052 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.432 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 91.9 p -102.83 -25.32 13.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.56 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -157.79 159.93 30.27 Favored Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.312 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -44.84 119.34 2.3 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 122.157 1.904 . . . . 0.0 111.607 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 66.2 t30 53.55 42.02 31.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.11 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mmm -148.39 118.76 7.35 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.915 0.388 . . . . 0.0 110.682 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 108' ' ' ALA . 17.7 m -100.79 146.14 27.64 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.149 178.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 101' ' ' THR . . . . . 0.432 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.0 m -122.24 123.94 42.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.627 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.401 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -87.74 156.84 52.69 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.644 -179.586 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.401 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -61.95 -19.95 67.76 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 122.469 2.113 . . . . 0.0 111.798 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -66.28 -17.23 64.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.459 179.116 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 107.12 -19.31 35.1 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -67.0 149.83 50.09 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.957 0.408 . . . . 0.0 110.253 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 94.7 mt -129.18 130.2 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.743 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.648 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.44 178.11 1.02 Allowed Pre-proline 0 CA--C 1.538 0.482 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.314 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.648 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 44.1 Cg_exo -57.67 -25.45 67.99 Favored 'Trans proline' 0 N--CA 1.499 1.837 0 C-N-CA 122.818 2.346 . . . . 0.0 111.968 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 95.5 p -149.83 162.33 40.51 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.499 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -26.85 48.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.667 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -124.09 78.18 0.36 Allowed Glycine 0 N--CA 1.467 0.745 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.4 t -61.82 -41.89 98.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.359 . . . . 0.0 110.335 179.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.7 mmm180 -127.14 145.22 50.83 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.657 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 93.1 p -99.6 -1.56 37.83 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.167 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.596 HG23 ' O ' ' A' ' 116' ' ' ILE . 21.1 tt -96.95 119.28 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.897 0.38 . . . . 0.0 110.061 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 117' ' ' GLN . . . . . 0.526 ' NE2' ' O ' ' A' ' 116' ' ' ILE . 99.3 mm-40 -142.18 41.71 1.65 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.17 -179.671 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.615 ' CG ' ' H ' ' A' ' 119' ' ' CYS . 59.1 t-80 -69.38 175.15 4.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.418 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.615 ' H ' ' CG ' ' A' ' 118' ' ' HIS . 0.8 OUTLIER -73.06 127.61 33.08 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.031 -179.607 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -98.5 13.73 30.77 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.745 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.625 HG22 ' N ' ' A' ' 122' ' ' ARG . 92.4 mt -119.24 165.52 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.204 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.625 ' N ' HG22 ' A' ' 121' ' ' ILE . 5.9 ptt85 -119.19 101.95 8.37 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.581 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 76.3 m -107.03 146.69 30.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.744 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.9 mtm -142.9 174.56 10.55 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.255 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 59.02 37.43 24.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.787 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 73.99 22.37 78.04 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.56 134.71 16.94 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 15.2 m -86.31 129.64 34.78 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 121.052 -0.259 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.413 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 4.3 t -87.12 85.28 7.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.574 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 133' ' ' HIS . 14.7 p -74.96 161.84 29.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.383 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -50.23 110.87 0.44 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.408 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.401 ' O ' ' CG ' ' A' ' 133' ' ' HIS . 98.6 m-20 52.35 28.59 5.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.555 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' HIS . . . . . 0.505 ' O ' ' N ' ' A' ' 130' ' ' SER . 31.5 m-70 -162.25 153.36 17.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.596 179.57 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 12.4 t -126.78 130.64 50.68 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.335 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.2 mt -102.06 131.07 48.74 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.902 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' CYS . . . . . 0.434 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 57.6 m -91.38 129.75 37.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.394 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -79.03 173.05 12.97 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.927 0.394 . . . . 0.0 110.575 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -63.42 134.2 55.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.334 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -21.62 37.79 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -129.02 139.62 51.98 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.772 0.32 . . . . 0.0 110.545 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 10.9 pt -134.09 176.79 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.986 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.434 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 107.52 169.08 21.88 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.5 m -62.08 -45.28 94.2 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.531 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.56 ' CE1' ' NH2' ' A' ' 122' ' ' ARG . 59.1 m80 -98.35 5.92 47.78 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.736 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 3.9 m 58.2 37.24 26.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -103.28 17.68 50.69 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 50.4 tp60 -119.19 96.73 50.22 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.754 0.277 . . . . 0.0 110.806 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -58.23 152.49 52.53 Favored 'Trans proline' 0 N--CA 1.499 1.819 0 C-N-CA 122.583 2.189 . . . . 0.0 111.916 178.716 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 70.8 t -89.94 129.76 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-O 121.048 0.452 . . . . 0.0 110.325 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.4 m -103.11 86.47 2.7 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -62.32 -46.43 88.77 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.267 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 90.0 p -111.99 -21.21 11.67 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.964 0.411 . . . . 0.0 110.502 179.25 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 49.67 177.91 0.02 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.6 m -98.54 139.8 33.73 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.934 0.397 . . . . 0.0 110.184 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 92.5 mt -63.22 -40.99 99.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.626 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.522 ' ND2' ' H ' ' A' ' 169' ' ' THR . 51.9 p30 -82.37 178.68 8.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.376 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.92 42.26 0.35 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.2 -176.57 19.15 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -130.15 142.18 50.61 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 98.6 m -76.69 102.45 6.19 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.037 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.8 t -83.17 -50.62 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.221 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.625 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -135.65 177.31 2.28 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.178 -178.935 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.625 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.71 133.12 52.73 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.821 1.68 . . . . 0.0 111.489 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 47.9 23.02 0.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.643 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -132.68 140.58 48.2 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.439 0.638 . . . . 0.0 111.025 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 5.8 p -149.1 155.69 41.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.379 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -89.92 143.88 26.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.65 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 168' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 66.1 m -85.05 155.14 21.66 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.612 -179.246 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.522 ' H ' ' ND2' ' A' ' 156' ' ' ASN . 97.9 m -62.08 -45.7 92.36 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.168 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.45 22.55 15.64 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.992 0.425 . . . . 0.0 111.262 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.13 35.09 91.31 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.408 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 2.7 m-85 -68.32 146.99 52.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.117 0.484 . . . . 0.0 110.643 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 60.6 p -81.58 166.67 20.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.179 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 91.28 154.62 30.81 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -67.83 -20.97 45.06 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.609 2.206 . . . . 0.0 112.405 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.476 ' C ' ' H ' ' A' ' 178' ' ' GLU . 75.0 mt-30 -111.26 18.79 18.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.737 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 79.7 m 50.19 11.55 0.07 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.29 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 178' ' ' GLU . . . . . 0.476 ' H ' ' C ' ' A' ' 176' ' ' GLN . 80.8 tt0 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.573 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 25.2 t . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.23 141.66 57.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.523 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ARG . . . . . 0.406 ' NH1' ' O ' ' A' ' 46' ' ' GLY . 22.6 tpt85 -74.11 131.72 41.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.421 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' O ' ' NH1' ' A' ' 45' ' ' ARG . . . -96.29 164.19 23.32 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 56.71 -137.1 48.99 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.33 168.71 40.59 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.11 167.86 44.13 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.689 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 34.0 m170 -134.57 141.08 46.56 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.81 0.338 . . . . 0.0 110.471 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.436 ' O ' ' O ' ' A' ' 52' ' ' ALA . 98.0 m-20 -70.26 -19.21 63.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.622 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.436 ' O ' ' O ' ' A' ' 51' ' ' ASP . . . 56.7 155.94 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.647 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.42 150.11 38.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.629 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -130.23 160.46 33.81 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 121.125 0.488 . . . . 0.0 110.142 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.6 174.76 36.46 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.04 -172.3 0.97 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.898 2.399 . . . . 0.0 111.81 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.402 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 24.5 m120 59.16 38.95 23.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.997 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.46 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 11.8 p -98.69 131.59 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.278 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -141.5 -178.75 5.78 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.251 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.47 162.3 29.03 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 13.6 m -82.52 172.84 12.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.4 ttt-85 -60.86 -43.03 98.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.483 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -62.12 -39.62 93.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.567 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -133.02 55.2 1.91 Allowed 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.669 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.2 142.29 52.45 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -155.21 169.56 23.89 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.997 0.427 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.453 ' SG ' HG22 ' A' ' 73' ' ' THR . 71.8 m -74.14 139.72 44.72 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.188 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.46 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 61.9 m -56.81 153.63 21.68 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.252 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.78 131.87 35.15 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 121.244 1.296 . . . . 0.0 112.203 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.92 -18.82 51.55 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.556 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 8.9 m95 -119.01 140.04 50.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.746 0.308 . . . . 0.0 110.649 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -121.6 -175.84 3.18 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.453 HG22 ' SG ' ' A' ' 67' ' ' CYS . 60.8 p -108.81 154.12 22.53 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.482 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.9 mt -83.37 152.43 64.3 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.688 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.406 ' C ' ' H ' ' A' ' 77' ' ' GLY . 74.0 Cg_exo -41.3 110.33 0.13 Allowed 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.017 1.811 . . . . 0.0 112.197 179.125 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.36 -4.78 7.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -89.09 173.64 41.37 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -135.94 11.96 3.37 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.969 0.414 . . . . 0.0 111.059 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -89.61 126.64 35.7 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.552 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -89.61 69.1 7.79 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.8 pt -122.05 21.78 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.96 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -118.87 86.72 31.48 Favored Pre-proline 0 N--CA 1.464 0.251 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.793 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.47 150.76 83.74 Favored 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.773 2.315 . . . . 0.0 111.994 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.495 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.4 mt -106.05 128.74 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.439 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 5.9 m -89.62 135.67 33.48 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.49 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.4 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.04 -45.59 92.89 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.18 0.514 . . . . 0.0 109.758 -179.208 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -119.0 167.86 11.36 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.64 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 96.4 p -57.15 137.81 55.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.544 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 31.5 m -86.06 -32.96 21.12 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.863 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.77 -108.91 2.74 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -93.74 0.96 56.62 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.744 0.306 . . . . 0.0 111.066 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.62 -176.25 31.12 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.449 ' C ' ' SG ' ' A' ' 100' ' ' CYS . 44.8 p90 -135.18 145.39 47.69 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.114 0.483 . . . . 0.0 110.902 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 85' ' ' CYS . 0.5 OUTLIER -70.11 113.41 7.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.54 -178.786 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 33.9 m -99.79 -21.04 15.92 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.535 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.0 mtt180 -160.2 164.74 19.11 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.662 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.22 127.85 25.19 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 121.676 1.584 . . . . 0.0 111.474 179.064 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.4 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 63.9 m-20 50.52 35.36 11.15 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.874 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 68.3 mmm -150.26 122.05 8.11 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.416 0.627 . . . . 0.0 110.485 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.449 ' SG ' ' C ' ' A' ' 93' ' ' PHE . 0.7 OUTLIER -120.79 161.64 21.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.059 179.65 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.5 m -127.75 127.45 43.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.693 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.94 156.7 36.9 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.24 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -50.89 -26.2 17.55 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.252 1.968 . . . . 0.0 111.896 177.975 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.12 -17.76 64.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.859 0.361 . . . . 0.0 110.489 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.1 -16.43 53.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.3 tp60 -63.91 150.34 45.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.909 0.385 . . . . 0.0 110.07 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.49 131.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.641 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -179.51 174.5 0.47 Allowed Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.558 178.798 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.641 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 40.6 Cg_exo -57.32 -22.03 47.39 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.708 2.272 . . . . 0.0 111.751 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.5 p -140.16 159.98 40.98 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.754 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.43 -32.01 48.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.452 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -175.85 -178.37 45.61 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 93.2 p -82.16 -6.42 59.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.659 0.266 . . . . 0.0 110.526 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.409 ' O ' ' O ' ' A' ' 115' ' ' SER . 75.9 ttt180 -65.73 123.62 20.23 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 115' ' ' SER . 14.2 p 38.31 93.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.4 pt -96.57 -4.56 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 -69.78 130.65 42.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.411 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.425 ' CG ' ' N ' ' A' ' 119' ' ' CYS . 47.1 p-80 -65.91 -44.45 85.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.471 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.425 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 14.9 m -138.57 138.78 38.26 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.998 0.428 . . . . 0.0 110.974 179.617 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -65.11 -40.55 94.67 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.26 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 25.3 pt -92.8 -170.83 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.624 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -107.53 108.56 19.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.215 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 57.7 m -114.81 139.39 49.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.992 178.671 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 90.0 mtp -138.97 168.23 20.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 2.4 m-20 59.56 41.75 18.47 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.249 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.7 20.21 79.6 Favored Glycine 0 CA--C 1.52 0.375 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.23 156.57 52.35 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.4 m -133.29 146.64 51.55 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.733 0.301 . . . . 0.0 110.247 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 7.6 p -91.53 130.1 37.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.377 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.6 t -148.11 137.69 22.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.058 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' OD2' ' O ' ' A' ' 131' ' ' ASP . 3.7 p-10 45.01 41.29 5.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.006 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t0 62.0 36.69 15.4 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.637 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 69.1 t60 -150.02 140.59 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.585 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 9.4 t -88.55 130.92 35.13 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.48 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.6 mt -105.4 130.51 53.48 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 15.6 m -101.88 145.39 29.29 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.518 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.89 175.39 9.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.742 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -66.14 129.92 41.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.54 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.84 -20.06 44.96 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -120.28 134.57 55.24 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.792 0.329 . . . . 0.0 110.235 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.93 173.32 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.227 -179.577 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 107.01 164.29 22.18 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 43.5 p -61.4 -44.78 96.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.754 0.311 . . . . 0.0 110.491 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 3.0 p-80 -98.52 14.41 28.39 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.431 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.525 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 5.2 m 46.39 43.4 11.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.11 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.74 12.31 42.1 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -121.45 119.28 29.44 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.63 0.215 . . . . 0.0 110.972 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -76.44 157.69 36.7 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.676 2.25 . . . . 0.0 112.266 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.0 t -99.31 111.19 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 121.015 0.436 . . . . 0.0 110.653 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.53 90.63 8.08 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.0 tt0 -70.18 -39.15 75.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.546 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 10.6 m -88.39 -12.9 41.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.65 161.4 0.02 OUTLIER Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 160' ' ' CYS . 25.6 m -106.55 159.18 16.37 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 155' ' ' LEU . . . . . 0.42 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 56.7 mt -62.37 -42.87 99.75 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.244 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.42 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 t-20 161.67 -58.92 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.747 0.654 . . . . 0.0 110.61 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.03 -42.21 99.72 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -71.41 168.83 50.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 22.8 mmm180 -130.03 149.07 51.91 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.912 0.386 . . . . 0.0 110.21 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 87.9 m -81.15 95.16 6.8 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.668 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 41.6 t -79.48 -47.86 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.577 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.676 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.24 177.79 2.06 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.341 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.676 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -55.08 134.85 66.07 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.833 1.689 . . . . 0.0 111.597 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 40.78 33.53 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.948 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -132.7 104.49 6.66 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 121.364 0.602 . . . . 0.0 111.316 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.16 132.15 36.85 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.151 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -92.7 141.1 28.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.029 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.4 m -90.99 132.87 35.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.098 0.475 . . . . 0.0 110.757 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.9 m -63.64 -46.29 86.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.496 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -104.36 24.04 12.22 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.952 0.405 . . . . 0.0 111.246 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 62.42 29.86 74.58 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -54.67 168.0 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.04 0.448 . . . . 0.0 110.508 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.4 p -81.89 164.66 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.217 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.06 151.81 0.14 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.77 -24.8 40.29 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.375 2.05 . . . . 0.0 112.232 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 177' ' ' CYS . 85.2 mt-30 -84.09 -11.38 56.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.556 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 176' ' ' GLN . 10.1 m 59.56 124.5 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.47 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.414 179.592 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 48.11 46.97 19.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.443 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 88.5 mtm-85 50.87 81.12 0.07 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.59 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.32 -169.91 37.64 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 143.28 -10.57 2.24 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 62.23 -129.22 42.96 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 86.21 5.18 83.19 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -86.8 -9.17 56.45 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.737 0.303 . . . . 0.0 110.637 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -85.42 112.03 20.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.971 0.415 . . . . 0.0 110.625 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.41 69.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.518 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.405 HD12 ' HB1' ' A' ' 65' ' ' ALA . 96.2 mt -68.98 143.73 54.31 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.995 0.426 . . . . 0.0 110.421 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -131.72 161.73 32.14 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.565 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.79 172.73 22.25 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.52 -167.46 0.18 Allowed 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 122.924 2.416 . . . . 0.0 111.885 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.581 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 5.2 m120 58.2 37.0 26.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.535 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.481 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 13.3 p -100.41 134.15 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 109.95 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 57.6 m -142.98 177.46 8.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.275 -179.186 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.55 162.64 31.83 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 65' ' ' ALA . 11.8 m -80.46 173.72 12.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.628 0.252 . . . . 0.0 110.465 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -60.6 -44.12 96.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.74 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -64.72 -39.26 93.34 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.421 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 58.6 t30 -125.39 51.12 1.73 Allowed 'General case' 0 CA--C 1.522 -0.113 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.819 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.5 142.52 50.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.466 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.421 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 10.2 p90 -160.2 167.54 27.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.219 0.533 . . . . 0.0 111.189 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.547 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 74.6 m -71.13 141.22 50.78 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.35 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.481 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 65.2 m -58.94 150.85 58.44 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.973 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -56.0 128.56 30.76 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.835 1.69 . . . . 0.0 112.037 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.1 47.02 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.581 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.3 m95 -125.39 135.29 52.24 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.025 0.441 . . . . 0.0 110.527 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -119.76 -177.36 3.37 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.437 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.547 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 19.2 p -129.24 165.6 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.285 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.5 mt -84.46 149.89 55.82 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.723 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -43.02 120.46 1.94 Allowed 'Trans proline' 0 N--CA 1.489 1.242 0 C-N-CA 121.881 1.721 . . . . 0.0 112.312 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.4 -0.25 55.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.901 -0.879 . . . . 0.0 110.901 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -89.84 171.17 37.27 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -136.64 2.15 2.64 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.038 0.447 . . . . 0.0 110.836 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -82.22 131.66 35.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.191 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.3 m -99.21 43.49 1.06 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -98.89 2.68 10.49 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.362 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.61 110.37 60.25 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.611 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -73.39 158.52 48.11 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.202 1.934 . . . . 0.0 112.226 -179.651 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -104.14 124.74 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.081 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.55 127.2 36.18 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.94 -45.29 93.15 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -136.81 154.96 50.39 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 17.0 m -60.08 136.39 58.0 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.321 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 1.8 t -94.03 4.04 54.47 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.562 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 61.73 -100.02 0.25 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.402 ' OD1' ' SG ' ' A' ' 102' ' ' CYS . 37.7 p30 -90.73 8.47 34.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.699 0.285 . . . . 0.0 110.838 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.87 -173.46 29.15 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.433 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -142.41 154.16 44.36 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.073 0.464 . . . . 0.0 110.9 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.8 m -72.15 106.42 4.36 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.804 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.433 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 2.1 m -95.9 -24.3 16.48 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.671 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.9 mtm-85 -159.96 167.17 14.49 Favored Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.891 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -51.96 125.4 17.07 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.73 1.62 . . . . 0.0 111.311 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 50.81 34.7 10.64 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.552 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.2 mmm -149.69 124.13 9.65 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.286 0.565 . . . . 0.0 110.614 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 10.1 p -123.92 163.58 21.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.794 179.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 94.8 m -125.46 130.63 52.19 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.705 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.402 ' SG ' ' OD1' ' A' ' 91' ' ' ASP . 0.1 OUTLIER -94.28 155.74 39.56 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -48.01 -29.6 12.39 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.443 2.095 . . . . 0.0 112.133 177.368 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 37.5 m -62.63 -19.87 64.22 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.975 0.417 . . . . 0.0 110.688 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.4 57.27 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -70.94 152.0 44.09 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 110.168 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.36 131.55 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.57 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.67 178.22 0.55 Allowed Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.584 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 31.6 Cg_exo -59.97 -18.57 50.84 Favored 'Trans proline' 0 N--CA 1.5 1.911 0 C-N-CA 122.794 2.329 . . . . 0.0 111.588 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.4 p -149.6 164.65 34.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.5 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.5 OUTLIER -79.42 132.1 36.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.5 -179.531 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 113' ' ' SER . . . 50.92 -176.46 0.06 OUTLIER Glycine 0 CA--C 1.521 0.45 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.204 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 112' ' ' GLY . 2.4 p 58.09 132.91 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.897 0.38 . . . . 0.0 110.637 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -99.66 135.01 41.71 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.293 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 20.3 m -71.07 143.09 50.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.385 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 95.0 mt -64.13 -44.26 97.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.711 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -169.23 145.23 3.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.621 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 60.9 t-80 -66.07 -44.98 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.679 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 95.2 m -80.36 97.34 7.0 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.182 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -63.91 -40.08 95.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.41 HG22 ' N ' ' A' ' 122' ' ' ARG . 21.0 mm -80.7 160.23 4.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.152 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.41 ' N ' HG22 ' A' ' 121' ' ' ILE . 88.8 mmt-85 -81.73 98.52 8.46 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.184 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -105.64 122.24 45.63 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -141.78 167.63 21.69 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.845 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.19 37.95 23.7 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.79 22.29 61.96 Favored Glycine 0 CA--C 1.522 0.485 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.06 119.25 9.44 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 7.3 m -80.2 138.59 36.88 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.487 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 22.6 m -91.08 128.48 36.92 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.774 0.321 . . . . 0.0 110.378 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.4 m -141.6 140.02 33.24 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' SER . 97.2 m-20 36.11 -97.15 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.965 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -136.02 22.25 3.27 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.728 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -132.48 147.04 52.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.496 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.98 125.65 44.49 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.861 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.1 mt -103.9 131.53 51.03 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.37 143.69 29.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.738 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -68.19 -174.77 0.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.319 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 27.8 tptp -69.02 132.09 46.09 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.541 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 96.93 -8.4 65.37 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -118.58 136.29 53.95 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.856 0.36 . . . . 0.0 110.559 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.7 pt -134.29 172.47 16.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.064 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 104.42 160.73 24.19 Favored Glycine 0 N--CA 1.461 0.342 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' THR . . . . . 0.436 ' H ' HG22 ' A' ' 143' ' ' THR . 0.1 OUTLIER -65.34 -42.74 92.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.738 0.304 . . . . 0.0 110.547 -179.897 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -97.13 5.17 50.69 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 31.0 m 58.12 37.31 26.38 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.371 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -100.73 5.28 56.67 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -119.8 107.8 39.83 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.801 0.3 . . . . 0.0 110.601 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.23 159.85 29.71 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 C-N-CA 122.65 2.233 . . . . 0.0 112.127 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.4 t -97.88 105.18 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -86.47 100.04 12.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.657 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -66.29 -45.57 79.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.283 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' SER . . . . . 0.443 ' O ' ' O ' ' A' ' 153' ' ' GLY . 23.4 t -89.53 -16.7 30.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.702 0.287 . . . . 0.0 110.883 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.49 156.15 0.01 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 10.9 m -93.95 133.08 37.76 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 64.3 mt -62.31 -43.9 97.76 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.189 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 178.23 -60.79 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 O-C-N 123.615 0.572 . . . . 0.0 110.52 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.84 51.13 1.54 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -166.82 154.62 25.18 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -123.25 129.32 51.21 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 2.4 t -75.33 102.84 5.23 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.068 0.461 . . . . 0.0 110.69 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.573 ' O ' HG22 ' A' ' 161' ' ' VAL . 4.6 p -107.34 -2.91 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.412 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.6 171.65 4.47 Favored Pre-proline 0 C--N 1.322 -0.599 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.581 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.6 Cg_exo -52.15 128.8 28.52 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 121.773 1.649 . . . . 0.0 111.395 178.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 40.93 36.14 0.4 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.682 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.528 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.8 OUTLIER -127.07 110.27 12.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.228 0.537 . . . . 0.0 110.409 -179.447 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.528 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 66.5 m -105.07 124.64 49.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.751 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -85.09 91.06 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.655 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.23 118.11 35.91 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.436 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.4 OUTLIER -111.27 11.36 21.7 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.63 -179.529 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.529 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 47.2 t80 -109.07 31.28 5.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.153 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 105.91 58.76 0.63 Allowed Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -53.02 126.12 19.53 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.534 -0.467 . . . . 0.0 110.325 -179.156 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.444 ' O ' ' O ' ' A' ' 174' ' ' GLY . 3.0 t -149.09 150.37 32.64 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.498 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 173' ' ' THR . . . 53.36 165.85 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.09 -18.66 45.73 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.83 2.353 . . . . 0.0 112.112 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -92.15 47.9 1.37 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.094 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 173' ' ' THR . 53.2 t 57.88 -89.27 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.697 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.483 179.572 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 80.8 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.67 141.17 58.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.214 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -128.97 127.68 42.19 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.311 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.11 177.13 31.1 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -82.22 -146.12 5.69 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -169.16 169.09 41.7 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 85.03 104.86 0.65 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -155.7 159.73 39.77 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.681 0.277 . . . . 0.0 110.41 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -92.21 108.95 20.32 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.211 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.518 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -102.61 156.35 17.68 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.443 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.469 HD12 ' HB1' ' A' ' 65' ' ' ALA . 88.9 mt -74.02 141.24 45.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.724 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.44 160.67 28.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.355 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.18 174.8 38.37 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.47 -169.36 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.991 2.461 . . . . 0.0 111.627 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 57.52 38.56 28.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.907 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.42 HG13 ' O ' ' A' ' 58' ' ' VAL . 12.0 p -99.91 130.8 48.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 59' ' ' CYS . . . . . 0.438 ' O ' ' O ' ' A' ' 66' ' ' TYR . 52.7 m -145.64 175.58 10.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.613 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.23 167.1 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -75.06 165.04 25.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.623 0.249 . . . . 0.0 110.391 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.8 ttt180 -60.89 -44.2 97.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.653 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -66.24 -39.24 89.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -123.84 49.91 1.69 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.645 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.95 143.88 50.73 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.47 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.438 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -159.38 166.59 30.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.991 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 53.9 m -72.66 133.24 44.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.763 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -45.62 162.52 0.23 Allowed Pre-proline 0 CA--C 1.538 0.494 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -55.12 134.36 63.32 Favored 'Trans proline' 0 N--CA 1.495 1.604 0 C-N-CA 122.547 2.165 . . . . 0.0 111.68 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.65 -14.67 64.5 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -115.88 141.64 47.83 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.81 0.338 . . . . 0.0 110.239 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -125.7 -157.99 0.82 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.138 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 73.3 p -127.23 164.46 21.64 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.945 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.2 mt -87.09 152.05 52.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.414 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.7 Cg_exo -40.66 105.98 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.146 1.897 . . . . 0.0 111.939 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.65 -12.33 6.19 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.05 176.65 53.89 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 44.9 p30 -134.66 11.22 3.72 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.803 0.335 . . . . 0.0 110.744 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -82.37 130.62 35.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.474 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 79.7 m -90.96 47.66 1.43 Allowed 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.811 0.339 . . . . 0.0 110.308 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 38.4 pt -107.39 24.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.49 94.07 48.62 Favored Pre-proline 0 CA--C 1.537 0.449 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.249 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.85 156.82 24.05 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.463 2.108 . . . . 0.0 111.981 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -101.99 125.77 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.025 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.03 119.28 38.52 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -45.37 94.74 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.969 0.414 . . . . 0.0 109.981 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -114.09 144.59 42.89 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.533 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.9 m -62.51 134.99 57.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.249 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 37.8 m -77.16 -31.72 55.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.633 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.08 -106.78 2.26 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.42 -8.01 52.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.664 0.269 . . . . 0.0 110.719 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.88 -161.48 18.81 Favored Glycine 0 N--CA 1.463 0.46 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.513 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -146.84 153.06 39.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.028 0.442 . . . . 0.0 110.755 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.25 114.56 5.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.28 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.513 ' OG ' ' CE2' ' A' ' 93' ' ' PHE . 75.7 m -105.11 -22.54 13.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.443 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 3.0 mtt180 -156.34 160.95 30.41 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.796 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -47.47 118.24 2.81 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 122.138 1.892 . . . . 0.0 111.519 179.04 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 62.1 t30 54.27 41.67 31.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.344 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 77.0 mtp -148.33 120.13 8.12 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.367 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' ALA . 46.5 m -103.75 148.95 25.47 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.831 179.382 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 101' ' ' THR . . . . . 0.403 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 97.5 m -118.51 123.06 44.2 Favored 'General case' 0 CA--C 1.515 -0.385 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.57 147.84 35.06 Favored Pre-proline 0 CA--C 1.541 0.598 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.651 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -47.39 -23.97 3.69 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.636 2.224 . . . . 0.0 112.09 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.9 t -64.35 -17.3 63.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.767 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.61 -14.99 56.26 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 59.6 tp60 -73.08 152.25 41.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.896 0.379 . . . . 0.0 110.248 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 91.4 mt -126.59 131.95 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.546 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.05 173.32 1.2 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.448 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 49.4 Cg_exo -55.08 -28.37 60.07 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.719 2.279 . . . . 0.0 112.142 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 p -136.61 164.25 28.64 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.567 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.05 145.68 33.71 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.648 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -139.59 58.89 0.59 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 85.8 p -66.26 -16.31 63.92 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.73 0.3 . . . . 0.0 110.209 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -44.51 125.52 4.81 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.629 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 84.4 p -76.71 160.9 28.95 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.521 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.5 mt -119.15 123.75 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.335 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -171.8 90.32 0.12 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.478 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 57.0 m170 42.31 -162.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.557 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 93.7 m -94.65 134.33 37.34 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.953 0.406 . . . . 0.0 110.7 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 46.1 t30 -161.75 29.59 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.442 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 18.5 tt -121.13 171.09 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.441 -179.238 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.442 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 27.2 mmt180 -95.86 127.46 41.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.928 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 85.0 m -117.52 134.78 54.48 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.971 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtt -138.24 156.53 47.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.231 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 58.92 51.47 7.31 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.059 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 66.48 26.9 72.84 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.52 139.5 35.45 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' SER . . . . . 0.51 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 51.5 m -110.3 141.75 42.87 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.2 t -85.01 126.16 33.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 0.0 110.621 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.457 ' O ' ' O ' ' A' ' 133' ' ' HIS . 11.4 p -148.5 127.91 13.09 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.448 0.642 . . . . 0.0 111.01 179.527 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.444 ' O ' ' CB ' ' A' ' 132' ' ' ASP . 9.6 t70 50.18 42.79 25.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.562 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 131' ' ' ASP . 9.5 t0 78.29 -40.68 0.29 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 133' ' ' HIS . . . . . 0.682 ' CD2' ' O ' ' A' ' 133' ' ' HIS . 3.9 p-80 -85.42 147.64 26.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.971 0.415 . . . . 0.0 110.531 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.3 t -99.93 149.09 23.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.847 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.5 137.27 49.54 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.25 144.67 27.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.481 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -59.95 176.13 0.33 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.658 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 49.7 tttm -66.61 131.22 45.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.641 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 99.01 -15.86 60.1 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -111.28 136.44 50.38 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.791 0.329 . . . . 0.0 110.35 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.45 171.7 17.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.973 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.72 158.36 10.58 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 98.6 m -62.53 -46.39 88.62 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.916 -0.314 . . . . 0.0 110.715 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 96.3 m-70 -105.28 11.82 32.48 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.491 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 14.6 m 60.68 139.13 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.809 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 153.13 -1.15 0.24 Allowed Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -113.09 108.66 52.84 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 121.303 -0.159 . . . . 0.0 110.785 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -77.43 159.32 32.61 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.676 2.25 . . . . 0.0 111.909 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 81.9 t -120.81 120.49 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-O 121.009 0.433 . . . . 0.0 110.12 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 60.5 m -91.44 114.65 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.56 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -64.03 -42.22 97.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.88 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.1 p -86.27 -6.36 58.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.532 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.11 166.31 0.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 73.4 m -100.27 102.9 14.29 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.879 0.371 . . . . 0.0 110.067 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.8 mt -63.62 -41.98 98.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.552 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.557 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.5 t30 -93.28 -176.97 4.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.387 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.523 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.79 23.25 0.41 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.557 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.41 174.99 26.35 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 52.3 mmm-85 -127.42 147.12 50.29 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.695 0.283 . . . . 0.0 110.449 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 21.5 m -86.01 111.67 20.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.09 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -97.16 -16.26 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.331 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.633 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -168.34 173.65 2.56 Favored Pre-proline 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.71 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.633 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.7 Cg_exo -57.08 135.65 71.92 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.068 1.845 . . . . 0.0 112.029 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.8 t30 44.43 32.79 0.77 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.837 179.295 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.86 101.0 3.77 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.386 0.612 . . . . 0.0 111.152 179.077 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 31.2 t -101.81 148.2 25.58 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.284 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.0 137.37 39.45 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.88 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 87.8 m -81.7 150.34 28.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.822 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.4 m -61.72 -45.99 91.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.735 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.541 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 53.3 t80 -110.36 25.71 11.48 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.058 0.456 . . . . 0.0 110.694 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 67.13 30.51 75.83 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' A' ' 173' ' ' THR . 65.9 t80 -58.76 159.35 6.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.83 0.348 . . . . 0.0 110.444 -179.522 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 8.1 p -81.94 167.09 19.29 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.392 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 104.36 142.0 11.36 Favored Glycine 0 CA--C 1.535 1.287 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.06 -33.01 20.23 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 122.524 2.149 . . . . 0.0 112.596 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.419 ' O ' ' O ' ' A' ' 177' ' ' CYS . 20.8 pt20 -108.05 1.15 22.2 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.566 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.419 ' O ' ' O ' ' A' ' 176' ' ' GLN . 1.1 t 57.17 159.8 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.421 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.257 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 m . . . . . 0 N--CA 1.491 1.624 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.74 146.28 54.63 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.734 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 86.9 mtm180 45.59 31.93 1.05 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.491 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -153.13 91.69 0.13 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -88.24 134.95 12.76 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -104.22 118.64 6.03 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 80.04 166.53 33.8 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -103.91 -55.07 2.44 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.735 0.302 . . . . 0.0 110.447 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -92.15 93.87 8.92 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -178.29 138.58 0.19 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.62 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 78.2 mt -78.57 149.04 33.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.967 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -138.5 159.84 41.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.526 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.58 169.1 29.22 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.59 -168.79 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.938 2.426 . . . . 0.0 111.821 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.626 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 46.4 m-80 59.35 41.04 20.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.743 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.43 HG13 ' O ' ' A' ' 58' ' ' VAL . 11.4 p -105.33 131.69 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.6 m -141.88 -175.45 4.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.128 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.37 173.5 49.71 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.746 -0.941 . . . . 0.0 110.746 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.4 m -72.88 155.96 39.36 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -58.99 -43.2 91.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.775 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.23 -41.87 98.8 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.173 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 95.2 m-20 -127.74 50.65 2.01 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.723 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.03 151.36 47.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.28 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -154.67 164.94 38.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.158 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.434 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 69.0 m -63.41 128.99 38.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.783 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 12.4 m -48.53 150.92 2.18 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.34 -178.915 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.61 133.5 38.37 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 121.572 1.514 . . . . 0.0 112.178 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.26 -7.94 64.42 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.626 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 54.6 m95 -118.89 138.71 52.57 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 110.592 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -127.83 -176.05 3.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.412 179.278 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.434 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 5.4 p -133.46 177.99 7.27 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.54 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 48.6 mt -89.91 148.86 40.67 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.507 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.41 116.16 0.47 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.108 1.872 . . . . 0.0 112.491 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.19 -4.56 54.3 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.33 171.1 43.59 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 19.5 p30 -133.58 9.19 3.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.977 0.418 . . . . 0.0 110.811 179.929 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -87.28 132.33 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.487 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -97.88 40.0 1.19 Allowed 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 35.4 pt -97.24 12.93 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.855 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.6 t -116.29 87.98 21.65 Favored Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.471 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo -60.69 148.87 90.23 Favored 'Trans proline' 0 N--CA 1.496 1.659 0 C-N-CA 122.819 2.346 . . . . 0.0 111.987 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 91.9 mt -89.17 123.55 41.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.47 110.1 22.74 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.17 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 2.1 mpt_? -65.31 -39.08 92.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.025 0.441 . . . . 0.0 110.328 178.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -119.05 143.36 47.15 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.104 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.7 p -60.86 134.46 57.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.397 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 60.3 m -77.89 -28.07 49.78 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.706 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.4 -102.56 1.74 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -89.19 2.37 54.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.658 0.266 . . . . 0.0 110.639 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.29 -168.86 22.96 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -138.71 150.53 46.26 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.124 0.488 . . . . 0.0 110.854 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 90.8 m -65.89 112.86 3.99 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.33 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 t -107.29 -25.87 11.29 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.467 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.4 mtt-85 -158.09 164.3 21.79 Favored Pre-proline 0 C--N 1.328 -0.334 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.66 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -51.01 121.77 8.79 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.96 1.773 . . . . 0.0 111.485 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 52.09 40.83 29.35 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 48.7 mtt -146.9 114.91 6.54 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.699 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' ALA . 65.3 m -100.05 146.84 26.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.232 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 66.6 m -115.61 121.6 43.09 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.87 149.55 37.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.498 -179.464 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.65 -21.81 2.58 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.567 2.178 . . . . 0.0 111.974 177.484 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.8 t -68.02 -17.91 64.55 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.8 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.87 -14.68 57.34 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -68.42 153.82 43.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.974 0.416 . . . . 0.0 110.243 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.42 133.15 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.677 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.637 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . 179.71 168.49 0.69 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.301 178.995 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.637 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 64.7 Cg_exo -48.8 -33.76 26.02 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 122.597 2.198 . . . . 0.0 112.083 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 38.8 m -133.01 165.6 24.34 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.538 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -78.18 123.69 27.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.484 . . . . 0.0 109.84 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 78.96 95.51 0.28 Allowed Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 10.3 t -152.33 -161.13 1.24 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.872 0.368 . . . . 0.0 110.54 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.9 148.47 46.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.482 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 66.4 m -128.48 148.55 50.74 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.121 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.889 HD13 ' H ' ' A' ' 116' ' ' ILE . 0.1 OUTLIER -133.2 165.1 33.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.467 -179.437 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -68.58 139.46 55.56 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.107 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.537 ' C ' ' H ' ' A' ' 120' ' ' ASN . 76.1 m80 -112.07 153.76 26.42 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.406 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.445 ' C ' ' H ' ' A' ' 121' ' ' ILE . 12.1 t -62.36 4.52 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.944 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' ASN . . . . . 0.537 ' H ' ' C ' ' A' ' 118' ' ' HIS . 47.3 t-20 61.09 3.22 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.595 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.445 ' H ' ' C ' ' A' ' 119' ' ' CYS . 18.8 tt -143.84 172.25 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.427 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.421 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 38.0 mtt85 -122.73 99.97 6.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.777 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 28.8 m -90.34 147.16 23.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.739 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.7 mtm -139.97 170.6 15.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.356 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.0 m120 67.48 39.13 2.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.508 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.55 32.44 83.26 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.31 -173.98 14.0 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.1 m -130.98 136.69 48.76 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.4 t -73.33 112.08 9.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.188 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 69.5 m -128.97 119.82 24.99 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.959 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 43.17 -108.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.746 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -121.81 19.81 10.97 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.507 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -131.87 156.02 46.82 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.955 0.407 . . . . 0.0 110.293 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 97.1 m -106.42 131.24 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.0 mt -99.22 131.35 45.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.672 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -100.3 143.2 30.78 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.438 -179.372 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.56 -179.09 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.57 132.84 49.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.53 -179.77 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.25 -19.36 46.1 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -118.11 136.99 53.25 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.784 0.326 . . . . 0.0 110.295 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.6 pt -130.94 171.79 17.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.992 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.01 157.73 10.48 Favored Glycine 0 N--CA 1.464 0.519 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 61.6 p -64.09 -42.53 96.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.835 0.35 . . . . 0.0 110.536 -179.579 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -105.8 5.64 31.0 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.692 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 5.0 m 65.04 140.1 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.076 0.465 . . . . 0.0 109.965 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 152.86 -11.04 0.59 Allowed Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -102.44 110.2 62.32 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.535 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.29 157.46 33.31 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.486 2.124 . . . . 0.0 112.31 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.46 116.66 50.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 120.989 0.423 . . . . 0.0 110.179 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.7 m -88.98 96.38 10.7 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -66.12 -38.5 88.34 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.426 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 97.4 p -82.42 -7.96 59.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.684 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 59.2 161.93 0.07 OUTLIER Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.06 114.5 28.73 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.57 -42.16 98.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.1 m-20 -100.07 -177.37 3.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.456 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -70.81 33.58 0.49 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.046 -0.821 . . . . 0.0 111.046 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.55 176.05 28.79 Favored Glycine 0 CA--C 1.52 0.349 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -126.03 142.33 51.57 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.68 0.276 . . . . 0.0 110.494 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.66 122.03 30.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.442 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.2 m -110.16 -9.87 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.308 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -171.91 170.97 2.34 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.41 -0.516 . . . . 0.0 110.737 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.9 Cg_exo -53.05 128.48 29.16 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 121.913 1.742 . . . . 0.0 111.402 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 52.58 32.69 12.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.119 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.76 127.8 37.52 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.15 0.5 . . . . 0.0 109.773 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 4.4 t -139.01 148.58 43.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.858 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.51 129.11 47.52 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.471 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 26.8 m -74.43 151.43 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.311 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.8 m -62.96 -45.8 90.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.204 -179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.96 19.52 19.29 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-O 121.077 0.465 . . . . 0.0 110.734 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 68.53 26.71 74.23 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -55.45 149.66 13.05 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 51.8 p -82.29 165.42 20.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.576 -179.32 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 87.44 150.45 18.85 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.82 -23.18 41.89 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.69 2.26 . . . . 0.0 112.272 -179.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 76.6 mt-30 -101.34 7.32 42.81 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.554 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 77.9 m 53.52 -92.68 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.185 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.517 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.8 t . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 48.99 35.11 6.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.541 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -65.05 -39.25 93.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.317 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -56.45 -103.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 92.04 -7.78 78.45 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.13 164.22 54.92 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.71 175.68 44.42 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -66.89 -41.29 87.43 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.526 ' O ' ' N ' ' A' ' 53' ' ' LEU . 99.6 m-20 53.08 83.02 0.07 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.794 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.556 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . 62.43 -68.19 0.07 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.898 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.526 ' N ' ' O ' ' A' ' 51' ' ' ASP . 13.0 mt -64.99 138.58 58.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.166 0.508 . . . . 0.0 110.225 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -133.22 163.03 30.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.32 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.47 160.31 23.13 Favored Glycine 0 CA--C 1.531 1.039 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.54 2.94 6.82 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.862 2.375 . . . . 0.0 112.212 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.441 ' OD1' ' CZ2' ' A' ' 71' ' ' TRP . 3.0 m-80 -114.95 69.07 0.71 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.355 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.457 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.1 t -120.42 130.83 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 93.1 m -141.15 176.8 8.54 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.032 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.22 169.15 45.49 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.557 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -74.51 163.25 27.97 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -59.27 -43.94 92.45 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.47 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -64.11 -39.96 95.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.007 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -122.54 46.62 2.1 Favored 'General case' 0 N--CA 1.461 0.079 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.783 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.557 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.92 145.09 48.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.52 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -156.05 168.19 28.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.821 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.5 m -67.47 130.11 42.04 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.189 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.457 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 53.5 m -49.21 153.29 1.73 Allowed Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.246 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -51.64 131.68 38.26 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 121.43 1.42 . . . . 0.0 112.398 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 100.9 -16.53 57.33 Favored Glycine 0 N--CA 1.467 0.737 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.55 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 9.1 m95 -115.63 139.58 49.97 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.787 0.327 . . . . 0.0 110.498 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.9 ptpt -120.23 -168.66 1.66 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.312 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 64.1 p -118.13 160.53 21.39 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.483 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.1 mt -87.4 152.84 52.96 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.744 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.44 107.58 0.08 OUTLIER 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.145 1.897 . . . . 0.0 112.184 179.309 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.34 -11.63 12.19 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -88.29 175.99 44.84 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.556 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 34.6 p30 -135.56 15.75 3.4 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.12 0.486 . . . . 0.0 110.639 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -79.87 128.53 33.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.495 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' CYS . . . . . 0.405 ' O ' ' ND2' ' A' ' 57' ' ' ASN . 29.9 m -96.9 55.68 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 30.3 pt -115.92 21.01 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.993 -179.217 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.5 t -119.32 85.74 31.62 Favored Pre-proline 0 N--CA 1.467 0.39 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.697 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -61.35 148.48 92.83 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.936 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.8 mt -90.9 128.63 42.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 3.2 m -99.62 109.02 21.54 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.229 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -65.88 -39.36 90.59 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.052 0.453 . . . . 0.0 109.906 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 61.3 m170 -110.51 142.06 42.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.002 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.5 t -59.62 130.07 45.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.681 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 61.2 m -80.28 -31.52 38.28 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.875 179.374 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.07 -112.48 3.67 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -81.91 -0.55 44.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.16 -175.74 30.35 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.0 147.79 52.47 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.018 0.437 . . . . 0.0 110.794 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.2 m -64.4 111.26 2.57 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.42 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 69.8 p -102.64 -27.51 12.69 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.302 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.1 mtt85 -157.83 163.94 23.03 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.583 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -51.55 121.9 9.32 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 121.634 1.556 . . . . 0.0 111.48 179.126 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 55.17 40.34 31.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.878 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.8 mmm -149.27 115.81 5.87 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.198 0.523 . . . . 0.0 109.97 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 86.7 m -101.23 151.12 22.25 Favored 'General case' 0 N--CA 1.461 0.116 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.674 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 97.1 m -121.91 126.26 48.26 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.68 151.59 40.12 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.642 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -50.02 -22.73 8.11 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.459 2.106 . . . . 0.0 111.867 177.59 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -66.85 -16.96 64.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.684 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.82 -18.5 49.89 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tt0 -68.05 153.16 44.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.894 0.378 . . . . 0.0 110.304 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.17 130.38 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.581 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.545 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.27 164.88 3.21 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.962 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.545 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 15.3 Cg_endo -57.44 -22.81 52.28 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.916 2.411 . . . . 0.0 111.829 178.66 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.9 p -135.38 154.53 51.45 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.97 0.414 . . . . 0.0 110.227 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.86 144.13 30.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.68 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 55.22 46.84 77.61 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.181 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.0 t -60.3 -44.59 95.29 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.697 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 115' ' ' SER . 77.0 ttt180 -167.77 -18.05 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.401 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 114' ' ' ARG . 0.9 OUTLIER 82.9 81.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.398 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.75 128.52 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-O 120.956 0.408 . . . . 0.0 110.319 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -81.53 111.26 17.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.411 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.541 ' CD2' ' H ' ' A' ' 118' ' ' HIS . 9.2 p80 -95.72 -50.57 4.87 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.931 0.396 . . . . 0.0 110.467 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.441 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 96.3 m -116.97 134.53 54.62 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.207 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -63.4 -40.21 96.61 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.444 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.539 HG22 ' H ' ' A' ' 122' ' ' ARG . 1.1 mt -113.31 -157.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.811 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.539 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.6 ptt-85 -120.59 121.72 38.99 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.7 m -124.86 147.0 49.01 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.15 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 70.9 mtm -145.17 174.13 11.34 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.315 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 5.7 m120 59.61 37.2 22.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.44 15.47 79.84 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.7 123.76 10.16 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.158 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 39.9 t -83.51 140.98 31.96 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.75 0.309 . . . . 0.0 110.881 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 5.8 m -83.32 129.94 35.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.18 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.4 m -126.45 158.3 36.38 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.134 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.442 ' O ' ' OD1' ' A' ' 131' ' ' ASP . 43.4 p-10 -48.24 109.35 0.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.09 0.472 . . . . 0.0 110.991 -178.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 50.24 30.26 4.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.531 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -159.78 154.9 24.95 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.495 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 47.6 t -129.55 132.32 46.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.784 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 80.3 mt -101.09 128.47 47.14 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.598 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 55.6 m -84.77 132.19 34.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.382 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -56.1 161.14 2.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.906 0.384 . . . . 0.0 110.352 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -59.25 130.81 48.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.873 0.368 . . . . 0.0 110.816 -179.552 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 94.5 -6.91 71.37 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -119.74 137.43 53.94 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.924 0.392 . . . . 0.0 110.098 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 22.3 pt -129.61 169.59 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.953 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 121.69 159.34 10.64 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.4 m -62.17 -45.64 92.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 0.0 110.687 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.505 ' NE2' ' NH2' ' A' ' 122' ' ' ARG . 31.9 m-70 -102.75 3.24 36.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.347 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.37 142.94 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.894 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 149.53 -8.24 0.86 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -101.39 109.38 58.73 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.371 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.3 157.49 45.65 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.359 2.039 . . . . 0.0 112.437 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.8 t -124.83 126.81 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.412 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 66.3 m -94.41 109.13 21.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.129 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -66.89 -39.54 87.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.9 m -88.66 -9.16 53.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.712 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.505 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 60.03 177.47 1.48 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 9.0 m -116.08 119.98 37.61 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.024 0.44 . . . . 0.0 110.191 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 94.9 mt -63.57 -42.38 98.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.506 ' C ' ' H ' ' A' ' 158' ' ' GLY . 18.9 m120 -93.6 -178.49 4.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.525 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.34 29.55 0.69 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.61 179.41 16.81 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -126.2 149.64 48.89 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.942 0.401 . . . . 0.0 110.349 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.52 105.09 17.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -88.41 -19.64 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.566 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.639 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -165.93 174.28 2.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.47 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.639 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.84 133.82 52.41 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 121.892 1.728 . . . . 0.0 111.854 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 64.7 t30 45.34 36.42 2.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.397 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -130.34 103.82 6.91 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.29 0.567 . . . . 0.0 110.909 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 153' ' ' GLY . 23.2 m -102.2 135.15 44.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.087 -0.961 . . . . 0.0 110.685 179.4 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.98 92.29 3.97 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 178.764 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.6 p -102.23 141.76 34.56 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.468 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.1 OUTLIER -111.6 13.79 21.28 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.298 0.57 . . . . 0.0 110.568 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -102.32 30.45 4.56 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.164 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 100.28 59.42 0.84 Allowed Glycine 0 N--CA 1.464 0.553 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 172' ' ' PHE . 21.9 t80 -44.51 119.04 1.73 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.033 0.444 . . . . 0.0 110.484 -179.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.949 ' H ' ' H ' ' A' ' 178' ' ' GLU . 7.3 m -153.3 130.61 11.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.375 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 78.03 164.71 24.83 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -66.94 -22.32 48.64 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.896 2.397 . . . . 0.0 112.253 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -89.09 14.01 11.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.951 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.79 111.69 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.021 0.438 . . . . 0.0 110.166 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 178' ' ' GLU . . . . . 0.949 ' H ' ' H ' ' A' ' 173' ' ' THR . 3.1 tm-20 . . . . . 0 C--N 1.324 -0.53 0 CA-C-O 118.1 -0.953 . . . . 0.0 110.555 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 66.5 p . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.4 143.87 57.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.244 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.3 ttp180 -128.67 133.75 48.31 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.263 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.12 21.01 61.66 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.34 129.3 19.92 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -103.76 -178.38 25.75 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -64.09 -29.57 75.29 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 55.4 68.62 0.84 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 110.439 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.457 ' O ' ' N ' ' A' ' 53' ' ' LEU . 38.3 t70 -70.19 135.97 49.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.527 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 51' ' ' ASP . . . 66.37 -65.98 0.18 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.909 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 51' ' ' ASP . 44.3 mt -72.81 147.71 45.22 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.413 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -135.42 161.8 34.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.037 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.9 163.92 26.88 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -75.03 -7.35 19.05 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 123.058 2.505 . . . . 0.0 112.344 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.447 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 71.9 m-80 -105.32 70.38 0.89 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.597 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.466 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 60.7 t -121.63 130.24 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.925 179.1 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 87.1 m -144.55 -174.1 4.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.009 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.28 171.43 47.51 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.6 m -84.19 167.56 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -59.52 -43.79 93.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.777 0.323 . . . . 0.0 110.738 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -63.97 -36.76 85.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.977 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -129.25 50.33 2.16 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.987 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -73.18 142.81 47.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.371 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -160.75 167.16 27.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.995 0.426 . . . . 0.0 111.03 179.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.426 ' SG ' HG22 ' A' ' 73' ' ' THR . 79.1 m -64.04 130.92 45.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.17 -179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.466 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 32.5 m -47.72 151.02 1.64 Allowed Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.103 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -49.62 129.76 24.37 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.498 1.465 . . . . 0.0 112.301 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.67 -18.54 47.09 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.447 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 98.6 m95 -111.77 134.76 53.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.965 0.412 . . . . 0.0 110.085 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -110.99 -167.75 1.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.133 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.426 HG22 ' SG ' ' A' ' 67' ' ' CYS . 71.1 p -129.83 165.29 22.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.049 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 12.1 mt -91.53 150.58 41.39 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.834 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_exo -44.21 115.4 0.75 Allowed 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.864 1.709 . . . . 0.0 112.036 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.12 -8.73 7.93 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.165 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -91.11 177.94 41.63 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 26.7 p30 -139.51 13.39 2.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.931 0.396 . . . . 0.0 110.864 179.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLN . . . . . 0.452 ' H ' ' CD ' ' A' ' 79' ' ' GLN . 1.1 mp0 -84.08 131.78 34.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.469 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 22.5 m -95.88 43.29 1.08 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.361 -0.382 . . . . 0.0 109.987 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 42.4 pt -98.2 6.89 8.66 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.246 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.734 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.66 112.54 60.52 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.417 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.29 156.87 29.52 Favored 'Trans proline' 0 N--CA 1.486 1.059 0 C-N-CA 122.01 1.807 . . . . 0.0 111.864 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.6 mt -100.72 118.91 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.8 115.42 27.12 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.402 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -64.73 -45.24 87.36 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.37 0.605 . . . . 0.0 110.106 179.242 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -119.41 -167.89 1.49 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.674 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.2 t -97.04 125.07 41.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.722 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.6 m -74.39 -32.16 62.62 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.776 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -106.08 2.23 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.439 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.4 p-10 -81.99 -2.63 52.21 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.719 0.295 . . . . 0.0 110.773 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.63 -176.36 27.14 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -133.72 146.12 50.5 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.058 0.456 . . . . 0.0 110.788 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 70.1 m -64.57 111.3 2.65 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.578 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 89.0 p -105.98 -26.07 11.83 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.33 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 -153.23 159.58 32.01 Favored Pre-proline 0 C--N 1.325 -0.464 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.291 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -48.92 119.07 3.96 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.477 2.118 . . . . 0.0 111.915 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.402 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 54.0 t30 55.11 42.88 30.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.228 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mtp -149.06 118.87 7.06 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.09 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' ALA . 69.2 m -100.64 148.72 24.54 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.792 179.178 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.5 m -119.99 115.59 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.422 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.44 154.0 68.66 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -50.07 -26.56 14.95 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.693 2.262 . . . . 0.0 112.016 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 m -66.49 -15.5 63.41 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.831 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.92 -15.18 58.37 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -65.86 149.31 50.39 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.2 130.64 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.656 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -170.29 179.43 0.74 Allowed Pre-proline 0 C--N 1.327 -0.406 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.446 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.656 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 35.7 Cg_exo -58.81 -22.71 63.34 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.877 2.385 . . . . 0.0 111.78 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 82.7 p -152.3 163.98 38.36 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.598 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -77.5 -27.55 51.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.315 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.8 98.14 0.46 Allowed Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.1 m -137.35 -24.14 1.08 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.789 0.328 . . . . 0.0 110.57 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -100.45 139.41 36.18 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.8 m -58.76 -40.54 84.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.573 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 79.0 mt -104.3 123.67 58.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.211 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -87.34 141.85 28.33 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.56 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.563 ' O ' ' N ' ' A' ' 120' ' ' ASN . 97.3 m-70 -78.97 150.39 32.02 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.309 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 75.8 m -51.67 82.43 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.224 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' ASN . . . . . 0.563 ' N ' ' O ' ' A' ' 118' ' ' HIS . 92.3 m-20 -64.36 -40.77 96.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.63 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.736 HG22 ' H ' ' A' ' 122' ' ' ARG . 24.7 mm -64.48 177.83 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.962 0.41 . . . . 0.0 109.999 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.736 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.8 mmt180 -117.46 98.27 6.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.721 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.2 m -94.33 135.27 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.322 179.175 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.6 mtm -130.17 170.13 14.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.346 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 m120 63.6 41.48 7.19 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.717 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.87 23.61 71.04 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.574 -1.01 . . . . 0.0 110.574 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.93 141.96 24.88 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.635 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 20.1 m -99.87 144.69 28.63 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.725 0.298 . . . . 0.0 110.314 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' CYS . . . . . 0.5 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 0.5 OUTLIER -93.99 129.79 40.35 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.682 179.897 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 28.8 t -149.36 134.99 18.61 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.394 178.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 51.11 45.82 27.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 56.95 33.65 23.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -143.98 138.2 28.26 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.467 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 95.9 m -91.05 131.4 36.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 110.828 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 76.6 mt -101.83 128.53 48.15 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.338 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' CYS . . . . . 0.452 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 8.4 m -89.01 135.78 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.53 -179.253 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -73.32 172.6 10.91 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.444 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -62.82 126.12 26.25 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.12 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 107.96 -26.27 17.93 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.61 133.73 54.5 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.946 0.403 . . . . 0.0 110.065 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 141' ' ' ILE . 23.3 pt -127.35 169.14 19.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.934 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.452 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 118.79 159.87 11.23 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.1 m -62.12 -46.07 90.67 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.566 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -100.68 2.14 41.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.58 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.6 m 62.85 132.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.996 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 164.91 -11.99 0.08 OUTLIER Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 27.2 tp60 -100.27 112.72 64.72 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -75.74 157.76 39.57 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 C-N-CA 122.42 2.08 . . . . 0.0 112.053 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 52.5 t -120.56 130.47 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 18.1 m -90.06 98.81 11.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.183 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.34 -39.36 92.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 0.0 110.418 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 83.1 p -81.83 -6.86 59.44 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.482 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 64.99 161.07 0.56 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.6 m -114.06 104.93 12.63 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.834 0.349 . . . . 0.0 110.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 85.5 mt -63.67 -42.19 98.08 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.561 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.9 t-20 -90.73 173.31 8.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.342 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.69 33.2 0.28 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.561 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.47 -179.01 26.38 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 53.4 mmm-85 -130.46 147.37 52.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.918 0.389 . . . . 0.0 110.218 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 84.0 m -83.99 111.05 18.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.362 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.9 m -95.38 -20.54 5.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.376 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.64 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.62 173.82 2.71 Favored Pre-proline 0 C--N 1.326 -0.455 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.627 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.64 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.97 130.89 41.61 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.164 1.909 . . . . 0.0 111.95 179.252 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 164' ' ' ASN . . . . . 0.408 ' O ' ' OD1' ' A' ' 164' ' ' ASN . 60.5 t-20 49.74 32.33 5.13 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.084 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -137.0 129.14 29.52 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.447 0.642 . . . . 0.0 110.045 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -131.79 145.38 51.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.0 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -97.13 137.15 36.62 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.703 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 168' ' ' CYS . . . . . 0.549 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 44.2 m -81.75 142.79 32.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.079 0.466 . . . . 0.0 111.054 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.9 m -63.38 -45.59 90.39 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.084 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -97.89 17.23 18.65 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.106 0.479 . . . . 0.0 111.086 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.79 24.18 77.01 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.549 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 3.1 m-85 -66.01 151.49 46.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.238 0.542 . . . . 0.0 110.191 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -87.61 166.05 14.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.97 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.83 148.51 11.52 Favored Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.17 -29.06 39.98 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 122.448 2.099 . . . . 0.0 112.409 -179.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -115.12 0.89 13.74 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.604 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 73.15 -72.68 0.11 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.784 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.218 -0.566 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.515 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.1 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 51.46 42.16 29.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.505 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -63.91 -39.75 94.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.403 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.84 110.77 0.24 Allowed Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 56.75 -135.74 50.68 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 69.86 -153.49 52.23 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.58 -10.24 68.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' HIS . . . . . 0.436 ' NE2' ' HB2' ' A' ' 52' ' ' ALA . 22.9 t-160 39.19 79.85 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.853 0.358 . . . . 0.0 110.874 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 52' ' ' ALA . 38.1 p-10 -65.11 -34.45 78.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.61 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.48 ' N ' ' OD1' ' A' ' 51' ' ' ASP . . . 52.7 -179.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.592 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt -74.34 151.17 39.82 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.58 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.42 165.0 22.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.655 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 70.18 172.43 10.7 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.55 -171.36 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.984 2.456 . . . . 0.0 111.794 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.425 ' OD1' ' CZ3' ' A' ' 71' ' ' TRP . 26.1 m120 58.78 38.78 24.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.081 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.451 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 7.4 p -95.53 133.72 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.288 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 59' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 60.6 m -151.22 -174.32 4.78 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.275 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.28 174.38 44.92 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.561 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.1 m -82.47 160.81 22.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.607 0.241 . . . . 0.0 110.437 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.53 -43.29 97.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.725 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -61.72 -41.15 97.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.273 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -133.61 54.66 1.94 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.649 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.11 147.54 53.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.291 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.417 ' O ' ' O ' ' A' ' 59' ' ' CYS . 11.7 p90 -153.81 170.16 21.62 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.005 0.431 . . . . 0.0 110.766 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.1 m -73.79 135.42 43.51 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -49.0 167.9 0.2 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.386 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -57.17 132.29 50.37 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.014 1.809 . . . . 0.0 111.643 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 97.14 -17.25 59.51 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.425 ' CZ3' ' OD1' ' A' ' 57' ' ' ASN . 31.5 m95 -113.61 139.79 48.73 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.927 0.394 . . . . 0.0 110.363 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -125.48 -174.01 2.97 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.192 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 74.6 p -115.48 161.51 18.48 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.432 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' A' ' 77' ' ' GLY . 17.8 mt -87.62 151.68 50.72 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.437 ' C ' ' H ' ' A' ' 77' ' ' GLY . 73.1 Cg_exo -39.21 107.03 0.06 OUTLIER 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 122.235 1.957 . . . . 0.0 112.116 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 72.98 -11.17 4.88 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.01 174.48 53.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -135.28 13.49 3.53 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.06 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -84.63 129.09 34.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.503 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 63.5 m -95.2 60.45 2.33 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 37.3 pt -119.17 26.65 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.855 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.3 t -123.06 84.45 51.03 Favored Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.953 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -63.32 150.26 89.04 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.597 2.198 . . . . 0.0 111.69 179.077 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.9 mt -94.0 121.98 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.33 129.81 45.57 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.403 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -63.18 -45.92 89.51 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.206 0.527 . . . . 0.0 110.169 179.951 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -122.38 146.57 47.22 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -52.42 125.42 16.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.376 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.8 m -66.56 -2.03 4.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.544 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 55.59 -116.23 6.84 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.8 p-10 -74.91 -1.26 21.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 110.676 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.61 -164.29 19.83 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.475 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 54.9 p90 -142.84 150.97 40.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.966 0.412 . . . . 0.0 110.646 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -69.64 114.97 8.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.832 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.475 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 5.0 m -105.25 -19.03 13.93 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.586 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.4 mtt85 -157.08 162.54 27.39 Favored Pre-proline 0 N--CA 1.454 -0.263 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.737 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -50.09 122.45 9.22 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 121.95 1.767 . . . . 0.0 111.341 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.403 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 72.0 m-20 52.93 38.64 27.52 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.982 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.7 mtp -146.29 118.76 8.47 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.492 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 37.8 m -105.95 150.42 25.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.718 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' THR . . . . . 0.432 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 64.7 m -119.69 113.38 20.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.582 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.64 157.19 72.51 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.629 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.3 -21.19 71.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.65 2.234 . . . . 0.0 111.474 178.897 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -67.71 -16.59 64.21 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.727 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 105.63 -20.38 36.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -68.75 151.54 46.51 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.888 0.375 . . . . 0.0 110.528 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -131.22 135.15 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.676 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -167.26 -179.19 0.75 Allowed Pre-proline 0 C--N 1.326 -0.447 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.647 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.676 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 31.5 Cg_exo -60.29 -16.02 38.43 Favored 'Trans proline' 0 N--CA 1.499 1.806 0 C-N-CA 122.953 2.435 . . . . 0.0 111.907 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 27.8 m -160.29 159.81 31.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.756 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -82.64 167.15 18.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.23 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.32 158.26 31.36 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 179.684 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.5 t -60.68 -42.83 97.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.747 0.308 . . . . 0.0 110.819 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 85.7 mtp180 -125.15 148.51 48.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.488 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.6 m -73.54 157.47 36.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.52 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 24.4 mm -71.89 131.8 34.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.107 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -137.01 162.01 34.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.538 -179.386 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 78.5 m80 44.87 -117.82 0.62 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.432 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 177.37 4.87 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.008 0.432 . . . . 0.0 110.082 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -62.6 -40.36 96.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.112 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.757 HG22 ' H ' ' A' ' 122' ' ' ARG . 36.1 mm -74.24 178.04 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.239 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.757 ' H ' HG22 ' A' ' 121' ' ' ILE . 1.0 OUTLIER -127.68 134.03 49.6 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.166 179.354 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.5 m -118.21 144.6 45.61 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtm -144.3 169.37 18.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.284 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 59.28 40.52 21.23 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.32 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 23.47 67.76 Favored Glycine 0 C--N 1.333 0.371 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.03 119.92 5.07 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 120.432 -0.89 . . . . 0.0 110.929 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.2 p -79.43 145.29 33.39 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.035 -0.266 . . . . 0.0 110.54 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.8 t -97.4 118.44 33.88 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.75 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.422 ' O ' ' N ' ' A' ' 133' ' ' HIS . 29.8 t -148.13 139.76 23.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.575 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 41.98 45.93 3.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 55.45 36.99 28.25 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.457 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' HIS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' SER . 58.4 m80 -142.7 141.89 31.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.261 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.467 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 81.4 m -99.93 119.82 38.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.497 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.6 mt -98.06 128.26 44.48 Favored 'General case' 0 CA--C 1.518 -0.267 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.79 134.61 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.858 -179.397 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 82.0 mt-30 -72.26 -173.77 1.16 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.34 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -67.77 129.13 38.97 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.731 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.64 -9.33 55.48 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -125.46 141.54 52.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.859 0.361 . . . . 0.0 110.528 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.6 pt -132.66 173.79 14.26 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.743 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 112.61 153.54 11.74 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.0 p -63.01 -45.5 92.1 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.698 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -97.83 1.75 48.6 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.511 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 16.4 m 62.62 133.21 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.871 -179.398 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 161.29 -6.71 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 39.2 tp60 -109.21 111.58 60.04 Favored Pre-proline 0 CA--C 1.543 0.693 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.58 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -75.64 156.77 40.23 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.517 2.145 . . . . 0.0 112.435 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 90.9 t -101.98 114.92 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.05 98.25 11.65 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.306 -179.064 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -65.77 -39.66 91.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.71 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 72.1 m -79.62 -7.55 58.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.84 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.46 161.69 0.05 OUTLIER Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 66.7 m -106.51 111.17 23.61 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 89.0 mt -63.18 -42.26 99.35 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.8 t30 -95.7 173.0 7.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.416 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.59 37.5 0.36 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -76.55 -172.05 34.5 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -132.21 143.46 49.96 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.872 0.367 . . . . 0.0 110.521 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.6 m -81.92 113.51 19.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.281 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.3 m -88.42 -23.69 6.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.536 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.5 171.99 3.81 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.511 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.6 Cg_exo -50.45 127.96 21.93 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.711 1.607 . . . . 0.0 112.01 178.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.8 t30 53.93 36.7 24.97 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.715 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.414 ' HD2' ' HB3' ' A' ' 162' ' ' ALA . 94.7 mtt-85 -141.42 132.8 26.7 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.207 0.527 . . . . 0.0 110.632 178.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 3.4 t -141.45 150.77 42.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.954 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.52 53.57 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.687 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.97 137.13 32.62 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.035 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.0 p -112.58 19.2 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.88 0.371 . . . . 0.0 111.44 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.476 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 34.3 t80 -114.49 31.75 6.42 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.725 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 79.34 15.63 79.69 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -108.26 163.22 13.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.281 0.562 . . . . 0.0 110.917 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.9 t -147.1 152.31 38.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 129.72 162.42 10.82 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.83 -22.86 36.01 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 122.721 2.281 . . . . 0.0 112.186 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -124.37 7.29 8.38 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.523 -179.071 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 73.2 m 48.36 61.96 2.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.642 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.111 -0.947 . . . . 0.0 110.584 -179.979 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.19 -40.39 95.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.452 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -69.19 -37.92 78.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.432 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -72.92 163.36 54.92 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -169.64 170.98 43.06 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.26 176.78 48.2 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.74 -177.34 48.1 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -81.34 137.56 35.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.846 0.355 . . . . 0.0 110.274 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 38.5 t0 -156.64 175.09 14.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.487 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.23 149.09 50.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.393 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 64.8 mt -66.14 151.48 46.85 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.491 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -127.0 161.16 29.03 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.377 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.55 169.7 44.33 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.41 -176.08 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 123.009 2.473 . . . . 0.0 111.908 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 58.9 42.05 20.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.459 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 50.3 t -107.86 133.72 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 59' ' ' CYS . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' TYR . 88.8 m -142.69 -179.02 6.07 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.025 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.34 164.37 40.06 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.531 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.3 m -79.74 168.21 19.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.786 0.327 . . . . 0.0 110.394 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.7 ttt-85 -61.04 -43.23 99.2 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.502 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -62.36 -40.54 96.75 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.962 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -129.35 52.87 1.94 Allowed 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.618 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.531 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.77 142.48 54.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.352 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.406 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -154.7 165.3 36.99 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.492 179.441 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.541 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 81.9 m -71.03 137.92 49.42 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.489 -0.484 . . . . 0.0 109.782 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.459 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 27.4 m -52.9 151.77 8.06 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.106 -178.852 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.93 130.75 32.32 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 121.559 1.506 . . . . 0.0 112.755 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -6.95 61.4 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -119.49 137.2 53.95 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.007 0.432 . . . . 0.0 110.79 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -123.85 -177.05 3.63 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.398 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.541 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 35.8 p -131.21 172.08 12.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.35 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.49 ' O ' ' N ' ' A' ' 77' ' ' GLY . 43.1 mt -90.31 148.59 39.43 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.67 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -40.49 111.49 0.14 Allowed 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.014 1.81 . . . . 0.0 112.574 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 82.02 -16.58 21.06 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -74.76 165.0 54.72 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.5 m-20 -129.72 8.66 5.36 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.045 0.45 . . . . 0.0 110.958 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -87.23 130.04 34.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.381 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 56.8 m -94.21 40.8 1.08 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -94.67 11.68 3.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.606 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.64 107.02 53.45 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.684 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -76.53 157.78 36.29 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.282 1.988 . . . . 0.0 112.243 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -103.12 126.18 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.063 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -100.16 127.08 46.48 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.27 -45.27 94.02 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.472 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -126.19 157.32 38.48 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.637 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -60.97 136.49 58.1 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.422 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 57.7 m -78.78 -26.03 44.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.809 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 82.68 -109.32 3.07 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 23.0 p-10 -78.87 -2.61 40.64 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.674 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.55 -160.46 16.16 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -147.73 153.15 38.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.977 0.418 . . . . 0.0 110.826 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.6 m -63.58 113.4 3.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.973 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 92.6 p -100.89 -22.91 14.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.309 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 mtp180 -158.68 161.14 28.9 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.688 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -45.91 119.47 2.9 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 121.926 1.751 . . . . 0.0 111.725 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 54.82 39.56 31.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.271 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 69.8 mmm -145.83 122.13 10.91 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.441 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 27.3 m -105.8 147.55 28.52 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.286 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 78.7 m -122.3 113.44 19.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.753 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.422 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -76.23 157.38 83.06 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.021 179.895 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.422 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -62.29 -21.67 72.97 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.837 2.358 . . . . 0.0 111.48 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 m -63.61 -33.69 76.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.555 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 123.32 -17.24 7.96 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' GLN . . . . . 0.467 ' NE2' ' H ' ' A' ' 107' ' ' ILE . 1.2 tm0? -69.29 145.0 53.42 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.902 0.382 . . . . 0.0 110.648 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.467 ' H ' ' NE2' ' A' ' 106' ' ' GLN . 92.0 mt -124.29 131.29 73.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.626 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.66 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -171.19 179.43 0.67 Allowed Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.416 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.66 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 35.4 Cg_exo -58.95 -21.8 59.94 Favored 'Trans proline' 0 N--CA 1.498 1.793 0 C-N-CA 122.772 2.315 . . . . 0.0 111.999 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 92.7 p -151.27 164.28 36.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.333 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.33 144.71 33.96 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.573 -179.479 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -173.36 139.61 5.19 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.7 m -84.13 -12.83 54.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.77 0.319 . . . . 0.0 110.35 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -80.57 142.98 33.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.448 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.468 ' O ' ' OG ' ' A' ' 115' ' ' SER . 3.8 p 59.47 100.28 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.293 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 94.3 mt -111.3 128.85 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.238 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -121.34 144.59 48.56 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.147 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.44 ' O ' ' O ' ' A' ' 119' ' ' CYS . 4.7 p80 -97.33 175.17 6.35 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.073 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.44 ' O ' ' O ' ' A' ' 118' ' ' HIS . 1.2 m 58.03 146.08 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.103 0.477 . . . . 0.0 110.756 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -63.97 -39.98 95.36 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.255 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.534 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 11.3 tt -112.17 169.7 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.188 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.691 HH21 ' CE1' ' A' ' 144' ' ' HIS . 28.5 ptt180 -83.21 118.88 23.92 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.034 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.7 143.14 50.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.64 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.573 ' SD ' ' N ' ' A' ' 124' ' ' MET . 2.1 mpp? -141.96 161.49 37.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.182 179.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 32.9 m120 57.98 51.79 8.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.282 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.79 19.08 77.89 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.44 143.22 40.31 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.0 t -121.4 141.12 51.28 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 10.5 p -93.15 131.55 38.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.76 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.546 ' O ' ' N ' ' A' ' 132' ' ' ASP . 44.1 t -138.19 131.47 30.39 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.187 179.11 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 60.8 t0 55.31 -80.57 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.504 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.546 ' N ' ' O ' ' A' ' 130' ' ' SER . 37.7 p-10 -155.42 23.28 0.41 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.734 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 43.1 m80 -141.79 158.05 44.27 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.519 -179.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.464 ' SG ' HG23 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -96.96 131.73 43.46 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.154 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.3 mt -92.68 128.86 38.69 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.756 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' CYS . . . . . 0.466 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -105.96 132.59 51.87 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.694 -179.595 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -79.83 173.06 12.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.359 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -63.06 133.7 54.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.288 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.62 -25.84 24.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.24 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.466 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 96.5 m-85 -116.13 130.94 57.04 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 28.7 pt -129.68 178.48 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.021 -179.319 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 115.92 159.72 12.07 Favored Glycine 0 N--CA 1.462 0.424 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.7 p -66.12 -33.86 76.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.765 0.317 . . . . 0.0 110.546 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.691 ' CE1' HH21 ' A' ' 122' ' ' ARG . 54.7 m-70 -103.97 1.64 31.41 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.751 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.414 ' O ' ' O ' ' A' ' 144' ' ' HIS . 41.8 t 59.82 122.9 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 159.64 -23.56 0.29 Allowed Glycine 0 CA--C 1.519 0.317 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 14.6 tp60 -76.89 118.04 69.06 Favored Pre-proline 0 CA--C 1.543 0.673 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.629 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -75.46 157.42 40.84 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.641 2.227 . . . . 0.0 112.393 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.6 t -121.11 129.8 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.445 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.1 m -92.96 98.97 11.7 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -67.07 -36.99 83.21 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.471 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.0 p -85.88 -6.4 59.09 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.93 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.94 -172.17 33.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 57.3 m -139.81 106.69 5.41 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 82.2 mt -63.45 -42.18 98.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.785 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.539 ' C ' ' H ' ' A' ' 158' ' ' GLY . 27.6 t-20 -90.56 170.28 10.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.8 35.38 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -71.77 -174.63 21.86 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -131.3 147.1 52.54 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.72 0.295 . . . . 0.0 110.812 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 3.6 t -88.12 112.87 23.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.719 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.47 -54.89 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.06 175.91 3.31 Favored Pre-proline 0 N--CA 1.466 0.328 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.196 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -53.22 130.29 37.59 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 121.813 1.675 . . . . 0.0 112.023 179.702 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 66.5 t30 51.38 35.78 14.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.47 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.7 ttt85 -137.08 124.34 21.83 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.588 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.9 t -130.21 138.27 50.49 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.02 140.65 29.67 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.768 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.3 m -81.23 143.3 32.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.839 0.352 . . . . 0.0 110.158 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.1 m -63.46 -45.37 91.12 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.024 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.525 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 80.3 t80 -98.56 24.54 7.32 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.169 0.509 . . . . 0.0 110.815 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.16 24.2 70.28 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -56.27 159.57 3.46 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.88 0.371 . . . . 0.0 110.18 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.563 HG22 ' N ' ' A' ' 174' ' ' GLY . 89.4 m -82.26 162.42 22.33 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.198 0.523 . . . . 0.0 111.143 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 174' ' ' GLY . . . . . 0.563 ' N ' HG22 ' A' ' 173' ' ' THR . . . 66.94 152.03 0.2 Allowed Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 179.423 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.57 -29.1 44.52 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.695 2.263 . . . . 0.0 112.056 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -78.75 -15.46 58.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.603 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 39.4 m 54.22 52.26 12.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.42 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.501 -179.968 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.3 m . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.08 141.07 57.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -93.11 139.33 30.68 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.463 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.78 155.5 13.1 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -102.44 120.6 6.88 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -94.43 177.22 36.05 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -140.1 123.72 2.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.629 -0.989 . . . . 0.0 110.629 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -134.07 131.59 38.98 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 110.336 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -74.67 142.01 44.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.558 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.405 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -150.95 131.56 13.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.511 179.644 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.6 mt -76.69 146.2 38.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.428 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.0 mtpt -128.86 160.4 32.73 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.3 0.571 . . . . 0.0 110.77 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 162.74 25.29 Favored Glycine 0 CA--C 1.528 0.904 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.08 3.08 7.35 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.704 2.269 . . . . 0.0 112.248 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.6 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 0.3 OUTLIER -112.58 61.3 0.63 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.105 0.479 . . . . 0.0 110.429 -179.654 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.9 t -109.71 129.68 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-O 121.193 0.52 . . . . 0.0 109.72 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 85.1 m -141.92 176.91 8.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.664 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 171.5 45.85 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.3 m -82.19 165.1 20.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.703 0.287 . . . . 0.0 110.457 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -60.02 -42.67 94.86 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.659 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -61.17 -41.36 96.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.006 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -132.72 54.75 1.93 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.489 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.52 142.49 56.54 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.493 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 13.6 p90 -151.45 165.89 32.77 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.186 0.517 . . . . 0.0 110.901 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 57' ' ' ASN . 1.6 t -73.59 138.42 44.89 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.436 179.51 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -58.42 157.97 16.3 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.859 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -60.76 137.35 72.4 Favored 'Trans proline' 0 N--CA 1.493 1.442 0 C-N-CA 121.903 1.735 . . . . 0.0 111.817 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.59 55.21 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.6 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.1 m95 -112.79 134.69 54.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 117.066 0.433 . . . . 0.0 109.84 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.8 ptpt -114.2 -175.1 2.6 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.5 p -125.4 165.94 17.49 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.67 149.19 45.66 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.721 -179.344 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.8 Cg_exo -44.77 123.15 4.61 Favored 'Trans proline' 0 N--CA 1.491 1.362 0 C-N-CA 121.693 1.596 . . . . 0.0 112.208 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.42 -7.56 0.9 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 179.564 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.77 179.48 38.48 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.405 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 46.9 p30 -138.0 11.89 2.86 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.831 0.348 . . . . 0.0 110.797 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -82.37 129.46 34.88 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 8.0 m -106.09 80.75 1.55 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.316 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.6 pt -129.69 15.88 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.651 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 t -126.77 99.77 29.01 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -77.45 163.16 30.05 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.364 2.043 . . . . 0.0 111.939 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 45.7 mm -94.99 122.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -95.71 121.39 37.38 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.41 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.74 -45.68 91.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.172 0.511 . . . . 0.0 109.766 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -112.77 137.92 50.37 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.087 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.9 m -60.56 134.35 56.99 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.958 0.409 . . . . 0.0 110.129 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 28.7 m -76.45 -31.78 58.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.182 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 66.88 -101.56 0.67 Allowed Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.437 -0.665 . . . . 0.0 111.437 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -67.54 -17.71 64.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.835 0.35 . . . . 0.0 111.004 -179.462 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.78 -161.56 21.11 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.435 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 54.8 p90 -143.2 151.7 40.93 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.903 0.382 . . . . 0.0 111.2 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.9 t -64.49 114.14 4.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.157 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.445 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 68.2 m -103.05 -23.75 13.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.769 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.7 mtt180 -162.31 165.47 15.58 Favored Pre-proline 0 CA--C 1.531 0.248 0 C-N-CA 120.396 -0.521 . . . . 0.0 110.407 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.6 123.55 11.65 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 121.601 1.534 . . . . 0.0 111.49 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.41 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 51.3 t30 51.57 40.51 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.033 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.9 mmm -147.47 114.48 6.16 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.576 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.42 ' N ' ' O ' ' A' ' 108' ' ' ALA . 35.5 m -101.28 149.28 24.18 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.323 178.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 101' ' ' THR . . . . . 0.445 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 63.6 m -120.97 119.68 33.25 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.706 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 157.28 60.32 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.143 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -62.7 -19.23 67.63 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.66 2.24 . . . . 0.0 111.78 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 42.0 m -69.79 -14.27 62.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.331 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.67 -20.4 39.32 Favored Glycine 0 N--CA 1.464 0.517 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -69.19 149.5 48.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.985 0.421 . . . . 0.0 110.092 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.33 133.6 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -166.55 -179.82 0.9 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.287 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.658 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 32.2 Cg_exo -59.52 -20.07 55.29 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.835 2.357 . . . . 0.0 112.162 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.7 p -155.58 163.03 40.51 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.414 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -86.49 141.03 29.38 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.68 -167.65 31.56 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 12.7 p -149.68 157.59 43.38 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.855 0.36 . . . . 0.0 110.059 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -90.43 135.79 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.541 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 12.2 p -154.11 153.16 31.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.275 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 19.6 tt -157.62 138.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.531 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -112.97 146.48 38.97 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.325 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.404 ' CD2' ' O ' ' A' ' 119' ' ' CYS . 49.5 p-80 -154.11 -163.53 1.65 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.26 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.404 ' O ' ' CD2' ' A' ' 118' ' ' HIS . 76.9 m -69.45 126.3 29.35 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 93.7 m-20 -92.14 9.34 33.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.027 0.441 . . . . 0.0 110.369 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.501 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 14.8 tt -134.11 169.19 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.607 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.501 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.6 ptm180 -100.12 106.45 18.17 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.04 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.9 m -99.73 138.04 37.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.099 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 66.2 mtt -143.23 160.64 40.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.249 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.618 ' ND2' ' CD1' ' A' ' 140' ' ' TYR . 98.0 m-20 59.86 40.18 19.58 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.841 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.52 28.58 63.2 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.01 128.79 23.3 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' SER . . . . . 0.483 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 13.3 m -88.87 137.84 31.95 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 122.739 -0.271 . . . . 0.0 110.537 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 62.4 m -77.63 129.67 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.166 179.725 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 40.9 t -143.85 136.39 27.03 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' SER . 96.5 m-20 33.75 -99.91 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.387 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -125.3 4.75 7.75 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.365 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -129.65 154.48 47.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.739 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.9 t -102.77 146.27 28.49 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.442 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.9 mt -98.61 131.26 44.94 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.155 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -97.83 134.26 41.22 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.68 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -80.67 178.23 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.707 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -66.59 133.24 49.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.283 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.54 35.08 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.618 ' CD1' ' ND2' ' A' ' 125' ' ' ASN . 92.9 m-85 -121.63 134.41 54.99 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.093 0.473 . . . . 0.0 110.531 179.52 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' ILE . . . . . 0.42 HG23 ' CG2' ' A' ' 149' ' ' VAL . 36.6 pt -121.94 -163.84 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.357 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.4 152.93 28.95 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.9 m -63.11 -45.03 93.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.881 0.372 . . . . 0.0 110.661 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -94.73 3.17 55.36 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.876 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 33.7 t 61.4 116.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.472 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 173.71 -20.59 0.06 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLN . . . . . 0.452 ' OE1' ' N ' ' A' ' 147' ' ' GLN . 0.0 OUTLIER -94.68 128.92 37.94 Favored Pre-proline 0 CA--C 1.548 0.888 0 CA-C-N 117.048 0.424 . . . . 0.0 110.267 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -76.99 161.72 32.64 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.821 2.347 . . . . 0.0 111.809 178.918 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' VAL . . . . . 0.42 ' CG2' HG23 ' A' ' 141' ' ' ILE . 54.7 t -99.15 127.9 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.3 -179.418 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -101.57 90.53 4.09 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -65.46 -43.09 91.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.519 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 85.8 p -89.15 -8.75 53.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.527 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.447 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 56.82 -179.46 0.63 Allowed Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.3 m -117.73 118.78 33.0 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.1 mt -63.21 -42.25 99.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.032 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.554 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.0 t-20 -93.18 179.93 5.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.434 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.22 32.93 0.32 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.554 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.44 177.16 26.23 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 23.2 mmm180 -128.49 143.61 51.01 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.811 0.338 . . . . 0.0 110.269 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 33.8 m -83.06 113.08 20.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -101.56 -18.25 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.704 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.97 171.4 6.39 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.248 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -51.7 129.16 28.84 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 121.705 1.603 . . . . 0.0 111.921 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 50.81 34.34 10.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.734 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.5 OUTLIER -127.55 119.03 25.09 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.028 0.442 . . . . 0.0 110.175 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.523 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 26.4 m -110.8 122.66 48.39 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.075 179.555 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -88.02 135.65 33.32 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 168' ' ' CYS . . . . . 0.582 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 87.8 m -84.05 141.4 31.18 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.039 0.447 . . . . 0.0 110.382 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.7 m -63.24 -45.58 90.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.283 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -104.78 18.58 22.04 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.133 0.492 . . . . 0.0 110.984 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 72.19 24.8 75.86 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.53 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 91.5 t80 -54.64 143.9 23.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.883 0.373 . . . . 0.0 110.403 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 96.3 m -103.86 125.56 50.37 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.375 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -179.21 162.05 28.62 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.28 -31.4 73.82 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.67 2.247 . . . . 0.0 112.4 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -110.27 4.57 20.99 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.292 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.582 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.7 t 49.74 71.67 0.38 Allowed 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.716 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.681 179.928 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 73.6 m . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -72.59 -10.34 59.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.534 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -68.46 140.27 55.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.578 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.73 -174.23 36.34 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.841 -0.903 . . . . 0.0 110.841 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -164.86 118.31 0.8 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 165.33 -172.36 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 141.38 49.75 0.05 OUTLIER Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.984 -0.847 . . . . 0.0 110.984 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' HIS . . . . . 0.716 ' CG ' ' H ' ' A' ' 51' ' ' ASP . 26.1 t-80 -63.19 -168.09 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.709 0.29 . . . . 0.0 110.373 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.716 ' H ' ' CG ' ' A' ' 50' ' ' HIS . 96.8 m-20 -61.9 -40.69 96.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.511 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -158.63 153.09 24.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.586 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.454 HD11 ' HA ' ' A' ' 66' ' ' TYR . 92.2 mt -82.34 161.9 22.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.662 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.7 mtpt -123.25 166.26 15.55 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.845 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 69.13 165.7 4.29 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.47 -166.17 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.956 2.437 . . . . 0.0 111.876 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 12.6 m-20 58.64 36.14 24.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.8 p -100.46 136.56 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.031 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 60.4 m -141.41 176.9 8.5 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.994 0.426 . . . . 0.0 110.283 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.15 161.71 31.43 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.1 m -77.91 171.07 15.54 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 44.9 ttm180 -59.98 -42.91 95.19 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.852 0.358 . . . . 0.0 110.392 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -62.89 -40.45 97.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.994 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.471 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 21.2 m120 -125.67 50.52 1.82 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.578 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.92 138.27 49.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.607 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.471 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.9 p90 -158.45 165.64 34.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.106 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 79.4 m -69.2 139.08 54.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.296 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 25.7 m -54.42 146.89 30.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.095 -179.155 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -48.01 125.58 11.85 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 C-N-CA 121.605 1.537 . . . . 0.0 112.344 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.424 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.45 -12.89 58.4 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 88.9 m95 -114.82 134.38 55.18 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 110.213 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -125.25 -170.26 2.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.51 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 3.2 p -131.33 168.9 16.77 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.332 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.76 ' H ' HD12 ' A' ' 74' ' ' LEU . 0.0 OUTLIER -87.29 164.46 35.56 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.436 -179.21 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -53.0 125.41 18.21 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 121.875 1.717 . . . . 0.0 112.035 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.05 -0.31 11.89 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.89 174.48 35.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -140.14 7.54 2.22 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.881 0.372 . . . . 0.0 110.698 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 -83.33 131.22 35.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 54.1 m -94.27 38.53 1.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.905 0.383 . . . . 0.0 110.11 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.09 6.54 6.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.646 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.0 t -107.03 117.08 57.36 Favored Pre-proline 0 CA--C 1.537 0.446 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.913 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.73 155.71 44.24 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.418 2.079 . . . . 0.0 112.433 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.424 ' N ' ' O ' ' A' ' 70' ' ' GLY . 83.2 mt -107.34 119.12 56.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.199 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.89 113.85 26.23 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.461 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 1.8 mpt_? -62.31 -40.21 95.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.375 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -109.59 127.8 54.76 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 109.842 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.6 p -49.41 122.13 5.81 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.209 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.63 -24.24 56.42 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.919 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.72 -115.48 4.26 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -77.52 -4.46 45.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.37 175.9 36.5 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 40.2 t80 -123.17 132.57 54.11 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.221 0.534 . . . . 0.0 111.172 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 94' ' ' CYS . . . . . 0.479 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 3.4 m -65.57 117.57 8.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.827 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 95' ' ' SER . . . . . 0.434 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 47.1 m -104.87 -21.94 13.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.53 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 -158.44 163.15 25.26 Favored Pre-proline 0 C--N 1.331 -0.214 0 C-N-CA 120.264 -0.575 . . . . 0.0 110.748 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -48.98 120.48 5.5 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.926 1.751 . . . . 0.0 111.501 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.422 ' O ' ' OD1' ' A' ' 98' ' ' ASN . 56.3 t-20 54.69 41.47 31.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.975 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.0 mmm -146.59 115.68 6.97 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.954 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' ALA . 91.0 m -99.15 146.74 25.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.71 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' THR . . . . . 0.434 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 32.8 m -118.84 114.19 22.25 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.151 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.9 158.75 64.45 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.997 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -55.36 -28.01 60.89 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 122.749 2.299 . . . . 0.0 111.817 178.027 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.3 t -63.97 -16.6 61.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.591 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.73 -13.64 59.27 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -69.46 149.85 47.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.918 0.389 . . . . 0.0 110.039 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.44 129.45 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.812 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.692 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -164.23 179.16 1.23 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.498 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.692 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 32.4 Cg_exo -59.21 -23.39 69.27 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.824 2.349 . . . . 0.0 111.944 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 36.2 p -155.53 162.95 40.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.677 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.35 -37.76 43.62 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.365 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.9 -40.05 96.96 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 42.0 t -68.44 138.6 55.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 85.8 mtp180 -125.11 47.77 2.11 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -69.62 149.09 48.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.583 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.443 HG23 ' O ' ' A' ' 116' ' ' ILE . 20.0 tt -68.45 130.3 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.459 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 51.08 -116.53 0.99 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.63 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -159.01 -40.24 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.326 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 5.1 m -95.94 78.42 3.21 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.537 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 98.1 m-20 -64.27 -39.79 94.66 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.216 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 19.7 tt -77.93 166.05 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.348 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -93.41 123.13 36.5 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.951 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.3 m -123.66 141.27 52.17 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.598 179.513 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.9 mtm -146.19 163.25 36.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.431 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.53 ' OD1' ' CE1' ' A' ' 140' ' ' TYR . 5.2 t-20 63.11 44.05 6.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.953 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 72.43 22.64 78.83 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.344 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.53 162.76 36.97 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.2 t -133.35 141.56 47.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.308 . . . . 0.0 110.204 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.31 123.15 36.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.77 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 25.1 t -148.45 134.34 19.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.605 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 48.46 46.77 20.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.5 t0 55.24 27.89 10.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.452 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -137.74 137.3 38.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.231 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 13.8 t -92.14 129.96 37.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.921 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 83.0 mt -113.5 143.57 44.3 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.115 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.6 m -103.99 144.51 31.44 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.54 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 47.3 mt-30 -68.19 174.55 3.83 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.422 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -66.28 131.3 45.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.578 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.57 -15.46 53.13 Favored Glycine 0 N--CA 1.467 0.762 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' TYR . . . . . 0.53 ' CE1' ' OD1' ' A' ' 125' ' ' ASN . 86.8 m-85 -116.88 134.83 54.28 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.275 -0.269 . . . . 0.0 110.275 179.533 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.8 pt -125.37 165.36 22.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 122.35 153.47 8.87 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 20.1 m -62.22 -47.07 86.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 110.681 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -99.58 2.98 45.17 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.79 136.84 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 154.6 -9.72 0.4 Allowed Glycine 0 CA--C 1.518 0.247 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -103.19 108.57 59.32 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.324 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.82 161.61 36.13 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.711 2.274 . . . . 0.0 112.069 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.5 t -116.54 129.31 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.01 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 21.5 m -97.46 107.24 19.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 3.8 mp0 -66.26 -40.16 89.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.448 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.8 m -86.36 -10.72 53.82 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 68.43 -177.47 25.46 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 22.5 m -128.91 114.14 16.1 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.0 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.6 mt -63.38 -42.13 98.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.549 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.427 ' C ' ' H ' ' A' ' 158' ' ' GLY . 98.0 m-20 -95.94 -172.36 2.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.389 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.65 38.24 1.24 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -72.55 176.38 42.29 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -130.2 148.36 52.03 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.2 m -85.05 120.18 26.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.081 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.8 m -104.01 -11.68 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.295 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.687 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -176.55 174.79 0.69 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.687 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 43.8 Cg_exo -55.24 125.13 18.14 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.163 1.908 . . . . 0.0 111.116 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 23.4 t30 56.15 34.66 24.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.682 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.1 mmt-85 -135.37 131.64 36.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.402 0.62 . . . . 0.0 110.624 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.48 ' O ' ' CE1' ' A' ' 172' ' ' PHE . 7.7 t -142.82 147.1 34.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.756 179.524 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -120.99 122.06 39.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.947 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.72 154.95 22.18 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.877 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.4 p -106.96 15.23 25.58 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.957 0.408 . . . . 0.0 110.836 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.414 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 23.9 t80 -119.71 32.94 5.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.933 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.46 57.52 1.64 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.779 -0.929 . . . . 0.0 110.779 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.48 ' CE1' ' O ' ' A' ' 166' ' ' CYS . 89.7 t80 -47.29 110.03 0.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.893 0.378 . . . . 0.0 110.646 -179.527 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 177' ' ' CYS . 91.0 m -129.16 126.86 40.17 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.22 179.272 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 64.15 166.44 1.05 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.364 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -55.88 -36.91 96.3 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 C-N-CA 122.75 2.3 . . . . 0.0 112.313 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -74.96 46.46 0.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.448 -179.107 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.44 ' O ' ' N ' ' A' ' 173' ' ' THR . 42.3 t 54.2 -93.35 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.646 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.953 -1.022 . . . . 0.0 110.198 -179.857 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 60.2 p . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -137.14 140.6 41.98 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.333 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 51.2 mmm-85 -76.71 147.6 37.3 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.436 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -62.21 -43.01 99.71 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 63.2 29.41 74.38 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -62.57 -38.65 96.73 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.441 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 55.97 95.51 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 74.7 m80 54.72 95.49 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 110.377 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' A' ' 53' ' ' LEU . 44.2 p-10 -143.05 177.09 8.61 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.33 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.524 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -60.26 -44.6 95.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.619 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.437 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 81.0 mt -76.45 153.04 35.96 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -138.36 159.84 41.02 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 120.997 0.427 . . . . 0.0 110.69 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.42 166.1 19.31 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -77.19 -1.31 11.48 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.902 2.402 . . . . 0.0 112.281 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.465 ' OD1' ' CE2' ' A' ' 71' ' ' TRP . 29.5 m120 -117.34 71.8 0.82 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.777 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.491 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.9 t -121.45 130.32 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 75.3 m -142.89 -174.7 4.25 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.201 -179.081 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.83 171.08 45.38 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.5 m -78.89 163.57 25.17 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -59.93 -42.88 94.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.555 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -61.67 -42.39 98.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -127.25 49.38 2.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.871 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.07 146.87 53.86 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.669 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -152.9 168.82 24.51 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.824 0.345 . . . . 0.0 110.949 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 91.5 m -70.51 131.32 43.84 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.188 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 62.1 m -49.35 152.37 2.21 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.076 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_exo -51.59 131.64 37.92 Favored 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 121.387 1.392 . . . . 0.0 112.459 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.84 -5.08 53.48 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.465 ' CE2' ' OD1' ' A' ' 57' ' ' ASN . 44.5 m95 -132.24 140.86 48.82 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.625 0.25 . . . . 0.0 110.455 179.314 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -115.4 -166.4 1.12 Allowed 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.005 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 76.9 p -115.87 158.21 23.3 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 77' ' ' GLY . 18.9 mt -89.91 151.08 44.88 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.604 -179.191 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.427 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.5 Cg_exo -39.94 106.68 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.206 1.937 . . . . 0.0 112.142 179.43 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.42 -10.57 2.66 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.19 171.81 52.18 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.524 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 55.1 p30 -127.87 11.39 6.62 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.551 0.215 . . . . 0.0 111.117 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -89.46 139.1 30.86 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.887 -179.48 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.2 m -99.26 43.18 1.07 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.921 0.391 . . . . 0.0 110.018 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 43.4 pt -94.2 19.23 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.474 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.32 95.05 49.03 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -77.59 159.79 31.87 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.265 1.976 . . . . 0.0 112.221 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.59 120.67 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.498 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.07 109.37 21.34 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.55 ' HE ' HD21 ' A' ' 98' ' ' ASN . 1.1 mpt_? -64.55 -39.6 94.05 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.521 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -103.42 133.47 48.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.147 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 31.2 t -61.94 134.43 56.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.33 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 32.4 m -78.97 -28.21 43.57 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.507 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 76.19 -104.72 1.87 Allowed Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 179.543 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -80.04 -3.48 48.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.659 0.266 . . . . 0.0 111.083 -179.492 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.3 -160.1 20.19 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -147.05 152.19 38.14 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.918 0.39 . . . . 0.0 111.33 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.41 115.61 5.28 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 20.7 t -109.84 -24.17 10.99 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.927 -179.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -156.14 158.43 31.58 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.095 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -52.51 125.63 18.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.043 1.829 . . . . 0.0 111.22 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.55 HD21 ' HE ' ' A' ' 86' ' ' ARG . 60.9 m-80 53.04 37.76 25.58 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.5 mtp -148.94 114.65 5.66 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-O 121.37 0.605 . . . . 0.0 110.895 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 108' ' ' ALA . 27.6 m -96.9 147.54 23.86 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.441 178.846 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 87.0 m -119.89 123.77 44.39 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.572 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.82 155.3 45.46 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.74 -20.03 67.53 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.332 2.021 . . . . 0.0 111.654 179.253 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.6 t -66.57 -17.04 64.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.282 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.28 -20.84 34.45 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 52.5 tp60 -67.87 150.7 48.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.839 0.352 . . . . 0.0 110.252 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.5 mt -130.54 132.56 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.858 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.665 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.42 177.75 1.08 Allowed Pre-proline 0 CA--C 1.536 0.433 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.28 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.665 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 51.4 Cg_exo -56.32 -23.76 47.93 Favored 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 122.602 2.201 . . . . 0.0 111.911 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 30.0 p -151.79 162.23 41.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.433 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -27.52 48.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.3 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -75.37 42.98 1.49 Allowed Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 39.9 t -62.96 139.76 58.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.038 0.447 . . . . 0.0 110.694 -179.565 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.1 mmt-85 -79.01 -13.67 59.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.371 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 47.7 t -73.34 101.6 3.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.313 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 42.4 pt -141.67 -159.85 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.669 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -56.84 134.32 55.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.098 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -58.78 -42.55 89.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.376 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' CYS . . . . . 0.497 ' SG ' ' N ' ' A' ' 120' ' ' ASN . 34.3 t -172.25 175.03 3.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.704 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' ASN . . . . . 0.497 ' N ' ' SG ' ' A' ' 119' ' ' CYS . 25.0 p-10 -95.96 10.44 37.36 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.687 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -139.31 165.46 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.785 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -77.41 98.62 5.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.75 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.2 m -111.07 119.06 37.76 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 95.9 mtp -139.82 165.26 27.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.447 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASN . . . . . 0.513 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 3.7 m-20 59.92 39.61 20.06 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.702 0.287 . . . . 0.0 110.992 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.15 25.22 69.29 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.16 126.55 26.03 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' SER . . . . . 0.496 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 4.9 m -82.21 133.38 35.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.65 0.262 . . . . 0.0 110.311 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.2 t -95.05 116.92 29.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.254 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 32.4 t -139.01 143.98 38.69 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.124 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 41.67 -116.8 0.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -119.57 21.93 11.88 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -143.0 145.67 33.14 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.522 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.3 t -105.11 140.76 37.81 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.247 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.0 mt -102.33 131.84 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.022 -179.657 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 20.6 m -92.25 134.37 34.95 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 -61.33 173.49 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' LYS . . . . . 0.449 ' HD3' ' N ' ' A' ' 138' ' ' LYS . 0.0 OUTLIER -62.95 136.18 57.7 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.368 0.604 . . . . 0.0 111.499 179.52 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 88.72 -8.61 78.91 Favored Glycine 0 CA--C 1.519 0.316 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.16 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -118.76 135.33 54.57 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.953 0.406 . . . . 0.0 110.326 179.564 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 48.7 pt -133.94 173.31 14.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.507 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.103 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 103.0 163.46 25.78 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.1 p -65.61 -39.68 91.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.609 0.242 . . . . 0.0 110.832 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.439 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -96.46 10.74 37.32 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.853 0.358 . . . . 0.0 110.461 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.513 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 14.7 m 45.76 41.16 7.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.037 -179.551 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.439 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -108.78 5.44 32.66 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 29.9 tt0 -112.38 110.62 53.01 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 116.793 0.297 . . . . 0.0 110.718 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.7 161.85 27.43 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.514 2.142 . . . . 0.0 112.193 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.7 t -111.99 129.08 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.188 0.518 . . . . 0.0 109.988 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -98.71 93.1 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -68.69 -42.01 78.39 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.4 m -97.77 -10.23 25.19 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.915 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 66.43 179.48 10.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -98.12 179.18 4.85 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 155' ' ' LEU . . . . . 0.589 ' CD1' ' H ' ' A' ' 177' ' ' CYS . 86.0 mt -88.18 -3.54 58.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.496 ' C ' ' H ' ' A' ' 158' ' ' GLY . 30.2 p-10 -170.64 -147.21 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.403 179.723 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -73.8 30.95 0.9 Allowed Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -61.68 173.49 7.34 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 71.9 ttt-85 -114.06 123.18 49.05 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.486 0.184 . . . . 0.0 110.903 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 69.0 m -68.23 91.32 0.37 Allowed 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.12 -27.48 14.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.301 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -156.95 173.87 4.58 Favored Pre-proline 0 C--N 1.329 -0.302 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -52.33 136.54 55.46 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 121.588 1.525 . . . . 0.0 111.941 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 41.89 25.74 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.627 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 163' ' ' PRO . 75.0 mmt-85 -134.21 140.55 46.56 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.709 0.766 . . . . 0.0 110.984 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 28.7 p -150.37 161.17 43.01 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.517 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.85 139.09 45.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.012 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 168' ' ' CYS . . . . . 0.6 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 88.2 m -70.08 138.59 52.16 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-O 121.012 0.435 . . . . 0.0 110.173 -179.319 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.0 m -62.66 -46.07 89.9 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.89 -178.615 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -117.48 28.27 8.56 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 59.4 30.09 67.44 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.454 ' CZ ' ' SG ' ' A' ' 168' ' ' CYS . 24.5 p90 -67.54 152.37 45.76 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.644 0.259 . . . . 0.0 110.829 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 20.4 p -80.96 143.22 32.75 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.002 -179.393 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -178.54 158.2 22.53 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.04 -51.44 2.21 Favored 'Trans proline' 0 N--CA 1.499 1.795 0 C-N-CA 122.422 2.081 . . . . 0.0 112.92 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.415 ' OE1' HD21 ' A' ' 155' ' ' LEU . 49.0 mt-30 -80.66 -50.08 10.39 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.086 0.469 . . . . 0.0 110.534 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.6 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 36.5 t -116.61 115.22 25.29 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.383 178.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 178' ' ' GLU . . . . . 0.442 ' OXT' ' O ' ' A' ' 172' ' ' PHE . 75.0 tt0 . . . . . 0 C--N 1.325 -0.471 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.988 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -74.44 99.43 3.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.301 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.8 mtt-85 -63.44 -38.53 91.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.208 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -80.42 167.65 50.8 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.79 156.36 25.27 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -95.65 172.19 29.76 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.53 112.66 4.34 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -111.72 124.36 52.17 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.926 0.393 . . . . 0.0 110.443 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.546 ' OD1' ' N ' ' A' ' 52' ' ' ALA . 45.7 p-10 -65.6 -35.21 80.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.616 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.546 ' N ' ' OD1' ' A' ' 51' ' ' ASP . . . -174.32 -13.66 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.512 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.437 ' H ' ' H ' ' A' ' 52' ' ' ALA . 29.0 mt -70.54 137.08 49.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.238 0.542 . . . . 0.0 110.795 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -142.91 164.01 31.24 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.53 22.8 Favored Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.212 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -76.01 7.43 3.26 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.792 2.328 . . . . 0.0 112.187 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 27.5 m120 -123.12 70.5 1.03 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.891 0.377 . . . . 0.0 111.087 -179.661 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.444 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 51.8 t -115.07 130.82 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 59' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 57.2 m -151.3 178.44 9.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.457 -179.673 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.3 172.23 39.98 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -81.18 163.76 22.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.63 0.253 . . . . 0.0 110.326 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 73.3 ttp85 -59.54 -43.25 93.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.685 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -62.9 -37.25 86.2 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASN . . . . . 0.434 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 41.9 t30 -132.51 53.75 1.99 Allowed 'General case' 0 C--O 1.23 0.078 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.906 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.543 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -72.51 142.56 48.52 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.266 179.247 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.434 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.8 p90 -159.36 171.21 20.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.4 m -67.97 135.33 52.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.153 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -48.36 168.43 0.17 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -178.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.47 133.62 58.12 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.093 1.862 . . . . 0.0 112.114 179.046 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 94.98 -17.19 59.78 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 86.8 m95 -112.79 138.18 50.0 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -122.25 -165.49 1.28 Allowed 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.2 p -126.04 164.7 20.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.202 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.501 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.6 mt -88.96 151.44 47.12 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.814 -179.119 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_exo -39.86 107.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.348 2.032 . . . . 0.0 112.121 179.171 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.17 -14.95 7.25 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.76 178.59 52.32 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -139.35 15.21 2.58 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 121.105 0.479 . . . . 0.0 110.7 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -80.34 131.99 35.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.262 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.93 47.89 1.11 Allowed 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.732 0.301 . . . . 0.0 110.403 -179.573 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.7 pt -105.71 22.38 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.758 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 t -124.45 97.78 39.05 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.725 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -78.76 157.15 27.82 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.691 2.261 . . . . 0.0 112.097 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.491 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.7 mt -109.51 118.63 57.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.963 0.411 . . . . 0.0 110.297 179.109 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 17.0 m -90.64 130.38 36.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.157 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.443 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -61.75 -45.44 93.92 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.183 0.515 . . . . 0.0 110.08 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -107.46 142.31 37.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.231 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.8 m -60.72 133.79 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.264 -179.499 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 52.8 m -76.1 -27.84 57.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.583 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.32 -113.45 3.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -72.57 -9.1 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.887 0.375 . . . . 0.0 110.785 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.42 -166.66 29.86 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -139.81 146.25 39.17 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.09 0.472 . . . . 0.0 110.902 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 18.6 t -69.05 116.3 9.34 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.5 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 83.6 p -105.26 -22.02 13.14 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.413 -179.317 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ARG . . . . . 0.477 ' CG ' HH11 ' A' ' 96' ' ' ARG . 0.1 OUTLIER -158.99 165.53 18.26 Favored Pre-proline 0 C--O 1.236 0.385 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.845 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -51.97 122.35 10.37 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 121.836 1.691 . . . . 0.0 111.581 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.443 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 60.4 t30 53.17 39.74 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.74 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 98.0 mtp -146.86 116.85 7.26 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 121.137 0.494 . . . . 0.0 110.408 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 56.6 m -104.53 149.67 25.27 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.77 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.6 m -121.06 122.91 41.09 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.864 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.53 155.44 43.97 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.604 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -51.61 -27.67 26.48 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.574 2.182 . . . . 0.0 111.906 177.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.57 -16.28 64.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.662 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.73 -15.37 55.73 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 106' ' ' GLN . . . . . 0.459 ' OE1' ' N ' ' A' ' 107' ' ' ILE . 1.7 tm0? -67.69 143.15 56.08 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 120.826 0.346 . . . . 0.0 110.271 179.821 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.459 ' N ' ' OE1' ' A' ' 106' ' ' GLN . 96.0 mt -122.26 130.48 74.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.812 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.671 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.01 173.23 1.41 Allowed Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.558 179.448 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 52.1 Cg_exo -53.09 -31.34 53.82 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 122.67 2.247 . . . . 0.0 112.233 179.071 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.1 m -136.46 159.28 42.26 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.66 145.31 34.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.338 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 165.04 116.69 0.37 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 46.9 t -147.87 141.62 25.67 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.756 0.312 . . . . 0.0 110.557 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 87.8 mtm-85 -69.76 -105.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.45 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -171.42 67.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.481 179.798 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.424 HG23 ' O ' ' A' ' 116' ' ' ILE . 20.2 tt -128.04 132.55 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.463 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -134.04 98.52 4.16 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.3 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -148.56 152.06 36.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.555 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 58.6 m -118.36 78.47 1.26 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.51 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -97.41 16.01 21.4 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.501 179.669 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.424 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 16.9 tt -118.11 166.19 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.517 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.424 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 31.7 mmt180 -89.96 99.54 12.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.441 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 59.8 m -103.71 128.99 51.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.17 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 73.8 mtm -139.72 165.55 26.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.079 -179.486 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 60.25 48.73 7.84 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 123.404 0.44 . . . . 0.0 111.151 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 64.72 33.12 86.38 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.75 130.76 9.9 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.3 p -91.61 142.1 27.99 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 122.747 -0.267 . . . . 0.0 110.439 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -105.11 123.18 47.37 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.891 0.377 . . . . 0.0 110.283 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 49.7 m -148.81 142.24 25.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.879 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 47.61 45.85 17.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.935 179.403 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.452 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 99.9 m-20 55.15 29.66 13.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' HIS . . . . . 0.452 ' ND1' ' O ' ' A' ' 132' ' ' ASP . 7.7 m-70 -139.41 145.38 38.84 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 179.528 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.2 t -99.32 119.73 38.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 68.9 mt -101.25 131.24 47.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.77 138.39 37.89 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.152 -179.128 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -64.68 177.4 0.93 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.59 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -59.03 135.4 57.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.643 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 92.39 -1.82 73.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -126.55 138.81 53.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.784 0.326 . . . . 0.0 110.329 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 42.6 pt -135.05 174.65 12.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.821 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 113.54 152.43 10.93 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.4 m -62.87 -44.83 95.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.7 0.286 . . . . 0.0 110.439 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' A' ' 145' ' ' CYS . 26.4 m80 -100.94 5.9 43.39 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.643 -179.682 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' O ' ' O ' ' A' ' 144' ' ' HIS . 39.3 m 60.32 138.78 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.072 0.463 . . . . 0.0 109.925 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 147.66 4.57 0.36 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -119.52 88.73 39.33 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-O 120.775 0.321 . . . . 0.0 110.484 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.45 160.97 15.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.97 2.447 . . . . 0.0 111.697 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 58.6 t -101.45 110.77 29.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 16.1 m -92.22 108.5 20.0 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -65.9 -40.88 91.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.467 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 152' ' ' SER . . . . . 0.407 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 14.2 t -83.55 -13.69 53.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.626 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 65.44 175.09 5.14 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 99.1 m -108.82 123.79 49.6 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.469 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 41.0 mt -63.96 -41.75 97.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.825 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.412 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.4 m-20 -105.03 -172.93 2.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.55 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.34 37.7 1.58 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -75.7 -172.04 31.78 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' ARG . . . . . 0.408 ' NH1' HG21 ' A' ' 169' ' ' THR . 1.2 mpt_? -129.84 149.71 51.46 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.657 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 59.5 m -86.36 119.31 26.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.516 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 93.8 t -83.05 -27.02 7.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.541 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.678 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.69 176.15 1.74 Allowed Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.586 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.678 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.2 Cg_exo -56.67 135.81 72.55 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.347 2.032 . . . . 0.0 111.733 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 63.4 t30 50.59 30.82 5.1 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.428 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 90.0 mtt180 -142.74 101.06 3.79 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.402 0.62 . . . . 0.0 111.232 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 167' ' ' ALA . 14.7 t -104.52 150.71 24.37 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.157 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 167' ' ' ALA . . . . . 0.429 ' N ' ' SG ' ' A' ' 166' ' ' CYS . . . -132.95 123.49 26.03 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.298 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 84.6 m -101.92 132.2 47.86 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 169' ' ' THR . . . . . 0.439 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.5 OUTLIER -111.21 19.24 18.55 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.228 0.537 . . . . 0.0 110.939 -179.451 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.535 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 49.8 t80 -93.79 31.65 1.57 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.577 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.72 3.69 80.29 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.524 ' CD1' ' OXT' ' A' ' 178' ' ' GLU . 49.7 m-85 -106.45 148.67 27.88 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.955 0.407 . . . . 0.0 110.547 179.707 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.0 t -138.74 154.33 48.54 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.256 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 152.39 177.43 26.05 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -65.11 -24.14 59.69 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.765 2.31 . . . . 0.0 111.897 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.407 ' OE1' ' OG ' ' A' ' 152' ' ' SER . 25.2 pt20 -127.87 -44.36 1.48 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.71 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 7.3 t -174.23 -74.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 178' ' ' GLU . . . . . 0.524 ' OXT' ' CD1' ' A' ' 172' ' ' PHE . 84.3 tt0 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.065 -0.969 . . . . 0.0 110.584 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.2 m . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.58 167.67 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.598 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -66.87 146.85 53.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.484 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.83 18.05 66.41 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.662 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 61.05 -128.3 44.4 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -153.02 151.74 23.49 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLY . . . . . 0.522 ' O ' ' NH1' ' A' ' 62' ' ' ARG . . . -100.57 179.57 29.27 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' HIS . . . . . 0.49 ' C ' ' H ' ' A' ' 52' ' ' ALA . 58.7 t-80 -66.99 -1.78 4.52 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.472 0.177 . . . . 0.0 110.707 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.3 t0 70.72 -13.07 0.5 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.562 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.49 ' H ' ' C ' ' A' ' 50' ' ' HIS . . . -65.3 -36.8 85.17 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.573 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 21.1 mt -75.55 148.78 38.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.828 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -134.42 162.48 32.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.272 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.75 159.21 28.66 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -76.12 -1.34 11.32 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.882 2.388 . . . . 0.0 112.304 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.505 ' ND2' ' CE3' ' A' ' 71' ' ' TRP . 5.5 m-80 -109.85 70.05 0.72 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.419 -179.756 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.483 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.8 t -121.85 130.06 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.379 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 99.3 m -142.03 -172.01 3.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.99 -179.588 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.13 168.08 43.39 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.8 m -77.39 165.04 24.93 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ARG . . . . . 0.522 ' NH1' ' O ' ' A' ' 49' ' ' GLY . 60.6 ttt85 -59.25 -43.4 92.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.676 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -62.38 -42.24 99.26 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.353 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -123.46 46.0 2.31 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.83 145.33 54.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.214 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.424 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 15.8 p90 -159.69 -174.97 4.89 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.915 0.388 . . . . 0.0 110.453 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.449 ' SG ' HG22 ' A' ' 73' ' ' THR . 74.0 m -78.45 129.25 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.772 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' CYS . . . . . 0.483 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 34.5 m -47.59 153.83 0.98 Allowed Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.347 -179.199 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -52.56 132.67 46.48 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 121.431 1.42 . . . . 0.0 112.208 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.59 -22.17 39.7 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.563 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 7.2 m95 -112.51 139.21 48.28 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.472 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.49 -166.83 1.16 Allowed 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.499 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.449 HG22 ' SG ' ' A' ' 67' ' ' CYS . 69.3 p -118.07 161.0 20.55 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.742 0.306 . . . . 0.0 110.349 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.565 HD22 ' N ' ' A' ' 74' ' ' LEU . 2.6 mm? -85.87 151.3 54.78 Favored Pre-proline 0 N--CA 1.448 -0.549 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.1 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -44.2 108.39 0.12 Allowed 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 121.718 1.612 . . . . 0.0 111.911 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.33 -8.08 27.46 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -96.37 -178.46 35.62 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -138.04 17.86 2.81 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.998 0.428 . . . . 0.0 110.884 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -79.0 128.29 33.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.39 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 19.7 m -99.18 70.41 1.77 Allowed 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.9 pt -129.96 19.69 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.106 -179.505 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.64 87.71 27.14 Favored Pre-proline 0 N--CA 1.465 0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.371 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.35 147.3 95.89 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.691 2.261 . . . . 0.0 111.976 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' ILE . . . . . 0.451 ' N ' ' O ' ' A' ' 70' ' ' GLY . 95.7 mt -99.12 119.9 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.027 179.08 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -90.77 127.3 36.29 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.444 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.6 OUTLIER -62.6 -45.55 92.37 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.147 0.499 . . . . 0.0 109.774 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -122.82 152.51 40.64 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.468 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 m -59.48 135.64 57.73 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.318 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.4 m -79.15 -26.13 42.81 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.811 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -113.02 3.62 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -72.75 -8.51 55.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.797 0.332 . . . . 0.0 110.657 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.81 -168.79 25.32 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -141.75 149.75 40.86 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.959 0.409 . . . . 0.0 110.882 179.623 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.1 m -65.68 113.0 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.13 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.5 t -102.78 -24.01 13.75 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.122 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.0 mtt85 -153.47 164.85 19.18 Favored Pre-proline 0 C--N 1.329 -0.284 0 C-N-CA 120.414 -0.515 . . . . 0.0 110.706 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.51 119.84 6.52 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.73 1.62 . . . . 0.0 111.662 179.293 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.444 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 14.8 m-20 55.51 39.66 31.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.113 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 63.9 mmm -147.86 119.96 8.28 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.129 0.49 . . . . 0.0 110.102 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -102.25 150.14 23.6 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.632 179.001 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 98.7 m -121.7 124.62 44.68 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.531 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.71 152.34 40.67 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.535 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -49.72 -24.86 10.47 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.536 2.157 . . . . 0.0 111.762 177.529 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -64.62 -17.57 64.13 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.589 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.63 -13.4 58.03 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -71.25 151.79 43.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.901 0.381 . . . . 0.0 110.294 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -127.93 131.21 69.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.652 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.65 177.84 0.74 Allowed Pre-proline 0 C--N 1.327 -0.402 0 C-N-CA 120.526 -0.469 . . . . 0.0 110.474 179.339 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -56.93 -23.34 50.83 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.816 2.344 . . . . 0.0 111.921 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 110' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 113' ' ' SER . 33.6 p -150.67 167.71 26.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 110.212 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.93 -28.57 58.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.748 -179.268 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -120.51 88.97 0.44 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 110' ' ' SER . 4.8 m -154.56 154.78 33.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.437 . . . . 0.0 110.409 179.617 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -91.52 -166.42 1.56 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.156 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 p -153.75 161.08 42.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.375 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 33.3 pt -82.1 44.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.816 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 95.0 mt-30 48.98 -116.89 0.89 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.502 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' HIS . . . . . 0.518 ' ND1' ' O ' ' A' ' 118' ' ' HIS . 57.9 t-80 40.66 43.4 1.6 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 6.3 p -102.55 175.96 5.33 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.586 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -63.25 -40.16 96.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.498 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.518 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 14.4 tt -87.68 174.08 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 121.145 0.497 . . . . 0.0 110.077 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.518 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 10.2 ptm180 -122.28 119.27 30.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.311 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 9.0 m -124.37 157.17 35.7 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.657 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 71.5 mtm -136.09 173.6 11.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.259 -179.483 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.9 m120 61.74 39.78 13.76 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.92 24.59 76.34 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.12 134.2 29.17 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.3 t -86.1 135.78 33.48 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.354 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 95.4 m -69.98 119.38 14.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.364 -179.597 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -131.36 100.62 5.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.195 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 48.79 -111.37 0.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.696 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -111.42 17.2 20.34 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.856 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -131.94 153.77 49.95 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.495 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 94.4 m -105.78 132.54 51.78 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 88.4 mt -97.91 127.21 43.71 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' CYS . . . . . 0.463 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 5.7 m -89.66 133.67 34.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.076 -179.017 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 -74.07 178.07 5.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.256 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -64.32 125.67 25.32 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.433 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.94 -18.65 45.95 Favored Glycine 0 N--CA 1.466 0.691 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -118.48 137.34 53.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.801 0.334 . . . . 0.0 110.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 18.9 pt -135.99 175.42 10.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.932 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.463 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 101.19 163.78 27.57 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 40.3 p -62.51 -42.74 99.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.817 0.341 . . . . 0.0 110.471 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -90.72 4.06 52.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.356 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 36.4 m 48.44 37.64 9.26 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.461 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.526 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -105.1 7.32 43.99 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.732 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -109.4 109.08 60.26 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.67 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -77.47 160.42 32.03 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.548 2.165 . . . . 0.0 112.191 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.4 t -115.61 131.04 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 55.9 m -99.18 101.98 13.5 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.963 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.48 -61.38 2.38 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.834 0.35 . . . . 0.0 110.232 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.5 t -116.93 -4.99 11.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.755 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -78.84 -178.72 50.88 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.488 ' H ' ' CB ' ' A' ' 166' ' ' CYS . 9.4 m 45.09 48.96 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.914 0.387 . . . . 0.0 110.505 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 81.5 mt -62.88 -42.04 99.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.864 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -109.88 -113.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.329 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.64 11.32 68.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.59 151.67 32.29 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 -179.379 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 159' ' ' ARG . . . . . 0.483 ' O ' ' SG ' ' A' ' 166' ' ' CYS . 3.2 mpt_? -102.3 136.17 42.61 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.527 0.203 . . . . 0.0 110.507 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 70.7 m -85.49 120.52 27.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.998 0.428 . . . . 0.0 111.085 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.5 t -104.01 -29.17 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.343 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -161.44 169.18 10.12 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.457 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 69.8 Cg_exo -49.87 127.98 20.53 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.093 1.862 . . . . 0.0 111.874 178.719 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 54.74 32.26 17.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.967 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.1 tpt85 -139.24 131.57 28.39 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-O 121.213 0.53 . . . . 0.0 110.231 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.488 ' CB ' ' H ' ' A' ' 154' ' ' CYS . 1.8 t -145.25 154.43 42.37 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.217 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -98.42 138.67 35.32 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.698 179.149 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 20.9 m -75.3 143.77 42.78 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.392 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.3 m -62.99 -45.47 92.28 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.741 -179.197 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -104.21 19.51 20.04 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 121.01 0.433 . . . . 0.0 110.861 -179.4 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.57 26.58 72.83 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 177' ' ' CYS . 2.2 t80 -56.66 169.79 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.927 0.394 . . . . 0.0 110.258 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 43.9 p -98.09 164.27 12.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.466 0.65 . . . . 0.0 110.518 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 79.09 144.08 2.74 Favored Glycine 0 CA--C 1.54 1.636 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.173 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -52.92 -39.45 78.59 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.506 2.137 . . . . 0.0 112.386 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.52 ' O ' ' N ' ' A' ' 178' ' ' GLU . 75.9 mt-30 -74.85 -9.71 58.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.663 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.42 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 91.9 m 55.75 -80.73 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.608 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 178' ' ' GLU . . . . . 0.52 ' N ' ' O ' ' A' ' 176' ' ' GLN . 80.0 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.685 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.5 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.28 -38.26 89.73 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.848 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 61.1 ttm-85 -60.66 -43.4 97.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.011 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.89 -125.5 5.72 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.39 -177.64 47.87 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -167.78 174.1 42.77 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.53 54.44 0.23 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 45.0 m80 -61.86 -41.67 98.13 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.82 0.343 . . . . 0.0 110.676 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 67.7 t0 -88.94 114.53 25.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.359 -179.819 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.9 147.42 53.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.664 -179.843 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.431 HD12 ' HB1' ' A' ' 65' ' ' ALA . 94.8 mt -71.75 152.8 42.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.718 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -126.82 161.72 27.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.465 0.65 . . . . 0.0 110.616 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.05 167.44 15.95 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.73 -168.24 0.35 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 123.029 2.486 . . . . 0.0 111.7 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.517 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 98.4 m-20 57.19 36.91 28.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.711 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.04 137.74 24.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.403 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 34.2 m -138.98 178.96 6.78 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.001 0.429 . . . . 0.0 110.232 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.06 164.13 31.62 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 65' ' ' ALA . 7.8 m -83.38 173.83 11.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.682 0.277 . . . . 0.0 110.561 179.715 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -61.85 -42.84 99.54 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.888 0.375 . . . . 0.0 110.518 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -62.78 -38.94 92.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.896 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -132.98 55.85 1.88 Allowed 'General case' 0 N--CA 1.457 -0.113 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.652 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.534 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.82 145.45 50.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.47 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -159.12 166.37 31.71 Favored 'General case' 0 CA--C 1.519 -0.221 0 CA-C-O 121.054 0.454 . . . . 0.0 110.995 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 75.0 m -72.04 142.03 49.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.187 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 63.8 m -58.67 150.09 59.34 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.814 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -56.05 119.44 6.61 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.17 1.913 . . . . 0.0 112.357 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 116.72 -14.82 14.5 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.517 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.0 m95 -119.55 132.73 55.81 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.109 0.481 . . . . 0.0 110.412 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -111.86 -177.04 3.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.292 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.539 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 51.2 p -130.63 166.34 20.89 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.515 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.4 ' HG ' HG21 ' A' ' 82' ' ' VAL . 87.6 mt -90.2 151.75 45.12 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.451 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.2 Cg_exo -47.52 128.44 15.2 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 121.51 1.473 . . . . 0.0 112.212 178.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.74 -5.82 7.12 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 179.67 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.561 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -91.87 171.95 34.95 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.561 ' ND2' ' O ' ' A' ' 77' ' ' GLY . 7.3 m120 -140.57 8.79 2.19 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.955 0.407 . . . . 0.0 110.992 179.477 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -86.67 129.29 34.92 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.435 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 18.4 m -92.86 46.23 1.22 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.856 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 45.2 pt -98.01 -4.45 9.68 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.528 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' VAL . . . . . 0.4 HG21 ' HG ' ' A' ' 74' ' ' LEU . 57.8 t -97.64 111.59 59.13 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.498 -0.481 . . . . 0.0 111.13 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.88 159.5 41.68 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.306 2.004 . . . . 0.0 111.962 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 93.4 mt -98.83 121.67 49.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.426 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.34 122.66 34.14 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.448 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -64.6 -45.32 87.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.372 0.606 . . . . 0.0 109.551 179.462 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 74.5 m-70 -137.17 149.46 47.27 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.646 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.5 p -52.3 128.87 26.6 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.361 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.5 m -72.31 -31.84 66.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.83 -112.81 3.54 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -70.42 -6.58 36.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.635 0.255 . . . . 0.0 110.496 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.07 -162.93 21.1 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.88 152.81 39.31 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.998 0.428 . . . . 0.0 110.772 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.77 113.92 5.93 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 36.9 t -106.5 -23.27 12.54 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.254 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -156.82 162.02 28.41 Favored Pre-proline 0 C--N 1.327 -0.378 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.542 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_exo -48.4 119.27 3.93 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 121.907 1.738 . . . . 0.0 111.331 179.091 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.448 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 96.4 m-20 54.33 40.58 31.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.35 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 83.4 mmm -146.84 115.04 6.61 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.484 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -96.72 145.88 25.39 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.148 178.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 61.0 m -119.99 114.39 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.771 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.413 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -79.57 157.63 74.53 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.71 -179.715 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.413 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 28.0 Cg_endo -63.43 -19.27 67.65 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.946 2.431 . . . . 0.0 111.352 178.759 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -69.41 -17.02 63.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.862 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 108.35 -21.79 28.05 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -65.98 150.89 47.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.086 0.47 . . . . 0.0 110.218 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.89 131.62 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.999 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.683 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.02 178.29 1.02 Allowed Pre-proline 0 C--N 1.325 -0.478 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.578 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.683 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -57.06 -23.79 54.44 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.771 2.314 . . . . 0.0 111.639 178.806 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.1 p -151.02 163.26 39.16 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.962 0.41 . . . . 0.0 110.291 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -80.18 140.75 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.302 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 113' ' ' SER . . . -84.27 -174.85 50.58 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.646 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 112' ' ' GLY . 8.6 t -58.52 -152.12 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.679 0.276 . . . . 0.0 110.453 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 54.92 80.89 0.12 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.7 t -154.88 164.02 39.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.381 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 37.5 mm -101.66 120.29 51.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.958 0.409 . . . . 0.0 109.96 -179.752 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -141.27 -7.52 1.02 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.429 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -75.01 70.77 2.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.378 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.8 t -129.76 126.74 38.89 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.542 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -93.63 4.06 54.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.324 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.465 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.6 tt -132.52 168.48 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.332 179.583 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.465 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.5 ptm180 -100.95 118.13 36.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.201 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' CYS . . . . . 0.445 ' C ' ' SD ' ' A' ' 124' ' ' MET . 61.7 m -116.17 138.58 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.689 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' MET . . . . . 0.531 ' SD ' ' N ' ' A' ' 124' ' ' MET . 3.2 mpp? -142.56 165.69 26.7 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.474 -179.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 59.15 51.22 7.18 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.454 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 70.84 26.16 74.48 Favored Glycine 0 C--N 1.331 0.27 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.81 114.49 3.92 Favored Glycine 0 CA--C 1.53 0.983 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 30.6 t -79.49 148.21 31.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.511 0.196 . . . . 0.0 110.976 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.4 m -92.38 102.83 15.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.185 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 35.1 t -149.04 138.59 21.77 Favored 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.498 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 98.5 m-20 51.72 36.57 17.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.788 0.328 . . . . 0.0 110.994 179.375 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 54.19 27.91 8.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.682 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 133' ' ' HIS . . . . . 0.498 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 44.2 m80 -136.34 143.09 43.93 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.961 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 120.44 31.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.093 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.68 120.02 37.3 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.22 137.6 32.21 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.642 -178.746 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.3 -174.1 0.62 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.021 0.439 . . . . 0.0 110.39 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 48.6 tttp -67.82 132.26 47.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 97.78 -7.88 63.31 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -122.1 137.95 54.63 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.866 0.365 . . . . 0.0 110.447 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.5 pt -138.11 -176.62 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.084 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 116.01 162.77 13.33 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.577 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 49.5 p -60.71 -45.04 95.74 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.409 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 12.2 m80 -120.64 27.53 8.49 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.59 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 5.8 m 58.05 118.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.086 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' GLY . . . . . 0.424 ' H ' ' H ' ' A' ' 147' ' ' GLN . . . 174.85 5.36 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLN . . . . . 0.424 ' H ' ' H ' ' A' ' 146' ' ' GLY . 8.0 tp-100 -132.51 114.9 14.62 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 120.894 -0.323 . . . . 0.0 110.596 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.35 158.59 40.75 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.772 2.315 . . . . 0.0 112.095 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.49 131.16 39.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.93 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 88.36 2.79 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.085 0.469 . . . . 0.0 109.85 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -59.02 -61.92 2.28 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.472 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 153' ' ' GLY . 97.3 p -117.95 -3.5 11.15 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.527 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 152' ' ' SER . . . -58.98 -152.42 0.01 OUTLIER Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.599 ' N ' ' SG ' ' A' ' 166' ' ' CYS . 73.5 m -68.88 126.39 29.63 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.758 0.314 . . . . 0.0 110.202 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.11 -42.93 99.65 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 -169.79 -25.93 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.66 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -60.16 -43.4 98.41 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.241 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 154' ' ' CYS . . . -97.64 179.14 32.92 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.462 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.5 ttp180 -110.55 131.05 55.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.781 0.324 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 61.4 m -83.24 122.93 29.06 Favored 'General case' 0 CA--C 1.52 -0.175 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.079 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.8 m -104.12 -18.35 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.628 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.61 172.81 5.0 Favored Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.622 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.628 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.4 Cg_exo -53.73 127.49 25.7 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 121.925 1.75 . . . . 0.0 111.687 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 51.88 34.26 13.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.255 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -140.75 134.7 30.64 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.391 0.615 . . . . 0.0 110.39 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.599 ' SG ' ' N ' ' A' ' 154' ' ' CYS . 11.9 p -154.94 166.9 32.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.039 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -122.03 142.76 50.01 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.059 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 168' ' ' CYS . . . . . 0.422 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 87.5 m -78.08 124.12 27.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.418 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.7 m -64.55 -46.25 83.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.575 -179.275 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -107.71 16.18 23.9 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.349 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 69.54 27.9 72.94 Favored Glycine 0 C--N 1.31 -0.872 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.516 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 13.9 m-85 -64.63 139.82 58.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.345 0.593 . . . . 0.0 110.045 -179.461 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -82.93 167.67 17.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.008 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.25 151.56 13.14 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -67.29 -24.15 44.0 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.628 2.219 . . . . 0.0 112.133 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.44 ' O ' ' O ' ' A' ' 177' ' ' CYS . 74.1 mt-30 -104.91 -7.99 18.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.577 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.516 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 2.6 t 39.33 95.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.197 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.674 -179.859 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 55.16 167.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.707 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 76.0 ttt180 49.55 78.99 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.49 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.6 -9.51 71.91 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.98 -131.01 50.13 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.82 162.47 24.04 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -69.61 162.14 52.35 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 50' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' A' ' 50' ' ' HIS . 11.0 p80 -129.49 124.16 33.29 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.779 0.323 . . . . 0.0 110.224 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ASP . . . . . 0.45 ' O ' ' O ' ' A' ' 52' ' ' ALA . 54.6 t0 -91.23 99.27 12.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.317 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' A' ' 51' ' ' ASP . . . 53.87 112.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.172 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.4 mt -74.0 144.81 45.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.12 0.486 . . . . 0.0 110.33 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -127.37 158.7 36.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.008 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.61 152.87 15.98 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.04 11.96 1.08 Allowed 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 122.67 2.246 . . . . 0.0 112.438 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 33.8 m120 -125.14 52.12 1.62 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.075 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.45 133.05 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 99.2 m -144.56 175.49 10.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 169.61 44.76 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.56 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.5 m -73.83 160.86 30.85 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.2 ttm-85 -59.28 -43.7 92.52 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.646 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -61.75 -43.53 98.67 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.899 -0.321 . . . . 0.0 111.395 -179.278 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -125.35 47.86 2.12 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.537 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.32 142.82 58.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.603 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 24.3 p90 -152.04 168.14 26.19 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 121.279 0.562 . . . . 0.0 110.437 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.5 t -71.56 139.0 49.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.208 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 159.49 19.37 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -60.29 135.01 58.99 Favored 'Trans proline' 0 N--CA 1.497 1.707 0 C-N-CA 122.131 1.887 . . . . 0.0 111.627 179.268 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.15 -23.5 34.26 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.432 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -114.32 135.93 53.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.732 0.266 . . . . 0.0 110.284 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -121.09 -174.04 2.74 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.159 179.441 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 70.8 p -124.1 163.49 21.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 0.0 110.183 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.432 ' O ' ' N ' ' A' ' 77' ' ' GLY . 86.1 mt -83.52 149.86 58.62 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.781 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 77' ' ' GLY . 76.0 Cg_exo -42.62 117.49 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.288 0 C-N-CA 121.734 1.623 . . . . 0.0 112.371 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.72 -3.96 5.9 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 179.348 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -91.76 175.1 38.37 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -134.68 8.28 3.57 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.646 0.26 . . . . 0.0 110.926 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -82.35 129.26 34.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.826 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 9.9 m -103.53 78.6 1.6 Allowed 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.538 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.7 pt -130.98 20.03 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -120.73 103.16 43.81 Favored Pre-proline 0 CA--C 1.537 0.479 0 CA-C-N 116.811 -0.177 . . . . 0.0 110.624 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.15 160.34 29.81 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 C-N-CA 122.165 1.91 . . . . 0.0 112.266 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 92.6 mt -105.82 127.39 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.413 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 85' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 100' ' ' CYS . 4.9 m -91.3 136.26 33.23 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.804 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.436 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -61.83 -44.87 95.98 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.401 -179.725 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 87' ' ' HIS . . . . . 0.427 ' NE2' ' NH1' ' A' ' 86' ' ' ARG . 96.1 m-70 -110.82 152.74 26.3 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.391 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -53.92 131.18 39.7 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.65 -33.08 53.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.039 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.06 -105.85 1.79 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -92.69 0.83 57.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.882 0.372 . . . . 0.0 110.573 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -98.27 172.05 26.16 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' PHE . . . . . 0.461 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 24.2 t80 -122.26 130.52 53.24 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.848 0.356 . . . . 0.0 110.943 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 94' ' ' CYS . . . . . 0.461 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 1.7 t -64.19 119.18 9.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.835 179.209 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 73.3 p -104.8 -19.14 14.0 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.478 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -162.03 164.88 16.86 Favored Pre-proline 0 CA--C 1.533 0.309 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.849 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -53.0 128.29 28.35 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 121.412 1.408 . . . . 0.0 111.041 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.436 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.2 m-20 51.46 37.97 20.76 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.718 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.1 mtp -147.75 108.95 4.27 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.218 0.532 . . . . 0.0 110.305 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 100' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 0.8 OUTLIER -97.13 149.05 22.41 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.606 179.266 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.1 m -120.5 122.8 41.44 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.54 158.98 35.89 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.488 -178.971 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -55.84 -26.82 59.37 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.496 2.131 . . . . 0.0 112.245 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.1 t -64.09 -17.43 63.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.575 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.43 -17.44 50.76 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -67.37 153.73 42.99 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.981 0.419 . . . . 0.0 110.124 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 90.0 mt -126.83 128.26 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.398 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.528 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -165.63 162.88 13.12 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.934 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.528 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 11.6 Cg_endo -52.36 -15.93 4.44 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.955 2.436 . . . . 0.0 112.165 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 97.2 p -155.51 159.39 39.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.28 179.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.51 -21.01 49.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.06 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -50.19 117.67 5.16 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 87.2 p -97.01 2.7 51.79 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.622 0.249 . . . . 0.0 110.664 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -71.39 -6.7 42.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.569 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.1 m -57.7 -35.96 71.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.648 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 116' ' ' ILE . . . . . 0.632 ' C ' HD12 ' A' ' 116' ' ' ILE . 2.6 pp -63.43 153.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.285 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -111.2 -17.76 13.12 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -139.43 148.23 42.49 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.626 -179.632 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 7.4 m -120.64 124.38 45.1 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.163 179.805 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -96.6 10.54 38.21 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.417 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 10.9 tp -125.44 156.96 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.521 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 12.6 mtt180 -106.91 120.19 41.38 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.542 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 12.0 m -121.11 142.5 49.8 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -143.25 169.61 17.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.108 -179.065 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 28.8 m120 58.81 41.76 21.04 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.549 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.44 18.33 76.15 Favored Glycine 0 CA--C 1.517 0.205 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.88 121.56 6.32 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.2 t -79.85 140.43 36.8 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.5 t -91.54 124.4 35.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.136 179.237 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 132' ' ' ASP . 31.8 t -141.75 143.04 33.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.213 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 41.14 -92.37 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 130' ' ' SER . 39.5 p-10 -146.5 23.68 1.27 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.755 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 53.4 m-70 -138.53 148.36 44.16 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.445 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 84.3 m -96.49 128.69 43.66 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.107 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.6 mt -92.69 126.13 37.64 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 16.7 m -89.33 127.5 35.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.58 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.75 174.89 4.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.343 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -63.42 127.01 29.39 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.091 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.37 -13.84 54.67 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 -179.592 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -121.59 136.44 54.95 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.931 0.396 . . . . 0.0 110.42 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -133.58 172.76 15.81 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.214 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 102.8 163.34 25.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 24.0 p -62.42 -43.84 97.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.749 0.309 . . . . 0.0 110.631 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 2.2 p-80 -94.77 10.75 33.96 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.096 0.474 . . . . 0.0 110.468 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 12.4 m 46.85 36.59 4.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.101 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -99.74 8.46 59.83 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 32.7 tt0 -116.08 112.77 41.97 Favored Pre-proline 0 CA--C 1.548 0.898 0 CA-C-N 116.76 0.28 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -78.39 159.6 29.23 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.441 2.094 . . . . 0.0 112.273 179.356 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.5 t -113.56 127.74 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 121.016 0.436 . . . . 0.0 110.142 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 150' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 2.2 m -100.05 98.18 8.95 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -62.88 -51.67 66.07 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.339 -178.375 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 79.3 p -118.37 -9.45 10.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.896 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -79.74 171.82 54.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.108 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 154' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 150' ' ' CYS . 17.9 m 57.08 59.99 3.18 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.885 0.374 . . . . 0.0 110.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 155' ' ' LEU . . . . . 0.526 HD12 ' N ' ' A' ' 155' ' ' LEU . 10.9 mp -62.93 -42.19 99.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.752 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' A' ' 157' ' ' GLY . 24.9 t-20 -121.5 -112.69 0.32 Allowed 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.994 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.527 ' N ' ' OD1' ' A' ' 156' ' ' ASN . . . -84.6 3.49 86.52 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -54.75 148.3 23.01 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 159' ' ' ARG . . . . . 0.479 ' C ' ' SG ' ' A' ' 166' ' ' CYS . 17.8 tpt180 -102.66 131.31 49.54 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.775 0.322 . . . . 0.0 110.451 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 4.8 t -76.04 100.3 4.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.088 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.5 t -76.91 -43.82 32.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.768 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.647 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -151.02 175.03 3.07 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.979 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.647 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 71.8 Cg_exo -51.73 130.06 32.43 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 121.605 1.537 . . . . 0.0 112.385 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.0 m-20 52.43 32.02 10.61 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.372 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 165' ' ' ARG . . . . . 0.442 ' O ' ' SG ' ' A' ' 150' ' ' CYS . 74.2 mtm180 -141.6 136.33 30.92 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.473 0.654 . . . . 0.0 110.921 179.212 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 166' ' ' CYS . . . . . 0.479 ' SG ' ' C ' ' A' ' 159' ' ' ARG . 1.7 t -144.35 156.22 44.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.994 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.37 143.5 42.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.69 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 76.0 m -72.21 127.44 32.55 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.232 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 98.7 m -63.37 -46.12 87.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.458 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 170' ' ' TYR . . . . . 0.537 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 74.7 t80 -110.54 27.95 9.14 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.992 0.425 . . . . 0.0 111.327 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.46 25.51 63.06 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 172' ' ' PHE . . . . . 0.462 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 66.8 t80 -63.53 131.76 49.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.421 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 173' ' ' THR . . . . . 0.439 ' O ' ' CE2' ' A' ' 172' ' ' PHE . 68.0 p -82.52 163.43 21.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.144 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 144.38 160.44 8.49 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 175' ' ' PRO . . . . . 0.424 ' O ' ' OE1' ' A' ' 176' ' ' GLN . 36.2 Cg_endo -63.51 -31.9 70.9 Favored 'Trans proline' 0 N--CA 1.496 1.671 0 C-N-CA 122.578 2.185 . . . . 0.0 112.4 -179.701 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 176' ' ' GLN . . . . . 0.424 ' OE1' ' O ' ' A' ' 175' ' ' PRO . 1.9 mp0 -131.4 8.66 4.65 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.201 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 1.8 t 49.82 96.97 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.267 -179.631 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.524 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 43' ' ' SER . . . . . 0.438 ' O ' ' O ' ' A' ' 44' ' ' ALA . 19.4 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.438 ' O ' ' O ' ' A' ' 43' ' ' SER . . . 55.53 161.02 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.604 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -148.52 143.9 26.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.618 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.78 14.87 78.96 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.76 -36.8 93.79 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -63.53 149.76 50.01 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.97 141.06 12.27 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 74.1 m80 -66.1 -43.06 88.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -106.68 141.42 37.97 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.335 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -125.72 137.65 53.84 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.349 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.2 mt -75.82 144.03 41.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -137.17 159.84 40.73 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.15 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.38 163.24 24.51 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.75 -5.87 17.42 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 123.089 2.526 . . . . 0.0 112.263 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASN . . . . . 0.454 ' OD1' ' CD2' ' A' ' 71' ' ' TRP . 31.7 m120 -103.59 68.32 0.93 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.56 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.9 t -119.96 129.41 75.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.838 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.2 m -134.76 173.6 11.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.002 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.92 164.65 37.44 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' ALA . 12.5 m -80.1 173.25 12.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -60.38 -42.82 96.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -62.16 -41.75 98.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -125.58 49.55 1.91 Allowed 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.747 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.21 140.44 52.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.304 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -155.3 165.71 35.8 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.978 0.418 . . . . 0.0 110.878 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 5.8 m -72.89 135.0 45.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.089 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 35.1 m -55.81 149.84 30.46 Favored Pre-proline 0 C--N 1.323 -0.577 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.213 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -56.23 134.98 67.56 Favored 'Trans proline' 0 N--CA 1.498 1.791 0 C-N-CA 121.498 1.465 . . . . 0.0 112.234 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.95 -14.95 52.31 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.454 ' CD2' ' OD1' ' A' ' 57' ' ' ASN . 85.4 m95 -115.92 134.99 54.41 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.758 0.314 . . . . 0.0 110.372 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 80' ' ' CYS . 17.4 ptpt -110.14 -175.95 2.87 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.333 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.436 HG22 ' SG ' ' A' ' 80' ' ' CYS . 41.4 p -123.09 161.19 24.85 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LEU . . . . . 0.58 HD22 ' N ' ' A' ' 74' ' ' LEU . 2.7 mm? -84.53 149.04 53.67 Favored Pre-proline 0 N--CA 1.449 -0.48 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.158 -179.534 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -46.23 112.59 0.47 Allowed 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.591 1.528 . . . . 0.0 112.236 179.1 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.15 -6.48 28.16 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.99 174.77 36.04 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -129.04 0.58 5.25 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.816 0.341 . . . . 0.0 110.643 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.2 mt-30 -78.84 134.4 36.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.688 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' CYS . . . . . 0.445 ' SG ' ' O ' ' A' ' 72' ' ' LYS . 1.5 m -115.0 79.03 1.22 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.164 0.507 . . . . 0.0 110.189 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.3 pt -120.74 14.59 6.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.657 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 t -117.55 107.01 45.46 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 121.273 -0.171 . . . . 0.0 110.796 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.14 159.97 33.33 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.21 1.94 . . . . 0.0 111.987 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.5 mt -99.54 123.17 52.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.85 125.31 35.7 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.124 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.5 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.9 OUTLIER -63.32 -45.77 89.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.27 0.557 . . . . 0.0 109.932 179.657 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -121.73 143.5 49.33 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.462 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -53.1 128.29 27.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.424 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.7 m -71.33 -27.87 63.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.573 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.45 -116.33 4.89 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -70.38 -8.73 52.96 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.737 0.304 . . . . 0.0 110.925 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.54 -164.81 25.34 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -142.65 150.38 40.14 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.995 0.426 . . . . 0.0 110.788 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.7 m -69.53 116.96 10.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.568 -179.305 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.3 t -104.11 -20.78 13.71 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.322 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.0 mtt85 -160.76 167.99 12.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.56 123.3 13.0 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.613 1.542 . . . . 0.0 111.143 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.5 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 49.2 t30 52.26 40.35 28.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.088 -179.58 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.2 mtp -146.95 115.72 6.81 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.362 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 58.0 m -102.07 148.08 25.82 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.438 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 84.1 m -121.47 117.73 27.58 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.971 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -84.38 157.84 61.35 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.801 179.683 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.423 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.0 Cg_endo -61.64 -22.24 73.96 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.743 2.296 . . . . 0.0 111.828 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.4 t -66.28 -16.62 64.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.19 -19.02 38.29 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.0 tp60 -65.19 149.1 50.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.011 0.434 . . . . 0.0 110.427 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.09 131.63 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.828 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.36 172.43 1.78 Allowed Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.471 179.453 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 73.8 Cg_exo -48.82 -23.63 6.04 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.454 2.103 . . . . 0.0 111.992 178.726 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.0 p -153.6 165.47 35.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.251 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.49 -24.57 50.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.246 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -113.22 32.48 6.09 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.3 m -76.92 -18.0 58.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.686 0.279 . . . . 0.0 110.577 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 114' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 115' ' ' SER . 99.7 mtt180 53.93 179.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.123 -179.279 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' SER . . . . . 0.479 ' O ' ' O ' ' A' ' 114' ' ' ARG . 15.9 m 49.79 108.52 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.119 0.485 . . . . 0.0 110.95 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 37.8 pt -78.61 138.32 20.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.815 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -146.31 150.07 35.04 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.397 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -153.53 164.46 38.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.627 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.1 m -68.92 110.38 4.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.496 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -64.01 -40.56 96.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.461 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.457 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.5 tt -80.18 166.26 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.229 179.689 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.457 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 20.3 mmm180 -98.75 98.07 9.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.775 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 87.4 m -92.98 134.47 35.08 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.88 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 72.6 mtm -145.31 165.07 29.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.86 39.9 19.94 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.039 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.56 24.78 69.41 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.97 128.24 22.81 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' SER . . . . . 0.498 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 17.3 m -86.24 137.68 32.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.661 0.267 . . . . 0.0 110.494 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.56 129.93 34.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.514 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.45 ' O ' ' O ' ' A' ' 133' ' ' HIS . 52.3 p -146.58 109.66 4.7 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.165 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 50.12 -116.52 0.93 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.516 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 132' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 132' ' ' ASP . 32.4 p-10 -106.95 9.29 30.75 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.885 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 130' ' ' SER . 69.2 m80 -131.15 153.02 49.84 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.95 0.405 . . . . 0.0 110.798 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.4 t -114.62 145.06 42.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.293 179.779 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.9 mt -100.8 129.96 46.75 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.676 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 10.5 m -96.34 139.22 32.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.455 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.55 179.15 0.85 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.533 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -67.33 129.71 40.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.613 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 98.07 -10.77 63.92 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -117.34 133.8 55.56 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.9 0.381 . . . . 0.0 110.638 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 45.8 pt -131.95 170.36 20.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.315 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 106.37 164.41 22.77 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.5 m -63.26 -45.52 91.15 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.449 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 84.6 m-70 -97.52 5.24 49.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.902 0.382 . . . . 0.0 110.682 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 6.0 m 59.87 37.25 21.79 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.123 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -98.88 5.72 59.86 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -119.65 107.09 41.09 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.679 0.239 . . . . 0.0 110.535 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.73 163.5 23.72 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.564 2.176 . . . . 0.0 111.911 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.2 t -106.15 126.3 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 121.158 0.504 . . . . 0.0 109.918 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.88 92.71 7.54 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -63.61 -46.53 85.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.761 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 9.9 m -89.93 -11.93 40.32 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.861 179.796 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.12 161.29 1.28 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.2 m -104.23 145.29 30.43 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 155' ' ' LEU . . . . . 0.509 ' H ' HD12 ' A' ' 155' ' ' LEU . 4.3 mp -62.95 -43.42 98.84 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.13 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 m-20 165.4 -58.38 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.352 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.53 -37.95 95.01 Favored Glycine 0 CA--C 1.517 0.164 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.35 159.86 50.5 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -127.43 145.91 50.66 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.725 0.297 . . . . 0.0 110.81 179.108 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 60.2 m -73.2 104.68 4.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.616 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 161' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 161' ' ' VAL . 70.2 t -106.49 -13.04 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.354 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.654 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.18 177.76 1.45 Allowed Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 120.369 -0.532 . . . . 0.0 110.341 179.807 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.654 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.3 Cg_exo -55.64 128.44 30.35 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 121.896 1.731 . . . . 0.0 111.539 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 55.6 t30 43.23 38.7 1.71 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.9 179.579 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -131.37 127.07 36.82 Favored 'General case' 0 C--O 1.24 0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 110.53 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 94.3 m -117.79 118.81 33.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.846 179.301 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -77.96 92.34 4.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.927 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.75 129.46 55.37 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.501 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.2 t -114.01 24.79 11.71 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.295 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -100.86 29.02 4.79 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.011 0.434 . . . . 0.0 110.945 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.98 28.71 73.89 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -50.41 163.24 0.18 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.769 0.319 . . . . 0.0 110.476 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -130.02 131.65 45.93 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.308 179.365 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 80.19 176.95 50.42 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -78.38 -10.7 16.1 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.809 2.339 . . . . 0.0 112.03 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 33.0 tt0 -83.45 6.32 20.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.846 -178.496 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 177' ' ' CYS . . . . . 0.515 ' SG ' ' O ' ' A' ' 177' ' ' CYS . 50.3 t 56.39 40.15 29.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.624 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.043 -0.98 . . . . 0.0 110.601 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.6 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.68 141.5 56.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.663 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -81.97 -7.22 59.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -62.55 -34.54 89.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.47 -162.7 38.28 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 84.49 179.89 51.5 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.711 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.31 175.9 44.74 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -89.72 171.48 9.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.757 0.313 . . . . 0.0 110.376 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.58 91.49 3.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.416 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -164.73 -79.36 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.328 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' LEU . . . . . 0.401 HD23 ' HB2' ' A' ' 78' ' ' ASN . 87.5 mt -70.03 176.03 4.06 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.331 179.604 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -135.85 165.87 24.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.784 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.69 168.63 9.92 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.26 -172.49 0.89 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 122.938 2.425 . . . . 0.0 111.805 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 57.48 42.14 24.95 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.094 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 58' ' ' VAL . 14.6 p -97.93 133.24 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.91 0.386 . . . . 0.0 110.101 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 m -140.12 175.88 9.22 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.425 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.94 160.18 26.05 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 65' ' ' ALA . 14.9 m -81.21 174.79 11.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.319 . . . . 0.0 110.398 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.4 ttt85 -60.59 -43.15 97.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.599 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -62.05 -39.12 91.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.917 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -131.84 53.57 1.99 Allowed 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.11 139.96 52.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.391 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -154.18 169.7 22.97 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.088 0.471 . . . . 0.0 110.641 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' CYS . . . . . 0.407 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 73.2 m -79.45 136.29 36.9 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 38.6 m -52.99 154.97 4.65 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.246 -178.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.84 132.51 42.3 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.103 1.202 . . . . 0.0 112.785 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.69 -7.27 57.61 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 71' ' ' TRP . . . . . 0.534 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 9.5 m95 -132.02 143.08 49.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.519 179.352 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -127.72 -166.08 1.57 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' THR . . . . . 0.407 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.3 p -123.49 164.76 18.31 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -108.4 156.56 38.39 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.206 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 77' ' ' GLY . 46.7 Cg_exo -52.88 138.66 60.82 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 121.379 1.386 . . . . 0.0 111.808 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.38 -38.08 0.34 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 77' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -82.7 169.83 49.34 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' ASN . . . . . 0.401 ' HB2' HD23 ' A' ' 53' ' ' LEU . 50.0 p30 -136.48 16.06 3.17 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.611 -0.294 . . . . 0.0 110.88 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -87.6 133.7 33.76 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.781 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 62.6 m -86.28 42.69 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.5 pt -94.02 26.45 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.253 -179.454 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.91 94.18 47.61 Favored Pre-proline 0 N--CA 1.466 0.37 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.76 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -79.48 161.26 25.39 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.198 1.932 . . . . 0.0 112.182 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.47 127.86 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.4 131.37 43.03 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ARG . . . . . 0.419 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -64.09 -45.88 86.73 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-O 121.177 0.513 . . . . 0.0 110.256 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -127.18 174.0 9.27 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.97 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 p -63.84 146.08 54.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.405 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 1.4 m -88.56 -32.4 18.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.53 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.29 -107.99 2.56 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.341 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -92.93 3.63 55.38 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.556 0.217 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.06 -161.67 17.45 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -146.94 152.18 38.23 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.985 0.421 . . . . 0.0 110.98 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.6 m -69.65 115.6 9.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.131 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.6 p -103.82 -17.35 15.09 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.952 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtp85 -159.74 163.6 22.4 Favored Pre-proline 0 CA--C 1.532 0.285 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.068 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -51.99 127.09 22.07 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.565 1.51 . . . . 0.0 111.034 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' ASN . . . . . 0.419 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 92.0 m-20 49.62 36.5 10.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.88 179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 38.1 mtt -147.6 122.31 9.88 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.36 0.6 . . . . 0.0 111.048 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 20.2 t -108.17 149.45 28.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.474 179.115 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 99.8 m -121.38 124.72 45.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.79 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 102' ' ' CYS . . . . . 0.404 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -93.73 157.78 37.66 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.543 -179.916 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 103' ' ' PRO . . . . . 0.404 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 27.3 Cg_endo -62.04 -20.44 69.67 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.551 2.167 . . . . 0.0 111.766 178.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 t -68.05 -22.85 64.93 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.601 178.827 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 113.88 -22.94 13.7 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 106' ' ' GLN . . . . . 0.468 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 8.1 tm0? -63.44 146.25 53.99 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.212 0.53 . . . . 0.0 110.362 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 107' ' ' ILE . . . . . 0.468 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 96.7 mt -129.89 133.78 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.402 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 108' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -178.64 171.61 0.71 Allowed Pre-proline 0 CA--C 1.535 0.392 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 109' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 56.9 Cg_exo -50.35 -25.77 14.46 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 122.645 2.23 . . . . 0.0 112.247 179.015 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.7 p -140.75 161.99 36.48 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.239 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.38 140.68 32.26 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.684 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -164.03 124.06 1.23 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.607 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.1 p -74.44 141.06 45.03 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.147 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -147.7 -50.34 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.911 0.386 . . . . 0.0 110.606 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.6 p -157.75 -159.32 0.82 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.253 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 21.8 pt -126.28 148.27 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.421 179.742 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -152.82 148.82 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.979 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 14.6 p-80 -113.86 39.48 2.68 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.505 -179.857 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 64.5 m -124.29 79.97 1.79 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.473 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 120' ' ' ASN . . . . . 0.416 ' O ' ' OD1' ' A' ' 120' ' ' ASN . 53.5 t-20 -63.58 -40.43 96.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.658 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 121' ' ' ILE . . . . . 0.661 HG22 ' H ' ' A' ' 122' ' ' ARG . 15.6 mm -82.71 174.33 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.956 -179.488 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 122' ' ' ARG . . . . . 0.661 ' H ' HG22 ' A' ' 121' ' ' ILE . 27.2 ptt180 -106.02 114.08 28.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.544 0.688 . . . . 0.0 110.534 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 94.2 m -124.26 148.03 47.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.263 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.2 mtm -142.27 174.24 10.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.916 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 10.8 m120 60.88 44.93 10.2 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.119 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.29 26.17 71.53 Favored Glycine 0 CA--C 1.518 0.261 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -66.52 156.66 50.78 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 28.3 t -109.62 134.51 51.86 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-O 121.05 0.452 . . . . 0.0 110.373 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 15.5 m -80.94 132.1 35.38 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 130' ' ' SER . . . . . 0.505 ' OG ' HD23 ' A' ' 135' ' ' LEU . 69.1 m -123.56 158.41 31.46 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.486 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 131' ' ' ASP . . . . . 0.501 ' C ' ' O ' ' A' ' 130' ' ' SER . 99.6 m-20 -12.01 -77.5 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 O-C-N 123.899 0.75 . . . . 0.0 112.725 -179.562 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -136.21 29.74 3.03 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.397 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -139.89 159.08 42.98 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.782 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 134' ' ' CYS . . . . . 0.407 ' C ' HD22 ' A' ' 135' ' ' LEU . 40.7 t -104.64 122.37 45.49 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.035 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 135' ' ' LEU . . . . . 0.505 HD23 ' OG ' ' A' ' 130' ' ' SER . 3.5 mm? -98.18 127.19 43.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.081 0.467 . . . . 0.0 110.169 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 61.1 m -106.98 140.43 39.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.807 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -76.8 168.94 19.21 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.32 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 56.1 tptt -64.71 133.31 51.85 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 108.76 -26.41 15.95 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -116.61 133.58 55.84 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 120.898 0.38 . . . . 0.0 110.67 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.6 pt -131.04 170.76 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.936 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.61 157.62 10.36 Favored Glycine 0 N--CA 1.464 0.565 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.6 p -64.07 -42.69 96.89 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.869 0.366 . . . . 0.0 110.602 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.21 5.02 34.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.25 139.29 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 151.41 -10.74 0.73 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -99.0 110.53 58.07 Favored Pre-proline 0 CA--C 1.544 0.715 0 O-C-N 122.517 -0.402 . . . . 0.0 110.422 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -76.77 159.01 35.14 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.175 1.916 . . . . 0.0 112.524 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.8 t -124.76 130.06 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.11 0.481 . . . . 0.0 110.577 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -104.35 117.68 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.087 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -65.75 -39.48 91.12 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.3 m -86.12 -7.44 58.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.531 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 45.73 -166.48 0.06 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 1.3 m -141.34 119.61 12.18 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.5 mt -63.9 -41.7 97.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.766 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 156' ' ' ASN . . . . . 0.526 ' C ' ' H ' ' A' ' 158' ' ' GLY . 6.1 t-20 -86.03 -167.88 2.02 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.332 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 157' ' ' GLY . . . . . 0.496 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.79 23.67 0.53 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 158' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -60.01 160.17 21.59 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -126.75 147.18 50.0 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.778 0.323 . . . . 0.0 110.668 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 12.3 t -90.88 104.78 17.33 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.853 0.359 . . . . 0.0 110.497 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.98 -35.04 20.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 162' ' ' ALA . . . . . 0.63 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -155.81 177.29 2.11 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.36 -179.309 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 163' ' ' PRO . . . . . 0.63 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.8 Cg_exo -54.26 132.22 49.36 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.023 1.816 . . . . 0.0 112.259 179.436 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.5 t30 49.33 31.79 4.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.259 179.728 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -135.42 102.09 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.58 0.705 . . . . 0.0 110.751 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -107.52 141.17 39.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.821 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.64 133.71 50.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.444 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 67.3 m -86.3 146.51 26.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.102 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -62.35 -45.1 94.73 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.118 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -97.52 15.93 21.8 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.322 0.582 . . . . 0.0 110.847 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.15 20.95 78.37 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.748 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -54.84 161.7 1.49 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.967 0.413 . . . . 0.0 110.595 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 8.8 t -82.54 160.52 22.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.479 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.6 142.52 0.05 OUTLIER Glycine 0 CA--C 1.539 1.534 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.694 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -53.48 -40.67 77.84 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.329 2.019 . . . . 0.0 112.971 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -67.3 -26.22 66.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.455 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 11.8 m 65.04 60.76 0.79 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.673 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.93 -179.935 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 17.6 mt . . . . . 0 N--CA 1.455 -0.22 0 CA-C-O 121.065 0.46 . . . . 0.0 110.606 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -135.61 -176.77 4.4 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.732 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.71 158.73 29.32 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -76.59 8.29 3.08 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.764 2.309 . . . . 0.0 112.105 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.578 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 81.2 m-20 -119.88 65.79 0.81 Allowed 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.658 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.459 ' O ' HG13 ' A' ' 58' ' ' VAL . 10.7 p -112.55 128.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -148.51 171.85 15.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.379 -179.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.55 166.46 34.97 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.7 m -79.08 165.04 23.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.7 0.286 . . . . 0.0 110.307 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.6 ttm-85 -58.85 -42.26 88.92 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.241 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -61.18 -39.42 90.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.832 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -131.63 51.13 2.17 Favored 'General case' 0 C--O 1.226 -0.151 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.033 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.08 142.83 50.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.536 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 11.8 p90 -160.94 176.32 11.55 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 121.069 0.461 . . . . 0.0 110.523 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.402 ' SG ' HG22 ' A' ' 73' ' ' THR . 62.8 m -73.39 133.89 43.89 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -47.1 169.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.033 -178.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -58.32 133.86 57.73 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 121.883 1.722 . . . . 0.0 112.364 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 93.39 -16.63 60.2 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.578 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 92.5 m95 -110.25 138.49 46.55 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -121.98 -164.52 1.16 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.316 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.402 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.3 p -125.07 164.83 19.35 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.486 ' O ' ' N ' ' A' ' 77' ' ' GLY . 24.6 mt -89.16 151.99 47.42 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 -179.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -40.44 107.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.256 0 C-N-CA 122.219 1.946 . . . . 0.0 112.259 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.27 -11.2 9.03 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -87.96 177.76 46.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.924 -0.871 . . . . 0.0 110.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -138.01 17.06 2.83 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.892 0.377 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -81.93 130.15 34.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.046 -179.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 53.6 m -95.66 55.26 1.64 Allowed 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.451 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.3 pt -114.32 22.05 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.995 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.04 99.51 40.92 Favored Pre-proline 0 N--CA 1.467 0.401 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.573 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.95 156.45 26.84 Favored 'Trans proline' 0 N--CA 1.487 1.113 0 C-N-CA 122.164 1.91 . . . . 0.0 112.202 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.438 ' O ' ' NH1' ' A' ' 86' ' ' ARG . 96.0 mt -101.57 122.12 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-O 120.945 0.403 . . . . 0.0 110.202 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.27 126.29 45.06 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.494 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 9.0 mpt_? -64.97 -40.33 94.82 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.743 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -117.71 145.68 44.27 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.192 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.2 m -63.24 136.29 57.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.0 0.429 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 44.5 m -77.95 -32.24 51.37 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.326 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.44 -107.19 2.25 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -68.38 -12.32 60.95 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.777 0.323 . . . . 0.0 110.797 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -110.53 -161.91 18.2 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -145.94 151.52 37.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.006 0.432 . . . . 0.0 111.072 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.7 m -66.95 115.18 6.39 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.225 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -106.46 -20.72 13.29 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.754 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -157.49 161.66 28.78 Favored Pre-proline 0 CA--C 1.531 0.238 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.364 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_exo -48.93 122.23 7.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 121.748 1.632 . . . . 0.0 111.254 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 52.05 41.74 30.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.004 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 80.9 mtp -148.33 116.72 6.54 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.62 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.44 ' N ' ' O ' ' A' ' 108' ' ' ALA . 33.7 m -100.44 148.28 24.92 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.366 178.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.6 m -120.58 123.28 42.48 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.741 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.16 157.92 53.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.275 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.71 -18.64 65.17 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.719 2.279 . . . . 0.0 111.855 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.8 m -71.95 -17.38 62.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.432 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 109.16 -20.32 28.57 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -66.82 150.03 49.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.934 0.397 . . . . 0.0 110.194 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.68 132.74 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.642 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -167.77 179.05 0.99 Allowed Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.379 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 38.8 Cg_exo -57.92 -22.76 56.11 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.814 2.343 . . . . 0.0 112.306 179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.2 p -153.74 161.84 41.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.243 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.885 179.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . 0.507 ' SG ' ' O ' ' A' ' 119' ' ' CYS . 45.0 t . . . . . 0 CA--C 1.528 0.104 0 CA-C-O 120.877 0.37 . . . . 0.0 110.735 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.69 30.61 20.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.128 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.3 tt -158.59 165.22 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.265 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.4 mmt85 -101.2 106.13 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.195 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.39 127.37 52.06 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -147.01 168.63 21.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 59.54 39.92 21.03 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 120.792 0.329 . . . . 0.0 111.064 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.33 20.85 65.97 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -65.02 149.15 51.74 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 36.9 m -127.16 144.66 50.98 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.903 0.383 . . . . 0.0 110.403 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 37.1 t -82.55 124.39 30.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.568 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.408 ' CB ' HD11 ' A' ' 135' ' ' LEU . 48.2 t -148.18 111.67 4.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.472 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.9 49.98 17.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.067 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 57.41 34.55 24.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -144.48 139.54 28.36 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.508 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.4 m -88.05 126.89 35.33 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.408 HD11 ' CB ' ' A' ' 130' ' ' SER . 86.2 mt -95.25 126.85 40.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -103.02 137.88 40.62 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.683 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -83.27 175.34 9.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.437 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.533 ' NZ ' ' OE2' ' A' ' 151' ' ' GLU . 64.6 tttm -63.29 133.15 53.7 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.444 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.53 -24.52 28.48 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.459 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 95.1 m-85 -123.74 138.25 54.55 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.911 0.386 . . . . 0.0 110.55 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 16.7 pt -139.73 -168.93 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.496 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.97 165.29 31.43 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -46.25 88.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.742 0.306 . . . . 0.0 110.35 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -84.58 -1.42 55.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.612 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 145' ' ' CYS . 33.7 t 55.14 63.47 2.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -140.51 -4.18 1.26 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -86.48 114.54 58.21 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.385 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.49 156.2 36.37 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 122.295 1.997 . . . . 0.0 112.4 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.2 t -119.61 124.55 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 120.954 0.407 . . . . 0.0 110.197 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.3 107.54 20.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.2 -179.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . 0.533 ' OE2' ' NZ ' ' A' ' 138' ' ' LYS . 96.7 mt-10 -69.32 -38.23 78.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.101 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 94.7 p -85.38 -9.11 58.0 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.032 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 63.5 -163.82 31.1 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 71.8 m -116.12 152.24 34.04 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 96.9 mt -82.03 -1.95 50.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.49 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.527 ' C ' ' H ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -170.66 -147.62 0.05 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.336 179.508 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.511 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.64 26.99 0.49 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.527 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -64.23 175.51 11.21 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 78.1 ttt180 -128.14 136.64 51.42 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.65 0.262 . . . . 0.0 110.849 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 81.3 m -79.56 98.46 6.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 69.7 t -75.91 -44.1 38.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.533 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.649 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -145.13 174.26 3.61 Favored Pre-proline 0 C--N 1.331 -0.222 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.649 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.27 129.59 32.01 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 121.95 1.767 . . . . 0.0 112.102 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 52.37 32.87 11.83 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.984 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.1 ttt85 -138.84 127.56 23.42 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.314 0.578 . . . . 0.0 110.691 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 42.1 t -139.37 149.99 44.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.722 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.24 134.31 49.57 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.566 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . 0.602 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 0.2 OUTLIER -81.0 120.28 24.58 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.846 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 12.1 m -70.38 -45.45 66.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.79 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -101.85 26.99 6.86 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.821 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.7 33.64 83.29 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -62.44 127.14 29.92 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -178.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 61.8 p -84.58 161.69 20.08 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.924 0.392 . . . . 0.0 110.979 -179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 143.24 160.25 8.31 Favored Glycine 0 CA--C 1.531 1.033 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.0 -25.41 44.38 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.537 2.158 . . . . 0.0 112.689 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -76.28 -49.27 17.45 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.45 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.0 t . . . . . 0 N--CA 1.47 0.548 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.736 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 74.9 mt . . . . . 0 N--CA 1.454 -0.235 0 CA-C-O 120.853 0.359 . . . . 0.0 110.067 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -104.77 162.83 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.952 -179.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.27 161.05 20.51 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -78.76 3.51 7.25 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.725 2.283 . . . . 0.0 112.146 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.63 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 1.7 m120 -123.51 68.69 1.02 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.77 0.319 . . . . 0.0 110.502 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.455 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.8 t -117.01 131.43 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-O 120.884 0.373 . . . . 0.0 110.032 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -142.56 175.96 9.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.333 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.83 170.28 46.86 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.538 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -77.77 167.66 21.19 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 43.7 ttm180 -60.98 -44.11 97.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.634 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -66.86 -39.3 87.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.225 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -121.91 47.45 1.89 Allowed 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.488 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.538 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -69.44 144.29 53.35 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.553 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.9 p90 -153.33 167.59 28.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.944 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 73' ' ' THR . 77.1 m -73.21 132.49 43.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.51 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.455 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 54.2 m -51.65 151.78 5.55 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.983 -179.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -46.37 129.35 13.28 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 C-N-CA 121.819 1.679 . . . . 0.0 112.424 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.93 -21.16 46.05 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.63 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 78.2 m95 -111.89 138.41 48.54 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.75 0.31 . . . . 0.0 110.279 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 ptpt -118.47 -176.05 3.0 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.324 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.511 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.5 p -106.94 153.71 22.15 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.493 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.509 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.1 mt -88.31 151.53 48.83 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.403 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.459 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.4 Cg_exo -39.04 105.47 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.187 1.925 . . . . 0.0 112.228 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.58 -9.2 2.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.16 168.94 47.36 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.443 ' OD1' ' NE2' ' A' ' 79' ' ' GLN . 42.7 p-10 -126.49 13.49 7.59 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.657 0.265 . . . . 0.0 110.784 179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . 0.443 ' NE2' ' OD1' ' A' ' 78' ' ' ASN . 10.8 mp0 -90.68 123.83 34.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.868 0.366 . . . . 0.0 110.898 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.48 68.57 4.87 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 27.2 pt -120.99 23.45 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.788 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.78 95.98 48.78 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.541 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.55 157.31 32.37 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.702 2.268 . . . . 0.0 112.236 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -111.63 131.53 62.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.755 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 28.6 m -84.78 139.4 31.97 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.408 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.439 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -63.04 -45.15 93.63 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.279 0.561 . . . . 0.0 110.251 -179.83 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -123.33 -118.08 0.29 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.29 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 t -143.81 133.71 23.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.35 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -94.05 -21.28 19.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.591 179.732 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.33 -99.18 0.7 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 39.5 p-10 -75.95 -1.71 26.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.772 0.32 . . . . 0.0 110.615 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.86 -175.29 26.79 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -141.12 153.86 45.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.934 0.397 . . . . 0.0 110.822 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.6 m -71.53 106.84 4.14 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.877 -179.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.7 p -96.69 -20.12 18.49 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.053 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mtt180 -162.14 168.92 10.11 Favored Pre-proline 0 C--O 1.235 0.329 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.987 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . 0.414 ' O ' ' CG ' ' A' ' 98' ' ' ASN . 52.4 Cg_exo -51.83 130.08 32.81 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 121.981 1.788 . . . . 0.0 110.827 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.439 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 12.6 p30 43.01 34.85 0.68 Allowed 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.692 0.62 . . . . 0.0 109.918 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 47.3 mmm -148.62 120.81 8.34 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 121.312 0.577 . . . . 0.0 110.571 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 13.8 p -119.82 161.68 20.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.023 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 77.8 m -119.41 128.08 53.71 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.431 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.46 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.1 OUTLIER -92.0 153.15 43.36 Favored Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.72 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 75.3 Cg_exo -46.45 -27.54 5.16 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.581 2.188 . . . . 0.0 112.011 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.8 t -63.43 -17.46 62.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.43 -3.01 63.32 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . 0.448 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 2.2 tm0? -81.0 148.54 29.69 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.785 0.326 . . . . 0.0 110.314 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.448 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 94.8 mt -122.06 135.18 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.549 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.685 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -176.74 175.69 0.6 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.691 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.685 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 45.6 Cg_exo -56.27 -25.78 58.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.769 2.313 . . . . 0.0 111.508 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 49.5 p -136.09 168.11 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.194 -179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.0 OUTLIER . . . . . 0 C--N 1.325 -0.488 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.597 -178.727 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 4.5 t . . . . . 0 N--CA 1.457 -0.109 0 CA-C-O 120.832 0.348 . . . . 0.0 110.306 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.28 7.22 33.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.531 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.505 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 12.7 tt -130.44 166.29 28.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.505 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 16.1 mmm180 -100.98 125.22 47.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.304 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 82.6 m -118.29 129.21 55.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.941 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.0 mtm -140.97 166.84 23.68 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.339 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 58.48 41.31 22.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.03 74.38 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.16 145.12 49.44 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . 0.505 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 30.3 t -102.39 128.33 49.03 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.745 0.307 . . . . 0.0 110.367 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 39.9 t -84.63 120.45 26.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.226 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 133' ' ' HIS . 39.7 t -142.35 136.37 29.58 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.305 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 39.88 -118.32 0.29 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.753 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -112.87 12.91 19.55 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.51 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.456 ' O ' ' O ' ' A' ' 130' ' ' SER . 78.2 t60 -133.08 152.99 51.92 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.856 0.36 . . . . 0.0 110.469 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 128' ' ' SER . 7.8 t -120.71 148.64 43.67 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.19 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.7 mt -105.73 134.29 49.09 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.351 -179.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 22.3 m -97.68 141.18 31.02 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.131 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -73.39 170.72 14.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.729 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -66.67 132.89 49.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 105.52 -20.03 38.01 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -122.27 137.03 54.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.796 0.331 . . . . 0.0 110.322 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -127.85 170.26 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.103 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 118.65 163.31 12.47 Favored Glycine 0 N--CA 1.464 0.516 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.3 p -63.39 -41.42 98.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.338 . . . . 0.0 110.562 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.445 ' C ' ' SG ' ' A' ' 145' ' ' CYS . 15.6 m170 -107.42 1.43 23.59 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.6 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.445 ' SG ' ' C ' ' A' ' 144' ' ' HIS . 1.8 m 71.14 140.65 0.05 OUTLIER 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.933 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 158.99 -26.95 0.38 Allowed Glycine 0 C--N 1.322 -0.224 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.64 117.1 67.71 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.45 -0.5 . . . . 0.0 110.482 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.51 153.39 39.36 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.432 2.088 . . . . 0.0 112.417 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 49.4 t -114.35 128.46 71.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.57 100.03 10.4 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.097 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 11.9 tm-20 -64.44 -36.73 85.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.274 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 80.0 p -83.6 -7.24 59.55 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 61.31 -168.89 10.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.1 m -140.41 115.87 10.05 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . 0.505 ' N ' HD12 ' A' ' 155' ' ' LEU . 10.7 mp -62.92 -42.07 99.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.663 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.547 ' C ' ' H ' ' A' ' 158' ' ' GLY . 63.9 t30 -93.45 173.34 7.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.524 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.17 34.6 0.31 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.547 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.03 174.42 26.02 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -123.75 138.25 54.55 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.807 0.337 . . . . 0.0 110.66 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 63.4 m -81.26 107.15 13.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.277 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.5 m -83.66 -29.98 7.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.547 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.677 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -158.93 172.38 6.21 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.54 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.677 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.5 Cg_exo -52.55 129.64 33.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.062 1.841 . . . . 0.0 111.926 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 11.0 m120 53.55 33.96 17.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.601 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? -139.06 125.25 20.13 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.054 0.454 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -128.54 145.31 51.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -118.25 146.2 44.45 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.123 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 10.9 m -82.78 135.73 34.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.552 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 20.5 m -63.76 -45.4 90.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.85 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.69 22.65 10.64 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.011 0.434 . . . . 0.0 110.633 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 63.74 30.88 78.96 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -54.65 157.16 3.11 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.351 . . . . 0.0 110.353 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.15 140.47 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.284 0.564 . . . . 0.0 110.452 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 101.79 147.49 19.98 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.13 -31.31 36.73 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.591 2.194 . . . . 0.0 112.215 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.442 ' O ' ' O ' ' A' ' 177' ' ' CYS . 1.0 OUTLIER -88.12 -9.37 53.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.303 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.442 ' O ' ' O ' ' A' ' 176' ' ' GLN . 34.3 m . . . . . 0 C--N 1.324 -0.51 0 O-C-N 123.481 0.488 . . . . 0.0 109.933 -179.83 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 CA--C 1.514 -0.409 0 CA-C-O 121.092 0.472 . . . . 0.0 110.559 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -137.45 162.46 33.59 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.308 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.71 161.13 23.03 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.51 -4.84 15.84 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 C-N-CA 122.953 2.435 . . . . 0.0 112.234 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.606 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 87.6 m-20 -112.54 74.42 0.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.074 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.462 ' O ' HG13 ' A' ' 58' ' ' VAL . 8.2 p -116.04 130.38 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.904 179.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -139.91 177.92 7.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.098 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.8 161.28 27.82 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.8 m -82.61 171.54 13.93 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.0 ttt-85 -59.21 -40.49 85.95 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.302 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -60.01 -40.2 88.44 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.68 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -135.56 52.51 2.01 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.699 -0.228 . . . . 0.0 110.944 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.4 141.88 52.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.791 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.409 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 9.7 p90 -158.7 172.35 18.42 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.2 0.524 . . . . 0.0 110.421 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.563 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 94.6 m -69.03 140.42 54.94 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.131 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.436 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 64.2 m -58.72 149.44 63.31 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -56.29 131.09 43.72 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 121.581 1.52 . . . . 0.0 112.291 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.55 -16.34 40.95 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.606 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 93.0 m95 -119.07 134.73 55.02 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-O 120.804 0.335 . . . . 0.0 110.228 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -115.04 -176.69 2.96 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.375 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.563 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 30.3 p -132.59 172.53 12.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.005 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.698 HD12 ' H ' ' A' ' 74' ' ' LEU . 0.2 OUTLIER -92.02 160.32 35.95 Favored Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.363 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.476 ' C ' ' H ' ' A' ' 77' ' ' GLY . 45.6 Cg_exo -53.83 132.5 49.84 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.591 1.528 . . . . 0.0 112.144 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.6 -8.01 1.83 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.56 178.77 38.4 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.431 ' ND2' ' O ' ' A' ' 77' ' ' GLY . 29.4 m120 -146.9 16.77 1.23 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.006 0.431 . . . . 0.0 110.719 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -84.83 121.3 27.52 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.058 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 7.0 m -88.43 39.23 0.9 Allowed 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.2 -1.72 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.619 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 90.4 t -97.93 114.52 65.17 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.664 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -75.28 155.59 41.68 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 C-N-CA 121.982 1.788 . . . . 0.0 112.564 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 81.9 mt -106.42 124.44 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.192 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -106.16 115.84 30.92 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -64.15 -40.4 96.07 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.797 0.332 . . . . 0.0 110.686 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -117.0 149.39 40.32 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.537 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 m -66.22 138.2 57.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.501 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 40.5 m -79.02 -26.81 43.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.715 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.78 -104.2 2.17 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -78.6 -4.11 47.23 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.78 0.324 . . . . 0.0 110.97 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.59 -156.42 12.01 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.5 p90 -152.6 157.25 40.74 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.97 0.414 . . . . 0.0 111.023 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -64.1 112.95 3.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.052 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.432 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 91.9 p -102.83 -25.32 13.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.56 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -157.79 159.93 30.27 Favored Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.312 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -44.84 119.34 2.3 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 122.157 1.904 . . . . 0.0 111.607 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 66.2 t30 53.55 42.02 31.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.11 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mmm -148.39 118.76 7.35 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.915 0.388 . . . . 0.0 110.682 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 108' ' ' ALA . 17.7 m -100.79 146.14 27.64 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.149 178.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . 0.432 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.0 m -122.24 123.94 42.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.627 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.401 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -87.74 156.84 52.69 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.644 -179.586 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.401 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -61.95 -19.95 67.76 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 122.469 2.113 . . . . 0.0 111.798 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -66.28 -17.23 64.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.459 179.116 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 107.12 -19.31 35.1 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -67.0 149.83 50.09 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.957 0.408 . . . . 0.0 110.253 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 94.7 mt -129.18 130.2 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.743 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.648 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.44 178.11 1.02 Allowed Pre-proline 0 CA--C 1.538 0.482 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.314 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.648 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 44.1 Cg_exo -57.67 -25.45 67.99 Favored 'Trans proline' 0 N--CA 1.499 1.837 0 C-N-CA 122.818 2.346 . . . . 0.0 111.968 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 95.5 p -149.83 162.33 40.51 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.499 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.667 -179.873 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.531 0.214 0 CA-C-O 121.048 0.451 . . . . 0.0 110.031 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -98.5 13.73 30.77 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.745 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.625 HG22 ' N ' ' A' ' 122' ' ' ARG . 92.4 mt -119.24 165.52 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.204 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.625 ' N ' HG22 ' A' ' 121' ' ' ILE . 5.9 ptt85 -119.19 101.95 8.37 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.581 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 76.3 m -107.03 146.69 30.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.744 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.9 mtm -142.9 174.56 10.55 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.255 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 59.02 37.43 24.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.787 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 73.99 22.37 78.04 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.56 134.71 16.94 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 15.2 m -86.31 129.64 34.78 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 121.052 -0.259 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.413 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 4.3 t -87.12 85.28 7.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.574 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 133' ' ' HIS . 14.7 p -74.96 161.84 29.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.383 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -50.23 110.87 0.44 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.408 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.401 ' O ' ' CG ' ' A' ' 133' ' ' HIS . 98.6 m-20 52.35 28.59 5.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.555 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.505 ' O ' ' N ' ' A' ' 130' ' ' SER . 31.5 m-70 -162.25 153.36 17.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.596 179.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 12.4 t -126.78 130.64 50.68 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.335 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.2 mt -102.06 131.07 48.74 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.902 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . 0.434 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 57.6 m -91.38 129.75 37.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.394 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -79.03 173.05 12.97 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.927 0.394 . . . . 0.0 110.575 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -63.42 134.2 55.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.334 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -21.62 37.79 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -129.02 139.62 51.98 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.772 0.32 . . . . 0.0 110.545 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 10.9 pt -134.09 176.79 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.986 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.434 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 107.52 169.08 21.88 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.5 m -62.08 -45.28 94.2 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.531 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.56 ' CE1' ' NH2' ' A' ' 122' ' ' ARG . 59.1 m80 -98.35 5.92 47.78 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.736 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 3.9 m 58.2 37.24 26.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -103.28 17.68 50.69 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 50.4 tp60 -119.19 96.73 50.22 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.754 0.277 . . . . 0.0 110.806 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -58.23 152.49 52.53 Favored 'Trans proline' 0 N--CA 1.499 1.819 0 C-N-CA 122.583 2.189 . . . . 0.0 111.916 178.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 70.8 t -89.94 129.76 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-O 121.048 0.452 . . . . 0.0 110.325 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.4 m -103.11 86.47 2.7 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -62.32 -46.43 88.77 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.267 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 90.0 p -111.99 -21.21 11.67 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.964 0.411 . . . . 0.0 110.502 179.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 49.67 177.91 0.02 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.6 m -98.54 139.8 33.73 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.934 0.397 . . . . 0.0 110.184 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 92.5 mt -63.22 -40.99 99.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.626 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.522 ' ND2' ' H ' ' A' ' 169' ' ' THR . 51.9 p30 -82.37 178.68 8.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.376 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.92 42.26 0.35 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.2 -176.57 19.15 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -130.15 142.18 50.61 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 98.6 m -76.69 102.45 6.19 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.037 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.8 t -83.17 -50.62 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.221 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.625 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -135.65 177.31 2.28 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.178 -178.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.625 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.71 133.12 52.73 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.821 1.68 . . . . 0.0 111.489 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 47.9 23.02 0.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.643 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -132.68 140.58 48.2 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.439 0.638 . . . . 0.0 111.025 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 5.8 p -149.1 155.69 41.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.379 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -89.92 143.88 26.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.65 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 66.1 m -85.05 155.14 21.66 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.612 -179.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.522 ' H ' ' ND2' ' A' ' 156' ' ' ASN . 97.9 m -62.08 -45.7 92.36 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.168 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.45 22.55 15.64 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.992 0.425 . . . . 0.0 111.262 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.13 35.09 91.31 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.408 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 2.7 m-85 -68.32 146.99 52.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.117 0.484 . . . . 0.0 110.643 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 60.6 p -81.58 166.67 20.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.179 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 91.28 154.62 30.81 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -67.83 -20.97 45.06 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.609 2.206 . . . . 0.0 112.405 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 75.0 mt-30 -111.26 18.79 18.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.737 -179.088 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 79.7 m . . . . . 0 C--N 1.327 -0.399 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.29 -179.762 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt . . . . . 0 N--CA 1.453 -0.31 0 CA-C-O 120.857 0.361 . . . . 0.0 110.629 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -130.23 160.46 33.81 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 121.125 0.488 . . . . 0.0 110.142 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.6 174.76 36.46 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.04 -172.3 0.97 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.898 2.399 . . . . 0.0 111.81 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.526 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 53.5 m-80 59.16 38.95 23.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.997 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.46 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 11.8 p -98.69 131.59 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.278 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -141.5 -178.75 5.78 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.251 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.47 162.3 29.03 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 13.6 m -82.52 172.84 12.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.4 ttt-85 -60.86 -43.03 98.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.483 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -62.12 -39.62 93.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -133.02 55.2 1.91 Allowed 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.669 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.2 142.29 52.45 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -155.21 169.56 23.89 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.997 0.427 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.453 ' SG ' HG22 ' A' ' 73' ' ' THR . 71.8 m -74.14 139.72 44.72 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.188 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.46 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 61.9 m -56.81 153.63 21.68 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.252 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.78 131.87 35.15 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 121.244 1.296 . . . . 0.0 112.203 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.92 -18.82 51.55 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.556 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 8.9 m95 -119.01 140.04 50.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.746 0.308 . . . . 0.0 110.649 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -121.6 -175.84 3.18 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.453 HG22 ' SG ' ' A' ' 67' ' ' CYS . 60.8 p -108.81 154.12 22.53 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.482 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.9 mt -83.37 152.43 64.3 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.688 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.406 ' C ' ' H ' ' A' ' 77' ' ' GLY . 74.0 Cg_exo -41.3 110.33 0.13 Allowed 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.017 1.811 . . . . 0.0 112.197 179.125 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.36 -4.78 7.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -89.09 173.64 41.37 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -135.94 11.96 3.37 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.969 0.414 . . . . 0.0 111.059 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -89.61 126.64 35.7 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.552 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -89.61 69.1 7.79 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.8 pt -122.05 21.78 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.96 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -118.87 86.72 31.48 Favored Pre-proline 0 N--CA 1.464 0.251 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.793 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.47 150.76 83.74 Favored 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.773 2.315 . . . . 0.0 111.994 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.495 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.4 mt -106.05 128.74 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.439 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 5.9 m -89.62 135.67 33.48 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.49 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.4 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.04 -45.59 92.89 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.18 0.514 . . . . 0.0 109.758 -179.208 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -119.0 167.86 11.36 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.64 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 96.4 p -57.15 137.81 55.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.544 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 31.5 m -86.06 -32.96 21.12 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.863 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.77 -108.91 2.74 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -93.74 0.96 56.62 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.744 0.306 . . . . 0.0 111.066 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.62 -176.25 31.12 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.449 ' C ' ' SG ' ' A' ' 100' ' ' CYS . 44.8 p90 -135.18 145.39 47.69 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.114 0.483 . . . . 0.0 110.902 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 85' ' ' CYS . 0.5 OUTLIER -70.11 113.41 7.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.54 -178.786 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 33.9 m -99.79 -21.04 15.92 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.535 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.0 mtt180 -160.2 164.74 19.11 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.662 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.22 127.85 25.19 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 121.676 1.584 . . . . 0.0 111.474 179.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.4 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 63.9 m-20 50.52 35.36 11.15 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.874 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 68.3 mmm -150.26 122.05 8.11 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.416 0.627 . . . . 0.0 110.485 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.449 ' SG ' ' C ' ' A' ' 93' ' ' PHE . 0.7 OUTLIER -120.79 161.64 21.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.059 179.65 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.5 m -127.75 127.45 43.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.693 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.94 156.7 36.9 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.24 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -50.89 -26.2 17.55 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.252 1.968 . . . . 0.0 111.896 177.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.12 -17.76 64.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.859 0.361 . . . . 0.0 110.489 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.1 -16.43 53.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.3 tp60 -63.91 150.34 45.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.909 0.385 . . . . 0.0 110.07 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.49 131.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.641 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -179.51 174.5 0.47 Allowed Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.558 178.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.641 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 40.6 Cg_exo -57.32 -22.03 47.39 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.708 2.272 . . . . 0.0 111.751 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.5 p -140.16 159.98 40.98 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.754 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.452 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 14.9 m . . . . . 0 N--CA 1.465 0.322 0 CA-C-O 120.998 0.428 . . . . 0.0 110.974 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -65.11 -40.55 94.67 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.26 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 25.3 pt -92.8 -170.83 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.624 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -107.53 108.56 19.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.215 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 57.7 m -114.81 139.39 49.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.992 178.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 90.0 mtp -138.97 168.23 20.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 2.4 m-20 59.56 41.75 18.47 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.249 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.7 20.21 79.6 Favored Glycine 0 CA--C 1.52 0.375 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.23 156.57 52.35 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.4 m -133.29 146.64 51.55 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.733 0.301 . . . . 0.0 110.247 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 7.6 p -91.53 130.1 37.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.377 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.6 t -148.11 137.69 22.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.058 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' O ' ' OD2' ' A' ' 131' ' ' ASP . 3.7 p-10 45.01 41.29 5.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.006 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t0 62.0 36.69 15.4 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.637 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 69.1 t60 -150.02 140.59 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.585 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 9.4 t -88.55 130.92 35.13 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.48 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.6 mt -105.4 130.51 53.48 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 15.6 m -101.88 145.39 29.29 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.518 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.89 175.39 9.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.742 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -66.14 129.92 41.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.54 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.84 -20.06 44.96 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -120.28 134.57 55.24 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.792 0.329 . . . . 0.0 110.235 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.93 173.32 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.227 -179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 107.01 164.29 22.18 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 43.5 p -61.4 -44.78 96.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.754 0.311 . . . . 0.0 110.491 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 3.0 p-80 -98.52 14.41 28.39 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.431 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.525 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 5.2 m 46.39 43.4 11.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.11 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.74 12.31 42.1 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -121.45 119.28 29.44 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.63 0.215 . . . . 0.0 110.972 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -76.44 157.69 36.7 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.676 2.25 . . . . 0.0 112.266 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.0 t -99.31 111.19 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 121.015 0.436 . . . . 0.0 110.653 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.53 90.63 8.08 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.0 tt0 -70.18 -39.15 75.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.546 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 10.6 m -88.39 -12.9 41.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.65 161.4 0.02 OUTLIER Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 160' ' ' CYS . 25.6 m -106.55 159.18 16.37 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . 0.42 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 56.7 mt -62.37 -42.87 99.75 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.244 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.42 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 t-20 161.67 -58.92 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.747 0.654 . . . . 0.0 110.61 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.03 -42.21 99.72 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -71.41 168.83 50.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 22.8 mmm180 -130.03 149.07 51.91 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.912 0.386 . . . . 0.0 110.21 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 87.9 m -81.15 95.16 6.8 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.668 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 41.6 t -79.48 -47.86 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.577 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.676 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.24 177.79 2.06 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.341 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.676 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -55.08 134.85 66.07 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.833 1.689 . . . . 0.0 111.597 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 40.78 33.53 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.948 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -132.7 104.49 6.66 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 121.364 0.602 . . . . 0.0 111.316 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.16 132.15 36.85 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.151 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -92.7 141.1 28.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.029 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.4 m -90.99 132.87 35.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.098 0.475 . . . . 0.0 110.757 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.9 m -63.64 -46.29 86.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.496 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -104.36 24.04 12.22 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.952 0.405 . . . . 0.0 111.246 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 62.42 29.86 74.58 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -54.67 168.0 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.04 0.448 . . . . 0.0 110.508 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.4 p -81.89 164.66 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.217 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.06 151.81 0.14 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.77 -24.8 40.29 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.375 2.05 . . . . 0.0 112.232 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 177' ' ' CYS . 85.2 mt-30 -84.09 -11.38 56.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.556 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 176' ' ' GLN . 10.1 m . . . . . 0 C--N 1.327 -0.385 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.47 179.964 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.405 HD12 ' HB1' ' A' ' 65' ' ' ALA . 96.2 mt . . . . . 0 N--CA 1.451 -0.39 0 CA-C-O 120.995 0.426 . . . . 0.0 110.421 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -131.72 161.73 32.14 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.565 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.79 172.73 22.25 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.52 -167.46 0.18 Allowed 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 122.924 2.416 . . . . 0.0 111.885 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.581 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 5.2 m120 58.2 37.0 26.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.535 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.481 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 13.3 p -100.41 134.15 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 109.95 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 57.6 m -142.98 177.46 8.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.275 -179.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.55 162.64 31.83 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 65' ' ' ALA . 11.8 m -80.46 173.72 12.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.628 0.252 . . . . 0.0 110.465 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -60.6 -44.12 96.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.74 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -64.72 -39.26 93.34 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.421 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 58.6 t30 -125.39 51.12 1.73 Allowed 'General case' 0 CA--C 1.522 -0.113 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.819 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.5 142.52 50.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.466 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.421 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 10.2 p90 -160.2 167.54 27.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.219 0.533 . . . . 0.0 111.189 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.547 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 74.6 m -71.13 141.22 50.78 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.35 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.481 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 65.2 m -58.94 150.85 58.44 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.973 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -56.0 128.56 30.76 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.835 1.69 . . . . 0.0 112.037 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.1 47.02 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.581 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.3 m95 -125.39 135.29 52.24 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.025 0.441 . . . . 0.0 110.527 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -119.76 -177.36 3.37 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.437 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.547 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 19.2 p -129.24 165.6 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.285 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.5 mt -84.46 149.89 55.82 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.723 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -43.02 120.46 1.94 Allowed 'Trans proline' 0 N--CA 1.489 1.242 0 C-N-CA 121.881 1.721 . . . . 0.0 112.312 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.4 -0.25 55.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.901 -0.879 . . . . 0.0 110.901 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -89.84 171.17 37.27 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -136.64 2.15 2.64 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.038 0.447 . . . . 0.0 110.836 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -82.22 131.66 35.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.191 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.3 m -99.21 43.49 1.06 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -98.89 2.68 10.49 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.362 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.61 110.37 60.25 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.611 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -73.39 158.52 48.11 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.202 1.934 . . . . 0.0 112.226 -179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -104.14 124.74 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.081 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.55 127.2 36.18 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.94 -45.29 93.15 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -136.81 154.96 50.39 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 17.0 m -60.08 136.39 58.0 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.321 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 1.8 t -94.03 4.04 54.47 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.562 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 61.73 -100.02 0.25 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.402 ' OD1' ' SG ' ' A' ' 102' ' ' CYS . 37.7 p30 -90.73 8.47 34.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.699 0.285 . . . . 0.0 110.838 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.87 -173.46 29.15 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.433 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -142.41 154.16 44.36 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.073 0.464 . . . . 0.0 110.9 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.8 m -72.15 106.42 4.36 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.804 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.433 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 2.1 m -95.9 -24.3 16.48 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.671 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.9 mtm-85 -159.96 167.17 14.49 Favored Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.891 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -51.96 125.4 17.07 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.73 1.62 . . . . 0.0 111.311 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 50.81 34.7 10.64 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.552 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.2 mmm -149.69 124.13 9.65 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.286 0.565 . . . . 0.0 110.614 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 10.1 p -123.92 163.58 21.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.794 179.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 94.8 m -125.46 130.63 52.19 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.705 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.402 ' SG ' ' OD1' ' A' ' 91' ' ' ASP . 0.1 OUTLIER -94.28 155.74 39.56 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -48.01 -29.6 12.39 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.443 2.095 . . . . 0.0 112.133 177.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 37.5 m -62.63 -19.87 64.22 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.975 0.417 . . . . 0.0 110.688 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.4 57.27 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -70.94 152.0 44.09 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 110.168 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.36 131.55 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.57 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.67 178.22 0.55 Allowed Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.584 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 31.6 Cg_exo -59.97 -18.57 50.84 Favored 'Trans proline' 0 N--CA 1.5 1.911 0 C-N-CA 122.794 2.329 . . . . 0.0 111.588 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.4 p -149.6 164.65 34.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.5 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.5 -179.531 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 95.2 m . . . . . 0 C--O 1.232 0.183 0 CA-C-O 120.875 0.369 . . . . 0.0 110.182 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -63.91 -40.08 95.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.41 HG22 ' N ' ' A' ' 122' ' ' ARG . 21.0 mm -80.7 160.23 4.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.152 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.41 ' N ' HG22 ' A' ' 121' ' ' ILE . 88.8 mmt-85 -81.73 98.52 8.46 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.184 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -105.64 122.24 45.63 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -141.78 167.63 21.69 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.845 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.19 37.95 23.7 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.79 22.29 61.96 Favored Glycine 0 CA--C 1.522 0.485 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.06 119.25 9.44 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 7.3 m -80.2 138.59 36.88 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.487 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 22.6 m -91.08 128.48 36.92 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.774 0.321 . . . . 0.0 110.378 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.4 m -141.6 140.02 33.24 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' SER . 97.2 m-20 36.11 -97.15 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.965 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -136.02 22.25 3.27 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.728 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -132.48 147.04 52.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.496 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.98 125.65 44.49 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.861 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.1 mt -103.9 131.53 51.03 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.37 143.69 29.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.738 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -68.19 -174.77 0.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.319 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 27.8 tptp -69.02 132.09 46.09 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.541 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 96.93 -8.4 65.37 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -118.58 136.29 53.95 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.856 0.36 . . . . 0.0 110.559 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.7 pt -134.29 172.47 16.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.064 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 104.42 160.73 24.19 Favored Glycine 0 N--CA 1.461 0.342 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . 0.436 ' H ' HG22 ' A' ' 143' ' ' THR . 0.1 OUTLIER -65.34 -42.74 92.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.738 0.304 . . . . 0.0 110.547 -179.897 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -97.13 5.17 50.69 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 31.0 m 58.12 37.31 26.38 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.371 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -100.73 5.28 56.67 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -119.8 107.8 39.83 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.801 0.3 . . . . 0.0 110.601 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.23 159.85 29.71 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 C-N-CA 122.65 2.233 . . . . 0.0 112.127 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.4 t -97.88 105.18 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -86.47 100.04 12.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.657 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -66.29 -45.57 79.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.283 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . 0.443 ' O ' ' O ' ' A' ' 153' ' ' GLY . 23.4 t -89.53 -16.7 30.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.702 0.287 . . . . 0.0 110.883 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.49 156.15 0.01 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 10.9 m -93.95 133.08 37.76 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 64.3 mt -62.31 -43.9 97.76 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.189 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 178.23 -60.79 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 O-C-N 123.615 0.572 . . . . 0.0 110.52 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.84 51.13 1.54 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -166.82 154.62 25.18 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -123.25 129.32 51.21 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 2.4 t -75.33 102.84 5.23 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.068 0.461 . . . . 0.0 110.69 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 161' ' ' VAL . 4.6 p -107.34 -2.91 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.412 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.6 171.65 4.47 Favored Pre-proline 0 C--N 1.322 -0.599 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.581 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.6 Cg_exo -52.15 128.8 28.52 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 121.773 1.649 . . . . 0.0 111.395 178.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 40.93 36.14 0.4 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.682 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.528 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.8 OUTLIER -127.07 110.27 12.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.228 0.537 . . . . 0.0 110.409 -179.447 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.528 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 66.5 m -105.07 124.64 49.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.751 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -85.09 91.06 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.655 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.23 118.11 35.91 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.436 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.4 OUTLIER -111.27 11.36 21.7 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.63 -179.529 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.529 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 47.2 t80 -109.07 31.28 5.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.153 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 105.91 58.76 0.63 Allowed Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -53.02 126.12 19.53 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.534 -0.467 . . . . 0.0 110.325 -179.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.444 ' O ' ' O ' ' A' ' 174' ' ' GLY . 3.0 t -149.09 150.37 32.64 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.498 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 173' ' ' THR . . . 53.36 165.85 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.09 -18.66 45.73 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.83 2.353 . . . . 0.0 112.112 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -92.15 47.9 1.37 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.094 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 173' ' ' THR . 53.2 t . . . . . 0 N--CA 1.462 0.17 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.697 179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.469 HD12 ' HB1' ' A' ' 65' ' ' ALA . 88.9 mt . . . . . 0 N--CA 1.451 -0.376 0 CA-C-O 120.88 0.371 . . . . 0.0 110.724 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.44 160.67 28.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.355 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.18 174.8 38.37 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.47 -169.36 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.991 2.461 . . . . 0.0 111.627 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 57.52 38.56 28.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.907 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.42 ' O ' HG13 ' A' ' 58' ' ' VAL . 12.0 p -99.91 130.8 48.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . 0.438 ' O ' ' O ' ' A' ' 66' ' ' TYR . 52.7 m -145.64 175.58 10.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.613 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.23 167.1 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -75.06 165.04 25.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.623 0.249 . . . . 0.0 110.391 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.8 ttt180 -60.89 -44.2 97.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.653 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -66.24 -39.24 89.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -123.84 49.91 1.69 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.645 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.95 143.88 50.73 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.47 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.438 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -159.38 166.59 30.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.991 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 53.9 m -72.66 133.24 44.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.763 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -45.62 162.52 0.23 Allowed Pre-proline 0 CA--C 1.538 0.494 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -55.12 134.36 63.32 Favored 'Trans proline' 0 N--CA 1.495 1.604 0 C-N-CA 122.547 2.165 . . . . 0.0 111.68 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.65 -14.67 64.5 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -115.88 141.64 47.83 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.81 0.338 . . . . 0.0 110.239 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -125.7 -157.99 0.82 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.138 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 73.3 p -127.23 164.46 21.64 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.945 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.2 mt -87.09 152.05 52.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.414 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.7 Cg_exo -40.66 105.98 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.146 1.897 . . . . 0.0 111.939 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.65 -12.33 6.19 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.05 176.65 53.89 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 44.9 p30 -134.66 11.22 3.72 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.803 0.335 . . . . 0.0 110.744 -179.905 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -82.37 130.62 35.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.474 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 79.7 m -90.96 47.66 1.43 Allowed 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.811 0.339 . . . . 0.0 110.308 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 38.4 pt -107.39 24.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.49 94.07 48.62 Favored Pre-proline 0 CA--C 1.537 0.449 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.249 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.85 156.82 24.05 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.463 2.108 . . . . 0.0 111.981 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -101.99 125.77 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.025 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.03 119.28 38.52 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -45.37 94.74 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.969 0.414 . . . . 0.0 109.981 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -114.09 144.59 42.89 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.533 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.9 m -62.51 134.99 57.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.249 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 37.8 m -77.16 -31.72 55.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.633 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.08 -106.78 2.26 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.42 -8.01 52.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.664 0.269 . . . . 0.0 110.719 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.88 -161.48 18.81 Favored Glycine 0 N--CA 1.463 0.46 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.513 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -146.84 153.06 39.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.028 0.442 . . . . 0.0 110.755 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.25 114.56 5.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.28 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.513 ' OG ' ' CE2' ' A' ' 93' ' ' PHE . 75.7 m -105.11 -22.54 13.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.443 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 3.0 mtt180 -156.34 160.95 30.41 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.796 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -47.47 118.24 2.81 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 122.138 1.892 . . . . 0.0 111.519 179.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 54.27 41.67 31.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.344 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 77.0 mtp -148.33 120.13 8.12 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.367 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' ALA . 46.5 m -103.75 148.95 25.47 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.831 179.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . 0.403 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 97.5 m -118.51 123.06 44.2 Favored 'General case' 0 CA--C 1.515 -0.385 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.57 147.84 35.06 Favored Pre-proline 0 CA--C 1.541 0.598 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.651 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -47.39 -23.97 3.69 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.636 2.224 . . . . 0.0 112.09 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.9 t -64.35 -17.3 63.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.767 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.61 -14.99 56.26 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 59.6 tp60 -73.08 152.25 41.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.896 0.379 . . . . 0.0 110.248 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 91.4 mt -126.59 131.95 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.546 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.05 173.32 1.2 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.448 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 49.4 Cg_exo -55.08 -28.37 60.07 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.719 2.279 . . . . 0.0 112.142 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 p -136.61 164.25 28.64 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.567 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.648 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 93.7 m . . . . . 0 N--CA 1.463 0.181 0 CA-C-O 120.953 0.406 . . . . 0.0 110.7 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -161.75 29.59 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.442 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 18.5 tt -121.13 171.09 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.441 -179.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.442 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 27.2 mmt180 -95.86 127.46 41.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.928 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 85.0 m -117.52 134.78 54.48 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.971 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtt -138.24 156.53 47.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.231 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 58.92 51.47 7.31 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.059 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 66.48 26.9 72.84 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.52 139.5 35.45 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . 0.51 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 51.5 m -110.3 141.75 42.87 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.2 t -85.01 126.16 33.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 0.0 110.621 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.457 ' O ' ' O ' ' A' ' 133' ' ' HIS . 11.4 p -148.5 127.91 13.09 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.448 0.642 . . . . 0.0 111.01 179.527 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.444 ' O ' ' CB ' ' A' ' 132' ' ' ASP . 9.6 t70 50.18 42.79 25.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.562 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 131' ' ' ASP . 9.5 t0 78.29 -40.68 0.29 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.482 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 6.8 p80 -85.42 147.64 26.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.971 0.415 . . . . 0.0 110.531 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.3 t -99.93 149.09 23.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.847 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.5 137.27 49.54 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.25 144.67 27.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.481 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -59.95 176.13 0.33 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.658 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 49.7 tttm -66.61 131.22 45.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.641 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 99.01 -15.86 60.1 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -111.28 136.44 50.38 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.791 0.329 . . . . 0.0 110.35 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.45 171.7 17.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.973 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.72 158.36 10.58 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 98.6 m -62.53 -46.39 88.62 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.916 -0.314 . . . . 0.0 110.715 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 96.3 m-70 -105.28 11.82 32.48 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.491 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 14.6 m 60.68 139.13 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.809 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 153.13 -1.15 0.24 Allowed Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -113.09 108.66 52.84 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 121.303 -0.159 . . . . 0.0 110.785 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -77.43 159.32 32.61 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.676 2.25 . . . . 0.0 111.909 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 81.9 t -120.81 120.49 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-O 121.009 0.433 . . . . 0.0 110.12 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 60.5 m -91.44 114.65 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.56 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -64.03 -42.22 97.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.88 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.1 p -86.27 -6.36 58.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.532 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.11 166.31 0.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 73.4 m -100.27 102.9 14.29 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.879 0.371 . . . . 0.0 110.067 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.8 mt -63.62 -41.98 98.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.552 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.557 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.5 t30 -93.28 -176.97 4.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.387 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.523 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.79 23.25 0.41 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.557 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.41 174.99 26.35 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 52.3 mmm-85 -127.42 147.12 50.29 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.695 0.283 . . . . 0.0 110.449 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 21.5 m -86.01 111.67 20.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.09 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -97.16 -16.26 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.331 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.633 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -168.34 173.65 2.56 Favored Pre-proline 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.71 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.633 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.7 Cg_exo -57.08 135.65 71.92 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.068 1.845 . . . . 0.0 112.029 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.8 t30 44.43 32.79 0.77 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.837 179.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.86 101.0 3.77 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.386 0.612 . . . . 0.0 111.152 179.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 31.2 t -101.81 148.2 25.58 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.284 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.0 137.37 39.45 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.88 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 87.8 m -81.7 150.34 28.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.822 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.4 m -61.72 -45.99 91.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.735 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.541 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 53.3 t80 -110.36 25.71 11.48 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.058 0.456 . . . . 0.0 110.694 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 67.13 30.51 75.83 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' A' ' 173' ' ' THR . 65.9 t80 -58.76 159.35 6.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.83 0.348 . . . . 0.0 110.444 -179.522 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 8.1 p -81.94 167.09 19.29 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.392 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 104.36 142.0 11.36 Favored Glycine 0 CA--C 1.535 1.287 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.06 -33.01 20.23 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 122.524 2.149 . . . . 0.0 112.596 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.419 ' O ' ' O ' ' A' ' 177' ' ' CYS . 20.8 pt20 -108.05 1.15 22.2 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.566 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.419 ' O ' ' O ' ' A' ' 176' ' ' GLN . 1.1 t . . . . . 0 C--N 1.326 -0.444 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.421 -179.916 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 78.2 mt . . . . . 0 N--CA 1.454 -0.261 0 CA-C-O 121.013 0.435 . . . . 0.0 110.967 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -138.5 159.84 41.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.526 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.58 169.1 29.22 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.59 -168.79 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.938 2.426 . . . . 0.0 111.821 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.626 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 46.4 m-80 59.35 41.04 20.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.743 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.43 ' O ' HG13 ' A' ' 58' ' ' VAL . 11.4 p -105.33 131.69 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.6 m -141.88 -175.45 4.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.128 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.37 173.5 49.71 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.746 -0.941 . . . . 0.0 110.746 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.4 m -72.88 155.96 39.36 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -58.99 -43.2 91.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.775 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.23 -41.87 98.8 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.173 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -127.74 50.65 2.01 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.723 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.03 151.36 47.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.28 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -154.67 164.94 38.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.158 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.434 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 69.0 m -63.41 128.99 38.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.783 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 12.4 m -48.53 150.92 2.18 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.34 -178.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.61 133.5 38.37 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 121.572 1.514 . . . . 0.0 112.178 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.26 -7.94 64.42 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.626 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 54.6 m95 -118.89 138.71 52.57 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 110.592 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -127.83 -176.05 3.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.412 179.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.434 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 5.4 p -133.46 177.99 7.27 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.54 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 48.6 mt -89.91 148.86 40.67 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.507 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.41 116.16 0.47 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.108 1.872 . . . . 0.0 112.491 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.19 -4.56 54.3 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.33 171.1 43.59 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.431 ' C ' ' ND2' ' A' ' 78' ' ' ASN . 0.5 OUTLIER -133.58 9.19 3.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.977 0.418 . . . . 0.0 110.811 179.929 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -87.28 132.33 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.487 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -97.88 40.0 1.19 Allowed 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 35.4 pt -97.24 12.93 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.855 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.6 t -116.29 87.98 21.65 Favored Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.471 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo -60.69 148.87 90.23 Favored 'Trans proline' 0 N--CA 1.496 1.659 0 C-N-CA 122.819 2.346 . . . . 0.0 111.987 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 91.9 mt -89.17 123.55 41.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.47 110.1 22.74 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.17 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 2.1 mpt_? -65.31 -39.08 92.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.025 0.441 . . . . 0.0 110.328 178.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -119.05 143.36 47.15 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.104 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.7 p -60.86 134.46 57.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.397 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 60.3 m -77.89 -28.07 49.78 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.706 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.4 -102.56 1.74 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -89.19 2.37 54.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.658 0.266 . . . . 0.0 110.639 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.29 -168.86 22.96 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -138.71 150.53 46.26 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.124 0.488 . . . . 0.0 110.854 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 90.8 m -65.89 112.86 3.99 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.33 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 t -107.29 -25.87 11.29 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.467 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.4 mtt-85 -158.09 164.3 21.79 Favored Pre-proline 0 C--N 1.328 -0.334 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.66 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -51.01 121.77 8.79 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.96 1.773 . . . . 0.0 111.485 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 52.09 40.83 29.35 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 48.7 mtt -146.9 114.91 6.54 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.699 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' ALA . 65.3 m -100.05 146.84 26.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.232 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 66.6 m -115.61 121.6 43.09 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.87 149.55 37.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.498 -179.464 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.65 -21.81 2.58 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.567 2.178 . . . . 0.0 111.974 177.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.8 t -68.02 -17.91 64.55 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.8 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.87 -14.68 57.34 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -68.42 153.82 43.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.974 0.416 . . . . 0.0 110.243 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.42 133.15 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.677 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.637 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . 179.71 168.49 0.69 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.301 178.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.637 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 64.7 Cg_exo -48.8 -33.76 26.02 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 122.597 2.198 . . . . 0.0 112.083 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 38.8 m -133.01 165.6 24.34 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.538 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.484 . . . . 0.0 109.84 -179.793 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . 0.445 ' C ' ' H ' ' A' ' 121' ' ' ILE . 12.1 t . . . . . 0 C--O 1.231 0.083 0 CA-C-O 120.803 0.335 . . . . 0.0 110.944 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 47.3 t-20 61.09 3.22 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.595 -179.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.445 ' H ' ' C ' ' A' ' 119' ' ' CYS . 18.8 tt -143.84 172.25 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.427 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.421 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 38.0 mtt85 -122.73 99.97 6.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.777 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 28.8 m -90.34 147.16 23.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.739 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.7 mtm -139.97 170.6 15.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.356 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.0 m120 67.48 39.13 2.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.508 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.55 32.44 83.26 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.31 -173.98 14.0 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.1 m -130.98 136.69 48.76 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.4 t -73.33 112.08 9.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.188 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 69.5 m -128.97 119.82 24.99 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.959 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 43.17 -108.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.746 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -121.81 19.81 10.97 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.507 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -131.87 156.02 46.82 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.955 0.407 . . . . 0.0 110.293 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 97.1 m -106.42 131.24 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.0 mt -99.22 131.35 45.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.672 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -100.3 143.2 30.78 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.438 -179.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.56 -179.09 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.57 132.84 49.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.53 -179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.25 -19.36 46.1 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -118.11 136.99 53.25 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.784 0.326 . . . . 0.0 110.295 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.6 pt -130.94 171.79 17.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.992 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.01 157.73 10.48 Favored Glycine 0 N--CA 1.464 0.519 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 61.6 p -64.09 -42.53 96.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.835 0.35 . . . . 0.0 110.536 -179.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -105.8 5.64 31.0 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.692 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 5.0 m 65.04 140.1 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.076 0.465 . . . . 0.0 109.965 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 152.86 -11.04 0.59 Allowed Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -102.44 110.2 62.32 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.535 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.29 157.46 33.31 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.486 2.124 . . . . 0.0 112.31 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.46 116.66 50.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 120.989 0.423 . . . . 0.0 110.179 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.7 m -88.98 96.38 10.7 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -66.12 -38.5 88.34 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.426 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 97.4 p -82.42 -7.96 59.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.684 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 59.2 161.93 0.07 OUTLIER Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.06 114.5 28.73 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.57 -42.16 98.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.1 m-20 -100.07 -177.37 3.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.456 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -70.81 33.58 0.49 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.046 -0.821 . . . . 0.0 111.046 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.55 176.05 28.79 Favored Glycine 0 CA--C 1.52 0.349 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -126.03 142.33 51.57 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.68 0.276 . . . . 0.0 110.494 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.66 122.03 30.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.442 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.2 m -110.16 -9.87 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.308 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -171.91 170.97 2.34 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.41 -0.516 . . . . 0.0 110.737 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.9 Cg_exo -53.05 128.48 29.16 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 121.913 1.742 . . . . 0.0 111.402 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 52.58 32.69 12.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.119 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.76 127.8 37.52 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.15 0.5 . . . . 0.0 109.773 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 4.4 t -139.01 148.58 43.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.858 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.51 129.11 47.52 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.471 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 26.8 m -74.43 151.43 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.311 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.8 m -62.96 -45.8 90.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.204 -179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.96 19.52 19.29 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-O 121.077 0.465 . . . . 0.0 110.734 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 68.53 26.71 74.23 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -55.45 149.66 13.05 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 51.8 p -82.29 165.42 20.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.576 -179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 87.44 150.45 18.85 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.82 -23.18 41.89 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.69 2.26 . . . . 0.0 112.272 -179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 76.6 mt-30 -101.34 7.32 42.81 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.554 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 77.9 m . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.185 -179.755 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 13.0 mt . . . . . 0 CA--C 1.517 -0.289 0 CA-C-O 121.166 0.508 . . . . 0.0 110.225 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -133.22 163.03 30.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.32 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.47 160.31 23.13 Favored Glycine 0 CA--C 1.531 1.039 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.54 2.94 6.82 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.862 2.375 . . . . 0.0 112.212 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.591 ' ND2' ' CZ2' ' A' ' 71' ' ' TRP . 3.0 m120 -114.95 69.07 0.71 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.355 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.457 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.1 t -120.42 130.83 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 93.1 m -141.15 176.8 8.54 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.032 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.22 169.15 45.49 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.557 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -74.51 163.25 27.97 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -59.27 -43.94 92.45 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.47 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -64.11 -39.96 95.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.007 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -122.54 46.62 2.1 Favored 'General case' 0 N--CA 1.461 0.079 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.783 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.557 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.92 145.09 48.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.52 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -156.05 168.19 28.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.821 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.5 m -67.47 130.11 42.04 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.189 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.457 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 53.5 m -49.21 153.29 1.73 Allowed Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.246 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -51.64 131.68 38.26 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 121.43 1.42 . . . . 0.0 112.398 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 100.9 -16.53 57.33 Favored Glycine 0 N--CA 1.467 0.737 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.591 ' CZ2' ' ND2' ' A' ' 57' ' ' ASN . 9.1 m95 -115.63 139.58 49.97 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.787 0.327 . . . . 0.0 110.498 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.9 ptpt -120.23 -168.66 1.66 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.312 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 64.1 p -118.13 160.53 21.39 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.483 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.1 mt -87.4 152.84 52.96 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.744 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.44 107.58 0.08 OUTLIER 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.145 1.897 . . . . 0.0 112.184 179.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.34 -11.63 12.19 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -88.29 175.99 44.84 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 34.6 p30 -135.56 15.75 3.4 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.12 0.486 . . . . 0.0 110.639 179.649 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -79.87 128.53 33.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.495 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 29.9 m -96.9 55.68 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 30.3 pt -115.92 21.01 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.993 -179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.5 t -119.32 85.74 31.62 Favored Pre-proline 0 N--CA 1.467 0.39 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.697 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -61.35 148.48 92.83 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.936 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.8 mt -90.9 128.63 42.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 3.2 m -99.62 109.02 21.54 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.229 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -65.88 -39.36 90.59 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.052 0.453 . . . . 0.0 109.906 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 61.3 m170 -110.51 142.06 42.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.002 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.5 t -59.62 130.07 45.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.681 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 61.2 m -80.28 -31.52 38.28 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.875 179.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.07 -112.48 3.67 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -81.91 -0.55 44.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.16 -175.74 30.35 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.0 147.79 52.47 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.018 0.437 . . . . 0.0 110.794 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.2 m -64.4 111.26 2.57 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.42 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 69.8 p -102.64 -27.51 12.69 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.302 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.1 mtt85 -157.83 163.94 23.03 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.583 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -51.55 121.9 9.32 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 121.634 1.556 . . . . 0.0 111.48 179.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 55.17 40.34 31.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.878 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.8 mmm -149.27 115.81 5.87 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.198 0.523 . . . . 0.0 109.97 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 86.7 m -101.23 151.12 22.25 Favored 'General case' 0 N--CA 1.461 0.116 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.674 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 97.1 m -121.91 126.26 48.26 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.68 151.59 40.12 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.642 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -50.02 -22.73 8.11 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.459 2.106 . . . . 0.0 111.867 177.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -66.85 -16.96 64.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.684 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.82 -18.5 49.89 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tt0 -68.05 153.16 44.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.894 0.378 . . . . 0.0 110.304 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.17 130.38 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.581 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.545 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.27 164.88 3.21 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.962 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.545 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 15.3 Cg_endo -57.44 -22.81 52.28 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.916 2.411 . . . . 0.0 111.829 178.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.9 p -135.38 154.53 51.45 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.97 0.414 . . . . 0.0 110.227 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.68 -179.644 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.3 m . . . . . 0 N--CA 1.468 0.429 0 CA-C-O 120.782 0.325 . . . . 0.0 110.207 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -63.4 -40.21 96.61 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.444 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.539 HG22 ' H ' ' A' ' 122' ' ' ARG . 1.1 mt -113.31 -157.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.811 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.539 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.6 ptt-85 -120.59 121.72 38.99 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.7 m -124.86 147.0 49.01 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.15 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 70.9 mtm -145.17 174.13 11.34 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.315 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 5.7 m120 59.61 37.2 22.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.44 15.47 79.84 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.7 123.76 10.16 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.158 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 39.9 t -83.51 140.98 31.96 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.75 0.309 . . . . 0.0 110.881 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 5.8 m -83.32 129.94 35.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.18 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.4 m -126.45 158.3 36.38 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.134 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 131' ' ' ASP . 43.4 p-10 -48.24 109.35 0.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.09 0.472 . . . . 0.0 110.991 -178.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 50.24 30.26 4.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.531 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -159.78 154.9 24.95 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.495 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 47.6 t -129.55 132.32 46.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.784 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 80.3 mt -101.09 128.47 47.14 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 55.6 m -84.77 132.19 34.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.382 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -56.1 161.14 2.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.906 0.384 . . . . 0.0 110.352 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -59.25 130.81 48.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.873 0.368 . . . . 0.0 110.816 -179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 94.5 -6.91 71.37 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -119.74 137.43 53.94 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.924 0.392 . . . . 0.0 110.098 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 22.3 pt -129.61 169.59 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.953 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 121.69 159.34 10.64 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.4 m -62.17 -45.64 92.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 0.0 110.687 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.505 ' NE2' ' NH2' ' A' ' 122' ' ' ARG . 31.9 m-70 -102.75 3.24 36.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.347 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.37 142.94 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.894 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 149.53 -8.24 0.86 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -101.39 109.38 58.73 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.371 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.3 157.49 45.65 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.359 2.039 . . . . 0.0 112.437 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.8 t -124.83 126.81 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.412 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 66.3 m -94.41 109.13 21.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.129 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -66.89 -39.54 87.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.9 m -88.66 -9.16 53.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.712 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . 0.505 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 60.03 177.47 1.48 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 9.0 m -116.08 119.98 37.61 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.024 0.44 . . . . 0.0 110.191 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 94.9 mt -63.57 -42.38 98.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.506 ' C ' ' H ' ' A' ' 158' ' ' GLY . 18.9 m120 -93.6 -178.49 4.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.525 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.34 29.55 0.69 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.61 179.41 16.81 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -126.2 149.64 48.89 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.942 0.401 . . . . 0.0 110.349 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.52 105.09 17.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -88.41 -19.64 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.566 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.639 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -165.93 174.28 2.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.47 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.639 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.84 133.82 52.41 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 121.892 1.728 . . . . 0.0 111.854 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 64.7 t30 45.34 36.42 2.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.397 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -130.34 103.82 6.91 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.29 0.567 . . . . 0.0 110.909 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 153' ' ' GLY . 23.2 m -102.2 135.15 44.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.087 -0.961 . . . . 0.0 110.685 179.4 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.98 92.29 3.97 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 178.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.6 p -102.23 141.76 34.56 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.468 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.1 OUTLIER -111.6 13.79 21.28 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.298 0.57 . . . . 0.0 110.568 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -102.32 30.45 4.56 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.164 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 100.28 59.42 0.84 Allowed Glycine 0 N--CA 1.464 0.553 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 172' ' ' PHE . 21.9 t80 -44.51 119.04 1.73 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.033 0.444 . . . . 0.0 110.484 -179.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.3 m -153.3 130.61 11.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.375 179.229 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 78.03 164.71 24.83 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -66.94 -22.32 48.64 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.896 2.397 . . . . 0.0 112.253 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -89.09 14.01 11.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.951 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.327 -0.377 0 CA-C-O 121.021 0.438 . . . . 0.0 110.166 -179.476 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 44.3 mt . . . . . 0 N--CA 1.452 -0.346 0 CA-C-O 120.862 0.363 . . . . 0.0 110.413 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -135.42 161.8 34.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.037 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.9 163.92 26.88 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -75.03 -7.35 19.05 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 123.058 2.505 . . . . 0.0 112.344 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.447 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 71.9 m-80 -105.32 70.38 0.89 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.597 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.466 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 60.7 t -121.63 130.24 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.925 179.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 87.1 m -144.55 -174.1 4.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.009 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.28 171.43 47.51 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.6 m -84.19 167.56 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -59.52 -43.79 93.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.777 0.323 . . . . 0.0 110.738 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -63.97 -36.76 85.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.977 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -129.25 50.33 2.16 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.987 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -73.18 142.81 47.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.371 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -160.75 167.16 27.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.995 0.426 . . . . 0.0 111.03 179.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.426 ' SG ' HG22 ' A' ' 73' ' ' THR . 79.1 m -64.04 130.92 45.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.17 -179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.466 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 32.5 m -47.72 151.02 1.64 Allowed Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.103 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -49.62 129.76 24.37 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.498 1.465 . . . . 0.0 112.301 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.67 -18.54 47.09 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.447 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 98.6 m95 -111.77 134.76 53.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.965 0.412 . . . . 0.0 110.085 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -110.99 -167.75 1.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.133 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.426 HG22 ' SG ' ' A' ' 67' ' ' CYS . 71.1 p -129.83 165.29 22.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.049 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 12.1 mt -91.53 150.58 41.39 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.834 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_exo -44.21 115.4 0.75 Allowed 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.864 1.709 . . . . 0.0 112.036 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.12 -8.73 7.93 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -91.11 177.94 41.63 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.704 ' H ' ' NE2' ' A' ' 79' ' ' GLN . 26.7 p30 -139.51 13.39 2.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.931 0.396 . . . . 0.0 110.864 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . 0.704 ' NE2' ' H ' ' A' ' 78' ' ' ASN . 12.1 mp0 -84.08 131.78 34.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.469 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 22.5 m -95.88 43.29 1.08 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.361 -0.382 . . . . 0.0 109.987 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 42.4 pt -98.2 6.89 8.66 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.246 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.734 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.66 112.54 60.52 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.417 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.29 156.87 29.52 Favored 'Trans proline' 0 N--CA 1.486 1.059 0 C-N-CA 122.01 1.807 . . . . 0.0 111.864 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.6 mt -100.72 118.91 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.8 115.42 27.12 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.402 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -64.73 -45.24 87.36 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.37 0.605 . . . . 0.0 110.106 179.242 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -119.41 -167.89 1.49 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.674 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.2 t -97.04 125.07 41.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.722 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.6 m -74.39 -32.16 62.62 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.776 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -106.08 2.23 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.439 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.4 p-10 -81.99 -2.63 52.21 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.719 0.295 . . . . 0.0 110.773 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.63 -176.36 27.14 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -133.72 146.12 50.5 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.058 0.456 . . . . 0.0 110.788 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 70.1 m -64.57 111.3 2.65 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.578 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 89.0 p -105.98 -26.07 11.83 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.33 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 -153.23 159.58 32.01 Favored Pre-proline 0 C--N 1.325 -0.464 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.291 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -48.92 119.07 3.96 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.477 2.118 . . . . 0.0 111.915 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.402 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 54.0 t30 55.11 42.88 30.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.228 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mtp -149.06 118.87 7.06 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.09 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' ALA . 69.2 m -100.64 148.72 24.54 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.792 179.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.5 m -119.99 115.59 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.422 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.44 154.0 68.66 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -50.07 -26.56 14.95 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.693 2.262 . . . . 0.0 112.016 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 m -66.49 -15.5 63.41 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.831 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.92 -15.18 58.37 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -65.86 149.31 50.39 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.2 130.64 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.656 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -170.29 179.43 0.74 Allowed Pre-proline 0 C--N 1.327 -0.406 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.446 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.656 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 35.7 Cg_exo -58.81 -22.71 63.34 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.877 2.385 . . . . 0.0 111.78 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 82.7 p -152.3 163.98 38.36 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.598 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.315 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 75.8 m . . . . . 0 CA--C 1.522 -0.131 0 CA-C-O 120.655 0.264 . . . . 0.0 111.224 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 92.3 m-20 -64.36 -40.77 96.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.63 179.753 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.736 HG22 ' H ' ' A' ' 122' ' ' ARG . 24.7 mm -64.48 177.83 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.962 0.41 . . . . 0.0 109.999 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.736 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.8 mmt180 -117.46 98.27 6.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.721 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.2 m -94.33 135.27 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.322 179.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.6 mtm -130.17 170.13 14.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.346 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 m120 63.6 41.48 7.19 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.717 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.87 23.61 71.04 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.574 -1.01 . . . . 0.0 110.574 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.93 141.96 24.88 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 20.1 m -99.87 144.69 28.63 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.725 0.298 . . . . 0.0 110.314 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . 0.5 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 0.5 OUTLIER -93.99 129.79 40.35 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.682 179.897 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 28.8 t -149.36 134.99 18.61 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.394 178.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 51.11 45.82 27.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 56.95 33.65 23.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -143.98 138.2 28.26 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.467 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 95.9 m -91.05 131.4 36.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 110.828 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 76.6 mt -101.83 128.53 48.15 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.338 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . 0.452 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 8.4 m -89.01 135.78 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.53 -179.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -73.32 172.6 10.91 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.444 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -62.82 126.12 26.25 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.12 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 107.96 -26.27 17.93 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.61 133.73 54.5 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.946 0.403 . . . . 0.0 110.065 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 141' ' ' ILE . 23.3 pt -127.35 169.14 19.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.934 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.452 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 118.79 159.87 11.23 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.1 m -62.12 -46.07 90.67 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.566 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -100.68 2.14 41.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.58 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.6 m 62.85 132.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.996 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 164.91 -11.99 0.08 OUTLIER Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -100.27 112.72 64.72 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -75.74 157.76 39.57 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 C-N-CA 122.42 2.08 . . . . 0.0 112.053 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 52.5 t -120.56 130.47 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 18.1 m -90.06 98.81 11.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.183 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.34 -39.36 92.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 0.0 110.418 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 83.1 p -81.83 -6.86 59.44 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.482 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 64.99 161.07 0.56 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.6 m -114.06 104.93 12.63 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.834 0.349 . . . . 0.0 110.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 85.5 mt -63.67 -42.19 98.08 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.561 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.9 t-20 -90.73 173.31 8.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.342 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.69 33.2 0.28 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.561 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.47 -179.01 26.38 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 53.4 mmm-85 -130.46 147.37 52.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.918 0.389 . . . . 0.0 110.218 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 84.0 m -83.99 111.05 18.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.362 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.9 m -95.38 -20.54 5.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.376 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.64 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.62 173.82 2.71 Favored Pre-proline 0 C--N 1.326 -0.455 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.627 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.64 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.97 130.89 41.61 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.164 1.909 . . . . 0.0 111.95 179.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . 0.408 ' O ' ' OD1' ' A' ' 164' ' ' ASN . 60.5 t-20 49.74 32.33 5.13 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.084 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -137.0 129.14 29.52 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.447 0.642 . . . . 0.0 110.045 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -131.79 145.38 51.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.0 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -97.13 137.15 36.62 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.703 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . 0.549 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 44.2 m -81.75 142.79 32.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.079 0.466 . . . . 0.0 111.054 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.9 m -63.38 -45.59 90.39 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.084 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -97.89 17.23 18.65 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.106 0.479 . . . . 0.0 111.086 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.79 24.18 77.01 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.549 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 3.1 m-85 -66.01 151.49 46.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.238 0.542 . . . . 0.0 110.191 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -87.61 166.05 14.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.97 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.83 148.51 11.52 Favored Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.17 -29.06 39.98 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 122.448 2.099 . . . . 0.0 112.409 -179.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -115.12 0.89 13.74 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.604 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.784 -179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt . . . . . 0 N--CA 1.451 -0.399 0 CA-C-O 120.985 0.421 . . . . 0.0 110.58 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.42 165.0 22.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.655 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 70.18 172.43 10.7 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.55 -171.36 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.984 2.456 . . . . 0.0 111.794 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.576 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 62.6 m-20 58.78 38.78 24.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.081 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.451 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 7.4 p -95.53 133.72 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.288 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 60.6 m -151.22 -174.32 4.78 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.275 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.28 174.38 44.92 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.561 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.1 m -82.47 160.81 22.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.607 0.241 . . . . 0.0 110.437 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.53 -43.29 97.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.725 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -61.72 -41.15 97.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.273 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -133.61 54.66 1.94 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.649 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.11 147.54 53.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.291 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.417 ' O ' ' O ' ' A' ' 59' ' ' CYS . 11.7 p90 -153.81 170.16 21.62 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.005 0.431 . . . . 0.0 110.766 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.1 m -73.79 135.42 43.51 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -49.0 167.9 0.2 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.386 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -57.17 132.29 50.37 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.014 1.809 . . . . 0.0 111.643 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 97.14 -17.25 59.51 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.576 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 31.5 m95 -113.61 139.79 48.73 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.927 0.394 . . . . 0.0 110.363 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -125.48 -174.01 2.97 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.192 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 74.6 p -115.48 161.51 18.48 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.432 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' A' ' 77' ' ' GLY . 17.8 mt -87.62 151.68 50.72 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.437 ' C ' ' H ' ' A' ' 77' ' ' GLY . 73.1 Cg_exo -39.21 107.03 0.06 OUTLIER 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 122.235 1.957 . . . . 0.0 112.116 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 72.98 -11.17 4.88 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.01 174.48 53.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -135.28 13.49 3.53 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.06 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -84.63 129.09 34.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.503 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 63.5 m -95.2 60.45 2.33 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 37.3 pt -119.17 26.65 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.855 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.3 t -123.06 84.45 51.03 Favored Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.953 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -63.32 150.26 89.04 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.597 2.198 . . . . 0.0 111.69 179.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.9 mt -94.0 121.98 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.33 129.81 45.57 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.403 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -63.18 -45.92 89.51 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.206 0.527 . . . . 0.0 110.169 179.951 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -122.38 146.57 47.22 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -52.42 125.42 16.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.376 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.8 m -66.56 -2.03 4.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.544 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 55.59 -116.23 6.84 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.8 p-10 -74.91 -1.26 21.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 110.676 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.61 -164.29 19.83 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.475 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 54.9 p90 -142.84 150.97 40.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.966 0.412 . . . . 0.0 110.646 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -69.64 114.97 8.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.832 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.475 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 5.0 m -105.25 -19.03 13.93 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.586 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.4 mtt85 -157.08 162.54 27.39 Favored Pre-proline 0 N--CA 1.454 -0.263 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.737 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -50.09 122.45 9.22 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 121.95 1.767 . . . . 0.0 111.341 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.403 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 72.0 m-20 52.93 38.64 27.52 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.982 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.7 mtp -146.29 118.76 8.47 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.492 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 37.8 m -105.95 150.42 25.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.718 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . 0.432 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 64.7 m -119.69 113.38 20.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.582 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.64 157.19 72.51 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.629 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.3 -21.19 71.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.65 2.234 . . . . 0.0 111.474 178.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -67.71 -16.59 64.21 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.727 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 105.63 -20.38 36.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -68.75 151.54 46.51 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.888 0.375 . . . . 0.0 110.528 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -131.22 135.15 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.676 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -167.26 -179.19 0.75 Allowed Pre-proline 0 C--N 1.326 -0.447 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.647 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.676 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 31.5 Cg_exo -60.29 -16.02 38.43 Favored 'Trans proline' 0 N--CA 1.499 1.806 0 C-N-CA 122.953 2.435 . . . . 0.0 111.907 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 27.8 m -160.29 159.81 31.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.756 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.296 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.23 179.43 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.467 0.424 0 CA-C-O 121.008 0.432 . . . . 0.0 110.082 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -62.6 -40.36 96.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.112 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.757 HG22 ' H ' ' A' ' 122' ' ' ARG . 36.1 mm -74.24 178.04 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.239 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.757 ' H ' HG22 ' A' ' 121' ' ' ILE . 1.0 OUTLIER -127.68 134.03 49.6 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.166 179.354 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.5 m -118.21 144.6 45.61 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtm -144.3 169.37 18.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.284 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 59.28 40.52 21.23 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.32 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 23.47 67.76 Favored Glycine 0 C--N 1.333 0.371 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.03 119.92 5.07 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 120.432 -0.89 . . . . 0.0 110.929 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.2 p -79.43 145.29 33.39 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.035 -0.266 . . . . 0.0 110.54 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.8 t -97.4 118.44 33.88 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.75 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.422 ' O ' ' N ' ' A' ' 133' ' ' HIS . 29.8 t -148.13 139.76 23.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.575 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 41.98 45.93 3.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 55.45 36.99 28.25 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.457 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' SER . 58.4 m80 -142.7 141.89 31.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.261 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.467 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 81.4 m -99.93 119.82 38.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.497 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.6 mt -98.06 128.26 44.48 Favored 'General case' 0 CA--C 1.518 -0.267 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.79 134.61 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.858 -179.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -72.26 -173.77 1.16 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.34 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -67.77 129.13 38.97 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.731 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.64 -9.33 55.48 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -125.46 141.54 52.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.859 0.361 . . . . 0.0 110.528 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.6 pt -132.66 173.79 14.26 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.743 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 112.61 153.54 11.74 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.0 p -63.01 -45.5 92.1 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.698 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -97.83 1.75 48.6 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.511 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 16.4 m 62.62 133.21 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.871 -179.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 161.29 -6.71 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -109.21 111.58 60.04 Favored Pre-proline 0 CA--C 1.543 0.693 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.58 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -75.64 156.77 40.23 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.517 2.145 . . . . 0.0 112.435 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 90.9 t -101.98 114.92 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.05 98.25 11.65 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.306 -179.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -65.77 -39.66 91.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.71 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 72.1 m -79.62 -7.55 58.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.84 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.46 161.69 0.05 OUTLIER Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 66.7 m -106.51 111.17 23.61 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 89.0 mt -63.18 -42.26 99.35 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.8 t30 -95.7 173.0 7.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.416 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.59 37.5 0.36 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -76.55 -172.05 34.5 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -132.21 143.46 49.96 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.872 0.367 . . . . 0.0 110.521 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.6 m -81.92 113.51 19.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.281 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.3 m -88.42 -23.69 6.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.536 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.5 171.99 3.81 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.511 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.6 Cg_exo -50.45 127.96 21.93 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.711 1.607 . . . . 0.0 112.01 178.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.8 t30 53.93 36.7 24.97 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.715 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.414 ' HD2' ' HB3' ' A' ' 162' ' ' ALA . 94.7 mtt-85 -141.42 132.8 26.7 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.207 0.527 . . . . 0.0 110.632 178.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 3.4 t -141.45 150.77 42.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.954 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.52 53.57 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.687 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.97 137.13 32.62 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.035 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.0 p -112.58 19.2 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.88 0.371 . . . . 0.0 111.44 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.476 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 34.3 t80 -114.49 31.75 6.42 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.725 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 79.34 15.63 79.69 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -108.26 163.22 13.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.281 0.562 . . . . 0.0 110.917 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.9 t -147.1 152.31 38.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 129.72 162.42 10.82 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.83 -22.86 36.01 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 122.721 2.281 . . . . 0.0 112.186 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -124.37 7.29 8.38 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.523 -179.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 73.2 m . . . . . 0 C--N 1.326 -0.428 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.642 -179.813 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 64.8 mt . . . . . 0 CA--C 1.516 -0.339 0 CA-C-O 120.823 0.344 . . . . 0.0 110.491 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -127.0 161.16 29.03 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.377 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.55 169.7 44.33 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.41 -176.08 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 123.009 2.473 . . . . 0.0 111.908 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 58.9 42.05 20.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.459 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 50.3 t -107.86 133.72 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' TYR . 88.8 m -142.69 -179.02 6.07 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.025 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.34 164.37 40.06 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.531 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.3 m -79.74 168.21 19.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.786 0.327 . . . . 0.0 110.394 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.7 ttt-85 -61.04 -43.23 99.2 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.502 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -62.36 -40.54 96.75 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.962 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -129.35 52.87 1.94 Allowed 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.618 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.531 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.77 142.48 54.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.352 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.406 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -154.7 165.3 36.99 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.492 179.441 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.541 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 81.9 m -71.03 137.92 49.42 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.489 -0.484 . . . . 0.0 109.782 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.459 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 27.4 m -52.9 151.77 8.06 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.106 -178.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.93 130.75 32.32 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 121.559 1.506 . . . . 0.0 112.755 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -6.95 61.4 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -119.49 137.2 53.95 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.007 0.432 . . . . 0.0 110.79 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -123.85 -177.05 3.63 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.398 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.541 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 35.8 p -131.21 172.08 12.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.35 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.49 ' O ' ' N ' ' A' ' 77' ' ' GLY . 43.1 mt -90.31 148.59 39.43 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.67 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -40.49 111.49 0.14 Allowed 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.014 1.81 . . . . 0.0 112.574 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 82.02 -16.58 21.06 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -74.76 165.0 54.72 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -129.72 8.66 5.36 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.045 0.45 . . . . 0.0 110.958 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -87.23 130.04 34.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.381 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 56.8 m -94.21 40.8 1.08 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -94.67 11.68 3.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.606 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.64 107.02 53.45 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.684 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -76.53 157.78 36.29 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.282 1.988 . . . . 0.0 112.243 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -103.12 126.18 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.063 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -100.16 127.08 46.48 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.27 -45.27 94.02 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -126.19 157.32 38.48 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.637 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -60.97 136.49 58.1 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.422 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 57.7 m -78.78 -26.03 44.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.809 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 82.68 -109.32 3.07 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 23.0 p-10 -78.87 -2.61 40.64 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.674 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.55 -160.46 16.16 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -147.73 153.15 38.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.977 0.418 . . . . 0.0 110.826 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.6 m -63.58 113.4 3.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.973 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 92.6 p -100.89 -22.91 14.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.309 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 mtp180 -158.68 161.14 28.9 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.688 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -45.91 119.47 2.9 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 121.926 1.751 . . . . 0.0 111.725 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 54.82 39.56 31.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.271 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 69.8 mmm -145.83 122.13 10.91 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.441 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 27.3 m -105.8 147.55 28.52 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.286 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 78.7 m -122.3 113.44 19.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.753 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.422 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -76.23 157.38 83.06 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.021 179.895 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.422 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -62.29 -21.67 72.97 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.837 2.358 . . . . 0.0 111.48 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 m -63.61 -33.69 76.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.555 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 123.32 -17.24 7.96 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . 0.467 ' NE2' ' H ' ' A' ' 107' ' ' ILE . 1.2 tm0? -69.29 145.0 53.42 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.902 0.382 . . . . 0.0 110.648 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.467 ' H ' ' NE2' ' A' ' 106' ' ' GLN . 92.0 mt -124.29 131.29 73.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.626 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.66 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -171.19 179.43 0.67 Allowed Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.416 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.66 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 35.4 Cg_exo -58.95 -21.8 59.94 Favored 'Trans proline' 0 N--CA 1.498 1.793 0 C-N-CA 122.772 2.315 . . . . 0.0 111.999 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 92.7 p -151.27 164.28 36.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.333 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.326 -0.432 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.573 -179.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.2 m . . . . . 0 CA--C 1.533 0.299 0 CA-C-O 121.103 0.477 . . . . 0.0 110.756 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -63.97 -39.98 95.36 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.255 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.534 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 11.3 tt -112.17 169.7 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.188 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.691 HH21 ' CE1' ' A' ' 144' ' ' HIS . 28.5 ptt180 -83.21 118.88 23.92 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.034 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.7 143.14 50.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.64 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.573 ' N ' ' SD ' ' A' ' 124' ' ' MET . 2.1 mpp? -141.96 161.49 37.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.182 179.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 57.98 51.79 8.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.282 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.79 19.08 77.89 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.44 143.22 40.31 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.0 t -121.4 141.12 51.28 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 10.5 p -93.15 131.55 38.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.76 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.546 ' O ' ' N ' ' A' ' 132' ' ' ASP . 44.1 t -138.19 131.47 30.39 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.187 179.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 60.8 t0 55.31 -80.57 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.504 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.546 ' N ' ' O ' ' A' ' 130' ' ' SER . 37.7 p-10 -155.42 23.28 0.41 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.734 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.443 ' CD2' ' OD1' ' A' ' 132' ' ' ASP . 96.0 m-70 -141.79 158.05 44.27 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.519 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.464 ' SG ' HG23 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -96.96 131.73 43.46 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.154 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.3 mt -92.68 128.86 38.69 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.756 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . 0.466 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -105.96 132.59 51.87 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.694 -179.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -79.83 173.06 12.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.359 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -63.06 133.7 54.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.288 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.62 -25.84 24.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.466 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 96.5 m-85 -116.13 130.94 57.04 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 28.7 pt -129.68 178.48 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.021 -179.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 115.92 159.72 12.07 Favored Glycine 0 N--CA 1.462 0.424 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.7 p -66.12 -33.86 76.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.765 0.317 . . . . 0.0 110.546 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.691 ' CE1' HH21 ' A' ' 122' ' ' ARG . 54.7 m-70 -103.97 1.64 31.41 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.751 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.414 ' O ' ' O ' ' A' ' 144' ' ' HIS . 41.8 t 59.82 122.9 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 159.64 -23.56 0.29 Allowed Glycine 0 CA--C 1.519 0.317 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 1.1 tp-100 -76.89 118.04 69.06 Favored Pre-proline 0 CA--C 1.543 0.673 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.629 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -75.46 157.42 40.84 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.641 2.227 . . . . 0.0 112.393 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.6 t -121.11 129.8 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.445 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.1 m -92.96 98.97 11.7 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -67.07 -36.99 83.21 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.471 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.0 p -85.88 -6.4 59.09 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.93 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.94 -172.17 33.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 57.3 m -139.81 106.69 5.41 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 82.2 mt -63.45 -42.18 98.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.785 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.539 ' C ' ' H ' ' A' ' 158' ' ' GLY . 27.6 t-20 -90.56 170.28 10.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.8 35.38 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -71.77 -174.63 21.86 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -131.3 147.1 52.54 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.72 0.295 . . . . 0.0 110.812 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 3.6 t -88.12 112.87 23.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.719 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.47 -54.89 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.06 175.91 3.31 Favored Pre-proline 0 N--CA 1.466 0.328 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.196 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -53.22 130.29 37.59 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 121.813 1.675 . . . . 0.0 112.023 179.702 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 66.5 t30 51.38 35.78 14.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.47 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.7 ttt85 -137.08 124.34 21.83 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.588 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.9 t -130.21 138.27 50.49 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.02 140.65 29.67 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.768 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.3 m -81.23 143.3 32.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.839 0.352 . . . . 0.0 110.158 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.1 m -63.46 -45.37 91.12 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.024 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.525 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 80.3 t80 -98.56 24.54 7.32 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.169 0.509 . . . . 0.0 110.815 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.16 24.2 70.28 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -56.27 159.57 3.46 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.88 0.371 . . . . 0.0 110.18 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.563 HG22 ' N ' ' A' ' 174' ' ' GLY . 89.4 m -82.26 162.42 22.33 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.198 0.523 . . . . 0.0 111.143 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . 0.563 ' N ' HG22 ' A' ' 173' ' ' THR . . . 66.94 152.03 0.2 Allowed Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 179.423 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.57 -29.1 44.52 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.695 2.263 . . . . 0.0 112.056 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -78.75 -15.46 58.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.603 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 39.4 m . . . . . 0 C--N 1.326 -0.434 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.42 179.612 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.6 mt . . . . . 0 N--CA 1.45 -0.47 0 CA-C-O 120.877 0.37 . . . . 0.0 110.428 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.0 mtpt -128.86 160.4 32.73 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.3 0.571 . . . . 0.0 110.77 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 162.74 25.29 Favored Glycine 0 CA--C 1.528 0.904 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.08 3.08 7.35 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.704 2.269 . . . . 0.0 112.248 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.6 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 0.3 OUTLIER -112.58 61.3 0.63 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.105 0.479 . . . . 0.0 110.429 -179.654 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.9 t -109.71 129.68 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-O 121.193 0.52 . . . . 0.0 109.72 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 85.1 m -141.92 176.91 8.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.664 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 171.5 45.85 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.3 m -82.19 165.1 20.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.703 0.287 . . . . 0.0 110.457 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -60.02 -42.67 94.86 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.659 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -61.17 -41.36 96.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.006 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -132.72 54.75 1.93 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.489 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.52 142.49 56.54 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.493 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 13.6 p90 -151.45 165.89 32.77 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.186 0.517 . . . . 0.0 110.901 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 57' ' ' ASN . 1.6 t -73.59 138.42 44.89 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.436 179.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -58.42 157.97 16.3 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.859 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -60.76 137.35 72.4 Favored 'Trans proline' 0 N--CA 1.493 1.442 0 C-N-CA 121.903 1.735 . . . . 0.0 111.817 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.59 55.21 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.6 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.1 m95 -112.79 134.69 54.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 117.066 0.433 . . . . 0.0 109.84 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.8 ptpt -114.2 -175.1 2.6 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.5 p -125.4 165.94 17.49 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.67 149.19 45.66 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.721 -179.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.8 Cg_exo -44.77 123.15 4.61 Favored 'Trans proline' 0 N--CA 1.491 1.362 0 C-N-CA 121.693 1.596 . . . . 0.0 112.208 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.42 -7.56 0.9 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 179.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.77 179.48 38.48 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 46.9 p30 -138.0 11.89 2.86 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.831 0.348 . . . . 0.0 110.797 179.675 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -82.37 129.46 34.88 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 8.0 m -106.09 80.75 1.55 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.316 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.6 pt -129.69 15.88 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.651 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 t -126.77 99.77 29.01 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -77.45 163.16 30.05 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.364 2.043 . . . . 0.0 111.939 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 45.7 mm -94.99 122.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -95.71 121.39 37.38 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.425 ' CB ' HD22 ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.74 -45.68 91.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.172 0.511 . . . . 0.0 109.766 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -112.77 137.92 50.37 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.087 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.9 m -60.56 134.35 56.99 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.958 0.409 . . . . 0.0 110.129 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 28.7 m -76.45 -31.78 58.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.182 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 66.88 -101.56 0.67 Allowed Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.437 -0.665 . . . . 0.0 111.437 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -67.54 -17.71 64.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.835 0.35 . . . . 0.0 111.004 -179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.78 -161.56 21.11 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.435 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 54.8 p90 -143.2 151.7 40.93 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.903 0.382 . . . . 0.0 111.2 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.9 t -64.49 114.14 4.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.157 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.445 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 68.2 m -103.05 -23.75 13.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.769 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.7 mtt180 -162.31 165.47 15.58 Favored Pre-proline 0 CA--C 1.531 0.248 0 C-N-CA 120.396 -0.521 . . . . 0.0 110.407 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.6 123.55 11.65 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 121.601 1.534 . . . . 0.0 111.49 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.425 HD22 ' CB ' ' A' ' 86' ' ' ARG . 8.2 t-20 51.57 40.51 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.033 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.9 mmm -147.47 114.48 6.16 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.576 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.42 ' N ' ' O ' ' A' ' 108' ' ' ALA . 35.5 m -101.28 149.28 24.18 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.323 178.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . 0.445 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 63.6 m -120.97 119.68 33.25 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.706 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 157.28 60.32 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.143 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -62.7 -19.23 67.63 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.66 2.24 . . . . 0.0 111.78 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 42.0 m -69.79 -14.27 62.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.331 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.67 -20.4 39.32 Favored Glycine 0 N--CA 1.464 0.517 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -69.19 149.5 48.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.985 0.421 . . . . 0.0 110.092 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.33 133.6 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -166.55 -179.82 0.9 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.287 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.658 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 32.2 Cg_exo -59.52 -20.07 55.29 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.835 2.357 . . . . 0.0 112.162 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.7 p -155.58 163.03 40.51 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.414 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.331 -0.204 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.35 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 76.9 m . . . . . 0 C--O 1.23 0.044 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -92.14 9.34 33.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.027 0.441 . . . . 0.0 110.369 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.501 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 14.8 tt -134.11 169.19 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.607 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.501 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.6 ptm180 -100.12 106.45 18.17 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.04 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.9 m -99.73 138.04 37.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.099 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 66.2 mtt -143.23 160.64 40.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.249 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.618 ' ND2' ' CD1' ' A' ' 140' ' ' TYR . 98.0 m-20 59.86 40.18 19.58 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.841 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.52 28.58 63.2 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.01 128.79 23.3 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . 0.483 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 13.3 m -88.87 137.84 31.95 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 122.739 -0.271 . . . . 0.0 110.537 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 62.4 m -77.63 129.67 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.166 179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 40.9 t -143.85 136.39 27.03 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' SER . 96.5 m-20 33.75 -99.91 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.387 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -125.3 4.75 7.75 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.365 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -129.65 154.48 47.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.739 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.9 t -102.77 146.27 28.49 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.442 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.9 mt -98.61 131.26 44.94 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.155 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -97.83 134.26 41.22 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.68 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -80.67 178.23 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.707 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -66.59 133.24 49.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.283 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.54 35.08 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.618 ' CD1' ' ND2' ' A' ' 125' ' ' ASN . 92.9 m-85 -121.63 134.41 54.99 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.093 0.473 . . . . 0.0 110.531 179.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . 0.42 HG23 ' CG2' ' A' ' 149' ' ' VAL . 36.6 pt -121.94 -163.84 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.357 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.4 152.93 28.95 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.9 m -63.11 -45.03 93.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.881 0.372 . . . . 0.0 110.661 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -94.73 3.17 55.36 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.876 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 33.7 t 61.4 116.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.472 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.583 ' N ' HE21 ' A' ' 147' ' ' GLN . . . 173.71 -20.59 0.06 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . 0.71 HE21 ' H ' ' A' ' 147' ' ' GLN . 0.0 OUTLIER -94.68 128.92 37.94 Favored Pre-proline 0 CA--C 1.548 0.888 0 CA-C-N 117.048 0.424 . . . . 0.0 110.267 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -76.99 161.72 32.64 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.821 2.347 . . . . 0.0 111.809 178.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . 0.42 ' CG2' HG23 ' A' ' 141' ' ' ILE . 54.7 t -99.15 127.9 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.3 -179.418 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -101.57 90.53 4.09 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -65.46 -43.09 91.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.519 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 85.8 p -89.15 -8.75 53.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.527 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . 0.447 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 56.82 -179.46 0.63 Allowed Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.3 m -117.73 118.78 33.0 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.1 mt -63.21 -42.25 99.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.032 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.554 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.0 t-20 -93.18 179.93 5.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.434 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.22 32.93 0.32 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.554 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.44 177.16 26.23 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 23.2 mmm180 -128.49 143.61 51.01 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.811 0.338 . . . . 0.0 110.269 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 33.8 m -83.06 113.08 20.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -101.56 -18.25 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.704 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.97 171.4 6.39 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.248 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -51.7 129.16 28.84 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 121.705 1.603 . . . . 0.0 111.921 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 50.81 34.34 10.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.734 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.5 OUTLIER -127.55 119.03 25.09 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.028 0.442 . . . . 0.0 110.175 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.523 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 26.4 m -110.8 122.66 48.39 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.075 179.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -88.02 135.65 33.32 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . 0.582 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 87.8 m -84.05 141.4 31.18 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.039 0.447 . . . . 0.0 110.382 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.7 m -63.24 -45.58 90.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.283 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -104.78 18.58 22.04 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.133 0.492 . . . . 0.0 110.984 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 72.19 24.8 75.86 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.53 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 91.5 t80 -54.64 143.9 23.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.883 0.373 . . . . 0.0 110.403 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 96.3 m -103.86 125.56 50.37 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.375 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -179.21 162.05 28.62 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.28 -31.4 73.82 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.67 2.247 . . . . 0.0 112.4 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -110.27 4.57 20.99 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.292 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.582 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.7 t . . . . . 0 C--N 1.33 -0.27 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.716 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.454 HD11 ' HA ' ' A' ' 66' ' ' TYR . 92.2 mt . . . . . 0 N--CA 1.452 -0.347 0 CA-C-O 120.899 0.38 . . . . 0.0 110.662 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.7 mtpt -123.25 166.26 15.55 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.845 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 69.13 165.7 4.29 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.47 -166.17 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.956 2.437 . . . . 0.0 111.876 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 4.0 m120 58.64 36.14 24.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.8 p -100.46 136.56 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.031 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 60.4 m -141.41 176.9 8.5 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.994 0.426 . . . . 0.0 110.283 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.15 161.71 31.43 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.1 m -77.91 171.07 15.54 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 44.9 ttm180 -59.98 -42.91 95.19 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.852 0.358 . . . . 0.0 110.392 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -62.89 -40.45 97.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.994 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.471 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 21.2 m120 -125.67 50.52 1.82 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.578 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.92 138.27 49.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.607 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.471 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.9 p90 -158.45 165.64 34.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.106 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 79.4 m -69.2 139.08 54.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.296 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 25.7 m -54.42 146.89 30.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.095 -179.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -48.01 125.58 11.85 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 C-N-CA 121.605 1.537 . . . . 0.0 112.344 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.424 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.45 -12.89 58.4 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 88.9 m95 -114.82 134.38 55.18 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 110.213 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -125.25 -170.26 2.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.51 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 3.2 p -131.33 168.9 16.77 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.332 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.76 HD12 ' H ' ' A' ' 74' ' ' LEU . 0.0 OUTLIER -87.29 164.46 35.56 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.436 -179.21 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -53.0 125.41 18.21 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 121.875 1.717 . . . . 0.0 112.035 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.05 -0.31 11.89 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.89 174.48 35.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -140.14 7.54 2.22 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.881 0.372 . . . . 0.0 110.698 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 -83.33 131.22 35.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 54.1 m -94.27 38.53 1.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.905 0.383 . . . . 0.0 110.11 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.09 6.54 6.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.646 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.0 t -107.03 117.08 57.36 Favored Pre-proline 0 CA--C 1.537 0.446 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.913 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.73 155.71 44.24 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.418 2.079 . . . . 0.0 112.433 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.424 ' N ' ' O ' ' A' ' 70' ' ' GLY . 83.2 mt -107.34 119.12 56.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.199 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.89 113.85 26.23 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.461 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 1.8 mpt_? -62.31 -40.21 95.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.375 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -109.59 127.8 54.76 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 109.842 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.6 p -49.41 122.13 5.81 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.209 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.63 -24.24 56.42 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.919 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.72 -115.48 4.26 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -77.52 -4.46 45.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.37 175.9 36.5 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 40.2 t80 -123.17 132.57 54.11 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.221 0.534 . . . . 0.0 111.172 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . 0.479 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 3.4 m -65.57 117.57 8.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.827 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . 0.434 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 47.1 m -104.87 -21.94 13.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.53 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 -158.44 163.15 25.26 Favored Pre-proline 0 C--N 1.331 -0.214 0 C-N-CA 120.264 -0.575 . . . . 0.0 110.748 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -48.98 120.48 5.5 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.926 1.751 . . . . 0.0 111.501 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 98' ' ' ASN . 56.3 t-20 54.69 41.47 31.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.975 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.0 mmm -146.59 115.68 6.97 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.954 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' ALA . 91.0 m -99.15 146.74 25.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.71 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . 0.434 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 32.8 m -118.84 114.19 22.25 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.9 158.75 64.45 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.997 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -55.36 -28.01 60.89 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 122.749 2.299 . . . . 0.0 111.817 178.027 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.3 t -63.97 -16.6 61.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.591 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.73 -13.64 59.27 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -69.46 149.85 47.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.918 0.389 . . . . 0.0 110.039 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.44 129.45 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.812 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.692 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -164.23 179.16 1.23 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.498 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.692 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 32.4 Cg_exo -59.21 -23.39 69.27 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.824 2.349 . . . . 0.0 111.944 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 36.2 p -155.53 162.95 40.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.677 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 CA--C 1.532 0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.365 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 5.1 m . . . . . 0 N--CA 1.464 0.267 0 CA-C-O 120.98 0.419 . . . . 0.0 110.537 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -64.27 -39.79 94.66 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.216 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 19.7 tt -77.93 166.05 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.348 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -93.41 123.13 36.5 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.951 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.3 m -123.66 141.27 52.17 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.598 179.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.9 mtm -146.19 163.25 36.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.431 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.53 ' OD1' ' CE1' ' A' ' 140' ' ' TYR . 5.2 t-20 63.11 44.05 6.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.953 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . 0.408 ' HA3' HE21 ' A' ' 137' ' ' GLN . . . 72.43 22.64 78.83 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.344 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.53 162.76 36.97 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.2 t -133.35 141.56 47.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.308 . . . . 0.0 110.204 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.31 123.15 36.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.77 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 25.1 t -148.45 134.34 19.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.605 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 48.46 46.77 20.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.5 t0 55.24 27.89 10.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.452 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -137.74 137.3 38.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.231 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 13.8 t -92.14 129.96 37.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.921 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 83.0 mt -113.5 143.57 44.3 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.115 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.6 m -103.99 144.51 31.44 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.54 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . 0.408 HE21 ' HA3' ' A' ' 126' ' ' GLY . 48.4 mt-30 -68.19 174.55 3.83 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.422 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -66.28 131.3 45.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.578 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.57 -15.46 53.13 Favored Glycine 0 N--CA 1.467 0.762 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . 0.53 ' CE1' ' OD1' ' A' ' 125' ' ' ASN . 86.8 m-85 -116.88 134.83 54.28 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.275 -0.269 . . . . 0.0 110.275 179.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.8 pt -125.37 165.36 22.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 122.35 153.47 8.87 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 20.1 m -62.22 -47.07 86.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 110.681 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -99.58 2.98 45.17 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.79 136.84 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 154.6 -9.72 0.4 Allowed Glycine 0 CA--C 1.518 0.247 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -103.19 108.57 59.32 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.324 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.82 161.61 36.13 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.711 2.274 . . . . 0.0 112.069 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.5 t -116.54 129.31 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.01 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 21.5 m -97.46 107.24 19.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . 0.444 ' HB2' HD22 ' A' ' 164' ' ' ASN . 3.8 mp0 -66.26 -40.16 89.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.448 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.8 m -86.36 -10.72 53.82 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 68.43 -177.47 25.46 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 22.5 m -128.91 114.14 16.1 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.0 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.6 mt -63.38 -42.13 98.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.427 ' C ' ' H ' ' A' ' 158' ' ' GLY . 98.0 m-20 -95.94 -172.36 2.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.389 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.65 38.24 1.24 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -72.55 176.38 42.29 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -130.2 148.36 52.03 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.2 m -85.05 120.18 26.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.081 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.8 m -104.01 -11.68 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.295 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.687 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -176.55 174.79 0.69 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.687 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 43.8 Cg_exo -55.24 125.13 18.14 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.163 1.908 . . . . 0.0 111.116 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . 0.444 HD22 ' HB2' ' A' ' 151' ' ' GLU . 16.3 t-20 56.15 34.66 24.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.682 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.1 mmt-85 -135.37 131.64 36.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.402 0.62 . . . . 0.0 110.624 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.48 ' O ' ' CE1' ' A' ' 172' ' ' PHE . 7.7 t -142.82 147.1 34.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.756 179.524 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -120.99 122.06 39.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.947 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.72 154.95 22.18 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.877 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.4 p -106.96 15.23 25.58 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.957 0.408 . . . . 0.0 110.836 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.414 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 23.9 t80 -119.71 32.94 5.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.933 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.46 57.52 1.64 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.779 -0.929 . . . . 0.0 110.779 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.48 ' CE1' ' O ' ' A' ' 166' ' ' CYS . 89.7 t80 -47.29 110.03 0.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.893 0.378 . . . . 0.0 110.646 -179.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 177' ' ' CYS . 91.0 m -129.16 126.86 40.17 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.22 179.272 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 64.15 166.44 1.05 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.364 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -55.88 -36.91 96.3 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 C-N-CA 122.75 2.3 . . . . 0.0 112.313 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -74.96 46.46 0.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.448 -179.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.44 ' O ' ' N ' ' A' ' 173' ' ' THR . 42.3 t . . . . . 0 C--N 1.325 -0.458 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.646 -179.707 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.0 mt . . . . . 0 N--CA 1.451 -0.424 0 CA-C-O 120.544 0.211 . . . . 0.0 110.55 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -138.36 159.84 41.02 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 120.997 0.427 . . . . 0.0 110.69 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.42 166.1 19.31 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -77.19 -1.31 11.48 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.902 2.402 . . . . 0.0 112.281 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.61 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 78.5 m-20 -117.34 71.8 0.82 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.777 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.491 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.9 t -121.45 130.32 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 75.3 m -142.89 -174.7 4.25 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.201 -179.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.83 171.08 45.38 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.5 m -78.89 163.57 25.17 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -59.93 -42.88 94.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.555 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -61.67 -42.39 98.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -127.25 49.38 2.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.871 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.07 146.87 53.86 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.669 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -152.9 168.82 24.51 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.824 0.345 . . . . 0.0 110.949 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 91.5 m -70.51 131.32 43.84 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.188 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 62.1 m -49.35 152.37 2.21 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.076 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_exo -51.59 131.64 37.92 Favored 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 121.387 1.392 . . . . 0.0 112.459 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.84 -5.08 53.48 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.61 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 44.5 m95 -132.24 140.86 48.82 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.625 0.25 . . . . 0.0 110.455 179.314 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -115.4 -166.4 1.12 Allowed 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.005 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 76.9 p -115.87 158.21 23.3 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 77' ' ' GLY . 18.9 mt -89.91 151.08 44.88 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.604 -179.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.427 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.5 Cg_exo -39.94 106.68 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.206 1.937 . . . . 0.0 112.142 179.43 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.42 -10.57 2.66 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.19 171.81 52.18 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 55.1 p30 -127.87 11.39 6.62 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.551 0.215 . . . . 0.0 111.117 -179.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -89.46 139.1 30.86 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.887 -179.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.2 m -99.26 43.18 1.07 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.921 0.391 . . . . 0.0 110.018 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 43.4 pt -94.2 19.23 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.474 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.32 95.05 49.03 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -77.59 159.79 31.87 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.265 1.976 . . . . 0.0 112.221 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.59 120.67 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.498 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.07 109.37 21.34 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.55 ' HE ' HD21 ' A' ' 98' ' ' ASN . 1.1 mpt_? -64.55 -39.6 94.05 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.521 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -103.42 133.47 48.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.147 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 31.2 t -61.94 134.43 56.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.33 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 32.4 m -78.97 -28.21 43.57 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.507 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 76.19 -104.72 1.87 Allowed Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 179.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -80.04 -3.48 48.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.659 0.266 . . . . 0.0 111.083 -179.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.3 -160.1 20.19 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -147.05 152.19 38.14 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.918 0.39 . . . . 0.0 111.33 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.41 115.61 5.28 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 20.7 t -109.84 -24.17 10.99 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.927 -179.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -156.14 158.43 31.58 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.095 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -52.51 125.63 18.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.043 1.829 . . . . 0.0 111.22 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.55 HD21 ' HE ' ' A' ' 86' ' ' ARG . 60.9 m-80 53.04 37.76 25.58 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.5 mtp -148.94 114.65 5.66 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-O 121.37 0.605 . . . . 0.0 110.895 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 108' ' ' ALA . 27.6 m -96.9 147.54 23.86 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.441 178.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 87.0 m -119.89 123.77 44.39 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.572 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.82 155.3 45.46 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.74 -20.03 67.53 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.332 2.021 . . . . 0.0 111.654 179.253 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.6 t -66.57 -17.04 64.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.282 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.28 -20.84 34.45 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 52.5 tp60 -67.87 150.7 48.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.839 0.352 . . . . 0.0 110.252 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.5 mt -130.54 132.56 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.858 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.665 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.42 177.75 1.08 Allowed Pre-proline 0 CA--C 1.536 0.433 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.28 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.665 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 51.4 Cg_exo -56.32 -23.76 47.93 Favored 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 122.602 2.201 . . . . 0.0 111.911 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 30.0 p -151.79 162.23 41.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.433 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.362 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.3 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . 0.497 ' SG ' ' N ' ' A' ' 120' ' ' ASN . 34.3 t . . . . . 0 N--CA 1.456 -0.145 0 CA-C-O 120.767 0.318 . . . . 0.0 110.704 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . 0.497 ' N ' ' SG ' ' A' ' 119' ' ' CYS . 25.0 p-10 -95.96 10.44 37.36 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.687 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -139.31 165.46 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.785 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -77.41 98.62 5.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.75 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.2 m -111.07 119.06 37.76 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 95.9 mtp -139.82 165.26 27.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.447 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.513 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 3.7 m-20 59.92 39.61 20.06 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.702 0.287 . . . . 0.0 110.992 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.15 25.22 69.29 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.16 126.55 26.03 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . 0.496 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 4.9 m -82.21 133.38 35.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.65 0.262 . . . . 0.0 110.311 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.2 t -95.05 116.92 29.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.254 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 32.4 t -139.01 143.98 38.69 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.124 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 41.67 -116.8 0.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -119.57 21.93 11.88 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -143.0 145.67 33.14 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.522 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.3 t -105.11 140.76 37.81 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.247 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.0 mt -102.33 131.84 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.022 -179.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 20.6 m -92.25 134.37 34.95 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -61.33 173.49 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . 0.449 ' HD3' ' N ' ' A' ' 138' ' ' LYS . 0.0 OUTLIER -62.95 136.18 57.7 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.368 0.604 . . . . 0.0 111.499 179.52 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 88.72 -8.61 78.91 Favored Glycine 0 CA--C 1.519 0.316 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -118.76 135.33 54.57 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.953 0.406 . . . . 0.0 110.326 179.564 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 48.7 pt -133.94 173.31 14.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.507 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.103 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 103.0 163.46 25.78 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.1 p -65.61 -39.68 91.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.609 0.242 . . . . 0.0 110.832 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.439 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -96.46 10.74 37.32 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.853 0.358 . . . . 0.0 110.461 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.513 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 14.7 m 45.76 41.16 7.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.037 -179.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.439 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -108.78 5.44 32.66 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -112.38 110.62 53.01 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 116.793 0.297 . . . . 0.0 110.718 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.7 161.85 27.43 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.514 2.142 . . . . 0.0 112.193 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.7 t -111.99 129.08 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.188 0.518 . . . . 0.0 109.988 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -98.71 93.1 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -68.69 -42.01 78.39 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.4 m -97.77 -10.23 25.19 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.915 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 66.43 179.48 10.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -98.12 179.18 4.85 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . 0.589 ' CD1' ' H ' ' A' ' 177' ' ' CYS . 86.0 mt -88.18 -3.54 58.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.551 HD22 ' N ' ' A' ' 156' ' ' ASN . 0.1 OUTLIER -170.64 -147.21 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.403 179.723 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -73.8 30.95 0.9 Allowed Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -61.68 173.49 7.34 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 71.9 ttt-85 -114.06 123.18 49.05 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.486 0.184 . . . . 0.0 110.903 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 69.0 m -68.23 91.32 0.37 Allowed 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.12 -27.48 14.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.301 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -156.95 173.87 4.58 Favored Pre-proline 0 C--N 1.329 -0.302 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -52.33 136.54 55.46 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 121.588 1.525 . . . . 0.0 111.941 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 41.89 25.74 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.627 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 163' ' ' PRO . 75.0 mmt-85 -134.21 140.55 46.56 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.709 0.766 . . . . 0.0 110.984 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 28.7 p -150.37 161.17 43.01 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.517 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.85 139.09 45.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.012 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . 0.6 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 88.2 m -70.08 138.59 52.16 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-O 121.012 0.435 . . . . 0.0 110.173 -179.319 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.0 m -62.66 -46.07 89.9 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.89 -178.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -117.48 28.27 8.56 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 59.4 30.09 67.44 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.454 ' CZ ' ' SG ' ' A' ' 168' ' ' CYS . 24.5 p90 -67.54 152.37 45.76 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.644 0.259 . . . . 0.0 110.829 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 20.4 p -80.96 143.22 32.75 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.002 -179.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -178.54 158.2 22.53 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.04 -51.44 2.21 Favored 'Trans proline' 0 N--CA 1.499 1.795 0 C-N-CA 122.422 2.081 . . . . 0.0 112.92 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.571 ' NE2' HD21 ' A' ' 155' ' ' LEU . 46.8 mt-30 -80.66 -50.08 10.39 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.086 0.469 . . . . 0.0 110.534 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.6 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 36.5 t . . . . . 0 CA--C 1.514 -0.43 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.383 178.775 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 29.0 mt . . . . . 0 CA--C 1.517 -0.29 0 CA-C-O 121.238 0.542 . . . . 0.0 110.795 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -142.91 164.01 31.24 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.53 22.8 Favored Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.212 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -76.01 7.43 3.26 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.792 2.328 . . . . 0.0 112.187 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.459 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 80.1 m-20 -123.12 70.5 1.03 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.891 0.377 . . . . 0.0 111.087 -179.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.444 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 51.8 t -115.07 130.82 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 57.2 m -151.3 178.44 9.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.457 -179.673 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.3 172.23 39.98 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -81.18 163.76 22.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.63 0.253 . . . . 0.0 110.326 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 73.3 ttp85 -59.54 -43.25 93.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.685 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -62.9 -37.25 86.2 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . 0.434 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 41.9 t30 -132.51 53.75 1.99 Allowed 'General case' 0 C--O 1.23 0.078 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.906 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.543 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -72.51 142.56 48.52 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.266 179.247 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.434 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.8 p90 -159.36 171.21 20.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.4 m -67.97 135.33 52.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.153 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -48.36 168.43 0.17 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -178.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.47 133.62 58.12 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.093 1.862 . . . . 0.0 112.114 179.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 94.98 -17.19 59.78 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.459 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.8 m95 -112.79 138.18 50.0 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -122.25 -165.49 1.28 Allowed 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.2 p -126.04 164.7 20.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.202 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.501 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.6 mt -88.96 151.44 47.12 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.814 -179.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_exo -39.86 107.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.348 2.032 . . . . 0.0 112.121 179.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.17 -14.95 7.25 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.76 178.59 52.32 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -139.35 15.21 2.58 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 121.105 0.479 . . . . 0.0 110.7 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -80.34 131.99 35.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.262 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.93 47.89 1.11 Allowed 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.732 0.301 . . . . 0.0 110.403 -179.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.7 pt -105.71 22.38 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.758 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 t -124.45 97.78 39.05 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.725 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -78.76 157.15 27.82 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.691 2.261 . . . . 0.0 112.097 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.491 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.7 mt -109.51 118.63 57.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.963 0.411 . . . . 0.0 110.297 179.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 17.0 m -90.64 130.38 36.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.157 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.443 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -61.75 -45.44 93.92 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.183 0.515 . . . . 0.0 110.08 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -107.46 142.31 37.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.231 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.8 m -60.72 133.79 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.264 -179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 52.8 m -76.1 -27.84 57.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.583 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.32 -113.45 3.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -72.57 -9.1 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.887 0.375 . . . . 0.0 110.785 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.42 -166.66 29.86 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -139.81 146.25 39.17 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.09 0.472 . . . . 0.0 110.902 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 18.6 t -69.05 116.3 9.34 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.5 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 83.6 p -105.26 -22.02 13.14 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.413 -179.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . 0.477 ' CG ' HH11 ' A' ' 96' ' ' ARG . 0.1 OUTLIER -158.99 165.53 18.26 Favored Pre-proline 0 C--O 1.236 0.385 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.845 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -51.97 122.35 10.37 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 121.836 1.691 . . . . 0.0 111.581 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.443 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 9.6 t-20 53.17 39.74 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.74 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 98.0 mtp -146.86 116.85 7.26 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 121.137 0.494 . . . . 0.0 110.408 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 56.6 m -104.53 149.67 25.27 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.77 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.6 m -121.06 122.91 41.09 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.864 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.53 155.44 43.97 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.604 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -51.61 -27.67 26.48 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.574 2.182 . . . . 0.0 111.906 177.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.57 -16.28 64.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.662 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.73 -15.37 55.73 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . 0.61 ' NE2' ' N ' ' A' ' 107' ' ' ILE . 0.0 OUTLIER -67.69 143.15 56.08 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 120.826 0.346 . . . . 0.0 110.271 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.61 ' N ' ' NE2' ' A' ' 106' ' ' GLN . 96.0 mt -122.26 130.48 74.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.812 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.671 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.01 173.23 1.41 Allowed Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.558 179.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 52.1 Cg_exo -53.09 -31.34 53.82 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 122.67 2.247 . . . . 0.0 112.233 179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.1 m -136.46 159.28 42.26 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.338 179.914 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 58.6 m . . . . . 0 N--CA 1.464 0.252 0 CA-C-O 121.075 0.464 . . . . 0.0 110.51 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -97.41 16.01 21.4 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.501 179.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.424 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 16.9 tt -118.11 166.19 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.517 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.424 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 31.7 mmt180 -89.96 99.54 12.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.441 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 59.8 m -103.71 128.99 51.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.17 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 73.8 mtm -139.72 165.55 26.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.079 -179.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 60.25 48.73 7.84 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 123.404 0.44 . . . . 0.0 111.151 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 64.72 33.12 86.38 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.75 130.76 9.9 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.3 p -91.61 142.1 27.99 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 122.747 -0.267 . . . . 0.0 110.439 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -105.11 123.18 47.37 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.891 0.377 . . . . 0.0 110.283 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 49.7 m -148.81 142.24 25.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.879 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 47.61 45.85 17.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.935 179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.452 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 99.9 m-20 55.15 29.66 13.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.452 ' ND1' ' O ' ' A' ' 132' ' ' ASP . 7.7 m-70 -139.41 145.38 38.84 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 179.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.2 t -99.32 119.73 38.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 68.9 mt -101.25 131.24 47.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.77 138.39 37.89 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.152 -179.128 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -64.68 177.4 0.93 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.59 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -59.03 135.4 57.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.643 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 92.39 -1.82 73.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -126.55 138.81 53.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.784 0.326 . . . . 0.0 110.329 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 42.6 pt -135.05 174.65 12.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.821 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 113.54 152.43 10.93 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.4 m -62.87 -44.83 95.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.7 0.286 . . . . 0.0 110.439 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' A' ' 145' ' ' CYS . 26.4 m80 -100.94 5.9 43.39 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.643 -179.682 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.434 ' O ' ' O ' ' A' ' 144' ' ' HIS . 39.3 m 60.32 138.78 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.072 0.463 . . . . 0.0 109.925 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 147.66 4.57 0.36 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -119.52 88.73 39.33 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-O 120.775 0.321 . . . . 0.0 110.484 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.45 160.97 15.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.97 2.447 . . . . 0.0 111.697 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 58.6 t -101.45 110.77 29.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 16.1 m -92.22 108.5 20.0 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -65.9 -40.88 91.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.467 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . 0.407 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 14.2 t -83.55 -13.69 53.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.626 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 65.44 175.09 5.14 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 99.1 m -108.82 123.79 49.6 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.469 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 41.0 mt -63.96 -41.75 97.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.825 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.412 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.4 m-20 -105.03 -172.93 2.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.55 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.34 37.7 1.58 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -75.7 -172.04 31.78 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . 0.408 ' NH1' HG21 ' A' ' 169' ' ' THR . 1.2 mpt_? -129.84 149.71 51.46 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.657 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 59.5 m -86.36 119.31 26.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.516 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 93.8 t -83.05 -27.02 7.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.541 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.678 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.69 176.15 1.74 Allowed Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.586 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.678 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.2 Cg_exo -56.67 135.81 72.55 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.347 2.032 . . . . 0.0 111.733 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 63.4 t30 50.59 30.82 5.1 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.428 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 90.0 mtt180 -142.74 101.06 3.79 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.402 0.62 . . . . 0.0 111.232 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 167' ' ' ALA . 14.7 t -104.52 150.71 24.37 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.157 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . 0.429 ' N ' ' SG ' ' A' ' 166' ' ' CYS . . . -132.95 123.49 26.03 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.298 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 84.6 m -101.92 132.2 47.86 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . 0.439 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.5 OUTLIER -111.21 19.24 18.55 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.228 0.537 . . . . 0.0 110.939 -179.451 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.535 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 49.8 t80 -93.79 31.65 1.57 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.577 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.72 3.69 80.29 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 49.7 m-85 -106.45 148.67 27.88 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.955 0.407 . . . . 0.0 110.547 179.707 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.0 t -138.74 154.33 48.54 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.256 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 152.39 177.43 26.05 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -65.11 -24.14 59.69 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.765 2.31 . . . . 0.0 111.897 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.407 ' OE1' ' OG ' ' A' ' 152' ' ' SER . 25.2 pt20 -127.87 -44.36 1.48 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.71 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 7.3 t . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.983 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 21.1 mt . . . . . 0 N--CA 1.453 -0.311 0 CA-C-O 121.212 0.529 . . . . 0.0 110.828 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -134.42 162.48 32.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.272 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.75 159.21 28.66 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -76.12 -1.34 11.32 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.882 2.388 . . . . 0.0 112.304 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -109.85 70.05 0.72 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.419 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.483 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.8 t -121.85 130.06 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 99.3 m -142.03 -172.01 3.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.99 -179.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.13 168.08 43.39 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.8 m -77.39 165.04 24.93 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 60.6 ttt85 -59.25 -43.4 92.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.676 179.934 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -62.38 -42.24 99.26 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.353 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -123.46 46.0 2.31 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.83 145.33 54.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.214 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.424 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 15.8 p90 -159.69 -174.97 4.89 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.915 0.388 . . . . 0.0 110.453 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.449 ' SG ' HG22 ' A' ' 73' ' ' THR . 74.0 m -78.45 129.25 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.772 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . 0.483 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 34.5 m -47.59 153.83 0.98 Allowed Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.347 -179.199 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -52.56 132.67 46.48 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 121.431 1.42 . . . . 0.0 112.208 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.59 -22.17 39.7 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.563 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 7.2 m95 -112.51 139.21 48.28 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.472 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.49 -166.83 1.16 Allowed 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.499 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.449 HG22 ' SG ' ' A' ' 67' ' ' CYS . 69.3 p -118.07 161.0 20.55 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.742 0.306 . . . . 0.0 110.349 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.565 ' N ' HD22 ' A' ' 74' ' ' LEU . 2.6 mm? -85.87 151.3 54.78 Favored Pre-proline 0 N--CA 1.448 -0.549 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.1 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -44.2 108.39 0.12 Allowed 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 121.718 1.612 . . . . 0.0 111.911 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.33 -8.08 27.46 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -96.37 -178.46 35.62 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -138.04 17.86 2.81 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.998 0.428 . . . . 0.0 110.884 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -79.0 128.29 33.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.39 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 19.7 m -99.18 70.41 1.77 Allowed 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.9 pt -129.96 19.69 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.106 -179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.64 87.71 27.14 Favored Pre-proline 0 N--CA 1.465 0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.371 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.35 147.3 95.89 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.691 2.261 . . . . 0.0 111.976 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . 0.451 ' N ' ' O ' ' A' ' 70' ' ' GLY . 95.7 mt -99.12 119.9 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.027 179.08 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -90.77 127.3 36.29 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.444 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.6 OUTLIER -62.6 -45.55 92.37 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.147 0.499 . . . . 0.0 109.774 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -122.82 152.51 40.64 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.468 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 m -59.48 135.64 57.73 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.318 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.4 m -79.15 -26.13 42.81 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.811 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -113.02 3.62 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -72.75 -8.51 55.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.797 0.332 . . . . 0.0 110.657 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.81 -168.79 25.32 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -141.75 149.75 40.86 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.959 0.409 . . . . 0.0 110.882 179.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.1 m -65.68 113.0 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.13 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.5 t -102.78 -24.01 13.75 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.122 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.0 mtt85 -153.47 164.85 19.18 Favored Pre-proline 0 C--N 1.329 -0.284 0 C-N-CA 120.414 -0.515 . . . . 0.0 110.706 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.51 119.84 6.52 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.73 1.62 . . . . 0.0 111.662 179.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.444 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 3.2 m120 55.51 39.66 31.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.113 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 63.9 mmm -147.86 119.96 8.28 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.129 0.49 . . . . 0.0 110.102 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -102.25 150.14 23.6 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.632 179.001 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 98.7 m -121.7 124.62 44.68 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.531 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.71 152.34 40.67 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.535 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -49.72 -24.86 10.47 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.536 2.157 . . . . 0.0 111.762 177.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -64.62 -17.57 64.13 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.589 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.63 -13.4 58.03 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -71.25 151.79 43.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.901 0.381 . . . . 0.0 110.294 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -127.93 131.21 69.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.652 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.65 177.84 0.74 Allowed Pre-proline 0 C--N 1.327 -0.402 0 C-N-CA 120.526 -0.469 . . . . 0.0 110.474 179.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -56.93 -23.34 50.83 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.816 2.344 . . . . 0.0 111.921 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.6 p -150.67 167.71 26.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 110.212 -179.85 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.327 -0.383 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.748 -179.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 6.3 p . . . . . 0 N--CA 1.464 0.258 0 CA-C-O 120.904 0.383 . . . . 0.0 110.586 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -63.25 -40.16 96.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.498 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.518 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 14.4 tt -87.68 174.08 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 121.145 0.497 . . . . 0.0 110.077 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.518 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 10.2 ptm180 -122.28 119.27 30.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.311 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 9.0 m -124.37 157.17 35.7 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.657 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.414 ' C ' HD22 ' A' ' 125' ' ' ASN . 71.5 mtm -136.09 173.6 11.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.259 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 4.0 m-80 61.74 39.78 13.76 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.92 24.59 76.34 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.12 134.2 29.17 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.3 t -86.1 135.78 33.48 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.354 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 95.4 m -69.98 119.38 14.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.364 -179.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -131.36 100.62 5.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.195 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 48.79 -111.37 0.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.696 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -111.42 17.2 20.34 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.856 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -131.94 153.77 49.95 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.495 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 94.4 m -105.78 132.54 51.78 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 88.4 mt -97.91 127.21 43.71 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . 0.463 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 5.7 m -89.66 133.67 34.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.076 -179.017 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 -74.07 178.07 5.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.256 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -64.32 125.67 25.32 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.433 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.94 -18.65 45.95 Favored Glycine 0 N--CA 1.466 0.691 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -118.48 137.34 53.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.801 0.334 . . . . 0.0 110.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 18.9 pt -135.99 175.42 10.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.932 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.463 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 101.19 163.78 27.57 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 40.3 p -62.51 -42.74 99.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.817 0.341 . . . . 0.0 110.471 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -90.72 4.06 52.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.356 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.446 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 36.4 m 48.44 37.64 9.26 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.461 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.526 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -105.1 7.32 43.99 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.732 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -109.4 109.08 60.26 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.67 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -77.47 160.42 32.03 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.548 2.165 . . . . 0.0 112.191 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.4 t -115.61 131.04 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 55.9 m -99.18 101.98 13.5 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.963 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.48 -61.38 2.38 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.834 0.35 . . . . 0.0 110.232 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.5 t -116.93 -4.99 11.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.755 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -78.84 -178.72 50.88 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.488 ' H ' ' CB ' ' A' ' 166' ' ' CYS . 9.4 m 45.09 48.96 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.914 0.387 . . . . 0.0 110.505 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 81.5 mt -62.88 -42.04 99.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.864 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -109.88 -113.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.329 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.64 11.32 68.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.59 151.67 32.29 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 -179.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . 0.483 ' O ' ' SG ' ' A' ' 166' ' ' CYS . 3.2 mpt_? -102.3 136.17 42.61 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.527 0.203 . . . . 0.0 110.507 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 70.7 m -85.49 120.52 27.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.998 0.428 . . . . 0.0 111.085 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.5 t -104.01 -29.17 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.343 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -161.44 169.18 10.12 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.457 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 69.8 Cg_exo -49.87 127.98 20.53 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.093 1.862 . . . . 0.0 111.874 178.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 54.74 32.26 17.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.967 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.1 tpt85 -139.24 131.57 28.39 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-O 121.213 0.53 . . . . 0.0 110.231 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.488 ' CB ' ' H ' ' A' ' 154' ' ' CYS . 1.8 t -145.25 154.43 42.37 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.217 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -98.42 138.67 35.32 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.698 179.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 20.9 m -75.3 143.77 42.78 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.392 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.3 m -62.99 -45.47 92.28 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.741 -179.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -104.21 19.51 20.04 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 121.01 0.433 . . . . 0.0 110.861 -179.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.57 26.58 72.83 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 177' ' ' CYS . 2.2 t80 -56.66 169.79 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.927 0.394 . . . . 0.0 110.258 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 43.9 p -98.09 164.27 12.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.466 0.65 . . . . 0.0 110.518 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 79.09 144.08 2.74 Favored Glycine 0 CA--C 1.54 1.636 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.173 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -52.92 -39.45 78.59 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.506 2.137 . . . . 0.0 112.386 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 75.9 mt-30 -74.85 -9.71 58.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.663 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.42 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 91.9 m . . . . . 0 C--N 1.33 -0.249 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.608 -179.869 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.431 HD12 ' HB1' ' A' ' 65' ' ' ALA . 94.8 mt . . . . . 0 N--CA 1.454 -0.228 0 CA-C-O 120.923 0.392 . . . . 0.0 110.718 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -126.82 161.72 27.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.465 0.65 . . . . 0.0 110.616 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.05 167.44 15.95 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.73 -168.24 0.35 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 123.029 2.486 . . . . 0.0 111.7 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.517 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 98.4 m-20 57.19 36.91 28.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.711 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.04 137.74 24.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.403 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 34.2 m -138.98 178.96 6.78 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.001 0.429 . . . . 0.0 110.232 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.06 164.13 31.62 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 65' ' ' ALA . 7.8 m -83.38 173.83 11.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.682 0.277 . . . . 0.0 110.561 179.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -61.85 -42.84 99.54 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.888 0.375 . . . . 0.0 110.518 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -62.78 -38.94 92.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.896 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -132.98 55.85 1.88 Allowed 'General case' 0 N--CA 1.457 -0.113 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.652 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.534 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.82 145.45 50.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.47 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -159.12 166.37 31.71 Favored 'General case' 0 CA--C 1.519 -0.221 0 CA-C-O 121.054 0.454 . . . . 0.0 110.995 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 75.0 m -72.04 142.03 49.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.187 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 63.8 m -58.67 150.09 59.34 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.814 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -56.05 119.44 6.61 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.17 1.913 . . . . 0.0 112.357 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 116.72 -14.82 14.5 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.517 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.0 m95 -119.55 132.73 55.81 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.109 0.481 . . . . 0.0 110.412 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -111.86 -177.04 3.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.292 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.539 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 51.2 p -130.63 166.34 20.89 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.515 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.4 ' HG ' HG21 ' A' ' 82' ' ' VAL . 87.6 mt -90.2 151.75 45.12 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.2 Cg_exo -47.52 128.44 15.2 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 121.51 1.473 . . . . 0.0 112.212 178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.74 -5.82 7.12 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 179.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.411 ' O ' ' OD1' ' A' ' 78' ' ' ASN . . . -91.87 171.95 34.95 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.411 ' OD1' ' O ' ' A' ' 77' ' ' GLY . 96.3 m-20 -140.57 8.79 2.19 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.955 0.407 . . . . 0.0 110.992 179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -86.67 129.29 34.92 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.435 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 18.4 m -92.86 46.23 1.22 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.856 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 45.2 pt -98.01 -4.45 9.68 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.528 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . 0.4 HG21 ' HG ' ' A' ' 74' ' ' LEU . 57.8 t -97.64 111.59 59.13 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.498 -0.481 . . . . 0.0 111.13 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.88 159.5 41.68 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.306 2.004 . . . . 0.0 111.962 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 93.4 mt -98.83 121.67 49.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.34 122.66 34.14 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.448 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -64.6 -45.32 87.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.372 0.606 . . . . 0.0 109.551 179.462 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 74.5 m-70 -137.17 149.46 47.27 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.646 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.5 p -52.3 128.87 26.6 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.361 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.5 m -72.31 -31.84 66.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.83 -112.81 3.54 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -70.42 -6.58 36.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.635 0.255 . . . . 0.0 110.496 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.07 -162.93 21.1 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.88 152.81 39.31 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.998 0.428 . . . . 0.0 110.772 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.77 113.92 5.93 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 36.9 t -106.5 -23.27 12.54 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.254 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -156.82 162.02 28.41 Favored Pre-proline 0 C--N 1.327 -0.378 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.542 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_exo -48.4 119.27 3.93 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 121.907 1.738 . . . . 0.0 111.331 179.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.448 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 96.4 m-20 54.33 40.58 31.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.35 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 83.4 mmm -146.84 115.04 6.61 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.484 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -96.72 145.88 25.39 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.148 178.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 61.0 m -119.99 114.39 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.771 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.413 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -79.57 157.63 74.53 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.71 -179.715 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.413 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 28.0 Cg_endo -63.43 -19.27 67.65 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.946 2.431 . . . . 0.0 111.352 178.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -69.41 -17.02 63.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.862 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 108.35 -21.79 28.05 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -65.98 150.89 47.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.086 0.47 . . . . 0.0 110.218 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.89 131.62 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.999 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.683 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.02 178.29 1.02 Allowed Pre-proline 0 C--N 1.325 -0.478 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.578 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.683 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -57.06 -23.79 54.44 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.771 2.314 . . . . 0.0 111.639 178.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.1 p -151.02 163.26 39.16 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.962 0.41 . . . . 0.0 110.291 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--N 1.329 -0.305 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.302 -179.688 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.8 t . . . . . 0 N--CA 1.467 0.38 0 CA-C-O 120.931 0.396 . . . . 0.0 110.542 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -93.63 4.06 54.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.324 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.465 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.6 tt -132.52 168.48 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.332 179.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.465 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.5 ptm180 -100.95 118.13 36.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.201 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . 0.445 ' C ' ' SD ' ' A' ' 124' ' ' MET . 61.7 m -116.17 138.58 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.689 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . 0.531 ' N ' ' SD ' ' A' ' 124' ' ' MET . 3.2 mpp? -142.56 165.69 26.7 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.474 -179.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 59.15 51.22 7.18 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.454 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 70.84 26.16 74.48 Favored Glycine 0 C--N 1.331 0.27 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.81 114.49 3.92 Favored Glycine 0 CA--C 1.53 0.983 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 30.6 t -79.49 148.21 31.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.511 0.196 . . . . 0.0 110.976 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.4 m -92.38 102.83 15.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.185 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 35.1 t -149.04 138.59 21.77 Favored 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.498 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 98.5 m-20 51.72 36.57 17.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.788 0.328 . . . . 0.0 110.994 179.375 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 54.19 27.91 8.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.682 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.498 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 44.2 m80 -136.34 143.09 43.93 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.961 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 120.44 31.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.093 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.68 120.02 37.3 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.22 137.6 32.21 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.642 -178.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.3 -174.1 0.62 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.021 0.439 . . . . 0.0 110.39 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 48.6 tttp -67.82 132.26 47.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 97.78 -7.88 63.31 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -122.1 137.95 54.63 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.866 0.365 . . . . 0.0 110.447 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.5 pt -138.11 -176.62 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.084 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 116.01 162.77 13.33 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.577 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 49.5 p -60.71 -45.04 95.74 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.409 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 12.2 m80 -120.64 27.53 8.49 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.59 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 5.8 m 58.05 118.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.086 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . 0.424 ' H ' ' H ' ' A' ' 147' ' ' GLN . . . 174.85 5.36 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . 0.424 ' H ' ' H ' ' A' ' 146' ' ' GLY . 55.4 tp60 -132.51 114.9 14.62 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 120.894 -0.323 . . . . 0.0 110.596 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.35 158.59 40.75 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.772 2.315 . . . . 0.0 112.095 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.49 131.16 39.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.93 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 88.36 2.79 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.085 0.469 . . . . 0.0 109.85 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -59.02 -61.92 2.28 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.472 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 153' ' ' GLY . 97.3 p -117.95 -3.5 11.15 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.527 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 152' ' ' SER . . . -58.98 -152.42 0.01 OUTLIER Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.599 ' N ' ' SG ' ' A' ' 166' ' ' CYS . 73.5 m -68.88 126.39 29.63 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.758 0.314 . . . . 0.0 110.202 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.11 -42.93 99.65 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 -169.79 -25.93 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.66 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -60.16 -43.4 98.41 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 154' ' ' CYS . . . -97.64 179.14 32.92 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.5 ttp180 -110.55 131.05 55.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.781 0.324 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 61.4 m -83.24 122.93 29.06 Favored 'General case' 0 CA--C 1.52 -0.175 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.079 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.8 m -104.12 -18.35 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.628 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.61 172.81 5.0 Favored Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.622 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.628 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.4 Cg_exo -53.73 127.49 25.7 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 121.925 1.75 . . . . 0.0 111.687 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 51.88 34.26 13.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.255 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -140.75 134.7 30.64 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.391 0.615 . . . . 0.0 110.39 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.599 ' SG ' ' N ' ' A' ' 154' ' ' CYS . 11.9 p -154.94 166.9 32.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.039 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -122.03 142.76 50.01 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.059 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . 0.422 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 87.5 m -78.08 124.12 27.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.418 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.7 m -64.55 -46.25 83.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.575 -179.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -107.71 16.18 23.9 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.349 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 69.54 27.9 72.94 Favored Glycine 0 C--N 1.31 -0.872 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.516 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 13.9 m-85 -64.63 139.82 58.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.345 0.593 . . . . 0.0 110.045 -179.461 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -82.93 167.67 17.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.008 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.25 151.56 13.14 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -67.29 -24.15 44.0 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.628 2.219 . . . . 0.0 112.133 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.44 ' O ' ' O ' ' A' ' 177' ' ' CYS . 74.1 mt-30 -104.91 -7.99 18.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.577 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.516 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 2.6 t . . . . . 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.197 -179.864 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.4 mt . . . . . 0 N--CA 1.452 -0.344 0 CA-C-O 121.12 0.486 . . . . 0.0 110.33 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -127.37 158.7 36.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.008 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.61 152.87 15.98 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.04 11.96 1.08 Allowed 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 122.67 2.246 . . . . 0.0 112.438 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -125.14 52.12 1.62 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.075 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.45 133.05 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 99.2 m -144.56 175.49 10.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 169.61 44.76 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.56 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.5 m -73.83 160.86 30.85 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.2 ttm-85 -59.28 -43.7 92.52 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.646 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -61.75 -43.53 98.67 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.899 -0.321 . . . . 0.0 111.395 -179.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -125.35 47.86 2.12 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.537 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.32 142.82 58.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.603 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 24.3 p90 -152.04 168.14 26.19 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 121.279 0.562 . . . . 0.0 110.437 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.5 t -71.56 139.0 49.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.208 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 159.49 19.37 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -60.29 135.01 58.99 Favored 'Trans proline' 0 N--CA 1.497 1.707 0 C-N-CA 122.131 1.887 . . . . 0.0 111.627 179.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.15 -23.5 34.26 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -114.32 135.93 53.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.732 0.266 . . . . 0.0 110.284 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -121.09 -174.04 2.74 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.159 179.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 70.8 p -124.1 163.49 21.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 0.0 110.183 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.432 ' O ' ' N ' ' A' ' 77' ' ' GLY . 86.1 mt -83.52 149.86 58.62 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.781 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 77' ' ' GLY . 76.0 Cg_exo -42.62 117.49 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.288 0 C-N-CA 121.734 1.623 . . . . 0.0 112.371 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.72 -3.96 5.9 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 179.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -91.76 175.1 38.37 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -134.68 8.28 3.57 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.646 0.26 . . . . 0.0 110.926 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -82.35 129.26 34.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.826 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 9.9 m -103.53 78.6 1.6 Allowed 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.538 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.7 pt -130.98 20.03 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -120.73 103.16 43.81 Favored Pre-proline 0 CA--C 1.537 0.479 0 CA-C-N 116.811 -0.177 . . . . 0.0 110.624 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.15 160.34 29.81 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 C-N-CA 122.165 1.91 . . . . 0.0 112.266 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 92.6 mt -105.82 127.39 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.413 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 100' ' ' CYS . 4.9 m -91.3 136.26 33.23 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.804 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.436 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -61.83 -44.87 95.98 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.401 -179.725 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . 0.427 ' NE2' ' NH1' ' A' ' 86' ' ' ARG . 96.1 m-70 -110.82 152.74 26.3 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.391 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -53.92 131.18 39.7 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.65 -33.08 53.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.039 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.06 -105.85 1.79 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -92.69 0.83 57.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.882 0.372 . . . . 0.0 110.573 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -98.27 172.05 26.16 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . 0.461 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 24.2 t80 -122.26 130.52 53.24 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.848 0.356 . . . . 0.0 110.943 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . 0.461 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 1.7 t -64.19 119.18 9.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.835 179.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 73.3 p -104.8 -19.14 14.0 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.478 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -162.03 164.88 16.86 Favored Pre-proline 0 CA--C 1.533 0.309 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.849 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -53.0 128.29 28.35 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 121.412 1.408 . . . . 0.0 111.041 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.436 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.2 m-20 51.46 37.97 20.76 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.718 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.1 mtp -147.75 108.95 4.27 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.218 0.532 . . . . 0.0 110.305 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 0.8 OUTLIER -97.13 149.05 22.41 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.606 179.266 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.1 m -120.5 122.8 41.44 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.54 158.98 35.89 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.488 -178.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -55.84 -26.82 59.37 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.496 2.131 . . . . 0.0 112.245 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.1 t -64.09 -17.43 63.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.575 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.43 -17.44 50.76 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -67.37 153.73 42.99 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.981 0.419 . . . . 0.0 110.124 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 90.0 mt -126.83 128.26 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.398 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.528 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -165.63 162.88 13.12 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.934 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.528 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 11.6 Cg_endo -52.36 -15.93 4.44 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.955 2.436 . . . . 0.0 112.165 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 97.2 p -155.51 159.39 39.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.28 179.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.06 179.691 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 7.4 m . . . . . 0 N--CA 1.465 0.304 0 CA-C-O 120.907 0.385 . . . . 0.0 110.163 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -96.6 10.54 38.21 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.417 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 10.9 tp -125.44 156.96 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.521 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 12.6 mtt180 -106.91 120.19 41.38 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.542 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 12.0 m -121.11 142.5 49.8 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -143.25 169.61 17.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.108 -179.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 67.6 m-80 58.81 41.76 21.04 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.549 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.44 18.33 76.15 Favored Glycine 0 CA--C 1.517 0.205 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.88 121.56 6.32 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.2 t -79.85 140.43 36.8 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.5 t -91.54 124.4 35.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.136 179.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 132' ' ' ASP . 31.8 t -141.75 143.04 33.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.213 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 41.14 -92.37 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 130' ' ' SER . 39.5 p-10 -146.5 23.68 1.27 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.755 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -138.53 148.36 44.16 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.445 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 84.3 m -96.49 128.69 43.66 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.107 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.6 mt -92.69 126.13 37.64 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 16.7 m -89.33 127.5 35.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.58 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.75 174.89 4.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.343 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -63.42 127.01 29.39 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.091 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.37 -13.84 54.67 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 -179.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -121.59 136.44 54.95 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.931 0.396 . . . . 0.0 110.42 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -133.58 172.76 15.81 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.214 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 102.8 163.34 25.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 24.0 p -62.42 -43.84 97.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.749 0.309 . . . . 0.0 110.631 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 2.2 p-80 -94.77 10.75 33.96 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.096 0.474 . . . . 0.0 110.468 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 12.4 m 46.85 36.59 4.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.101 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -99.74 8.46 59.83 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 32.7 tt0 -116.08 112.77 41.97 Favored Pre-proline 0 CA--C 1.548 0.898 0 CA-C-N 116.76 0.28 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -78.39 159.6 29.23 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.441 2.094 . . . . 0.0 112.273 179.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.5 t -113.56 127.74 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 121.016 0.436 . . . . 0.0 110.142 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 2.2 m -100.05 98.18 8.95 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -62.88 -51.67 66.07 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.339 -178.375 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 79.3 p -118.37 -9.45 10.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.896 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -79.74 171.82 54.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 150' ' ' CYS . 17.9 m 57.08 59.99 3.18 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.885 0.374 . . . . 0.0 110.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . 0.526 ' N ' HD12 ' A' ' 155' ' ' LEU . 10.9 mp -62.93 -42.19 99.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.752 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' A' ' 157' ' ' GLY . 24.9 t-20 -121.5 -112.69 0.32 Allowed 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.994 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.527 ' N ' ' OD1' ' A' ' 156' ' ' ASN . . . -84.6 3.49 86.52 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -54.75 148.3 23.01 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . 0.479 ' C ' ' SG ' ' A' ' 166' ' ' CYS . 17.8 tpt180 -102.66 131.31 49.54 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.775 0.322 . . . . 0.0 110.451 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 4.8 t -76.04 100.3 4.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.088 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.5 t -76.91 -43.82 32.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.768 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.647 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -151.02 175.03 3.07 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.979 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.647 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 71.8 Cg_exo -51.73 130.06 32.43 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 121.605 1.537 . . . . 0.0 112.385 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.0 m-20 52.43 32.02 10.61 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.372 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . 0.442 ' O ' ' SG ' ' A' ' 150' ' ' CYS . 74.2 mtm180 -141.6 136.33 30.92 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.473 0.654 . . . . 0.0 110.921 179.212 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . 0.479 ' SG ' ' C ' ' A' ' 159' ' ' ARG . 1.7 t -144.35 156.22 44.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.994 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.37 143.5 42.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.69 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 76.0 m -72.21 127.44 32.55 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.232 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 98.7 m -63.37 -46.12 87.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.458 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . 0.537 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 74.7 t80 -110.54 27.95 9.14 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.992 0.425 . . . . 0.0 111.327 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.46 25.51 63.06 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . 0.462 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 66.8 t80 -63.53 131.76 49.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.421 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . 0.439 ' O ' ' CE2' ' A' ' 172' ' ' PHE . 68.0 p -82.52 163.43 21.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.144 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 144.38 160.44 8.49 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . 0.424 ' O ' ' OE1' ' A' ' 176' ' ' GLN . 36.2 Cg_endo -63.51 -31.9 70.9 Favored 'Trans proline' 0 N--CA 1.496 1.671 0 C-N-CA 122.578 2.185 . . . . 0.0 112.4 -179.701 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . 0.424 ' OE1' ' O ' ' A' ' 175' ' ' PRO . 1.9 mp0 -131.4 8.66 4.65 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.201 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 1.8 t . . . . . 0 C--N 1.326 -0.415 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.267 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.2 mt . . . . . 0 N--CA 1.451 -0.385 0 CA-C-O 121.019 0.438 . . . . 0.0 110.725 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -137.17 159.84 40.73 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.15 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.38 163.24 24.51 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.75 -5.87 17.42 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 123.089 2.526 . . . . 0.0 112.263 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . 0.604 ' ND2' ' CD2' ' A' ' 71' ' ' TRP . 78.9 m-20 -103.59 68.32 0.93 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.56 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.9 t -119.96 129.41 75.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.838 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.2 m -134.76 173.6 11.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.002 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.92 164.65 37.44 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' ALA . 12.5 m -80.1 173.25 12.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -60.38 -42.82 96.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -62.16 -41.75 98.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -125.58 49.55 1.91 Allowed 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.747 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.21 140.44 52.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.304 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -155.3 165.71 35.8 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.978 0.418 . . . . 0.0 110.878 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 5.8 m -72.89 135.0 45.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.089 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 35.1 m -55.81 149.84 30.46 Favored Pre-proline 0 C--N 1.323 -0.577 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.213 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -56.23 134.98 67.56 Favored 'Trans proline' 0 N--CA 1.498 1.791 0 C-N-CA 121.498 1.465 . . . . 0.0 112.234 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.95 -14.95 52.31 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.604 ' CD2' ' ND2' ' A' ' 57' ' ' ASN . 85.4 m95 -115.92 134.99 54.41 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.758 0.314 . . . . 0.0 110.372 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 80' ' ' CYS . 17.4 ptpt -110.14 -175.95 2.87 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.333 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.436 HG22 ' SG ' ' A' ' 80' ' ' CYS . 41.4 p -123.09 161.19 24.85 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . 0.58 ' N ' HD22 ' A' ' 74' ' ' LEU . 2.7 mm? -84.53 149.04 53.67 Favored Pre-proline 0 N--CA 1.449 -0.48 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.158 -179.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -46.23 112.59 0.47 Allowed 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.591 1.528 . . . . 0.0 112.236 179.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.15 -6.48 28.16 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.99 174.77 36.04 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -129.04 0.58 5.25 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.816 0.341 . . . . 0.0 110.643 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.2 mt-30 -78.84 134.4 36.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.688 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . 0.445 ' SG ' ' O ' ' A' ' 72' ' ' LYS . 1.5 m -115.0 79.03 1.22 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.164 0.507 . . . . 0.0 110.189 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.3 pt -120.74 14.59 6.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.657 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 t -117.55 107.01 45.46 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 121.273 -0.171 . . . . 0.0 110.796 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.14 159.97 33.33 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.21 1.94 . . . . 0.0 111.987 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.5 mt -99.54 123.17 52.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.85 125.31 35.7 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.5 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.9 OUTLIER -63.32 -45.77 89.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.27 0.557 . . . . 0.0 109.932 179.657 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -121.73 143.5 49.33 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.462 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -53.1 128.29 27.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.424 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.7 m -71.33 -27.87 63.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.573 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.45 -116.33 4.89 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -70.38 -8.73 52.96 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.737 0.304 . . . . 0.0 110.925 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.54 -164.81 25.34 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -142.65 150.38 40.14 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.995 0.426 . . . . 0.0 110.788 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.7 m -69.53 116.96 10.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.568 -179.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.3 t -104.11 -20.78 13.71 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.322 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.0 mtt85 -160.76 167.99 12.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.56 123.3 13.0 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.613 1.542 . . . . 0.0 111.143 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.5 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.1 t-20 52.26 40.35 28.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.088 -179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.2 mtp -146.95 115.72 6.81 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.362 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 58.0 m -102.07 148.08 25.82 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.438 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 84.1 m -121.47 117.73 27.58 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.971 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -84.38 157.84 61.35 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.801 179.683 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.423 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.0 Cg_endo -61.64 -22.24 73.96 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.743 2.296 . . . . 0.0 111.828 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.4 t -66.28 -16.62 64.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.19 -19.02 38.29 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.0 tp60 -65.19 149.1 50.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.011 0.434 . . . . 0.0 110.427 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.09 131.63 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.828 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.36 172.43 1.78 Allowed Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.471 179.453 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 73.8 Cg_exo -48.82 -23.63 6.04 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.454 2.103 . . . . 0.0 111.992 178.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.0 p -153.6 165.47 35.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.251 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.327 -0.373 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.246 179.908 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.1 m . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.854 0.359 . . . . 0.0 110.496 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -64.01 -40.56 96.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.461 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.457 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.5 tt -80.18 166.26 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.229 179.689 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.457 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 20.3 mmm180 -98.75 98.07 9.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.775 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 87.4 m -92.98 134.47 35.08 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.88 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 72.6 mtm -145.31 165.07 29.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.86 39.9 19.94 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.039 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.56 24.78 69.41 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.97 128.24 22.81 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . 0.498 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 17.3 m -86.24 137.68 32.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.661 0.267 . . . . 0.0 110.494 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.56 129.93 34.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.514 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.45 ' O ' ' O ' ' A' ' 133' ' ' HIS . 52.3 p -146.58 109.66 4.7 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.165 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 50.12 -116.52 0.93 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.516 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 132' ' ' ASP . 32.4 p-10 -106.95 9.29 30.75 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.885 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 130' ' ' SER . 69.2 m80 -131.15 153.02 49.84 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.95 0.405 . . . . 0.0 110.798 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.4 t -114.62 145.06 42.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.293 179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.9 mt -100.8 129.96 46.75 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.676 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 10.5 m -96.34 139.22 32.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.455 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.55 179.15 0.85 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.533 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -67.33 129.71 40.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.613 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 98.07 -10.77 63.92 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -117.34 133.8 55.56 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.9 0.381 . . . . 0.0 110.638 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 45.8 pt -131.95 170.36 20.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.315 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 106.37 164.41 22.77 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.5 m -63.26 -45.52 91.15 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.449 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -97.52 5.24 49.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.902 0.382 . . . . 0.0 110.682 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 6.0 m 59.87 37.25 21.79 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.123 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -98.88 5.72 59.86 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -119.65 107.09 41.09 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.679 0.239 . . . . 0.0 110.535 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.73 163.5 23.72 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.564 2.176 . . . . 0.0 111.911 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.2 t -106.15 126.3 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 121.158 0.504 . . . . 0.0 109.918 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.88 92.71 7.54 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -63.61 -46.53 85.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.761 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . 0.533 ' OG ' ' ND2' ' A' ' 164' ' ' ASN . 9.9 m -89.93 -11.93 40.32 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.861 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.12 161.29 1.28 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.2 m -104.23 145.29 30.43 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . 0.509 ' H ' HD12 ' A' ' 155' ' ' LEU . 4.3 mp -62.95 -43.42 98.84 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.13 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 m-20 165.4 -58.38 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.352 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.53 -37.95 95.01 Favored Glycine 0 CA--C 1.517 0.164 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.35 159.86 50.5 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -127.43 145.91 50.66 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.725 0.297 . . . . 0.0 110.81 179.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 60.2 m -73.2 104.68 4.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.616 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 161' ' ' VAL . 70.2 t -106.49 -13.04 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.354 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.654 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.18 177.76 1.45 Allowed Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 120.369 -0.532 . . . . 0.0 110.341 179.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.654 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.3 Cg_exo -55.64 128.44 30.35 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 121.896 1.731 . . . . 0.0 111.539 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . 0.533 ' ND2' ' OG ' ' A' ' 152' ' ' SER . 2.8 t-20 43.23 38.7 1.71 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.9 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -131.37 127.07 36.82 Favored 'General case' 0 C--O 1.24 0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 110.53 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 94.3 m -117.79 118.81 33.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.846 179.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -77.96 92.34 4.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.927 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.75 129.46 55.37 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.501 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.2 t -114.01 24.79 11.71 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.295 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -100.86 29.02 4.79 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.011 0.434 . . . . 0.0 110.945 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.98 28.71 73.89 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -50.41 163.24 0.18 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.769 0.319 . . . . 0.0 110.476 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -130.02 131.65 45.93 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.308 179.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 80.19 176.95 50.42 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -78.38 -10.7 16.1 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.809 2.339 . . . . 0.0 112.03 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -83.45 6.32 20.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.846 -178.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . 0.515 ' SG ' ' O ' ' A' ' 177' ' ' CYS . 50.3 t . . . . . 0 C--N 1.33 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.624 179.685 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' LEU . . . . . 0.401 HD23 ' HB2' ' A' ' 78' ' ' ASN . 87.5 mt . . . . . 0 N--CA 1.452 -0.351 0 CA-C-O 120.897 0.379 . . . . 0.0 110.331 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -135.85 165.87 24.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.784 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.69 168.63 9.92 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.26 -172.49 0.89 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 122.938 2.425 . . . . 0.0 111.805 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 57.48 42.14 24.95 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.094 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 58' ' ' VAL . 14.6 p -97.93 133.24 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.91 0.386 . . . . 0.0 110.101 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 m -140.12 175.88 9.22 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.425 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.94 160.18 26.05 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 65' ' ' ALA . 14.9 m -81.21 174.79 11.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.319 . . . . 0.0 110.398 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.4 ttt85 -60.59 -43.15 97.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.599 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -62.05 -39.12 91.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.917 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -131.84 53.57 1.99 Allowed 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.11 139.96 52.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.391 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -154.18 169.7 22.97 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.088 0.471 . . . . 0.0 110.641 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' CYS . . . . . 0.407 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 73.2 m -79.45 136.29 36.9 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 38.6 m -52.99 154.97 4.65 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.246 -178.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.84 132.51 42.3 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.103 1.202 . . . . 0.0 112.785 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.69 -7.27 57.61 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' TRP . . . . . 0.534 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 9.5 m95 -132.02 143.08 49.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.519 179.352 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -127.72 -166.08 1.57 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' THR . . . . . 0.407 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.3 p -123.49 164.76 18.31 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -108.4 156.56 38.39 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.206 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 77' ' ' GLY . 46.7 Cg_exo -52.88 138.66 60.82 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 121.379 1.386 . . . . 0.0 111.808 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.38 -38.08 0.34 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -82.7 169.83 49.34 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' ASN . . . . . 0.401 ' HB2' HD23 ' A' ' 53' ' ' LEU . 50.0 p30 -136.48 16.06 3.17 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.611 -0.294 . . . . 0.0 110.88 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -87.6 133.7 33.76 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.781 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 62.6 m -86.28 42.69 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.5 pt -94.02 26.45 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.253 -179.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.91 94.18 47.61 Favored Pre-proline 0 N--CA 1.466 0.37 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.76 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -79.48 161.26 25.39 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.198 1.932 . . . . 0.0 112.182 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.47 127.86 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.4 131.37 43.03 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' ARG . . . . . 0.419 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -64.09 -45.88 86.73 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-O 121.177 0.513 . . . . 0.0 110.256 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -127.18 174.0 9.27 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.97 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 p -63.84 146.08 54.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.405 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 1.4 m -88.56 -32.4 18.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.53 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.29 -107.99 2.56 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -92.93 3.63 55.38 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.556 0.217 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.06 -161.67 17.45 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -146.94 152.18 38.23 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.985 0.421 . . . . 0.0 110.98 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.6 m -69.65 115.6 9.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.131 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.6 p -103.82 -17.35 15.09 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.952 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtp85 -159.74 163.6 22.4 Favored Pre-proline 0 CA--C 1.532 0.285 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.068 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -51.99 127.09 22.07 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.565 1.51 . . . . 0.0 111.034 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 98' ' ' ASN . . . . . 0.419 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 92.0 m-20 49.62 36.5 10.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.88 179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 38.1 mtt -147.6 122.31 9.88 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.36 0.6 . . . . 0.0 111.048 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 20.2 t -108.17 149.45 28.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.474 179.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 99.8 m -121.38 124.72 45.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.79 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 102' ' ' CYS . . . . . 0.404 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -93.73 157.78 37.66 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.543 -179.916 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 103' ' ' PRO . . . . . 0.404 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 27.3 Cg_endo -62.04 -20.44 69.67 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.551 2.167 . . . . 0.0 111.766 178.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 t -68.05 -22.85 64.93 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.601 178.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 113.88 -22.94 13.7 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 106' ' ' GLN . . . . . 0.468 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 8.1 tm0? -63.44 146.25 53.99 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.212 0.53 . . . . 0.0 110.362 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 107' ' ' ILE . . . . . 0.468 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 96.7 mt -129.89 133.78 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.402 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 108' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -178.64 171.61 0.71 Allowed Pre-proline 0 CA--C 1.535 0.392 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 109' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 56.9 Cg_exo -50.35 -25.77 14.46 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 122.645 2.23 . . . . 0.0 112.247 179.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.7 p -140.75 161.99 36.48 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.239 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.324 -0.501 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.684 -179.576 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 64.5 m . . . . . 0 N--CA 1.469 0.495 0 CA-C-O 120.908 0.385 . . . . 0.0 110.473 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 120' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' A' ' 120' ' ' ASN . 53.5 t-20 -63.58 -40.43 96.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.658 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 121' ' ' ILE . . . . . 0.661 HG22 ' H ' ' A' ' 122' ' ' ARG . 15.6 mm -82.71 174.33 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.956 -179.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 122' ' ' ARG . . . . . 0.661 ' H ' HG22 ' A' ' 121' ' ' ILE . 27.2 ptt180 -106.02 114.08 28.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.544 0.688 . . . . 0.0 110.534 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 94.2 m -124.26 148.03 47.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.263 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.2 mtm -142.27 174.24 10.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.916 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 10.8 m120 60.88 44.93 10.2 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.119 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.29 26.17 71.53 Favored Glycine 0 CA--C 1.518 0.261 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -66.52 156.66 50.78 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 28.3 t -109.62 134.51 51.86 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-O 121.05 0.452 . . . . 0.0 110.373 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 15.5 m -80.94 132.1 35.38 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 130' ' ' SER . . . . . 0.505 ' OG ' HD23 ' A' ' 135' ' ' LEU . 69.1 m -123.56 158.41 31.46 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.486 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 131' ' ' ASP . . . . . 0.501 ' C ' ' O ' ' A' ' 130' ' ' SER . 99.6 m-20 -12.01 -77.5 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 O-C-N 123.899 0.75 . . . . 0.0 112.725 -179.562 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -136.21 29.74 3.03 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.397 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -139.89 159.08 42.98 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.782 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 134' ' ' CYS . . . . . 0.407 ' C ' HD22 ' A' ' 135' ' ' LEU . 40.7 t -104.64 122.37 45.49 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.035 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 135' ' ' LEU . . . . . 0.505 HD23 ' OG ' ' A' ' 130' ' ' SER . 3.5 mm? -98.18 127.19 43.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.081 0.467 . . . . 0.0 110.169 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 61.1 m -106.98 140.43 39.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.807 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -76.8 168.94 19.21 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.32 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 56.1 tptt -64.71 133.31 51.85 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 108.76 -26.41 15.95 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -116.61 133.58 55.84 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 120.898 0.38 . . . . 0.0 110.67 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.6 pt -131.04 170.76 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.936 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.61 157.62 10.36 Favored Glycine 0 N--CA 1.464 0.565 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.6 p -64.07 -42.69 96.89 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.869 0.366 . . . . 0.0 110.602 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.21 5.02 34.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.25 139.29 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 151.41 -10.74 0.73 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -99.0 110.53 58.07 Favored Pre-proline 0 CA--C 1.544 0.715 0 O-C-N 122.517 -0.402 . . . . 0.0 110.422 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -76.77 159.01 35.14 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.175 1.916 . . . . 0.0 112.524 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.8 t -124.76 130.06 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.11 0.481 . . . . 0.0 110.577 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -104.35 117.68 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.087 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -65.75 -39.48 91.12 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.3 m -86.12 -7.44 58.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.531 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 45.73 -166.48 0.06 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 1.3 m -141.34 119.61 12.18 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.5 mt -63.9 -41.7 97.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.766 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 156' ' ' ASN . . . . . 0.526 ' C ' ' H ' ' A' ' 158' ' ' GLY . 6.1 t-20 -86.03 -167.88 2.02 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.332 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 157' ' ' GLY . . . . . 0.496 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.79 23.67 0.53 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 158' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -60.01 160.17 21.59 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -126.75 147.18 50.0 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.778 0.323 . . . . 0.0 110.668 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 12.3 t -90.88 104.78 17.33 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.853 0.359 . . . . 0.0 110.497 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.98 -35.04 20.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 162' ' ' ALA . . . . . 0.63 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -155.81 177.29 2.11 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.36 -179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 163' ' ' PRO . . . . . 0.63 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.8 Cg_exo -54.26 132.22 49.36 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.023 1.816 . . . . 0.0 112.259 179.436 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 49.33 31.79 4.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.259 179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -135.42 102.09 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.58 0.705 . . . . 0.0 110.751 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -107.52 141.17 39.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.821 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.64 133.71 50.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.444 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 67.3 m -86.3 146.51 26.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.102 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -62.35 -45.1 94.73 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.118 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -97.52 15.93 21.8 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.322 0.582 . . . . 0.0 110.847 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.15 20.95 78.37 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -54.84 161.7 1.49 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.967 0.413 . . . . 0.0 110.595 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 8.8 t -82.54 160.52 22.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.479 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.6 142.52 0.05 OUTLIER Glycine 0 CA--C 1.539 1.534 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -53.48 -40.67 77.84 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.329 2.019 . . . . 0.0 112.971 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -67.3 -26.22 66.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.455 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 11.8 m . . . . . 0 C--N 1.327 -0.379 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.673 -179.88 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 69.2 m . . . . . 0 N--CA 1.491 1.576 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -63.75 -38.55 91.51 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.551 -179.933 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -74.56 152.65 39.27 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.393 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -154.29 161.9 30.32 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.877 -0.889 . . . . 0.0 110.877 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 86.69 7.09 79.14 Favored Glycine 0 CA--C 1.526 0.766 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -63.89 -39.87 97.78 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.979 -0.848 . . . . 0.0 110.979 179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 90.21 164.6 39.96 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 55.2 p-80 -82.4 -16.7 48.09 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-O 120.857 0.361 . . . . 0.0 110.566 179.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.431 ' OD1' ' O ' ' A' ' 51' ' ' ASP . 58.4 p30 -73.21 148.9 43.3 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.753 -179.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -63.61 -36.54 84.16 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.101 -0.5 . . . . 0.0 110.462 -179.96 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 17.6 mt -70.93 142.93 51.06 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.606 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.7 mttt -135.61 -176.77 4.4 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.732 -179.693 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 84.71 158.73 29.32 Favored Glycine 0 CA--C 1.531 1.072 0 N-CA-C 111.082 -0.807 . . . . 0.0 111.082 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.5 Cg_endo -76.59 8.29 3.08 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.764 2.309 . . . . 0.0 112.105 179.705 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.578 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 81.2 m-20 -119.88 65.79 0.81 Allowed 'General case' 0 N--CA 1.466 0.343 0 CA-C-N 116.389 -0.369 . . . . 0.0 110.658 179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.459 ' O ' HG13 ' A' ' 58' ' ' VAL . 10.7 p -112.55 128.79 69.02 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -148.51 171.85 15.43 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.86 -0.609 . . . . 0.0 110.379 -179.153 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 95.55 166.46 34.97 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.634 -0.986 . . . . 0.0 110.634 -179.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.7 m -79.08 165.04 23.8 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.7 0.286 . . . . 0.0 110.307 179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.6 ttm-85 -58.85 -42.26 88.92 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.241 179.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.4 m-85 -61.18 -39.42 90.12 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.832 -179.685 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 18.2 t-20 -131.63 51.13 2.17 Favored 'General case' 0 C--O 1.226 -0.151 0 CA-C-N 116.413 -0.358 . . . . 0.0 111.033 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.08 142.83 50.82 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.562 -0.29 . . . . 0.0 110.536 179.804 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 11.8 p90 -160.94 176.32 11.55 Favored 'General case' 0 N--CA 1.463 0.184 0 CA-C-O 121.069 0.461 . . . . 0.0 110.523 179.448 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.402 ' SG ' HG22 ' A' ' 73' ' ' THR . 62.8 m -73.39 133.89 43.89 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.175 -179.735 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -47.1 169.0 0.12 Allowed Pre-proline 0 CA--C 1.534 0.34 0 CA-C-N 116.446 -0.343 . . . . 0.0 111.033 -178.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.5 Cg_exo -58.32 133.86 57.73 Favored 'Trans proline' 0 N--CA 1.496 1.651 0 C-N-CA 121.883 1.722 . . . . 0.0 112.364 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 93.39 -16.63 60.2 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.973 -0.851 . . . . 0.0 110.973 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.578 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 92.5 m95 -110.25 138.49 46.55 Favored 'General case' 0 N--CA 1.464 0.261 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 -179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -121.98 -164.52 1.16 Allowed 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.439 -0.346 . . . . 0.0 110.316 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.402 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.3 p -125.07 164.83 19.35 Favored 'General case' 0 C--N 1.329 -0.31 0 N-CA-C 109.756 -0.461 . . . . 0.0 109.756 179.726 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.486 ' O ' ' N ' ' A' ' 77' ' ' GLY . 24.6 mt -89.16 151.99 47.42 Favored Pre-proline 0 CA--C 1.535 0.371 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.768 -179.074 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.2 Cg_exo -40.44 107.76 0.07 OUTLIER 'Trans proline' 0 N--CA 1.489 1.256 0 C-N-CA 122.219 1.946 . . . . 0.0 112.259 179.321 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.27 -11.2 9.03 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.993 -0.843 . . . . 0.0 110.993 179.523 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.486 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -87.96 177.76 46.43 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.924 -0.871 . . . . 0.0 110.924 179.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 89.6 m-20 -138.01 17.06 2.83 Favored 'General case' 0 C--O 1.235 0.304 0 CA-C-O 120.892 0.377 . . . . 0.0 110.882 -179.992 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.5 mt-30 -81.93 130.15 34.99 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.046 -179.243 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 53.6 m -95.66 55.26 1.64 Allowed 'General case' 0 N--CA 1.464 0.253 0 CA-C-N 116.664 -0.244 . . . . 0.0 110.451 -179.757 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.3 pt -114.32 22.05 5.95 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.526 -0.306 . . . . 0.0 110.995 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 22.0 t -123.04 99.51 40.92 Favored Pre-proline 0 N--CA 1.467 0.401 0 CA-C-N 116.698 -0.228 . . . . 0.0 110.573 -179.691 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.3 Cg_endo -78.95 156.45 26.84 Favored 'Trans proline' 0 N--CA 1.487 1.113 0 C-N-CA 122.164 1.91 . . . . 0.0 112.202 -179.969 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.438 ' O ' ' NH1' ' A' ' 86' ' ' ARG . 96.0 mt -101.57 122.12 53.33 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.394 0 CA-C-O 120.945 0.403 . . . . 0.0 110.202 179.935 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -99.27 126.29 45.06 Favored 'General case' 0 CA--C 1.533 0.292 0 N-CA-C 109.359 -0.608 . . . . 0.0 109.359 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.494 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 9.0 mpt_? -64.97 -40.33 94.82 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.762 -0.375 . . . . 0.0 110.743 179.186 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.9 m-70 -117.71 145.68 44.27 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.192 -179.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.2 m -63.24 136.29 57.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 121.0 0.429 . . . . 0.0 110.267 -179.814 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 44.5 m -77.95 -32.24 51.37 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.326 179.846 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.44 -107.19 2.25 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 179.755 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 98.0 m-20 -68.38 -12.32 60.95 Favored 'General case' 0 CA--C 1.52 -0.195 0 CA-C-O 120.777 0.323 . . . . 0.0 110.797 -179.632 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -110.53 -161.91 18.2 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.632 -0.987 . . . . 0.0 110.632 179.88 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -145.94 151.52 37.95 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 121.006 0.432 . . . . 0.0 111.072 -179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.7 m -66.95 115.18 6.39 Favored 'General case' 0 CA--C 1.518 -0.265 0 CA-C-N 115.956 -0.565 . . . . 0.0 110.225 -179.9 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 93.6 p -106.46 -20.72 13.29 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.754 -179.765 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -157.49 161.66 28.78 Favored Pre-proline 0 CA--C 1.531 0.238 0 C-N-CA 120.551 -0.46 . . . . 0.0 110.364 -179.86 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_exo -48.93 122.23 7.94 Favored 'Trans proline' 0 N--CA 1.49 1.299 0 C-N-CA 121.748 1.632 . . . . 0.0 111.254 179.002 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 52.05 41.74 30.02 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.004 179.936 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 80.9 mtp -148.33 116.72 6.54 Favored 'General case' 0 C--O 1.237 0.411 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.62 179.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.44 ' N ' ' O ' ' A' ' 108' ' ' ALA . 33.7 m -100.44 148.28 24.92 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.366 178.947 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.6 m -120.58 123.28 42.48 Favored 'General case' 0 CA--C 1.514 -0.428 0 CA-C-N 115.608 -0.724 . . . . 0.0 109.741 179.71 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -87.16 157.92 53.18 Favored Pre-proline 0 C--N 1.325 -0.485 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.275 -179.604 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.3 Cg_endo -62.71 -18.64 65.17 Favored 'Trans proline' 0 C--N 1.308 -1.598 0 C-N-CA 122.719 2.279 . . . . 0.0 111.855 178.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 17.8 m -71.95 -17.38 62.08 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.432 179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 109.16 -20.32 28.57 Favored Glycine 0 N--CA 1.466 0.637 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 42.0 tp60 -66.82 150.03 49.72 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-O 120.934 0.397 . . . . 0.0 110.194 -179.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -130.68 132.74 64.13 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.815 -0.629 . . . . 0.0 110.642 179.774 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -167.77 179.05 0.99 Allowed Pre-proline 0 CA--C 1.535 0.383 0 C-N-CA 120.57 -0.452 . . . . 0.0 110.379 179.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 38.8 Cg_exo -57.92 -22.76 56.11 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.814 2.343 . . . . 0.0 112.306 179.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.2 p -153.74 161.84 41.75 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.243 179.697 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -85.72 127.77 34.61 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.2 -0.455 . . . . 0.0 109.885 179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 170.01 160.51 18.51 Favored Glycine 0 CA--C 1.524 0.612 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.661 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 33.4 t -68.43 -18.81 64.52 Favored 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 121.01 -0.276 . . . . 0.0 110.833 179.793 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 80.6 mtp85 -73.67 127.37 32.6 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-O 120.872 0.368 . . . . 0.0 110.621 -179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 43.6 t -170.87 165.89 7.74 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.357 179.804 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.5 mt -92.49 122.06 43.64 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.173 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.128 179.405 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 67.1 tp60 -171.8 118.47 0.42 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.11 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.641 ' ND1' ' N ' ' A' ' 119' ' ' CYS . 59.0 t-80 49.39 -106.01 0.19 Allowed 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.65 179.962 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.641 ' N ' ' ND1' ' A' ' 118' ' ' HIS . 45.0 t -80.48 7.34 10.06 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-O 120.877 0.37 . . . . 0.0 110.735 -179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 63.3 m-20 58.69 30.61 20.17 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.052 -0.522 . . . . 0.0 111.128 179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 18.3 tt -158.59 165.22 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.265 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 23.4 mmt85 -101.2 106.13 17.32 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.195 -179.768 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -104.39 127.37 52.06 Favored 'General case' 0 C--N 1.332 -0.167 0 N-CA-C 109.01 -0.737 . . . . 0.0 109.01 179.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -147.01 168.63 21.04 Favored 'General case' 0 C--N 1.329 -0.292 0 N-CA-C 109.99 -0.374 . . . . 0.0 109.99 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 3.3 m-80 59.54 39.92 21.03 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-O 120.792 0.329 . . . . 0.0 111.064 179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.33 20.85 65.97 Favored Glycine 0 CA--C 1.52 0.379 0 N-CA-C 110.672 -0.971 . . . . 0.0 110.672 179.792 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -65.02 149.15 51.74 Favored Glycine 0 CA--C 1.522 0.476 0 N-CA-C 110.621 -0.991 . . . . 0.0 110.621 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 36.9 m -127.16 144.66 50.98 Favored 'General case' 0 N--CA 1.47 0.573 0 CA-C-O 120.903 0.383 . . . . 0.0 110.403 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 37.1 t -82.55 124.39 30.08 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.568 -179.719 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.408 ' CB ' HD11 ' A' ' 135' ' ' LEU . 48.2 t -148.18 111.67 4.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.472 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.4 m-20 53.9 49.98 17.84 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.381 -0.372 . . . . 0.0 111.067 179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 57.41 34.55 24.82 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 116.374 -0.376 . . . . 0.0 110.407 -179.988 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 42.5 t-80 -144.48 139.54 28.36 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.508 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.4 m -88.05 126.89 35.33 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.497 179.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.408 HD11 ' CB ' ' A' ' 130' ' ' SER . 86.2 mt -95.25 126.85 40.85 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.924 -0.58 . . . . 0.0 109.628 179.736 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . 0.459 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -103.02 137.88 40.62 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 115.851 -0.613 . . . . 0.0 110.683 -179.643 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.4 mm-40 -83.27 175.34 9.98 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.87 -0.604 . . . . 0.0 110.437 179.763 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.533 ' NZ ' ' OE2' ' A' ' 151' ' ' GLU . 64.6 tttm -63.29 133.15 53.7 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.444 -179.815 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.53 -24.52 28.48 Favored Glycine 0 N--CA 1.465 0.608 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 -179.507 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.459 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 95.1 m-85 -123.74 138.25 54.55 Favored 'General case' 0 N--CA 1.467 0.414 0 CA-C-O 120.911 0.386 . . . . 0.0 110.55 179.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 16.7 pt -139.73 -168.93 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.464 0.264 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.496 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.97 165.29 31.43 Favored Glycine 0 CA--C 1.523 0.57 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.783 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -63.13 -46.25 88.12 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-O 120.742 0.306 . . . . 0.0 110.35 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 18.8 p-80 -84.58 -1.42 55.9 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.612 179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 145' ' ' CYS . 33.7 t 55.14 63.47 2.1 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.974 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -140.51 -4.18 1.26 Allowed Glycine 0 CA--C 1.521 0.457 0 N-CA-C 110.834 -0.907 . . . . 0.0 110.834 179.749 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 10.4 tt0 -86.48 114.54 58.21 Favored Pre-proline 0 CA--C 1.54 0.585 0 C-N-CA 120.841 -0.344 . . . . 0.0 110.385 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 92.3 Cg_endo -76.49 156.2 36.37 Favored 'Trans proline' 0 N--CA 1.491 1.355 0 C-N-CA 122.295 1.997 . . . . 0.0 112.4 -179.879 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.2 t -119.61 124.55 73.11 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.483 0 CA-C-O 120.954 0.407 . . . . 0.0 110.197 179.45 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -98.3 107.54 20.03 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.445 -0.343 . . . . 0.0 110.2 -179.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . 0.533 ' OE2' ' NZ ' ' A' ' 138' ' ' LYS . 96.7 mt-10 -69.32 -38.23 78.11 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.025 -0.534 . . . . 0.0 111.101 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 94.7 p -85.38 -9.11 58.0 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.412 -0.358 . . . . 0.0 111.032 -179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 63.5 -163.82 31.1 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.625 -0.99 . . . . 0.0 110.625 179.671 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 71.8 m -116.12 152.24 34.04 Favored 'General case' 0 N--CA 1.466 0.339 0 N-CA-C 110.011 -0.366 . . . . 0.0 110.011 179.454 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 96.9 mt -82.03 -1.95 50.07 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.371 -0.377 . . . . 0.0 110.49 -179.732 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.527 ' C ' ' H ' ' A' ' 158' ' ' GLY . 0.4 OUTLIER -170.66 -147.62 0.05 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.336 179.508 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.511 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.64 26.99 0.49 Allowed Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.527 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -64.23 175.51 11.21 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.737 -0.945 . . . . 0.0 110.737 179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 78.1 ttt180 -128.14 136.64 51.42 Favored 'General case' 0 N--CA 1.466 0.37 0 CA-C-O 120.65 0.262 . . . . 0.0 110.849 -179.655 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 81.3 m -79.56 98.46 6.87 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.547 -179.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 69.7 t -75.91 -44.1 38.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 115.991 -0.55 . . . . 0.0 111.533 -179.544 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.649 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -145.13 174.26 3.61 Favored Pre-proline 0 C--N 1.331 -0.222 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 -179.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.649 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.27 129.59 32.01 Favored 'Trans proline' 0 C--N 1.312 -1.389 0 C-N-CA 121.95 1.767 . . . . 0.0 112.102 179.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 21.3 m-20 52.37 32.87 11.83 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.718 -0.674 . . . . 0.0 109.984 -179.82 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.1 ttt85 -138.84 127.56 23.42 Favored 'General case' 0 C--O 1.237 0.418 0 CA-C-O 121.314 0.578 . . . . 0.0 110.691 179.936 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 42.1 t -139.37 149.99 44.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.722 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.24 134.31 49.57 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.566 179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . 0.644 ' SG ' ' N ' ' A' ' 178' ' ' GLU . 0.2 OUTLIER -81.0 120.28 24.58 Favored 'General case' 0 C--N 1.327 -0.412 0 N-CA-C 109.482 -0.562 . . . . 0.0 109.482 -178.846 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 12.1 m -70.38 -45.45 66.01 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.128 -0.487 . . . . 0.0 111.79 -178.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.5 m-85 -101.85 26.99 6.86 Favored 'General case' 0 CA--C 1.52 -0.176 0 CA-C-N 116.068 -0.514 . . . . 0.0 110.821 -179.154 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.7 33.64 83.29 Favored Glycine 0 CA--C 1.522 0.498 0 N-CA-C 110.026 -1.23 . . . . 0.0 110.026 -179.986 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 24.6 t80 -62.44 127.14 29.92 Favored 'General case' 0 C--N 1.328 -0.361 0 N-CA-C 109.943 -0.392 . . . . 0.0 109.943 -178.77 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 61.8 p -84.58 161.69 20.08 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.924 0.392 . . . . 0.0 110.979 -179.341 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 143.24 160.25 8.31 Favored Glycine 0 CA--C 1.531 1.033 0 N-CA-C 110.994 -0.842 . . . . 0.0 110.994 179.764 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -67.0 -25.41 44.38 Favored 'Trans proline' 0 C--N 1.305 -1.732 0 C-N-CA 122.537 2.158 . . . . 0.0 112.689 -179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 78.0 mt-30 -76.28 -49.27 17.45 Favored 'General case' 0 C--N 1.331 -0.196 0 C-N-CA 120.862 -0.335 . . . . 0.0 111.45 -179.35 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.602 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.0 t -111.61 -104.93 0.38 Allowed 'General case' 0 N--CA 1.47 0.548 0 CA-C-N 116.613 -0.267 . . . . 0.0 110.736 -179.801 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . 0.644 ' N ' ' SG ' ' A' ' 168' ' ' CYS . 81.1 tt0 . . . . . 0 C--N 1.325 -0.478 0 CA-C-O 117.959 -1.019 . . . . 0.0 110.661 -179.419 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.459 ' OG ' ' N ' ' A' ' 44' ' ' ALA . 18.0 t . . . . . 0 N--CA 1.49 1.539 0 N-CA-C 109.371 -0.603 . . . . 0.0 109.371 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.459 ' N ' ' OG ' ' A' ' 43' ' ' SER . . . -66.36 139.62 58.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.297 -0.411 . . . . 0.0 110.534 179.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 31.5 mmt180 -80.52 145.13 31.99 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.455 -179.803 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -81.0 176.23 54.68 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.024 -0.83 . . . . 0.0 111.024 -179.821 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -170.49 170.55 43.12 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.916 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -176.3 -168.51 36.55 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.95 -0.86 . . . . 0.0 110.95 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -63.72 172.17 14.86 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 -179.981 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . 0.553 ' C ' ' HD1' ' A' ' 50' ' ' HIS . 0.8 OUTLIER -64.68 -44.65 89.63 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.709 0.29 . . . . 0.0 110.664 -179.633 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 60.9 t0 -64.22 -36.69 84.89 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.491 179.996 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.32 150.26 48.57 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.53 179.888 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 74.9 mt -63.2 143.97 57.33 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.356 -0.383 . . . . 0.0 110.067 -179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . 0.455 ' HZ1' ' HA ' ' A' ' 50' ' ' HIS . 64.0 mttp -104.77 162.83 12.97 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.489 . . . . 0.0 109.952 -179.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.27 161.05 20.51 Favored Glycine 0 CA--C 1.531 1.036 0 N-CA-C 111.094 -0.802 . . . . 0.0 111.094 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -78.76 3.51 7.25 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.725 2.283 . . . . 0.0 112.146 179.617 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.63 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 1.7 m120 -123.51 68.69 1.02 Allowed 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.77 0.319 . . . . 0.0 110.502 -179.799 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.455 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.8 t -117.01 131.43 69.75 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.212 0 CA-C-O 120.884 0.373 . . . . 0.0 110.032 -179.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -142.56 175.96 9.39 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.333 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.83 170.28 46.86 Favored Glycine 0 CA--C 1.525 0.673 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.538 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -77.77 167.66 21.19 Favored 'General case' 0 C--N 1.331 -0.22 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 179.974 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 43.7 ttm180 -60.98 -44.11 97.85 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.464 -0.334 . . . . 0.0 110.634 -179.894 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.6 m-85 -66.86 -39.3 87.52 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.346 -0.388 . . . . 0.0 111.225 179.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 31.7 m120 -121.91 47.45 1.89 Allowed 'General case' 0 N--CA 1.451 -0.376 0 CA-C-N 116.365 -0.38 . . . . 0.0 110.488 -179.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.538 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -69.44 144.29 53.35 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.553 179.709 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 17.9 p90 -153.33 167.59 28.88 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.017 -0.538 . . . . 0.0 110.944 179.985 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.511 ' SG ' HG22 ' A' ' 73' ' ' THR . 77.1 m -73.21 132.49 43.25 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.51 179.936 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.455 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 54.2 m -51.65 151.78 5.55 Favored Pre-proline 0 CA--C 1.531 0.241 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.983 -179.1 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 75.3 Cg_exo -46.37 129.35 13.28 Favored 'Trans proline' 0 N--CA 1.488 1.162 0 C-N-CA 121.819 1.679 . . . . 0.0 112.424 179.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 99.93 -21.16 46.05 Favored Glycine 0 CA--C 1.521 0.443 0 N-CA-C 110.694 -0.962 . . . . 0.0 110.694 -179.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.63 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 78.2 m95 -111.89 138.41 48.54 Favored 'General case' 0 N--CA 1.465 0.288 0 CA-C-O 120.75 0.31 . . . . 0.0 110.279 179.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.1 ptpt -118.47 -176.05 3.0 Favored 'General case' 0 N--CA 1.468 0.444 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.324 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.511 HG22 ' SG ' ' A' ' 67' ' ' CYS . 72.5 p -106.94 153.71 22.15 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.493 -179.615 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.509 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.1 mt -88.31 151.53 48.83 Favored Pre-proline 0 C--N 1.329 -0.304 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.403 -179.374 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.459 ' C ' ' H ' ' A' ' 77' ' ' GLY . 77.4 Cg_exo -39.04 105.47 0.05 OUTLIER 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.187 1.925 . . . . 0.0 112.228 179.522 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.58 -9.2 2.67 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.965 -0.854 . . . . 0.0 110.965 179.437 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.16 168.94 47.36 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.68 -0.968 . . . . 0.0 110.68 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.443 ' OD1' ' NE2' ' A' ' 79' ' ' GLN . 42.7 p-10 -126.49 13.49 7.59 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-O 120.657 0.265 . . . . 0.0 110.784 179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . 0.443 ' NE2' ' OD1' ' A' ' 78' ' ' ASN . 10.8 mp0 -90.68 123.83 34.6 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.868 0.366 . . . . 0.0 110.898 179.965 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.48 68.57 4.87 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.438 -0.579 . . . . 0.0 109.438 179.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 27.2 pt -120.99 23.45 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.346 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.788 -179.436 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 61.0 t -117.78 95.98 48.78 Favored Pre-proline 0 CA--C 1.535 0.403 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.541 179.796 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -77.55 157.31 32.37 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.702 2.268 . . . . 0.0 112.236 -179.409 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -111.63 131.53 62.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 115.793 -0.639 . . . . 0.0 110.755 179.694 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 28.6 m -84.78 139.4 31.97 Favored 'General case' 0 C--N 1.333 -0.147 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.408 179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.439 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -63.04 -45.15 93.63 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.279 0.561 . . . . 0.0 110.251 -179.83 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.5 m-70 -123.33 -118.08 0.29 Allowed 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 115.904 -0.589 . . . . 0.0 110.29 -179.657 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.1 t -143.81 133.71 23.99 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.35 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 0.5 OUTLIER -94.05 -21.28 19.25 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.591 179.732 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 70.33 -99.18 0.7 Allowed Glycine 0 CA--C 1.525 0.694 0 N-CA-C 110.922 -0.871 . . . . 0.0 110.922 -179.867 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.402 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 39.5 p-10 -75.95 -1.71 26.88 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.772 0.32 . . . . 0.0 110.615 -179.631 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.86 -175.29 26.79 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.62 -0.992 . . . . 0.0 110.62 179.646 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.7 p90 -141.12 153.86 45.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.934 0.397 . . . . 0.0 110.822 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.6 m -71.53 106.84 4.14 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.989 -0.55 . . . . 0.0 110.877 -179.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.7 p -96.69 -20.12 18.49 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.053 -179.848 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 mtt180 -162.14 168.92 10.11 Favored Pre-proline 0 C--O 1.235 0.329 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.987 179.81 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . 0.414 ' O ' ' CG ' ' A' ' 98' ' ' ASN . 52.4 Cg_exo -51.83 130.08 32.81 Favored 'Trans proline' 0 N--CA 1.49 1.269 0 C-N-CA 121.981 1.788 . . . . 0.0 110.827 178.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.439 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 12.6 p30 43.01 34.85 0.68 Allowed 'General case' 0 C--N 1.33 -0.251 0 O-C-N 123.692 0.62 . . . . 0.0 109.918 -179.854 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 47.3 mmm -148.62 120.81 8.34 Favored 'General case' 0 C--O 1.237 0.423 0 CA-C-O 121.312 0.577 . . . . 0.0 110.571 -179.677 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 13.8 p -119.82 161.68 20.38 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.887 -0.597 . . . . 0.0 110.023 179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 77.8 m -119.41 128.08 53.71 Favored 'General case' 0 CA--C 1.516 -0.351 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.431 -179.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.46 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.1 OUTLIER -92.0 153.15 43.36 Favored Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 109.55 -0.537 . . . . 0.0 109.55 -179.72 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.46 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 75.3 Cg_exo -46.45 -27.54 5.16 Favored 'Trans proline' 0 N--CA 1.493 1.469 0 C-N-CA 122.581 2.188 . . . . 0.0 112.011 178.494 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 35.8 t -63.43 -17.46 62.7 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-O 120.873 0.368 . . . . 0.0 110.485 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 96.43 -3.01 63.32 Favored Glycine 0 N--CA 1.464 0.558 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . 0.448 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 2.2 tm0? -81.0 148.54 29.69 Favored 'General case' 0 N--CA 1.454 -0.261 0 CA-C-O 120.785 0.326 . . . . 0.0 110.314 179.87 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.448 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 94.8 mt -122.06 135.18 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.966 -0.561 . . . . 0.0 110.549 -179.847 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.685 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -176.74 175.69 0.6 Allowed Pre-proline 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.691 179.741 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.685 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 45.6 Cg_exo -56.27 -25.78 58.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.769 2.313 . . . . 0.0 111.508 178.445 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.448 ' C ' ' H ' ' A' ' 112' ' ' GLY . 49.5 p -136.09 168.11 19.99 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.194 -179.362 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 0.829 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.0 OUTLIER -76.25 20.31 0.21 Allowed 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.597 -178.727 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.448 ' H ' ' C ' ' A' ' 110' ' ' SER . . . -90.52 118.77 5.41 Favored Glycine 0 CA--C 1.522 0.482 0 N-CA-C 110.337 -1.105 . . . . 0.0 110.337 179.521 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 40.2 t -63.62 128.22 34.83 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 120.789 -0.364 . . . . 0.0 110.731 -179.43 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 78.2 ttt-85 -68.57 -42.85 77.73 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.452 179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 62.8 m -148.22 145.39 28.24 Favored 'General case' 0 N--CA 1.462 0.162 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.561 179.864 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.7 mt -64.7 -44.25 96.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.637 179.951 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.3 mt-30 -90.19 117.23 28.79 Favored 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.585 -179.783 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.577 ' CG ' ' N ' ' A' ' 119' ' ' CYS . 86.4 t60 -174.13 172.52 3.31 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.991 -0.549 . . . . 0.0 110.595 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.577 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 4.5 t -61.13 121.57 12.84 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.306 179.402 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -88.28 7.22 33.25 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.531 -179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.505 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 12.7 tt -130.44 166.29 28.45 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.467 179.334 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.505 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 16.1 mmm180 -100.98 125.22 47.57 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.304 179.79 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 82.6 m -118.29 129.21 55.33 Favored 'General case' 0 N--CA 1.463 0.211 0 CA-C-N 115.882 -0.599 . . . . 0.0 109.941 179.579 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.0 mtm -140.97 166.84 23.68 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.251 -0.431 . . . . 0.0 110.339 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.4 m-20 58.48 41.31 22.89 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 116.372 -0.376 . . . . 0.0 110.878 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 76.24 22.03 74.38 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.844 -0.902 . . . . 0.0 110.844 179.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.16 145.12 49.44 Favored Glycine 0 CA--C 1.522 0.481 0 N-CA-C 110.663 -0.975 . . . . 0.0 110.663 -179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . 0.505 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 30.3 t -102.39 128.33 49.03 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-O 120.745 0.307 . . . . 0.0 110.367 -179.882 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 39.9 t -84.63 120.45 26.39 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.226 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.456 ' O ' ' O ' ' A' ' 133' ' ' HIS . 39.7 t -142.35 136.37 29.58 Favored 'General case' 0 N--CA 1.462 0.131 0 CA-C-N 116.451 -0.341 . . . . 0.0 110.305 179.695 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 81.9 m-20 39.88 -118.32 0.29 Allowed 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.753 -179.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 34.6 p30 -112.87 12.91 19.55 Favored 'General case' 0 C--N 1.333 -0.118 0 CA-C-N 116.438 -0.347 . . . . 0.0 110.51 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.456 ' O ' ' O ' ' A' ' 130' ' ' SER . 78.2 t60 -133.08 152.99 51.92 Favored 'General case' 0 N--CA 1.463 0.2 0 CA-C-O 120.856 0.36 . . . . 0.0 110.469 -179.719 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 128' ' ' SER . 7.8 t -120.71 148.64 43.67 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.19 -179.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.7 mt -105.73 134.29 49.09 Favored 'General case' 0 CA--C 1.516 -0.362 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.351 -179.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 22.3 m -97.68 141.18 31.02 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.131 -179.748 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.3 mt-30 -73.39 170.72 14.5 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.284 -0.417 . . . . 0.0 110.729 -179.762 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.1 tttt -66.67 132.89 49.1 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.38 -179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 105.52 -20.03 38.01 Favored Glycine 0 N--CA 1.466 0.667 0 N-CA-C 110.717 -0.953 . . . . 0.0 110.717 -179.322 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 99.7 m-85 -122.27 137.03 54.98 Favored 'General case' 0 N--CA 1.465 0.314 0 CA-C-O 120.796 0.331 . . . . 0.0 110.322 179.592 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -127.85 170.26 17.92 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.296 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.103 -179.791 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 118.65 163.31 12.47 Favored Glycine 0 N--CA 1.464 0.516 0 N-CA-C 110.686 -0.966 . . . . 0.0 110.686 179.892 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 67.3 p -63.39 -41.42 98.77 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.811 0.338 . . . . 0.0 110.562 -179.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.445 ' C ' ' SG ' ' A' ' 145' ' ' CYS . 15.6 m170 -107.42 1.43 23.59 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.6 179.734 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.445 ' SG ' ' C ' ' A' ' 144' ' ' HIS . 1.8 m 71.14 140.65 0.05 OUTLIER 'General case' 0 N--CA 1.453 -0.321 0 CA-C-N 116.087 -0.506 . . . . 0.0 109.933 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 158.99 -26.95 0.38 Allowed Glycine 0 C--N 1.322 -0.224 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 0.5 OUTLIER -83.64 117.1 67.71 Favored Pre-proline 0 CA--C 1.542 0.636 0 C-N-CA 120.45 -0.5 . . . . 0.0 110.482 -179.242 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -75.51 153.39 39.36 Favored 'Trans proline' 0 C--N 1.309 -1.519 0 C-N-CA 122.432 2.088 . . . . 0.0 112.417 179.561 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 49.4 t -114.35 128.46 71.37 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.168 0 N-CA-C 109.847 -0.427 . . . . 0.0 109.847 179.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 36.8 m -101.57 100.03 10.4 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.934 -0.576 . . . . 0.0 110.097 179.582 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 11.9 tm-20 -64.44 -36.73 85.12 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.274 -179.692 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 80.0 p -83.6 -7.24 59.55 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.434 179.856 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 61.31 -168.89 10.91 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.1 m -140.41 115.87 10.05 Favored 'General case' 0 N--CA 1.464 0.23 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 179.818 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . 0.505 ' N ' HD12 ' A' ' 155' ' ' LEU . 10.7 mp -62.92 -42.07 99.68 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.663 -179.278 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.547 ' C ' ' H ' ' A' ' 158' ' ' GLY . 63.9 t30 -93.45 173.34 7.75 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.524 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.17 34.6 0.31 Allowed Glycine 0 CA--C 1.526 0.775 0 N-CA-C 110.945 -0.862 . . . . 0.0 110.945 179.839 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.547 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.03 174.42 26.02 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.769 -0.933 . . . . 0.0 110.769 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 58.9 ttp180 -123.75 138.25 54.55 Favored 'General case' 0 N--CA 1.465 0.309 0 CA-C-O 120.807 0.337 . . . . 0.0 110.66 -179.713 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 63.4 m -81.26 107.15 13.81 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.277 -179.615 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 32.5 m -83.66 -29.98 7.77 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.547 179.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.677 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -158.93 172.38 6.21 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.54 179.818 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.677 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.5 Cg_exo -52.55 129.64 33.0 Favored 'Trans proline' 0 N--CA 1.494 1.539 0 C-N-CA 122.062 1.841 . . . . 0.0 111.926 179.268 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 11.0 m120 53.55 33.96 17.43 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.601 179.83 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 2.5 tpm_? -139.06 125.25 20.13 Favored 'General case' 0 C--O 1.237 0.408 0 CA-C-O 121.054 0.454 . . . . 0.0 110.283 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -128.54 145.31 51.16 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.716 -0.675 . . . . 0.0 110.911 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -118.25 146.2 44.45 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.123 179.776 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 10.9 m -82.78 135.73 34.89 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.552 -179.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 20.5 m -63.76 -45.4 90.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.85 -179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.7 m-85 -99.69 22.65 10.64 Favored 'General case' 0 C--N 1.333 -0.145 0 CA-C-O 121.011 0.434 . . . . 0.0 110.633 -179.54 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 63.74 30.88 78.96 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.401 -1.08 . . . . 0.0 110.401 179.911 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.7 t80 -54.65 157.16 3.11 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 120.836 0.351 . . . . 0.0 110.353 -178.801 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 82.3 p -81.15 140.47 34.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-O 121.284 0.564 . . . . 0.0 110.452 -179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 101.79 147.49 19.98 Favored Glycine 0 CA--C 1.532 1.119 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 179.633 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -67.13 -31.31 36.73 Favored 'Trans proline' 0 N--CA 1.494 1.53 0 C-N-CA 122.591 2.194 . . . . 0.0 112.215 -179.624 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.442 ' O ' ' O ' ' A' ' 177' ' ' CYS . 1.0 OUTLIER -88.12 -9.37 53.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.303 -179.195 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.442 ' O ' ' O ' ' A' ' 176' ' ' GLN . 34.3 m 58.75 119.62 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.51 0 O-C-N 123.481 0.488 . . . . 0.0 109.933 -179.83 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 . . . . . 0 C--O 1.219 -0.502 0 CA-C-O 117.878 -1.058 . . . . 0.0 110.488 179.902 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 66.2 m . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.05 56.63 0.76 Allowed 'General case' 0 N--CA 1.464 0.272 0 CA-C-N 116.28 -0.418 . . . . 0.0 110.401 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 80.8 mtp85 41.54 85.31 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.716 -179.914 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 87.34 3.79 81.44 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 110.593 -1.003 . . . . 0.0 110.593 -179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -65.5 -27.29 72.4 Favored Glycine 0 CA--C 1.523 0.585 0 N-CA-C 111.068 -0.813 . . . . 0.0 111.068 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -56.08 -40.34 82.72 Favored Glycine 0 CA--C 1.524 0.649 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.269 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 165.8 -166.24 38.47 Favored Glycine 0 CA--C 1.522 0.503 0 N-CA-C 110.916 -0.874 . . . . 0.0 110.916 179.805 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . 0.533 ' CG ' ' OD1' ' A' ' 78' ' ' ASN . 45.0 p-80 -69.35 135.84 50.92 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.89 0.376 . . . . 0.0 110.304 179.855 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -62.61 -42.84 99.81 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.816 -179.627 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . 179.2 -167.78 0.08 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.344 -179.877 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 15.9 mt -73.24 151.68 41.32 Favored 'General case' 0 CA--C 1.514 -0.409 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.559 179.599 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -137.45 162.46 33.59 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 115.589 -0.732 . . . . 0.0 110.308 -179.56 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.71 161.13 23.03 Favored Glycine 0 CA--C 1.531 1.081 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 73.5 Cg_endo -75.51 -4.84 15.84 Favored 'Trans proline' 0 N--CA 1.496 1.625 0 C-N-CA 122.953 2.435 . . . . 0.0 112.234 179.819 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.606 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 87.6 m-20 -112.54 74.42 0.86 Allowed 'General case' 0 N--CA 1.464 0.226 0 CA-C-N 116.355 -0.384 . . . . 0.0 111.074 -179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.462 ' O ' HG13 ' A' ' 58' ' ' VAL . 8.2 p -116.04 130.38 70.85 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.399 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.904 179.465 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 69.6 m -139.91 177.92 7.62 Favored 'General case' 0 C--N 1.331 -0.239 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.098 -179.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.8 161.28 27.82 Favored Glycine 0 CA--C 1.522 0.49 0 N-CA-C 110.641 -0.984 . . . . 0.0 110.641 179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.8 m -82.61 171.54 13.93 Favored 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 110.24 -0.281 . . . . 0.0 110.24 179.799 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.0 ttt-85 -59.21 -40.49 85.95 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.405 -0.362 . . . . 0.0 110.302 179.936 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 68.0 m-85 -60.01 -40.2 88.44 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.374 -0.375 . . . . 0.0 110.68 -179.85 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 14.2 t-20 -135.56 52.51 2.01 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.699 -0.228 . . . . 0.0 110.944 179.933 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.4 141.88 52.12 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.405 -0.361 . . . . 0.0 110.791 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.409 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 9.7 p90 -158.7 172.35 18.42 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 121.2 0.524 . . . . 0.0 110.421 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.563 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 94.6 m -69.03 140.42 54.94 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.131 179.763 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.436 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 64.2 m -58.72 149.44 63.31 Favored Pre-proline 0 C--N 1.325 -0.477 0 CA-C-N 116.04 -0.527 . . . . 0.0 110.96 -179.489 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -56.29 131.09 43.72 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 121.581 1.52 . . . . 0.0 112.291 -179.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 106.55 -16.34 40.95 Favored Glycine 0 CA--C 1.528 0.886 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.606 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 93.0 m95 -119.07 134.73 55.02 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-O 120.804 0.335 . . . . 0.0 110.228 179.252 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -115.04 -176.69 2.96 Favored 'General case' 0 N--CA 1.465 0.282 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.375 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.563 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 30.3 p -132.59 172.53 12.4 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.005 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.698 HD12 ' H ' ' A' ' 74' ' ' LEU . 0.2 OUTLIER -92.02 160.32 35.95 Favored Pre-proline 0 CA--C 1.536 0.439 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.363 -179.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.476 ' C ' ' H ' ' A' ' 77' ' ' GLY . 45.6 Cg_exo -53.83 132.5 49.84 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.591 1.528 . . . . 0.0 112.144 179.356 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 67.6 -8.01 1.83 Allowed Glycine 0 CA--C 1.526 0.733 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 179.377 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.476 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.56 178.77 38.4 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.138 -0.785 . . . . 0.0 111.138 -179.645 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.533 ' OD1' ' CG ' ' A' ' 50' ' ' HIS . 29.4 m120 -146.9 16.77 1.23 Allowed 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.006 0.431 . . . . 0.0 110.719 179.814 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.2 mt-30 -84.83 121.3 27.52 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.058 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 7.0 m -88.43 39.23 0.9 Allowed 'General case' 0 N--CA 1.463 0.192 0 N-CA-C 109.784 -0.45 . . . . 0.0 109.784 179.97 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.0 pt -95.2 -1.72 10.66 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.619 -179.215 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 90.4 t -97.93 114.52 65.17 Favored Pre-proline 0 CA--C 1.538 0.512 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.664 -179.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 98.3 Cg_endo -75.28 155.59 41.68 Favored 'Trans proline' 0 N--CA 1.491 1.33 0 C-N-CA 121.982 1.788 . . . . 0.0 112.564 -179.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 81.9 mt -106.42 124.44 61.87 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.354 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.192 179.839 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -106.16 115.84 30.92 Favored 'General case' 0 N--CA 1.467 0.421 0 N-CA-C 109.414 -0.587 . . . . 0.0 109.414 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 2.7 mpt_? -64.15 -40.4 96.07 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 120.797 0.332 . . . . 0.0 110.686 179.65 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -117.0 149.39 40.32 Favored 'General case' 0 N--CA 1.466 0.337 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.537 -179.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.5 m -66.22 138.2 57.51 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.501 -179.794 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 40.5 m -79.02 -26.81 43.21 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.715 179.748 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 79.78 -104.2 2.17 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 111.179 -0.768 . . . . 0.0 111.179 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 97.0 m-20 -78.6 -4.11 47.23 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.78 0.324 . . . . 0.0 110.97 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -113.59 -156.42 12.01 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 -179.909 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.5 p90 -152.6 157.25 40.74 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.97 0.414 . . . . 0.0 111.023 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -64.1 112.95 3.22 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.052 -179.749 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.432 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 91.9 p -102.83 -25.32 13.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.56 -179.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 35.5 mtt180 -157.79 159.93 30.27 Favored Pre-proline 0 CA--C 1.532 0.287 0 C-N-CA 120.453 -0.499 . . . . 0.0 110.312 179.713 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.8 Cg_exo -44.84 119.34 2.3 Favored 'Trans proline' 0 N--CA 1.489 1.225 0 C-N-CA 122.157 1.904 . . . . 0.0 111.607 179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 66.2 t30 53.55 42.02 31.99 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.11 179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mmm -148.39 118.76 7.35 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-O 120.915 0.388 . . . . 0.0 110.682 179.827 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.432 ' N ' ' O ' ' A' ' 108' ' ' ALA . 17.7 m -100.79 146.14 27.64 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.797 -0.638 . . . . 0.0 110.149 178.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . 0.432 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 64.0 m -122.24 123.94 42.63 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.627 179.658 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.401 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -87.74 156.84 52.69 Favored Pre-proline 0 C--N 1.323 -0.56 0 CA-C-N 115.8 -0.636 . . . . 0.0 109.644 -179.586 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.401 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -61.95 -19.95 67.76 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 122.469 2.113 . . . . 0.0 111.798 178.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -66.28 -17.23 64.62 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.459 179.116 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 107.12 -19.31 35.1 Favored Glycine 0 N--CA 1.467 0.713 0 N-CA-C 110.946 -0.862 . . . . 0.0 110.946 -179.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tp60 -67.0 149.83 50.09 Favored 'General case' 0 N--CA 1.456 -0.141 0 CA-C-O 120.957 0.408 . . . . 0.0 110.253 -179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 94.7 mt -129.18 130.2 67.85 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.437 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.743 179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.648 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.44 178.11 1.02 Allowed Pre-proline 0 CA--C 1.538 0.482 0 C-N-CA 120.61 -0.436 . . . . 0.0 110.314 179.502 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.648 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 44.1 Cg_exo -57.67 -25.45 67.99 Favored 'Trans proline' 0 N--CA 1.499 1.837 0 C-N-CA 122.818 2.346 . . . . 0.0 111.968 179.367 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 95.5 p -149.83 162.33 40.51 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.499 -179.745 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.06 -26.85 48.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.667 -179.873 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -124.09 78.18 0.36 Allowed Glycine 0 N--CA 1.467 0.745 0 N-CA-C 110.938 -0.865 . . . . 0.0 110.938 -179.806 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.4 t -61.82 -41.89 98.34 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.853 0.359 . . . . 0.0 110.335 179.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 21.7 mmm180 -127.14 145.22 50.83 Favored 'General case' 0 N--CA 1.464 0.27 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.657 -179.454 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 93.1 p -99.6 -1.56 37.83 Favored 'General case' 0 N--CA 1.467 0.376 0 CA-C-N 115.829 -0.623 . . . . 0.0 111.167 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.596 ' O ' HG23 ' A' ' 116' ' ' ILE . 21.1 tt -96.95 119.28 44.81 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-O 120.897 0.38 . . . . 0.0 110.061 -179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . 0.526 ' NE2' ' O ' ' A' ' 116' ' ' ILE . 99.3 mm-40 -142.18 41.71 1.65 Allowed 'General case' 0 N--CA 1.464 0.227 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.17 -179.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.615 ' CG ' ' H ' ' A' ' 119' ' ' CYS . 59.1 t-80 -69.38 175.15 4.18 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.418 179.769 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.615 ' H ' ' CG ' ' A' ' 118' ' ' HIS . 0.8 OUTLIER -73.06 127.61 33.08 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.031 -179.607 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -98.5 13.73 30.77 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.762 -0.654 . . . . 0.0 110.745 -179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.625 HG22 ' N ' ' A' ' 122' ' ' ARG . 92.4 mt -119.24 165.52 14.49 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.389 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.204 -179.749 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.625 ' N ' HG22 ' A' ' 121' ' ' ILE . 5.9 ptt85 -119.19 101.95 8.37 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.71 -0.677 . . . . 0.0 110.581 -179.835 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 76.3 m -107.03 146.69 30.84 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.803 -0.635 . . . . 0.0 109.744 -179.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.9 mtm -142.9 174.56 10.55 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.262 -0.427 . . . . 0.0 110.255 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 59.02 37.43 24.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.787 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 73.99 22.37 78.04 Favored Glycine 0 CA--C 1.521 0.444 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.636 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.56 134.71 16.94 Favored Glycine 0 CA--C 1.524 0.619 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 15.2 m -86.31 129.64 34.78 Favored 'General case' 0 C--N 1.329 -0.3 0 C-N-CA 121.052 -0.259 . . . . 0.0 110.383 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.413 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 4.3 t -87.12 85.28 7.21 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 120.856 0.36 . . . . 0.0 110.574 179.789 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.505 ' N ' ' O ' ' A' ' 133' ' ' HIS . 14.7 p -74.96 161.84 29.13 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.383 179.571 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 29.6 t70 -50.23 110.87 0.44 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.286 -0.415 . . . . 0.0 111.408 -179.233 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.401 ' O ' ' CG ' ' A' ' 133' ' ' HIS . 98.6 m-20 52.35 28.59 5.89 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.824 -0.626 . . . . 0.0 110.555 179.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.505 ' O ' ' N ' ' A' ' 130' ' ' SER . 31.5 m-70 -162.25 153.36 17.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.596 179.57 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 12.4 t -126.78 130.64 50.68 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.335 179.516 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 87.2 mt -102.06 131.07 48.74 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.902 -179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . 0.434 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 57.6 m -91.38 129.75 37.32 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.394 -179.703 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 29.7 mm100 -79.03 173.05 12.97 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-O 120.927 0.394 . . . . 0.0 110.575 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 20.9 tptp -63.42 134.2 55.27 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.334 179.924 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -21.62 37.79 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 -179.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 92.0 m-85 -129.02 139.62 51.98 Favored 'General case' 0 N--CA 1.466 0.365 0 CA-C-O 120.772 0.32 . . . . 0.0 110.545 179.659 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 10.9 pt -134.09 176.79 8.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.353 0 CA-C-N 116.325 -0.398 . . . . 0.0 109.986 -179.871 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.434 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 107.52 169.08 21.88 Favored Glycine 0 N--CA 1.465 0.601 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.568 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.5 m -62.08 -45.28 94.2 Favored 'General case' 0 C--N 1.325 -0.468 0 C-N-CA 120.93 -0.308 . . . . 0.0 110.531 -179.72 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.56 ' CE1' ' NH2' ' A' ' 122' ' ' ARG . 59.1 m80 -98.35 5.92 47.78 Favored 'General case' 0 N--CA 1.466 0.348 0 CA-C-N 116.367 -0.379 . . . . 0.0 110.736 -179.864 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 3.9 m 58.2 37.24 26.22 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.976 -0.556 . . . . 0.0 110.503 -179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -103.28 17.68 50.69 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.967 -0.853 . . . . 0.0 110.967 -179.874 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 50.4 tp60 -119.19 96.73 50.22 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-N 116.754 0.277 . . . . 0.0 110.806 -179.764 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 39.1 Cg_exo -58.23 152.49 52.53 Favored 'Trans proline' 0 N--CA 1.499 1.819 0 C-N-CA 122.583 2.189 . . . . 0.0 111.916 178.716 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 70.8 t -89.94 129.76 40.31 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.218 0 CA-C-O 121.048 0.452 . . . . 0.0 110.325 -179.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.4 m -103.11 86.47 2.7 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -62.32 -46.43 88.77 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.536 -0.465 . . . . 0.0 110.267 -178.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 90.0 p -111.99 -21.21 11.67 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 120.964 0.411 . . . . 0.0 110.502 179.25 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 49.67 177.91 0.02 OUTLIER Glycine 0 CA--C 1.524 0.62 0 N-CA-C 111.141 -0.784 . . . . 0.0 111.141 -179.691 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.6 m -98.54 139.8 33.73 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-O 120.934 0.397 . . . . 0.0 110.184 179.571 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 92.5 mt -63.22 -40.99 99.04 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.953 -0.567 . . . . 0.0 110.626 -179.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.522 ' ND2' ' H ' ' A' ' 169' ' ' THR . 51.9 p30 -82.37 178.68 8.11 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.888 -0.597 . . . . 0.0 110.376 179.993 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.92 42.26 0.35 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.926 -0.87 . . . . 0.0 110.926 -179.779 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.474 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.2 -176.57 19.15 Favored Glycine 0 CA--C 1.521 0.432 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 4.5 mpt_? -130.15 142.18 50.61 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 179.802 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 98.6 m -76.69 102.45 6.19 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.285 -0.416 . . . . 0.0 111.037 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.8 t -83.17 -50.62 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.221 179.744 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.625 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -135.65 177.31 2.28 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.178 -178.935 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.625 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.71 133.12 52.73 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 121.821 1.68 . . . . 0.0 111.489 179.53 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 56.1 t-20 47.9 23.02 0.42 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.643 -179.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 32.3 mmt180 -132.68 140.58 48.2 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.439 0.638 . . . . 0.0 111.025 -179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 5.8 p -149.1 155.69 41.09 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.379 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -89.92 143.88 26.4 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.983 -0.553 . . . . 0.0 109.65 179.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . 0.408 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 66.1 m -85.05 155.14 21.66 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.612 -179.246 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.522 ' H ' ' ND2' ' A' ' 156' ' ' ASN . 97.9 m -62.08 -45.7 92.36 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.127 -0.488 . . . . 0.0 111.168 -179.427 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -109.45 22.55 15.64 Favored 'General case' 0 CA--C 1.519 -0.22 0 CA-C-O 120.992 0.425 . . . . 0.0 111.262 -179.611 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.13 35.09 91.31 Favored Glycine 0 CA--C 1.524 0.627 0 N-CA-C 110.998 -0.841 . . . . 0.0 110.998 179.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.408 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 2.7 m-85 -68.32 146.99 52.78 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 121.117 0.484 . . . . 0.0 110.643 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 60.6 p -81.58 166.67 20.02 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.558 -0.746 . . . . 0.0 110.179 -179.618 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 91.28 154.62 30.81 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -67.83 -20.97 45.06 Favored 'Trans proline' 0 N--CA 1.497 1.725 0 C-N-CA 122.609 2.206 . . . . 0.0 112.405 -179.576 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.476 ' C ' ' H ' ' A' ' 178' ' ' GLU . 75.0 mt-30 -111.26 18.79 18.95 Favored 'General case' 0 N--CA 1.468 0.46 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.737 -179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 79.7 m 50.19 11.55 0.07 Allowed 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.29 -179.762 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . 0.476 ' H ' ' C ' ' A' ' 176' ' ' GLN . 80.8 tt0 . . . . . 0 C--O 1.22 -0.469 0 CA-C-O 118.026 -0.988 . . . . 0.0 110.573 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 25.2 t . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.23 141.66 57.97 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.523 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . 0.406 ' NH1' ' O ' ' A' ' 46' ' ' GLY . 22.6 tpt85 -74.11 131.72 41.58 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.331 -0.395 . . . . 0.0 110.421 -179.965 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . 0.406 ' O ' ' NH1' ' A' ' 45' ' ' ARG . . . -96.29 164.19 23.32 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.751 -0.94 . . . . 0.0 110.751 179.752 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 56.71 -137.1 48.99 Favored Glycine 0 CA--C 1.523 0.562 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 179.889 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.33 168.71 40.59 Favored Glycine 0 CA--C 1.524 0.638 0 N-CA-C 110.853 -0.899 . . . . 0.0 110.853 179.698 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -84.11 167.86 44.13 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.689 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 34.0 m170 -134.57 141.08 46.56 Favored 'General case' 0 N--CA 1.465 0.317 0 CA-C-O 120.81 0.338 . . . . 0.0 110.471 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.436 ' O ' ' O ' ' A' ' 52' ' ' ALA . 98.0 m-20 -70.26 -19.21 63.13 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.622 179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.436 ' O ' ' O ' ' A' ' 51' ' ' ASP . . . 56.7 155.94 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.647 -179.993 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt -75.42 150.11 38.39 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.629 -179.816 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -130.23 160.46 33.81 Favored 'General case' 0 C--O 1.237 0.399 0 CA-C-O 121.125 0.488 . . . . 0.0 110.142 -179.405 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 75.6 174.76 36.46 Favored Glycine 0 CA--C 1.526 0.727 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 -179.754 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.4 Cg_endo -73.04 -172.3 0.97 Allowed 'Trans proline' 0 C--N 1.307 -1.618 0 C-N-CA 122.898 2.399 . . . . 0.0 111.81 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.526 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 53.5 m-80 59.16 38.95 23.49 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.997 179.847 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.46 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 11.8 p -98.69 131.59 45.56 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.278 179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 59.9 m -141.5 -178.75 5.78 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.251 -179.268 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.47 162.3 29.03 Favored Glycine 0 CA--C 1.521 0.466 0 N-CA-C 110.762 -0.935 . . . . 0.0 110.762 179.604 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 13.6 m -82.52 172.84 12.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-O 120.783 0.325 . . . . 0.0 110.448 179.694 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.4 ttt-85 -60.86 -43.03 98.92 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.246 -0.434 . . . . 0.0 110.483 179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.9 m-85 -62.12 -39.62 93.16 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.828 -179.567 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 38.0 t30 -133.02 55.2 1.91 Allowed 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.669 -179.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.2 142.29 52.45 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.244 179.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 9.9 p90 -155.21 169.56 23.89 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.997 0.427 . . . . 0.0 110.856 -179.988 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.453 ' SG ' HG22 ' A' ' 73' ' ' THR . 71.8 m -74.14 139.72 44.72 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.188 179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.46 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 61.9 m -56.81 153.63 21.68 Favored Pre-proline 0 C--N 1.326 -0.423 0 CA-C-N 116.043 -0.526 . . . . 0.0 111.252 -179.136 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_exo -50.78 131.87 35.15 Favored 'Trans proline' 0 N--CA 1.495 1.585 0 C-N-CA 121.244 1.296 . . . . 0.0 112.203 179.579 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.495 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.92 -18.82 51.55 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 -179.723 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.556 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 8.9 m95 -119.01 140.04 50.69 Favored 'General case' 0 N--CA 1.468 0.446 0 CA-C-O 120.746 0.308 . . . . 0.0 110.649 179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.7 ptpt -121.6 -175.84 3.18 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.363 179.562 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.453 HG22 ' SG ' ' A' ' 67' ' ' CYS . 60.8 p -108.81 154.12 22.53 Favored 'General case' 0 C--N 1.328 -0.366 0 N-CA-C 109.931 -0.396 . . . . 0.0 109.931 179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.482 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.9 mt -83.37 152.43 64.3 Favored Pre-proline 0 C--N 1.326 -0.42 0 CA-C-N 116.033 -0.531 . . . . 0.0 110.688 -179.073 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.406 ' C ' ' H ' ' A' ' 77' ' ' GLY . 74.0 Cg_exo -41.3 110.33 0.13 Allowed 'Trans proline' 0 N--CA 1.491 1.329 0 C-N-CA 122.017 1.811 . . . . 0.0 112.197 179.125 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.36 -4.78 7.99 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.364 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.482 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -89.09 173.64 41.37 Favored Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 179.89 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 97.7 m-20 -135.94 11.96 3.37 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.969 0.414 . . . . 0.0 111.059 179.848 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 7.6 mp0 -89.61 126.64 35.7 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 116.338 -0.392 . . . . 0.0 110.552 -179.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -89.61 69.1 7.79 Favored 'General case' 0 N--CA 1.463 0.224 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.969 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.8 pt -122.05 21.78 4.91 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.484 0 CA-C-N 116.497 -0.32 . . . . 0.0 110.96 -179.415 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 86.4 t -118.87 86.72 31.48 Favored Pre-proline 0 N--CA 1.464 0.251 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.793 179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.1 Cg_exo -61.47 150.76 83.74 Favored 'Trans proline' 0 N--CA 1.494 1.552 0 C-N-CA 122.773 2.315 . . . . 0.0 111.994 179.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.495 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.4 mt -106.05 128.74 60.14 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.439 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 5.9 m -89.62 135.67 33.48 Favored 'General case' 0 N--CA 1.463 0.178 0 CA-C-N 115.929 -0.578 . . . . 0.0 109.49 179.302 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.4 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.04 -45.59 92.89 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.18 0.514 . . . . 0.0 109.758 -179.208 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -119.0 167.86 11.36 Favored 'General case' 0 N--CA 1.468 0.457 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.64 -179.825 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 96.4 p -57.15 137.81 55.38 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.544 -179.466 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.564 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 31.5 m -86.06 -32.96 21.12 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.863 179.715 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.77 -108.91 2.74 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.783 -0.927 . . . . 0.0 110.783 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 10.6 m-20 -93.74 0.96 56.62 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-O 120.744 0.306 . . . . 0.0 111.066 -179.906 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.62 -176.25 31.12 Favored Glycine 0 CA--C 1.523 0.533 0 N-CA-C 110.86 -0.896 . . . . 0.0 110.86 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.449 ' C ' ' SG ' ' A' ' 100' ' ' CYS . 44.8 p90 -135.18 145.39 47.69 Favored 'General case' 0 N--CA 1.468 0.464 0 CA-C-O 121.114 0.483 . . . . 0.0 110.902 179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 85' ' ' CYS . 0.5 OUTLIER -70.11 113.41 7.27 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.54 -178.786 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 33.9 m -99.79 -21.04 15.92 Favored 'General case' 0 CA--C 1.516 -0.337 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.535 -179.548 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.0 mtt180 -160.2 164.74 19.11 Favored Pre-proline 0 N--CA 1.452 -0.338 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.662 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -52.22 127.85 25.19 Favored 'Trans proline' 0 N--CA 1.491 1.369 0 C-N-CA 121.676 1.584 . . . . 0.0 111.474 179.064 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.4 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 63.9 m-20 50.52 35.36 11.15 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.702 -0.681 . . . . 0.0 109.874 -179.987 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 68.3 mmm -150.26 122.05 8.11 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.416 0.627 . . . . 0.0 110.485 -179.711 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.449 ' SG ' ' C ' ' A' ' 93' ' ' PHE . 0.7 OUTLIER -120.79 161.64 21.13 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.059 179.65 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.5 m -127.75 127.45 43.64 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 115.752 -0.658 . . . . 0.0 109.693 179.928 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -95.94 156.7 36.9 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 116.465 -0.334 . . . . 0.0 110.24 -179.476 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_exo -50.89 -26.2 17.55 Favored 'Trans proline' 0 N--CA 1.497 1.711 0 C-N-CA 122.252 1.968 . . . . 0.0 111.896 177.975 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.12 -17.76 64.92 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-O 120.859 0.361 . . . . 0.0 110.489 -179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.1 -16.43 53.85 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.909 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.3 tp60 -63.91 150.34 45.2 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.909 0.385 . . . . 0.0 110.07 -179.844 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.9 mt -129.49 131.14 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.407 0 CA-C-N 116.051 -0.522 . . . . 0.0 110.544 179.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.641 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -179.51 174.5 0.47 Allowed Pre-proline 0 CA--C 1.535 0.394 0 C-N-CA 120.801 -0.36 . . . . 0.0 110.558 178.798 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.641 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 40.6 Cg_exo -57.32 -22.03 47.39 Favored 'Trans proline' 0 N--CA 1.498 1.772 0 C-N-CA 122.708 2.272 . . . . 0.0 111.751 179.009 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.5 p -140.16 159.98 40.98 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.754 -179.811 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.43 -32.01 48.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.021 -0.536 . . . . 0.0 110.452 179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -175.85 -178.37 45.61 Favored Glycine 0 CA--C 1.522 0.494 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 93.2 p -82.16 -6.42 59.18 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.659 0.266 . . . . 0.0 110.526 179.891 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.409 ' O ' ' O ' ' A' ' 115' ' ' SER . 75.9 ttt180 -65.73 123.62 20.23 Favored 'General case' 0 C--N 1.329 -0.316 0 N-CA-C 109.831 -0.433 . . . . 0.0 109.831 -179.876 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.45 ' O ' ' OG ' ' A' ' 115' ' ' SER . 14.2 p 38.31 93.17 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.926 -179.735 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 45.4 pt -96.57 -4.56 10.03 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.208 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.715 -179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 77.6 mt-30 -69.78 130.65 42.88 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.411 179.995 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.425 ' CG ' ' N ' ' A' ' 119' ' ' CYS . 47.1 p-80 -65.91 -44.45 85.17 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.255 -0.429 . . . . 0.0 110.471 -179.839 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.425 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 14.9 m -138.57 138.78 38.26 Favored 'General case' 0 N--CA 1.465 0.322 0 CA-C-O 120.998 0.428 . . . . 0.0 110.974 179.617 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.1 m-20 -65.11 -40.55 94.67 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.26 179.357 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 25.3 pt -92.8 -170.83 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.232 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.624 179.608 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 93.3 mtt-85 -107.53 108.56 19.92 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 115.983 -0.553 . . . . 0.0 111.215 -179.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 57.7 m -114.81 139.39 49.78 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.992 178.671 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 90.0 mtp -138.97 168.23 20.28 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.266 -178.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.525 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 2.4 m-20 59.56 41.75 18.47 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.487 -0.324 . . . . 0.0 111.249 179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.7 20.21 79.6 Favored Glycine 0 CA--C 1.52 0.375 0 N-CA-C 111.017 -0.833 . . . . 0.0 111.017 179.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -72.23 156.57 52.35 Favored Glycine 0 CA--C 1.523 0.54 0 N-CA-C 110.683 -0.967 . . . . 0.0 110.683 179.779 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 47.4 m -133.29 146.64 51.55 Favored 'General case' 0 N--CA 1.464 0.271 0 CA-C-O 120.733 0.301 . . . . 0.0 110.247 179.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 7.6 p -91.53 130.1 37.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.377 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.6 t -148.11 137.69 22.31 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.058 179.136 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' O ' ' OD2' ' A' ' 131' ' ' ASP . 3.7 p-10 45.01 41.29 5.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.461 -0.336 . . . . 0.0 111.006 179.562 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 32.5 t0 62.0 36.69 15.4 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.637 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 69.1 t60 -150.02 140.59 22.52 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.585 179.657 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 9.4 t -88.55 130.92 35.13 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-O 120.889 0.376 . . . . 0.0 110.48 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.6 mt -105.4 130.51 53.48 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.083 -0.508 . . . . 0.0 109.741 179.9 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 15.6 m -101.88 145.39 29.29 Favored 'General case' 0 N--CA 1.461 0.122 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.518 -179.455 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.89 175.39 9.55 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.053 -0.521 . . . . 0.0 110.742 179.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 60.9 tttp -66.14 129.92 41.47 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.54 179.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.84 -20.06 44.96 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 111.156 -0.778 . . . . 0.0 111.156 179.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -120.28 134.57 55.24 Favored 'General case' 0 N--CA 1.468 0.455 0 CA-C-O 120.792 0.329 . . . . 0.0 110.235 179.532 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 44.9 pt -132.93 173.32 15.02 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.227 -179.577 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 107.01 164.29 22.18 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.775 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 43.5 p -61.4 -44.78 96.54 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-O 120.754 0.311 . . . . 0.0 110.491 -179.648 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 3.0 p-80 -98.52 14.41 28.39 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.431 179.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.525 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 5.2 m 46.39 43.4 11.78 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.11 -179.835 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -106.74 12.31 42.1 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.991 -0.844 . . . . 0.0 110.991 -179.578 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 41.3 tt0 -121.45 119.28 29.44 Favored Pre-proline 0 CA--C 1.545 0.78 0 CA-C-N 116.63 0.215 . . . . 0.0 110.972 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 96.0 Cg_endo -76.44 157.69 36.7 Favored 'Trans proline' 0 N--CA 1.497 1.69 0 C-N-CA 122.676 2.25 . . . . 0.0 112.266 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 89.0 t -99.31 111.19 28.26 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.246 0 CA-C-O 121.015 0.436 . . . . 0.0 110.653 179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.53 90.63 8.08 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 179.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.0 tt0 -70.18 -39.15 75.42 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.546 -179.336 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . 0.415 ' O ' ' O ' ' A' ' 153' ' ' GLY . 10.6 m -88.39 -12.9 41.95 Favored 'General case' 0 N--CA 1.465 0.281 0 CA-C-N 116.347 -0.388 . . . . 0.0 111.167 -179.832 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.415 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.65 161.4 0.02 OUTLIER Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.731 -0.948 . . . . 0.0 110.731 -179.869 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 160' ' ' CYS . 25.6 m -106.55 159.18 16.37 Favored 'General case' 0 C--N 1.331 -0.206 0 N-CA-C 109.693 -0.484 . . . . 0.0 109.693 -179.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . 0.42 ' O ' ' CB ' ' A' ' 156' ' ' ASN . 56.7 mt -62.37 -42.87 99.75 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.244 -178.46 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.42 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 t-20 161.67 -58.92 0.0 OUTLIER 'General case' 0 N--CA 1.468 0.435 0 O-C-N 123.747 0.654 . . . . 0.0 110.61 179.741 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.03 -42.21 99.72 Favored Glycine 0 CA--C 1.521 0.449 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -178.947 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -71.41 168.83 50.56 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.575 -1.01 . . . . 0.0 110.575 179.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 22.8 mmm180 -130.03 149.07 51.91 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-O 120.912 0.386 . . . . 0.0 110.21 -179.456 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . 0.638 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 87.9 m -81.15 95.16 6.8 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.668 -179.738 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 41.6 t -79.48 -47.86 21.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 C-N-CA 120.583 -0.447 . . . . 0.0 110.577 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.676 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.24 177.79 2.06 Favored Pre-proline 0 CA--C 1.533 0.295 0 CA-C-N 116.529 -0.305 . . . . 0.0 110.341 -179.223 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.676 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -55.08 134.85 66.07 Favored 'Trans proline' 0 N--CA 1.493 1.467 0 C-N-CA 121.833 1.689 . . . . 0.0 111.597 179.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 5.8 m-20 40.78 33.53 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.948 179.258 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.5 ttt85 -132.7 104.49 6.66 Favored 'General case' 0 C--O 1.238 0.465 0 CA-C-O 121.364 0.602 . . . . 0.0 111.316 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 57.3 m -92.16 132.15 36.85 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.151 179.298 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -92.7 141.1 28.84 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.956 -0.566 . . . . 0.0 110.029 179.919 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.4 m -90.99 132.87 35.72 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 121.098 0.475 . . . . 0.0 110.757 -179.733 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.9 m -63.64 -46.29 86.35 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.689 -0.687 . . . . 0.0 111.496 -179.269 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 95.1 m-85 -104.36 24.04 12.22 Favored 'General case' 0 CA--C 1.52 -0.21 0 CA-C-O 120.952 0.405 . . . . 0.0 111.246 -179.059 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 62.42 29.86 74.58 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.69 -0.964 . . . . 0.0 110.69 179.569 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 1.2 m-85 -54.67 168.0 0.31 Allowed 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 121.04 0.448 . . . . 0.0 110.508 -179.55 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.4 p -81.89 164.66 21.42 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.749 -0.66 . . . . 0.0 110.217 -179.526 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.06 151.81 0.14 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.85 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -67.77 -24.8 40.29 Favored 'Trans proline' 0 N--CA 1.497 1.717 0 C-N-CA 122.375 2.05 . . . . 0.0 112.232 -179.633 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.432 ' O ' ' O ' ' A' ' 177' ' ' CYS . 85.2 mt-30 -84.09 -11.38 56.77 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.556 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.432 ' O ' ' O ' ' A' ' 176' ' ' GLN . 10.1 m 59.56 124.5 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.47 179.964 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 . . . . . 0 C--O 1.219 -0.501 0 CA-C-O 117.945 -1.026 . . . . 0.0 110.414 179.592 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 64.8 m . . . . . 0 N--CA 1.489 1.492 0 N-CA-C 109.377 -0.601 . . . . 0.0 109.377 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 48.11 46.97 19.5 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.443 -179.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 88.5 mtm-85 50.87 81.12 0.07 Allowed 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.59 -179.981 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -175.32 -169.91 37.64 Favored Glycine 0 CA--C 1.526 0.748 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 143.28 -10.57 2.24 Favored Glycine 0 CA--C 1.524 0.613 0 N-CA-C 110.856 -0.897 . . . . 0.0 110.856 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 62.23 -129.22 42.96 Favored Glycine 0 CA--C 1.527 0.795 0 N-CA-C 110.886 -0.886 . . . . 0.0 110.886 179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 86.21 5.18 83.19 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 -179.934 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 89.5 m-70 -86.8 -9.17 56.45 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-O 120.737 0.303 . . . . 0.0 110.637 179.742 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -85.42 112.03 20.49 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.971 0.415 . . . . 0.0 110.625 -179.814 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -62.33 -28.41 69.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.518 179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.405 HD12 ' HB1' ' A' ' 65' ' ' ALA . 96.2 mt -68.98 143.73 54.31 Favored 'General case' 0 N--CA 1.451 -0.39 0 CA-C-O 120.995 0.426 . . . . 0.0 110.421 -179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -131.72 161.73 32.14 Favored 'General case' 0 C--O 1.237 0.419 0 CA-C-N 115.674 -0.694 . . . . 0.0 110.565 -179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 72.79 172.73 22.25 Favored Glycine 0 CA--C 1.529 0.962 0 N-CA-C 110.56 -1.016 . . . . 0.0 110.56 -179.653 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 42.7 Cg_endo -68.52 -167.46 0.18 Allowed 'Trans proline' 0 N--CA 1.495 1.605 0 C-N-CA 122.924 2.416 . . . . 0.0 111.885 179.787 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.581 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 5.2 m120 58.2 37.0 26.2 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.535 179.628 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.481 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 13.3 p -100.41 134.15 41.11 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.266 0 CA-C-N 116.174 -0.467 . . . . 0.0 109.95 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 57.6 m -142.98 177.46 8.34 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.275 -179.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 82.55 162.64 31.83 Favored Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.789 -0.924 . . . . 0.0 110.789 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.517 ' O ' ' N ' ' A' ' 65' ' ' ALA . 11.8 m -80.46 173.72 12.31 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.628 0.252 . . . . 0.0 110.465 179.778 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.6 ttt180 -60.6 -44.12 96.64 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.74 -179.903 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -64.72 -39.26 93.34 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 116.335 -0.393 . . . . 0.0 111.094 179.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.421 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 58.6 t30 -125.39 51.12 1.73 Allowed 'General case' 0 CA--C 1.522 -0.113 0 CA-C-N 115.996 -0.547 . . . . 0.0 110.819 -179.268 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.517 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.5 142.52 50.15 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.94 -0.573 . . . . 0.0 110.466 179.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.421 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 10.2 p90 -160.2 167.54 27.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 121.219 0.533 . . . . 0.0 111.189 179.613 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.547 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 74.6 m -71.13 141.22 50.78 Favored 'General case' 0 C--N 1.327 -0.406 0 C-N-CA 120.347 -0.541 . . . . 0.0 110.35 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.481 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 65.2 m -58.94 150.85 58.44 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.973 -179.65 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 17.8 Cg_endo -56.0 128.56 30.76 Favored 'Trans proline' 0 N--CA 1.495 1.571 0 C-N-CA 121.835 1.69 . . . . 0.0 112.037 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 105.16 -10.1 47.02 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.302 -0.719 . . . . 0.0 111.302 -179.604 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.581 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.3 m95 -125.39 135.29 52.24 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-O 121.025 0.441 . . . . 0.0 110.527 179.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -119.76 -177.36 3.37 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-N 115.606 -0.724 . . . . 0.0 110.437 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.547 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 19.2 p -129.24 165.6 21.07 Favored 'General case' 0 N--CA 1.467 0.395 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.285 -179.452 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 64.5 mt -84.46 149.89 55.82 Favored Pre-proline 0 C--N 1.328 -0.363 0 CA-C-N 116.296 -0.411 . . . . 0.0 110.723 -179.889 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_exo -43.02 120.46 1.94 Allowed 'Trans proline' 0 N--CA 1.489 1.242 0 C-N-CA 121.881 1.721 . . . . 0.0 112.312 179.223 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.4 -0.25 55.41 Favored Glycine 0 CA--C 1.527 0.825 0 N-CA-C 110.901 -0.879 . . . . 0.0 110.901 179.41 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -89.84 171.17 37.27 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 179.98 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 53.4 p30 -136.64 2.15 2.64 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 121.038 0.447 . . . . 0.0 110.836 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 63.6 mt-30 -82.22 131.66 35.23 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.191 179.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.3 m -99.21 43.49 1.06 Allowed 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.889 -0.411 . . . . 0.0 109.889 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -98.89 2.68 10.49 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.358 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.362 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.5 t -100.61 110.37 60.25 Favored Pre-proline 0 CA--C 1.537 0.452 0 C-N-CA 120.831 -0.348 . . . . 0.0 110.611 -179.519 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 66.0 Cg_endo -73.39 158.52 48.11 Favored 'Trans proline' 0 N--CA 1.495 1.592 0 C-N-CA 122.202 1.934 . . . . 0.0 112.226 -179.651 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -104.14 124.74 58.76 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.081 179.837 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.6 m -90.55 127.2 36.18 Favored 'General case' 0 N--CA 1.465 0.29 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 179.746 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -62.94 -45.29 93.15 Favored 'General case' 0 CA--C 1.539 0.553 0 N-CA-C 109.5 -0.556 . . . . 0.0 109.5 179.922 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 83.5 m-70 -136.81 154.96 50.39 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.739 179.756 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 17.0 m -60.08 136.39 58.0 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.967 -0.561 . . . . 0.0 110.321 -179.451 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 111' ' ' CYS . 1.8 t -94.03 4.04 54.47 Favored 'General case' 0 N--CA 1.463 0.175 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.562 179.437 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 61.73 -100.02 0.25 Allowed Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.96 -0.856 . . . . 0.0 110.96 179.628 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.402 ' OD1' ' SG ' ' A' ' 102' ' ' CYS . 37.7 p30 -90.73 8.47 34.41 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-O 120.699 0.285 . . . . 0.0 110.838 -179.635 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.87 -173.46 29.15 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.58 -1.008 . . . . 0.0 110.58 179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.433 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -142.41 154.16 44.36 Favored 'General case' 0 N--CA 1.467 0.381 0 CA-C-O 121.073 0.464 . . . . 0.0 110.9 179.789 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 81.8 m -72.15 106.42 4.36 Favored 'General case' 0 CA--C 1.516 -0.331 0 CA-C-N 115.756 -0.657 . . . . 0.0 110.804 -179.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.433 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 2.1 m -95.9 -24.3 16.48 Favored 'General case' 0 CA--C 1.514 -0.435 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.671 -179.61 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.9 mtm-85 -159.96 167.17 14.49 Favored Pre-proline 0 C--N 1.327 -0.385 0 C-N-CA 120.783 -0.367 . . . . 0.0 110.891 -179.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -51.96 125.4 17.07 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.73 1.62 . . . . 0.0 111.311 178.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 98.8 m-20 50.81 34.7 10.64 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.511 -0.768 . . . . 0.0 109.552 179.679 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 64.2 mmm -149.69 124.13 9.65 Favored 'General case' 0 C--O 1.235 0.329 0 CA-C-O 121.286 0.565 . . . . 0.0 110.614 -179.319 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 10.1 p -123.92 163.58 21.03 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.811 -0.631 . . . . 0.0 109.794 179.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 94.8 m -125.46 130.63 52.19 Favored 'General case' 0 CA--C 1.51 -0.567 0 CA-C-N 115.915 -0.584 . . . . 0.0 109.705 -179.008 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.402 ' SG ' ' OD1' ' A' ' 91' ' ' ASP . 0.1 OUTLIER -94.28 155.74 39.56 Favored Pre-proline 0 CA--C 1.541 0.607 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.363 -179.709 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 69.9 Cg_exo -48.01 -29.6 12.39 Favored 'Trans proline' 0 N--CA 1.496 1.673 0 C-N-CA 122.443 2.095 . . . . 0.0 112.133 177.368 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 37.5 m -62.63 -19.87 64.22 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-O 120.975 0.417 . . . . 0.0 110.688 179.821 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.93 -7.4 57.27 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.754 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 50.2 tt0 -70.94 152.0 44.09 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-O 120.995 0.426 . . . . 0.0 110.168 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.36 131.55 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.42 0 CA-C-N 115.901 -0.59 . . . . 0.0 110.57 179.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.643 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.67 178.22 0.55 Allowed Pre-proline 0 CA--C 1.536 0.44 0 C-N-CA 120.426 -0.51 . . . . 0.0 110.584 178.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.643 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 31.6 Cg_exo -59.97 -18.57 50.84 Favored 'Trans proline' 0 N--CA 1.5 1.911 0 C-N-CA 122.794 2.329 . . . . 0.0 111.588 178.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.4 p -149.6 164.65 34.54 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.5 -179.396 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . 1.056 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 0.5 OUTLIER -79.42 132.1 36.28 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.5 -179.531 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 113' ' ' SER . . . 50.92 -176.46 0.06 OUTLIER Glycine 0 CA--C 1.521 0.45 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.204 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.475 ' O ' ' O ' ' A' ' 112' ' ' GLY . 2.4 p 58.09 132.91 0.0 OUTLIER 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.897 0.38 . . . . 0.0 110.637 -179.934 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -99.66 135.01 41.71 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.293 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 20.3 m -71.07 143.09 50.8 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.385 -179.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 95.0 mt -64.13 -44.26 97.58 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.301 -0.408 . . . . 0.0 110.711 179.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 64.9 tt0 -169.23 145.23 3.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.621 -179.662 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 60.9 t-80 -66.07 -44.98 82.92 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.679 179.932 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 95.2 m -80.36 97.34 7.0 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.182 179.818 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 11.4 m120 -63.91 -40.08 95.67 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.45 -179.93 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.41 HG22 ' N ' ' A' ' 122' ' ' ARG . 21.0 mm -80.7 160.23 4.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.152 -179.98 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.41 ' N ' HG22 ' A' ' 121' ' ' ILE . 88.8 mmt-85 -81.73 98.52 8.46 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.184 -179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -105.64 122.24 45.63 Favored 'General case' 0 C--N 1.33 -0.253 0 N-CA-C 109.231 -0.655 . . . . 0.0 109.231 179.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -141.78 167.63 21.69 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.09 -0.504 . . . . 0.0 109.845 -179.874 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.19 37.95 23.7 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.842 179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 80.79 22.29 61.96 Favored Glycine 0 CA--C 1.522 0.485 0 N-CA-C 110.882 -0.887 . . . . 0.0 110.882 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.06 119.25 9.44 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.771 -0.932 . . . . 0.0 110.771 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 7.3 m -80.2 138.59 36.88 Favored 'General case' 0 C--N 1.328 -0.353 0 C-N-CA 120.836 -0.346 . . . . 0.0 110.487 179.611 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 22.6 m -91.08 128.48 36.92 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.774 0.321 . . . . 0.0 110.378 179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.408 ' O ' ' C ' ' A' ' 131' ' ' ASP . 69.4 m -141.6 140.02 33.24 Favored 'General case' 0 C--N 1.331 -0.218 0 N-CA-C 109.843 -0.429 . . . . 0.0 109.843 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.408 ' C ' ' O ' ' A' ' 130' ' ' SER . 97.2 m-20 36.11 -97.15 0.02 OUTLIER 'General case' 0 N--CA 1.463 0.184 0 CA-C-N 116.139 -0.482 . . . . 0.0 110.965 -179.964 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 -136.02 22.25 3.27 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.728 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 78.4 m80 -132.48 147.04 52.36 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-N 116.496 -0.32 . . . . 0.0 110.496 -179.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 1.1 m -98.98 125.65 44.49 Favored 'General case' 0 CA--C 1.529 0.144 0 CA-C-N 116.201 -0.454 . . . . 0.0 109.861 179.621 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.1 mt -103.9 131.53 51.03 Favored 'General case' 0 C--N 1.33 -0.26 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -99.37 143.69 29.34 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.043 -0.526 . . . . 0.0 110.738 -179.576 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.1 mt-30 -68.19 -174.77 0.53 Allowed 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.319 -179.906 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 27.8 tptp -69.02 132.09 46.09 Favored 'General case' 0 C--N 1.323 -0.566 0 C-N-CA 120.488 -0.485 . . . . 0.0 110.541 -179.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 96.93 -8.4 65.37 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 111.005 -0.838 . . . . 0.0 111.005 179.63 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -118.58 136.29 53.95 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-O 120.856 0.36 . . . . 0.0 110.559 179.505 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.7 pt -134.29 172.47 16.15 Favored 'Isoleucine or valine' 0 C--O 1.236 0.379 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.064 -179.996 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 104.42 160.73 24.19 Favored Glycine 0 N--CA 1.461 0.342 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . 0.436 ' H ' HG22 ' A' ' 143' ' ' THR . 0.1 OUTLIER -65.34 -42.74 92.55 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 120.738 0.304 . . . . 0.0 110.547 -179.897 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 46.8 m-70 -97.13 5.17 50.69 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.408 -179.515 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 31.0 m 58.12 37.31 26.38 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 115.852 -0.613 . . . . 0.0 110.371 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -100.73 5.28 56.67 Favored Glycine 0 CA--C 1.519 0.305 0 N-CA-C 110.836 -0.906 . . . . 0.0 110.836 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 11.8 tt0 -119.8 107.8 39.83 Favored Pre-proline 0 CA--C 1.547 0.832 0 CA-C-N 116.801 0.3 . . . . 0.0 110.601 179.941 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 84.2 Cg_endo -78.23 159.85 29.71 Favored 'Trans proline' 0 N--CA 1.492 1.383 0 C-N-CA 122.65 2.233 . . . . 0.0 112.127 179.409 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 94.4 t -97.88 105.18 16.87 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -86.47 100.04 12.08 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.257 -0.429 . . . . 0.0 110.657 -179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -66.29 -45.57 79.97 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.3 -0.409 . . . . 0.0 111.283 -179.494 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . 0.443 ' O ' ' O ' ' A' ' 153' ' ' GLY . 23.4 t -89.53 -16.7 30.1 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-O 120.702 0.287 . . . . 0.0 110.883 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.443 ' O ' ' O ' ' A' ' 152' ' ' SER . . . 56.49 156.15 0.01 OUTLIER Glycine 0 CA--C 1.523 0.564 0 N-CA-C 110.704 -0.958 . . . . 0.0 110.704 -179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 10.9 m -93.95 133.08 37.76 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 64.3 mt -62.31 -43.9 97.76 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 120.775 -0.37 . . . . 0.0 111.189 -179.002 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 178.23 -60.79 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.278 0 O-C-N 123.615 0.572 . . . . 0.0 110.52 179.632 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.84 51.13 1.54 Allowed Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 -179.861 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -166.82 154.62 25.18 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.909 -0.876 . . . . 0.0 110.909 179.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.9 ttt85 -123.25 129.32 51.21 Favored 'General case' 0 N--CA 1.464 0.265 0 N-CA-C 110.268 -0.271 . . . . 0.0 110.268 -179.849 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 2.4 t -75.33 102.84 5.23 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-O 121.068 0.461 . . . . 0.0 110.69 -179.86 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 161' ' ' VAL . 4.6 p -107.34 -2.91 10.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.378 0 CA-C-N 115.792 -0.64 . . . . 0.0 110.412 -179.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.626 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.6 171.65 4.47 Favored Pre-proline 0 C--N 1.322 -0.599 0 C-N-CA 120.158 -0.617 . . . . 0.0 110.581 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.626 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.6 Cg_exo -52.15 128.8 28.52 Favored 'Trans proline' 0 C--N 1.313 -1.313 0 C-N-CA 121.773 1.649 . . . . 0.0 111.395 178.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 40.93 36.14 0.4 Allowed 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.682 179.574 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.528 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.8 OUTLIER -127.07 110.27 12.76 Favored 'General case' 0 C--O 1.237 0.429 0 CA-C-O 121.228 0.537 . . . . 0.0 110.409 -179.447 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.528 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 66.5 m -105.07 124.64 49.89 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.751 178.889 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -85.09 91.06 8.01 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.88 -0.6 . . . . 0.0 109.655 179.601 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.23 118.11 35.91 Favored 'General case' 0 N--CA 1.466 0.356 0 N-CA-C 109.767 -0.457 . . . . 0.0 109.767 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.436 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.4 OUTLIER -111.27 11.36 21.7 Favored 'General case' 0 N--CA 1.469 0.504 0 CA-C-N 115.999 -0.546 . . . . 0.0 110.63 -179.529 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.529 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 47.2 t80 -109.07 31.28 5.83 Favored 'General case' 0 C--N 1.323 -0.555 0 CA-C-N 115.59 -0.732 . . . . 0.0 111.153 -179.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 105.91 58.76 0.63 Allowed Glycine 0 N--CA 1.465 0.606 0 N-CA-C 110.761 -0.936 . . . . 0.0 110.761 179.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 82.1 t80 -53.02 126.12 19.53 Favored 'General case' 0 C--N 1.329 -0.311 0 C-N-CA 120.534 -0.467 . . . . 0.0 110.325 -179.156 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.444 ' O ' ' O ' ' A' ' 174' ' ' GLY . 3.0 t -149.09 150.37 32.64 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.498 179.677 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.444 ' O ' ' O ' ' A' ' 173' ' ' THR . . . 53.36 165.85 0.01 OUTLIER Glycine 0 CA--C 1.53 0.986 0 N-CA-C 110.987 -0.845 . . . . 0.0 110.987 179.795 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -68.09 -18.66 45.73 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.83 2.353 . . . . 0.0 112.112 -179.924 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.8 mt-30 -92.15 47.9 1.37 Allowed 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.094 -178.817 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 173' ' ' THR . 53.2 t 57.88 -89.27 0.02 OUTLIER 'General case' 0 N--CA 1.462 0.17 0 CA-C-N 116.443 -0.344 . . . . 0.0 110.697 179.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 80.0 mm-40 . . . . . 0 C--O 1.221 -0.427 0 CA-C-O 117.998 -1.001 . . . . 0.0 110.483 179.572 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 80.8 p . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.39 -0.596 . . . . 0.0 109.39 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.67 141.17 58.87 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.316 -0.402 . . . . 0.0 110.214 179.946 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 72.8 ttt180 -128.97 127.68 42.19 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.311 -179.804 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -98.11 177.13 31.1 Favored Glycine 0 CA--C 1.522 0.529 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 179.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -82.22 -146.12 5.69 Favored Glycine 0 CA--C 1.524 0.636 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.782 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -169.16 169.09 41.7 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.874 -0.891 . . . . 0.0 110.874 179.854 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 85.03 104.86 0.65 Allowed Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.954 -0.858 . . . . 0.0 110.954 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 14.0 p80 -155.7 159.73 39.77 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-O 120.681 0.277 . . . . 0.0 110.41 179.867 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 99.8 m-20 -92.21 108.95 20.32 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.211 179.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.518 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -102.61 156.35 17.68 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.443 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.469 HD12 ' HB1' ' A' ' 65' ' ' ALA . 88.9 mt -74.02 141.24 45.81 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.724 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.7 mttm -125.44 160.67 28.87 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.853 -0.612 . . . . 0.0 110.355 179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.18 174.8 38.37 Favored Glycine 0 CA--C 1.529 0.911 0 N-CA-C 110.843 -0.903 . . . . 0.0 110.843 -179.517 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.2 Cg_endo -73.47 -169.36 0.52 Allowed 'Trans proline' 0 C--N 1.308 -1.558 0 C-N-CA 122.991 2.461 . . . . 0.0 111.627 179.876 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 57.52 38.56 28.07 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.907 179.729 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.42 ' O ' HG13 ' A' ' 58' ' ' VAL . 12.0 p -99.91 130.8 48.48 Favored 'Isoleucine or valine' 0 C--O 1.231 0.125 0 N-CA-C 109.93 -0.396 . . . . 0.0 109.93 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . 0.438 ' O ' ' O ' ' A' ' 66' ' ' TYR . 52.7 m -145.64 175.58 10.27 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.613 -178.869 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 91.23 167.1 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.978 -0.849 . . . . 0.0 110.978 -179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.551 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -75.06 165.04 25.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.623 0.249 . . . . 0.0 110.391 -179.865 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.8 ttt180 -60.89 -44.2 97.44 Favored 'General case' 0 C--N 1.325 -0.465 0 CA-C-N 116.4 -0.363 . . . . 0.0 110.653 179.968 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -66.24 -39.24 89.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.955 179.747 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.8 t30 -123.84 49.91 1.69 Allowed 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.645 -179.534 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.551 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.95 143.88 50.73 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-N 116.066 -0.515 . . . . 0.0 110.47 -179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.438 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -159.38 166.59 30.77 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.247 -0.433 . . . . 0.0 110.991 179.204 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 53.9 m -72.66 133.24 44.54 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.123 -0.49 . . . . 0.0 109.763 -179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -45.62 162.52 0.23 Allowed Pre-proline 0 CA--C 1.538 0.494 0 N-CA-C 110.197 -0.298 . . . . 0.0 110.197 -179.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 14.0 Cg_endo -55.12 134.36 63.32 Favored 'Trans proline' 0 N--CA 1.495 1.604 0 C-N-CA 122.547 2.165 . . . . 0.0 111.68 179.762 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 95.65 -14.67 64.5 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.888 -0.885 . . . . 0.0 110.888 -179.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 89.3 m95 -115.88 141.64 47.83 Favored 'General case' 0 N--CA 1.466 0.331 0 CA-C-O 120.81 0.338 . . . . 0.0 110.239 179.824 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -125.7 -157.99 0.82 Allowed 'General case' 0 N--CA 1.466 0.326 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.138 179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 73.3 p -127.23 164.46 21.64 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-N 116.217 -0.447 . . . . 0.0 109.945 179.709 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.506 ' O ' ' N ' ' A' ' 77' ' ' GLY . 14.2 mt -87.09 152.05 52.57 Favored Pre-proline 0 C--N 1.328 -0.364 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.925 -179.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.414 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.7 Cg_exo -40.66 105.98 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.385 0 C-N-CA 122.146 1.897 . . . . 0.0 111.939 179.208 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 74.65 -12.33 6.19 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.898 -0.881 . . . . 0.0 110.898 179.721 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.506 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.05 176.65 53.89 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.727 -0.949 . . . . 0.0 110.727 179.954 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.518 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 44.9 p30 -134.66 11.22 3.72 Favored 'General case' 0 N--CA 1.466 0.326 0 CA-C-O 120.803 0.335 . . . . 0.0 110.744 -179.905 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -82.37 130.62 35.14 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.474 -179.825 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 79.7 m -90.96 47.66 1.43 Allowed 'General case' 0 N--CA 1.463 0.207 0 CA-C-O 120.811 0.339 . . . . 0.0 110.308 179.906 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 38.4 pt -107.39 24.38 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.393 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.877 -179.636 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.49 94.07 48.62 Favored Pre-proline 0 CA--C 1.537 0.449 0 CA-C-N 116.489 -0.323 . . . . 0.0 110.249 -179.586 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -79.85 156.82 24.05 Favored 'Trans proline' 0 C--N 1.31 -1.448 0 C-N-CA 122.463 2.108 . . . . 0.0 111.981 179.678 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.1 mt -101.99 125.77 56.09 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.265 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.025 179.545 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -101.03 119.28 38.52 Favored 'General case' 0 N--CA 1.465 0.312 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -45.37 94.74 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 120.969 0.414 . . . . 0.0 109.981 -179.772 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 94.4 m-70 -114.09 144.59 42.89 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.533 179.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.9 m -62.51 134.99 57.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.964 -0.562 . . . . 0.0 110.249 -179.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 37.8 m -77.16 -31.72 55.71 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.633 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.08 -106.78 2.26 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.061 -0.816 . . . . 0.0 111.061 179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.3 m-20 -72.42 -8.01 52.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.664 0.269 . . . . 0.0 110.719 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.88 -161.48 18.81 Favored Glycine 0 N--CA 1.463 0.46 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 179.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.513 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 52.7 p90 -146.84 153.06 39.71 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 121.028 0.442 . . . . 0.0 110.755 179.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.2 m -66.25 114.56 5.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.28 -179.748 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.513 ' OG ' ' CE2' ' A' ' 93' ' ' PHE . 75.7 m -105.11 -22.54 13.07 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.443 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 3.0 mtt180 -156.34 160.95 30.41 Favored Pre-proline 0 CA--C 1.532 0.27 0 C-N-CA 120.576 -0.45 . . . . 0.0 110.796 179.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -47.47 118.24 2.81 Favored 'Trans proline' 0 N--CA 1.491 1.328 0 C-N-CA 122.138 1.892 . . . . 0.0 111.519 179.04 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 3.9 t-20 54.27 41.67 31.87 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.344 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 77.0 mtp -148.33 120.13 8.12 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.367 179.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.47 ' N ' ' O ' ' A' ' 108' ' ' ALA . 46.5 m -103.75 148.95 25.47 Favored 'General case' 0 N--CA 1.462 0.159 0 CA-C-N 115.714 -0.676 . . . . 0.0 110.831 179.382 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . 0.403 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 97.5 m -118.51 123.06 44.2 Favored 'General case' 0 CA--C 1.515 -0.385 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 179.373 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.57 147.84 35.06 Favored Pre-proline 0 CA--C 1.541 0.598 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.651 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.3 Cg_exo -47.39 -23.97 3.69 Favored 'Trans proline' 0 N--CA 1.496 1.65 0 C-N-CA 122.636 2.224 . . . . 0.0 112.09 177.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.9 t -64.35 -17.3 63.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 116.406 -0.361 . . . . 0.0 110.767 -179.914 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.61 -14.99 56.26 Favored Glycine 0 CA--C 1.523 0.565 0 N-CA-C 110.816 -0.914 . . . . 0.0 110.816 -179.674 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 59.6 tp60 -73.08 152.25 41.31 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.896 0.379 . . . . 0.0 110.248 179.837 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 91.4 mt -126.59 131.95 70.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.942 -0.572 . . . . 0.0 110.546 179.921 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -174.05 173.32 1.2 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.448 179.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.658 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 49.4 Cg_exo -55.08 -28.37 60.07 Favored 'Trans proline' 0 N--CA 1.498 1.789 0 C-N-CA 122.719 2.279 . . . . 0.0 112.142 179.282 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 15.2 p -136.61 164.25 28.64 Favored 'General case' 0 N--CA 1.464 0.251 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.567 -179.459 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -79.05 145.68 33.71 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.648 -179.887 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -139.59 58.89 0.59 Allowed Glycine 0 CA--C 1.524 0.597 0 N-CA-C 110.664 -0.974 . . . . 0.0 110.664 179.892 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 85.8 p -66.26 -16.31 63.92 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-O 120.73 0.3 . . . . 0.0 110.209 179.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.5 mtt180 -44.51 125.52 4.81 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.629 -179.836 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 84.4 p -76.71 160.9 28.95 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.98 -0.554 . . . . 0.0 110.521 -179.982 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 96.5 mt -119.15 123.75 71.91 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.33 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.335 179.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -171.8 90.32 0.12 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.478 -179.961 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 57.0 m170 42.31 -162.8 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.299 -0.41 . . . . 0.0 110.557 179.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 93.7 m -94.65 134.33 37.34 Favored 'General case' 0 N--CA 1.463 0.181 0 CA-C-O 120.953 0.406 . . . . 0.0 110.7 179.6 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 1.6 t-20 -161.75 29.59 0.12 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.799 -179.706 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.442 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 18.5 tt -121.13 171.09 10.33 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.322 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.441 -179.238 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.442 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 27.2 mmt180 -95.86 127.46 41.9 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.874 -0.603 . . . . 0.0 109.928 179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 85.0 m -117.52 134.78 54.48 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-N 115.78 -0.646 . . . . 0.0 109.971 179.437 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtt -138.24 156.53 47.59 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.262 -0.426 . . . . 0.0 110.231 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 82.8 m-20 58.92 51.47 7.31 Favored 'General case' 0 C--N 1.333 -0.138 0 CA-C-N 116.402 -0.363 . . . . 0.0 111.059 -179.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 66.48 26.9 72.84 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 179.458 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.52 139.5 35.45 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.741 -0.944 . . . . 0.0 110.741 -179.862 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . 0.51 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 51.5 m -110.3 141.75 42.87 Favored 'General case' 0 N--CA 1.464 0.267 0 N-CA-C 110.223 -0.288 . . . . 0.0 110.223 179.868 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.2 t -85.01 126.16 33.31 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.915 0.388 . . . . 0.0 110.621 179.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.457 ' O ' ' O ' ' A' ' 133' ' ' HIS . 11.4 p -148.5 127.91 13.09 Favored 'General case' 0 C--O 1.233 0.191 0 CA-C-O 121.448 0.642 . . . . 0.0 111.01 179.527 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.444 ' O ' ' CB ' ' A' ' 132' ' ' ASP . 9.6 t70 50.18 42.79 25.8 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.893 -0.594 . . . . 0.0 110.562 179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.444 ' CB ' ' O ' ' A' ' 131' ' ' ASP . 9.5 t0 78.29 -40.68 0.29 Allowed 'General case' 0 C--O 1.232 0.165 0 CA-C-N 116.407 -0.361 . . . . 0.0 110.892 -179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.482 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 6.8 p80 -85.42 147.64 26.39 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-O 120.971 0.415 . . . . 0.0 110.531 -179.652 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.51 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.3 t -99.93 149.09 23.78 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.847 179.669 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 73.5 mt -111.5 137.27 49.54 Favored 'General case' 0 N--CA 1.464 0.229 0 N-CA-C 109.593 -0.521 . . . . 0.0 109.593 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.25 144.67 27.43 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.022 -0.535 . . . . 0.0 110.481 -179.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -59.95 176.13 0.33 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.306 -0.407 . . . . 0.0 110.658 -179.963 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 49.7 tttm -66.61 131.22 45.53 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.318 -0.401 . . . . 0.0 110.641 179.849 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 99.01 -15.86 60.1 Favored Glycine 0 CA--C 1.526 0.75 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 179.649 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -111.28 136.44 50.38 Favored 'General case' 0 N--CA 1.463 0.194 0 CA-C-O 120.791 0.329 . . . . 0.0 110.35 179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.1 pt -133.45 171.7 17.62 Favored 'Isoleucine or valine' 0 C--O 1.233 0.202 0 CA-C-N 116.113 -0.494 . . . . 0.0 109.973 -179.888 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.72 158.36 10.58 Favored Glycine 0 N--CA 1.464 0.551 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.637 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 98.6 m -62.53 -46.39 88.62 Favored 'General case' 0 C--N 1.326 -0.427 0 C-N-CA 120.916 -0.314 . . . . 0.0 110.715 -179.814 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 96.3 m-70 -105.28 11.82 32.48 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.491 -179.922 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 14.6 m 60.68 139.13 0.01 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 116.092 -0.504 . . . . 0.0 109.809 -179.624 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 153.13 -1.15 0.24 Allowed Glycine 0 CA--C 1.519 0.308 0 N-CA-C 110.977 -0.849 . . . . 0.0 110.977 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 43.4 tt0 -113.09 108.66 52.84 Favored Pre-proline 0 CA--C 1.542 0.669 0 C-N-CA 121.303 -0.159 . . . . 0.0 110.785 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 77.6 Cg_endo -77.43 159.32 32.61 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.676 2.25 . . . . 0.0 111.909 179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 81.9 t -120.81 120.49 62.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-O 121.009 0.433 . . . . 0.0 110.12 179.259 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 60.5 m -91.44 114.65 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.56 179.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 71.1 mm-40 -64.03 -42.22 97.16 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.88 -179.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.1 p -86.27 -6.36 58.98 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.532 179.796 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.11 166.31 0.11 Allowed Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.676 -0.97 . . . . 0.0 110.676 179.857 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 73.4 m -100.27 102.9 14.29 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.879 0.371 . . . . 0.0 110.067 179.524 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.8 mt -63.62 -41.98 98.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.012 -0.54 . . . . 0.0 110.552 -179.35 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.557 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.5 t30 -93.28 -176.97 4.3 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.387 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.523 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.79 23.25 0.41 Allowed Glycine 0 CA--C 1.526 0.756 0 N-CA-C 111.025 -0.83 . . . . 0.0 111.025 179.686 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.557 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.41 174.99 26.35 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.734 -0.946 . . . . 0.0 110.734 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 52.3 mmm-85 -127.42 147.12 50.29 Favored 'General case' 0 N--CA 1.463 0.205 0 CA-C-O 120.695 0.283 . . . . 0.0 110.449 -179.264 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 21.5 m -86.01 111.67 20.51 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.09 -179.805 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -97.16 -16.26 7.17 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.258 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.331 -179.76 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.633 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -168.34 173.65 2.56 Favored Pre-proline 0 C--N 1.326 -0.451 0 C-N-CA 120.435 -0.506 . . . . 0.0 110.71 179.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.633 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.7 Cg_exo -57.08 135.65 71.92 Favored 'Trans proline' 0 N--CA 1.495 1.588 0 C-N-CA 122.068 1.845 . . . . 0.0 112.029 179.294 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.8 t30 44.43 32.79 0.77 Allowed 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.837 179.295 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 99.4 mtt180 -142.86 101.0 3.77 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.386 0.612 . . . . 0.0 111.152 179.077 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 31.2 t -101.81 148.2 25.58 Favored 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.284 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.0 137.37 39.45 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.892 -0.595 . . . . 0.0 109.88 179.711 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 87.8 m -81.7 150.34 28.05 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.822 -179.621 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.4 m -61.72 -45.99 91.59 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.735 -179.358 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.541 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 53.3 t80 -110.36 25.71 11.48 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.058 0.456 . . . . 0.0 110.694 -179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 67.13 30.51 75.83 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.766 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.545 ' CD2' ' O ' ' A' ' 173' ' ' THR . 65.9 t80 -58.76 159.35 6.88 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-O 120.83 0.348 . . . . 0.0 110.444 -179.522 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.545 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 8.1 p -81.94 167.09 19.29 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.392 -179.458 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 104.36 142.0 11.36 Favored Glycine 0 CA--C 1.535 1.287 0 N-CA-C 111.007 -0.837 . . . . 0.0 111.007 179.485 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 54.4 Cg_endo -69.06 -33.01 20.23 Favored 'Trans proline' 0 N--CA 1.497 1.684 0 C-N-CA 122.524 2.149 . . . . 0.0 112.596 -179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.419 ' O ' ' O ' ' A' ' 177' ' ' CYS . 20.8 pt20 -108.05 1.15 22.2 Favored 'General case' 0 N--CA 1.467 0.393 0 CA-C-N 116.052 -0.522 . . . . 0.0 110.566 -179.466 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.419 ' O ' ' O ' ' A' ' 176' ' ' GLN . 1.1 t 57.17 159.8 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.07 -0.514 . . . . 0.0 110.421 -179.916 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 36.2 tp10 . . . . . 0 C--O 1.22 -0.477 0 CA-C-O 118.012 -0.994 . . . . 0.0 110.257 -179.922 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 30.0 m . . . . . 0 N--CA 1.491 1.624 0 N-CA-C 109.419 -0.586 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -66.74 146.28 54.63 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.734 -179.894 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 86.9 mtm180 45.59 31.93 1.05 Allowed 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.491 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -153.13 91.69 0.13 Allowed Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.974 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -88.24 134.95 12.76 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.783 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -104.22 118.64 6.03 Favored Glycine 0 N--CA 1.465 0.61 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 179.834 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 80.04 166.53 33.8 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.743 -0.943 . . . . 0.0 110.743 179.836 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 99.7 m-70 -103.91 -55.07 2.44 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.735 0.302 . . . . 0.0 110.447 179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 47.2 t0 -92.15 93.87 8.92 Favored 'General case' 0 C--N 1.333 -0.12 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.667 179.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -178.29 138.58 0.19 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.62 179.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 78.2 mt -78.57 149.04 33.1 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.967 179.607 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -138.5 159.84 41.07 Favored 'General case' 0 C--O 1.237 0.396 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.526 179.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 76.58 169.1 29.22 Favored Glycine 0 CA--C 1.528 0.893 0 N-CA-C 110.787 -0.925 . . . . 0.0 110.787 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -69.59 -168.79 0.28 Allowed 'Trans proline' 0 C--N 1.308 -1.579 0 C-N-CA 122.938 2.426 . . . . 0.0 111.821 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.626 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 46.4 m-80 59.35 41.04 20.33 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.743 -179.954 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.43 ' O ' HG13 ' A' ' 58' ' ' VAL . 11.4 p -105.33 131.69 54.03 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.286 0 N-CA-C 109.776 -0.453 . . . . 0.0 109.776 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 95.6 m -141.88 -175.45 4.41 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.128 -179.39 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 85.37 173.5 49.71 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.746 -0.941 . . . . 0.0 110.746 179.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.4 m -72.88 155.96 39.36 Favored 'General case' 0 C--N 1.329 -0.288 0 N-CA-C 110.133 -0.321 . . . . 0.0 110.133 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -58.99 -43.2 91.4 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-N 116.486 -0.325 . . . . 0.0 110.775 179.956 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -62.23 -41.87 98.8 Favored 'General case' 0 C--N 1.326 -0.421 0 CA-C-N 116.409 -0.36 . . . . 0.0 111.173 -179.83 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 7.8 m120 -127.74 50.65 2.01 Favored 'General case' 0 N--CA 1.454 -0.226 0 CA-C-O 120.912 0.387 . . . . 0.0 110.723 -179.562 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.03 151.36 47.19 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.28 179.849 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.1 p90 -154.67 164.94 38.01 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.158 179.433 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.434 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 69.0 m -63.41 128.99 38.33 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.136 -0.483 . . . . 0.0 109.783 -179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 12.4 m -48.53 150.92 2.18 Favored Pre-proline 0 C--N 1.325 -0.479 0 CA-C-N 116.283 -0.417 . . . . 0.0 111.34 -178.915 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.0 Cg_exo -50.61 133.5 38.37 Favored 'Trans proline' 0 N--CA 1.494 1.545 0 C-N-CA 121.572 1.514 . . . . 0.0 112.178 179.285 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 97.26 -7.94 64.42 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.717 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.626 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 54.6 m95 -118.89 138.71 52.57 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-O 120.934 0.397 . . . . 0.0 110.592 179.977 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.1 ptmt -127.83 -176.05 3.66 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.412 179.278 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.434 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 5.4 p -133.46 177.99 7.27 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.54 -179.346 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 48.6 mt -89.91 148.86 40.67 Favored Pre-proline 0 C--N 1.328 -0.34 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.507 -179.785 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.41 116.16 0.47 Allowed 'Trans proline' 0 N--CA 1.488 1.204 0 C-N-CA 122.108 1.872 . . . . 0.0 112.491 179.358 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.19 -4.56 54.3 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 111.262 -0.735 . . . . 0.0 111.262 179.257 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -86.33 171.1 43.59 Favored Glycine 0 CA--C 1.525 0.669 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.431 ' C ' ' ND2' ' A' ' 78' ' ' ASN . 0.5 OUTLIER -133.58 9.19 3.95 Favored 'General case' 0 N--CA 1.466 0.374 0 CA-C-O 120.977 0.418 . . . . 0.0 110.811 179.929 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 69.3 mt-30 -87.28 132.33 33.95 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.487 -179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 30.9 m -97.88 40.0 1.19 Allowed 'General case' 0 N--CA 1.467 0.412 0 N-CA-C 109.792 -0.447 . . . . 0.0 109.792 179.795 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 35.4 pt -97.24 12.93 4.42 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.418 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.855 -179.216 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 38.6 t -116.29 87.98 21.65 Favored Pre-proline 0 N--CA 1.464 0.234 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.471 -179.666 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_exo -60.69 148.87 90.23 Favored 'Trans proline' 0 N--CA 1.496 1.659 0 C-N-CA 122.819 2.346 . . . . 0.0 111.987 179.267 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 91.9 mt -89.17 123.55 41.46 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 179.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -98.47 110.1 22.74 Favored 'General case' 0 CA--C 1.533 0.305 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.17 -179.815 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 2.1 mpt_? -65.31 -39.08 92.03 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.025 0.441 . . . . 0.0 110.328 178.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 18.0 m-70 -119.05 143.36 47.15 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.104 179.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 8.7 p -60.86 134.46 57.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.397 -179.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 60.3 m -77.89 -28.07 49.78 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.706 179.507 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.4 -102.56 1.74 Allowed Glycine 0 CA--C 1.525 0.693 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 83.0 m-20 -89.19 2.37 54.32 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.658 0.266 . . . . 0.0 110.639 -179.714 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -106.29 -168.86 22.96 Favored Glycine 0 CA--C 1.524 0.63 0 N-CA-C 110.701 -0.96 . . . . 0.0 110.701 179.71 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.2 p90 -138.71 150.53 46.26 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 121.124 0.488 . . . . 0.0 110.854 179.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 90.8 m -65.89 112.86 3.99 Favored 'General case' 0 CA--C 1.512 -0.509 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.33 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 30.3 t -107.29 -25.87 11.29 Favored 'General case' 0 CA--C 1.511 -0.52 0 CA-C-N 115.634 -0.712 . . . . 0.0 110.467 -179.342 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 11.4 mtt-85 -158.09 164.3 21.79 Favored Pre-proline 0 C--N 1.328 -0.334 0 C-N-CA 120.311 -0.556 . . . . 0.0 110.66 179.87 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_exo -51.01 121.77 8.79 Favored 'Trans proline' 0 N--CA 1.491 1.335 0 C-N-CA 121.96 1.773 . . . . 0.0 111.485 178.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 40.9 t-20 52.09 40.83 29.35 Favored 'General case' 0 C--N 1.326 -0.456 0 N-CA-C 109.571 -0.529 . . . . 0.0 109.571 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 48.7 mtt -146.9 114.91 6.54 Favored 'General case' 0 C--O 1.24 0.583 0 CA-C-N 115.95 -0.568 . . . . 0.0 110.699 -179.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.472 ' N ' ' O ' ' A' ' 108' ' ' ALA . 65.3 m -100.05 146.84 26.29 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.232 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 66.6 m -115.61 121.6 43.09 Favored 'General case' 0 CA--C 1.512 -0.482 0 N-CA-C 109.374 -0.602 . . . . 0.0 109.374 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -92.87 149.55 37.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.498 -179.464 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 65.3 Cg_exo -47.65 -21.81 2.58 Favored 'Trans proline' 0 N--CA 1.495 1.559 0 C-N-CA 122.567 2.178 . . . . 0.0 111.974 177.484 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 19.8 t -68.02 -17.91 64.55 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.8 179.885 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.87 -14.68 57.34 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -179.519 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 55.4 tt0 -68.42 153.82 43.01 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 120.974 0.416 . . . . 0.0 110.243 179.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.0 mt -129.42 133.15 65.88 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.369 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.677 179.787 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.637 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . 179.71 168.49 0.69 Allowed Pre-proline 0 C--N 1.327 -0.412 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.301 178.995 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.637 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 64.7 Cg_exo -48.8 -33.76 26.02 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 122.597 2.198 . . . . 0.0 112.083 179.041 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 38.8 m -133.01 165.6 24.34 Favored 'General case' 0 N--CA 1.466 0.353 0 CA-C-N 116.286 -0.416 . . . . 0.0 110.538 179.938 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -78.18 123.69 27.19 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.134 -0.484 . . . . 0.0 109.84 -179.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 78.96 95.51 0.28 Allowed Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.829 -0.908 . . . . 0.0 110.829 179.965 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 10.3 t -152.33 -161.13 1.24 Allowed 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.872 0.368 . . . . 0.0 110.54 -179.993 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 99.8 mtt180 -71.9 148.47 46.05 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.482 -179.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 66.4 m -128.48 148.55 50.74 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.121 179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.889 HD13 ' H ' ' A' ' 116' ' ' ILE . 0.1 OUTLIER -133.2 165.1 33.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.78 -0.646 . . . . 0.0 110.467 -179.437 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 97.0 mm-40 -68.58 139.46 55.56 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.107 179.383 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.537 ' C ' ' H ' ' A' ' 120' ' ' ASN . 76.1 m80 -112.07 153.76 26.42 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.301 -0.409 . . . . 0.0 110.406 -179.678 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.445 ' C ' ' H ' ' A' ' 121' ' ' ILE . 12.1 t -62.36 4.52 0.14 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.944 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . 0.537 ' H ' ' C ' ' A' ' 118' ' ' HIS . 47.3 t-20 61.09 3.22 0.66 Allowed 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.595 -179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.445 ' H ' ' C ' ' A' ' 119' ' ' CYS . 18.8 tt -143.84 172.25 6.76 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.2 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.427 179.6 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.421 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 38.0 mtt85 -122.73 99.97 6.67 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.78 -0.645 . . . . 0.0 110.777 179.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 28.8 m -90.34 147.16 23.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.007 -0.542 . . . . 0.0 109.739 179.394 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.7 mtm -139.97 170.6 15.56 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.356 -179.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 6.0 m120 67.48 39.13 2.95 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.508 -179.614 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 62.55 32.44 83.26 Favored Glycine 0 CA--C 1.521 0.441 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 179.487 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -70.31 -173.98 14.0 Favored Glycine 0 CA--C 1.523 0.559 0 N-CA-C 110.615 -0.994 . . . . 0.0 110.615 -179.816 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 35.1 m -130.98 136.69 48.76 Favored 'General case' 0 C--O 1.235 0.301 0 CA-C-O 120.807 0.337 . . . . 0.0 110.287 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 2.4 t -73.33 112.08 9.05 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.921 -0.581 . . . . 0.0 110.188 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 69.5 m -128.97 119.82 24.99 Favored 'General case' 0 N--CA 1.463 0.187 0 CA-C-N 116.246 -0.434 . . . . 0.0 109.959 179.329 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 6.5 m-20 43.17 -108.37 0.11 Allowed 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.746 -179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 -121.81 19.81 10.97 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.507 179.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 95.5 m-70 -131.87 156.02 46.82 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 120.955 0.407 . . . . 0.0 110.293 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 97.1 m -106.42 131.24 53.85 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.429 179.752 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.0 mt -99.22 131.35 45.31 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.08 -0.509 . . . . 0.0 109.672 179.648 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -100.3 143.2 30.78 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.438 -179.372 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.1 mm-40 -76.56 -179.09 5.04 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.755 179.652 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.3 tttt -66.57 132.84 49.08 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.53 -179.77 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.25 -19.36 46.1 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.804 -0.918 . . . . 0.0 110.804 -179.617 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.9 m-85 -118.11 136.99 53.25 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-O 120.784 0.326 . . . . 0.0 110.295 179.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 23.6 pt -130.94 171.79 17.27 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 CA-C-N 116.128 -0.487 . . . . 0.0 109.992 179.983 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.01 157.73 10.48 Favored Glycine 0 N--CA 1.464 0.519 0 N-CA-C 110.666 -0.974 . . . . 0.0 110.666 179.799 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 61.6 p -64.09 -42.53 96.9 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.835 0.35 . . . . 0.0 110.536 -179.579 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 80.7 m80 -105.8 5.64 31.0 Favored 'General case' 0 N--CA 1.467 0.41 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.692 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 5.0 m 65.04 140.1 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 121.076 0.465 . . . . 0.0 109.965 -179.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 152.86 -11.04 0.59 Allowed Glycine 0 CA--C 1.519 0.336 0 N-CA-C 110.845 -0.902 . . . . 0.0 110.845 -179.928 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 45.6 tt0 -102.44 110.2 62.32 Favored Pre-proline 0 CA--C 1.542 0.666 0 C-N-CA 120.819 -0.352 . . . . 0.0 110.535 179.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 95.9 Cg_endo -77.29 157.46 33.31 Favored 'Trans proline' 0 N--CA 1.493 1.494 0 C-N-CA 122.486 2.124 . . . . 0.0 112.31 179.674 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.5 t -106.46 116.66 50.69 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.227 0 CA-C-O 120.989 0.423 . . . . 0.0 110.179 179.759 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.7 m -88.98 96.38 10.7 Favored 'General case' 0 C--N 1.329 -0.294 0 N-CA-C 108.588 -0.893 . . . . 0.0 108.588 178.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.1 tt0 -66.12 -38.5 88.34 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.426 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 97.4 p -82.42 -7.96 59.63 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 116.42 -0.355 . . . . 0.0 110.684 -179.773 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 59.2 161.93 0.07 OUTLIER Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.619 -0.993 . . . . 0.0 110.619 -179.918 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.9 m -105.06 114.5 28.73 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.969 -0.382 . . . . 0.0 109.969 179.822 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 97.7 mt -63.57 -42.16 98.33 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.851 -179.406 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.522 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.1 m-20 -100.07 -177.37 3.51 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.456 -179.928 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -70.81 33.58 0.49 Allowed Glycine 0 CA--C 1.524 0.656 0 N-CA-C 111.046 -0.821 . . . . 0.0 111.046 179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.522 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.55 176.05 28.79 Favored Glycine 0 CA--C 1.52 0.349 0 N-CA-C 110.699 -0.96 . . . . 0.0 110.699 179.94 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.3 mpp_? -126.03 142.33 51.57 Favored 'General case' 0 N--CA 1.469 0.481 0 CA-C-O 120.68 0.276 . . . . 0.0 110.494 -179.922 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 79.6 m -87.66 122.03 30.82 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.442 -179.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 27.2 m -110.16 -9.87 11.55 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.486 0 CA-C-N 115.91 -0.586 . . . . 0.0 110.308 -179.884 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -171.91 170.97 2.34 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.41 -0.516 . . . . 0.0 110.737 179.622 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.9 Cg_exo -53.05 128.48 29.16 Favored 'Trans proline' 0 N--CA 1.492 1.425 0 C-N-CA 121.913 1.742 . . . . 0.0 111.402 178.768 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 13.6 m-20 52.58 32.69 12.11 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.119 179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -131.76 127.8 37.52 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-O 121.15 0.5 . . . . 0.0 109.773 -179.858 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 4.4 t -139.01 148.58 43.61 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.517 -0.765 . . . . 0.0 110.858 179.467 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -101.51 129.11 47.52 Favored 'General case' 0 CA--C 1.519 -0.229 0 CA-C-N 115.907 -0.588 . . . . 0.0 109.471 179.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 26.8 m -74.43 151.43 39.64 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.311 -179.169 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 18.8 m -62.96 -45.8 90.76 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.204 -179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 97.7 m-85 -102.96 19.52 19.29 Favored 'General case' 0 CA--C 1.52 -0.19 0 CA-C-O 121.077 0.465 . . . . 0.0 110.734 -179.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 68.53 26.71 74.23 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.764 -0.934 . . . . 0.0 110.764 179.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.4 t80 -55.45 149.66 13.05 Favored 'General case' 0 C--N 1.327 -0.39 0 N-CA-C 110.002 -0.37 . . . . 0.0 110.002 -179.241 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 51.8 p -82.29 165.42 20.4 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.576 -179.32 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 87.44 150.45 18.85 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -67.82 -23.18 41.89 Favored 'Trans proline' 0 N--CA 1.497 1.693 0 C-N-CA 122.69 2.26 . . . . 0.0 112.272 -179.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 76.6 mt-30 -101.34 7.32 42.81 Favored 'General case' 0 N--CA 1.467 0.412 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.554 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 77.9 m 53.52 -92.68 0.03 OUTLIER 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.185 -179.755 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 83.7 tt0 . . . . . 0 C--O 1.221 -0.446 0 CA-C-O 118.053 -0.975 . . . . 0.0 110.517 -179.976 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 6.8 t . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 48.99 35.11 6.27 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.541 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 91.5 mtm-85 -65.05 -39.25 93.03 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.317 -179.895 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -56.45 -103.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.648 0 N-CA-C 110.939 -0.864 . . . . 0.0 110.939 -179.861 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 92.04 -7.78 78.45 Favored Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.867 -0.893 . . . . 0.0 110.867 179.956 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -73.13 164.22 54.92 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.821 -0.911 . . . . 0.0 110.821 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -170.71 175.68 44.42 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.874 -0.89 . . . . 0.0 110.874 -179.992 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 7.9 m170 -66.89 -41.29 87.43 Favored 'General case' 0 C--N 1.327 -0.392 0 N-CA-C 110.046 -0.353 . . . . 0.0 110.046 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.526 ' O ' ' N ' ' A' ' 53' ' ' LEU . 99.6 m-20 53.08 83.02 0.07 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.794 179.76 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.556 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . 62.43 -68.19 0.07 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.898 179.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.526 ' N ' ' O ' ' A' ' 51' ' ' ASP . 13.0 mt -64.99 138.58 58.45 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-O 121.166 0.508 . . . . 0.0 110.225 -179.903 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.2 mttm -133.22 163.03 30.2 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 115.477 -0.783 . . . . 0.0 110.32 -179.337 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.47 160.31 23.13 Favored Glycine 0 CA--C 1.531 1.039 0 N-CA-C 111.034 -0.826 . . . . 0.0 111.034 179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -76.54 2.94 6.82 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 122.862 2.375 . . . . 0.0 112.212 179.605 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.591 ' ND2' ' CZ2' ' A' ' 71' ' ' TRP . 3.0 m120 -114.95 69.07 0.71 Allowed 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.411 -0.359 . . . . 0.0 110.355 179.858 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.457 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.1 t -120.42 130.83 73.99 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.477 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 93.1 m -141.15 176.8 8.54 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.032 -179.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.22 169.15 45.49 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.848 -0.901 . . . . 0.0 110.848 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.557 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.0 m -74.51 163.25 27.97 Favored 'General case' 0 C--N 1.329 -0.314 0 N-CA-C 110.175 -0.306 . . . . 0.0 110.175 179.843 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 78.4 ttt-85 -59.27 -43.94 92.45 Favored 'General case' 0 C--N 1.321 -0.631 0 C-N-CA 120.753 -0.379 . . . . 0.0 110.47 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 94.1 m-85 -64.11 -39.96 95.17 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.366 -0.379 . . . . 0.0 111.007 179.735 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 57.9 t30 -122.54 46.62 2.1 Favored 'General case' 0 N--CA 1.461 0.079 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.783 -179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.557 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -71.92 145.09 48.7 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.52 179.861 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -156.05 168.19 28.05 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 121.008 0.432 . . . . 0.0 110.821 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 71.5 m -67.47 130.11 42.04 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 120.276 -0.569 . . . . 0.0 110.189 -180.0 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.457 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 53.5 m -49.21 153.29 1.73 Allowed Pre-proline 0 CA--C 1.535 0.37 0 CA-C-N 116.013 -0.539 . . . . 0.0 111.246 -179.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -51.64 131.68 38.26 Favored 'Trans proline' 0 N--CA 1.496 1.675 0 C-N-CA 121.43 1.42 . . . . 0.0 112.398 179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.416 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 100.9 -16.53 57.33 Favored Glycine 0 N--CA 1.467 0.737 0 N-CA-C 110.861 -0.895 . . . . 0.0 110.861 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.591 ' CZ2' ' ND2' ' A' ' 57' ' ' ASN . 9.1 m95 -115.63 139.58 49.97 Favored 'General case' 0 N--CA 1.469 0.491 0 CA-C-O 120.787 0.327 . . . . 0.0 110.498 179.364 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.9 ptpt -120.23 -168.66 1.66 Allowed 'General case' 0 N--CA 1.469 0.489 0 CA-C-N 116.333 -0.394 . . . . 0.0 110.312 179.761 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 64.1 p -118.13 160.53 21.39 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 109.918 -0.401 . . . . 0.0 109.918 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.483 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.1 mt -87.4 152.84 52.96 Favored Pre-proline 0 CA--C 1.533 0.308 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.744 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_exo -41.44 107.58 0.08 OUTLIER 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.145 1.897 . . . . 0.0 112.184 179.309 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.34 -11.63 12.19 Favored Glycine 0 CA--C 1.523 0.591 0 N-CA-C 111.091 -0.804 . . . . 0.0 111.091 179.517 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.483 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -88.29 175.99 44.84 Favored Glycine 0 CA--C 1.526 0.733 0 N-CA-C 110.871 -0.892 . . . . 0.0 110.871 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.556 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 34.6 p30 -135.56 15.75 3.4 Favored 'General case' 0 N--CA 1.468 0.428 0 CA-C-O 121.12 0.486 . . . . 0.0 110.639 179.649 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 73.3 mt-30 -79.87 128.53 33.56 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.495 179.817 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 29.9 m -96.9 55.68 1.37 Allowed 'General case' 0 C--N 1.331 -0.216 0 N-CA-C 109.911 -0.404 . . . . 0.0 109.911 179.848 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 30.3 pt -115.92 21.01 6.53 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.488 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.993 -179.217 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 15.5 t -119.32 85.74 31.62 Favored Pre-proline 0 N--CA 1.467 0.39 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.697 -179.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_exo -61.35 148.48 92.83 Favored 'Trans proline' 0 N--CA 1.494 1.548 0 C-N-CA 122.645 2.23 . . . . 0.0 111.936 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.416 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.8 mt -90.9 128.63 42.6 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.206 0 N-CA-C 109.761 -0.459 . . . . 0.0 109.761 179.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 89' ' ' CYS . 3.2 m -99.62 109.02 21.54 Favored 'General case' 0 N--CA 1.468 0.44 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.229 -179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 8.6 mpt_? -65.88 -39.36 90.59 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-O 121.052 0.453 . . . . 0.0 109.906 178.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 61.3 m170 -110.51 142.06 42.8 Favored 'General case' 0 C--N 1.326 -0.423 0 CA-C-N 115.695 -0.684 . . . . 0.0 110.002 179.855 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 36.5 t -59.62 130.07 45.04 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.681 -179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . 0.509 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 61.2 m -80.28 -31.52 38.28 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.875 179.374 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.07 -112.48 3.67 Favored Glycine 0 CA--C 1.524 0.656 0 N-CA-C 110.997 -0.841 . . . . 0.0 110.997 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -81.91 -0.55 44.26 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.769 0.319 . . . . 0.0 110.846 -179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -100.16 -175.74 30.35 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.563 -1.015 . . . . 0.0 110.563 179.794 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.0 p90 -132.0 147.79 52.47 Favored 'General case' 0 N--CA 1.469 0.492 0 CA-C-O 121.018 0.437 . . . . 0.0 110.794 179.901 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 91.2 m -64.4 111.26 2.57 Favored 'General case' 0 CA--C 1.514 -0.431 0 CA-C-N 115.688 -0.687 . . . . 0.0 110.42 -179.115 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 69.8 p -102.64 -27.51 12.69 Favored 'General case' 0 CA--C 1.512 -0.486 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.302 -179.494 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 6.1 mtt85 -157.83 163.94 23.03 Favored Pre-proline 0 C--N 1.33 -0.274 0 C-N-CA 120.267 -0.573 . . . . 0.0 110.583 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -51.55 121.9 9.32 Favored 'Trans proline' 0 N--CA 1.491 1.373 0 C-N-CA 121.634 1.556 . . . . 0.0 111.48 179.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 53.3 t-20 55.17 40.34 31.72 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.099 -0.5 . . . . 0.0 109.878 -179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 88.8 mmm -149.27 115.81 5.87 Favored 'General case' 0 C--O 1.241 0.648 0 CA-C-O 121.198 0.523 . . . . 0.0 109.97 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 86.7 m -101.23 151.12 22.25 Favored 'General case' 0 N--CA 1.461 0.116 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.674 179.556 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 97.1 m -121.91 126.26 48.26 Favored 'General case' 0 CA--C 1.513 -0.461 0 N-CA-C 109.533 -0.543 . . . . 0.0 109.533 179.666 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.68 151.59 40.12 Favored Pre-proline 0 CA--C 1.54 0.574 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.642 -179.188 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -50.02 -22.73 8.11 Favored 'Trans proline' 0 N--CA 1.495 1.566 0 C-N-CA 122.459 2.106 . . . . 0.0 111.867 177.59 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -66.85 -16.96 64.65 Favored 'General case' 0 N--CA 1.464 0.23 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.684 179.931 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.82 -18.5 49.89 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.884 -0.886 . . . . 0.0 110.884 -179.869 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.0 tt0 -68.05 153.16 44.3 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-O 120.894 0.378 . . . . 0.0 110.304 -179.925 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.7 mt -125.17 130.38 73.06 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.523 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.581 179.823 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.545 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.27 164.88 3.21 Favored Pre-proline 0 C--N 1.327 -0.377 0 CA-C-N 116.051 -0.522 . . . . 0.0 109.962 -179.538 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.545 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 15.3 Cg_endo -57.44 -22.81 52.28 Favored 'Trans proline' 0 N--CA 1.499 1.845 0 C-N-CA 122.916 2.411 . . . . 0.0 111.829 178.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 35.9 p -135.38 154.53 51.45 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.97 0.414 . . . . 0.0 110.227 179.799 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -82.86 144.13 30.3 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.68 -179.644 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 55.22 46.84 77.61 Favored Glycine 0 CA--C 1.523 0.55 0 N-CA-C 111.181 -0.768 . . . . 0.0 111.181 179.181 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 7.0 t -60.3 -44.59 95.29 Favored 'General case' 0 C--N 1.328 -0.355 0 C-N-CA 120.786 -0.366 . . . . 0.0 110.697 -179.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.477 ' O ' ' CB ' ' A' ' 115' ' ' SER . 77.0 ttt180 -167.77 -18.05 0.02 OUTLIER 'General case' 0 C--N 1.328 -0.35 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.401 179.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.477 ' CB ' ' O ' ' A' ' 114' ' ' ARG . 0.9 OUTLIER 82.9 81.91 0.03 OUTLIER 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.398 179.92 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 97.2 mt -120.75 128.52 76.06 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.419 0 CA-C-O 120.956 0.408 . . . . 0.0 110.319 179.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 57.8 tt0 -81.53 111.26 17.68 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.055 -0.521 . . . . 0.0 110.411 -179.937 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.541 ' H ' ' CD2' ' A' ' 118' ' ' HIS . 9.2 p80 -95.72 -50.57 4.87 Favored 'General case' 0 N--CA 1.463 0.217 0 CA-C-O 120.931 0.396 . . . . 0.0 110.467 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.441 ' N ' ' CG ' ' A' ' 118' ' ' HIS . 96.3 m -116.97 134.53 54.62 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.207 179.73 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 34.6 t30 -63.4 -40.21 96.61 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.444 179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.539 HG22 ' H ' ' A' ' 122' ' ' ARG . 1.1 mt -113.31 -157.57 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.309 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.811 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.539 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.6 ptt-85 -120.59 121.72 38.99 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.179 -179.445 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.7 m -124.86 147.0 49.01 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.827 -0.624 . . . . 0.0 110.15 -179.658 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 70.9 mtm -145.17 174.13 11.34 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.315 -179.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 5.7 m120 59.61 37.2 22.65 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.993 -0.549 . . . . 0.0 111.372 179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 79.44 15.47 79.84 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.814 -0.915 . . . . 0.0 110.814 179.637 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -71.7 123.76 10.16 Favored Glycine 0 CA--C 1.525 0.681 0 C-N-CA 120.547 -0.835 . . . . 0.0 111.158 -179.296 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 39.9 t -83.51 140.98 31.96 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-O 120.75 0.309 . . . . 0.0 110.881 179.78 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 5.8 m -83.32 129.94 35.03 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.18 179.787 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 36.4 m -126.45 158.3 36.38 Favored 'General case' 0 N--CA 1.468 0.429 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.134 -179.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.442 ' OD1' ' O ' ' A' ' 131' ' ' ASP . 43.4 p-10 -48.24 109.35 0.23 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.09 0.472 . . . . 0.0 110.991 -178.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.7 m-20 50.24 30.26 4.26 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.531 179.744 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 59.6 t-80 -159.78 154.9 24.95 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.495 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 47.6 t -129.55 132.32 46.81 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.784 179.234 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 80.3 mt -101.09 128.47 47.14 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.469 -0.567 . . . . 0.0 109.469 179.598 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 55.6 m -84.77 132.19 34.46 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.382 -179.64 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 44.8 tt0 -56.1 161.14 2.53 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.906 0.384 . . . . 0.0 110.352 -179.457 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -59.25 130.81 48.78 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.873 0.368 . . . . 0.0 110.816 -179.552 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 94.5 -6.91 71.37 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 -179.912 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.3 m-85 -119.74 137.43 53.94 Favored 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.924 0.392 . . . . 0.0 110.098 179.742 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 22.3 pt -129.61 169.59 20.46 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.953 -179.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 121.69 159.34 10.64 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 179.585 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 23.4 m -62.17 -45.64 92.5 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 120.782 0.325 . . . . 0.0 110.687 179.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.505 ' NE2' ' NH2' ' A' ' 122' ' ' ARG . 31.9 m-70 -102.75 3.24 36.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.347 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.37 142.94 0.03 OUTLIER 'General case' 0 N--CA 1.449 -0.476 0 CA-C-N 115.981 -0.554 . . . . 0.0 109.894 -179.774 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 149.53 -8.24 0.86 Allowed Glycine 0 CA--C 1.522 0.521 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 15.7 tt0 -101.39 109.38 58.73 Favored Pre-proline 0 CA--C 1.544 0.724 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.371 179.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -74.3 157.49 45.65 Favored 'Trans proline' 0 N--CA 1.495 1.612 0 C-N-CA 122.359 2.039 . . . . 0.0 112.437 -179.475 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 53.8 t -124.83 126.81 71.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.336 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.412 179.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 66.3 m -94.41 109.13 21.01 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.129 179.253 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -66.89 -39.54 87.51 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.968 -0.56 . . . . 0.0 110.492 -179.886 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.9 m -88.66 -9.16 53.07 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.712 179.807 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.505 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 60.03 177.47 1.48 Allowed Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.585 -1.006 . . . . 0.0 110.585 179.953 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 9.0 m -116.08 119.98 37.61 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-O 121.024 0.44 . . . . 0.0 110.191 179.763 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 94.9 mt -63.57 -42.38 98.32 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.213 -178.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.506 ' C ' ' H ' ' A' ' 158' ' ' GLY . 18.9 m120 -93.6 -178.49 4.72 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.525 179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -72.34 29.55 0.69 Allowed Glycine 0 CA--C 1.523 0.593 0 N-CA-C 111.077 -0.809 . . . . 0.0 111.077 179.988 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.506 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -67.61 179.41 16.81 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.561 -1.016 . . . . 0.0 110.561 179.77 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 2.1 mpt_? -126.2 149.64 48.89 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-O 120.942 0.401 . . . . 0.0 110.349 -179.479 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 22.5 m -88.52 105.09 17.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.072 -0.513 . . . . 0.0 110.063 -179.53 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.1 m -88.41 -19.64 7.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.566 -179.954 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.639 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -165.93 174.28 2.96 Favored Pre-proline 0 C--N 1.325 -0.459 0 C-N-CA 120.531 -0.468 . . . . 0.0 110.47 -179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.639 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.9 Cg_exo -52.84 133.82 52.41 Favored 'Trans proline' 0 C--N 1.31 -1.478 0 C-N-CA 121.892 1.728 . . . . 0.0 111.854 179.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 64.7 t30 45.34 36.42 2.31 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.079 -0.509 . . . . 0.0 110.397 179.873 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 12.7 tpp180 -130.34 103.82 6.91 Favored 'General case' 0 C--O 1.239 0.527 0 CA-C-O 121.29 0.567 . . . . 0.0 110.909 -179.838 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.505 ' SG ' ' O ' ' A' ' 153' ' ' GLY . 23.2 m -102.2 135.15 44.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.087 -0.961 . . . . 0.0 110.685 179.4 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.98 92.29 3.97 Favored 'General case' 0 C--N 1.328 -0.368 0 N-CA-C 109.179 -0.674 . . . . 0.0 109.179 178.764 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.6 p -102.23 141.76 34.56 Favored 'General case' 0 N--CA 1.465 0.306 0 N-CA-C 109.917 -0.401 . . . . 0.0 109.917 -179.592 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.468 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.1 OUTLIER -111.6 13.79 21.28 Favored 'General case' 0 N--CA 1.469 0.513 0 CA-C-O 121.298 0.57 . . . . 0.0 110.568 -179.514 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 88.3 m-85 -102.32 30.45 4.56 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.726 -0.67 . . . . 0.0 111.164 -179.818 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 100.28 59.42 0.84 Allowed Glycine 0 N--CA 1.464 0.553 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.422 ' CD1' ' C ' ' A' ' 172' ' ' PHE . 21.9 t80 -44.51 119.04 1.73 Allowed 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 121.033 0.444 . . . . 0.0 110.484 -179.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.949 ' H ' ' H ' ' A' ' 178' ' ' GLU . 7.3 m -153.3 130.61 11.27 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.375 179.229 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 78.03 164.71 24.83 Favored Glycine 0 CA--C 1.528 0.865 0 N-CA-C 111.257 -0.737 . . . . 0.0 111.257 179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 42.0 Cg_endo -66.94 -22.32 48.64 Favored 'Trans proline' 0 N--CA 1.497 1.687 0 C-N-CA 122.896 2.397 . . . . 0.0 112.253 -179.659 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.7 mt-30 -89.09 14.01 11.74 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.951 -179.61 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.79 111.69 0.03 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 121.021 0.438 . . . . 0.0 110.166 -179.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . 0.949 ' H ' ' H ' ' A' ' 173' ' ' THR . 3.1 tm-20 . . . . . 0 C--N 1.324 -0.53 0 CA-C-O 118.1 -0.953 . . . . 0.0 110.555 179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 66.5 p . . . . . 0 N--CA 1.489 1.496 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -64.4 143.87 57.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.244 179.897 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 62.3 ttp180 -128.67 133.75 48.31 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.263 -179.781 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.12 21.01 61.66 Favored Glycine 0 CA--C 1.522 0.509 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -70.34 129.3 19.92 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.745 -0.942 . . . . 0.0 110.745 179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -103.76 -178.38 25.75 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.946 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -64.09 -29.57 75.29 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.691 -0.964 . . . . 0.0 110.691 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 89.8 m-70 55.4 68.62 0.84 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.908 0.385 . . . . 0.0 110.439 -179.377 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.457 ' O ' ' N ' ' A' ' 53' ' ' LEU . 38.3 t70 -70.19 135.97 49.59 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.527 179.857 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.442 ' HB3' ' O ' ' A' ' 51' ' ' ASP . . . 66.37 -65.98 0.18 Allowed 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.909 179.927 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.457 ' N ' ' O ' ' A' ' 51' ' ' ASP . 44.3 mt -72.81 147.71 45.22 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.413 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.5 mttt -135.42 161.8 34.42 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.037 -179.404 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 101.9 163.92 26.88 Favored Glycine 0 CA--C 1.531 1.052 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 68.4 Cg_endo -75.03 -7.35 19.05 Favored 'Trans proline' 0 N--CA 1.496 1.638 0 C-N-CA 123.058 2.505 . . . . 0.0 112.344 179.774 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.447 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 71.9 m-80 -105.32 70.38 0.89 Allowed 'General case' 0 N--CA 1.463 0.216 0 CA-C-N 116.5 -0.318 . . . . 0.0 110.597 -179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.466 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 60.7 t -121.63 130.24 74.79 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.433 0 CA-C-N 116.166 -0.47 . . . . 0.0 109.925 179.1 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 87.1 m -144.55 -174.1 4.23 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.009 -179.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.28 171.43 47.51 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 110.645 -0.982 . . . . 0.0 110.645 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.535 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.6 m -84.19 167.56 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 N-CA-C 110.211 -0.292 . . . . 0.0 110.211 179.791 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 79.3 ttt-85 -59.52 -43.79 93.34 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-O 120.777 0.323 . . . . 0.0 110.738 179.72 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.2 m-85 -63.97 -36.76 85.02 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.977 179.836 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 32.9 t30 -129.25 50.33 2.16 Favored 'General case' 0 CA--C 1.528 0.114 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.987 -179.139 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.535 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -73.18 142.81 47.39 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.371 179.776 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 12.3 p90 -160.75 167.16 27.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.995 0.426 . . . . 0.0 111.03 179.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.426 ' SG ' HG22 ' A' ' 73' ' ' THR . 79.1 m -64.04 130.92 45.93 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.069 -0.514 . . . . 0.0 110.17 -179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.466 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 32.5 m -47.72 151.02 1.64 Allowed Pre-proline 0 C--N 1.325 -0.497 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.266 -179.103 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -49.62 129.76 24.37 Favored 'Trans proline' 0 N--CA 1.493 1.473 0 C-N-CA 121.498 1.465 . . . . 0.0 112.301 179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.67 -18.54 47.09 Favored Glycine 0 CA--C 1.529 0.961 0 N-CA-C 111.124 -0.791 . . . . 0.0 111.124 -179.249 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.447 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 98.6 m95 -111.77 134.76 53.12 Favored 'General case' 0 N--CA 1.466 0.325 0 CA-C-O 120.965 0.412 . . . . 0.0 110.085 179.351 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.5 ptmt -110.99 -167.75 1.22 Allowed 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.133 -179.832 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.426 HG22 ' SG ' ' A' ' 67' ' ' CYS . 71.1 p -129.83 165.29 22.29 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.049 -179.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 12.1 mt -91.53 150.58 41.39 Favored Pre-proline 0 C--N 1.326 -0.419 0 C-N-CA 120.656 -0.418 . . . . 0.0 110.834 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_exo -44.21 115.4 0.75 Allowed 'Trans proline' 0 N--CA 1.49 1.273 0 C-N-CA 121.864 1.709 . . . . 0.0 112.036 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.12 -8.73 7.93 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 111.103 -0.799 . . . . 0.0 111.103 179.165 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -91.11 177.94 41.63 Favored Glycine 0 CA--C 1.526 0.721 0 N-CA-C 110.719 -0.952 . . . . 0.0 110.719 -179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.704 ' H ' ' NE2' ' A' ' 79' ' ' GLN . 26.7 p30 -139.51 13.39 2.55 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 120.931 0.396 . . . . 0.0 110.864 179.879 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . 0.704 ' NE2' ' H ' ' A' ' 78' ' ' ASN . 12.1 mp0 -84.08 131.78 34.77 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.364 -0.38 . . . . 0.0 110.469 -179.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 22.5 m -95.88 43.29 1.08 Allowed 'General case' 0 N--CA 1.463 0.202 0 CA-C-N 116.361 -0.382 . . . . 0.0 109.987 179.803 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 42.4 pt -98.2 6.89 8.66 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.246 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.734 -179.63 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -108.66 112.54 60.52 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 116.657 -0.247 . . . . 0.0 110.417 -179.391 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 82.8 Cg_endo -78.29 156.87 29.52 Favored 'Trans proline' 0 N--CA 1.486 1.059 0 C-N-CA 122.01 1.807 . . . . 0.0 111.864 179.229 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.6 mt -100.72 118.91 48.12 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.244 0 N-CA-C 109.554 -0.535 . . . . 0.0 109.554 179.344 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.8 115.42 27.12 Favored 'General case' 0 N--CA 1.467 0.395 0 N-CA-C 109.608 -0.515 . . . . 0.0 109.608 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.402 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -64.73 -45.24 87.36 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.37 0.605 . . . . 0.0 110.106 179.242 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.1 m-70 -119.41 -167.89 1.49 Allowed 'General case' 0 N--CA 1.466 0.331 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.674 -179.953 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 29.2 t -97.04 125.07 41.23 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.722 -179.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.6 m -74.39 -32.16 62.62 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 115.916 -0.583 . . . . 0.0 110.776 179.778 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -106.08 2.23 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.023 -0.831 . . . . 0.0 111.023 179.957 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.439 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.4 p-10 -81.99 -2.63 52.21 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.719 0.295 . . . . 0.0 110.773 -179.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -102.63 -176.36 27.14 Favored Glycine 0 CA--C 1.521 0.421 0 N-CA-C 110.739 -0.944 . . . . 0.0 110.739 179.557 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 55.9 p90 -133.72 146.12 50.5 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-O 121.058 0.456 . . . . 0.0 110.788 179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 70.1 m -64.57 111.3 2.65 Favored 'General case' 0 CA--C 1.516 -0.33 0 CA-C-N 115.658 -0.701 . . . . 0.0 109.578 -179.378 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 89.0 p -105.98 -26.07 11.83 Favored 'General case' 0 CA--C 1.512 -0.511 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.33 -179.262 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 36.6 mtt180 -153.23 159.58 32.01 Favored Pre-proline 0 C--N 1.325 -0.464 0 C-N-CA 120.49 -0.484 . . . . 0.0 110.291 -179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 9.0 Cg_endo -48.92 119.07 3.96 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.477 2.118 . . . . 0.0 111.915 179.648 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.402 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 54.0 t30 55.11 42.88 30.38 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.015 -0.539 . . . . 0.0 110.228 -179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.8 mtp -149.06 118.87 7.06 Favored 'General case' 0 C--O 1.243 0.727 0 CA-C-N 115.89 -0.595 . . . . 0.0 110.09 179.874 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.431 ' N ' ' O ' ' A' ' 108' ' ' ALA . 69.2 m -100.64 148.72 24.54 Favored 'General case' 0 C--O 1.233 0.202 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.792 179.178 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 86.5 m -119.99 115.59 24.07 Favored 'General case' 0 C--N 1.326 -0.449 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.422 179.174 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.44 154.0 68.66 Favored Pre-proline 0 CA--C 1.539 0.534 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.869 -179.522 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -50.07 -26.56 14.95 Favored 'Trans proline' 0 N--CA 1.498 1.777 0 C-N-CA 122.693 2.262 . . . . 0.0 112.016 177.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.4 m -66.49 -15.5 63.41 Favored 'General case' 0 C--O 1.233 0.205 0 CA-C-N 116.447 -0.342 . . . . 0.0 110.831 -179.614 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.92 -15.18 58.37 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 54.1 tp60 -65.86 149.31 50.39 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-O 120.921 0.391 . . . . 0.0 109.971 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.3 mt -128.2 130.64 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.869 -179.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.656 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -170.29 179.43 0.74 Allowed Pre-proline 0 C--N 1.327 -0.406 0 C-N-CA 120.506 -0.478 . . . . 0.0 110.446 179.266 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.656 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 35.7 Cg_exo -58.81 -22.71 63.34 Favored 'Trans proline' 0 N--CA 1.499 1.808 0 C-N-CA 122.877 2.385 . . . . 0.0 111.78 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 82.7 p -152.3 163.98 38.36 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.598 -179.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -77.5 -27.55 51.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.315 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -67.8 98.14 0.46 Allowed Glycine 0 CA--C 1.523 0.574 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 -179.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.1 m -137.35 -24.14 1.08 Allowed 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.789 0.328 . . . . 0.0 110.57 179.917 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 80.3 mtp85 -100.45 139.41 36.18 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.349 179.893 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.8 m -58.76 -40.54 84.21 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.573 -179.754 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 79.0 mt -104.3 123.67 58.3 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.15 0 CA-C-N 116.346 -0.388 . . . . 0.0 110.211 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.2 mt-30 -87.34 141.85 28.33 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.56 -179.799 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.563 ' O ' ' N ' ' A' ' 120' ' ' ASN . 97.3 m-70 -78.97 150.39 32.02 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.309 179.858 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 75.8 m -51.67 82.43 0.0 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.333 -0.394 . . . . 0.0 111.224 -179.707 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . 0.563 ' N ' ' O ' ' A' ' 118' ' ' HIS . 92.3 m-20 -64.36 -40.77 96.5 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.63 179.753 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.736 HG22 ' H ' ' A' ' 122' ' ' ARG . 24.7 mm -64.48 177.83 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-O 120.962 0.41 . . . . 0.0 109.999 -179.131 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.736 ' H ' HG22 ' A' ' 121' ' ' ILE . 36.8 mmt180 -117.46 98.27 6.32 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.721 179.46 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.2 m -94.33 135.27 35.91 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.322 179.175 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.6 mtm -130.17 170.13 14.45 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.346 -178.867 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 4.7 m120 63.6 41.48 7.19 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.339 -0.391 . . . . 0.0 110.717 -179.817 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.87 23.61 71.04 Favored Glycine 0 CA--C 1.521 0.41 0 N-CA-C 110.574 -1.01 . . . . 0.0 110.574 179.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.93 141.96 24.88 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.786 -0.926 . . . . 0.0 110.786 -179.635 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 20.1 m -99.87 144.69 28.63 Favored 'General case' 0 N--CA 1.465 0.279 0 CA-C-O 120.725 0.298 . . . . 0.0 110.314 179.76 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . 0.5 ' O ' ' SG ' ' A' ' 129' ' ' CYS . 0.5 OUTLIER -93.99 129.79 40.35 Favored 'General case' 0 N--CA 1.462 0.166 0 CA-C-N 116.399 -0.364 . . . . 0.0 110.682 179.897 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 28.8 t -149.36 134.99 18.61 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.358 -0.383 . . . . 0.0 110.394 178.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 9.8 m-20 51.11 45.82 27.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.373 -0.376 . . . . 0.0 110.903 179.421 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.0 m-20 56.95 33.65 23.62 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.471 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 84.2 t60 -143.98 138.2 28.26 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.467 -179.93 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 95.9 m -91.05 131.4 36.66 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-O 120.944 0.402 . . . . 0.0 110.828 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 76.6 mt -101.83 128.53 48.15 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.338 178.992 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . 0.452 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 8.4 m -89.01 135.78 33.37 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.53 -179.253 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.2 mt-30 -73.32 172.6 10.91 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.444 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.6 tttt -62.82 126.12 26.25 Favored 'General case' 0 C--N 1.327 -0.375 0 C-N-CA 120.644 -0.422 . . . . 0.0 110.12 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 107.96 -26.27 17.93 Favored Glycine 0 CA--C 1.529 0.958 0 N-CA-C 111.216 -0.754 . . . . 0.0 111.216 -179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 90.4 m-85 -112.61 133.73 54.5 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-O 120.946 0.403 . . . . 0.0 110.065 179.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.409 HD13 HG21 ' A' ' 141' ' ' ILE . 23.3 pt -127.35 169.14 19.25 Favored 'Isoleucine or valine' 0 C--O 1.237 0.401 0 CA-C-N 115.962 -0.563 . . . . 0.0 109.934 -179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.452 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 118.79 159.87 11.23 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 179.469 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.1 m -62.12 -46.07 90.67 Favored 'General case' 0 C--N 1.327 -0.389 0 C-N-CA 120.938 -0.305 . . . . 0.0 110.566 179.954 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -100.68 2.14 41.22 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.58 -179.931 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.6 m 62.85 132.08 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.996 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 164.91 -11.99 0.08 OUTLIER Glycine 0 C--N 1.32 -0.313 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 -179.466 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 2.6 tp-100 -100.27 112.72 64.72 Favored Pre-proline 0 CA--C 1.544 0.726 0 C-N-CA 120.465 -0.494 . . . . 0.0 110.516 179.715 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 76.6 Cg_endo -75.74 157.76 39.57 Favored 'Trans proline' 0 N--CA 1.492 1.385 0 C-N-CA 122.42 2.08 . . . . 0.0 112.053 -179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 52.5 t -120.56 130.47 74.46 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.287 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 18.1 m -90.06 98.81 11.99 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.183 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 96.3 mt-10 -62.34 -39.36 92.83 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-O 120.918 0.39 . . . . 0.0 110.418 -179.813 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 83.1 p -81.83 -6.86 59.44 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.482 179.896 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 64.99 161.07 0.56 Allowed Glycine 0 CA--C 1.527 0.782 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 58.6 m -114.06 104.93 12.63 Favored 'General case' 0 N--CA 1.466 0.332 0 CA-C-O 120.834 0.349 . . . . 0.0 110.12 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 85.5 mt -63.67 -42.19 98.08 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.948 -179.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.561 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.9 t-20 -90.73 173.31 8.09 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.342 -179.942 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.69 33.2 0.28 Allowed Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.929 -0.869 . . . . 0.0 110.929 179.768 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.561 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -70.47 -179.01 26.38 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.736 -0.946 . . . . 0.0 110.736 179.959 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 53.4 mmm-85 -130.46 147.37 52.15 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.918 0.389 . . . . 0.0 110.218 -179.606 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 84.0 m -83.99 111.05 18.92 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.362 -179.853 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.9 m -95.38 -20.54 5.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.869 -0.605 . . . . 0.0 110.376 -179.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.64 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.62 173.82 2.71 Favored Pre-proline 0 C--N 1.326 -0.455 0 C-N-CA 120.454 -0.498 . . . . 0.0 110.627 179.926 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.64 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.7 Cg_exo -53.97 130.89 41.61 Favored 'Trans proline' 0 N--CA 1.493 1.482 0 C-N-CA 122.164 1.909 . . . . 0.0 111.95 179.252 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . 0.408 ' O ' ' OD1' ' A' ' 164' ' ' ASN . 60.5 t-20 49.74 32.33 5.13 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.084 179.826 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 1.5 tpm_? -137.0 129.14 29.52 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.447 0.642 . . . . 0.0 110.045 179.806 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.4 t -131.79 145.38 51.55 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.0 179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -97.13 137.15 36.62 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.659 -0.701 . . . . 0.0 109.703 179.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . 0.549 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 44.2 m -81.75 142.79 32.31 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.079 0.466 . . . . 0.0 111.054 179.872 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.9 m -63.38 -45.59 90.39 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.716 -0.675 . . . . 0.0 111.084 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.4 m-85 -97.89 17.23 18.65 Favored 'General case' 0 CA--C 1.52 -0.178 0 CA-C-O 121.106 0.479 . . . . 0.0 111.086 -179.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.79 24.18 77.01 Favored Glycine 0 CA--C 1.524 0.637 0 N-CA-C 111.054 -0.818 . . . . 0.0 111.054 179.411 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.549 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 3.1 m-85 -66.01 151.49 46.7 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-O 121.238 0.542 . . . . 0.0 110.191 -179.633 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 7.4 t -87.61 166.05 14.99 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.97 -179.618 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.83 148.51 11.52 Favored Glycine 0 CA--C 1.533 1.207 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.581 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.2 Cg_endo -67.17 -29.06 39.98 Favored 'Trans proline' 0 N--CA 1.498 1.745 0 C-N-CA 122.448 2.099 . . . . 0.0 112.409 -179.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -115.12 0.89 13.74 Favored 'General case' 0 N--CA 1.468 0.437 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.604 -179.089 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER 73.15 -72.68 0.11 Allowed 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.784 -179.864 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.218 -0.566 0 CA-C-O 118.082 -0.961 . . . . 0.0 110.515 -179.995 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 31.1 t . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.405 -0.591 . . . . 0.0 109.405 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 51.46 42.16 29.07 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.505 179.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.2 mtt180 -63.91 -39.75 94.91 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.403 -179.88 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 171.84 110.77 0.24 Allowed Glycine 0 CA--C 1.524 0.631 0 N-CA-C 110.92 -0.872 . . . . 0.0 110.92 179.736 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 56.75 -135.74 50.68 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.872 -0.891 . . . . 0.0 110.872 179.793 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 69.86 -153.49 52.23 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 110.852 -0.899 . . . . 0.0 110.852 179.896 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 95.58 -10.24 68.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.964 -0.854 . . . . 0.0 110.964 179.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . 0.436 ' NE2' ' HB2' ' A' ' 52' ' ' ALA . 22.9 t-160 39.19 79.85 0.03 OUTLIER 'General case' 0 C--N 1.332 -0.192 0 CA-C-O 120.853 0.358 . . . . 0.0 110.874 -179.916 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.48 ' OD1' ' N ' ' A' ' 52' ' ' ALA . 38.1 p-10 -65.11 -34.45 78.44 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.61 -179.991 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.48 ' N ' ' OD1' ' A' ' 51' ' ' ASP . . . 52.7 -179.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.592 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 96.0 mt -74.34 151.17 39.82 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.58 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.1 mttt -129.42 165.0 22.44 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.655 -179.606 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 70.18 172.43 10.7 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.639 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 61.7 Cg_endo -74.55 -171.36 0.92 Allowed 'Trans proline' 0 C--N 1.308 -1.589 0 C-N-CA 122.984 2.456 . . . . 0.0 111.794 179.999 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.576 ' ND2' ' CZ3' ' A' ' 71' ' ' TRP . 62.6 m-20 58.78 38.78 24.68 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.224 -0.443 . . . . 0.0 111.081 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.451 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 7.4 p -95.53 133.72 35.56 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.221 0 CA-C-N 116.35 -0.386 . . . . 0.0 110.288 179.634 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . 0.451 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 60.6 m -151.22 -174.32 4.78 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.275 -179.312 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 90.28 174.38 44.92 Favored Glycine 0 CA--C 1.525 0.667 0 N-CA-C 110.784 -0.926 . . . . 0.0 110.784 -179.731 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.561 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.1 m -82.47 160.81 22.59 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-O 120.607 0.241 . . . . 0.0 110.437 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 62.0 ttp180 -60.53 -43.29 97.3 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.725 179.549 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.6 m-85 -61.72 -41.15 97.23 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.272 -0.422 . . . . 0.0 111.273 -179.453 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 71.7 m-20 -133.61 54.66 1.94 Allowed 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.649 -179.561 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.561 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.11 147.54 53.28 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.291 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.417 ' O ' ' O ' ' A' ' 59' ' ' CYS . 11.7 p90 -153.81 170.16 21.62 Favored 'General case' 0 CA--C 1.519 -0.228 0 CA-C-O 121.005 0.431 . . . . 0.0 110.766 -179.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 58.1 m -73.79 135.42 43.51 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 109.534 -0.543 . . . . 0.0 109.534 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -49.0 167.9 0.2 Allowed Pre-proline 0 CA--C 1.534 0.349 0 CA-C-N 116.542 -0.299 . . . . 0.0 111.386 -178.937 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 33.8 Cg_exo -57.17 132.29 50.37 Favored 'Trans proline' 0 N--CA 1.494 1.542 0 C-N-CA 122.014 1.809 . . . . 0.0 111.643 178.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 97.14 -17.25 59.51 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.722 -0.951 . . . . 0.0 110.722 179.782 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.576 ' CZ3' ' ND2' ' A' ' 57' ' ' ASN . 31.5 m95 -113.61 139.79 48.73 Favored 'General case' 0 C--O 1.233 0.225 0 CA-C-O 120.927 0.394 . . . . 0.0 110.363 179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -125.48 -174.01 2.97 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.192 179.587 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 74.6 p -115.48 161.51 18.48 Favored 'General case' 0 CA--C 1.518 -0.262 0 CA-C-N 116.018 -0.537 . . . . 0.0 110.432 179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.524 ' O ' ' N ' ' A' ' 77' ' ' GLY . 17.8 mt -87.62 151.68 50.72 Favored Pre-proline 0 C--N 1.328 -0.339 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.881 -179.599 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.437 ' C ' ' H ' ' A' ' 77' ' ' GLY . 73.1 Cg_exo -39.21 107.03 0.06 OUTLIER 'Trans proline' 0 C--N 1.314 -1.247 0 C-N-CA 122.235 1.957 . . . . 0.0 112.116 179.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 72.98 -11.17 4.88 Favored Glycine 0 CA--C 1.525 0.665 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.459 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.524 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.01 174.48 53.77 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.6 m-20 -135.28 13.49 3.53 Favored 'General case' 0 C--O 1.236 0.346 0 CA-C-O 120.85 0.357 . . . . 0.0 111.06 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -84.63 129.09 34.88 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.503 179.95 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 63.5 m -95.2 60.45 2.33 Favored 'General case' 0 N--CA 1.463 0.2 0 N-CA-C 109.982 -0.377 . . . . 0.0 109.982 -179.921 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 37.3 pt -119.17 26.65 3.81 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.515 0 CA-C-N 116.277 -0.419 . . . . 0.0 110.855 -179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 46.3 t -123.06 84.45 51.03 Favored Pre-proline 0 N--CA 1.464 0.263 0 CA-C-N 116.42 -0.354 . . . . 0.0 110.953 -179.734 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -63.32 150.26 89.04 Favored 'Trans proline' 0 N--CA 1.495 1.616 0 C-N-CA 122.597 2.198 . . . . 0.0 111.69 179.077 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.407 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.9 mt -94.0 121.98 45.08 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 178.837 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -99.33 129.81 45.57 Favored 'General case' 0 N--CA 1.465 0.302 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 -179.8 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.403 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -63.18 -45.92 89.51 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 121.206 0.527 . . . . 0.0 110.169 179.951 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.1 m-70 -122.38 146.57 47.22 Favored 'General case' 0 N--CA 1.466 0.375 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.467 179.765 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -52.42 125.42 16.15 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.376 -179.635 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.8 m -66.56 -2.03 4.31 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.692 -0.685 . . . . 0.0 110.544 179.887 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 55.59 -116.23 6.84 Favored Glycine 0 CA--C 1.523 0.566 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.431 ' N ' ' OD1' ' A' ' 91' ' ' ASP . 31.8 p-10 -74.91 -1.26 21.63 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.551 0.215 . . . . 0.0 110.676 -179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -109.61 -164.29 19.83 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.7 -0.96 . . . . 0.0 110.7 179.763 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.475 ' CE1' ' OG ' ' A' ' 95' ' ' SER . 54.9 p90 -142.84 150.97 40.6 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-O 120.966 0.412 . . . . 0.0 110.646 179.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.8 m -69.64 114.97 8.35 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.035 -0.53 . . . . 0.0 109.832 -179.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.475 ' OG ' ' CE1' ' A' ' 93' ' ' PHE . 5.0 m -105.25 -19.03 13.93 Favored 'General case' 0 CA--C 1.513 -0.453 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.586 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 16.4 mtt85 -157.08 162.54 27.39 Favored Pre-proline 0 N--CA 1.454 -0.263 0 C-N-CA 120.423 -0.511 . . . . 0.0 110.737 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -50.09 122.45 9.22 Favored 'Trans proline' 0 N--CA 1.49 1.32 0 C-N-CA 121.95 1.767 . . . . 0.0 111.341 178.844 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.403 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 72.0 m-20 52.93 38.64 27.52 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 116.132 -0.486 . . . . 0.0 109.982 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.7 mtp -146.29 118.76 8.47 Favored 'General case' 0 C--O 1.236 0.377 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.492 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 37.8 m -105.95 150.42 25.7 Favored 'General case' 0 C--O 1.232 0.178 0 CA-C-N 115.45 -0.795 . . . . 0.0 110.718 179.199 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . 0.432 ' HG1' ' CB ' ' A' ' 95' ' ' SER . 64.7 m -119.69 113.38 20.58 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 115.529 -0.76 . . . . 0.0 109.582 179.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -80.64 157.19 72.51 Favored Pre-proline 0 C--N 1.327 -0.401 0 CA-C-N 116.002 -0.544 . . . . 0.0 110.629 -179.805 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_endo -63.3 -21.19 71.71 Favored 'Trans proline' 0 C--N 1.309 -1.504 0 C-N-CA 122.65 2.234 . . . . 0.0 111.474 178.897 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.8 t -67.71 -16.59 64.21 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.727 179.429 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 105.63 -20.38 36.97 Favored Glycine 0 CA--C 1.524 0.617 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.7 tp60 -68.75 151.54 46.51 Favored 'General case' 0 N--CA 1.454 -0.263 0 CA-C-O 120.888 0.375 . . . . 0.0 110.528 -179.938 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -131.22 135.15 60.21 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.371 0 CA-C-N 115.988 -0.551 . . . . 0.0 110.711 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.676 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -167.26 -179.19 0.75 Allowed Pre-proline 0 C--N 1.326 -0.447 0 C-N-CA 120.522 -0.471 . . . . 0.0 110.647 179.318 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.676 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 31.5 Cg_exo -60.29 -16.02 38.43 Favored 'Trans proline' 0 N--CA 1.499 1.806 0 C-N-CA 122.953 2.435 . . . . 0.0 111.907 179.398 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 27.8 m -160.29 159.81 31.79 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.756 179.723 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -82.64 167.15 18.54 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.23 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -61.32 158.26 31.36 Favored Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.681 -0.967 . . . . 0.0 110.681 179.684 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 11.5 t -60.68 -42.83 97.91 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.747 0.308 . . . . 0.0 110.819 -179.875 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 85.7 mtp180 -125.15 148.51 48.55 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.488 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 15.6 m -73.54 157.47 36.67 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.52 -179.951 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 24.4 mm -71.89 131.8 34.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.107 -179.704 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 96.9 mt-30 -137.01 162.01 34.48 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.11 -0.495 . . . . 0.0 110.538 -179.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 78.5 m80 44.87 -117.82 0.62 Allowed 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.895 -0.593 . . . . 0.0 110.432 -179.746 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 177.37 4.87 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.008 0.432 . . . . 0.0 110.082 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 16.2 m120 -62.6 -40.36 96.68 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.855 -0.611 . . . . 0.0 110.112 179.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.757 HG22 ' H ' ' A' ' 122' ' ' ARG . 36.1 mm -74.24 178.04 0.52 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.239 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.757 ' H ' HG22 ' A' ' 121' ' ' ILE . 1.0 OUTLIER -127.68 134.03 49.6 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.166 179.354 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 11.5 m -118.21 144.6 45.61 Favored 'General case' 0 C--N 1.332 -0.168 0 N-CA-C 109.404 -0.591 . . . . 0.0 109.404 179.495 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 63.6 mtm -144.3 169.37 18.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.284 -179.089 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 59.28 40.52 21.23 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.348 -0.387 . . . . 0.0 111.32 179.743 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 77.46 23.47 67.76 Favored Glycine 0 C--N 1.333 0.371 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.03 119.92 5.07 Favored Glycine 0 CA--C 1.525 0.661 0 C-N-CA 120.432 -0.89 . . . . 0.0 110.929 -179.6 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.2 p -79.43 145.29 33.39 Favored 'General case' 0 C--N 1.331 -0.201 0 C-N-CA 121.035 -0.266 . . . . 0.0 110.54 -179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.8 t -97.4 118.44 33.88 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.75 179.826 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.422 ' O ' ' N ' ' A' ' 133' ' ' HIS . 29.8 t -148.13 139.76 23.73 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.575 179.491 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 4.5 p-10 41.98 45.93 3.43 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.126 178.974 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.2 m-20 55.45 36.99 28.25 Favored 'General case' 0 C--N 1.33 -0.28 0 C-N-CA 120.852 -0.339 . . . . 0.0 110.457 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.422 ' N ' ' O ' ' A' ' 130' ' ' SER . 58.4 m80 -142.7 141.89 31.9 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.261 179.895 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.467 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 81.4 m -99.93 119.82 38.83 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.363 -0.38 . . . . 0.0 110.497 179.556 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.6 mt -98.06 128.26 44.48 Favored 'General case' 0 CA--C 1.518 -0.267 0 N-CA-C 109.278 -0.638 . . . . 0.0 109.278 179.662 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -89.79 134.61 34.09 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.858 -179.397 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 35.1 mt-30 -72.26 -173.77 1.16 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.34 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.7 tttm -67.77 129.13 38.97 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 116.48 -0.327 . . . . 0.0 110.731 -179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 102.64 -9.33 55.48 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 111.172 -0.771 . . . . 0.0 111.172 -179.991 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 97.8 m-85 -125.46 141.54 52.0 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.859 0.361 . . . . 0.0 110.528 179.454 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 27.6 pt -132.66 173.79 14.26 Favored 'Isoleucine or valine' 0 C--O 1.24 0.563 0 CA-C-N 116.012 -0.54 . . . . 0.0 109.743 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 112.61 153.54 11.74 Favored Glycine 0 CA--C 1.522 0.531 0 N-CA-C 110.608 -0.997 . . . . 0.0 110.608 179.257 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.0 p -63.01 -45.5 92.1 Favored 'General case' 0 C--N 1.328 -0.332 0 C-N-CA 120.741 -0.384 . . . . 0.0 110.698 -179.872 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -97.83 1.75 48.6 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.511 179.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 16.4 m 62.62 133.21 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.472 0 CA-C-N 115.996 -0.547 . . . . 0.0 109.871 -179.398 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 161.29 -6.71 0.1 OUTLIER Glycine 0 N--CA 1.45 -0.391 0 N-CA-C 110.588 -1.005 . . . . 0.0 110.588 -179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 6.3 tp-100 -109.21 111.58 60.04 Favored Pre-proline 0 CA--C 1.543 0.693 0 C-N-CA 120.747 -0.381 . . . . 0.0 110.58 179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.0 Cg_endo -75.64 156.77 40.23 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.517 2.145 . . . . 0.0 112.435 -179.901 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 90.9 t -101.98 114.92 42.77 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.295 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.912 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.05 98.25 11.65 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 116.09 -0.505 . . . . 0.0 110.306 -179.064 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 98.5 mt-10 -65.77 -39.66 91.25 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.71 -179.756 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 72.1 m -79.62 -7.55 58.62 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.84 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 58.46 161.69 0.05 OUTLIER Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 179.864 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 66.7 m -106.51 111.17 23.61 Favored 'General case' 0 N--CA 1.466 0.346 0 N-CA-C 109.819 -0.437 . . . . 0.0 109.819 179.631 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 89.0 mt -63.18 -42.26 99.35 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.861 -179.647 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.521 ' C ' ' H ' ' A' ' 158' ' ' GLY . 64.8 t30 -95.7 173.0 7.69 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.866 -0.606 . . . . 0.0 110.416 -179.99 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -69.59 37.5 0.36 Allowed Glycine 0 CA--C 1.524 0.64 0 N-CA-C 110.837 -0.905 . . . . 0.0 110.837 179.766 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.521 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -76.55 -172.05 34.5 Favored Glycine 0 CA--C 1.523 0.539 0 N-CA-C 110.677 -0.969 . . . . 0.0 110.677 179.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 9.9 tpt180 -132.21 143.46 49.96 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 120.872 0.367 . . . . 0.0 110.521 -179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.6 m -81.92 113.51 19.89 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.281 -179.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 34.3 m -88.42 -23.69 6.32 Favored 'Isoleucine or valine' 0 CA--C 1.519 -0.232 0 CA-C-N 115.93 -0.577 . . . . 0.0 110.536 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.5 171.99 3.81 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.511 179.95 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.6 Cg_exo -50.45 127.96 21.93 Favored 'Trans proline' 0 C--N 1.312 -1.372 0 C-N-CA 121.711 1.607 . . . . 0.0 112.01 178.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 58.8 t30 53.93 36.7 24.97 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.649 -0.705 . . . . 0.0 110.715 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.414 ' HD2' ' HB3' ' A' ' 162' ' ' ALA . 94.7 mtt-85 -141.42 132.8 26.7 Favored 'General case' 0 C--O 1.236 0.345 0 CA-C-O 121.207 0.527 . . . . 0.0 110.632 178.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 3.4 t -141.45 150.77 42.71 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.954 179.529 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -124.13 135.52 53.57 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 115.801 -0.636 . . . . 0.0 109.687 179.431 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.97 137.13 32.62 Favored 'General case' 0 C--N 1.329 -0.302 0 N-CA-C 109.537 -0.542 . . . . 0.0 109.537 -179.035 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 5.0 p -112.58 19.2 17.73 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-O 120.88 0.371 . . . . 0.0 111.44 179.764 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.476 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 34.3 t80 -114.49 31.75 6.42 Favored 'General case' 0 C--N 1.324 -0.511 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.725 -179.401 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 79.34 15.63 79.69 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 110.857 -0.897 . . . . 0.0 110.857 179.919 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 12.7 m-85 -108.26 163.22 13.37 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.281 0.562 . . . . 0.0 110.917 -179.858 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 2.9 t -147.1 152.31 38.27 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.576 -0.738 . . . . 0.0 110.035 179.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 129.72 162.42 10.82 Favored Glycine 0 CA--C 1.529 0.914 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 179.673 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 50.4 Cg_endo -68.83 -22.86 36.01 Favored 'Trans proline' 0 N--CA 1.495 1.615 0 C-N-CA 122.721 2.281 . . . . 0.0 112.186 -179.447 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 47.9 mt-30 -124.37 7.29 8.38 Favored 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.523 -179.071 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 73.2 m 48.36 61.96 2.77 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.642 -179.813 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 . . . . . 0 C--O 1.22 -0.478 0 CA-C-O 118.111 -0.947 . . . . 0.0 110.584 -179.979 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 12.4 t . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.491 -0.559 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -62.19 -40.39 95.91 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.31 -0.404 . . . . 0.0 110.452 -179.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 17.8 ptp180 -69.19 -37.92 78.39 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.432 179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -72.92 163.36 54.92 Favored Glycine 0 CA--C 1.523 0.536 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.833 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -169.64 170.98 43.06 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.879 -0.889 . . . . 0.0 110.879 179.919 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -177.26 176.78 48.2 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.884 -0.887 . . . . 0.0 110.884 179.918 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 179.74 -177.34 48.1 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 77.8 m80 -81.34 137.56 35.74 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.846 0.355 . . . . 0.0 110.274 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 38.5 t0 -156.64 175.09 14.51 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.487 -179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.23 149.09 50.53 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.393 179.867 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 64.8 mt -66.14 151.48 46.85 Favored 'General case' 0 CA--C 1.516 -0.339 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.491 -179.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -127.0 161.16 29.03 Favored 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.377 -179.566 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 82.55 169.7 44.33 Favored Glycine 0 CA--C 1.528 0.858 0 N-CA-C 110.64 -0.984 . . . . 0.0 110.64 -179.439 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -71.41 -176.08 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.718 0 C-N-CA 123.009 2.473 . . . . 0.0 111.908 179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 69.7 m-20 58.9 42.05 20.24 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.912 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.459 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 50.3 t -107.86 133.72 51.83 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.456 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 179.954 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . 0.406 ' O ' ' O ' ' A' ' 66' ' ' TYR . 88.8 m -142.69 -179.02 6.07 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.868 -0.606 . . . . 0.0 110.025 -179.431 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 87.34 164.37 40.06 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.531 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.3 m -79.74 168.21 19.61 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 120.786 0.327 . . . . 0.0 110.394 179.966 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.7 ttt-85 -61.04 -43.23 99.2 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.502 -179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.9 m-85 -62.36 -40.54 96.75 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.962 -179.652 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -129.35 52.87 1.94 Allowed 'General case' 0 N--CA 1.451 -0.396 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.618 -179.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.531 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -68.77 142.48 54.92 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.352 179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.406 ' O ' ' O ' ' A' ' 59' ' ' CYS . 12.2 p90 -154.7 165.3 36.99 Favored 'General case' 0 N--CA 1.465 0.302 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.492 179.441 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.541 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 81.9 m -71.03 137.92 49.42 Favored 'General case' 0 C--N 1.326 -0.442 0 C-N-CA 120.489 -0.484 . . . . 0.0 109.782 -179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.459 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 27.4 m -52.9 151.77 8.06 Favored Pre-proline 0 C--N 1.325 -0.474 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.106 -178.852 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.93 130.75 32.32 Favored 'Trans proline' 0 N--CA 1.495 1.577 0 C-N-CA 121.559 1.506 . . . . 0.0 112.755 -179.917 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 98.46 -6.95 61.4 Favored Glycine 0 CA--C 1.525 0.718 0 N-CA-C 111.052 -0.819 . . . . 0.0 111.052 -179.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 95.1 m95 -119.49 137.2 53.95 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.007 0.432 . . . . 0.0 110.79 179.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.1 ptmt -123.85 -177.05 3.63 Favored 'General case' 0 C--O 1.233 0.203 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.398 179.775 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.541 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 35.8 p -131.21 172.08 12.55 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.35 -179.405 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.49 ' O ' ' N ' ' A' ' 77' ' ' GLY . 43.1 mt -90.31 148.59 39.43 Favored Pre-proline 0 C--N 1.329 -0.323 0 CA-C-N 116.049 -0.523 . . . . 0.0 110.67 -179.563 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 74.6 Cg_exo -40.49 111.49 0.14 Allowed 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.014 1.81 . . . . 0.0 112.574 179.336 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 82.02 -16.58 21.06 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 111.168 -0.773 . . . . 0.0 111.168 179.589 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.49 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -74.76 165.0 54.72 Favored Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 14.6 m120 -129.72 8.66 5.36 Favored 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.045 0.45 . . . . 0.0 110.958 179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 99.0 mt-30 -87.23 130.04 34.73 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.381 -179.872 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 56.8 m -94.21 40.8 1.08 Allowed 'General case' 0 N--CA 1.468 0.426 0 N-CA-C 109.732 -0.47 . . . . 0.0 109.732 179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 36.4 pt -94.67 11.68 3.93 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.606 -179.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 48.9 t -113.64 107.02 53.45 Favored Pre-proline 0 CA--C 1.538 0.498 0 CA-C-N 116.323 -0.398 . . . . 0.0 110.684 -179.76 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -76.53 157.78 36.29 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.282 1.988 . . . . 0.0 112.243 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.0 mt -103.12 126.18 57.47 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.306 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.063 179.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -100.16 127.08 46.48 Favored 'General case' 0 N--CA 1.465 0.296 0 N-CA-C 109.368 -0.604 . . . . 0.0 109.368 -179.969 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -62.27 -45.27 94.02 Favored 'General case' 0 C--N 1.326 -0.428 0 N-CA-C 109.684 -0.487 . . . . 0.0 109.684 -179.472 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -126.19 157.32 38.48 Favored 'General case' 0 N--CA 1.468 0.439 0 CA-C-N 115.987 -0.551 . . . . 0.0 110.637 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -60.97 136.49 58.1 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.422 -179.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 57.7 m -78.78 -26.03 44.43 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-N 115.778 -0.646 . . . . 0.0 110.809 179.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 82.68 -109.32 3.07 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 111.39 -0.684 . . . . 0.0 111.39 179.926 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . 0.493 ' OD1' ' N ' ' A' ' 91' ' ' ASP . 23.0 p-10 -78.87 -2.61 40.64 Favored 'General case' 0 C--N 1.33 -0.246 0 C-N-CA 121.113 -0.235 . . . . 0.0 110.674 -179.634 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.55 -160.46 16.16 Favored Glycine 0 CA--C 1.522 0.505 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 179.845 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 53.8 p90 -147.73 153.15 38.91 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 120.977 0.418 . . . . 0.0 110.826 179.794 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 2.6 m -63.58 113.4 3.29 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.004 -0.544 . . . . 0.0 109.973 -179.692 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 92.6 p -100.89 -22.91 14.68 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.121 -0.49 . . . . 0.0 110.309 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 15.2 mtp180 -158.68 161.14 28.9 Favored Pre-proline 0 CA--C 1.531 0.236 0 C-N-CA 120.255 -0.578 . . . . 0.0 110.688 179.696 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -45.91 119.47 2.9 Favored 'Trans proline' 0 N--CA 1.491 1.378 0 C-N-CA 121.926 1.751 . . . . 0.0 111.725 179.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . . . . . . . . . 64.1 m-20 54.82 39.56 31.5 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.34 -0.391 . . . . 0.0 110.271 179.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 69.8 mmm -145.83 122.13 10.91 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.297 -0.41 . . . . 0.0 110.441 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 27.3 m -105.8 147.55 28.52 Favored 'General case' 0 C--O 1.232 0.165 0 CA-C-N 115.838 -0.619 . . . . 0.0 110.286 178.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 78.7 m -122.3 113.44 19.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.753 179.49 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.422 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -76.23 157.38 83.06 Favored Pre-proline 0 C--N 1.326 -0.447 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.021 179.895 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.422 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.4 Cg_endo -62.29 -21.67 72.97 Favored 'Trans proline' 0 N--CA 1.494 1.519 0 C-N-CA 122.837 2.358 . . . . 0.0 111.48 178.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 1.5 m -63.61 -33.69 76.17 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.555 178.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 123.32 -17.24 7.96 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 -179.443 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . 0.467 ' NE2' ' H ' ' A' ' 107' ' ' ILE . 1.2 tm0? -69.29 145.0 53.42 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-O 120.902 0.382 . . . . 0.0 110.648 179.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.467 ' H ' ' NE2' ' A' ' 106' ' ' GLN . 92.0 mt -124.29 131.29 73.04 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.626 179.85 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.66 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -171.19 179.43 0.67 Allowed Pre-proline 0 C--N 1.326 -0.431 0 CA-C-N 116.264 -0.425 . . . . 0.0 110.416 179.259 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.66 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 35.4 Cg_exo -58.95 -21.8 59.94 Favored 'Trans proline' 0 N--CA 1.498 1.793 0 C-N-CA 122.772 2.315 . . . . 0.0 111.999 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 92.7 p -151.27 164.28 36.97 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 116.103 -0.499 . . . . 0.0 110.333 -179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -79.33 144.71 33.96 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.573 -179.479 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -173.36 139.61 5.19 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 8.7 m -84.13 -12.83 54.34 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.77 0.319 . . . . 0.0 110.35 -179.964 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.4 mmt-85 -80.57 142.98 33.56 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.448 -179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.468 ' O ' ' OG ' ' A' ' 115' ' ' SER . 3.8 p 59.47 100.28 0.02 OUTLIER 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.828 -0.624 . . . . 0.0 110.293 -179.763 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 94.3 mt -111.3 128.85 67.52 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.236 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.238 179.856 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -121.34 144.59 48.56 Favored 'General case' 0 N--CA 1.465 0.316 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.147 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.44 ' O ' ' O ' ' A' ' 119' ' ' CYS . 4.7 p80 -97.33 175.17 6.35 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.073 179.917 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.44 ' O ' ' O ' ' A' ' 118' ' ' HIS . 1.2 m 58.03 146.08 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.103 0.477 . . . . 0.0 110.756 -179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 44.3 t30 -63.97 -39.98 95.36 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.255 179.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.534 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 11.3 tt -112.17 169.7 4.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.465 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.188 179.658 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.691 HH21 ' CE1' ' A' ' 144' ' ' HIS . 28.5 ptt180 -83.21 118.88 23.92 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.034 179.732 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -123.7 143.14 50.45 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 115.826 -0.624 . . . . 0.0 109.64 179.841 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.573 ' N ' ' SD ' ' A' ' 124' ' ' MET . 2.1 mpp? -141.96 161.49 37.85 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.037 -0.529 . . . . 0.0 110.182 179.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 70.1 m-80 57.98 51.79 8.53 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.282 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 71.79 19.08 77.89 Favored Glycine 0 CA--C 1.52 0.39 0 N-CA-C 110.653 -0.979 . . . . 0.0 110.653 179.496 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.44 143.22 40.31 Favored Glycine 0 CA--C 1.521 0.446 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 179.985 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.0 t -121.4 141.12 51.28 Favored 'General case' 0 N--CA 1.468 0.456 0 N-CA-C 109.975 -0.379 . . . . 0.0 109.975 179.788 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 10.5 p -93.15 131.55 38.11 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-O 120.83 0.348 . . . . 0.0 110.76 179.805 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.546 ' O ' ' N ' ' A' ' 132' ' ' ASP . 44.1 t -138.19 131.47 30.39 Favored 'General case' 0 N--CA 1.463 0.222 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.187 179.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 60.8 t0 55.31 -80.57 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.504 -179.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.546 ' N ' ' O ' ' A' ' 130' ' ' SER . 37.7 p-10 -155.42 23.28 0.41 Allowed 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 116.279 -0.419 . . . . 0.0 110.734 179.774 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.443 ' CD2' ' OD1' ' A' ' 132' ' ' ASP . 96.0 m-70 -141.79 158.05 44.27 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.391 -0.368 . . . . 0.0 110.519 -179.742 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.464 ' SG ' HG23 ' A' ' 121' ' ' ILE . 0.8 OUTLIER -96.96 131.73 43.46 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.0 -0.545 . . . . 0.0 110.154 179.854 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 86.3 mt -92.68 128.86 38.69 Favored 'General case' 0 C--O 1.237 0.426 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.756 179.948 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . 0.466 ' SG ' ' O ' ' A' ' 140' ' ' TYR . 1.3 t -105.96 132.59 51.87 Favored 'General case' 0 N--CA 1.465 0.312 0 CA-C-N 115.726 -0.67 . . . . 0.0 110.694 -179.595 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.9 mm-40 -79.83 173.06 12.97 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 116.048 -0.524 . . . . 0.0 110.359 179.784 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -63.06 133.7 54.93 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.354 -0.385 . . . . 0.0 110.288 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 104.62 -25.84 24.45 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.72 -0.952 . . . . 0.0 110.72 -179.24 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.466 ' O ' ' SG ' ' A' ' 136' ' ' CYS . 96.5 m-85 -116.13 130.94 57.04 Favored 'General case' 0 N--CA 1.466 0.352 0 N-CA-C 110.083 -0.339 . . . . 0.0 110.083 179.282 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 28.7 pt -129.68 178.48 5.16 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.35 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.021 -179.319 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 115.92 159.72 12.07 Favored Glycine 0 N--CA 1.462 0.424 0 N-CA-C 110.798 -0.921 . . . . 0.0 110.798 179.51 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 37.7 p -66.12 -33.86 76.75 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.765 0.317 . . . . 0.0 110.546 -179.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.691 ' CE1' HH21 ' A' ' 122' ' ' ARG . 54.7 m-70 -103.97 1.64 31.41 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.751 -179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.414 ' O ' ' O ' ' A' ' 144' ' ' HIS . 41.8 t 59.82 122.9 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.881 0.372 . . . . 0.0 110.758 179.956 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 159.64 -23.56 0.29 Allowed Glycine 0 CA--C 1.519 0.317 0 N-CA-C 110.85 -0.9 . . . . 0.0 110.85 -179.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 1.1 tp-100 -76.89 118.04 69.06 Favored Pre-proline 0 CA--C 1.543 0.673 0 C-N-CA 120.432 -0.507 . . . . 0.0 110.629 -179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_endo -75.46 157.42 40.84 Favored 'Trans proline' 0 N--CA 1.496 1.64 0 C-N-CA 122.641 2.227 . . . . 0.0 112.393 -179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.6 t -121.11 129.8 75.32 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.445 179.85 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.1 m -92.96 98.97 11.7 Favored 'General case' 0 C--N 1.329 -0.323 0 N-CA-C 108.781 -0.822 . . . . 0.0 108.781 178.629 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 77.7 tt0 -67.07 -36.99 83.21 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.471 -179.061 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 89.0 p -85.88 -6.4 59.09 Favored 'General case' 0 N--CA 1.463 0.196 0 CA-C-N 116.325 -0.398 . . . . 0.0 110.93 -179.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.94 -172.17 33.66 Favored Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.564 -1.014 . . . . 0.0 110.564 179.797 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 57.3 m -139.81 106.69 5.41 Favored 'General case' 0 N--CA 1.464 0.274 0 N-CA-C 109.915 -0.402 . . . . 0.0 109.915 179.75 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 82.2 mt -63.45 -42.18 98.65 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.264 -0.426 . . . . 0.0 110.785 -179.773 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.539 ' C ' ' H ' ' A' ' 158' ' ' GLY . 27.6 t-20 -90.56 170.28 10.31 Favored 'General case' 0 C--N 1.327 -0.411 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.405 179.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -68.8 35.38 0.28 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.859 -0.896 . . . . 0.0 110.859 179.657 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.539 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -71.77 -174.63 21.86 Favored Glycine 0 CA--C 1.522 0.47 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.931 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 77.6 mtm180 -131.3 147.1 52.54 Favored 'General case' 0 N--CA 1.467 0.379 0 CA-C-O 120.72 0.295 . . . . 0.0 110.812 179.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 3.6 t -88.12 112.87 23.17 Favored 'General case' 0 N--CA 1.463 0.19 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.719 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.2 t -90.47 -54.89 6.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.663 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -131.06 175.91 3.31 Favored Pre-proline 0 N--CA 1.466 0.328 0 CA-C-N 116.433 -0.349 . . . . 0.0 110.196 -179.498 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.3 Cg_exo -53.22 130.29 37.59 Favored 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 121.813 1.675 . . . . 0.0 112.023 179.702 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 66.5 t30 51.38 35.78 14.83 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.934 -0.575 . . . . 0.0 110.47 179.814 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 59.7 ttt85 -137.08 124.34 21.83 Favored 'General case' 0 C--O 1.236 0.384 0 CA-C-N 116.081 -0.509 . . . . 0.0 110.588 179.681 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 2.9 t -130.21 138.27 50.49 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.549 179.384 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -95.02 140.65 29.67 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.822 -0.626 . . . . 0.0 109.768 179.416 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 59.3 m -81.23 143.3 32.41 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.839 0.352 . . . . 0.0 110.158 -179.406 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 96.1 m -63.46 -45.37 91.12 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 115.992 -0.549 . . . . 0.0 111.024 -179.424 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.525 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 80.3 t80 -98.56 24.54 7.32 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-O 121.169 0.509 . . . . 0.0 110.815 -179.308 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.16 24.2 70.28 Favored Glycine 0 CA--C 1.522 0.513 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 179.567 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 2.5 t80 -56.27 159.57 3.46 Favored 'General case' 0 C--N 1.327 -0.403 0 CA-C-O 120.88 0.371 . . . . 0.0 110.18 -179.369 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.563 HG22 ' N ' ' A' ' 174' ' ' GLY . 89.4 m -82.26 162.42 22.33 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.198 0.523 . . . . 0.0 111.143 -179.749 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . 0.563 ' N ' HG22 ' A' ' 173' ' ' THR . . . 66.94 152.03 0.2 Allowed Glycine 0 CA--C 1.533 1.21 0 N-CA-C 111.461 -0.656 . . . . 0.0 111.461 179.423 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 41.8 Cg_endo -66.57 -29.1 44.52 Favored 'Trans proline' 0 N--CA 1.497 1.734 0 C-N-CA 122.695 2.263 . . . . 0.0 112.056 179.99 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 77.1 mt-30 -78.75 -15.46 58.4 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.603 -179.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 39.4 m 54.22 52.26 12.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.42 179.612 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 18.4 mm-40 . . . . . 0 C--O 1.22 -0.451 0 CA-C-O 118.063 -0.97 . . . . 0.0 110.501 -179.968 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 39.3 m . . . . . 0 N--CA 1.491 1.598 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.08 141.07 57.61 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.559 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 85.1 mtp180 -93.11 139.33 30.68 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.463 179.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 111.78 155.5 13.1 Favored Glycine 0 N--CA 1.465 0.611 0 N-CA-C 110.831 -0.908 . . . . 0.0 110.831 -179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -102.44 120.6 6.88 Favored Glycine 0 CA--C 1.523 0.575 0 N-CA-C 110.966 -0.854 . . . . 0.0 110.966 179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -94.43 177.22 36.05 Favored Glycine 0 CA--C 1.525 0.675 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 179.7 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -140.1 123.72 2.5 Favored Glycine 0 CA--C 1.523 0.542 0 N-CA-C 110.629 -0.989 . . . . 0.0 110.629 179.659 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 97.3 m-70 -134.07 131.59 38.98 Favored 'General case' 0 N--CA 1.466 0.341 0 CA-C-O 120.791 0.329 . . . . 0.0 110.336 179.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 97.9 m-20 -74.67 142.01 44.52 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.558 179.872 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.405 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -150.95 131.56 13.93 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.409 -0.359 . . . . 0.0 110.511 179.644 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 81.6 mt -76.69 146.2 38.22 Favored 'General case' 0 N--CA 1.45 -0.47 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.428 179.679 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 56.0 mtpt -128.86 160.4 32.73 Favored 'General case' 0 CA--C 1.518 -0.254 0 CA-C-O 121.3 0.571 . . . . 0.0 110.77 -179.54 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 103.48 162.74 25.29 Favored Glycine 0 CA--C 1.528 0.904 0 N-CA-C 110.807 -0.917 . . . . 0.0 110.807 179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -78.08 3.08 7.35 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.704 2.269 . . . . 0.0 112.248 179.794 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.6 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 0.3 OUTLIER -112.58 61.3 0.63 Allowed 'General case' 0 N--CA 1.471 0.603 0 CA-C-O 121.105 0.479 . . . . 0.0 110.429 -179.654 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 55.9 t -109.71 129.68 64.17 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.408 0 CA-C-O 121.193 0.52 . . . . 0.0 109.72 179.73 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 85.1 m -141.92 176.91 8.56 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.664 -178.558 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 171.5 45.85 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.694 -0.963 . . . . 0.0 110.694 -179.463 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.548 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.3 m -82.19 165.1 20.78 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-O 120.703 0.287 . . . . 0.0 110.457 179.926 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 77.0 ttt180 -60.02 -42.67 94.86 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.659 179.673 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -61.17 -41.36 96.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.248 -0.433 . . . . 0.0 111.006 -179.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 94.5 m-20 -132.72 54.75 1.93 Allowed 'General case' 0 N--CA 1.451 -0.417 0 CA-C-N 116.397 -0.365 . . . . 0.0 110.489 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.548 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.52 142.49 56.54 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.493 179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 13.6 p90 -151.45 165.89 32.77 Favored 'General case' 0 N--CA 1.464 0.253 0 CA-C-O 121.186 0.517 . . . . 0.0 110.901 179.917 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 57' ' ' ASN . 1.6 t -73.59 138.42 44.89 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 115.922 -0.581 . . . . 0.0 110.436 179.51 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -58.42 157.97 16.3 Favored Pre-proline 0 C--N 1.323 -0.55 0 CA-C-N 115.974 -0.557 . . . . 0.0 109.859 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 28.4 Cg_endo -60.76 137.35 72.4 Favored 'Trans proline' 0 N--CA 1.493 1.442 0 C-N-CA 121.903 1.735 . . . . 0.0 111.817 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.32 -18.59 55.21 Favored Glycine 0 CA--C 1.528 0.871 0 N-CA-C 110.97 -0.852 . . . . 0.0 110.97 -179.563 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.6 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.1 m95 -112.79 134.69 54.19 Favored 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 117.066 0.433 . . . . 0.0 109.84 179.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 12.8 ptpt -114.2 -175.1 2.6 Favored 'General case' 0 N--CA 1.469 0.5 0 N-CA-C 109.96 -0.385 . . . . 0.0 109.96 179.552 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 40.5 p -125.4 165.94 17.49 Favored 'General case' 0 N--CA 1.466 0.37 0 N-CA-C 109.935 -0.395 . . . . 0.0 109.935 179.732 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 59.6 mt -87.67 149.19 45.66 Favored Pre-proline 0 CA--C 1.536 0.418 0 CA-C-N 116.592 -0.276 . . . . 0.0 110.721 -179.344 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.509 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.8 Cg_exo -44.77 123.15 4.61 Favored 'Trans proline' 0 N--CA 1.491 1.362 0 C-N-CA 121.693 1.596 . . . . 0.0 112.208 179.722 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 65.42 -7.56 0.9 Allowed Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.991 -0.843 . . . . 0.0 110.991 179.564 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.509 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -93.77 179.48 38.48 Favored Glycine 0 CA--C 1.523 0.574 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 -179.605 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.405 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 46.9 p30 -138.0 11.89 2.86 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-O 120.831 0.348 . . . . 0.0 110.797 179.675 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.1 mt-30 -82.37 129.46 34.88 Favored 'General case' 0 C--N 1.333 -0.143 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.856 179.975 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 8.0 m -106.09 80.75 1.55 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.316 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 2.6 pt -129.69 15.88 2.44 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.651 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 2.5 t -126.77 99.77 29.01 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 110.086 -0.338 . . . . 0.0 110.086 179.811 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_endo -77.45 163.16 30.05 Favored 'Trans proline' 0 N--CA 1.49 1.266 0 C-N-CA 122.364 2.043 . . . . 0.0 111.939 -179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 45.7 mm -94.99 122.46 46.46 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -95.71 121.39 37.38 Favored 'General case' 0 C--N 1.33 -0.245 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.425 ' CB ' HD22 ' A' ' 98' ' ' ASN . 0.0 OUTLIER -62.74 -45.68 91.59 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-O 121.172 0.511 . . . . 0.0 109.766 -179.999 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.4 m-70 -112.77 137.92 50.37 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-N 116.007 -0.542 . . . . 0.0 110.087 179.385 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 19.9 m -60.56 134.35 56.99 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-O 120.958 0.409 . . . . 0.0 110.129 -179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 28.7 m -76.45 -31.78 58.03 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.182 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 66.88 -101.56 0.67 Allowed Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.437 -0.665 . . . . 0.0 111.437 179.505 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 84.7 m-20 -67.54 -17.71 64.75 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.835 0.35 . . . . 0.0 111.004 -179.462 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -107.78 -161.56 21.11 Favored Glycine 0 CA--C 1.526 0.778 0 N-CA-C 110.729 -0.948 . . . . 0.0 110.729 -179.966 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.435 ' CE2' ' OG ' ' A' ' 95' ' ' SER . 54.8 p90 -143.2 151.7 40.93 Favored 'General case' 0 N--CA 1.468 0.426 0 CA-C-O 120.903 0.382 . . . . 0.0 111.2 -179.93 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.9 t -64.49 114.14 4.14 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.064 -0.517 . . . . 0.0 111.157 -179.684 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.445 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 68.2 m -103.05 -23.75 13.66 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.771 -0.649 . . . . 0.0 110.769 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.7 mtt180 -162.31 165.47 15.58 Favored Pre-proline 0 CA--C 1.531 0.248 0 C-N-CA 120.396 -0.521 . . . . 0.0 110.407 179.85 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -50.6 123.55 11.65 Favored 'Trans proline' 0 N--CA 1.493 1.476 0 C-N-CA 121.601 1.534 . . . . 0.0 111.49 179.608 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.425 HD22 ' CB ' ' A' ' 86' ' ' ARG . 8.2 t-20 51.57 40.51 27.23 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 110.033 179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.9 mmm -147.47 114.48 6.16 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.576 179.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.42 ' N ' ' O ' ' A' ' 108' ' ' ALA . 35.5 m -101.28 149.28 24.18 Favored 'General case' 0 N--CA 1.464 0.261 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.323 178.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . 0.445 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 63.6 m -120.97 119.68 33.25 Favored 'General case' 0 CA--C 1.514 -0.41 0 CA-C-N 115.714 -0.675 . . . . 0.0 109.706 179.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -84.93 157.28 60.32 Favored Pre-proline 0 C--N 1.326 -0.435 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.143 -179.596 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -62.7 -19.23 67.63 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 C-N-CA 122.66 2.24 . . . . 0.0 111.78 179.127 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 42.0 m -69.79 -14.27 62.69 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.331 179.657 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 104.67 -20.4 39.32 Favored Glycine 0 N--CA 1.464 0.517 0 N-CA-C 111.01 -0.836 . . . . 0.0 111.01 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 51.8 tp60 -69.19 149.5 48.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.985 0.421 . . . . 0.0 110.092 -179.772 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.8 mt -129.33 133.6 65.23 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.508 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.627 179.825 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.658 ' HB1' ' CD ' ' A' ' 109' ' ' PRO . . . -166.55 -179.82 0.9 Allowed Pre-proline 0 CA--C 1.536 0.436 0 C-N-CA 120.559 -0.457 . . . . 0.0 110.287 179.604 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.658 ' CD ' ' HB1' ' A' ' 108' ' ' ALA . 32.2 Cg_exo -59.52 -20.07 55.29 Favored 'Trans proline' 0 N--CA 1.5 1.903 0 C-N-CA 122.835 2.357 . . . . 0.0 112.162 179.492 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 86.7 p -155.58 163.03 40.51 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.958 -0.565 . . . . 0.0 110.414 -179.862 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -86.49 141.03 29.38 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.35 179.924 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 152.68 -167.65 31.56 Favored Glycine 0 CA--C 1.522 0.496 0 N-CA-C 110.692 -0.963 . . . . 0.0 110.692 179.814 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 12.7 p -149.68 157.59 43.38 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.855 0.36 . . . . 0.0 110.059 179.591 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 41.6 ttm180 -90.43 135.79 33.47 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.541 -179.612 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 12.2 p -154.11 153.16 31.37 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.275 179.09 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 19.6 tt -157.62 138.92 5.03 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.531 179.808 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -112.97 146.48 38.97 Favored 'General case' 0 N--CA 1.466 0.344 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.325 179.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.404 ' CD2' ' O ' ' A' ' 119' ' ' CYS . 49.5 p-80 -154.11 -163.53 1.65 Allowed 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.273 -0.421 . . . . 0.0 110.26 -179.8 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.404 ' O ' ' CD2' ' A' ' 118' ' ' HIS . 76.9 m -69.45 126.3 29.35 Favored 'General case' 0 C--N 1.329 -0.318 0 N-CA-C 109.903 -0.406 . . . . 0.0 109.903 179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -92.14 9.34 33.96 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 121.027 0.441 . . . . 0.0 110.369 -179.688 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.501 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 14.8 tt -134.11 169.19 22.16 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.271 0 CA-C-N 115.846 -0.615 . . . . 0.0 110.607 179.851 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.501 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.6 ptm180 -100.12 106.45 18.17 Favored 'General case' 0 C--N 1.325 -0.499 0 CA-C-N 115.441 -0.8 . . . . 0.0 110.04 179.616 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.9 m -99.73 138.04 37.36 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.541 -0.754 . . . . 0.0 110.099 -179.883 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 66.2 mtt -143.23 160.64 40.09 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.249 -179.834 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.618 ' ND2' ' CD1' ' A' ' 140' ' ' TYR . 98.0 m-20 59.86 40.18 19.58 Favored 'General case' 0 C--N 1.332 -0.159 0 CA-C-N 116.394 -0.366 . . . . 0.0 110.841 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 74.52 28.58 63.2 Favored Glycine 0 CA--C 1.523 0.59 0 N-CA-C 111.105 -0.798 . . . . 0.0 111.105 179.41 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.01 128.79 23.3 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.796 -0.921 . . . . 0.0 110.796 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . 0.483 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 13.3 m -88.87 137.84 31.95 Favored 'General case' 0 C--N 1.329 -0.311 0 O-C-N 122.739 -0.271 . . . . 0.0 110.537 179.64 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 62.4 m -77.63 129.67 35.88 Favored 'General case' 0 C--N 1.329 -0.295 0 C-N-CA 120.827 -0.349 . . . . 0.0 110.166 179.725 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.417 ' O ' ' C ' ' A' ' 131' ' ' ASP . 40.9 t -143.85 136.39 27.03 Favored 'General case' 0 C--N 1.33 -0.244 0 N-CA-C 109.811 -0.44 . . . . 0.0 109.811 179.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 130' ' ' SER . 96.5 m-20 33.75 -99.91 0.02 OUTLIER 'General case' 0 N--CA 1.465 0.277 0 CA-C-N 116.392 -0.367 . . . . 0.0 111.387 -179.673 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 97.8 m-20 -125.3 4.75 7.75 Favored 'General case' 0 N--CA 1.467 0.378 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.365 179.651 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.9 m80 -129.65 154.48 47.08 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.739 -179.773 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.483 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.9 t -102.77 146.27 28.49 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 116.041 -0.527 . . . . 0.0 110.442 179.683 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.9 mt -98.61 131.26 44.94 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.155 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -97.83 134.26 41.22 Favored 'General case' 0 N--CA 1.463 0.197 0 CA-C-N 115.947 -0.57 . . . . 0.0 110.68 -179.725 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.5 mm-40 -80.67 178.23 8.49 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.707 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 86.2 tttt -66.59 133.24 49.88 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.283 -179.555 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.85 -22.54 35.08 Favored Glycine 0 N--CA 1.466 0.645 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.618 ' CD1' ' ND2' ' A' ' 125' ' ' ASN . 92.9 m-85 -121.63 134.41 54.99 Favored 'General case' 0 N--CA 1.465 0.306 0 CA-C-O 121.093 0.473 . . . . 0.0 110.531 179.52 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . 0.42 HG23 ' CG2' ' A' ' 149' ' ' VAL . 36.6 pt -121.94 -163.84 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.313 0 CA-C-N 115.775 -0.648 . . . . 0.0 110.357 -179.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 97.4 152.93 28.95 Favored Glycine 0 CA--C 1.524 0.615 0 N-CA-C 110.674 -0.971 . . . . 0.0 110.674 179.898 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 19.9 m -63.11 -45.03 93.92 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-O 120.881 0.372 . . . . 0.0 110.661 -179.922 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 97.8 m-70 -94.73 3.17 55.36 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.876 -179.68 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 33.7 t 61.4 116.78 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.329 -0.396 . . . . 0.0 110.472 -179.798 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.583 ' N ' HE21 ' A' ' 147' ' ' GLN . . . 173.71 -20.59 0.06 OUTLIER Glycine 0 CA--C 1.526 0.74 0 N-CA-C 111.165 -0.774 . . . . 0.0 111.165 179.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . 0.71 HE21 ' H ' ' A' ' 147' ' ' GLN . 0.0 OUTLIER -94.68 128.92 37.94 Favored Pre-proline 0 CA--C 1.548 0.888 0 CA-C-N 117.048 0.424 . . . . 0.0 110.267 -179.868 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -76.99 161.72 32.64 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.821 2.347 . . . . 0.0 111.809 178.918 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . 0.42 ' CG2' HG23 ' A' ' 141' ' ' ILE . 54.7 t -99.15 127.9 51.36 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.303 0 CA-C-O 120.84 0.352 . . . . 0.0 110.3 -179.418 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -101.57 90.53 4.09 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 178.98 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 80.0 tt0 -65.46 -43.09 91.42 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 116.077 -0.511 . . . . 0.0 110.519 -178.643 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 85.8 p -89.15 -8.75 53.09 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.527 179.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.447 ' O ' ' SG ' ' A' ' 166' ' ' CYS . . . 56.82 -179.46 0.63 Allowed Glycine 0 CA--C 1.522 0.519 0 N-CA-C 110.626 -0.99 . . . . 0.0 110.626 -179.899 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 11.3 m -117.73 118.78 33.0 Favored 'General case' 0 N--CA 1.465 0.32 0 N-CA-C 109.714 -0.476 . . . . 0.0 109.714 179.34 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.1 mt -63.21 -42.25 99.26 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.084 -0.507 . . . . 0.0 111.032 -179.162 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.554 ' C ' ' H ' ' A' ' 158' ' ' GLY . 11.0 t-20 -93.18 179.93 5.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.339 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.434 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -69.22 32.93 0.32 Allowed Glycine 0 CA--C 1.525 0.712 0 N-CA-C 111.029 -0.828 . . . . 0.0 111.029 179.886 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.554 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -68.44 177.16 26.23 Favored Glycine 0 CA--C 1.521 0.414 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.942 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 23.2 mmm180 -128.49 143.61 51.01 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-O 120.811 0.338 . . . . 0.0 110.269 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 33.8 m -83.06 113.08 20.36 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.293 179.987 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 24.0 m -101.56 -18.25 6.51 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.489 0 CA-C-N 116.537 -0.301 . . . . 0.0 110.704 -179.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.611 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.97 171.4 6.39 Favored Pre-proline 0 C--N 1.328 -0.361 0 CA-C-N 116.361 -0.381 . . . . 0.0 110.248 179.967 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.611 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -51.7 129.16 28.84 Favored 'Trans proline' 0 N--CA 1.491 1.349 0 C-N-CA 121.705 1.603 . . . . 0.0 111.921 179.361 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 41.8 m-20 50.81 34.34 10.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.097 -0.501 . . . . 0.0 110.734 179.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.523 ' NH1' ' O ' ' A' ' 166' ' ' CYS . 0.5 OUTLIER -127.55 119.03 25.09 Favored 'General case' 0 N--CA 1.467 0.421 0 CA-C-O 121.028 0.442 . . . . 0.0 110.175 -179.793 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.523 ' O ' ' NH1' ' A' ' 165' ' ' ARG . 26.4 m -110.8 122.66 48.39 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 115.408 -0.815 . . . . 0.0 110.075 179.555 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -88.02 135.65 33.32 Favored 'General case' 0 C--N 1.328 -0.355 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 179.53 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . 0.582 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 87.8 m -84.05 141.4 31.18 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-O 121.039 0.447 . . . . 0.0 110.382 -179.545 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.7 m -63.24 -45.58 90.91 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 115.762 -0.654 . . . . 0.0 111.283 -179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 93.5 m-85 -104.78 18.58 22.04 Favored 'General case' 0 CA--C 1.518 -0.26 0 CA-C-O 121.133 0.492 . . . . 0.0 110.984 -179.456 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 72.19 24.8 75.86 Favored Glycine 0 CA--C 1.524 0.642 0 N-CA-C 110.659 -0.976 . . . . 0.0 110.659 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.53 ' O ' ' SG ' ' A' ' 168' ' ' CYS . 91.5 t80 -54.64 143.9 23.45 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.883 0.373 . . . . 0.0 110.403 -179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 96.3 m -103.86 125.56 50.37 Favored 'General case' 0 N--CA 1.464 0.248 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.375 -179.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -179.21 162.05 28.62 Favored Glycine 0 CA--C 1.528 0.869 0 N-CA-C 110.905 -0.878 . . . . 0.0 110.905 179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 35.4 Cg_endo -63.28 -31.4 73.82 Favored 'Trans proline' 0 N--CA 1.498 1.759 0 C-N-CA 122.67 2.247 . . . . 0.0 112.4 -179.601 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 3.5 mp0 -110.27 4.57 20.99 Favored 'General case' 0 N--CA 1.467 0.415 0 CA-C-N 116.233 -0.439 . . . . 0.0 110.292 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.582 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 12.7 t 49.74 71.67 0.38 Allowed 'General case' 0 C--N 1.33 -0.27 0 C-N-CA 120.709 -0.397 . . . . 0.0 110.716 179.894 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 117.895 -1.05 . . . . 0.0 110.681 179.928 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 73.6 m . . . . . 0 N--CA 1.491 1.613 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -72.59 -10.34 59.68 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.534 179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 90.8 mtm180 -68.46 140.27 55.73 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.578 -179.473 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 69.73 -174.23 36.34 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.841 -0.903 . . . . 0.0 110.841 179.982 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -164.86 118.31 0.8 Allowed Glycine 0 CA--C 1.524 0.626 0 N-CA-C 110.84 -0.904 . . . . 0.0 110.84 179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 165.33 -172.36 40.88 Favored Glycine 0 CA--C 1.525 0.684 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 141.38 49.75 0.05 OUTLIER Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.984 -0.847 . . . . 0.0 110.984 179.92 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . 0.716 ' CG ' ' H ' ' A' ' 51' ' ' ASP . 26.1 t-80 -63.19 -168.09 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-O 120.709 0.29 . . . . 0.0 110.373 179.916 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.716 ' H ' ' CG ' ' A' ' 50' ' ' HIS . 96.8 m-20 -61.9 -40.69 96.3 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.366 -0.379 . . . . 0.0 110.511 -179.879 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -158.63 153.09 24.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.586 179.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.454 HD11 ' HA ' ' A' ' 66' ' ' TYR . 92.2 mt -82.34 161.9 22.41 Favored 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.662 179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 55.7 mtpt -123.25 166.26 15.55 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.845 -179.605 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 69.13 165.7 4.29 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 111.003 -0.839 . . . . 0.0 111.003 -179.678 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -68.47 -166.17 0.14 Allowed 'Trans proline' 0 C--N 1.308 -1.601 0 C-N-CA 122.956 2.437 . . . . 0.0 111.876 179.811 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 4.0 m120 58.64 36.14 24.87 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.358 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 12.8 p -100.46 136.56 31.39 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.24 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.031 -179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 60.4 m -141.41 176.9 8.5 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.994 0.426 . . . . 0.0 110.283 -179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.15 161.71 31.43 Favored Glycine 0 CA--C 1.523 0.541 0 N-CA-C 110.908 -0.877 . . . . 0.0 110.908 179.815 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.527 ' O ' ' N ' ' A' ' 65' ' ' ALA . 6.1 m -77.91 171.07 15.54 Favored 'General case' 0 C--N 1.328 -0.353 0 N-CA-C 110.361 -0.237 . . . . 0.0 110.361 179.711 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 44.9 ttm180 -59.98 -42.91 95.19 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.852 0.358 . . . . 0.0 110.392 179.872 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.1 m-85 -62.89 -40.45 97.58 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.994 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.471 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 21.2 m120 -125.67 50.52 1.82 Allowed 'General case' 0 N--CA 1.454 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.578 -179.646 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.527 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.92 138.27 49.95 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-N 116.046 -0.525 . . . . 0.0 110.607 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.471 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.9 p90 -158.45 165.64 34.13 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.969 -0.56 . . . . 0.0 111.106 179.761 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 79.4 m -69.2 139.08 54.52 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.296 179.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 25.7 m -54.42 146.89 30.94 Favored Pre-proline 0 C--N 1.329 -0.292 0 CA-C-N 116.313 -0.403 . . . . 0.0 111.095 -179.155 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_exo -48.01 125.58 11.85 Favored 'Trans proline' 0 N--CA 1.49 1.315 0 C-N-CA 121.605 1.537 . . . . 0.0 112.344 179.804 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.424 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.45 -12.89 58.4 Favored Glycine 0 CA--C 1.527 0.783 0 N-CA-C 111.144 -0.782 . . . . 0.0 111.144 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 88.9 m95 -114.82 134.38 55.18 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-O 121.019 0.438 . . . . 0.0 110.213 179.503 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 21.9 ptmt -125.25 -170.26 2.14 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.92 -0.582 . . . . 0.0 110.51 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 3.2 p -131.33 168.9 16.77 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 116.004 -0.543 . . . . 0.0 110.332 -179.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.76 HD12 ' H ' ' A' ' 74' ' ' LEU . 0.0 OUTLIER -87.29 164.46 35.56 Favored Pre-proline 0 C--N 1.325 -0.472 0 CA-C-N 115.72 -0.673 . . . . 0.0 110.436 -179.21 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 44.5 Cg_exo -53.0 125.41 18.21 Favored 'Trans proline' 0 C--N 1.31 -1.46 0 C-N-CA 121.875 1.717 . . . . 0.0 112.035 179.56 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.05 -0.31 11.89 Favored Glycine 0 CA--C 1.524 0.601 0 N-CA-C 111.03 -0.828 . . . . 0.0 111.03 179.247 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.89 174.48 35.9 Favored Glycine 0 CA--C 1.523 0.593 0 N-CA-C 110.913 -0.875 . . . . 0.0 110.913 -179.865 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.9 m-20 -140.14 7.54 2.22 Favored 'General case' 0 C--O 1.234 0.24 0 CA-C-O 120.881 0.372 . . . . 0.0 110.698 179.625 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 51.0 mt-30 -83.33 131.22 35.08 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.374 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 54.1 m -94.27 38.53 1.09 Allowed 'General case' 0 N--CA 1.465 0.31 0 CA-C-O 120.905 0.383 . . . . 0.0 110.11 179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 19.5 pt -94.09 6.54 6.8 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.421 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.646 -179.525 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 99.0 t -107.03 117.08 57.36 Favored Pre-proline 0 CA--C 1.537 0.446 0 CA-C-N 116.507 -0.315 . . . . 0.0 110.913 179.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.73 155.71 44.24 Favored 'Trans proline' 0 N--CA 1.49 1.27 0 C-N-CA 122.418 2.079 . . . . 0.0 112.433 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.424 ' N ' ' O ' ' A' ' 70' ' ' GLY . 83.2 mt -107.34 119.12 56.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-N 116.292 -0.413 . . . . 0.0 110.199 179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.89 113.85 26.23 Favored 'General case' 0 C--N 1.327 -0.393 0 N-CA-C 109.181 -0.674 . . . . 0.0 109.181 179.632 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.461 ' N ' ' CD ' ' A' ' 86' ' ' ARG . 1.8 mpt_? -62.31 -40.21 95.57 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.375 179.898 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 64.7 m-70 -109.59 127.8 54.76 Favored 'General case' 0 N--CA 1.464 0.234 0 CA-C-O 121.043 0.449 . . . . 0.0 109.842 179.87 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 5.6 p -49.41 122.13 5.81 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.209 -179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 56.1 m -75.63 -24.24 56.42 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.946 -0.57 . . . . 0.0 110.919 -179.645 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.72 -115.48 4.26 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.808 -0.917 . . . . 0.0 110.808 -179.684 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.1 m-20 -77.52 -4.46 45.79 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-O 120.705 0.288 . . . . 0.0 110.674 179.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -93.37 175.9 36.5 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.479 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 40.2 t80 -123.17 132.57 54.11 Favored 'General case' 0 N--CA 1.465 0.321 0 CA-C-O 121.221 0.534 . . . . 0.0 111.172 -179.662 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . 0.479 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 3.4 m -65.57 117.57 8.24 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.827 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . 0.434 ' OG ' ' OG1' ' A' ' 101' ' ' THR . 47.1 m -104.87 -21.94 13.24 Favored 'General case' 0 CA--C 1.515 -0.392 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.53 -179.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 20.6 mtt180 -158.44 163.15 25.26 Favored Pre-proline 0 C--N 1.331 -0.214 0 C-N-CA 120.264 -0.575 . . . . 0.0 110.748 179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 50.8 Cg_exo -48.98 120.48 5.5 Favored 'Trans proline' 0 N--CA 1.489 1.254 0 C-N-CA 121.926 1.751 . . . . 0.0 111.501 178.661 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.422 ' OD1' ' O ' ' A' ' 98' ' ' ASN . 56.3 t-20 54.69 41.47 31.91 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.838 -0.619 . . . . 0.0 109.975 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 84.0 mmm -146.59 115.68 6.97 Favored 'General case' 0 C--O 1.237 0.428 0 CA-C-N 116.188 -0.46 . . . . 0.0 109.954 179.988 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.447 ' N ' ' O ' ' A' ' 108' ' ' ALA . 91.0 m -99.15 146.74 25.82 Favored 'General case' 0 C--O 1.232 0.134 0 CA-C-N 115.636 -0.711 . . . . 0.0 110.71 179.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . 0.434 ' OG1' ' OG ' ' A' ' 95' ' ' SER . 32.8 m -118.84 114.19 22.25 Favored 'General case' 0 CA--C 1.513 -0.462 0 N-CA-C 109.285 -0.635 . . . . 0.0 109.285 179.151 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -82.9 158.75 64.45 Favored Pre-proline 0 C--N 1.326 -0.446 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.997 -179.085 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_exo -55.36 -28.01 60.89 Favored 'Trans proline' 0 N--CA 1.497 1.701 0 C-N-CA 122.749 2.299 . . . . 0.0 111.817 178.027 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 22.3 t -63.97 -16.6 61.93 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.591 -179.76 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 100.73 -13.64 59.27 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.698 -0.961 . . . . 0.0 110.698 -179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.3 tp60 -69.46 149.85 47.85 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.918 0.389 . . . . 0.0 110.039 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.4 mt -125.44 129.45 72.92 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.385 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.812 179.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.692 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -164.23 179.16 1.23 Allowed Pre-proline 0 C--N 1.327 -0.407 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.498 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.692 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 32.4 Cg_exo -59.21 -23.39 69.27 Favored 'Trans proline' 0 N--CA 1.497 1.694 0 C-N-CA 122.824 2.349 . . . . 0.0 111.944 179.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 36.2 p -155.53 162.95 40.58 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.272 -0.422 . . . . 0.0 110.677 -179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.35 -37.76 43.62 Favored 'General case' 0 CA--C 1.532 0.281 0 CA-C-N 116.303 -0.408 . . . . 0.0 110.365 179.769 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -64.9 -40.05 96.96 Favored Glycine 0 CA--C 1.52 0.399 0 N-CA-C 110.935 -0.866 . . . . 0.0 110.935 -179.735 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 42.0 t -68.44 138.6 55.41 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.786 0.327 . . . . 0.0 110.372 179.876 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 85.8 mtp180 -125.11 47.77 2.11 Favored 'General case' 0 N--CA 1.467 0.408 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.578 179.831 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 33.1 t -69.62 149.09 48.5 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.583 179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.443 ' O ' HG23 ' A' ' 116' ' ' ILE . 20.0 tt -68.45 130.3 33.48 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.229 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.459 -179.896 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 51.08 -116.53 0.99 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.63 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 4.9 p80 -159.01 -40.24 0.06 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.337 -0.392 . . . . 0.0 110.326 -179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 5.1 m -95.94 78.42 3.21 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.537 -179.609 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 10.1 m120 -64.27 -39.79 94.66 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.216 179.551 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 19.7 tt -77.93 166.05 2.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.348 179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 2.4 mpt_? -93.41 123.13 36.5 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.951 179.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 77.3 m -123.66 141.27 52.17 Favored 'General case' 0 N--CA 1.463 0.215 0 CA-C-N 115.713 -0.676 . . . . 0.0 110.598 179.513 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.9 mtm -146.19 163.25 36.01 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.431 -179.995 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.53 ' OD1' ' CE1' ' A' ' 140' ' ' TYR . 5.2 t-20 63.11 44.05 6.05 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.962 -0.563 . . . . 0.0 110.953 179.806 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . 0.408 ' HA3' HE21 ' A' ' 137' ' ' GLN . . . 72.43 22.64 78.83 Favored Glycine 0 CA--C 1.521 0.442 0 N-CA-C 111.126 -0.79 . . . . 0.0 111.126 179.344 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.53 162.76 36.97 Favored Glycine 0 CA--C 1.524 0.611 0 N-CA-C 110.589 -1.004 . . . . 0.0 110.589 -179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.2 t -133.35 141.56 47.99 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.748 0.308 . . . . 0.0 110.204 -179.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 4.0 m -93.31 123.15 36.4 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.77 -179.793 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 25.1 t -148.45 134.34 19.05 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.605 179.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 65.9 m-20 48.46 46.77 20.6 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.847 179.336 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 21.5 t0 55.24 27.89 10.4 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.311 -0.404 . . . . 0.0 110.452 -179.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 36.5 t-80 -137.74 137.3 38.15 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.231 179.965 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 13.8 t -92.14 129.96 37.97 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.921 -179.78 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 83.0 mt -113.5 143.57 44.3 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.115 179.803 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 1.6 m -103.99 144.51 31.44 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.54 -179.721 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . 0.408 HE21 ' HA3' ' A' ' 126' ' ' GLY . 48.4 mt-30 -68.19 174.55 3.83 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.136 -0.484 . . . . 0.0 110.422 -179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.4 tttm -66.28 131.3 45.81 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.505 -0.316 . . . . 0.0 110.578 -179.838 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.57 -15.46 53.13 Favored Glycine 0 N--CA 1.467 0.762 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.534 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . 0.53 ' CE1' ' OD1' ' A' ' 125' ' ' ASN . 86.8 m-85 -116.88 134.83 54.28 Favored 'General case' 0 N--CA 1.465 0.308 0 N-CA-C 110.275 -0.269 . . . . 0.0 110.275 179.533 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 33.8 pt -125.37 165.36 22.93 Favored 'Isoleucine or valine' 0 C--O 1.238 0.48 0 N-CA-C 109.619 -0.512 . . . . 0.0 109.619 -179.797 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 122.35 153.47 8.87 Favored Glycine 0 CA--C 1.522 0.501 0 N-CA-C 110.638 -0.985 . . . . 0.0 110.638 179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 20.1 m -62.22 -47.07 86.07 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.908 0.385 . . . . 0.0 110.681 -179.932 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 95.8 m-70 -99.58 2.98 45.17 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.693 -179.917 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 4.8 m 65.79 136.84 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.304 -179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 154.6 -9.72 0.4 Allowed Glycine 0 CA--C 1.518 0.247 0 N-CA-C 110.708 -0.957 . . . . 0.0 110.708 -179.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.2 tt0 -103.19 108.57 59.32 Favored Pre-proline 0 CA--C 1.542 0.652 0 C-N-CA 120.735 -0.386 . . . . 0.0 110.324 179.808 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -75.82 161.61 36.13 Favored 'Trans proline' 0 N--CA 1.491 1.339 0 C-N-CA 122.711 2.274 . . . . 0.0 112.069 179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.5 t -116.54 129.31 73.22 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.01 -179.979 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 21.5 m -97.46 107.24 19.71 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.351 -0.386 . . . . 0.0 110.14 179.488 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . 0.444 ' HB2' HD22 ' A' ' 164' ' ' ASN . 3.8 mp0 -66.26 -40.16 89.96 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.448 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 67.8 m -86.36 -10.72 53.82 Favored 'General case' 0 C--N 1.326 -0.429 0 CA-C-O 120.811 0.339 . . . . 0.0 110.6 -179.704 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 68.43 -177.47 25.46 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.582 -1.007 . . . . 0.0 110.582 179.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 22.5 m -128.91 114.14 16.1 Favored 'General case' 0 N--CA 1.465 0.293 0 CA-C-O 120.881 0.372 . . . . 0.0 110.0 179.769 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 95.6 mt -63.38 -42.13 98.83 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.852 -179.549 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.427 ' C ' ' H ' ' A' ' 158' ' ' GLY . 98.0 m-20 -95.94 -172.36 2.56 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.389 -179.904 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -75.65 38.24 1.24 Allowed Glycine 0 CA--C 1.522 0.481 0 N-CA-C 111.066 -0.814 . . . . 0.0 111.066 179.933 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.427 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -72.55 176.38 42.29 Favored Glycine 0 CA--C 1.523 0.579 0 N-CA-C 110.769 -0.932 . . . . 0.0 110.769 179.935 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 1.9 mpt_? -130.2 148.36 52.03 Favored 'General case' 0 N--CA 1.465 0.305 0 CA-C-O 120.833 0.349 . . . . 0.0 110.568 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 90.2 m -85.05 120.18 26.27 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.081 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 33.8 m -104.01 -11.68 9.3 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.288 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.295 -179.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.687 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -176.55 174.79 0.69 Allowed Pre-proline 0 C--N 1.326 -0.426 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.818 179.957 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.687 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 43.8 Cg_exo -55.24 125.13 18.14 Favored 'Trans proline' 0 N--CA 1.492 1.431 0 C-N-CA 122.163 1.908 . . . . 0.0 111.116 178.99 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . 0.444 HD22 ' HB2' ' A' ' 151' ' ' GLU . 16.3 t-20 56.15 34.66 24.3 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.682 179.819 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 82.1 mmt-85 -135.37 131.64 36.61 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-O 121.402 0.62 . . . . 0.0 110.624 179.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.48 ' O ' ' CE1' ' A' ' 172' ' ' PHE . 7.7 t -142.82 147.1 34.89 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.756 179.524 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -120.99 122.06 39.32 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 115.969 -0.559 . . . . 0.0 109.947 179.255 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 62.3 m -109.72 154.95 22.18 Favored 'General case' 0 N--CA 1.464 0.266 0 CA-C-N 116.115 -0.493 . . . . 0.0 109.877 -179.907 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 2.4 p -106.96 15.23 25.58 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.957 0.408 . . . . 0.0 110.836 -179.104 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.414 ' CD2' ' O ' ' A' ' 170' ' ' TYR . 23.9 t80 -119.71 32.94 5.83 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.768 -0.651 . . . . 0.0 110.933 -179.665 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 90.46 57.52 1.64 Allowed Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.779 -0.929 . . . . 0.0 110.779 -179.784 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.48 ' CE1' ' O ' ' A' ' 166' ' ' CYS . 89.7 t80 -47.29 110.03 0.26 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.893 0.378 . . . . 0.0 110.646 -179.527 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.44 ' N ' ' O ' ' A' ' 177' ' ' CYS . 91.0 m -129.16 126.86 40.17 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 115.943 -0.571 . . . . 0.0 110.22 179.272 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 64.15 166.44 1.05 Allowed Glycine 0 CA--C 1.531 1.047 0 CA-C-N 115.636 -0.711 . . . . 0.0 111.364 179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 38.2 Cg_exo -55.88 -36.91 96.3 Favored 'Trans proline' 0 N--CA 1.498 1.773 0 C-N-CA 122.75 2.3 . . . . 0.0 112.313 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 81.3 mt-30 -74.96 46.46 0.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.448 -179.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.44 ' O ' ' N ' ' A' ' 173' ' ' THR . 42.3 t 54.2 -93.35 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.646 -179.707 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 47.8 tp10 . . . . . 0 C--O 1.22 -0.487 0 CA-C-O 117.953 -1.022 . . . . 0.0 110.198 -179.857 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 60.2 p . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -137.14 140.6 41.98 Favored 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.333 179.74 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 51.2 mmm-85 -76.71 147.6 37.3 Favored 'General case' 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.436 -179.704 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -62.21 -43.01 99.71 Favored Glycine 0 CA--C 1.525 0.687 0 N-CA-C 111.076 -0.81 . . . . 0.0 111.076 -179.827 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 63.2 29.41 74.38 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.645 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -62.57 -38.65 96.73 Favored Glycine 0 CA--C 1.526 0.775 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.441 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . 55.97 95.51 0.01 OUTLIER Glycine 0 CA--C 1.524 0.629 0 N-CA-C 110.953 -0.859 . . . . 0.0 110.953 179.926 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 74.7 m80 54.72 95.49 0.02 OUTLIER 'General case' 0 C--N 1.33 -0.257 0 CA-C-O 120.785 0.326 . . . . 0.0 110.377 -179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.437 ' OD1' ' O ' ' A' ' 53' ' ' LEU . 44.2 p-10 -143.05 177.09 8.61 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.33 -179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.524 ' O ' ' ND2' ' A' ' 78' ' ' ASN . . . -60.26 -44.6 95.16 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.619 -179.629 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.437 ' O ' ' OD1' ' A' ' 51' ' ' ASP . 81.0 mt -76.45 153.04 35.96 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.55 179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -138.36 159.84 41.02 Favored 'General case' 0 CA--C 1.521 -0.172 0 CA-C-O 120.997 0.427 . . . . 0.0 110.69 179.401 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 110.42 166.1 19.31 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.037 -0.825 . . . . 0.0 111.037 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 76.9 Cg_endo -77.19 -1.31 11.48 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 C-N-CA 122.902 2.402 . . . . 0.0 112.281 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.61 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 78.5 m-20 -117.34 71.8 0.82 Allowed 'General case' 0 N--CA 1.468 0.431 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.777 -179.996 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.491 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 55.9 t -121.45 130.32 74.74 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.459 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 179.27 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 75.3 m -142.89 -174.7 4.25 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.201 -179.081 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.83 171.08 45.38 Favored Glycine 0 CA--C 1.523 0.581 0 N-CA-C 110.896 -0.882 . . . . 0.0 110.896 179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.552 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.5 m -78.89 163.57 25.17 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.061 -0.348 . . . . 0.0 110.061 179.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.8 ttp180 -59.93 -42.88 94.94 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.555 179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 97.9 m-85 -61.67 -42.39 98.85 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.257 -0.429 . . . . 0.0 111.158 -179.741 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 81.5 m-20 -127.25 49.38 2.1 Favored 'General case' 0 N--CA 1.449 -0.482 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.871 -179.411 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.552 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.07 146.87 53.86 Favored 'General case' 0 C--N 1.325 -0.486 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.669 -179.78 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 14.0 p90 -152.9 168.82 24.51 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-O 120.824 0.345 . . . . 0.0 110.949 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 91.5 m -70.51 131.32 43.84 Favored 'General case' 0 C--N 1.329 -0.323 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.188 179.808 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.491 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 62.1 m -49.35 152.37 2.21 Favored Pre-proline 0 CA--C 1.53 0.211 0 CA-C-N 116.144 -0.48 . . . . 0.0 111.076 -179.129 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_exo -51.59 131.64 37.92 Favored 'Trans proline' 0 N--CA 1.493 1.474 0 C-N-CA 121.387 1.392 . . . . 0.0 112.459 179.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 101.84 -5.08 53.48 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.703 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.61 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 44.5 m95 -132.24 140.86 48.82 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-O 120.625 0.25 . . . . 0.0 110.455 179.314 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.0 ptpt -115.4 -166.4 1.12 Allowed 'General case' 0 N--CA 1.468 0.475 0 CA-C-N 116.263 -0.426 . . . . 0.0 110.005 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 76.9 p -115.87 158.21 23.3 Favored 'General case' 0 N--CA 1.468 0.457 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.464 ' O ' ' N ' ' A' ' 77' ' ' GLY . 18.9 mt -89.91 151.08 44.88 Favored Pre-proline 0 CA--C 1.531 0.227 0 CA-C-N 116.513 -0.312 . . . . 0.0 110.604 -179.191 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.427 ' C ' ' H ' ' A' ' 77' ' ' GLY . 75.5 Cg_exo -39.94 106.68 0.06 OUTLIER 'Trans proline' 0 N--CA 1.492 1.388 0 C-N-CA 122.206 1.937 . . . . 0.0 112.142 179.43 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.42 -10.57 2.66 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 111.162 -0.775 . . . . 0.0 111.162 179.626 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -82.19 171.81 52.18 Favored Glycine 0 CA--C 1.524 0.623 0 N-CA-C 110.849 -0.9 . . . . 0.0 110.849 -179.79 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.524 ' ND2' ' O ' ' A' ' 52' ' ' ALA . 55.1 p30 -127.87 11.39 6.62 Favored 'General case' 0 N--CA 1.465 0.296 0 CA-C-O 120.551 0.215 . . . . 0.0 111.117 -179.828 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -89.46 139.1 30.86 Favored 'General case' 0 N--CA 1.465 0.298 0 CA-C-N 116.52 -0.309 . . . . 0.0 110.887 -179.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 33.2 m -99.26 43.18 1.07 Allowed 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 120.921 0.391 . . . . 0.0 110.018 -179.744 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 43.4 pt -94.2 19.23 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.474 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -120.32 95.05 49.03 Favored Pre-proline 0 CA--C 1.542 0.639 0 N-CA-C 110.019 -0.363 . . . . 0.0 110.019 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 95.6 Cg_endo -77.59 159.79 31.87 Favored 'Trans proline' 0 N--CA 1.494 1.544 0 C-N-CA 122.265 1.976 . . . . 0.0 112.221 -179.56 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 17.1 mm -98.59 120.67 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.32 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.498 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 1.8 m -105.07 109.37 21.34 Favored 'General case' 0 N--CA 1.465 0.288 0 N-CA-C 109.725 -0.472 . . . . 0.0 109.725 179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.55 ' HE ' HD21 ' A' ' 98' ' ' ASN . 1.1 mpt_? -64.55 -39.6 94.05 Favored 'General case' 0 C--N 1.328 -0.33 0 C-N-CA 120.923 -0.311 . . . . 0.0 110.521 179.465 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -103.42 133.47 48.42 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.147 179.9 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 31.2 t -61.94 134.43 56.65 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.33 -179.383 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 32.4 m -78.97 -28.21 43.57 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.031 -0.532 . . . . 0.0 110.507 -179.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 76.19 -104.72 1.87 Allowed Glycine 0 CA--C 1.526 0.745 0 N-CA-C 111.52 -0.632 . . . . 0.0 111.52 179.543 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 94.6 m-20 -80.04 -3.48 48.68 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 120.659 0.266 . . . . 0.0 111.083 -179.492 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.3 -160.1 20.19 Favored Glycine 0 CA--C 1.528 0.874 0 N-CA-C 110.55 -1.02 . . . . 0.0 110.55 179.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.7 p90 -147.05 152.19 38.14 Favored 'General case' 0 N--CA 1.467 0.413 0 CA-C-O 120.918 0.39 . . . . 0.0 111.33 -179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 4.7 t -64.41 115.61 5.28 Favored 'General case' 0 CA--C 1.517 -0.311 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.924 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 20.7 t -109.84 -24.17 10.99 Favored 'General case' 0 N--CA 1.468 0.458 0 CA-C-N 115.749 -0.659 . . . . 0.0 110.927 -179.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 45.4 mtt180 -156.14 158.43 31.58 Favored Pre-proline 0 C--N 1.328 -0.329 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.095 -179.453 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 11.0 Cg_endo -52.51 125.63 18.35 Favored 'Trans proline' 0 C--N 1.31 -1.479 0 C-N-CA 122.043 1.829 . . . . 0.0 111.22 -179.535 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.55 HD21 ' HE ' ' A' ' 86' ' ' ARG . 60.9 m-80 53.04 37.76 25.58 Favored 'General case' 0 C--N 1.33 -0.257 0 N-CA-C 109.266 -0.642 . . . . 0.0 109.266 -179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.5 mtp -148.94 114.65 5.66 Favored 'General case' 0 C--O 1.242 0.705 0 CA-C-O 121.37 0.605 . . . . 0.0 110.895 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.411 ' N ' ' O ' ' A' ' 108' ' ' ALA . 27.6 m -96.9 147.54 23.86 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.441 178.846 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 87.0 m -119.89 123.77 44.39 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.912 -0.585 . . . . 0.0 109.572 179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.82 155.3 45.46 Favored Pre-proline 0 C--N 1.324 -0.515 0 CA-C-N 115.973 -0.558 . . . . 0.0 109.859 -179.576 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 25.2 Cg_endo -61.74 -20.03 67.53 Favored 'Trans proline' 0 N--CA 1.495 1.574 0 C-N-CA 122.332 2.021 . . . . 0.0 111.654 179.253 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 34.6 t -66.57 -17.04 64.6 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.282 179.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.28 -20.84 34.45 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 111.088 -0.805 . . . . 0.0 111.088 -179.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 52.5 tp60 -67.87 150.7 48.23 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-O 120.839 0.352 . . . . 0.0 110.252 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.5 mt -130.54 132.56 64.47 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.503 0 CA-C-N 116.091 -0.504 . . . . 0.0 110.858 179.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.665 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.42 177.75 1.08 Allowed Pre-proline 0 CA--C 1.536 0.433 0 C-N-CA 120.768 -0.373 . . . . 0.0 110.28 179.769 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.665 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 51.4 Cg_exo -56.32 -23.76 47.93 Favored 'Trans proline' 0 N--CA 1.498 1.778 0 C-N-CA 122.602 2.201 . . . . 0.0 111.911 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 30.0 p -151.79 162.23 41.37 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.145 -0.48 . . . . 0.0 110.433 179.862 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.14 -27.52 48.21 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.96 -0.564 . . . . 0.0 110.3 179.796 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -75.37 42.98 1.49 Allowed Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.856 -0.898 . . . . 0.0 110.856 -179.899 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 39.9 t -62.96 139.76 58.79 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-O 121.038 0.447 . . . . 0.0 110.694 -179.565 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 88.1 mmt-85 -79.01 -13.67 59.65 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.918 -0.583 . . . . 0.0 110.371 -179.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 47.7 t -73.34 101.6 3.49 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.313 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 42.4 pt -141.67 -159.85 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 116.06 -0.518 . . . . 0.0 110.669 -179.628 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.4 mt-30 -56.84 134.32 55.15 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.342 -0.39 . . . . 0.0 110.098 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 74.0 m80 -58.78 -42.55 89.24 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.376 -179.51 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . 0.497 ' SG ' ' N ' ' A' ' 120' ' ' ASN . 34.3 t -172.25 175.03 3.78 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.969 -0.56 . . . . 0.0 110.704 179.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . 0.497 ' N ' ' SG ' ' A' ' 119' ' ' CYS . 25.0 p-10 -95.96 10.44 37.36 Favored 'General case' 0 N--CA 1.464 0.24 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.687 179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -139.31 165.46 23.16 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.411 0 CA-C-N 116.041 -0.527 . . . . 0.0 109.785 -179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . . . . . . . . . 98.7 mtt180 -77.41 98.62 5.32 Favored 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.75 179.796 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 89.2 m -111.07 119.06 37.76 Favored 'General case' 0 C--N 1.331 -0.222 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 179.181 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 95.9 mtp -139.82 165.26 27.76 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.447 -178.882 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.513 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 3.7 m-20 59.92 39.61 20.06 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.702 0.287 . . . . 0.0 110.992 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.15 25.22 69.29 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 179.32 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -67.16 126.55 26.03 Favored Glycine 0 CA--C 1.521 0.427 0 N-CA-C 110.362 -1.095 . . . . 0.0 110.362 179.8 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . 0.496 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 4.9 m -82.21 133.38 35.25 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-O 120.65 0.262 . . . . 0.0 110.311 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.2 t -95.05 116.92 29.32 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.336 -0.393 . . . . 0.0 110.254 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 32.4 t -139.01 143.98 38.69 Favored 'General case' 0 N--CA 1.464 0.264 0 CA-C-N 116.308 -0.405 . . . . 0.0 110.124 179.941 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 98.9 m-20 41.67 -116.8 0.34 Allowed 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.185 -0.462 . . . . 0.0 110.885 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.1 m-20 -119.57 21.93 11.88 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.458 -179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 92.6 m-70 -143.0 145.67 33.14 Favored 'General case' 0 C--O 1.234 0.241 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.522 179.951 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.496 ' SG ' ' O ' ' A' ' 128' ' ' SER . 1.3 t -105.11 140.76 37.81 Favored 'General case' 0 N--CA 1.465 0.313 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.247 179.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 81.0 mt -102.33 131.84 48.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.083 -0.508 . . . . 0.0 110.022 -179.657 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 20.6 m -92.25 134.37 34.95 Favored 'General case' 0 CA--C 1.519 -0.237 0 CA-C-N 116.31 -0.405 . . . . 0.0 110.898 -179.99 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 27.1 mt-30 -61.33 173.49 0.88 Allowed 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.389 179.758 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . 0.449 ' HD3' ' N ' ' A' ' 138' ' ' LYS . 0.0 OUTLIER -62.95 136.18 57.7 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.368 0.604 . . . . 0.0 111.499 179.52 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 88.72 -8.61 78.91 Favored Glycine 0 CA--C 1.519 0.316 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 179.16 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -118.76 135.33 54.57 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.953 0.406 . . . . 0.0 110.326 179.564 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 48.7 pt -133.94 173.31 14.86 Favored 'Isoleucine or valine' 0 C--O 1.239 0.507 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.103 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 103.0 163.46 25.78 Favored Glycine 0 CA--C 1.524 0.605 0 N-CA-C 111.011 -0.836 . . . . 0.0 111.011 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 30.1 p -65.61 -39.68 91.8 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-O 120.609 0.242 . . . . 0.0 110.832 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.439 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -96.46 10.74 37.32 Favored 'General case' 0 N--CA 1.464 0.273 0 CA-C-O 120.853 0.358 . . . . 0.0 110.461 179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.513 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 14.7 m 45.76 41.16 7.18 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.016 -0.538 . . . . 0.0 110.037 -179.551 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.439 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -108.78 5.44 32.66 Favored Glycine 0 CA--C 1.521 0.465 0 N-CA-C 110.896 -0.881 . . . . 0.0 110.896 -179.865 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -112.38 110.62 53.01 Favored Pre-proline 0 CA--C 1.54 0.58 0 CA-C-N 116.793 0.297 . . . . 0.0 110.718 -179.6 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 88.0 Cg_endo -78.7 161.85 27.43 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.514 2.142 . . . . 0.0 112.193 -179.666 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.7 t -111.99 129.08 68.09 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.473 0 CA-C-O 121.188 0.518 . . . . 0.0 109.988 179.942 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -98.71 93.1 5.91 Favored 'General case' 0 C--N 1.329 -0.315 0 N-CA-C 108.823 -0.806 . . . . 0.0 108.823 179.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 78.4 tt0 -68.69 -42.01 78.39 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-N 116.05 -0.523 . . . . 0.0 110.647 -178.921 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 8.4 m -97.77 -10.23 25.19 Favored 'General case' 0 N--CA 1.464 0.25 0 CA-C-N 116.488 -0.324 . . . . 0.0 110.915 179.713 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 66.43 179.48 10.4 Favored Glycine 0 CA--C 1.527 0.789 0 N-CA-C 111.027 -0.829 . . . . 0.0 111.027 -179.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -98.12 179.18 4.85 Favored 'General case' 0 N--CA 1.466 0.345 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . 0.589 ' CD1' ' H ' ' A' ' 177' ' ' CYS . 86.0 mt -88.18 -3.54 58.86 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.532 -179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.551 HD22 ' N ' ' A' ' 156' ' ' ASN . 0.1 OUTLIER -170.64 -147.21 0.05 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.403 179.723 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -73.8 30.95 0.9 Allowed Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.802 -0.919 . . . . 0.0 110.802 179.639 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.496 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -61.68 173.49 7.34 Favored Glycine 0 CA--C 1.522 0.5 0 N-CA-C 110.623 -0.991 . . . . 0.0 110.623 -179.795 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 71.9 ttt-85 -114.06 123.18 49.05 Favored 'General case' 0 N--CA 1.464 0.267 0 CA-C-O 120.486 0.184 . . . . 0.0 110.903 -179.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 69.0 m -68.23 91.32 0.37 Allowed 'General case' 0 C--N 1.329 -0.32 0 N-CA-C 109.511 -0.551 . . . . 0.0 109.511 179.314 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 7.8 p -78.12 -27.48 14.75 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.482 0 CA-C-N 115.909 -0.587 . . . . 0.0 111.301 -179.602 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.644 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -156.95 173.87 4.58 Favored Pre-proline 0 C--N 1.329 -0.302 0 N-CA-C 109.888 -0.412 . . . . 0.0 109.888 -179.818 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.644 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 51.3 Cg_exo -52.33 136.54 55.46 Favored 'Trans proline' 0 C--N 1.31 -1.493 0 C-N-CA 121.588 1.525 . . . . 0.0 111.941 179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 57.8 t-20 41.89 25.74 0.04 OUTLIER 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.627 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.421 ' N ' ' O ' ' A' ' 163' ' ' PRO . 75.0 mmt-85 -134.21 140.55 46.56 Favored 'General case' 0 N--CA 1.466 0.343 0 CA-C-O 121.709 0.766 . . . . 0.0 110.984 -179.994 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 28.7 p -150.37 161.17 43.01 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.517 179.302 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -109.85 139.09 45.32 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.012 179.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . 0.6 ' N ' ' SG ' ' A' ' 177' ' ' CYS . 88.2 m -70.08 138.59 52.16 Favored 'General case' 0 N--CA 1.436 -1.161 0 CA-C-O 121.012 0.435 . . . . 0.0 110.173 -179.319 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.0 m -62.66 -46.07 89.9 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.837 -0.619 . . . . 0.0 111.89 -178.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 96.1 m-85 -117.48 28.27 8.56 Favored 'General case' 0 CA--C 1.52 -0.179 0 N-CA-C 111.845 0.313 . . . . 0.0 111.845 -178.938 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 59.4 30.09 67.44 Favored Glycine 0 CA--C 1.522 0.522 0 N-CA-C 110.093 -1.203 . . . . 0.0 110.093 179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.454 ' CZ ' ' SG ' ' A' ' 168' ' ' CYS . 24.5 p90 -67.54 152.37 45.76 Favored 'General case' 0 C--N 1.325 -0.462 0 CA-C-O 120.644 0.259 . . . . 0.0 110.829 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 20.4 p -80.96 143.22 32.75 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 116.323 -0.399 . . . . 0.0 111.002 -179.393 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . -178.54 158.2 22.53 Favored Glycine 0 CA--C 1.531 1.06 0 N-CA-C 111.133 -0.787 . . . . 0.0 111.133 -179.991 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 37.2 Cg_endo -64.04 -51.44 2.21 Favored 'Trans proline' 0 N--CA 1.499 1.795 0 C-N-CA 122.422 2.081 . . . . 0.0 112.92 -179.461 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.571 ' NE2' HD21 ' A' ' 155' ' ' LEU . 46.8 mt-30 -80.66 -50.08 10.39 Favored 'General case' 0 C--N 1.331 -0.197 0 CA-C-O 121.086 0.469 . . . . 0.0 110.534 -179.615 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.6 ' SG ' ' N ' ' A' ' 168' ' ' CYS . 36.5 t -116.61 115.22 25.29 Favored 'General case' 0 CA--C 1.514 -0.43 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.383 178.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . 0.442 ' OXT' ' O ' ' A' ' 172' ' ' PHE . 75.0 tt0 . . . . . 0 C--N 1.325 -0.471 0 CA-C-O 117.846 -1.073 . . . . 0.0 109.988 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 89.3 p . . . . . 0 N--CA 1.49 1.559 0 N-CA-C 109.438 -0.578 . . . . 0.0 109.438 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -74.44 99.43 3.55 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.301 179.855 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.8 mtt-85 -63.44 -38.53 91.5 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.235 -0.439 . . . . 0.0 110.208 -179.891 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -80.42 167.65 50.8 Favored Glycine 0 CA--C 1.524 0.624 0 N-CA-C 110.65 -0.98 . . . . 0.0 110.65 179.759 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.79 156.36 25.27 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.705 -0.958 . . . . 0.0 110.705 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -95.65 172.19 29.76 Favored Glycine 0 CA--C 1.523 0.538 0 N-CA-C 110.797 -0.921 . . . . 0.0 110.797 179.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -93.53 112.66 4.34 Favored Glycine 0 CA--C 1.521 0.458 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 179.81 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 99.3 m-70 -111.72 124.36 52.17 Favored 'General case' 0 N--CA 1.466 0.356 0 CA-C-O 120.926 0.393 . . . . 0.0 110.443 -179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.546 ' OD1' ' N ' ' A' ' 52' ' ' ALA . 45.7 p-10 -65.6 -35.21 80.16 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.984 -0.553 . . . . 0.0 110.616 179.886 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.546 ' N ' ' OD1' ' A' ' 51' ' ' ASP . . . -174.32 -13.66 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.092 -0.504 . . . . 0.0 110.512 -179.962 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.437 ' H ' ' H ' ' A' ' 52' ' ' ALA . 29.0 mt -70.54 137.08 49.84 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 121.238 0.542 . . . . 0.0 110.795 179.943 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 64.0 mttp -142.91 164.01 31.24 Favored 'General case' 0 CA--C 1.518 -0.281 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.418 179.991 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 105.69 159.53 22.8 Favored Glycine 0 CA--C 1.534 1.228 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.212 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 67.7 Cg_endo -76.01 7.43 3.26 Favored 'Trans proline' 0 N--CA 1.494 1.504 0 C-N-CA 122.792 2.328 . . . . 0.0 112.187 179.613 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.459 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 80.1 m-20 -123.12 70.5 1.03 Allowed 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 120.891 0.377 . . . . 0.0 111.087 -179.661 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.444 ' O ' ' SG ' ' A' ' 59' ' ' CYS . 51.8 t -115.07 130.82 68.93 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . 0.444 ' SG ' ' O ' ' A' ' 58' ' ' VAL . 57.2 m -151.3 178.44 9.25 Favored 'General case' 0 C--N 1.327 -0.39 0 CA-C-N 115.725 -0.671 . . . . 0.0 110.457 -179.673 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 93.3 172.23 39.98 Favored Glycine 0 CA--C 1.524 0.6 0 N-CA-C 110.725 -0.95 . . . . 0.0 110.725 -179.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.543 ' O ' ' N ' ' A' ' 65' ' ' ALA . 5.1 m -81.18 163.76 22.82 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.63 0.253 . . . . 0.0 110.326 -179.81 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 73.3 ttp85 -59.54 -43.25 93.56 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.463 -0.335 . . . . 0.0 110.685 179.951 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.3 m-85 -62.9 -37.25 86.2 Favored 'General case' 0 C--N 1.327 -0.407 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.775 -179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . 0.434 ' O ' ' CD2' ' A' ' 66' ' ' TYR . 41.9 t30 -132.51 53.75 1.99 Allowed 'General case' 0 C--O 1.23 0.078 0 CA-C-N 116.302 -0.408 . . . . 0.0 110.906 -179.639 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.543 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -72.51 142.56 48.52 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.266 179.247 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.434 ' CD2' ' O ' ' A' ' 64' ' ' ASN . 8.8 p90 -159.36 171.21 20.19 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.1 -0.5 . . . . 0.0 111.051 -179.867 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 62.4 m -67.97 135.33 52.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.057 -0.519 . . . . 0.0 110.153 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -48.36 168.43 0.17 Allowed Pre-proline 0 C--N 1.328 -0.356 0 CA-C-N 116.249 -0.432 . . . . 0.0 111.177 -178.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 32.1 Cg_exo -57.47 133.62 58.12 Favored 'Trans proline' 0 N--CA 1.493 1.463 0 C-N-CA 122.093 1.862 . . . . 0.0 112.114 179.046 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.491 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 94.98 -17.19 59.78 Favored Glycine 0 CA--C 1.52 0.374 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 179.904 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.459 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 86.8 m95 -112.79 138.18 50.0 Favored 'General case' 0 N--CA 1.463 0.181 0 N-CA-C 109.951 -0.389 . . . . 0.0 109.951 -179.979 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 17.8 ptpt -122.25 -165.49 1.28 Allowed 'General case' 0 CA--C 1.518 -0.261 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.21 179.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 69.2 p -126.04 164.7 20.27 Favored 'General case' 0 CA--C 1.516 -0.35 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.202 -179.928 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.501 ' O ' ' N ' ' A' ' 77' ' ' GLY . 13.6 mt -88.96 151.44 47.12 Favored Pre-proline 0 C--N 1.327 -0.382 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.814 -179.119 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 77.7 Cg_exo -39.86 107.21 0.06 OUTLIER 'Trans proline' 0 C--N 1.312 -1.387 0 C-N-CA 122.348 2.032 . . . . 0.0 112.121 179.171 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.17 -14.95 7.25 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 111.067 -0.813 . . . . 0.0 111.067 179.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.501 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -83.76 178.59 52.32 Favored Glycine 0 CA--C 1.524 0.641 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 24.5 m120 -139.35 15.21 2.58 Favored 'General case' 0 C--O 1.238 0.45 0 CA-C-O 121.105 0.479 . . . . 0.0 110.7 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 88.0 mt-30 -80.34 131.99 35.72 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.262 -179.847 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 55.7 m -95.93 47.89 1.11 Allowed 'General case' 0 N--CA 1.463 0.199 0 CA-C-O 120.732 0.301 . . . . 0.0 110.403 -179.573 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 25.7 pt -105.71 22.38 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.758 179.971 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 31.5 t -124.45 97.78 39.05 Favored Pre-proline 0 CA--C 1.536 0.426 0 CA-C-N 116.381 -0.372 . . . . 0.0 110.725 179.478 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.1 Cg_endo -78.76 157.15 27.82 Favored 'Trans proline' 0 C--N 1.315 -1.23 0 C-N-CA 122.691 2.261 . . . . 0.0 112.097 -179.795 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.491 ' N ' ' O ' ' A' ' 70' ' ' GLY . 96.7 mt -109.51 118.63 57.17 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-O 120.963 0.411 . . . . 0.0 110.297 179.109 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 17.0 m -90.64 130.38 36.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.108 -0.496 . . . . 0.0 110.157 179.654 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.443 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.7 OUTLIER -61.75 -45.44 93.92 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.183 0.515 . . . . 0.0 110.08 -179.635 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 98.6 m-70 -107.46 142.31 37.51 Favored 'General case' 0 N--CA 1.465 0.32 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.231 -179.553 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 14.8 m -60.72 133.79 56.44 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.264 -179.499 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 52.8 m -76.1 -27.84 57.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 115.923 -0.58 . . . . 0.0 110.583 179.658 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.32 -113.45 3.95 Favored Glycine 0 CA--C 1.523 0.578 0 N-CA-C 110.992 -0.843 . . . . 0.0 110.992 -179.878 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.2 m-20 -72.57 -9.1 58.17 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 120.887 0.375 . . . . 0.0 110.785 -179.938 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -99.42 -166.66 29.86 Favored Glycine 0 N--CA 1.462 0.397 0 N-CA-C 110.579 -1.009 . . . . 0.0 110.579 179.719 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -139.81 146.25 39.17 Favored 'General case' 0 N--CA 1.467 0.384 0 CA-C-O 121.09 0.472 . . . . 0.0 110.902 179.854 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 18.6 t -69.05 116.3 9.34 Favored 'General case' 0 CA--C 1.518 -0.271 0 CA-C-N 115.734 -0.667 . . . . 0.0 110.5 -179.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 83.6 p -105.26 -22.02 13.14 Favored 'General case' 0 CA--C 1.51 -0.569 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.413 -179.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . 0.477 ' CG ' HH11 ' A' ' 96' ' ' ARG . 0.1 OUTLIER -158.99 165.53 18.26 Favored Pre-proline 0 C--O 1.236 0.385 0 C-N-CA 120.362 -0.535 . . . . 0.0 110.845 179.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -51.97 122.35 10.37 Favored 'Trans proline' 0 N--CA 1.49 1.289 0 C-N-CA 121.836 1.691 . . . . 0.0 111.581 178.684 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.443 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 9.6 t-20 53.17 39.74 30.14 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.844 -0.616 . . . . 0.0 109.74 179.958 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 98.0 mtp -146.86 116.85 7.26 Favored 'General case' 0 C--O 1.24 0.581 0 CA-C-O 121.137 0.494 . . . . 0.0 110.408 -179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 56.6 m -104.53 149.67 25.27 Favored 'General case' 0 CA--C 1.52 -0.184 0 CA-C-N 115.57 -0.741 . . . . 0.0 110.77 179.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.6 m -121.06 122.91 41.09 Favored 'General case' 0 CA--C 1.511 -0.522 0 CA-C-N 115.83 -0.623 . . . . 0.0 109.864 179.602 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -91.53 155.44 43.97 Favored Pre-proline 0 CA--C 1.54 0.562 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.604 -179.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -51.61 -27.67 26.48 Favored 'Trans proline' 0 N--CA 1.493 1.488 0 C-N-CA 122.574 2.182 . . . . 0.0 111.906 177.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.6 m -66.57 -16.28 64.04 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.662 -179.644 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 102.73 -15.37 55.73 Favored Glycine 0 CA--C 1.522 0.523 0 N-CA-C 111.033 -0.827 . . . . 0.0 111.033 -179.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . 0.61 ' NE2' ' N ' ' A' ' 107' ' ' ILE . 0.0 OUTLIER -67.69 143.15 56.08 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-O 120.826 0.346 . . . . 0.0 110.271 179.821 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.61 ' N ' ' NE2' ' A' ' 106' ' ' GLN . 96.0 mt -122.26 130.48 74.5 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.412 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.812 179.835 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.671 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -173.01 173.23 1.41 Allowed Pre-proline 0 C--N 1.327 -0.38 0 CA-C-N 115.971 -0.559 . . . . 0.0 110.558 179.448 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 52.1 Cg_exo -53.09 -31.34 53.82 Favored 'Trans proline' 0 N--CA 1.496 1.662 0 C-N-CA 122.67 2.247 . . . . 0.0 112.233 179.071 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 58.1 m -136.46 159.28 42.26 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-N 116.03 -0.532 . . . . 0.0 110.869 -179.827 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -78.66 145.31 34.67 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.338 179.914 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . 165.04 116.69 0.37 Allowed Glycine 0 CA--C 1.523 0.555 0 N-CA-C 110.885 -0.886 . . . . 0.0 110.885 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 46.9 t -147.87 141.62 25.67 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.756 0.312 . . . . 0.0 110.557 179.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 87.8 mtm-85 -69.76 -105.41 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.45 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 23.3 t -171.42 67.6 0.04 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.481 179.798 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.424 ' O ' HG23 ' A' ' 116' ' ' ILE . 20.2 tt -128.04 132.55 68.47 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.187 0 CA-C-N 116.319 -0.4 . . . . 0.0 110.463 -179.887 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -134.04 98.52 4.16 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.3 -179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 81.4 m-70 -148.56 152.06 36.15 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.555 179.808 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 58.6 m -118.36 78.47 1.26 Allowed 'General case' 0 N--CA 1.464 0.252 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.51 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -97.41 16.01 21.4 Favored 'General case' 0 C--N 1.332 -0.181 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.501 179.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.424 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 16.9 tt -118.11 166.19 12.71 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.255 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.517 -179.828 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.424 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 31.7 mmt180 -89.96 99.54 12.53 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.441 -179.23 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 59.8 m -103.71 128.99 51.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.849 -0.614 . . . . 0.0 110.17 179.254 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 73.8 mtm -139.72 165.55 26.98 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.079 -179.486 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 98.2 m-20 60.25 48.73 7.84 Favored 'General case' 0 C--N 1.332 -0.186 0 O-C-N 123.404 0.44 . . . . 0.0 111.151 -179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 64.72 33.12 86.38 Favored Glycine 0 CA--C 1.522 0.518 0 N-CA-C 110.93 -0.868 . . . . 0.0 110.93 179.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -82.75 130.76 9.9 Favored Glycine 0 CA--C 1.523 0.572 0 N-CA-C 110.87 -0.892 . . . . 0.0 110.87 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 9.3 p -91.61 142.1 27.99 Favored 'General case' 0 C--N 1.329 -0.299 0 O-C-N 122.747 -0.267 . . . . 0.0 110.439 179.623 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 1.0 OUTLIER -105.11 123.18 47.37 Favored 'General case' 0 N--CA 1.464 0.239 0 CA-C-O 120.891 0.377 . . . . 0.0 110.283 179.607 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 49.7 m -148.81 142.24 25.27 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.879 179.508 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 72.1 m-20 47.61 45.85 17.83 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 116.312 -0.404 . . . . 0.0 110.935 179.403 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.452 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 99.9 m-20 55.15 29.66 13.02 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.748 -179.944 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.452 ' ND1' ' O ' ' A' ' 132' ' ' ASP . 7.7 m-70 -139.41 145.38 38.84 Favored 'General case' 0 CA--C 1.517 -0.292 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.24 179.528 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 4.2 t -99.32 119.73 38.41 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.823 -0.626 . . . . 0.0 111.159 179.933 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 68.9 mt -101.25 131.24 47.35 Favored 'General case' 0 CA--C 1.518 -0.285 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -100.77 138.39 37.89 Favored 'General case' 0 C--N 1.332 -0.186 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.152 -179.128 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 99.0 mm-40 -64.68 177.4 0.93 Allowed 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 116.12 -0.491 . . . . 0.0 110.59 179.865 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 63.0 pttt -59.03 135.4 57.62 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.643 -179.996 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 92.39 -1.82 73.35 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 111.27 -0.732 . . . . 0.0 111.27 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 94.0 m-85 -126.55 138.81 53.52 Favored 'General case' 0 N--CA 1.464 0.249 0 CA-C-O 120.784 0.326 . . . . 0.0 110.329 179.633 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 42.6 pt -135.05 174.65 12.56 Favored 'Isoleucine or valine' 0 C--O 1.24 0.562 0 CA-C-N 116.093 -0.503 . . . . 0.0 109.821 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 113.54 152.43 10.93 Favored Glycine 0 CA--C 1.521 0.433 0 N-CA-C 110.571 -1.012 . . . . 0.0 110.571 179.136 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 70.4 m -62.87 -44.83 95.06 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-O 120.7 0.286 . . . . 0.0 110.439 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.434 ' O ' ' O ' ' A' ' 145' ' ' CYS . 26.4 m80 -100.94 5.9 43.39 Favored 'General case' 0 N--CA 1.463 0.225 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.643 -179.682 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.434 ' O ' ' O ' ' A' ' 144' ' ' HIS . 39.3 m 60.32 138.78 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.255 0 CA-C-O 121.072 0.463 . . . . 0.0 109.925 -179.899 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 147.66 4.57 0.36 Allowed Glycine 0 CA--C 1.519 0.322 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.979 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.7 tp-100 -119.52 88.73 39.33 Favored Pre-proline 0 CA--C 1.534 0.358 0 CA-C-O 120.775 0.321 . . . . 0.0 110.484 179.925 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_exo -58.45 160.97 15.33 Favored 'Trans proline' 0 C--N 1.308 -1.593 0 C-N-CA 122.97 2.447 . . . . 0.0 111.697 178.784 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 58.6 t -101.45 110.77 29.12 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.375 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 16.1 m -92.22 108.5 20.0 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.145 179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 75.8 mt-10 -65.9 -40.88 91.93 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.073 -0.512 . . . . 0.0 110.467 -179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . 0.407 ' OG ' ' OE1' ' A' ' 176' ' ' GLN . 14.2 t -83.55 -13.69 53.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 116.455 -0.339 . . . . 0.0 110.626 179.749 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 65.44 175.09 5.14 Favored Glycine 0 CA--C 1.524 0.614 0 N-CA-C 110.559 -1.017 . . . . 0.0 110.559 179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 99.1 m -108.82 123.79 49.6 Favored 'General case' 0 N--CA 1.466 0.346 0 CA-C-O 120.837 0.351 . . . . 0.0 110.469 179.687 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 41.0 mt -63.96 -41.75 97.49 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.025 -0.534 . . . . 0.0 110.825 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.412 ' C ' ' H ' ' A' ' 158' ' ' GLY . 99.4 m-20 -105.03 -172.93 2.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.55 179.947 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -77.34 37.7 1.58 Allowed Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.763 -0.935 . . . . 0.0 110.763 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.412 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -75.7 -172.04 31.78 Favored Glycine 0 CA--C 1.523 0.552 0 N-CA-C 110.776 -0.93 . . . . 0.0 110.776 179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . 0.408 ' NH1' HG21 ' A' ' 169' ' ' THR . 1.2 mpt_? -129.84 149.71 51.46 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.971 0.415 . . . . 0.0 110.657 -179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 59.5 m -86.36 119.31 26.49 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.086 -0.506 . . . . 0.0 110.516 -179.868 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 93.8 t -83.05 -27.02 7.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.311 0 CA-C-N 116.001 -0.545 . . . . 0.0 110.541 179.922 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.678 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -167.69 176.15 1.74 Allowed Pre-proline 0 C--N 1.326 -0.442 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.586 179.802 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.678 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 41.2 Cg_exo -56.67 135.81 72.55 Favored 'Trans proline' 0 N--CA 1.495 1.561 0 C-N-CA 122.347 2.032 . . . . 0.0 111.733 179.154 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 63.4 t30 50.59 30.82 5.1 Favored 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.428 179.717 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 90.0 mtt180 -142.74 101.06 3.79 Favored 'General case' 0 C--O 1.237 0.438 0 CA-C-O 121.402 0.62 . . . . 0.0 111.232 179.166 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.429 ' SG ' ' N ' ' A' ' 167' ' ' ALA . 14.7 t -104.52 150.71 24.37 Favored 'General case' 0 N--CA 1.464 0.268 0 CA-C-N 115.751 -0.659 . . . . 0.0 110.157 179.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . 0.429 ' N ' ' SG ' ' A' ' 166' ' ' CYS . . . -132.95 123.49 26.03 Favored 'General case' 0 C--O 1.234 0.247 0 CA-C-N 116.127 -0.488 . . . . 0.0 110.298 179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 84.6 m -101.92 132.2 47.86 Favored 'General case' 0 CA--C 1.518 -0.277 0 N-CA-C 109.694 -0.484 . . . . 0.0 109.694 179.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . 0.439 ' O ' ' OG1' ' A' ' 169' ' ' THR . 0.5 OUTLIER -111.21 19.24 18.55 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.228 0.537 . . . . 0.0 110.939 -179.451 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.535 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 49.8 t80 -93.79 31.65 1.57 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-N 115.669 -0.696 . . . . 0.0 110.577 -179.965 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 87.72 3.69 80.29 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 111.115 -0.794 . . . . 0.0 111.115 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.524 ' CD1' ' OXT' ' A' ' 178' ' ' GLU . 49.7 m-85 -106.45 148.67 27.88 Favored 'General case' 0 N--CA 1.463 0.224 0 CA-C-O 120.955 0.407 . . . . 0.0 110.547 179.707 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 4.0 t -138.74 154.33 48.54 Favored 'General case' 0 CA--C 1.519 -0.218 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.256 -180.0 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 152.39 177.43 26.05 Favored Glycine 0 CA--C 1.527 0.781 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.747 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 36.1 Cg_endo -65.11 -24.14 59.69 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.765 2.31 . . . . 0.0 111.897 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.407 ' OE1' ' OG ' ' A' ' 152' ' ' SER . 25.2 pt20 -127.87 -44.36 1.48 Allowed 'General case' 0 N--CA 1.463 0.204 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.71 -179.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 7.3 t -174.23 -74.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.585 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . 0.524 ' OXT' ' CD1' ' A' ' 172' ' ' PHE . 84.3 tt0 . . . . . 0 C--O 1.22 -0.461 0 CA-C-O 118.065 -0.969 . . . . 0.0 110.584 -179.781 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 28.2 m . . . . . 0 N--CA 1.491 1.578 0 N-CA-C 109.297 -0.631 . . . . 0.0 109.297 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -158.58 167.67 28.97 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.598 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 95.5 mtt-85 -66.87 146.85 53.97 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.484 -179.91 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 82.83 18.05 66.41 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 110.897 -0.881 . . . . 0.0 110.897 -179.662 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 61.05 -128.3 44.4 Favored Glycine 0 CA--C 1.524 0.598 0 N-CA-C 110.651 -0.98 . . . . 0.0 110.651 179.894 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -153.02 151.74 23.49 Favored Glycine 0 CA--C 1.525 0.663 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . 0.522 ' O ' ' NH1' ' A' ' 62' ' ' ARG . . . -100.57 179.57 29.27 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 110.952 -0.859 . . . . 0.0 110.952 -179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . 0.49 ' C ' ' H ' ' A' ' 52' ' ' ALA . 58.7 t-80 -66.99 -1.78 4.52 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-O 120.472 0.177 . . . . 0.0 110.707 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 30.3 t0 70.72 -13.07 0.5 Allowed 'General case' 0 N--CA 1.465 0.285 0 CA-C-N 115.965 -0.562 . . . . 0.0 110.562 -179.679 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.49 ' H ' ' C ' ' A' ' 50' ' ' HIS . . . -65.3 -36.8 85.17 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.573 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 21.1 mt -75.55 148.78 38.63 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.828 -179.84 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 99.3 mttt -134.42 162.48 32.1 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.709 -0.678 . . . . 0.0 110.272 -179.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 99.75 159.21 28.66 Favored Glycine 0 CA--C 1.534 1.223 0 N-CA-C 110.893 -0.883 . . . . 0.0 110.893 179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 71.5 Cg_endo -76.12 -1.34 11.32 Favored 'Trans proline' 0 N--CA 1.496 1.628 0 C-N-CA 122.882 2.388 . . . . 0.0 112.304 179.628 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 5.5 m120 -109.85 70.05 0.72 Allowed 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.46 -0.336 . . . . 0.0 110.419 -179.756 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.483 ' C ' ' SG ' ' A' ' 68' ' ' CYS . 53.8 t -121.85 130.06 74.91 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.44 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 179.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 99.3 m -142.03 -172.01 3.48 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.912 -0.586 . . . . 0.0 109.99 -179.588 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 84.13 168.08 43.39 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 110.66 -0.976 . . . . 0.0 110.66 -179.966 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.523 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.8 m -77.39 165.04 24.93 Favored 'General case' 0 C--N 1.326 -0.42 0 N-CA-C 109.952 -0.388 . . . . 0.0 109.952 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . 0.522 ' NH1' ' O ' ' A' ' 49' ' ' GLY . 60.6 ttt85 -59.25 -43.4 92.44 Favored 'General case' 0 C--N 1.325 -0.485 0 CA-C-N 116.427 -0.352 . . . . 0.0 110.676 179.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.1 m-85 -62.38 -42.24 99.26 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 116.277 -0.42 . . . . 0.0 111.353 -179.896 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.3 m-20 -123.46 46.0 2.31 Favored 'General case' 0 C--O 1.231 0.123 0 CA-C-O 120.85 0.357 . . . . 0.0 111.051 -179.182 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.523 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -67.83 145.33 54.75 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.214 179.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.424 ' CD2' ' O ' ' A' ' 67' ' ' CYS . 15.8 p90 -159.69 -174.97 4.89 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-O 120.915 0.388 . . . . 0.0 110.453 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.449 ' SG ' HG22 ' A' ' 73' ' ' THR . 74.0 m -78.45 129.25 34.69 Favored 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.772 -179.757 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . 0.483 ' SG ' ' C ' ' A' ' 58' ' ' VAL . 34.5 m -47.59 153.83 0.98 Allowed Pre-proline 0 C--N 1.325 -0.495 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.347 -179.199 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -52.56 132.67 46.48 Favored 'Trans proline' 0 N--CA 1.494 1.526 0 C-N-CA 121.431 1.42 . . . . 0.0 112.208 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . 0.451 ' O ' ' N ' ' A' ' 84' ' ' ILE . . . 101.59 -22.17 39.7 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 111.167 -0.773 . . . . 0.0 111.167 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.563 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 7.2 m95 -112.51 139.21 48.28 Favored 'General case' 0 N--CA 1.465 0.282 0 N-CA-C 110.034 -0.358 . . . . 0.0 110.034 179.472 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 18.2 ptpt -115.49 -166.83 1.16 Allowed 'General case' 0 N--CA 1.468 0.438 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.499 179.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.449 HG22 ' SG ' ' A' ' 67' ' ' CYS . 69.3 p -118.07 161.0 20.55 Favored 'General case' 0 CA--C 1.514 -0.413 0 CA-C-O 120.742 0.306 . . . . 0.0 110.349 179.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.565 ' N ' HD22 ' A' ' 74' ' ' LEU . 2.6 mm? -85.87 151.3 54.78 Favored Pre-proline 0 N--CA 1.448 -0.549 0 C-N-CA 120.632 -0.427 . . . . 0.0 111.1 -179.312 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -44.2 108.39 0.12 Allowed 'Trans proline' 0 C--N 1.314 -1.288 0 C-N-CA 121.718 1.612 . . . . 0.0 111.911 179.389 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 76.33 -8.08 27.46 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 111.183 -0.767 . . . . 0.0 111.183 179.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.435 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -96.37 -178.46 35.62 Favored Glycine 0 CA--C 1.527 0.815 0 N-CA-C 110.838 -0.905 . . . . 0.0 110.838 179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -138.04 17.86 2.81 Favored 'General case' 0 C--O 1.236 0.352 0 CA-C-O 120.998 0.428 . . . . 0.0 110.884 179.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 44.7 mt-30 -79.0 128.29 33.06 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.39 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 19.7 m -99.18 70.41 1.77 Allowed 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 33.9 pt -129.96 19.69 2.23 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.424 0 CA-C-N 116.358 -0.383 . . . . 0.0 111.106 -179.505 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 92.6 t -117.64 87.71 27.14 Favored Pre-proline 0 N--CA 1.465 0.303 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.371 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -61.35 147.3 95.89 Favored 'Trans proline' 0 N--CA 1.493 1.492 0 C-N-CA 122.691 2.261 . . . . 0.0 111.976 179.239 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . 0.451 ' N ' ' O ' ' A' ' 70' ' ' GLY . 95.7 mt -99.12 119.9 47.73 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.197 0 CA-C-N 116.359 -0.382 . . . . 0.0 110.027 179.08 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -90.77 127.3 36.29 Favored 'General case' 0 N--CA 1.465 0.318 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 -179.992 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.444 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.6 OUTLIER -62.6 -45.55 92.37 Favored 'General case' 0 C--N 1.325 -0.496 0 CA-C-O 121.147 0.499 . . . . 0.0 109.774 -179.878 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.8 m-70 -122.82 152.51 40.64 Favored 'General case' 0 N--CA 1.466 0.371 0 CA-C-N 116.095 -0.502 . . . . 0.0 110.468 -179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 11.6 m -59.48 135.64 57.73 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.318 -179.615 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 58.4 m -79.15 -26.13 42.81 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.811 179.716 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 77.95 -113.02 3.62 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.792 -0.923 . . . . 0.0 110.792 -179.651 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 81.1 m-20 -72.75 -8.51 55.76 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 120.797 0.332 . . . . 0.0 110.657 179.949 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.81 -168.79 25.32 Favored Glycine 0 CA--C 1.522 0.489 0 N-CA-C 110.75 -0.94 . . . . 0.0 110.75 179.78 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -141.75 149.75 40.86 Favored 'General case' 0 N--CA 1.465 0.289 0 CA-C-O 120.959 0.409 . . . . 0.0 110.882 179.623 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 3.1 m -65.68 113.0 3.94 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.13 -179.558 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 25.5 t -102.78 -24.01 13.75 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-N 116.118 -0.492 . . . . 0.0 110.122 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 14.0 mtt85 -153.47 164.85 19.18 Favored Pre-proline 0 C--N 1.329 -0.284 0 C-N-CA 120.414 -0.515 . . . . 0.0 110.706 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.1 Cg_exo -52.51 119.84 6.52 Favored 'Trans proline' 0 N--CA 1.494 1.522 0 C-N-CA 121.73 1.62 . . . . 0.0 111.662 179.293 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.444 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 3.2 m120 55.51 39.66 31.08 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.113 179.912 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 63.9 mmm -147.86 119.96 8.28 Favored 'General case' 0 C--O 1.241 0.654 0 CA-C-O 121.129 0.49 . . . . 0.0 110.102 -179.962 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.421 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -102.25 150.14 23.6 Favored 'General case' 0 C--O 1.233 0.217 0 CA-C-N 115.623 -0.717 . . . . 0.0 110.632 179.001 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 98.7 m -121.7 124.62 44.68 Favored 'General case' 0 C--N 1.325 -0.48 0 CA-C-N 115.858 -0.61 . . . . 0.0 109.531 179.516 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.71 152.34 40.67 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.535 -179.658 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -49.72 -24.86 10.47 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 122.536 2.157 . . . . 0.0 111.762 177.529 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.7 m -64.62 -17.57 64.13 Favored 'General case' 0 C--N 1.332 -0.152 0 CA-C-N 116.427 -0.351 . . . . 0.0 110.589 -179.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 101.63 -13.4 58.03 Favored Glycine 0 CA--C 1.524 0.61 0 N-CA-C 110.972 -0.851 . . . . 0.0 110.972 -179.933 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 56.8 tp60 -71.25 151.79 43.93 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-O 120.901 0.381 . . . . 0.0 110.294 179.913 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.6 mt -127.93 131.21 69.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.652 179.737 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.666 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.65 177.84 0.74 Allowed Pre-proline 0 C--N 1.327 -0.402 0 C-N-CA 120.526 -0.469 . . . . 0.0 110.474 179.339 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.666 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -56.93 -23.34 50.83 Favored 'Trans proline' 0 N--CA 1.499 1.821 0 C-N-CA 122.816 2.344 . . . . 0.0 111.921 179.363 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 113' ' ' SER . 33.6 p -150.67 167.71 26.51 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.938 0.399 . . . . 0.0 110.212 -179.85 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -75.93 -28.57 58.03 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.748 -179.268 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -120.51 88.97 0.44 Allowed Glycine 0 CA--C 1.525 0.658 0 N-CA-C 110.785 -0.926 . . . . 0.0 110.785 -179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.462 ' OG ' ' OG ' ' A' ' 110' ' ' SER . 4.8 m -154.56 154.78 33.63 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 121.017 0.437 . . . . 0.0 110.409 179.617 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.9 mtp180 -91.52 -166.42 1.56 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.781 -0.645 . . . . 0.0 110.156 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.2 p -153.75 161.08 42.41 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.375 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 33.3 pt -82.1 44.72 0.05 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.816 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 48.98 -116.89 0.89 Allowed 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.502 179.975 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.518 ' O ' ' ND1' ' A' ' 118' ' ' HIS . 57.9 t-80 40.66 43.4 1.6 Allowed 'General case' 0 C--N 1.332 -0.182 0 CA-C-O 120.88 0.371 . . . . 0.0 110.847 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 6.3 p -102.55 175.96 5.33 Favored 'General case' 0 N--CA 1.464 0.258 0 CA-C-N 116.099 -0.5 . . . . 0.0 110.586 -179.847 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 26.5 m120 -63.25 -40.16 96.64 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.498 -179.892 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.518 ' CG1' ' H ' ' A' ' 122' ' ' ARG . 14.4 tt -87.68 174.08 0.83 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.15 0 CA-C-O 121.145 0.497 . . . . 0.0 110.077 179.648 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.518 ' H ' ' CG1' ' A' ' 121' ' ' ILE . 10.2 ptm180 -122.28 119.27 30.67 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.741 -0.663 . . . . 0.0 110.311 179.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 9.0 m -124.37 157.17 35.7 Favored 'General case' 0 C--O 1.233 0.188 0 CA-C-N 116.048 -0.523 . . . . 0.0 109.657 179.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.414 ' C ' HD22 ' A' ' 125' ' ' ASN . 71.5 mtm -136.09 173.6 11.54 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.259 -179.483 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . 0.446 ' ND2' ' O ' ' A' ' 145' ' ' CYS . 4.0 m-80 61.74 39.78 13.76 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.193 179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 69.92 24.59 76.34 Favored Glycine 0 CA--C 1.519 0.326 0 N-CA-C 110.647 -0.981 . . . . 0.0 110.647 179.447 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.12 134.2 29.17 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 110.74 -0.944 . . . . 0.0 110.74 -179.583 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 33.3 t -86.1 135.78 33.48 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.784 0.326 . . . . 0.0 110.354 179.768 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 95.4 m -69.98 119.38 14.1 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.364 -179.597 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 48.2 t -131.36 100.62 5.23 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.321 -0.4 . . . . 0.0 110.195 179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 48.79 -111.37 0.44 Allowed 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.939 -0.573 . . . . 0.0 110.696 -179.88 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 95.5 m-20 -111.42 17.2 20.34 Favored 'General case' 0 N--CA 1.466 0.362 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.856 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 80.5 m80 -131.94 153.77 49.95 Favored 'General case' 0 N--CA 1.465 0.275 0 CA-C-N 116.29 -0.414 . . . . 0.0 110.495 -179.391 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 94.4 m -105.78 132.54 51.78 Favored 'General case' 0 N--CA 1.465 0.287 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.555 179.829 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 88.4 mt -97.91 127.21 43.71 Favored 'General case' 0 C--N 1.33 -0.271 0 N-CA-C 109.331 -0.618 . . . . 0.0 109.331 179.678 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . 0.463 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 5.7 m -89.66 133.67 34.53 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 116.077 -0.51 . . . . 0.0 111.076 -179.017 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.3 mt-30 -74.07 178.07 5.27 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.256 179.776 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 87.9 tttt -64.32 125.67 25.32 Favored 'General case' 0 C--N 1.328 -0.352 0 C-N-CA 120.657 -0.417 . . . . 0.0 110.433 179.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.94 -18.65 45.95 Favored Glycine 0 N--CA 1.466 0.691 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -179.59 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -118.48 137.34 53.25 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 120.801 0.334 . . . . 0.0 110.594 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 18.9 pt -135.99 175.42 10.58 Favored 'Isoleucine or valine' 0 C--O 1.235 0.329 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.932 -179.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.463 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 101.19 163.78 27.57 Favored Glycine 0 N--CA 1.464 0.502 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 179.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 40.3 p -62.51 -42.74 99.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.817 0.341 . . . . 0.0 110.471 -179.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.526 ' CE1' ' H ' ' A' ' 146' ' ' GLY . 0.0 OUTLIER -90.72 4.06 52.57 Favored 'General case' 0 N--CA 1.463 0.188 0 CA-C-N 116.135 -0.484 . . . . 0.0 110.356 179.773 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.446 ' O ' ' ND2' ' A' ' 125' ' ' ASN . 36.4 m 48.44 37.64 9.26 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 115.746 -0.661 . . . . 0.0 110.461 -179.892 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.526 ' H ' ' CE1' ' A' ' 144' ' ' HIS . . . -105.1 7.32 43.99 Favored Glycine 0 CA--C 1.519 0.306 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 179.732 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 9.4 tp-100 -109.4 109.08 60.26 Favored Pre-proline 0 CA--C 1.543 0.686 0 C-N-CA 120.996 -0.281 . . . . 0.0 110.67 -179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 82.9 Cg_endo -77.47 160.42 32.03 Favored 'Trans proline' 0 N--CA 1.491 1.345 0 C-N-CA 122.548 2.165 . . . . 0.0 112.191 179.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 55.4 t -115.61 131.04 69.18 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.23 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 -179.856 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 55.9 m -99.18 101.98 13.5 Favored 'General case' 0 N--CA 1.463 0.176 0 CA-C-N 115.957 -0.565 . . . . 0.0 109.963 179.767 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -55.48 -61.38 2.38 Favored 'General case' 0 C--N 1.326 -0.415 0 CA-C-O 120.834 0.35 . . . . 0.0 110.232 -179.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 7.5 t -116.93 -4.99 11.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.755 179.426 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -78.84 -178.72 50.88 Favored Glycine 0 CA--C 1.523 0.58 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 -179.58 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.488 ' H ' ' CB ' ' A' ' 166' ' ' CYS . 9.4 m 45.09 48.96 9.71 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.914 0.387 . . . . 0.0 110.505 -179.764 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 81.5 mt -62.88 -42.04 99.62 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.864 -179.796 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 44.4 t30 -109.88 -113.99 0.31 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.103 -0.498 . . . . 0.0 110.329 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -95.64 11.32 68.44 Favored Glycine 0 CA--C 1.524 0.616 0 N-CA-C 110.923 -0.871 . . . . 0.0 110.923 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -58.59 151.67 32.29 Favored Glycine 0 CA--C 1.521 0.447 0 N-CA-C 110.545 -1.022 . . . . 0.0 110.545 -179.379 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . 0.483 ' O ' ' SG ' ' A' ' 166' ' ' CYS . 3.2 mpt_? -102.3 136.17 42.61 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.527 0.203 . . . . 0.0 110.507 -179.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 70.7 m -85.49 120.52 27.04 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-O 120.998 0.428 . . . . 0.0 111.085 -179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 61.5 t -104.01 -29.17 2.89 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.343 -179.668 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.597 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -161.44 169.18 10.12 Favored Pre-proline 0 CA--C 1.534 0.336 0 C-N-CA 120.683 -0.407 . . . . 0.0 110.457 179.699 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.597 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 69.8 Cg_exo -49.87 127.98 20.53 Favored 'Trans proline' 0 C--N 1.312 -1.393 0 C-N-CA 122.093 1.862 . . . . 0.0 111.874 178.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 7.5 m-20 54.74 32.26 17.08 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.967 -179.803 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 22.1 tpt85 -139.24 131.57 28.39 Favored 'General case' 0 C--O 1.235 0.294 0 CA-C-O 121.213 0.53 . . . . 0.0 110.231 179.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.488 ' CB ' ' H ' ' A' ' 154' ' ' CYS . 1.8 t -145.25 154.43 42.37 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.76 -0.655 . . . . 0.0 111.217 179.586 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -98.42 138.67 35.32 Favored 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.698 179.149 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 20.9 m -75.3 143.77 42.78 Favored 'General case' 0 C--O 1.233 0.194 0 CA-C-N 115.955 -0.566 . . . . 0.0 110.392 -179.349 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 17.3 m -62.99 -45.47 92.28 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.975 -0.557 . . . . 0.0 110.741 -179.197 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -104.21 19.51 20.04 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-O 121.01 0.433 . . . . 0.0 110.861 -179.4 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.57 26.58 72.83 Favored Glycine 0 CA--C 1.525 0.682 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 179.79 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.42 ' CD2' ' O ' ' A' ' 177' ' ' CYS . 2.2 t80 -56.66 169.79 0.45 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-O 120.927 0.394 . . . . 0.0 110.258 -178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 43.9 p -98.09 164.27 12.41 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 121.466 0.65 . . . . 0.0 110.518 179.958 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 79.09 144.08 2.74 Favored Glycine 0 CA--C 1.54 1.636 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.173 179.51 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_exo -52.92 -39.45 78.59 Favored 'Trans proline' 0 N--CA 1.5 1.898 0 C-N-CA 122.506 2.137 . . . . 0.0 112.386 178.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.52 ' O ' ' N ' ' A' ' 178' ' ' GLU . 75.9 mt-30 -74.85 -9.71 58.81 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 116.125 -0.489 . . . . 0.0 110.663 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.42 ' O ' ' CD2' ' A' ' 172' ' ' PHE . 91.9 m 55.75 -80.73 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.608 -179.869 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . 0.52 ' N ' ' O ' ' A' ' 176' ' ' GLN . 80.0 mm-40 . . . . . 0 C--O 1.219 -0.503 0 CA-C-O 117.977 -1.011 . . . . 0.0 110.685 179.942 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.5 p . . . . . 0 N--CA 1.491 1.584 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -65.28 -38.26 89.73 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.848 179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 61.1 ttm-85 -60.66 -43.4 97.68 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.274 -0.421 . . . . 0.0 111.011 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 124.89 -125.5 5.72 Favored Glycine 0 CA--C 1.523 0.563 0 N-CA-C 110.693 -0.963 . . . . 0.0 110.693 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -179.39 -177.64 47.87 Favored Glycine 0 CA--C 1.524 0.655 0 N-CA-C 110.91 -0.876 . . . . 0.0 110.91 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -167.78 174.1 42.77 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.894 -0.882 . . . . 0.0 110.894 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -167.53 54.44 0.23 Allowed Glycine 0 CA--C 1.524 0.621 0 N-CA-C 110.901 -0.88 . . . . 0.0 110.901 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 45.0 m80 -61.86 -41.67 98.13 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 120.82 0.343 . . . . 0.0 110.676 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.581 ' CG ' HD22 ' A' ' 78' ' ' ASN . 67.7 t0 -88.94 114.53 25.66 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.359 -179.819 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -65.9 147.42 53.39 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.664 -179.843 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.431 HD12 ' HB1' ' A' ' 65' ' ' ALA . 94.8 mt -71.75 152.8 42.45 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.718 -179.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 50.1 mtmt -126.82 161.72 27.55 Favored 'General case' 0 C--O 1.236 0.369 0 CA-C-O 121.465 0.65 . . . . 0.0 110.616 -179.579 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 74.05 167.44 15.95 Favored Glycine 0 CA--C 1.528 0.877 0 N-CA-C 110.812 -0.915 . . . . 0.0 110.812 -179.676 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 57.7 Cg_endo -71.73 -168.24 0.35 Allowed 'Trans proline' 0 N--CA 1.495 1.584 0 C-N-CA 123.029 2.486 . . . . 0.0 111.7 179.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.517 ' ND2' ' CE2' ' A' ' 71' ' ' TRP . 98.4 m-20 57.19 36.91 28.05 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.932 -0.576 . . . . 0.0 110.711 179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 14.1 p -98.04 137.74 24.73 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.152 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.403 -179.716 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 34.2 m -138.98 178.96 6.78 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-O 121.001 0.429 . . . . 0.0 110.232 -179.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.06 164.13 31.62 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.805 -0.918 . . . . 0.0 110.805 179.987 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.534 ' O ' ' N ' ' A' ' 65' ' ' ALA . 7.8 m -83.38 173.83 11.2 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-O 120.682 0.277 . . . . 0.0 110.561 179.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 75.3 ttt180 -61.85 -42.84 99.54 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-O 120.888 0.375 . . . . 0.0 110.518 -179.997 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -62.78 -38.94 92.63 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.141 -0.482 . . . . 0.0 110.896 -179.826 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -132.98 55.85 1.88 Allowed 'General case' 0 N--CA 1.457 -0.113 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.652 -179.827 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.534 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.82 145.45 50.32 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.865 -0.607 . . . . 0.0 110.47 179.62 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.9 p90 -159.12 166.37 31.71 Favored 'General case' 0 CA--C 1.519 -0.221 0 CA-C-O 121.054 0.454 . . . . 0.0 110.995 179.456 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.539 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 75.0 m -72.04 142.03 49.29 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.187 179.948 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 63.8 m -58.67 150.09 59.34 Favored Pre-proline 0 C--N 1.327 -0.381 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.814 -179.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 16.6 Cg_endo -56.05 119.44 6.61 Favored 'Trans proline' 0 N--CA 1.494 1.52 0 C-N-CA 122.17 1.913 . . . . 0.0 112.357 -179.699 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 116.72 -14.82 14.5 Favored Glycine 0 CA--C 1.525 0.657 0 N-CA-C 111.137 -0.785 . . . . 0.0 111.137 179.832 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.517 ' CE2' ' ND2' ' A' ' 57' ' ' ASN . 89.0 m95 -119.55 132.73 55.81 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-O 121.109 0.481 . . . . 0.0 110.412 179.456 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 22.2 ptmt -111.86 -177.04 3.08 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.292 179.429 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.539 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 51.2 p -130.63 166.34 20.89 Favored 'General case' 0 N--CA 1.466 0.372 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.515 -179.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.4 ' HG ' HG21 ' A' ' 82' ' ' VAL . 87.6 mt -90.2 151.75 45.12 Favored Pre-proline 0 C--N 1.33 -0.25 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.865 -179.451 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.408 ' C ' ' H ' ' A' ' 77' ' ' GLY . 53.2 Cg_exo -47.52 128.44 15.2 Favored 'Trans proline' 0 N--CA 1.491 1.337 0 C-N-CA 121.51 1.473 . . . . 0.0 112.212 178.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 70.74 -5.82 7.12 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 179.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.411 ' O ' ' OD1' ' A' ' 78' ' ' ASN . . . -91.87 171.95 34.95 Favored Glycine 0 CA--C 1.523 0.589 0 N-CA-C 110.971 -0.852 . . . . 0.0 110.971 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.581 HD22 ' CG ' ' A' ' 51' ' ' ASP . 96.3 m-20 -140.57 8.79 2.19 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 120.955 0.407 . . . . 0.0 110.992 179.477 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 4.6 mp0 -86.67 129.29 34.92 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 116.254 -0.43 . . . . 0.0 110.435 -179.611 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 18.4 m -92.86 46.23 1.22 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.118 -0.492 . . . . 0.0 109.856 179.903 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 45.2 pt -98.01 -4.45 9.68 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-N 116.418 -0.356 . . . . 0.0 110.528 -179.824 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . 0.4 HG21 ' HG ' ' A' ' 74' ' ' LEU . 57.8 t -97.64 111.59 59.13 Favored Pre-proline 0 CA--C 1.536 0.435 0 C-N-CA 120.498 -0.481 . . . . 0.0 111.13 -179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 73.3 Cg_endo -74.88 159.5 41.68 Favored 'Trans proline' 0 N--CA 1.49 1.285 0 C-N-CA 122.306 2.004 . . . . 0.0 111.962 179.818 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 93.4 mt -98.83 121.67 49.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 N-CA-C 109.916 -0.402 . . . . 0.0 109.916 179.426 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -91.34 122.66 34.14 Favored 'General case' 0 N--CA 1.468 0.473 0 N-CA-C 109.834 -0.432 . . . . 0.0 109.834 -179.827 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.448 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -64.6 -45.32 87.46 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 121.372 0.606 . . . . 0.0 109.551 179.462 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 74.5 m-70 -137.17 149.46 47.27 Favored 'General case' 0 N--CA 1.466 0.329 0 CA-C-N 115.811 -0.631 . . . . 0.0 110.646 -179.912 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 7.5 p -52.3 128.87 26.6 Favored 'General case' 0 C--N 1.327 -0.397 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.361 -179.545 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.5 m -72.31 -31.84 66.04 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.872 -0.604 . . . . 0.0 110.607 179.986 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.83 -112.81 3.54 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 179.85 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 2.6 m-20 -70.42 -6.58 36.74 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.635 0.255 . . . . 0.0 110.496 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -108.07 -162.93 21.1 Favored Glycine 0 CA--C 1.528 0.861 0 N-CA-C 110.684 -0.966 . . . . 0.0 110.684 179.917 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 52.8 p90 -146.88 152.81 39.31 Favored 'General case' 0 N--CA 1.464 0.241 0 CA-C-O 120.998 0.428 . . . . 0.0 110.772 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 64.3 m -67.77 113.92 5.93 Favored 'General case' 0 CA--C 1.519 -0.23 0 CA-C-N 115.845 -0.616 . . . . 0.0 109.668 -179.72 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 36.9 t -106.5 -23.27 12.54 Favored 'General case' 0 CA--C 1.513 -0.459 0 CA-C-N 116.066 -0.516 . . . . 0.0 110.254 -179.46 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 19.8 mtt180 -156.82 162.02 28.41 Favored Pre-proline 0 C--N 1.327 -0.378 0 C-N-CA 120.292 -0.563 . . . . 0.0 110.542 179.631 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 67.4 Cg_exo -48.4 119.27 3.93 Favored 'Trans proline' 0 N--CA 1.49 1.302 0 C-N-CA 121.907 1.738 . . . . 0.0 111.331 179.091 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.448 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 96.4 m-20 54.33 40.58 31.87 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.35 179.514 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 83.4 mmm -146.84 115.04 6.61 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.308 -179.729 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.484 ' N ' ' O ' ' A' ' 108' ' ' ALA . 55.7 m -96.72 145.88 25.39 Favored 'General case' 0 N--CA 1.463 0.214 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.148 178.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 61.0 m -119.99 114.39 21.95 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.771 179.775 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.413 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -79.57 157.63 74.53 Favored Pre-proline 0 CA--C 1.54 0.576 0 CA-C-N 115.871 -0.604 . . . . 0.0 109.71 -179.715 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.413 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 28.0 Cg_endo -63.43 -19.27 67.65 Favored 'Trans proline' 0 N--CA 1.496 1.624 0 C-N-CA 122.946 2.431 . . . . 0.0 111.352 178.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.2 m -69.41 -17.02 63.62 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.454 -0.339 . . . . 0.0 110.862 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 108.35 -21.79 28.05 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.013 -0.835 . . . . 0.0 111.013 -179.715 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 53.3 tt0 -65.98 150.89 47.94 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.086 0.47 . . . . 0.0 110.218 179.834 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 95.8 mt -130.89 131.62 64.25 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.445 0 CA-C-N 115.766 -0.652 . . . . 0.0 110.999 -179.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.683 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -169.02 178.29 1.02 Allowed Pre-proline 0 C--N 1.325 -0.478 0 C-N-CA 120.482 -0.487 . . . . 0.0 110.578 179.429 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.683 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 46.1 Cg_exo -57.06 -23.79 54.44 Favored 'Trans proline' 0 N--CA 1.498 1.787 0 C-N-CA 122.771 2.314 . . . . 0.0 111.639 178.806 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 33.1 p -151.02 163.26 39.16 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-O 120.962 0.41 . . . . 0.0 110.291 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.6 OUTLIER -80.18 140.75 36.19 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.036 -0.529 . . . . 0.0 110.302 -179.688 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . 0.418 ' O ' ' O ' ' A' ' 113' ' ' SER . . . -84.27 -174.85 50.58 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.773 -0.931 . . . . 0.0 110.773 179.646 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . 0.418 ' O ' ' O ' ' A' ' 112' ' ' GLY . 8.6 t -58.52 -152.12 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 120.679 0.276 . . . . 0.0 110.453 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 76.3 ttt180 54.92 80.89 0.12 Allowed 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.45 -179.854 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 35.7 t -154.88 164.02 39.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.381 -179.924 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 37.5 mm -101.66 120.29 51.07 Favored 'Isoleucine or valine' 0 C--O 1.234 0.25 0 CA-C-O 120.958 0.409 . . . . 0.0 109.96 -179.752 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -141.27 -7.52 1.02 Allowed 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.429 -179.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 94.9 m-70 -75.01 70.77 2.04 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.304 -0.407 . . . . 0.0 110.378 179.947 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 1.8 t -129.76 126.74 38.89 Favored 'General case' 0 N--CA 1.467 0.38 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.542 -179.937 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 83.4 m-20 -93.63 4.06 54.52 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 116.064 -0.516 . . . . 0.0 110.324 179.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.465 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.6 tt -132.52 168.48 24.05 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.404 0 CA-C-N 116.042 -0.526 . . . . 0.0 110.332 179.583 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.465 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 11.5 ptm180 -100.95 118.13 36.37 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.67 -0.696 . . . . 0.0 110.201 179.821 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . 0.445 ' C ' ' SD ' ' A' ' 124' ' ' MET . 61.7 m -116.17 138.58 51.15 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.689 -179.785 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . 0.531 ' N ' ' SD ' ' A' ' 124' ' ' MET . 3.2 mpp? -142.56 165.69 26.7 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.881 -0.6 . . . . 0.0 110.474 -179.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.9 m-20 59.15 51.22 7.18 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.045 -0.525 . . . . 0.0 111.454 -179.876 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 70.84 26.16 74.48 Favored Glycine 0 C--N 1.331 0.27 0 N-CA-C 110.721 -0.952 . . . . 0.0 110.721 179.634 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.81 114.49 3.92 Favored Glycine 0 CA--C 1.53 0.983 0 N-CA-C 110.512 -1.035 . . . . 0.0 110.512 -179.55 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 30.6 t -79.49 148.21 31.94 Favored 'General case' 0 N--CA 1.463 0.179 0 CA-C-O 120.511 0.196 . . . . 0.0 110.976 179.865 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 19.4 m -92.38 102.83 15.31 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 116.477 -0.328 . . . . 0.0 110.185 179.521 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . . . . . . . . . 35.1 t -149.04 138.59 21.77 Favored 'General case' 0 C--O 1.231 0.123 0 N-CA-C 110.308 -0.256 . . . . 0.0 110.308 179.59 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.498 ' O ' ' ND1' ' A' ' 133' ' ' HIS . 98.5 m-20 51.72 36.57 17.98 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-O 120.788 0.328 . . . . 0.0 110.994 179.375 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 98.5 m-20 54.19 27.91 8.4 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.682 -179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.498 ' ND1' ' O ' ' A' ' 131' ' ' ASP . 44.2 m80 -136.34 143.09 43.93 Favored 'General case' 0 N--CA 1.463 0.21 0 CA-C-N 116.234 -0.439 . . . . 0.0 109.961 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . . . . . . . . . 65.7 m -90.14 120.44 31.31 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.093 -179.464 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 82.6 mt -97.68 120.02 37.3 Favored 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.22 137.6 32.21 Favored 'General case' 0 N--CA 1.463 0.198 0 CA-C-N 115.951 -0.568 . . . . 0.0 110.642 -178.746 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.3 -174.1 0.62 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.021 0.439 . . . . 0.0 110.39 -179.967 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 48.6 tttp -67.82 132.26 47.06 Favored 'General case' 0 C--N 1.325 -0.477 0 CA-C-N 115.993 -0.549 . . . . 0.0 110.839 -179.902 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 97.78 -7.88 63.31 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.979 -0.849 . . . . 0.0 110.979 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.1 m-85 -122.1 137.95 54.63 Favored 'General case' 0 N--CA 1.464 0.269 0 CA-C-O 120.866 0.365 . . . . 0.0 110.447 179.636 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.5 pt -138.11 -176.62 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.211 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.084 179.835 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 116.01 162.77 13.33 Favored Glycine 0 N--CA 1.464 0.537 0 N-CA-C 110.794 -0.922 . . . . 0.0 110.794 179.577 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 49.5 p -60.71 -45.04 95.74 Favored 'General case' 0 C--N 1.326 -0.42 0 C-N-CA 120.876 -0.329 . . . . 0.0 110.409 -179.668 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . 0.436 ' O ' ' O ' ' A' ' 145' ' ' CYS . 12.2 m80 -120.64 27.53 8.49 Favored 'General case' 0 N--CA 1.469 0.493 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.59 179.676 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . 0.436 ' O ' ' O ' ' A' ' 144' ' ' HIS . 5.8 m 58.05 118.54 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.972 -0.558 . . . . 0.0 110.086 -179.804 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . 0.424 ' H ' ' H ' ' A' ' 147' ' ' GLN . . . 174.85 5.36 0.02 OUTLIER Glycine 0 N--CA 1.45 -0.406 0 N-CA-C 110.517 -1.033 . . . . 0.0 110.517 -179.723 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . 0.424 ' H ' ' H ' ' A' ' 146' ' ' GLY . 55.4 tp60 -132.51 114.9 14.62 Favored Pre-proline 0 CA--C 1.547 0.842 0 C-N-CA 120.894 -0.323 . . . . 0.0 110.596 179.332 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_endo -75.35 158.59 40.75 Favored 'Trans proline' 0 N--CA 1.495 1.589 0 C-N-CA 122.772 2.315 . . . . 0.0 112.095 179.711 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.2 t -91.49 131.16 39.35 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 116.126 -0.488 . . . . 0.0 109.93 -179.846 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -105.94 88.36 2.79 Favored 'General case' 0 N--CA 1.467 0.394 0 CA-C-O 121.085 0.469 . . . . 0.0 109.85 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 56.7 mp0 -59.02 -61.92 2.28 Favored 'General case' 0 C--N 1.326 -0.452 0 C-N-CA 120.539 -0.465 . . . . 0.0 110.472 -178.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . 0.407 ' O ' ' O ' ' A' ' 153' ' ' GLY . 97.3 p -117.95 -3.5 11.15 Favored 'General case' 0 N--CA 1.466 0.357 0 CA-C-N 116.317 -0.401 . . . . 0.0 110.527 178.965 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . 0.407 ' O ' ' O ' ' A' ' 152' ' ' SER . . . -58.98 -152.42 0.01 OUTLIER Glycine 0 CA--C 1.519 0.299 0 N-CA-C 110.959 -0.857 . . . . 0.0 110.959 -179.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.599 ' N ' ' SG ' ' A' ' 166' ' ' CYS . 73.5 m -68.88 126.39 29.63 Favored 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 120.758 0.314 . . . . 0.0 110.202 -179.465 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 79.8 mt -63.11 -42.93 99.65 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.059 -179.602 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . . . . . . . . . 41.8 t-20 -169.79 -25.93 0.02 OUTLIER 'General case' 0 C--N 1.324 -0.529 0 CA-C-N 116.032 -0.531 . . . . 0.0 110.66 179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -60.16 -43.4 98.41 Favored Glycine 0 CA--C 1.524 0.647 0 N-CA-C 111.188 -0.765 . . . . 0.0 111.188 -179.241 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 154' ' ' CYS . . . -97.64 179.14 32.92 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.76 -0.936 . . . . 0.0 110.76 179.462 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 57.5 ttp180 -110.55 131.05 55.38 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-O 120.781 0.324 . . . . 0.0 110.527 179.998 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 61.4 m -83.24 122.93 29.06 Favored 'General case' 0 CA--C 1.52 -0.175 0 CA-C-N 116.398 -0.365 . . . . 0.0 110.079 -179.656 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 26.8 m -104.12 -18.35 6.83 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.421 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.365 -179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.628 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -162.61 172.81 5.0 Favored Pre-proline 0 C--N 1.326 -0.439 0 C-N-CA 120.412 -0.515 . . . . 0.0 110.622 179.467 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.628 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.4 Cg_exo -53.73 127.49 25.7 Favored 'Trans proline' 0 N--CA 1.493 1.471 0 C-N-CA 121.925 1.75 . . . . 0.0 111.687 178.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 65.4 t30 51.88 34.26 13.12 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.806 -0.634 . . . . 0.0 110.255 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 76.5 ttt180 -140.75 134.7 30.64 Favored 'General case' 0 C--O 1.234 0.259 0 CA-C-O 121.391 0.615 . . . . 0.0 110.39 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.599 ' SG ' ' N ' ' A' ' 154' ' ' CYS . 11.9 p -154.94 166.9 32.09 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.875 -0.602 . . . . 0.0 111.039 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -122.03 142.76 50.01 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.059 179.653 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . 0.422 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 87.5 m -78.08 124.12 27.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.737 -0.665 . . . . 0.0 110.418 -179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.7 m -64.55 -46.25 83.63 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.575 -179.275 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 6.8 m-85 -107.71 16.18 23.9 Favored 'General case' 0 N--CA 1.472 0.637 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.349 179.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 69.54 27.9 72.94 Favored Glycine 0 C--N 1.31 -0.872 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.265 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.516 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 13.9 m-85 -64.63 139.82 58.8 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 121.345 0.593 . . . . 0.0 110.045 -179.461 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -82.93 167.67 17.78 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.008 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 110.25 151.56 13.14 Favored Glycine 0 CA--C 1.533 1.193 0 N-CA-C 110.951 -0.86 . . . . 0.0 110.951 179.584 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -67.29 -24.15 44.0 Favored 'Trans proline' 0 N--CA 1.496 1.663 0 C-N-CA 122.628 2.219 . . . . 0.0 112.133 -179.669 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.44 ' O ' ' O ' ' A' ' 177' ' ' CYS . 74.1 mt-30 -104.91 -7.99 18.95 Favored 'General case' 0 N--CA 1.464 0.235 0 CA-C-N 116.244 -0.435 . . . . 0.0 110.577 -179.385 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.516 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 2.6 t 39.33 95.4 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.197 -179.864 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 . . . . . 0 C--O 1.219 -0.528 0 CA-C-O 117.99 -1.005 . . . . 0.0 110.674 -179.859 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 51.8 p . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.35 -0.611 . . . . 0.0 109.35 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . 55.16 167.52 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.707 -179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 76.0 ttt180 49.55 78.99 0.09 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.002 -0.545 . . . . 0.0 110.49 -179.998 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -87.6 -9.51 71.91 Favored Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.976 -0.85 . . . . 0.0 110.976 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 59.98 -131.01 50.13 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.767 -0.933 . . . . 0.0 110.767 -179.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 104.82 162.47 24.04 Favored Glycine 0 CA--C 1.524 0.651 0 N-CA-C 110.975 -0.85 . . . . 0.0 110.975 179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -69.61 162.14 52.35 Favored Glycine 0 CA--C 1.523 0.586 0 N-CA-C 110.753 -0.939 . . . . 0.0 110.753 179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . 0.404 ' O ' ' ND1' ' A' ' 50' ' ' HIS . 11.0 p80 -129.49 124.16 33.29 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-O 120.779 0.323 . . . . 0.0 110.224 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . 0.45 ' O ' ' O ' ' A' ' 52' ' ' ALA . 54.6 t0 -91.23 99.27 12.29 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 116.265 -0.425 . . . . 0.0 110.317 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . 0.45 ' O ' ' O ' ' A' ' 51' ' ' ASP . . . 53.87 112.52 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.075 -0.512 . . . . 0.0 111.172 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.4 mt -74.0 144.81 45.01 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-O 121.12 0.486 . . . . 0.0 110.33 179.613 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 68.5 mttm -127.37 158.7 36.57 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.716 -0.674 . . . . 0.0 110.008 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 108.61 152.87 15.98 Favored Glycine 0 CA--C 1.534 1.231 0 N-CA-C 110.957 -0.857 . . . . 0.0 110.957 179.754 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -74.04 11.96 1.08 Allowed 'Trans proline' 0 N--CA 1.498 1.785 0 C-N-CA 122.67 2.246 . . . . 0.0 112.438 179.656 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 72.8 m-80 -125.14 52.12 1.62 Allowed 'General case' 0 N--CA 1.467 0.375 0 CA-C-N 116.587 -0.279 . . . . 0.0 111.075 -179.717 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 7.4 p -98.45 133.05 42.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.361 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . 0.429 ' O ' ' O ' ' A' ' 66' ' ' TYR . 99.2 m -144.56 175.49 10.11 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.971 -178.339 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 88.94 169.61 44.76 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 111.223 -0.751 . . . . 0.0 111.223 -179.771 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.56 ' O ' ' N ' ' A' ' 65' ' ' ALA . 4.5 m -73.83 160.86 30.85 Favored 'General case' 0 C--N 1.33 -0.261 0 N-CA-C 110.157 -0.312 . . . . 0.0 110.157 179.842 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 61.2 ttm-85 -59.28 -43.7 92.52 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.431 -0.35 . . . . 0.0 110.646 -179.646 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 95.8 m-85 -61.75 -43.53 98.67 Favored 'General case' 0 C--N 1.33 -0.247 0 C-N-CA 120.899 -0.321 . . . . 0.0 111.395 -179.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 99.7 m-20 -125.35 47.86 2.12 Favored 'General case' 0 N--CA 1.453 -0.287 0 CA-C-N 116.335 -0.393 . . . . 0.0 110.537 -179.563 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.56 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -65.32 142.82 58.12 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.282 -0.417 . . . . 0.0 110.603 -179.718 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . 0.429 ' O ' ' O ' ' A' ' 59' ' ' CYS . 24.3 p90 -152.04 168.14 26.19 Favored 'General case' 0 N--CA 1.464 0.252 0 CA-C-O 121.279 0.562 . . . . 0.0 110.437 179.693 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 1.5 t -71.56 139.0 49.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.208 -179.41 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -59.85 159.49 19.37 Favored Pre-proline 0 C--N 1.324 -0.52 0 N-CA-C 109.574 -0.528 . . . . 0.0 109.574 179.452 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_endo -60.29 135.01 58.99 Favored 'Trans proline' 0 N--CA 1.497 1.707 0 C-N-CA 122.131 1.887 . . . . 0.0 111.627 179.268 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 102.15 -23.5 34.26 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 -179.432 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . . . . . . . . . 92.0 m95 -114.32 135.93 53.53 Favored 'General case' 0 N--CA 1.465 0.292 0 CA-C-N 116.732 0.266 . . . . 0.0 110.284 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 19.3 ptpt -121.09 -174.04 2.74 Favored 'General case' 0 N--CA 1.467 0.386 0 CA-C-N 116.464 -0.335 . . . . 0.0 110.159 179.441 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . . . . . . . . . 70.8 p -124.1 163.49 21.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.886 0.374 . . . . 0.0 110.183 179.766 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.432 ' O ' ' N ' ' A' ' 77' ' ' GLY . 86.1 mt -83.52 149.86 58.62 Favored Pre-proline 0 C--N 1.327 -0.397 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.781 -179.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.416 ' C ' ' H ' ' A' ' 77' ' ' GLY . 76.0 Cg_exo -42.62 117.49 0.88 Allowed 'Trans proline' 0 N--CA 1.49 1.288 0 C-N-CA 121.734 1.623 . . . . 0.0 112.371 179.566 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 68.72 -3.96 5.9 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 111.019 -0.833 . . . . 0.0 111.019 179.348 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.432 ' N ' ' O ' ' A' ' 74' ' ' LEU . . . -91.76 175.1 38.37 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -179.927 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 27.6 m120 -134.68 8.28 3.57 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-O 120.646 0.26 . . . . 0.0 110.926 179.783 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 75.6 mt-30 -82.35 129.26 34.83 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.826 179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 9.9 m -103.53 78.6 1.6 Allowed 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.538 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 4.7 pt -130.98 20.03 1.88 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.356 0 CA-C-N 116.274 -0.421 . . . . 0.0 110.707 179.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 6.5 t -120.73 103.16 43.81 Favored Pre-proline 0 CA--C 1.537 0.479 0 CA-C-N 116.811 -0.177 . . . . 0.0 110.624 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 71.8 Cg_endo -78.15 160.34 29.81 Favored 'Trans proline' 0 N--CA 1.488 1.183 0 C-N-CA 122.165 1.91 . . . . 0.0 112.266 -179.529 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 92.6 mt -105.82 127.39 60.86 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.388 0 CA-C-N 116.224 -0.443 . . . . 0.0 110.413 179.821 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 100' ' ' CYS . 4.9 m -91.3 136.26 33.23 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.897 -0.592 . . . . 0.0 109.804 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.436 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.0 OUTLIER -61.83 -44.87 95.98 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.401 -179.725 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . 0.427 ' NE2' ' NH1' ' A' ' 86' ' ' ARG . 96.1 m-70 -110.82 152.74 26.3 Favored 'General case' 0 N--CA 1.464 0.254 0 CA-C-N 116.061 -0.518 . . . . 0.0 110.391 179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 6.0 p -53.92 131.18 39.7 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.214 -179.381 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -77.65 -33.08 53.63 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.039 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 72.06 -105.85 1.79 Allowed Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.25 -1.14 . . . . 0.0 110.25 -179.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 89.2 m-20 -92.69 0.83 57.48 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.882 0.372 . . . . 0.0 110.573 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -98.27 172.05 26.16 Favored Glycine 0 CA--C 1.52 0.397 0 N-CA-C 111.124 -0.79 . . . . 0.0 111.124 179.896 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . 0.461 ' CE2' ' O ' ' A' ' 94' ' ' CYS . 24.2 t80 -122.26 130.52 53.24 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-O 120.848 0.356 . . . . 0.0 110.943 -179.537 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . 0.461 ' O ' ' CE2' ' A' ' 93' ' ' PHE . 1.7 t -64.19 119.18 9.74 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.013 -0.539 . . . . 0.0 109.835 179.209 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 73.3 p -104.8 -19.14 14.0 Favored 'General case' 0 CA--C 1.516 -0.34 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.478 179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 9.7 mtt180 -162.03 164.88 16.86 Favored Pre-proline 0 CA--C 1.533 0.309 0 C-N-CA 120.155 -0.618 . . . . 0.0 110.849 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -53.0 128.29 28.35 Favored 'Trans proline' 0 N--CA 1.492 1.411 0 C-N-CA 121.412 1.408 . . . . 0.0 111.041 178.749 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.436 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.2 m-20 51.46 37.97 20.76 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.07 -0.514 . . . . 0.0 109.718 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 97.1 mtp -147.75 108.95 4.27 Favored 'General case' 0 C--O 1.235 0.327 0 CA-C-O 121.218 0.532 . . . . 0.0 110.305 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . 0.603 ' SG ' ' SG ' ' A' ' 85' ' ' CYS . 0.8 OUTLIER -97.13 149.05 22.41 Favored 'General case' 0 CA--C 1.528 0.117 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.606 179.266 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 96.1 m -120.5 122.8 41.44 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 109.036 -0.727 . . . . 0.0 109.036 179.663 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -93.54 158.98 35.89 Favored Pre-proline 0 CA--C 1.537 0.478 0 CA-C-N 116.491 -0.322 . . . . 0.0 110.488 -178.971 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -55.84 -26.82 59.37 Favored 'Trans proline' 0 N--CA 1.499 1.804 0 C-N-CA 122.496 2.131 . . . . 0.0 112.245 178.207 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 33.1 t -64.09 -17.43 63.41 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.575 -179.733 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 103.43 -17.44 50.76 Favored Glycine 0 CA--C 1.523 0.557 0 N-CA-C 110.831 -0.907 . . . . 0.0 110.831 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 58.8 tt0 -67.37 153.73 42.99 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 120.981 0.419 . . . . 0.0 110.124 179.917 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 90.0 mt -126.83 128.26 70.72 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.388 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.398 179.953 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.528 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -165.63 162.88 13.12 Favored Pre-proline 0 C--N 1.327 -0.391 0 CA-C-N 116.143 -0.48 . . . . 0.0 109.934 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.528 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 11.6 Cg_endo -52.36 -15.93 4.44 Favored 'Trans proline' 0 N--CA 1.498 1.746 0 C-N-CA 122.955 2.436 . . . . 0.0 112.165 179.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 97.2 p -155.51 159.39 39.71 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 116.375 -0.375 . . . . 0.0 110.28 179.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -78.51 -21.01 49.54 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.06 179.691 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -50.19 117.67 5.16 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.995 -0.842 . . . . 0.0 110.995 -179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 87.2 p -97.01 2.7 51.79 Favored 'General case' 0 N--CA 1.463 0.209 0 CA-C-O 120.622 0.249 . . . . 0.0 110.664 179.817 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.5 mtp180 -71.39 -6.7 42.18 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.307 -0.406 . . . . 0.0 110.569 -179.585 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 50.1 m -57.7 -35.96 71.33 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.047 -0.524 . . . . 0.0 110.648 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . 0.632 ' C ' HD12 ' A' ' 116' ' ' ILE . 2.6 pp -63.43 153.93 6.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 116.414 -0.357 . . . . 0.0 110.285 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 88.9 mt-30 -111.2 -17.76 13.12 Favored 'General case' 0 N--CA 1.464 0.265 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 -179.707 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 98.2 m-70 -139.43 148.23 42.49 Favored 'General case' 0 N--CA 1.465 0.319 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.626 -179.632 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 7.4 m -120.64 124.38 45.1 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-N 116.102 -0.499 . . . . 0.0 110.163 179.805 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.2 m-20 -96.6 10.54 38.21 Favored 'General case' 0 N--CA 1.463 0.221 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.417 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . . . . . . . . . 10.9 tp -125.44 156.96 34.89 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.439 0 CA-C-N 115.767 -0.651 . . . . 0.0 110.296 -179.964 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.521 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 12.6 mtt180 -106.91 120.19 41.38 Favored 'General case' 0 CA--C 1.515 -0.394 0 CA-C-N 115.481 -0.781 . . . . 0.0 110.542 -179.654 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 12.0 m -121.11 142.5 49.8 Favored 'General case' 0 C--N 1.329 -0.303 0 N-CA-C 109.237 -0.653 . . . . 0.0 109.237 179.201 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 76.2 mtm -143.25 169.61 17.31 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.108 -179.065 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 67.6 m-80 58.81 41.76 21.04 Favored 'General case' 0 N--CA 1.463 0.213 0 CA-C-N 116.373 -0.376 . . . . 0.0 111.549 179.493 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 78.44 18.33 76.15 Favored Glycine 0 CA--C 1.517 0.205 0 N-CA-C 110.656 -0.977 . . . . 0.0 110.656 179.573 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -75.88 121.56 6.32 Favored Glycine 0 CA--C 1.525 0.705 0 N-CA-C 110.511 -1.036 . . . . 0.0 110.511 -179.791 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 29.2 t -79.85 140.43 36.8 Favored 'General case' 0 C--N 1.329 -0.326 0 C-N-CA 120.984 -0.286 . . . . 0.0 110.74 -179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 3.5 t -91.54 124.4 35.67 Favored 'General case' 0 N--CA 1.465 0.278 0 CA-C-N 116.394 -0.367 . . . . 0.0 110.136 179.237 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.502 ' O ' ' N ' ' A' ' 132' ' ' ASP . 31.8 t -141.75 143.04 33.29 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.213 179.585 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 97.6 m-20 41.14 -92.37 0.01 OUTLIER 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.905 -179.866 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.502 ' N ' ' O ' ' A' ' 130' ' ' SER . 39.5 p-10 -146.5 23.68 1.27 Allowed 'General case' 0 N--CA 1.464 0.263 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.755 179.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 33.7 m170 -138.53 148.36 44.16 Favored 'General case' 0 N--CA 1.465 0.28 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.445 -179.803 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.521 ' SG ' ' O ' ' A' ' 122' ' ' ARG . 84.3 m -96.49 128.69 43.66 Favored 'General case' 0 CA--C 1.52 -0.205 0 CA-C-N 116.242 -0.436 . . . . 0.0 110.107 179.483 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 89.6 mt -92.69 126.13 37.64 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.372 -0.603 . . . . 0.0 109.372 179.697 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . 0.421 ' SG ' ' O ' ' A' ' 142' ' ' GLY . 16.7 m -89.33 127.5 35.8 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.031 -0.531 . . . . 0.0 110.58 -179.553 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.6 mt-30 -69.75 174.89 4.67 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.343 -179.976 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 62.5 tttp -63.42 127.01 29.39 Favored 'General case' 0 C--N 1.328 -0.358 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.091 -179.918 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 103.37 -13.84 54.67 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 111.1 -0.8 . . . . 0.0 111.1 -179.592 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 98.2 m-85 -121.59 136.44 54.95 Favored 'General case' 0 N--CA 1.467 0.405 0 CA-C-O 120.931 0.396 . . . . 0.0 110.42 179.786 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 47.2 pt -133.58 172.76 15.81 Favored 'Isoleucine or valine' 0 C--O 1.237 0.412 0 CA-C-N 115.992 -0.549 . . . . 0.0 110.214 -179.898 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . 0.421 ' O ' ' SG ' ' A' ' 136' ' ' CYS . . . 102.8 163.34 25.97 Favored Glycine 0 CA--C 1.522 0.524 0 N-CA-C 110.875 -0.89 . . . . 0.0 110.875 179.81 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 24.0 p -62.42 -43.84 97.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 120.749 0.309 . . . . 0.0 110.631 -179.681 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 2.2 p-80 -94.77 10.75 33.96 Favored 'General case' 0 N--CA 1.465 0.318 0 CA-C-O 121.096 0.474 . . . . 0.0 110.468 179.762 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 12.4 m 46.85 36.59 4.03 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.101 -179.829 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -99.74 8.46 59.83 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 111.086 -0.806 . . . . 0.0 111.086 -179.991 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 32.7 tt0 -116.08 112.77 41.97 Favored Pre-proline 0 CA--C 1.548 0.898 0 CA-C-N 116.76 0.28 . . . . 0.0 110.875 -179.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.0 Cg_endo -78.39 159.6 29.23 Favored 'Trans proline' 0 N--CA 1.494 1.556 0 C-N-CA 122.441 2.094 . . . . 0.0 112.273 179.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 41.5 t -113.56 127.74 70.76 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.521 0 CA-C-O 121.016 0.436 . . . . 0.0 110.142 -179.709 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 154' ' ' CYS . 2.2 m -100.05 98.18 8.95 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 178.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 tt0 -62.88 -51.67 66.07 Favored 'General case' 0 N--CA 1.447 -0.587 0 CA-C-N 115.847 -0.615 . . . . 0.0 110.339 -178.375 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 79.3 p -118.37 -9.45 10.38 Favored 'General case' 0 N--CA 1.471 0.597 0 CA-C-N 116.283 -0.417 . . . . 0.0 110.896 179.24 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . -79.74 171.82 54.71 Favored Glycine 0 CA--C 1.524 0.643 0 N-CA-C 111.228 -0.749 . . . . 0.0 111.228 -179.108 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . 0.622 ' SG ' ' SG ' ' A' ' 150' ' ' CYS . 17.9 m 57.08 59.99 3.18 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-O 120.885 0.374 . . . . 0.0 110.922 179.773 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . 0.526 ' N ' HD12 ' A' ' 155' ' ' LEU . 10.9 mp -62.93 -42.19 99.72 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.107 -0.497 . . . . 0.0 110.752 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.527 ' OD1' ' N ' ' A' ' 157' ' ' GLY . 24.9 t-20 -121.5 -112.69 0.32 Allowed 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 116.344 -0.389 . . . . 0.0 110.994 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.527 ' N ' ' OD1' ' A' ' 156' ' ' ASN . . . -84.6 3.49 86.52 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 111.121 -0.792 . . . . 0.0 111.121 -179.776 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -54.75 148.3 23.01 Favored Glycine 0 CA--C 1.524 0.652 0 N-CA-C 110.171 -1.172 . . . . 0.0 110.171 -179.779 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . 0.479 ' C ' ' SG ' ' A' ' 166' ' ' CYS . 17.8 tpt180 -102.66 131.31 49.54 Favored 'General case' 0 N--CA 1.466 0.349 0 CA-C-O 120.775 0.322 . . . . 0.0 110.451 -179.002 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 4.8 t -76.04 100.3 4.88 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.267 -0.424 . . . . 0.0 111.088 -179.577 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 59.5 t -76.91 -43.82 32.48 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.357 0 CA-C-N 115.932 -0.577 . . . . 0.0 110.768 179.832 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.647 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -151.02 175.03 3.07 Favored Pre-proline 0 CA--C 1.533 0.311 0 CA-C-N 116.237 -0.438 . . . . 0.0 109.979 -179.686 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.647 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 71.8 Cg_exo -51.73 130.06 32.43 Favored 'Trans proline' 0 C--N 1.311 -1.409 0 C-N-CA 121.605 1.537 . . . . 0.0 112.385 179.322 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 40.0 m-20 52.43 32.02 10.61 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 115.581 -0.736 . . . . 0.0 110.372 179.641 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . 0.442 ' O ' ' SG ' ' A' ' 150' ' ' CYS . 74.2 mtm180 -141.6 136.33 30.92 Favored 'General case' 0 C--O 1.236 0.366 0 CA-C-O 121.473 0.654 . . . . 0.0 110.921 179.212 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . 0.479 ' SG ' ' C ' ' A' ' 159' ' ' ARG . 1.7 t -144.35 156.22 44.15 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 115.607 -0.724 . . . . 0.0 110.994 179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -111.37 143.5 42.07 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.69 179.823 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 76.0 m -72.21 127.44 32.55 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.232 -179.767 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 98.7 m -63.37 -46.12 87.96 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.507 -0.315 . . . . 0.0 111.458 -179.61 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . 0.537 ' O ' ' CD2' ' A' ' 170' ' ' TYR . 74.7 t80 -110.54 27.95 9.14 Favored 'General case' 0 N--CA 1.465 0.304 0 CA-C-O 120.992 0.425 . . . . 0.0 111.327 -179.033 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 60.46 25.51 63.06 Favored Glycine 0 CA--C 1.522 0.527 0 N-CA-C 110.393 -1.083 . . . . 0.0 110.393 179.81 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . 0.462 ' O ' ' SG ' ' A' ' 177' ' ' CYS . 66.8 t80 -63.53 131.76 49.14 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.941 0.4 . . . . 0.0 110.421 -179.346 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . 0.439 ' O ' ' CE2' ' A' ' 172' ' ' PHE . 68.0 p -82.52 163.43 21.55 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 116.105 -0.498 . . . . 0.0 110.144 -179.877 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 144.38 160.44 8.49 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.752 -0.939 . . . . 0.0 110.752 179.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . 0.424 ' O ' ' OE1' ' A' ' 176' ' ' GLN . 36.2 Cg_endo -63.51 -31.9 70.9 Favored 'Trans proline' 0 N--CA 1.496 1.671 0 C-N-CA 122.578 2.185 . . . . 0.0 112.4 -179.701 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . 0.424 ' OE1' ' O ' ' A' ' 175' ' ' PRO . 1.9 mp0 -131.4 8.66 4.65 Favored 'General case' 0 N--CA 1.468 0.451 0 CA-C-N 116.357 -0.383 . . . . 0.0 110.201 -179.751 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.462 ' SG ' ' O ' ' A' ' 172' ' ' PHE . 1.8 t 49.82 96.97 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.415 0 CA-C-N 116.424 -0.353 . . . . 0.0 110.267 -179.631 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 . . . . . 0 C--O 1.22 -0.486 0 CA-C-O 118.024 -0.989 . . . . 0.0 110.524 -179.986 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . 0.438 ' O ' ' O ' ' A' ' 44' ' ' ALA . 19.4 m . . . . . 0 N--CA 1.49 1.567 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.438 ' O ' ' O ' ' A' ' 43' ' ' SER . . . 55.53 161.02 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.604 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 34.0 ptt180 -148.52 143.9 26.97 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.618 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . 80.78 14.87 78.96 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 -179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . -63.76 -36.8 93.79 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.912 -0.875 . . . . 0.0 110.912 -179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . -63.53 149.76 50.01 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.671 -0.972 . . . . 0.0 110.671 179.96 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -127.97 141.06 12.27 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.863 -0.895 . . . . 0.0 110.863 -179.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 74.1 m80 -66.1 -43.06 88.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.827 0.346 . . . . 0.0 110.771 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 96.5 m-20 -106.68 141.42 37.97 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-N 116.035 -0.529 . . . . 0.0 110.335 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -125.72 137.65 53.84 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-N 116.062 -0.517 . . . . 0.0 110.349 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . . . . . . . . . 88.2 mt -75.82 144.03 41.54 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 115.957 -0.565 . . . . 0.0 110.725 179.961 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -137.17 159.84 40.73 Favored 'General case' 0 CA--C 1.517 -0.32 0 CA-C-N 115.828 -0.623 . . . . 0.0 110.15 179.925 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 104.38 163.24 24.51 Favored Glycine 0 CA--C 1.53 1.013 0 N-CA-C 110.948 -0.861 . . . . 0.0 110.948 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -74.75 -5.87 17.42 Favored 'Trans proline' 0 N--CA 1.497 1.708 0 C-N-CA 123.089 2.526 . . . . 0.0 112.263 179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . 0.604 ' ND2' ' CD2' ' A' ' 71' ' ' TRP . 78.9 m-20 -103.59 68.32 0.93 Allowed 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.479 -0.328 . . . . 0.0 110.56 -179.624 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . . . . . . . . . 49.9 t -119.96 129.41 75.47 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.475 0 CA-C-N 116.098 -0.501 . . . . 0.0 109.838 178.905 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 53.2 m -134.76 173.6 11.51 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.002 -179.889 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 83.92 164.65 37.44 Favored Glycine 0 CA--C 1.524 0.602 0 N-CA-C 110.823 -0.911 . . . . 0.0 110.823 179.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.542 ' O ' ' N ' ' A' ' 65' ' ' ALA . 12.5 m -80.1 173.25 12.78 Favored 'General case' 0 C--N 1.329 -0.321 0 N-CA-C 110.294 -0.262 . . . . 0.0 110.294 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 76.1 ttt180 -60.38 -42.82 96.67 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 116.305 -0.407 . . . . 0.0 110.356 179.943 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 98.5 m-85 -62.16 -41.75 98.6 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 116.27 -0.423 . . . . 0.0 110.88 -179.871 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 89.7 m-20 -125.58 49.55 1.91 Allowed 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.747 -179.616 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.542 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.21 140.44 52.48 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 116.314 -0.403 . . . . 0.0 110.304 179.991 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 10.4 p90 -155.3 165.71 35.8 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-O 120.978 0.418 . . . . 0.0 110.878 179.599 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . . . . . . . . . 5.8 m -72.89 135.0 45.04 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.089 179.534 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 35.1 m -55.81 149.84 30.46 Favored Pre-proline 0 C--N 1.323 -0.577 0 C-N-CA 120.38 -0.528 . . . . 0.0 111.213 -178.816 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -56.23 134.98 67.56 Favored 'Trans proline' 0 N--CA 1.498 1.791 0 C-N-CA 121.498 1.465 . . . . 0.0 112.234 179.8 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 103.95 -14.95 52.31 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 111.266 -0.734 . . . . 0.0 111.266 179.885 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.604 ' CD2' ' ND2' ' A' ' 57' ' ' ASN . 85.4 m95 -115.92 134.99 54.41 Favored 'General case' 0 N--CA 1.466 0.368 0 CA-C-O 120.758 0.314 . . . . 0.0 110.372 179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . 0.445 ' O ' ' SG ' ' A' ' 80' ' ' CYS . 17.4 ptpt -110.14 -175.95 2.87 Favored 'General case' 0 N--CA 1.466 0.352 0 CA-C-N 116.417 -0.356 . . . . 0.0 110.333 179.556 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.436 HG22 ' SG ' ' A' ' 80' ' ' CYS . 41.4 p -123.09 161.19 24.85 Favored 'General case' 0 N--CA 1.467 0.398 0 N-CA-C 109.962 -0.384 . . . . 0.0 109.962 179.875 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . 0.58 ' N ' HD22 ' A' ' 74' ' ' LEU . 2.7 mm? -84.53 149.04 53.67 Favored Pre-proline 0 N--CA 1.449 -0.48 0 C-N-CA 120.604 -0.438 . . . . 0.0 111.158 -179.534 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . . . . . . . . . 52.6 Cg_exo -46.23 112.59 0.47 Allowed 'Trans proline' 0 N--CA 1.49 1.313 0 C-N-CA 121.591 1.528 . . . . 0.0 112.236 179.1 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 75.15 -6.48 28.16 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 111.164 -0.774 . . . . 0.0 111.164 179.368 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -92.99 174.77 36.04 Favored Glycine 0 CA--C 1.524 0.608 0 N-CA-C 111.079 -0.809 . . . . 0.0 111.079 179.923 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . . . . . . . . . 90.8 m-20 -129.04 0.58 5.25 Favored 'General case' 0 N--CA 1.467 0.391 0 CA-C-O 120.816 0.341 . . . . 0.0 110.643 179.5 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 96.2 mt-30 -78.84 134.4 36.95 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.688 179.785 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . 0.445 ' SG ' ' O ' ' A' ' 72' ' ' LYS . 1.5 m -115.0 79.03 1.22 Allowed 'General case' 0 N--CA 1.466 0.363 0 CA-C-O 121.164 0.507 . . . . 0.0 110.189 179.78 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 1.3 pt -120.74 14.59 6.34 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.376 0 CA-C-N 115.652 -0.704 . . . . 0.0 110.657 179.619 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 3.3 t -117.55 107.01 45.46 Favored Pre-proline 0 CA--C 1.536 0.404 0 C-N-CA 121.273 -0.171 . . . . 0.0 110.796 -179.867 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 72.3 Cg_endo -77.14 159.97 33.33 Favored 'Trans proline' 0 N--CA 1.49 1.287 0 C-N-CA 122.21 1.94 . . . . 0.0 111.987 179.897 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 88.5 mt -99.54 123.17 52.12 Favored 'Isoleucine or valine' 0 C--O 1.234 0.242 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -90.85 125.31 35.7 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 -179.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.5 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.9 OUTLIER -63.32 -45.77 89.73 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-O 121.27 0.557 . . . . 0.0 109.932 179.657 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 99.6 m-70 -121.73 143.5 49.33 Favored 'General case' 0 N--CA 1.467 0.402 0 CA-C-N 116.059 -0.519 . . . . 0.0 110.462 179.74 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 93.6 p -53.1 128.29 27.12 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.424 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 59.7 m -71.33 -27.87 63.69 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.573 179.788 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 75.45 -116.33 4.89 Favored Glycine 0 CA--C 1.525 0.697 0 N-CA-C 111.229 -0.748 . . . . 0.0 111.229 179.737 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 96.6 m-20 -70.38 -8.73 52.96 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-O 120.737 0.304 . . . . 0.0 110.925 -179.396 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -103.54 -164.81 25.34 Favored Glycine 0 CA--C 1.525 0.707 0 N-CA-C 110.688 -0.965 . . . . 0.0 110.688 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.6 p90 -142.65 150.38 40.14 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.995 0.426 . . . . 0.0 110.788 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.7 m -69.53 116.96 10.54 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.568 -179.305 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 43.3 t -104.11 -20.78 13.71 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.777 -0.647 . . . . 0.0 110.322 179.976 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 5.0 mtt85 -160.76 167.99 12.6 Favored Pre-proline 0 C--N 1.329 -0.31 0 C-N-CA 120.022 -0.671 . . . . 0.0 110.798 179.859 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -53.56 123.3 13.0 Favored 'Trans proline' 0 N--CA 1.495 1.565 0 C-N-CA 121.613 1.542 . . . . 0.0 111.143 179.288 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.5 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 1.1 t-20 52.26 40.35 28.87 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.963 -0.562 . . . . 0.0 110.088 -179.58 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 96.2 mtp -146.95 115.72 6.81 Favored 'General case' 0 C--O 1.237 0.437 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.362 -179.729 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 58.0 m -102.07 148.08 25.82 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.438 179.026 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 84.1 m -121.47 117.73 27.58 Favored 'General case' 0 C--N 1.327 -0.376 0 CA-C-N 115.91 -0.586 . . . . 0.0 109.971 179.574 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.423 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -84.38 157.84 61.35 Favored Pre-proline 0 CA--C 1.537 0.456 0 CA-C-N 116.076 -0.511 . . . . 0.0 109.801 179.683 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.423 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 24.0 Cg_endo -61.64 -22.24 73.96 Favored 'Trans proline' 0 N--CA 1.495 1.587 0 C-N-CA 122.743 2.296 . . . . 0.0 111.828 179.195 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 25.4 t -66.28 -16.62 64.17 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-O 120.987 0.422 . . . . 0.0 110.536 179.413 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 106.19 -19.02 38.29 Favored Glycine 0 CA--C 1.523 0.544 0 N-CA-C 110.861 -0.896 . . . . 0.0 110.861 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . . . . . . . . . 57.0 tp60 -65.19 149.1 50.5 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 121.011 0.434 . . . . 0.0 110.427 179.98 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . . . . . . . . . 96.4 mt -132.09 131.63 61.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.373 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.828 179.945 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.663 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -172.36 172.43 1.78 Allowed Pre-proline 0 CA--C 1.536 0.412 0 C-N-CA 120.679 -0.408 . . . . 0.0 110.471 179.453 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.663 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 73.8 Cg_exo -48.82 -23.63 6.04 Favored 'Trans proline' 0 N--CA 1.493 1.498 0 C-N-CA 122.454 2.103 . . . . 0.0 111.992 178.726 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 8.0 p -153.6 165.47 35.81 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.251 179.594 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.9 OUTLIER -77.49 -24.57 50.1 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.246 179.908 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -113.22 32.48 6.09 Favored Glycine 0 CA--C 1.528 0.859 0 N-CA-C 110.981 -0.848 . . . . 0.0 110.981 -179.764 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 4.3 m -76.92 -18.0 58.57 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 120.686 0.279 . . . . 0.0 110.577 179.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . 0.479 ' O ' ' O ' ' A' ' 115' ' ' SER . 99.7 mtt180 53.93 179.08 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.361 -0.382 . . . . 0.0 110.123 -179.279 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . 0.479 ' O ' ' O ' ' A' ' 114' ' ' ARG . 15.9 m 49.79 108.52 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 121.119 0.485 . . . . 0.0 110.95 -179.85 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 37.8 pt -78.61 138.32 20.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.914 -0.584 . . . . 0.0 110.815 179.884 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 54.2 tt0 -146.31 150.07 35.04 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.397 -179.989 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . . . . . . . . . 80.6 m80 -153.53 164.46 38.19 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.983 -0.553 . . . . 0.0 110.627 -179.895 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 96.1 m -68.92 110.38 4.38 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.496 179.84 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . . . . . . . . . 99.0 m-20 -64.01 -40.56 96.62 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.461 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.457 ' CG1' ' N ' ' A' ' 122' ' ' ARG . 15.5 tt -80.18 166.26 2.54 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.221 0 CA-C-N 115.836 -0.62 . . . . 0.0 110.229 179.689 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.457 ' N ' ' CG1' ' A' ' 121' ' ' ILE . 20.3 mmm180 -98.75 98.07 9.23 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.101 -0.5 . . . . 0.0 109.775 -179.847 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 87.4 m -92.98 134.47 35.08 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.594 -0.73 . . . . 0.0 109.88 179.464 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 72.6 mtm -145.31 165.07 29.5 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.106 -0.497 . . . . 0.0 110.15 -179.631 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 97.8 m-20 59.86 39.9 19.94 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 116.371 -0.377 . . . . 0.0 111.039 -179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 75.56 24.78 69.41 Favored Glycine 0 CA--C 1.522 0.472 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 179.558 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.97 128.24 22.81 Favored Glycine 0 CA--C 1.525 0.671 0 N-CA-C 110.804 -0.919 . . . . 0.0 110.804 -179.775 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . 0.498 ' O ' ' SG ' ' A' ' 134' ' ' CYS . 17.3 m -86.24 137.68 32.44 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-O 120.661 0.267 . . . . 0.0 110.494 179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 75.5 m -79.56 129.93 34.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.514 179.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.45 ' O ' ' O ' ' A' ' 133' ' ' HIS . 52.3 p -146.58 109.66 4.7 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.165 179.695 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . . . . . . . . . 99.6 m-20 50.12 -116.52 0.93 Allowed 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 116.111 -0.495 . . . . 0.0 110.516 -179.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . 0.432 ' OD1' ' N ' ' A' ' 132' ' ' ASP . 32.4 p-10 -106.95 9.29 30.75 Favored 'General case' 0 N--CA 1.466 0.351 0 CA-C-N 116.53 -0.305 . . . . 0.0 110.885 -179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . 0.45 ' O ' ' O ' ' A' ' 130' ' ' SER . 69.2 m80 -131.15 153.02 49.84 Favored 'General case' 0 N--CA 1.464 0.257 0 CA-C-O 120.95 0.405 . . . . 0.0 110.798 -179.691 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.498 ' SG ' ' O ' ' A' ' 128' ' ' SER . 2.4 t -114.62 145.06 42.44 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.998 -0.547 . . . . 0.0 110.293 179.779 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . . . . . . . . . 77.9 mt -100.8 129.96 46.75 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 116.073 -0.512 . . . . 0.0 109.676 -179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 10.5 m -96.34 139.22 32.78 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.455 -179.449 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 87.1 mt-30 -65.55 179.15 0.85 Allowed 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.533 -179.972 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 64.8 tttm -67.33 129.71 40.76 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.306 -0.406 . . . . 0.0 110.613 179.916 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 98.07 -10.77 63.92 Favored Glycine 0 CA--C 1.524 0.628 0 N-CA-C 111.038 -0.825 . . . . 0.0 111.038 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 96.6 m-85 -117.34 133.8 55.56 Favored 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.9 0.381 . . . . 0.0 110.638 179.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 45.8 pt -131.95 170.36 20.01 Favored 'Isoleucine or valine' 0 C--O 1.239 0.537 0 CA-C-N 115.925 -0.58 . . . . 0.0 110.315 179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 106.37 164.41 22.77 Favored Glycine 0 CA--C 1.522 0.497 0 N-CA-C 110.842 -0.903 . . . . 0.0 110.842 179.603 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 22.5 m -63.26 -45.52 91.15 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 120.864 -0.334 . . . . 0.0 110.449 -179.424 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 36.3 m80 -97.52 5.24 49.88 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-O 120.902 0.382 . . . . 0.0 110.682 -179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 6.0 m 59.87 37.25 21.79 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 116.08 -0.509 . . . . 0.0 110.123 -179.751 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . -98.88 5.72 59.86 Favored Glycine 0 CA--C 1.521 0.436 0 N-CA-C 110.627 -0.989 . . . . 0.0 110.627 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 8.4 tt0 -119.65 107.09 41.09 Favored Pre-proline 0 CA--C 1.54 0.592 0 CA-C-N 116.679 0.239 . . . . 0.0 110.535 179.988 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.73 163.5 23.72 Favored 'Trans proline' 0 N--CA 1.49 1.305 0 C-N-CA 122.564 2.176 . . . . 0.0 111.911 179.462 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 42.2 t -106.15 126.3 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.338 0 CA-C-O 121.158 0.504 . . . . 0.0 109.918 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 1.8 m -93.88 92.71 7.54 Favored 'General case' 0 C--N 1.327 -0.378 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 179.257 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 79.2 tt0 -63.61 -46.53 85.35 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.761 -178.559 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . 0.533 ' OG ' ' ND2' ' A' ' 164' ' ' ASN . 9.9 m -89.93 -11.93 40.32 Favored 'General case' 0 N--CA 1.465 0.291 0 CA-C-N 116.472 -0.331 . . . . 0.0 110.861 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 67.12 161.29 1.28 Allowed Glycine 0 CA--C 1.522 0.508 0 N-CA-C 110.858 -0.897 . . . . 0.0 110.858 -179.966 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 61.2 m -104.23 145.29 30.43 Favored 'General case' 0 C--O 1.233 0.204 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 179.473 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . 0.509 ' H ' HD12 ' A' ' 155' ' ' LEU . 4.3 mp -62.95 -43.42 98.84 Favored 'General case' 0 C--N 1.321 -0.633 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.13 -178.043 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.425 ' CB ' ' O ' ' A' ' 155' ' ' LEU . 6.8 m-20 165.4 -58.38 0.0 OUTLIER 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.352 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . . . . . . . . . . . -61.53 -37.95 95.01 Favored Glycine 0 CA--C 1.517 0.164 0 N-CA-C 110.61 -0.996 . . . . 0.0 110.61 -179.406 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . . . . . . . . . . . -76.35 159.86 50.5 Favored Glycine 0 CA--C 1.524 0.653 0 N-CA-C 110.968 -0.853 . . . . 0.0 110.968 179.758 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 95.4 mtt-85 -127.43 145.91 50.66 Favored 'General case' 0 N--CA 1.469 0.517 0 CA-C-O 120.725 0.297 . . . . 0.0 110.81 179.108 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 60.2 m -73.2 104.68 4.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.341 -0.39 . . . . 0.0 110.616 -179.746 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . 0.444 ' O ' HG12 ' A' ' 161' ' ' VAL . 70.2 t -106.49 -13.04 9.83 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.354 179.626 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.654 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -166.18 177.76 1.45 Allowed Pre-proline 0 CA--C 1.534 0.36 0 C-N-CA 120.369 -0.532 . . . . 0.0 110.341 179.807 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.654 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 52.3 Cg_exo -55.64 128.44 30.35 Favored 'Trans proline' 0 N--CA 1.492 1.403 0 C-N-CA 121.896 1.731 . . . . 0.0 111.539 179.905 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . 0.533 ' ND2' ' OG ' ' A' ' 152' ' ' SER . 2.8 t-20 43.23 38.7 1.71 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.423 -0.353 . . . . 0.0 110.9 179.579 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 58.2 ttt85 -131.37 127.07 36.82 Favored 'General case' 0 C--O 1.24 0.559 0 CA-C-O 120.995 0.426 . . . . 0.0 110.53 179.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 94.3 m -117.79 118.81 33.06 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.908 -0.587 . . . . 0.0 109.846 179.301 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -77.96 92.34 4.3 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 116.023 -0.535 . . . . 0.0 109.927 179.672 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 1.8 m -108.75 129.46 55.37 Favored 'General case' 0 N--CA 1.466 0.345 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.501 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 1.2 t -114.01 24.79 11.71 Favored 'General case' 0 N--CA 1.466 0.34 0 CA-C-N 116.42 -0.354 . . . . 0.0 111.295 179.676 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 99.3 m-85 -100.86 29.02 4.79 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-O 121.011 0.434 . . . . 0.0 110.945 -179.22 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 65.98 28.71 73.89 Favored Glycine 0 CA--C 1.52 0.402 0 N-CA-C 110.63 -0.988 . . . . 0.0 110.63 179.983 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 29.2 p90 -50.41 163.24 0.18 Allowed 'General case' 0 C--N 1.325 -0.487 0 CA-C-O 120.769 0.319 . . . . 0.0 110.476 -179.313 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 63.3 p -130.02 131.65 45.93 Favored 'General case' 0 N--CA 1.465 0.284 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.308 179.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 80.19 176.95 50.42 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 179.808 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -78.38 -10.7 16.1 Favored 'Trans proline' 0 C--N 1.31 -1.498 0 C-N-CA 122.809 2.339 . . . . 0.0 112.03 -179.292 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 7.0 tt0 -83.45 6.32 20.65 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.278 -0.419 . . . . 0.0 110.846 -178.496 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . 0.515 ' SG ' ' O ' ' A' ' 177' ' ' CYS . 50.3 t 56.39 40.15 29.82 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.293 -0.412 . . . . 0.0 110.624 179.685 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 82.1 tt0 . . . . . 0 C--O 1.22 -0.496 0 CA-C-O 118.043 -0.98 . . . . 0.0 110.601 179.875 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' SER . . . . . . . . . . . . . 13.6 t . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.416 -0.587 . . . . 0.0 109.416 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -67.68 141.5 56.65 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.663 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ARG . . . . . . . . . . . . . 94.1 mtt180 -81.97 -7.22 59.6 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.635 179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' GLY . . . . . . . . . . . . . . . -62.55 -34.54 89.8 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLY . . . . . . . . . . . . . . . 84.47 -162.7 38.28 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 111.053 -0.819 . . . . 0.0 111.053 -179.862 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' GLY . . . . . . . . . . . . . . . 84.49 179.89 51.5 Favored Glycine 0 CA--C 1.525 0.715 0 N-CA-C 110.791 -0.924 . . . . 0.0 110.791 -179.711 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLY . . . . . . . . . . . . . . . -171.31 175.9 44.74 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.925 -0.87 . . . . 0.0 110.925 -179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' HIS . . . . . . . . . . . . . 97.9 m-70 -89.72 171.48 9.62 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 120.757 0.313 . . . . 0.0 110.376 -179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ASP . . . . . . . . . . . . . 98.8 m-20 -77.58 91.49 3.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.287 -0.415 . . . . 0.0 110.416 -179.811 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' ALA . . . . . . . . . . . . . . . -164.73 -79.36 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.328 179.963 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' LEU . . . . . 0.401 HD23 ' HB2' ' A' ' 78' ' ' ASN . 87.5 mt -70.03 176.03 4.06 Favored 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.331 179.604 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' LYS . . . . . . . . . . . . . 98.4 mttt -135.85 165.87 24.63 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.784 -179.61 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLY . . . . . . . . . . . . . . . 71.69 168.63 9.92 Favored Glycine 0 CA--C 1.528 0.848 0 N-CA-C 110.906 -0.878 . . . . 0.0 110.906 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' PRO . . . . . . . . . . . . . 60.3 Cg_endo -72.26 -172.49 0.89 Allowed 'Trans proline' 0 N--CA 1.498 1.741 0 C-N-CA 122.938 2.425 . . . . 0.0 111.805 179.985 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 57.48 42.14 24.95 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 120.85 -0.34 . . . . 0.0 111.094 179.735 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.403 ' O ' HG13 ' A' ' 58' ' ' VAL . 14.6 p -97.93 133.24 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.269 0 CA-C-O 120.91 0.386 . . . . 0.0 110.101 179.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' CYS . . . . . . . . . . . . . 48.9 m -140.12 175.88 9.22 Favored 'General case' 0 N--CA 1.463 0.208 0 CA-C-N 116.038 -0.528 . . . . 0.0 110.425 -179.66 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLY . . . . . . . . . . . . . . . 81.94 160.18 26.05 Favored Glycine 0 CA--C 1.526 0.747 0 N-CA-C 110.876 -0.89 . . . . 0.0 110.876 179.729 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' SER . . . . . 0.533 ' O ' ' N ' ' A' ' 65' ' ' ALA . 14.9 m -81.21 174.79 11.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-O 120.769 0.319 . . . . 0.0 110.398 179.601 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' ARG . . . . . . . . . . . . . 59.4 ttt85 -60.59 -43.15 97.71 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-N 116.24 -0.436 . . . . 0.0 110.599 179.767 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' TYR . . . . . . . . . . . . . 89.7 m-85 -62.05 -39.12 91.28 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-N 116.332 -0.394 . . . . 0.0 110.917 -179.51 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASN . . . . . . . . . . . . . 84.9 m-20 -131.84 53.57 1.99 Allowed 'General case' 0 N--CA 1.449 -0.48 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.867 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ALA . . . . . 0.533 ' N ' ' O ' ' A' ' 61' ' ' SER . . . -70.11 139.96 52.6 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 116.441 -0.345 . . . . 0.0 110.391 179.848 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' TYR . . . . . . . . . . . . . 16.7 p90 -154.18 169.7 22.97 Favored 'General case' 0 N--CA 1.465 0.301 0 CA-C-O 121.088 0.471 . . . . 0.0 110.641 179.81 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' CYS . . . . . 0.407 ' SG ' ' CG2' ' A' ' 73' ' ' THR . 73.2 m -79.45 136.29 36.9 Favored 'General case' 0 C--N 1.326 -0.439 0 N-CA-C 109.603 -0.517 . . . . 0.0 109.603 179.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' CYS . . . . . . . . . . . . . 38.6 m -52.99 154.97 4.65 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.246 -178.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' PRO . . . . . . . . . . . . . 52.9 Cg_exo -51.84 132.51 42.3 Favored 'Trans proline' 0 N--CA 1.497 1.729 0 C-N-CA 121.103 1.202 . . . . 0.0 112.785 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLY . . . . . . . . . . . . . . . 100.69 -7.27 57.61 Favored Glycine 0 CA--C 1.53 0.989 0 N-CA-C 110.919 -0.872 . . . . 0.0 110.919 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' TRP . . . . . 0.534 ' N ' ' CD1' ' A' ' 71' ' ' TRP . 9.5 m95 -132.02 143.08 49.81 Favored 'General case' 0 N--CA 1.465 0.286 0 CA-C-N 115.688 -0.256 . . . . 0.0 110.519 179.352 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' LYS . . . . . . . . . . . . . 16.2 ptpt -127.72 -166.08 1.57 Allowed 'General case' 0 N--CA 1.471 0.609 0 N-CA-C 110.173 -0.306 . . . . 0.0 110.173 179.612 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' THR . . . . . 0.407 ' CG2' ' SG ' ' A' ' 67' ' ' CYS . 71.3 p -123.49 164.76 18.31 Favored 'General case' 0 CA--C 1.515 -0.393 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.681 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -108.4 156.56 38.39 Favored Pre-proline 0 CA--C 1.537 0.472 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.206 -179.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PRO . . . . . 0.473 ' C ' ' H ' ' A' ' 77' ' ' GLY . 46.7 Cg_exo -52.88 138.66 60.82 Favored 'Trans proline' 0 N--CA 1.495 1.593 0 C-N-CA 121.379 1.386 . . . . 0.0 111.808 178.293 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 69.38 -38.08 0.34 Allowed Glycine 0 CA--C 1.525 0.679 0 N-CA-C 111.498 -0.641 . . . . 0.0 111.498 179.709 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . 0.473 ' H ' ' C ' ' A' ' 75' ' ' PRO . . . -82.7 169.83 49.34 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 111.476 -0.65 . . . . 0.0 111.476 -179.595 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' ASN . . . . . 0.401 ' HB2' HD23 ' A' ' 53' ' ' LEU . 50.0 p30 -136.48 16.06 3.17 Favored 'General case' 0 N--CA 1.466 0.333 0 CA-C-N 115.611 -0.294 . . . . 0.0 110.88 179.909 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLN . . . . . . . . . . . . . 86.9 mt-30 -87.6 133.7 33.76 Favored 'General case' 0 N--CA 1.464 0.274 0 CA-C-N 116.519 -0.309 . . . . 0.0 110.781 -179.815 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' CYS . . . . . . . . . . . . . 62.6 m -86.28 42.69 1.01 Allowed 'General case' 0 N--CA 1.463 0.206 0 N-CA-C 109.665 -0.495 . . . . 0.0 109.665 179.766 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' ILE . . . . . . . . . . . . . 26.5 pt -94.02 26.45 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.415 0 CA-C-N 116.058 -0.519 . . . . 0.0 111.253 -179.454 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' VAL . . . . . . . . . . . . . 40.1 t -122.91 94.18 47.61 Favored Pre-proline 0 N--CA 1.466 0.37 0 CA-C-N 116.617 -0.265 . . . . 0.0 110.76 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 96.2 Cg_endo -79.48 161.26 25.39 Favored 'Trans proline' 0 N--CA 1.489 1.227 0 C-N-CA 122.198 1.932 . . . . 0.0 112.182 179.952 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' ILE . . . . . . . . . . . . . 96.6 mt -100.47 127.86 53.09 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 109.905 -0.406 . . . . 0.0 109.905 179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -96.4 131.37 43.03 Favored 'General case' 0 CA--C 1.537 0.465 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 -179.279 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ARG . . . . . 0.419 ' H ' ' HA ' ' A' ' 98' ' ' ASN . 0.8 OUTLIER -64.09 -45.88 86.73 Favored 'General case' 0 CA--C 1.536 0.433 0 CA-C-O 121.177 0.513 . . . . 0.0 110.256 -179.954 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' HIS . . . . . . . . . . . . . 95.2 m-70 -127.18 174.0 9.27 Favored 'General case' 0 N--CA 1.468 0.442 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.97 -179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' SER . . . . . . . . . . . . . 9.2 p -63.84 146.08 54.62 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.405 -179.705 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' CYS . . . . . . . . . . . . . 1.4 m -88.56 -32.4 18.17 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.902 -0.59 . . . . 0.0 110.53 -179.933 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' GLY . . . . . . . . . . . . . . . 78.29 -107.99 2.56 Favored Glycine 0 CA--C 1.527 0.826 0 N-CA-C 111.002 -0.839 . . . . 0.0 111.002 -179.341 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -92.93 3.63 55.38 Favored 'General case' 0 N--CA 1.466 0.369 0 CA-C-O 120.556 0.217 . . . . 0.0 111.34 -179.696 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' GLY . . . . . . . . . . . . . . . -111.06 -161.67 17.45 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 110.628 -0.989 . . . . 0.0 110.628 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' PHE . . . . . . . . . . . . . 54.9 p90 -146.94 152.18 38.23 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 120.985 0.421 . . . . 0.0 110.98 -179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' CYS . . . . . . . . . . . . . 11.6 m -69.65 115.6 9.08 Favored 'General case' 0 CA--C 1.517 -0.316 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.131 -179.986 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' SER . . . . . . . . . . . . . 85.6 p -103.82 -17.35 15.09 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 116.044 -0.525 . . . . 0.0 110.952 -179.099 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtp85 -159.74 163.6 22.4 Favored Pre-proline 0 CA--C 1.532 0.285 0 C-N-CA 120.513 -0.475 . . . . 0.0 110.068 -179.527 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' PRO . . . . . . . . . . . . . 53.1 Cg_exo -51.99 127.09 22.07 Favored 'Trans proline' 0 C--N 1.313 -1.335 0 C-N-CA 121.565 1.51 . . . . 0.0 111.034 178.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' ASN . . . . . 0.419 ' HA ' ' H ' ' A' ' 86' ' ' ARG . 92.0 m-20 49.62 36.5 10.66 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.757 -0.656 . . . . 0.0 109.88 179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 99' ' ' MET . . . . . . . . . . . . . 38.1 mtt -147.6 122.31 9.88 Favored 'General case' 0 C--O 1.235 0.335 0 CA-C-O 121.36 0.6 . . . . 0.0 111.048 179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 100' ' ' CYS . . . . . . . . . . . . . 20.2 t -108.17 149.45 28.52 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.689 -0.687 . . . . 0.0 110.474 179.115 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 101' ' ' THR . . . . . . . . . . . . . 99.8 m -121.38 124.72 45.21 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.72 -0.673 . . . . 0.0 109.79 179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 102' ' ' CYS . . . . . 0.404 ' SG ' ' HD2' ' A' ' 103' ' ' PRO . 0.0 OUTLIER -93.73 157.78 37.66 Favored Pre-proline 0 CA--C 1.538 0.492 0 CA-C-N 115.876 -0.602 . . . . 0.0 109.543 -179.916 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 103' ' ' PRO . . . . . 0.404 ' HD2' ' SG ' ' A' ' 102' ' ' CYS . 27.3 Cg_endo -62.04 -20.44 69.67 Favored 'Trans proline' 0 N--CA 1.495 1.607 0 C-N-CA 122.551 2.167 . . . . 0.0 111.766 178.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 104' ' ' SER . . . . . . . . . . . . . 6.9 t -68.05 -22.85 64.93 Favored 'General case' 0 CA--C 1.531 0.241 0 CA-C-N 116.289 -0.414 . . . . 0.0 110.601 178.827 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 105' ' ' GLY . . . . . . . . . . . . . . . 113.88 -22.94 13.7 Favored Glycine 0 N--CA 1.467 0.717 0 N-CA-C 110.999 -0.841 . . . . 0.0 110.999 -179.753 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 106' ' ' GLN . . . . . 0.468 ' CD ' ' N ' ' A' ' 107' ' ' ILE . 8.1 tm0? -63.44 146.25 53.99 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-O 121.212 0.53 . . . . 0.0 110.362 179.812 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 107' ' ' ILE . . . . . 0.468 ' N ' ' CD ' ' A' ' 106' ' ' GLN . 96.7 mt -129.89 133.78 64.09 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.323 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.402 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 108' ' ' ALA . . . . . 0.623 ' HB1' ' HD2' ' A' ' 109' ' ' PRO . . . -178.64 171.61 0.71 Allowed Pre-proline 0 CA--C 1.535 0.392 0 N-CA-C 110.013 -0.366 . . . . 0.0 110.013 179.168 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 109' ' ' PRO . . . . . 0.623 ' HD2' ' HB1' ' A' ' 108' ' ' ALA . 56.9 Cg_exo -50.35 -25.77 14.46 Favored 'Trans proline' 0 N--CA 1.5 1.877 0 C-N-CA 122.645 2.23 . . . . 0.0 112.247 179.015 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 110' ' ' SER . . . . . . . . . . . . . 32.7 p -140.75 161.99 36.48 Favored 'General case' 0 N--CA 1.466 0.347 0 CA-C-N 116.071 -0.513 . . . . 0.0 110.239 -179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 111' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -83.38 140.68 32.26 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.646 -0.706 . . . . 0.0 110.684 -179.576 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 112' ' ' GLY . . . . . . . . . . . . . . . -164.03 124.06 1.23 Allowed Glycine 0 CA--C 1.522 0.517 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 179.607 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 113' ' ' SER . . . . . . . . . . . . . 13.1 p -74.44 141.06 45.03 Favored 'General case' 0 C--N 1.327 -0.384 0 C-N-CA 120.642 -0.423 . . . . 0.0 110.147 179.807 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 114' ' ' ARG . . . . . . . . . . . . . 84.0 mtt85 -147.7 -50.34 0.18 Allowed 'General case' 0 N--CA 1.466 0.33 0 CA-C-O 120.911 0.386 . . . . 0.0 110.606 179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 115' ' ' SER . . . . . . . . . . . . . 49.6 p -157.75 -159.32 0.82 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.0 -0.546 . . . . 0.0 110.253 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 116' ' ' ILE . . . . . . . . . . . . . 21.8 pt -126.28 148.27 30.99 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.421 179.742 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 117' ' ' GLN . . . . . . . . . . . . . 68.6 tp60 -152.82 148.82 27.65 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.979 179.589 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 118' ' ' HIS . . . . . 0.512 ' H ' ' CD2' ' A' ' 118' ' ' HIS . 5.7 p80 -113.86 39.48 2.68 Favored 'General case' 0 N--CA 1.468 0.462 0 CA-C-N 116.32 -0.4 . . . . 0.0 110.505 -179.857 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 119' ' ' CYS . . . . . . . . . . . . . 64.5 m -124.29 79.97 1.79 Allowed 'General case' 0 N--CA 1.469 0.495 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.473 -179.972 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 120' ' ' ASN . . . . . 0.416 ' OD1' ' O ' ' A' ' 120' ' ' ASN . 53.5 t-20 -63.58 -40.43 96.94 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.973 -0.558 . . . . 0.0 110.658 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 121' ' ' ILE . . . . . 0.661 HG22 ' H ' ' A' ' 122' ' ' ARG . 15.6 mm -82.71 174.33 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.212 0 CA-C-N 116.157 -0.474 . . . . 0.0 109.956 -179.488 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 122' ' ' ARG . . . . . 0.661 ' H ' HG22 ' A' ' 121' ' ' ILE . 27.2 ptt180 -106.02 114.08 28.0 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 121.544 0.688 . . . . 0.0 110.534 -179.726 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 123' ' ' CYS . . . . . . . . . . . . . 94.2 m -124.26 148.03 47.66 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.538 -0.756 . . . . 0.0 110.263 -179.938 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 124' ' ' MET . . . . . . . . . . . . . 77.2 mtm -142.27 174.24 10.8 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.084 -0.507 . . . . 0.0 109.916 179.899 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 125' ' ' ASN . . . . . . . . . . . . . 10.8 m120 60.88 44.93 10.2 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.119 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 126' ' ' GLY . . . . . . . . . . . . . . . 65.29 26.17 71.53 Favored Glycine 0 CA--C 1.518 0.261 0 N-CA-C 110.584 -1.006 . . . . 0.0 110.584 179.154 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -66.52 156.66 50.78 Favored Glycine 0 CA--C 1.52 0.401 0 N-CA-C 110.351 -1.099 . . . . 0.0 110.351 179.878 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 128' ' ' SER . . . . . . . . . . . . . 28.3 t -109.62 134.51 51.86 Favored 'General case' 0 CA--C 1.517 -0.306 0 CA-C-O 121.05 0.452 . . . . 0.0 110.373 -179.825 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 129' ' ' CYS . . . . . . . . . . . . . 15.5 m -80.94 132.1 35.38 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-N 116.077 -0.51 . . . . 0.0 110.22 -179.812 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 130' ' ' SER . . . . . 0.505 ' OG ' HD23 ' A' ' 135' ' ' LEU . 69.1 m -123.56 158.41 31.46 Favored 'General case' 0 N--CA 1.467 0.388 0 CA-C-N 115.645 -0.707 . . . . 0.0 109.486 -179.949 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 131' ' ' ASP . . . . . 0.501 ' C ' ' O ' ' A' ' 130' ' ' SER . 99.6 m-20 -12.01 -77.5 0.0 OUTLIER 'General case' 0 N--CA 1.476 0.869 0 O-C-N 123.899 0.75 . . . . 0.0 112.725 -179.562 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 132' ' ' ASP . . . . . . . . . . . . . 99.4 m-20 -136.21 29.74 3.03 Favored 'General case' 0 N--CA 1.467 0.406 0 CA-C-N 116.322 -0.399 . . . . 0.0 110.397 179.295 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 133' ' ' HIS . . . . . . . . . . . . . 79.0 m80 -139.89 159.08 42.98 Favored 'General case' 0 N--CA 1.466 0.367 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.782 -179.718 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 134' ' ' CYS . . . . . 0.407 ' C ' HD22 ' A' ' 135' ' ' LEU . 40.7 t -104.64 122.37 45.49 Favored 'General case' 0 N--CA 1.465 0.276 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.035 179.434 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 135' ' ' LEU . . . . . 0.505 HD23 ' OG ' ' A' ' 130' ' ' SER . 3.5 mm? -98.18 127.19 43.99 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-O 121.081 0.467 . . . . 0.0 110.169 -179.511 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 136' ' ' CYS . . . . . . . . . . . . . 61.1 m -106.98 140.43 39.79 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.807 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 137' ' ' GLN . . . . . . . . . . . . . 98.4 mm-40 -76.8 168.94 19.21 Favored 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.687 -0.688 . . . . 0.0 110.32 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 138' ' ' LYS . . . . . . . . . . . . . 56.1 tptt -64.71 133.31 51.85 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 109.789 -0.449 . . . . 0.0 109.789 -179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 108.76 -26.41 15.95 Favored Glycine 0 CA--C 1.524 0.609 0 N-CA-C 111.285 -0.726 . . . . 0.0 111.285 -179.591 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 140' ' ' TYR . . . . . . . . . . . . . 93.7 m-85 -116.61 133.58 55.84 Favored 'General case' 0 N--CA 1.463 0.186 0 CA-C-O 120.898 0.38 . . . . 0.0 110.67 179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 141' ' ' ILE . . . . . . . . . . . . . 15.6 pt -131.04 170.76 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.326 0 CA-C-N 115.994 -0.548 . . . . 0.0 109.936 -179.739 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 142' ' ' GLY . . . . . . . . . . . . . . . 119.61 157.62 10.36 Favored Glycine 0 N--CA 1.464 0.565 0 N-CA-C 110.716 -0.954 . . . . 0.0 110.716 179.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 143' ' ' THR . . . . . . . . . . . . . 59.6 p -64.07 -42.69 96.89 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-O 120.869 0.366 . . . . 0.0 110.602 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 144' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -104.21 5.02 34.55 Favored 'General case' 0 N--CA 1.466 0.336 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.606 179.923 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 145' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER 64.25 139.29 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.431 0 N-CA-C 109.759 -0.46 . . . . 0.0 109.759 -179.786 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 146' ' ' GLY . . . . . . . . . . . . . . . 151.41 -10.74 0.73 Allowed Glycine 0 CA--C 1.524 0.645 0 N-CA-C 111.001 -0.84 . . . . 0.0 111.001 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 147' ' ' GLN . . . . . . . . . . . . . 40.8 tt0 -99.0 110.53 58.07 Favored Pre-proline 0 CA--C 1.544 0.715 0 O-C-N 122.517 -0.402 . . . . 0.0 110.422 179.831 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 148' ' ' PRO . . . . . . . . . . . . . 90.7 Cg_endo -76.77 159.01 35.14 Favored 'Trans proline' 0 N--CA 1.496 1.627 0 C-N-CA 122.175 1.916 . . . . 0.0 112.524 -179.84 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 149' ' ' VAL . . . . . . . . . . . . . 84.8 t -124.76 130.06 73.45 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.514 0 CA-C-O 121.11 0.481 . . . . 0.0 110.577 179.754 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 150' ' ' CYS . . . . . . . . . . . . . 2.1 m -104.35 117.68 34.79 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.291 -0.413 . . . . 0.0 110.087 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 151' ' ' GLU . . . . . . . . . . . . . 76.5 mt-10 -65.75 -39.48 91.12 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.937 -0.574 . . . . 0.0 110.477 -179.915 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 152' ' ' SER . . . . . . . . . . . . . 66.3 m -86.12 -7.44 58.58 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.531 179.95 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 153' ' ' GLY . . . . . . . . . . . . . . . 45.73 -166.48 0.06 OUTLIER Glycine 0 CA--C 1.526 0.744 0 N-CA-C 110.895 -0.882 . . . . 0.0 110.895 179.967 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 154' ' ' CYS . . . . . . . . . . . . . 1.3 m -141.34 119.61 12.18 Favored 'General case' 0 N--CA 1.466 0.343 0 N-CA-C 109.94 -0.392 . . . . 0.0 109.94 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 155' ' ' LEU . . . . . . . . . . . . . 88.5 mt -63.9 -41.7 97.63 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.766 179.549 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 156' ' ' ASN . . . . . 0.526 ' C ' ' H ' ' A' ' 158' ' ' GLY . 6.1 t-20 -86.03 -167.88 2.02 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.99 -0.55 . . . . 0.0 110.332 -179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 157' ' ' GLY . . . . . 0.496 ' H ' ' CG ' ' A' ' 156' ' ' ASN . . . -70.79 23.67 0.53 Allowed Glycine 0 CA--C 1.525 0.681 0 N-CA-C 111.112 -0.795 . . . . 0.0 111.112 -179.968 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 158' ' ' GLY . . . . . 0.526 ' H ' ' C ' ' A' ' 156' ' ' ASN . . . -60.01 160.17 21.59 Favored Glycine 0 CA--C 1.524 0.625 0 N-CA-C 110.685 -0.966 . . . . 0.0 110.685 -179.973 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 159' ' ' ARG . . . . . . . . . . . . . 90.8 mtm-85 -126.75 147.18 50.0 Favored 'General case' 0 N--CA 1.465 0.3 0 CA-C-O 120.778 0.323 . . . . 0.0 110.668 -179.526 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 160' ' ' CYS . . . . . . . . . . . . . 12.3 t -90.88 104.78 17.33 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-O 120.853 0.359 . . . . 0.0 110.497 -179.785 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 161' ' ' VAL . . . . . . . . . . . . . 35.7 m -77.98 -35.04 20.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.106 -179.714 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 162' ' ' ALA . . . . . 0.63 ' HB1' ' HD2' ' A' ' 163' ' ' PRO . . . -155.81 177.29 2.11 Favored Pre-proline 0 CA--C 1.536 0.409 0 C-N-CA 120.744 -0.382 . . . . 0.0 110.36 -179.309 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 163' ' ' PRO . . . . . 0.63 ' HD2' ' HB1' ' A' ' 162' ' ' ALA . 50.8 Cg_exo -54.26 132.22 49.36 Favored 'Trans proline' 0 N--CA 1.495 1.595 0 C-N-CA 122.023 1.816 . . . . 0.0 112.259 179.436 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 164' ' ' ASN . . . . . . . . . . . . . 15.9 t-20 49.33 31.79 4.03 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.259 179.728 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 165' ' ' ARG . . . . . . . . . . . . . 28.5 mmt180 -135.42 102.09 5.03 Favored 'General case' 0 C--O 1.236 0.355 0 CA-C-O 121.58 0.705 . . . . 0.0 110.751 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 166' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -107.52 141.17 39.37 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.821 179.674 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 167' ' ' ALA . . . . . . . . . . . . . . . -106.64 133.71 50.89 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.804 -0.635 . . . . 0.0 109.444 179.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 168' ' ' CYS . . . . . . . . . . . . . 67.3 m -86.3 146.51 26.47 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-O 120.857 0.36 . . . . 0.0 110.102 -179.318 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 169' ' ' THR . . . . . . . . . . . . . 19.3 m -62.35 -45.1 94.73 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 116.083 -0.508 . . . . 0.0 111.118 -179.117 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 170' ' ' TYR . . . . . . . . . . . . . 98.0 m-85 -97.52 15.93 21.8 Favored 'General case' 0 CA--C 1.516 -0.333 0 CA-C-O 121.322 0.582 . . . . 0.0 110.847 -179.299 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 171' ' ' GLY . . . . . . . . . . . . . . . 71.15 20.95 78.37 Favored Glycine 0 CA--C 1.522 0.528 0 N-CA-C 110.59 -1.004 . . . . 0.0 110.59 179.748 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 172' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -54.84 161.7 1.49 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 120.967 0.413 . . . . 0.0 110.595 -179.713 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 173' ' ' THR . . . . . . . . . . . . . 8.8 t -82.54 160.52 22.58 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.479 -179.854 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 174' ' ' GLY . . . . . . . . . . . . . . . 66.6 142.52 0.05 OUTLIER Glycine 0 CA--C 1.539 1.534 0 N-CA-C 110.733 -0.947 . . . . 0.0 110.733 -179.694 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 175' ' ' PRO . . . . . . . . . . . . . 44.8 Cg_exo -53.48 -40.67 77.84 Favored 'Trans proline' 0 N--CA 1.502 1.977 0 C-N-CA 122.329 2.019 . . . . 0.0 112.971 179.076 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 176' ' ' GLN . . . . . . . . . . . . . 83.9 mt-30 -67.3 -26.22 66.42 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.79 -0.641 . . . . 0.0 110.455 -178.594 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 177' ' ' CYS . . . . . . . . . . . . . 11.8 m 65.04 60.76 0.79 Allowed 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.673 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 178' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 . . . . . 0 C--O 1.219 -0.504 0 CA-C-O 118.003 -0.999 . . . . 0.0 110.93 -179.935 . . . . . . . . 0 0 . 1 stop_ save_